<?xml version='1.0' encoding='UTF-8'?>
		<PROJECTS xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<row><APPLICATION_ID>8867454</APPLICATION_ID><ACTIVITY>I01</ACTIVITY><ADMINISTERING_IC>VA</ADMINISTERING_IC><APPLICATION_TYPE>1</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>04/20/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>999</CFDA_CODE><CORE_PROJECT_NUM>I01RX001691</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-RX-14-011</FOA_NUMBER><FULL_PROJECT_NUM>1I01RX001691-01A1</FULL_PROJECT_NUM><FUNDING_ICs>VA:273312\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>Veterans Affairs</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>SAN DIEGO</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>52</ORG_DISTRICT><ORG_DUNS>073358855</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[VA SAN DIEGO HEALTHCARE SYSTEM]]></ORG_NAME><ORG_STATE>CA</ORG_STATE><ORG_ZIPCODE>921610002</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE:    
Over 80,000 Veterans with Parkinson's disease (PD) obtain their medical care within the Veterans Administration (VA) Health Care System and this number is expected to increase due to the greater longevity of the population. Cognitive impairment is one of the most debilitating aspects of PD; however, there are few treatment options available for these individuals. The aim of this project is to study the efficacy of a novel, manualized cognitive rehabilitation program fo individuals with PD and cognitive impairment. Given that a large proportion of Veterans with PD will develop cognitive deficits, it is imperative to develop an empirically-validated intervention that can slow or even reverse cognitive decline and improve quality of life in these individuals. The proposed program of research is wholly consistent with the VA's clinical care goals and will greatly benefit the VA and its role as a leader in providing high quality care and empirically-validated treatments to Veterans.   
   
      

]]></PHR><PIS><PI><PI_NAME>SCHIEHSER, DAWN M.</PI_NAME><PI_ID>9845253</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>11/01/2015</PROJECT_START><PROJECT_END>10/31/2019</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Accounting]]></TERM><TERM><![CDATA[Aftercare]]></TERM><TERM><![CDATA[Attenuated]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Blinded]]></TERM><TERM><![CDATA[Caring]]></TERM><TERM><![CDATA[clinical care]]></TERM><TERM><![CDATA[Cognition]]></TERM><TERM><![CDATA[Cognitive]]></TERM><TERM><![CDATA[cognitive change]]></TERM><TERM><![CDATA[Cognitive deficits]]></TERM><TERM><![CDATA[cognitive function]]></TERM><TERM><![CDATA[cognitive rehabilitation]]></TERM><TERM><![CDATA[Control Groups]]></TERM><TERM><![CDATA[Controlled Study]]></TERM><TERM><![CDATA[coping]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Dementia]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Diagnosis]]></TERM><TERM><![CDATA[Educational process of instructing]]></TERM><TERM><![CDATA[executive function]]></TERM><TERM><![CDATA[follow-up]]></TERM><TERM><![CDATA[Foundations]]></TERM><TERM><![CDATA[functional outcomes]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[group intervention]]></TERM><TERM><![CDATA[Health Status]]></TERM><TERM><![CDATA[Healthcare Systems]]></TERM><TERM><![CDATA[Impaired cognition]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[Institutes]]></TERM><TERM><![CDATA[Intervention]]></TERM><TERM><![CDATA[intervention effect]]></TERM><TERM><![CDATA[Investigation]]></TERM><TERM><![CDATA[Knowledge]]></TERM><TERM><![CDATA[Longevity]]></TERM><TERM><![CDATA[Measures]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[Mediator of activation protein]]></TERM><TERM><![CDATA[Medical]]></TERM><TERM><![CDATA[meetings]]></TERM><TERM><![CDATA[Memory]]></TERM><TERM><![CDATA[mild cognitive impairment]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Moods]]></TERM><TERM><![CDATA[Motor]]></TERM><TERM><![CDATA[Movement Disorders]]></TERM><TERM><![CDATA[neglect]]></TERM><TERM><![CDATA[Neurobehavioral Manifestations]]></TERM><TERM><![CDATA[neuropsychiatry]]></TERM><TERM><![CDATA[neuropsychological]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[Parkinson Disease]]></TERM><TERM><![CDATA[Participant]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Phase]]></TERM><TERM><![CDATA[Population]]></TERM><TERM><![CDATA[post intervention]]></TERM><TERM><![CDATA[prevent]]></TERM><TERM><![CDATA[primary outcome]]></TERM><TERM><![CDATA[programs]]></TERM><TERM><![CDATA[Psychosocial Stress]]></TERM><TERM><![CDATA[public health relevance]]></TERM><TERM><![CDATA[Quality of Care]]></TERM><TERM><![CDATA[Quality of life]]></TERM><TERM><![CDATA[Randomized]]></TERM><TERM><![CDATA[Recruitment Activity]]></TERM><TERM><![CDATA[Rehabilitation therapy]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Severity of illness]]></TERM><TERM><![CDATA[skills training]]></TERM><TERM><![CDATA[Sleep]]></TERM><TERM><![CDATA[Societies]]></TERM><TERM><![CDATA[Supportive care]]></TERM><TERM><![CDATA[symptom management]]></TERM><TERM><![CDATA[Symptoms]]></TERM><TERM><![CDATA[Techniques]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[treatment effect]]></TERM><TERM><![CDATA[United States Department of Veterans Affairs]]></TERM><TERM><![CDATA[Veterans]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Cognitive Rehabilitation for Individuals with Parkinson's Disease and MCI]]></PROJECT_TITLE><SERIAL_NUMBER>001691</SERIAL_NUMBER><STUDY_SECTION>RRD6</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Blank ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>01</SUPPORT_YEAR><SUFFIX>A1</SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST></TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8959618</APPLICATION_ID><ACTIVITY>R21</ACTIVITY><ADMINISTERING_IC>AI</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/27/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>855</CFDA_CODE><CORE_PROJECT_NUM>R21AI114335</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[OVERALL MEDICAL]]></ED_INST_TYPE><FOA_NUMBER>PA-13-303</FOA_NUMBER><FULL_PROJECT_NUM>5R21AI114335-02</FULL_PROJECT_NUM><FUNDING_ICs>NIAID:198125\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>HOUSTON</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[NONE]]></ORG_DEPT><ORG_DISTRICT>09</ORG_DISTRICT><ORG_DUNS>051113330</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[BAYLOR COLLEGE OF MEDICINE]]></ORG_NAME><ORG_STATE>TX</ORG_STATE><ORG_ZIPCODE>770303411</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: We will identify mechanisms involved in the HIV-1 replication cycle, specifically the step in the viral life cycle in which viral RNA is exported from the nucleu after synthesis by cellular RNA Polymerase II. Identification of these mechanisms may lead to new therapeutic strategies to treat HIV-1 infection. Additionally, the research may reveal insight into general biological processes of relevance to other human diseases.]]></PHR><PIS><PI><PI_NAME>RICE, ANDREW P</PI_NAME><PI_ID>1877896</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>KUO, LILLIAN S.</PROGRAM_OFFICER_NAME><PROJECT_START>11/01/2014</PROJECT_START><PROJECT_END>10/31/2016</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Back]]></TERM><TERM><![CDATA[Binding (Molecular Function)]]></TERM><TERM><![CDATA[Biological Process]]></TERM><TERM><![CDATA[Cell membrane]]></TERM><TERM><![CDATA[Cell Nucleolus]]></TERM><TERM><![CDATA[Cell Nucleus]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[cellular imaging]]></TERM><TERM><![CDATA[Cleaved cell]]></TERM><TERM><![CDATA[Complex]]></TERM><TERM><![CDATA[Cytomegalovirus]]></TERM><TERM><![CDATA[Cytoplasm]]></TERM><TERM><![CDATA[Databases]]></TERM><TERM><![CDATA[Elements]]></TERM><TERM><![CDATA[env Gene Products]]></TERM><TERM><![CDATA[exportin 1 protein]]></TERM><TERM><![CDATA[gp160]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[HIV]]></TERM><TERM><![CDATA[HIV Envelope Protein gp120]]></TERM><TERM><![CDATA[HIV Infections]]></TERM><TERM><![CDATA[HIV-1]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[human disease]]></TERM><TERM><![CDATA[Hydrolysis]]></TERM><TERM><![CDATA[Infection]]></TERM><TERM><![CDATA[inhibitor/antagonist]]></TERM><TERM><![CDATA[innovation]]></TERM><TERM><![CDATA[insight]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[leptomycin B]]></TERM><TERM><![CDATA[Life]]></TERM><TERM><![CDATA[Life Cycle Stages]]></TERM><TERM><![CDATA[Link]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[Messenger RNA]]></TERM><TERM><![CDATA[Mining]]></TERM><TERM><![CDATA[Mouse Mammary Tumor Virus]]></TERM><TERM><![CDATA[Names]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[novel therapeutics]]></TERM><TERM><![CDATA[Nuclear]]></TERM><TERM><![CDATA[Nuclear Export]]></TERM><TERM><![CDATA[Nuclear Pore]]></TERM><TERM><![CDATA[Nuclear Protein]]></TERM><TERM><![CDATA[Nuclear Structure]]></TERM><TERM><![CDATA[Pathway interactions]]></TERM><TERM><![CDATA[Peptide Hydrolases]]></TERM><TERM><![CDATA[Plasmids]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[Proteins]]></TERM><TERM><![CDATA[Reporter]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Research Personnel]]></TERM><TERM><![CDATA[Research Project Grants]]></TERM><TERM><![CDATA[research study]]></TERM><TERM><![CDATA[Response Elements]]></TERM><TERM><![CDATA[Retroviridae]]></TERM><TERM><![CDATA[rev Protein]]></TERM><TERM><![CDATA[RNA]]></TERM><TERM><![CDATA[RNA Polymerase II]]></TERM><TERM><![CDATA[RNA Recognition Motif]]></TERM><TERM><![CDATA[RNA Splicing]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[Small Interfering RNA]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[trafficking]]></TERM><TERM><![CDATA[trans-Golgi Network]]></TERM><TERM><![CDATA[Viral]]></TERM><TERM><![CDATA[viral RNA]]></TERM><TERM><![CDATA[Virion]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Mechanisms of Action of Novel HIV Rev Co-factors]]></PROJECT_TITLE><SERIAL_NUMBER>114335</SERIAL_NUMBER><STUDY_SECTION>AMCB</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[AIDS Molecular and Cellular Biology Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>125000</DIRECT_COST_AMT><INDIRECT_COST_AMT>73125</INDIRECT_COST_AMT><TOTAL_COST>198125</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8959891</APPLICATION_ID><ACTIVITY>R00</ACTIVITY><ADMINISTERING_IC>HD</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/04/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>865</CFDA_CODE><CORE_PROJECT_NUM>R00HD073327</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF PUBLIC HEALTH]]></ED_INST_TYPE><FOA_NUMBER>PA-11-197</FOA_NUMBER><FULL_PROJECT_NUM>5R00HD073327-05</FULL_PROJECT_NUM><FUNDING_ICs>NICHD:215303\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &amp; HUMAN DEVELOPMENT</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>BALTIMORE</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[PUBLIC HEALTH & PREV MEDICINE]]></ORG_DEPT><ORG_DISTRICT>07</ORG_DISTRICT><ORG_DUNS>001910777</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[JOHNS HOPKINS UNIVERSITY]]></ORG_NAME><ORG_STATE>MD</ORG_STATE><ORG_ZIPCODE>212051832</ORG_ZIPCODE><PHR><![CDATA[Relevance
Obesity is inversely related to socioeconomic status and disproportionately represented among racial/ethnic
minority populations in the United States. This study will address the extent to which improvements in
economic resources among American Indian/Alaska Natives communities can lead to decreased risk of obesity
for women and children in these populations.]]></PHR><PIS><PI><PI_NAME>JONES-SMITH, JESSICA </PI_NAME><PI_ID>10948784</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>KING, ROSALIND B</PROGRAM_OFFICER_NAME><PROJECT_START>12/08/2013</PROJECT_START><PROJECT_END>10/31/2016</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[Adult]]></TERM><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[American Indian and Alaska Native]]></TERM><TERM><![CDATA[American Indians]]></TERM><TERM><![CDATA[Area]]></TERM><TERM><![CDATA[Award]]></TERM><TERM><![CDATA[Birth]]></TERM><TERM><![CDATA[Birth Records]]></TERM><TERM><![CDATA[Birth Weight]]></TERM><TERM><![CDATA[California]]></TERM><TERM><![CDATA[career]]></TERM><TERM><![CDATA[Child]]></TERM><TERM><![CDATA[Childhood]]></TERM><TERM><![CDATA[Collection]]></TERM><TERM><![CDATA[Communities]]></TERM><TERM><![CDATA[Community Developments]]></TERM><TERM><![CDATA[Community Health]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Data Analyses]]></TERM><TERM><![CDATA[Data Collection]]></TERM><TERM><![CDATA[Economically Deprived Population]]></TERM><TERM><![CDATA[Economics]]></TERM><TERM><![CDATA[Epidemiology]]></TERM><TERM><![CDATA[ethnic minority population]]></TERM><TERM><![CDATA[Etiology]]></TERM><TERM><![CDATA[evidence base]]></TERM><TERM><![CDATA[Experimental Designs]]></TERM><TERM><![CDATA[Family]]></TERM><TERM><![CDATA[feeding]]></TERM><TERM><![CDATA[fitness]]></TERM><TERM><![CDATA[Food]]></TERM><TERM><![CDATA[Funding]]></TERM><TERM><![CDATA[Gestational Age]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[health economics]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[Income]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[infancy]]></TERM><TERM><![CDATA[Infant]]></TERM><TERM><![CDATA[Intervention]]></TERM><TERM><![CDATA[Knowledge]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[Life]]></TERM><TERM><![CDATA[Life Cycle Stages]]></TERM><TERM><![CDATA[Link]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[Mentors]]></TERM><TERM><![CDATA[Methods]]></TERM><TERM><![CDATA[Mining]]></TERM><TERM><![CDATA[Morbidity - disease rate]]></TERM><TERM><![CDATA[Mortality Vital Statistics]]></TERM><TERM><![CDATA[Natural experiment]]></TERM><TERM><![CDATA[nutrition]]></TERM><TERM><![CDATA[Obesity]]></TERM><TERM><![CDATA[obesity in children]]></TERM><TERM><![CDATA[obesity risk]]></TERM><TERM><![CDATA[Observational Study]]></TERM><TERM><![CDATA[Outcome]]></TERM><TERM><![CDATA[Pathway interactions]]></TERM><TERM><![CDATA[Phase]]></TERM><TERM><![CDATA[Physical activity]]></TERM><TERM><![CDATA[Plague]]></TERM><TERM><![CDATA[Policies]]></TERM><TERM><![CDATA[Policy Maker]]></TERM><TERM><![CDATA[Population]]></TERM><TERM><![CDATA[population health]]></TERM><TERM><![CDATA[Pregnancy]]></TERM><TERM><![CDATA[prevent]]></TERM><TERM><![CDATA[Price]]></TERM><TERM><![CDATA[psychosocial]]></TERM><TERM><![CDATA[public health medicine (field)]]></TERM><TERM><![CDATA[Publications]]></TERM><TERM><![CDATA[racial and ethnic]]></TERM><TERM><![CDATA[Reading]]></TERM><TERM><![CDATA[Records]]></TERM><TERM><![CDATA[Recreation]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Research Activity]]></TERM><TERM><![CDATA[research study]]></TERM><TERM><![CDATA[Research Training]]></TERM><TERM><![CDATA[Resources]]></TERM><TERM><![CDATA[Risk]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Schools]]></TERM><TERM><![CDATA[Shock]]></TERM><TERM><![CDATA[skills]]></TERM><TERM><![CDATA[social]]></TERM><TERM><![CDATA[Social Psychology]]></TERM><TERM><![CDATA[Social Welfare]]></TERM><TERM><![CDATA[Socioeconomic Status]]></TERM><TERM><![CDATA[socioeconomics]]></TERM><TERM><![CDATA[Staging]]></TERM><TERM><![CDATA[stem]]></TERM><TERM><![CDATA[symposium]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[theories]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[tool]]></TERM><TERM><![CDATA[Training]]></TERM><TERM><![CDATA[Training Activity]]></TERM><TERM><![CDATA[tribal member]]></TERM><TERM><![CDATA[United States]]></TERM><TERM><![CDATA[Variant]]></TERM><TERM><![CDATA[Vendor]]></TERM><TERM><![CDATA[Weight]]></TERM><TERM><![CDATA[Weight Gain]]></TERM><TERM><![CDATA[Woman]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Effects of Increasing Economic Resources and Obesity: A Quasi-Experimental Study]]></PROJECT_TITLE><SERIAL_NUMBER>073327</SERIAL_NUMBER><STUDY_SECTION>NSS</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>05</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>137811</DIRECT_COST_AMT><INDIRECT_COST_AMT>77492</INDIRECT_COST_AMT><TOTAL_COST>215303</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8960355</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>MH</ADMINISTERING_IC><APPLICATION_TYPE>4</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/26/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>242</CFDA_CODE><CORE_PROJECT_NUM>R01MH099559</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>RFA-MH-13-010</FOA_NUMBER><FULL_PROJECT_NUM>4R01MH099559-04</FULL_PROJECT_NUM><FUNDING_ICs>NIMH:346500\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF MENTAL HEALTH</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>LOS ANGELES</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[PHYSIOLOGY]]></ORG_DEPT><ORG_DISTRICT>33</ORG_DISTRICT><ORG_DUNS>092530369</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIVERSITY OF CALIFORNIA LOS ANGELES]]></ORG_NAME><ORG_STATE>CA</ORG_STATE><ORG_ZIPCODE>900952000</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: We will generate new tools to study the physiological properties and functional roles of calcium signals in astrocytes from regions of the brain known to be involved in mental illness such as insomnia and schizophrenia. Our data will provide new information to explore the roles of astrocytes in the normal healthy brain and in diseases of the nervous system, including the processes that lead to the development of psychiatric disorders.]]></PHR><PIS><PI><PI_NAME>KHAKH, BALJIT </PI_NAME><PI_ID>8662239</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>ASANUMA, CHIIKO </PROGRAM_OFFICER_NAME><PROJECT_START>01/15/2013</PROJECT_START><PROJECT_END>10/31/2017</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Astrocytes]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Brain]]></TERM><TERM><![CDATA[Brain Part]]></TERM><TERM><![CDATA[Brain region]]></TERM><TERM><![CDATA[Breeding]]></TERM><TERM><![CDATA[Calcium]]></TERM><TERM><![CDATA[calcium indicator]]></TERM><TERM><![CDATA[Calcium Signaling]]></TERM><TERM><![CDATA[cell body (neuron)]]></TERM><TERM><![CDATA[Cell Nucleus]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Communities]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Dependovirus]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Distal]]></TERM><TERM><![CDATA[Dynamite]]></TERM><TERM><![CDATA[Fluorescence-Activated Cell Sorting]]></TERM><TERM><![CDATA[Gene Deletion]]></TERM><TERM><![CDATA[Gene Expression Profile]]></TERM><TERM><![CDATA[Genes]]></TERM><TERM><![CDATA[Genetic]]></TERM><TERM><![CDATA[GLAST Protein]]></TERM><TERM><![CDATA[Glial Fibrillary Acidic Protein]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Heterogeneity]]></TERM><TERM><![CDATA[Image]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[innovation]]></TERM><TERM><![CDATA[interest]]></TERM><TERM><![CDATA[Knock-in Mouse]]></TERM><TERM><![CDATA[Laboratories]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[Measurement]]></TERM><TERM><![CDATA[Measures]]></TERM><TERM><![CDATA[Membrane]]></TERM><TERM><![CDATA[Mental disorders]]></TERM><TERM><![CDATA[Methods]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[Monitor]]></TERM><TERM><![CDATA[Morphology]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[nervous system disorder]]></TERM><TERM><![CDATA[Neurons]]></TERM><TERM><![CDATA[non-invasive imaging]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[Optical reporter]]></TERM><TERM><![CDATA[Optics]]></TERM><TERM><![CDATA[Peripheral]]></TERM><TERM><![CDATA[Physiological]]></TERM><TERM><![CDATA[Population]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[Promotor (Genetics)]]></TERM><TERM><![CDATA[Property]]></TERM><TERM><![CDATA[recombinase]]></TERM><TERM><![CDATA[Recording of previous events]]></TERM><TERM><![CDATA[Regulation]]></TERM><TERM><![CDATA[Reporter]]></TERM><TERM><![CDATA[Research Personnel]]></TERM><TERM><![CDATA[research study]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Schizophrenia]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[Sleep]]></TERM><TERM><![CDATA[Sleeplessness]]></TERM><TERM><![CDATA[Slice]]></TERM><TERM><![CDATA[Specific qualifier value]]></TERM><TERM><![CDATA[Structure]]></TERM><TERM><![CDATA[Tamoxifen]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Thalamic structure]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[tool]]></TERM><TERM><![CDATA[Transgenic Mice]]></TERM><TERM><![CDATA[Transgenic Organisms]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[New Optical and Genetic Tools to Study Diverse Calcium Signals in Astrocytes]]></PROJECT_TITLE><SERIAL_NUMBER>099559</SERIAL_NUMBER><STUDY_SECTION>ZMH1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>04</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>225000</DIRECT_COST_AMT><INDIRECT_COST_AMT>121500</INDIRECT_COST_AMT><TOTAL_COST>346500</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8960939</APPLICATION_ID><ACTIVITY>P01</ACTIVITY><ADMINISTERING_IC>HL</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/26/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>P01HL029582</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>PAR-13-316</FOA_NUMBER><FULL_PROJECT_NUM>5P01HL029582-32</FULL_PROJECT_NUM><FUNDING_ICs>NHLBI:120369\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL HEART, LUNG, AND BLOOD INSTITUTE</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>CLEVELAND</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>11</ORG_DISTRICT><ORG_DUNS>135781701</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[CLEVELAND CLINIC LERNER COM-CWRU]]></ORG_NAME><ORG_STATE>OH</ORG_STATE><ORG_ZIPCODE>441950001</ORG_ZIPCODE><PHR><![CDATA[Atherosclerosis and Lipoprotein Analysis Core (Core C). Project Narrative
Core C will provide services to all three projects to increase productivity. These services include providing
lipoproteins, the determination of lipoprotein cholesterol and triglyceride levels by buoyant density and size
(FPLC) fractionation, and the determination of mouse atherosclerotic lesion areas in the aortic root and
brachiocephalic artery.]]></PHR><PIS><PI><PI_NAME>SMITH, JONATHAN D</PI_NAME><PI_ID>1916685</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START></PROJECT_START><PROJECT_END></PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[abstracting]]></TERM><TERM><![CDATA[Aorta]]></TERM><TERM><![CDATA[Area]]></TERM><TERM><![CDATA[Arterial Fatty Streak]]></TERM><TERM><![CDATA[Arteries]]></TERM><TERM><![CDATA[Atherosclerosis]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Biological Assay]]></TERM><TERM><![CDATA[Cell Culture Techniques]]></TERM><TERM><![CDATA[Centrifugation]]></TERM><TERM><![CDATA[Cholesterol]]></TERM><TERM><![CDATA[Collaborations]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[density]]></TERM><TERM><![CDATA[Doctor of Philosophy]]></TERM><TERM><![CDATA[Educational process of instructing]]></TERM><TERM><![CDATA[fast protein liquid chromatography]]></TERM><TERM><![CDATA[Fractionation]]></TERM><TERM><![CDATA[High Density Lipoproteins]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[Human Resources]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[Inflammation]]></TERM><TERM><![CDATA[investigator training]]></TERM><TERM><![CDATA[Laboratories]]></TERM><TERM><![CDATA[Learning]]></TERM><TERM><![CDATA[Lesion]]></TERM><TERM><![CDATA[Link]]></TERM><TERM><![CDATA[Lipids]]></TERM><TERM><![CDATA[lipoprotein cholesterol]]></TERM><TERM><![CDATA[lipoprotein triglyceride]]></TERM><TERM><![CDATA[Lipoproteins]]></TERM><TERM><![CDATA[Measurement]]></TERM><TERM><![CDATA[Measures]]></TERM><TERM><![CDATA[Metabolism]]></TERM><TERM><![CDATA[Methods]]></TERM><TERM><![CDATA[Molecular Sieve Chromatography]]></TERM><TERM><![CDATA[mouse model]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[Plant Roots]]></TERM><TERM><![CDATA[Plasma]]></TERM><TERM><![CDATA[Precipitation]]></TERM><TERM><![CDATA[Preparation]]></TERM><TERM><![CDATA[Productivity]]></TERM><TERM><![CDATA[research study]]></TERM><TERM><![CDATA[Sampling]]></TERM><TERM><![CDATA[Services]]></TERM><TERM><![CDATA[Standardization]]></TERM><TERM><![CDATA[Surface]]></TERM><TERM><![CDATA[Tissues]]></TERM><TERM><![CDATA[training project]]></TERM><TERM><![CDATA[Triglycerides]]></TERM><TERM><![CDATA[Ultracentrifugation]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Atherosclerosis and Lipoprotein Analysis Core C]]></PROJECT_TITLE><SERIAL_NUMBER>029582</SERIAL_NUMBER><STUDY_SECTION>ZHL1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID>7863</SUBPROJECT_ID><SUPPORT_YEAR>32</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>75943</DIRECT_COST_AMT><INDIRECT_COST_AMT>44426</INDIRECT_COST_AMT><TOTAL_COST /><TOTAL_COST_SUB_PROJECT>120369</TOTAL_COST_SUB_PROJECT></row>
<row><APPLICATION_ID>8962138</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>AI</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/28/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>855</CFDA_CODE><CORE_PROJECT_NUM>R01AI072194</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>PA-13-302</FOA_NUMBER><FULL_PROJECT_NUM>5R01AI072194-07</FULL_PROJECT_NUM><FUNDING_ICs>NIAID:439750\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>NEW YORK</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>12</ORG_DISTRICT><ORG_DUNS>064931884</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[SLOAN-KETTERING INST CAN RESEARCH]]></ORG_NAME><ORG_STATE>NY</ORG_STATE><ORG_ZIPCODE>100656007</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Class switch recombination is essential for human B cells to mount an efficient immune response to invading pathogens. A failure to undergo class switching leads to immunodeficiency syndromes in humans. On the other hand, aberrant class switch recombination is directly responsible for the ontogeny of mature B cell lymphomas, the most common lymphomas in humans. Mechanistically elucidating class switch recombination, the focus of this proposal, is thus related to both human immunodeficiencies and B cell lymphomas.]]></PHR><PIS><PI><PI_NAME>CHAUDHURI, JAYANTA </PI_NAME><PI_ID>8518223</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>NASSERI, M. FARAZ </PROGRAM_OFFICER_NAME><PROJECT_START>07/01/2009</PROJECT_START><PROJECT_END>10/31/2019</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[activation-induced cytidine deaminase]]></TERM><TERM><![CDATA[Antibodies]]></TERM><TERM><![CDATA[arm]]></TERM><TERM><![CDATA[Ataxia-Telangiectasia-Mutated protein kinase]]></TERM><TERM><![CDATA[ATM function]]></TERM><TERM><![CDATA[B-Cell Lymphomas]]></TERM><TERM><![CDATA[B-Lymphocytes]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Base Excision Repairs]]></TERM><TERM><![CDATA[Binding (Molecular Function)]]></TERM><TERM><![CDATA[Biological Models]]></TERM><TERM><![CDATA[cancer type]]></TERM><TERM><![CDATA[Cell Death]]></TERM><TERM><![CDATA[cell mediated immune response]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Chromosomal translocation]]></TERM><TERM><![CDATA[constant region gene]]></TERM><TERM><![CDATA[Coupling]]></TERM><TERM><![CDATA[Cyclic AMP-Dependent Protein Kinases]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Deaminase]]></TERM><TERM><![CDATA[Deamination]]></TERM><TERM><![CDATA[Defect]]></TERM><TERM><![CDATA[density]]></TERM><TERM><![CDATA[Deoxycytidine]]></TERM><TERM><![CDATA[Deoxyuridine]]></TERM><TERM><![CDATA[DNA]]></TERM><TERM><![CDATA[DNA Damage]]></TERM><TERM><![CDATA[DNA Double Strand Break]]></TERM><TERM><![CDATA[DNA Repair]]></TERM><TERM><![CDATA[DNA Repair Pathway]]></TERM><TERM><![CDATA[Double Strand Break Repair]]></TERM><TERM><![CDATA[Elements]]></TERM><TERM><![CDATA[endodeoxyribonuclease SceI]]></TERM><TERM><![CDATA[endonuclease]]></TERM><TERM><![CDATA[Endonuclease I]]></TERM><TERM><![CDATA[Ensure]]></TERM><TERM><![CDATA[Excision]]></TERM><TERM><![CDATA[Exons]]></TERM><TERM><![CDATA[Failure (biologic function)]]></TERM><TERM><![CDATA[Feedback]]></TERM><TERM><![CDATA[G1 Phase]]></TERM><TERM><![CDATA[Generations]]></TERM><TERM><![CDATA[Genetic Recombination]]></TERM><TERM><![CDATA[Growth]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[human APEX1 protein]]></TERM><TERM><![CDATA[IgE]]></TERM><TERM><![CDATA[Immune response]]></TERM><TERM><![CDATA[Immunoglobulin A]]></TERM><TERM><![CDATA[Immunoglobulin Class Switching]]></TERM><TERM><![CDATA[Immunoglobulin Constant Region]]></TERM><TERM><![CDATA[Immunoglobulin G]]></TERM><TERM><![CDATA[Immunoglobulin M]]></TERM><TERM><![CDATA[Immunoglobulin Switch Recombination]]></TERM><TERM><![CDATA[Immunologic Deficiency Syndromes]]></TERM><TERM><![CDATA[In Vitro]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[insight]]></TERM><TERM><![CDATA[Invaded]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[Lesion]]></TERM><TERM><![CDATA[Lymphoma]]></TERM><TERM><![CDATA[Lymphomagenesis]]></TERM><TERM><![CDATA[Mature B-Lymphocyte]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[Mismatch Repair]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[mutant]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[Organism]]></TERM><TERM><![CDATA[pathogen]]></TERM><TERM><![CDATA[Pathway interactions]]></TERM><TERM><![CDATA[phosphodiester]]></TERM><TERM><![CDATA[Phosphorylation]]></TERM><TERM><![CDATA[Play]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[Proteins]]></TERM><TERM><![CDATA[Reaction]]></TERM><TERM><![CDATA[Recruitment Activity]]></TERM><TERM><![CDATA[repair enzyme]]></TERM><TERM><![CDATA[repaired]]></TERM><TERM><![CDATA[Repetitive Sequence]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[sensor]]></TERM><TERM><![CDATA[Serine]]></TERM><TERM><![CDATA[single molecule]]></TERM><TERM><![CDATA[Single-Stranded DNA]]></TERM><TERM><![CDATA[Site]]></TERM><TERM><![CDATA[System]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Uracil]]></TERM><TERM><![CDATA[uracil-DNA glycosylase]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Elucidation of Immunoglobulin Class Switch Recombination]]></PROJECT_TITLE><SERIAL_NUMBER>072194</SERIAL_NUMBER><STUDY_SECTION>CMIA</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Cellular and Molecular Immunology - A Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>07</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>250000</DIRECT_COST_AMT><INDIRECT_COST_AMT>189750</INDIRECT_COST_AMT><TOTAL_COST>439750</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8962155</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>HL</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/26/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>837</CFDA_CODE><CORE_PROJECT_NUM>R01HL077213</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-13-302</FOA_NUMBER><FULL_PROJECT_NUM>5R01HL077213-11</FULL_PROJECT_NUM><FUNDING_ICs>NHLBI:351275\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL HEART, LUNG, AND BLOOD INSTITUTE</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>CLEVELAND</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[OTHER BASIC SCIENCES]]></ORG_DEPT><ORG_DISTRICT>11</ORG_DISTRICT><ORG_DUNS>135781701</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[CLEVELAND CLINIC LERNER COM-CWRU]]></ORG_NAME><ORG_STATE>OH</ORG_STATE><ORG_ZIPCODE>441950001</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: The likelihood of thrombosis is increased in dyslipidemia. An important contributing factor is heightened platelet reactivity, i.e., a drastically increased response of platelets to agonists. We are identifying novel molecules accumulating in circulation in dyslipidemia that can promote platelet reactivity via a set of receptors that was not previously
associated with platelet function. Interaction of these receptors with novel ligands activates pathways common to the innate immunity system, and connects this signaling to the platelet activation network eventually leading to accelerated thrombosis. Our studies of these pathways will allow the identification of new approaches preventing thrombosis in dyslipidemia.]]></PHR><PIS><PI><PI_NAME>PODREZ, EUGENE A</PI_NAME><PI_ID>7840936</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>CHEN, JUE </PROGRAM_OFFICER_NAME><PROJECT_START>07/01/2004</PROJECT_START><PROJECT_END>10/31/2018</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[acute coronary syndrome]]></TERM><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[adduct]]></TERM><TERM><![CDATA[Affinity]]></TERM><TERM><![CDATA[Agonist]]></TERM><TERM><![CDATA[Amino Acids]]></TERM><TERM><![CDATA[Atherosclerosis]]></TERM><TERM><![CDATA[atherothrombosis]]></TERM><TERM><![CDATA[Blood Circulation]]></TERM><TERM><![CDATA[Blood Platelets]]></TERM><TERM><![CDATA[CD36 gene]]></TERM><TERM><![CDATA[Collaborations]]></TERM><TERM><![CDATA[Complex]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Diabetes Mellitus]]></TERM><TERM><![CDATA[Dyslipidemias]]></TERM><TERM><![CDATA[Elements]]></TERM><TERM><![CDATA[Family]]></TERM><TERM><![CDATA[Functional disorder]]></TERM><TERM><![CDATA[Generations]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Hyperlipidemia]]></TERM><TERM><![CDATA[In Vitro]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[Integrins]]></TERM><TERM><![CDATA[Investigation]]></TERM><TERM><![CDATA[Knowledge]]></TERM><TERM><![CDATA[Lecithin]]></TERM><TERM><![CDATA[Ligands]]></TERM><TERM><![CDATA[Ligation]]></TERM><TERM><![CDATA[Link]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[Metabolic syndrome]]></TERM><TERM><![CDATA[Modification]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[monocyte]]></TERM><TERM><![CDATA[Natural Immunity]]></TERM><TERM><![CDATA[neutrophil]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[novel strategies]]></TERM><TERM><![CDATA[Oxidative Stress]]></TERM><TERM><![CDATA[oxidized lipid]]></TERM><TERM><![CDATA[Pathway interactions]]></TERM><TERM><![CDATA[Pattern recognition receptor]]></TERM><TERM><![CDATA[Phosphatidylethanolamine]]></TERM><TERM><![CDATA[Phospholipase A2]]></TERM><TERM><![CDATA[Phospholipids]]></TERM><TERM><![CDATA[Platelet Activation]]></TERM><TERM><![CDATA[Play]]></TERM><TERM><![CDATA[prevent]]></TERM><TERM><![CDATA[Proteins]]></TERM><TERM><![CDATA[Publishing]]></TERM><TERM><![CDATA[receptor]]></TERM><TERM><![CDATA[Regulation]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[Risk Factors]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Rupture]]></TERM><TERM><![CDATA[scavenger receptor]]></TERM><TERM><![CDATA[sensor]]></TERM><TERM><![CDATA[Signal Pathway]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[Site]]></TERM><TERM><![CDATA[System]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Thrombosis]]></TERM><TERM><![CDATA[TLR1 gene]]></TERM><TERM><![CDATA[TLR2 gene]]></TERM><TERM><![CDATA[TLR6 gene]]></TERM><TERM><![CDATA[Toll-like receptors]]></TERM><TERM><![CDATA[TRAF6 gene]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Pathophysiological Activities of of Oxidized Phospholipids]]></PROJECT_TITLE><SERIAL_NUMBER>077213</SERIAL_NUMBER><STUDY_SECTION>AICS</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Atherosclerosis and Inflammation of the Cardiovascular System Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>11</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>221625</DIRECT_COST_AMT><INDIRECT_COST_AMT>129650</INDIRECT_COST_AMT><TOTAL_COST>351275</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8963420</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>AI</ADMINISTERING_IC><APPLICATION_TYPE>4</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/23/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>855</CFDA_CODE><CORE_PROJECT_NUM>R01AI103003</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-11-260</FOA_NUMBER><FULL_PROJECT_NUM>4R01AI103003-04</FULL_PROJECT_NUM><FUNDING_ICs>NIAID:274500\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>BURLINGTON</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[MICROBIOLOGY/IMMUN/VIROLOGY]]></ORG_DEPT><ORG_DISTRICT>00</ORG_DISTRICT><ORG_DUNS>066811191</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIVERSITY OF VERMONT & ST AGRIC COLLEGE]]></ORG_NAME><ORG_STATE>VT</ORG_STATE><ORG_ZIPCODE>054051704</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: The research proposed here is relevant to human health because bacterial detection and modulation of host immune responses is used by pathogens to cause infections, and S1P degradation represents a novel mechanism for P. aeruginosa virulence. This proposal is relevant to the NIH mission both in terms of developing fundamental knowledge about pathogens to benefit human health and because S1P degradation by bacterial pathogens may represent therapeutic targets to treat infections.]]></PHR><PIS><PI><PI_NAME>WARGO, MATTHEW J</PI_NAME><PI_ID>7879712</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>TAYLOR, CHRISTOPHER E.,</PROGRAM_OFFICER_NAME><PROJECT_START>11/15/2012</PROJECT_START><PROJECT_END>10/31/2017</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Acinetobacter]]></TERM><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[Alcaligenes]]></TERM><TERM><![CDATA[Antibiotic Resistance]]></TERM><TERM><![CDATA[antimicrobial]]></TERM><TERM><![CDATA[Area]]></TERM><TERM><![CDATA[B-Lymphocytes]]></TERM><TERM><![CDATA[Bacteria]]></TERM><TERM><![CDATA[Binding (Molecular Function)]]></TERM><TERM><![CDATA[Biological Assay]]></TERM><TERM><![CDATA[Biology]]></TERM><TERM><![CDATA[Burkholderia]]></TERM><TERM><![CDATA[care burden]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Chronic Obstructive Airway Disease]]></TERM><TERM><![CDATA[Cystic Fibrosis]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Degradation Pathway]]></TERM><TERM><![CDATA[Detection]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[DNA Binding]]></TERM><TERM><![CDATA[Enzymes]]></TERM><TERM><![CDATA[Escherichia coli]]></TERM><TERM><![CDATA[fitness]]></TERM><TERM><![CDATA[Gene Expression]]></TERM><TERM><![CDATA[Gene Expression Regulation]]></TERM><TERM><![CDATA[Genes]]></TERM><TERM><![CDATA[Genetic Screening]]></TERM><TERM><![CDATA[Genetic Transcription]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Healthcare]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[Immune]]></TERM><TERM><![CDATA[Immune response]]></TERM><TERM><![CDATA[Immune system]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[In Vitro]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[Infection]]></TERM><TERM><![CDATA[Inflammatory]]></TERM><TERM><![CDATA[innovation]]></TERM><TERM><![CDATA[insight]]></TERM><TERM><![CDATA[interest]]></TERM><TERM><![CDATA[Knowledge]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[Life]]></TERM><TERM><![CDATA[Ligand Binding]]></TERM><TERM><![CDATA[Ligands]]></TERM><TERM><![CDATA[Link]]></TERM><TERM><![CDATA[Lung]]></TERM><TERM><![CDATA[macrophage]]></TERM><TERM><![CDATA[Maps]]></TERM><TERM><![CDATA[Mechanical ventilation]]></TERM><TERM><![CDATA[Metabolic]]></TERM><TERM><![CDATA[Metabolic Pathway]]></TERM><TERM><![CDATA[Metabolism]]></TERM><TERM><![CDATA[Microarray Analysis]]></TERM><TERM><![CDATA[migration]]></TERM><TERM><![CDATA[Mission]]></TERM><TERM><![CDATA[mouse model]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[mutant]]></TERM><TERM><![CDATA[Mycobacterium tuberculosis]]></TERM><TERM><![CDATA[new therapeutic target]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[novel therapeutics]]></TERM><TERM><![CDATA[pathogen]]></TERM><TERM><![CDATA[Pathogenesis]]></TERM><TERM><![CDATA[Pathway interactions]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Phosphoric Monoester Hydrolases]]></TERM><TERM><![CDATA[Physiological]]></TERM><TERM><![CDATA[Play]]></TERM><TERM><![CDATA[Promotor (Genetics)]]></TERM><TERM><![CDATA[Pseudomonas]]></TERM><TERM><![CDATA[Pseudomonas aeruginosa]]></TERM><TERM><![CDATA[Regulation]]></TERM><TERM><![CDATA[Regulon]]></TERM><TERM><![CDATA[Reporter]]></TERM><TERM><![CDATA[Reporting]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[screening]]></TERM><TERM><![CDATA[Signal Pathway]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[Signaling Molecule]]></TERM><TERM><![CDATA[Specificity]]></TERM><TERM><![CDATA[Sphingolipids]]></TERM><TERM><![CDATA[Sphingosine]]></TERM><TERM><![CDATA[sphingosine 1-phosphate]]></TERM><TERM><![CDATA[sphingosine-1-phosphate phosphatase]]></TERM><TERM><![CDATA[Stenotrophomonas maltophilia]]></TERM><TERM><![CDATA[Surveys]]></TERM><TERM><![CDATA[System]]></TERM><TERM><![CDATA[T-Cell Activation]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Therapeutic Agents]]></TERM><TERM><![CDATA[therapeutic target]]></TERM><TERM><![CDATA[Tight Junctions]]></TERM><TERM><![CDATA[transcription factor]]></TERM><TERM><![CDATA[United States National Institutes of Health]]></TERM><TERM><![CDATA[Virulence]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Pseudomonas detection and metabolism of sphingosine]]></PROJECT_TITLE><SERIAL_NUMBER>103003</SERIAL_NUMBER><STUDY_SECTION>BACP</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Bacterial Pathogenesis Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>04</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>180000</DIRECT_COST_AMT><INDIRECT_COST_AMT>94500</INDIRECT_COST_AMT><TOTAL_COST>274500</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8963477</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>HL</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/29/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>837</CFDA_CODE><CORE_PROJECT_NUM>R01HL123061</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-13-302</FOA_NUMBER><FULL_PROJECT_NUM>5R01HL123061-02</FULL_PROJECT_NUM><FUNDING_ICs>NHLBI:498373\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL HEART, LUNG, AND BLOOD INSTITUTE</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>NEW YORK</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[PHARMACOLOGY]]></ORG_DEPT><ORG_DISTRICT>13</ORG_DISTRICT><ORG_DUNS>621889815</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[COLUMBIA UNIVERSITY HEALTH SCIENCES]]></ORG_NAME><ORG_STATE>NY</ORG_STATE><ORG_ZIPCODE>100320049</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Protein kinase C-delta (PKCd) is a signaling enzyme that has been implicated in both ischemia/reperfusion injury and pathways that contribute to ischemic preconditioning and cardiomyocyte survival. This application focuses on a revised model of PKCd activation that allows for agonist-specific PKCd signaling 'modes' that link to functionally distinct cellular responses. The proposed studies examine the role of novel molecular determinants on PKCd that specify its cellular actions and represent targets for the design of small-molecule inhibitors tailored to abrogate PKCd-dependent pathological cardiac remodeling.]]></PHR><PIS><PI><PI_NAME>STEINBERG, SUSAN F</PI_NAME><PI_ID>1879518</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>ADHIKARI, BISHOW B.</PROGRAM_OFFICER_NAME><PROJECT_START>11/15/2014</PROJECT_START><PROJECT_END>10/31/2018</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[1,2-diacylglycerol]]></TERM><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[Agonist]]></TERM><TERM><![CDATA[Alleles]]></TERM><TERM><![CDATA[analog]]></TERM><TERM><![CDATA[Apoptosis]]></TERM><TERM><![CDATA[Binding (Molecular Function)]]></TERM><TERM><![CDATA[Biochemical]]></TERM><TERM><![CDATA[C2 Domain]]></TERM><TERM><![CDATA[Cardiac]]></TERM><TERM><![CDATA[Cardiac Myocytes]]></TERM><TERM><![CDATA[Catalytic Domain]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[cofactor]]></TERM><TERM><![CDATA[Collaborations]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[Diglycerides]]></TERM><TERM><![CDATA[Docking]]></TERM><TERM><![CDATA[Engineering]]></TERM><TERM><![CDATA[Enzymatic Biochemistry]]></TERM><TERM><![CDATA[Enzymes]]></TERM><TERM><![CDATA[Figs - dietary]]></TERM><TERM><![CDATA[G Protein-Coupled Receptor Signaling]]></TERM><TERM><![CDATA[G-Protein-Coupled Receptors]]></TERM><TERM><![CDATA[Gene Silencing]]></TERM><TERM><![CDATA[genetic regulatory protein]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Growth]]></TERM><TERM><![CDATA[Growth Factor]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Heart]]></TERM><TERM><![CDATA[Heart Hypertrophy]]></TERM><TERM><![CDATA[In Vitro]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[inhibitor/antagonist]]></TERM><TERM><![CDATA[Injury]]></TERM><TERM><![CDATA[innovation]]></TERM><TERM><![CDATA[Interphase Cell]]></TERM><TERM><![CDATA[Ischemic Preconditioning]]></TERM><TERM><![CDATA[Laboratories]]></TERM><TERM><![CDATA[Link]]></TERM><TERM><![CDATA[Lipids]]></TERM><TERM><![CDATA[Membrane]]></TERM><TERM><![CDATA[Membrane Lipids]]></TERM><TERM><![CDATA[Microfilaments]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[Molecular Conformation]]></TERM><TERM><![CDATA[mouse model]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[mutant]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[overexpression]]></TERM><TERM><![CDATA[Oxidation-Reduction]]></TERM><TERM><![CDATA[Oxidative Stress]]></TERM><TERM><![CDATA[Pathogenesis]]></TERM><TERM><![CDATA[Pathologic]]></TERM><TERM><![CDATA[Pathway interactions]]></TERM><TERM><![CDATA[Phosphorylation]]></TERM><TERM><![CDATA[Phosphorylation Site]]></TERM><TERM><![CDATA[Phosphotransferases]]></TERM><TERM><![CDATA[Play]]></TERM><TERM><![CDATA[Post-Translational Protein Processing]]></TERM><TERM><![CDATA[preference]]></TERM><TERM><![CDATA[prevent]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[Property]]></TERM><TERM><![CDATA[Protein Dephosphorylation]]></TERM><TERM><![CDATA[Protein Kinase C]]></TERM><TERM><![CDATA[protein kinase C-delta]]></TERM><TERM><![CDATA[Proteins]]></TERM><TERM><![CDATA[Publishing]]></TERM><TERM><![CDATA[Recruitment Activity]]></TERM><TERM><![CDATA[Reperfusion Injury]]></TERM><TERM><![CDATA[Resources]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[response to injury]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Signal Pathway]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[Site]]></TERM><TERM><![CDATA[skills]]></TERM><TERM><![CDATA[small molecule]]></TERM><TERM><![CDATA[Specific qualifier value]]></TERM><TERM><![CDATA[Specificity]]></TERM><TERM><![CDATA[Stimulus]]></TERM><TERM><![CDATA[Structure]]></TERM><TERM><![CDATA[Translating]]></TERM><TERM><![CDATA[Troponin I]]></TERM><TERM><![CDATA[Troponin T]]></TERM><TERM><![CDATA[Ventricular Remodeling]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Distinct Protein Kinase C-Delta Signaling Modes in Cardiomyocytes]]></PROJECT_TITLE><SERIAL_NUMBER>123061</SERIAL_NUMBER><STUDY_SECTION>MIM</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Myocardial Ischemia and Metabolism Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>376873</DIRECT_COST_AMT><INDIRECT_COST_AMT>121500</INDIRECT_COST_AMT><TOTAL_COST>498373</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8966694</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>HL</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/26/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>837</CFDA_CODE><CORE_PROJECT_NUM>R01HL121697</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>PA-13-302</FOA_NUMBER><FULL_PROJECT_NUM>5R01HL121697-02</FULL_PROJECT_NUM><FUNDING_ICs>NHLBI:429706\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL HEART, LUNG, AND BLOOD INSTITUTE</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>LA JOLLA</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>52</ORG_DISTRICT><ORG_DUNS>603880287</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[LA JOLLA INST FOR ALLERGY & IMMUNOLGY]]></ORG_NAME><ORG_STATE>CA</ORG_STATE><ORG_ZIPCODE>920371387</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: The consequences of stroke, heart and peripheral artery disease account for about 32% of all deaths in the US. The underlying disease process, atherosclerosis, is driven by fat deposits and inflammation in the wall of blood vessels (arteries) We found five short peptide sequences derived from the main protein in low density lipoprotein (the bad cholesterol) that protects mice from atherosclerosis when given as a vaccine. The proposed research is designed to find out how this protection works: we think the vaccination induces a type of white blood cells called regulatory T cells to make interleukin-10, an anti-inflammatory mediator of the immune system. We also propose to optimize the vaccination. We found that peptides that protect mice from atherosclerosis, but not others, bind very well to a key
molecule of the immune system called MHC-II. Using this knowledge, we discovered 30 human peptides that can potentially be developed as a vaccine to protect people from atherosclerosis. At least one of these peptides will be thoroughly tested in mice for safety and efficacy. When this work is completed, we will know how our atherosclerosis vaccine protects mice and whether a candidate peptide for a vaccine to protect humans from atherosclerosis is effective in mice.]]></PHR><PIS><PI><PI_NAME>LEY, KLAUS F.</PI_NAME><PI_ID>1881151</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>HASAN, AHMED A.K.</PROGRAM_OFFICER_NAME><PROJECT_START>11/15/2014</PROJECT_START><PROJECT_END>10/31/2018</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Accounting]]></TERM><TERM><![CDATA[adaptive immunity]]></TERM><TERM><![CDATA[Adjuvant]]></TERM><TERM><![CDATA[Adverse effects]]></TERM><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[Affinity]]></TERM><TERM><![CDATA[Alleles]]></TERM><TERM><![CDATA[Animal Model]]></TERM><TERM><![CDATA[Anti-inflammatory]]></TERM><TERM><![CDATA[Anti-Inflammatory Agents]]></TERM><TERM><![CDATA[Antibodies]]></TERM><TERM><![CDATA[Antigen-Presenting Cells]]></TERM><TERM><![CDATA[Antigens]]></TERM><TERM><![CDATA[Aorta]]></TERM><TERM><![CDATA[Apolipoprotein E]]></TERM><TERM><![CDATA[Apolipoproteins]]></TERM><TERM><![CDATA[Apolipoproteins B]]></TERM><TERM><![CDATA[Arterial Fatty Streak]]></TERM><TERM><![CDATA[Arteries]]></TERM><TERM><![CDATA[atheroprotective]]></TERM><TERM><![CDATA[Atherosclerosis]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Binding (Molecular Function)]]></TERM><TERM><![CDATA[Biological Assay]]></TERM><TERM><![CDATA[Biological Markers]]></TERM><TERM><![CDATA[Blood Vessels]]></TERM><TERM><![CDATA[Bovine Serum Albumin]]></TERM><TERM><![CDATA[C57BL/6 Mouse]]></TERM><TERM><![CDATA[Cardiovascular system]]></TERM><TERM><![CDATA[CD4 Positive T Lymphocytes]]></TERM><TERM><![CDATA[Cell surface]]></TERM><TERM><![CDATA[cell type]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Centers for Disease Control and Prevention (U.S.)]]></TERM><TERM><![CDATA[Cessation of life]]></TERM><TERM><![CDATA[chemokine]]></TERM><TERM><![CDATA[Cholesterol]]></TERM><TERM><![CDATA[Chronic]]></TERM><TERM><![CDATA[Core Protein]]></TERM><TERM><![CDATA[cytokine]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Dendritic Cells]]></TERM><TERM><![CDATA[Deposition]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Dose]]></TERM><TERM><![CDATA[Epitopes]]></TERM><TERM><![CDATA[Evaluation]]></TERM><TERM><![CDATA[Event]]></TERM><TERM><![CDATA[experience]]></TERM><TERM><![CDATA[Face]]></TERM><TERM><![CDATA[Fatty acid glycerol esters]]></TERM><TERM><![CDATA[Foundations]]></TERM><TERM><![CDATA[Frequencies (time pattern)]]></TERM><TERM><![CDATA[Government]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Health Benefit]]></TERM><TERM><![CDATA[Heart]]></TERM><TERM><![CDATA[HLA-DR Antigens]]></TERM><TERM><![CDATA[HLA-DRB1]]></TERM><TERM><![CDATA[Homing]]></TERM><TERM><![CDATA[Host Defense]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[hypercholesterolemia]]></TERM><TERM><![CDATA[Hypersensitivity]]></TERM><TERM><![CDATA[Image]]></TERM><TERM><![CDATA[Immune]]></TERM><TERM><![CDATA[Immune system]]></TERM><TERM><![CDATA[Immunization]]></TERM><TERM><![CDATA[Immunology]]></TERM><TERM><![CDATA[In Vitro]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[Inflammation]]></TERM><TERM><![CDATA[Inflammation Mediators]]></TERM><TERM><![CDATA[Inflammatory]]></TERM><TERM><![CDATA[Institutes]]></TERM><TERM><![CDATA[Interleukin-10]]></TERM><TERM><![CDATA[Knockout Mice]]></TERM><TERM><![CDATA[Knowledge]]></TERM><TERM><![CDATA[LDL Cholesterol Lipoproteins]]></TERM><TERM><![CDATA[Lesion]]></TERM><TERM><![CDATA[Leukocytes]]></TERM><TERM><![CDATA[Life]]></TERM><TERM><![CDATA[Low-Density Lipoproteins]]></TERM><TERM><![CDATA[macrophage]]></TERM><TERM><![CDATA[Maintenance]]></TERM><TERM><![CDATA[Major Histocompatibility Complex]]></TERM><TERM><![CDATA[mouse model]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[Oils]]></TERM><TERM><![CDATA[oxidized low density lipoprotein]]></TERM><TERM><![CDATA[Peptides]]></TERM><TERM><![CDATA[Peripheral arterial disease]]></TERM><TERM><![CDATA[Persons]]></TERM><TERM><![CDATA[Phenotype]]></TERM><TERM><![CDATA[prevent]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[Production]]></TERM><TERM><![CDATA[Proliferating]]></TERM><TERM><![CDATA[protein aminoacid sequence]]></TERM><TERM><![CDATA[Proteins]]></TERM><TERM><![CDATA[public health medicine (field)]]></TERM><TERM><![CDATA[Publishing]]></TERM><TERM><![CDATA[receptor]]></TERM><TERM><![CDATA[Regimen]]></TERM><TERM><![CDATA[Regulatory T-Lymphocyte]]></TERM><TERM><![CDATA[Reporter]]></TERM><TERM><![CDATA[Reporting]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[research study]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Safety]]></TERM><TERM><![CDATA[screening]]></TERM><TERM><![CDATA[Staining method]]></TERM><TERM><![CDATA[Stains]]></TERM><TERM><![CDATA[stroke]]></TERM><TERM><![CDATA[T-Lymphocyte]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Th1 Cells]]></TERM><TERM><![CDATA[Transgenic Mice]]></TERM><TERM><![CDATA[Translating]]></TERM><TERM><![CDATA[Vaccinated]]></TERM><TERM><![CDATA[Vaccination]]></TERM><TERM><![CDATA[vaccination strategy]]></TERM><TERM><![CDATA[Vaccines]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Vaccination with MHC-II restricted ApoB100 peptides to prevent atherosclerosis]]></PROJECT_TITLE><SERIAL_NUMBER>121697</SERIAL_NUMBER><STUDY_SECTION>AICS</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Atherosclerosis and Inflammation of the Cardiovascular System Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>259055</DIRECT_COST_AMT><INDIRECT_COST_AMT>170651</INDIRECT_COST_AMT><TOTAL_COST>429706</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8966698</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>MH</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/26/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>242</CFDA_CODE><CORE_PROJECT_NUM>R01MH080046</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-13-302</FOA_NUMBER><FULL_PROJECT_NUM>5R01MH080046-09</FULL_PROJECT_NUM><FUNDING_ICs>NIMH:384670\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF MENTAL HEALTH</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>BALTIMORE</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[PHYSIOLOGY]]></ORG_DEPT><ORG_DISTRICT>07</ORG_DISTRICT><ORG_DUNS>188435911</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIVERSITY OF MARYLAND BALTIMORE]]></ORG_NAME><ORG_STATE>MD</ORG_STATE><ORG_ZIPCODE>212011508</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: New experiences are encoded in brain circuits by altering the performance of the synaptic connections between neurons. This project aims to assess previously unexplored features of synapses that may allow their performance to be adjusted in heretofore unexpected ways, and will thus help understand the biological basis of memory formation. Further, because mental illness frequently arises from aberrant synapse function, these experiments will help determine the origin and potential treatments for diseases including schizophrenia and autism.]]></PHR><PIS><PI><PI_NAME>BLANPIED, THOMAS A</PI_NAME><PI_ID>1885680</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>ASANUMA, CHIIKO </PROGRAM_OFFICER_NAME><PROJECT_START>04/05/2007</PROJECT_START><PROJECT_END>10/31/2019</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Actins]]></TERM><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[Adhesions]]></TERM><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[AMPA Receptors]]></TERM><TERM><![CDATA[Architecture]]></TERM><TERM><![CDATA[autism spectrum disorder]]></TERM><TERM><![CDATA[Autistic Disorder]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Biological]]></TERM><TERM><![CDATA[Biological Assay]]></TERM><TERM><![CDATA[Biology]]></TERM><TERM><![CDATA[Brain]]></TERM><TERM><![CDATA[Caliber]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Color]]></TERM><TERM><![CDATA[Cytoskeletal Proteins]]></TERM><TERM><![CDATA[Cytoskeleton]]></TERM><TERM><![CDATA[density]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Electrophysiology (science)]]></TERM><TERM><![CDATA[Elements]]></TERM><TERM><![CDATA[Excitatory Synapse]]></TERM><TERM><![CDATA[experience]]></TERM><TERM><![CDATA[Failure (biologic function)]]></TERM><TERM><![CDATA[Family]]></TERM><TERM><![CDATA[follow-up]]></TERM><TERM><![CDATA[Foundations]]></TERM><TERM><![CDATA[Funding]]></TERM><TERM><![CDATA[Glutamates]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Grant]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Heart]]></TERM><TERM><![CDATA[Hippocampus (Brain)]]></TERM><TERM><![CDATA[human disease]]></TERM><TERM><![CDATA[Image]]></TERM><TERM><![CDATA[Lateral]]></TERM><TERM><![CDATA[Learning]]></TERM><TERM><![CDATA[Life]]></TERM><TERM><![CDATA[Link]]></TERM><TERM><![CDATA[Location]]></TERM><TERM><![CDATA[Maps]]></TERM><TERM><![CDATA[Measurement]]></TERM><TERM><![CDATA[Measures]]></TERM><TERM><![CDATA[Membrane]]></TERM><TERM><![CDATA[Memory]]></TERM><TERM><![CDATA[Mental disorders]]></TERM><TERM><![CDATA[Methods]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[Monitor]]></TERM><TERM><![CDATA[N-Methyl-D-Aspartate Receptors]]></TERM><TERM><![CDATA[nanoscale]]></TERM><TERM><![CDATA[Nanostructures]]></TERM><TERM><![CDATA[neural circuit]]></TERM><TERM><![CDATA[neurodevelopment]]></TERM><TERM><![CDATA[Neuronal Plasticity]]></TERM><TERM><![CDATA[Neurons]]></TERM><TERM><![CDATA[Neurosciences]]></TERM><TERM><![CDATA[Neurotransmitter Receptor]]></TERM><TERM><![CDATA[neurotransmitter release]]></TERM><TERM><![CDATA[Obsessive-Compulsive Disorder]]></TERM><TERM><![CDATA[Optics]]></TERM><TERM><![CDATA[patch clamp]]></TERM><TERM><![CDATA[Performance]]></TERM><TERM><![CDATA[Physiology]]></TERM><TERM><![CDATA[postsynaptic]]></TERM><TERM><![CDATA[postsynaptic density protein]]></TERM><TERM><![CDATA[presynaptic]]></TERM><TERM><![CDATA[presynaptic density protein 95]]></TERM><TERM><![CDATA[Presynaptic Terminals]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[Protein Binding]]></TERM><TERM><![CDATA[protein distribution]]></TERM><TERM><![CDATA[Protein Family]]></TERM><TERM><![CDATA[Protein Isoforms]]></TERM><TERM><![CDATA[Proteins]]></TERM><TERM><![CDATA[Publishing]]></TERM><TERM><![CDATA[Rattus]]></TERM><TERM><![CDATA[Reading]]></TERM><TERM><![CDATA[receptor]]></TERM><TERM><![CDATA[Receptor Activation]]></TERM><TERM><![CDATA[research study]]></TERM><TERM><![CDATA[Resolution]]></TERM><TERM><![CDATA[RNA Splicing]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[scaffold]]></TERM><TERM><![CDATA[Scaffolding Protein]]></TERM><TERM><![CDATA[Schizophrenia]]></TERM><TERM><![CDATA[Shapes]]></TERM><TERM><![CDATA[Signal Pathway]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[Signaling Protein]]></TERM><TERM><![CDATA[single molecule]]></TERM><TERM><![CDATA[Site]]></TERM><TERM><![CDATA[Stretching]]></TERM><TERM><![CDATA[Structure]]></TERM><TERM><![CDATA[Synapses]]></TERM><TERM><![CDATA[synaptic function]]></TERM><TERM><![CDATA[Synaptic plasticity]]></TERM><TERM><![CDATA[Synaptic Transmission]]></TERM><TERM><![CDATA[Tertiary Protein Structure]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[theories]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[tool]]></TERM><TERM><![CDATA[transmission process]]></TERM><TERM><![CDATA[Use of New Techniques]]></TERM><TERM><![CDATA[Vertebral column]]></TERM><TERM><![CDATA[Vesicle]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Internal Dynamics of the Postsynaptic Density]]></PROJECT_TITLE><SERIAL_NUMBER>080046</SERIAL_NUMBER><STUDY_SECTION>SYN</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Synapses, Cytoskeleton and Trafficking Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>09</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>250600</DIRECT_COST_AMT><INDIRECT_COST_AMT>134070</INDIRECT_COST_AMT><TOTAL_COST>384670</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8974858</APPLICATION_ID><ACTIVITY>R21</ACTIVITY><ADMINISTERING_IC>MH</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/02/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>242</CFDA_CODE><CORE_PROJECT_NUM>R21MH105574</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PAR-11-177</FOA_NUMBER><FULL_PROJECT_NUM>5R21MH105574-02</FULL_PROJECT_NUM><FUNDING_ICs>NIMH:202512\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF MENTAL HEALTH</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>CHAPEL HILL</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[PSYCHIATRY]]></ORG_DEPT><ORG_DISTRICT>04</ORG_DISTRICT><ORG_DUNS>608195277</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIV OF NORTH CAROLINA CHAPEL HILL]]></ORG_NAME><ORG_STATE>NC</ORG_STATE><ORG_ZIPCODE>275990001</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: The proposed research is relevant to public health since the development of a non-invasive, non- pharmacological treatment for medication-refractory auditory hallucinations in patients with schizophrenia addresses a dire need of mental health care. Thus, the proposed research is relevant to the NIMH's mission to develop new and better treatment interventions.]]></PHR><PIS><PI><PI_NAME>FROHLICH, FLAVIO  (contact)</PI_NAME><PI_ID>10450045 (contact)</PI_ID></PI><PI><PI_NAME>JARSKOG, LARS FREDRIK</PI_NAME><PI_ID>1900710</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>MORRIS, SARAH E</PROGRAM_OFFICER_NAME><PROJECT_START>12/01/2014</PROJECT_START><PROJECT_END>10/31/2016</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[Area]]></TERM><TERM><![CDATA[Auditory Hallucination]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Biological Assay]]></TERM><TERM><![CDATA[Biological Markers]]></TERM><TERM><![CDATA[Brain]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[Clinical Trials]]></TERM><TERM><![CDATA[Controlled Clinical Trials]]></TERM><TERM><![CDATA[Cortical Synchronization]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Dose]]></TERM><TERM><![CDATA[Double-Blind Method]]></TERM><TERM><![CDATA[effective therapy]]></TERM><TERM><![CDATA[Effectiveness]]></TERM><TERM><![CDATA[Electroencephalogram]]></TERM><TERM><![CDATA[Electroencephalography]]></TERM><TERM><![CDATA[Entropy]]></TERM><TERM><![CDATA[Etiology]]></TERM><TERM><![CDATA[Exhibits]]></TERM><TERM><![CDATA[follow-up]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Healthcare]]></TERM><TERM><![CDATA[Hyperactive behavior]]></TERM><TERM><![CDATA[Impairment]]></TERM><TERM><![CDATA[Intervention]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[Maintenance]]></TERM><TERM><![CDATA[Measures]]></TERM><TERM><![CDATA[Mental Health]]></TERM><TERM><![CDATA[Mission]]></TERM><TERM><![CDATA[Modality]]></TERM><TERM><![CDATA[Neurobehavioral Manifestations]]></TERM><TERM><![CDATA[Neurons]]></TERM><TERM><![CDATA[North Carolina]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[Outpatients]]></TERM><TERM><![CDATA[Parietal]]></TERM><TERM><![CDATA[Pathology]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Pharmaceutical Preparations]]></TERM><TERM><![CDATA[Pharmacological Treatment]]></TERM><TERM><![CDATA[Phase]]></TERM><TERM><![CDATA[Placebo Control]]></TERM><TERM><![CDATA[Placebos]]></TERM><TERM><![CDATA[Predictive Value]]></TERM><TERM><![CDATA[primary outcome]]></TERM><TERM><![CDATA[public health medicine (field)]]></TERM><TERM><![CDATA[Quality of life]]></TERM><TERM><![CDATA[Randomized]]></TERM><TERM><![CDATA[Refractory]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Resistance]]></TERM><TERM><![CDATA[Rest]]></TERM><TERM><![CDATA[Schizophrenia]]></TERM><TERM><![CDATA[secondary outcome]]></TERM><TERM><![CDATA[success]]></TERM><TERM><![CDATA[Symptoms]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[treatment duration]]></TERM><TERM><![CDATA[Treatment outcome]]></TERM><TERM><![CDATA[Universities]]></TERM><TERM><![CDATA[Visit]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Targeting Auditory Hallucinations with Alternating Current Stimulation]]></PROJECT_TITLE><SERIAL_NUMBER>105574</SERIAL_NUMBER><STUDY_SECTION>ZMH1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>133232</DIRECT_COST_AMT><INDIRECT_COST_AMT>69280</INDIRECT_COST_AMT><TOTAL_COST>202512</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8977501</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>DA</ADMINISTERING_IC><APPLICATION_TYPE>4</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/04/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>279</CFDA_CODE><CORE_PROJECT_NUM>R01DA031299</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>PAS-08-186</FOA_NUMBER><FULL_PROJECT_NUM>4R01DA031299-05</FULL_PROJECT_NUM><FUNDING_ICs>NIDA:384874\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE ON DRUG ABUSE</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>Belmont</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>05</ORG_DISTRICT><ORG_DUNS>046514535</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[MCLEAN HOSPITAL]]></ORG_NAME><ORG_STATE>MA</ORG_STATE><ORG_ZIPCODE>02478</ORG_ZIPCODE><PHR><![CDATA[There is a clear medical need for new candidate medications to manage the Increasing dual heroin/cocaine ('speedball') abuse and addiction poses a grave public health problem for which no effective medications exist. Previous findings indicate that 2-adrenergic agonists can attenuate addiction-related effects of, separately, heroin and cocaine. We will address this public health problem of dual heroin/cocaine abuse and addiction by evaluating 2 adrenergic agonists as candidate pharmacotherapeutics to counteract 'speedball' abuse and aid in relapse prevention.]]></PHR><PIS><PI><PI_NAME>BERGMAN, JACK  (contact)</PI_NAME><PI_ID>1877433 (contact)</PI_ID></PI><PI><PI_NAME>SPEALMAN, ROGER D</PI_NAME><PI_ID>1863826</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>LYNCH, MINDA </PROGRAM_OFFICER_NAME><PROJECT_START>07/01/2011</PROJECT_START><PROJECT_END>10/31/2016</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Abstinence]]></TERM><TERM><![CDATA[Acute]]></TERM><TERM><![CDATA[addiction]]></TERM><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[adrenergic]]></TERM><TERM><![CDATA[Adrenergic Agents]]></TERM><TERM><![CDATA[Adrenergic Agonists]]></TERM><TERM><![CDATA[Adrenergic Receptor]]></TERM><TERM><![CDATA[Adverse effects]]></TERM><TERM><![CDATA[Agonist]]></TERM><TERM><![CDATA[Attenuated]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Behavior]]></TERM><TERM><![CDATA[Chronic]]></TERM><TERM><![CDATA[Clonidine]]></TERM><TERM><![CDATA[Cocaine]]></TERM><TERM><![CDATA[Cocaine Abuse]]></TERM><TERM><![CDATA[Cocaine Dependences]]></TERM><TERM><![CDATA[Cues]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[disorder later incidence prevention]]></TERM><TERM><![CDATA[Distress]]></TERM><TERM><![CDATA[Dose]]></TERM><TERM><![CDATA[drug abstinence]]></TERM><TERM><![CDATA[Drug Addiction]]></TERM><TERM><![CDATA[Drug Combinations]]></TERM><TERM><![CDATA[drug discrimination]]></TERM><TERM><![CDATA[Drug Metabolic Detoxication]]></TERM><TERM><![CDATA[drug seeking behavior]]></TERM><TERM><![CDATA[Drug usage]]></TERM><TERM><![CDATA[effective therapy]]></TERM><TERM><![CDATA[Event]]></TERM><TERM><![CDATA[Exhibits]]></TERM><TERM><![CDATA[expectation]]></TERM><TERM><![CDATA[Exposure to]]></TERM><TERM><![CDATA[FDA approved]]></TERM><TERM><![CDATA[Food]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Heroin]]></TERM><TERM><![CDATA[Heroin Abuse]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[Injection of therapeutic agent]]></TERM><TERM><![CDATA[Intake]]></TERM><TERM><![CDATA[Investigation]]></TERM><TERM><![CDATA[Laboratories]]></TERM><TERM><![CDATA[Laboratory Animals]]></TERM><TERM><![CDATA[Ligands]]></TERM><TERM><![CDATA[lofexidine]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[Medical]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Monkeys]]></TERM><TERM><![CDATA[nonhuman primate]]></TERM><TERM><![CDATA[noradrenergic]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[Observational Study]]></TERM><TERM><![CDATA[Opiates]]></TERM><TERM><![CDATA[Opioid]]></TERM><TERM><![CDATA[opioid abuse]]></TERM><TERM><![CDATA[Pharmaceutical Preparations]]></TERM><TERM><![CDATA[Pharmacotherapy]]></TERM><TERM><![CDATA[Play]]></TERM><TERM><![CDATA[pre-clinical]]></TERM><TERM><![CDATA[prevent]]></TERM><TERM><![CDATA[Procedures]]></TERM><TERM><![CDATA[Psychological reinforcement]]></TERM><TERM><![CDATA[public health medicine (field)]]></TERM><TERM><![CDATA[Recording of previous events]]></TERM><TERM><![CDATA[Regimen]]></TERM><TERM><![CDATA[Relapse]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Research Design]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Schedule]]></TERM><TERM><![CDATA[Sedation procedure]]></TERM><TERM><![CDATA[sedative]]></TERM><TERM><![CDATA[Self Administration]]></TERM><TERM><![CDATA[Self-Administered]]></TERM><TERM><![CDATA[Series]]></TERM><TERM><![CDATA[Signs and Symptoms]]></TERM><TERM><![CDATA[Stimulus]]></TERM><TERM><![CDATA[Stress]]></TERM><TERM><![CDATA[Stressful Event]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Treatment Protocols]]></TERM><TERM><![CDATA[treatment strategy]]></TERM><TERM><![CDATA[visual stimulus]]></TERM><TERM><![CDATA[Withdrawal]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Alpha Adrenergic Pharmacotherapy for Polydrug (Stimulant/Opiate) Abuse]]></PROJECT_TITLE><SERIAL_NUMBER>031299</SERIAL_NUMBER><STUDY_SECTION>BRLE</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Biobehavioral Regulation, Learning and Ethology Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>05</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>314686</DIRECT_COST_AMT><INDIRECT_COST_AMT>70188</INDIRECT_COST_AMT><TOTAL_COST>384874</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8978240</APPLICATION_ID><ACTIVITY>F32</ACTIVITY><ADMINISTERING_IC>GM</ADMINISTERING_IC><APPLICATION_TYPE>1</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>09/01/2015</AWARD_NOTICE_DATE><BUDGET_START>09/09/2015</BUDGET_START><BUDGET_END>09/08/2016</BUDGET_END><CFDA_CODE>859</CFDA_CODE><CORE_PROJECT_NUM>F32GM116402</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF ARTS AND SCIENCES]]></ED_INST_TYPE><FOA_NUMBER>PA-14-149</FOA_NUMBER><FULL_PROJECT_NUM>1F32GM116402-01</FULL_PROJECT_NUM><FUNDING_ICs>NIGMS:50690\</FUNDING_ICs><FUNDING_MECHANISM>TRAINING, INDIVIDUAL</FUNDING_MECHANISM><FY>2015</FY><IC_NAME>NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES</IC_NAME><NIH_SPENDING_CATS><CATEGORY><![CDATA[Bioengineering]]></CATEGORY><CATEGORY><![CDATA[Neurosciences]]></CATEGORY><CATEGORY><![CDATA[Pain Research]]></CATEGORY></NIH_SPENDING_CATS><ORG_CITY>STANFORD</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[CHEMISTRY]]></ORG_DEPT><ORG_DISTRICT>18</ORG_DISTRICT><ORG_DUNS>009214214</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[STANFORD UNIVERSITY]]></ORG_NAME><ORG_STATE>CA</ORG_STATE><ORG_ZIPCODE>943041222</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Voltage-gated sodium ion channels are integral to life, being responsible for both neuronal and muscular signaling, and yet, the dynamic function of these proteins remains poorly understood. This proposal outlines a research plan in the fields of organic chemistry and chemical biology designed to explore the ion conduction pore of the mammalian voltage-gated sodium ion channel using synthetic probe molecules related to the known voltage-gated sodium ion channel activating natural product veratridine. Testing of these probes with wild-type and single amino acid mutations of voltage-gated sodium ion channels will reveal intimate details of the channel architecture that enable mechanical coupling between the ion pore and voltage-sensing domains, thus adding to our fundamental understanding of how voltage-gated ion channel proteins function.   
      

]]></PHR><PIS><PI><PI_NAME>CRAIG, ROBERT A</PI_NAME><PI_ID>11338919</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>BARSKI, OLEG </PROGRAM_OFFICER_NAME><PROJECT_START>09/09/2015</PROJECT_START><PROJECT_END>09/08/2018</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Acute Pain]]></TERM><TERM><![CDATA[Affinity]]></TERM><TERM><![CDATA[Agonist]]></TERM><TERM><![CDATA[Alkaloids]]></TERM><TERM><![CDATA[Amino Acids]]></TERM><TERM><![CDATA[analog]]></TERM><TERM><![CDATA[Architecture]]></TERM><TERM><![CDATA[Batrachotoxins]]></TERM><TERM><![CDATA[Behavior]]></TERM><TERM><![CDATA[Binding (Molecular Function)]]></TERM><TERM><![CDATA[Binding Proteins]]></TERM><TERM><![CDATA[Binding Sites]]></TERM><TERM><![CDATA[Biochemical]]></TERM><TERM><![CDATA[Biological]]></TERM><TERM><![CDATA[Biological Factors]]></TERM><TERM><![CDATA[Biology]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[chronic pain]]></TERM><TERM><![CDATA[Communities]]></TERM><TERM><![CDATA[Computer Simulation]]></TERM><TERM><![CDATA[Congenital Pain Insensitivity]]></TERM><TERM><![CDATA[Coupling]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Dependency (Psychology)]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Disseminated Malignant Neoplasm]]></TERM><TERM><![CDATA[Electrophysiology (science)]]></TERM><TERM><![CDATA[Epilepsy]]></TERM><TERM><![CDATA[Erythromelalgia]]></TERM><TERM><![CDATA[Esters]]></TERM><TERM><![CDATA[functional group]]></TERM><TERM><![CDATA[Gated Ion Channel]]></TERM><TERM><![CDATA[hemiketal]]></TERM><TERM><![CDATA[human disease]]></TERM><TERM><![CDATA[insight]]></TERM><TERM><![CDATA[Integral Membrane Protein]]></TERM><TERM><![CDATA[Ion Channel]]></TERM><TERM><![CDATA[Ion Channel Gating]]></TERM><TERM><![CDATA[Ion Channel Protein]]></TERM><TERM><![CDATA[Ions]]></TERM><TERM><![CDATA[Kinetics]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[Life]]></TERM><TERM><![CDATA[Ligand Binding]]></TERM><TERM><![CDATA[Ligands]]></TERM><TERM><![CDATA[Ligation]]></TERM><TERM><![CDATA[Mechanics]]></TERM><TERM><![CDATA[Membrane Potentials]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[Molecular Probes]]></TERM><TERM><![CDATA[Muscle]]></TERM><TERM><![CDATA[mutant]]></TERM><TERM><![CDATA[Mutate]]></TERM><TERM><![CDATA[Mutation]]></TERM><TERM><![CDATA[Neurons]]></TERM><TERM><![CDATA[Organic Chemicals]]></TERM><TERM><![CDATA[Organic Chemistry]]></TERM><TERM><![CDATA[Output]]></TERM><TERM><![CDATA[Pharmacologic Substance]]></TERM><TERM><![CDATA[Pore Proteins]]></TERM><TERM><![CDATA[Principal Investigator]]></TERM><TERM><![CDATA[programs]]></TERM><TERM><![CDATA[protein complex]]></TERM><TERM><![CDATA[protein function]]></TERM><TERM><![CDATA[Protein Isoforms]]></TERM><TERM><![CDATA[Proteins]]></TERM><TERM><![CDATA[public health relevance]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Roentgen Rays]]></TERM><TERM><![CDATA[Series]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[Site]]></TERM><TERM><![CDATA[small molecule]]></TERM><TERM><![CDATA[Sodium Channel]]></TERM><TERM><![CDATA[Source]]></TERM><TERM><![CDATA[Specificity]]></TERM><TERM><![CDATA[Structure]]></TERM><TERM><![CDATA[Synthesis Chemistry]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[tool]]></TERM><TERM><![CDATA[Toxin]]></TERM><TERM><![CDATA[Training]]></TERM><TERM><![CDATA[Veratridine]]></TERM><TERM><![CDATA[voltage]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Exploration of Voltage-Gated Sodium Ion Channel Functioning using Veratridine]]></PROJECT_TITLE><SERIAL_NUMBER>116402</SERIAL_NUMBER><STUDY_SECTION>ZRG1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>01</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>50690</DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>50690</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8981979</APPLICATION_ID><ACTIVITY>F30</ACTIVITY><ADMINISTERING_IC>AI</ADMINISTERING_IC><APPLICATION_TYPE>1</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>05/01/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>855</CFDA_CODE><CORE_PROJECT_NUM>F30AI120527</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-14-150</FOA_NUMBER><FULL_PROJECT_NUM>1F30AI120527-01</FULL_PROJECT_NUM><FUNDING_ICs>NIAID:35005\</FUNDING_ICs><FUNDING_MECHANISM>TRAINING, INDIVIDUAL</FUNDING_MECHANISM><FY>2015</FY><IC_NAME>NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES</IC_NAME><NIH_SPENDING_CATS><CATEGORY><![CDATA[Genetics]]></CATEGORY></NIH_SPENDING_CATS><ORG_CITY>SAN FRANCISCO</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[NONE]]></ORG_DEPT><ORG_DISTRICT>12</ORG_DISTRICT><ORG_DUNS>094878337</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIVERSITY OF CALIFORNIA, SAN FRANCISCO]]></ORG_NAME><ORG_STATE>CA</ORG_STATE><ORG_ZIPCODE>941186215</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Millions of Americans suffer from inflammatory diseases, such as metabolic syndrome and atherosclerosis, which are associated with high cholesterol levels; however, how cholesterol promotes inflammation is poorly understood. We hope to understand how the cholesterol biosynthetic pathway influences the production of a key inflammatory mediator, IL-1&#223;, which will provide a first step in developing therapies for linked metabolic- inflammatory diseases.   
      

]]></PHR><PIS><PI><PI_NAME>DANG, ERIC VAN</PI_NAME><PI_ID>10973588</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>PROGRAIS, LAWRENCE J.</PROGRAM_OFFICER_NAME><PROJECT_START>11/01/2015</PROJECT_START><PROJECT_END>10/31/2017</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[25-hydroxycholesterol]]></TERM><TERM><![CDATA[Adaptor Signaling Protein]]></TERM><TERM><![CDATA[Agonist]]></TERM><TERM><![CDATA[American]]></TERM><TERM><![CDATA[Atherosclerosis]]></TERM><TERM><![CDATA[Bacteria]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Binding Proteins]]></TERM><TERM><![CDATA[Biochemical]]></TERM><TERM><![CDATA[Bone Marrow]]></TERM><TERM><![CDATA[Caspase-1]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Cholesterol]]></TERM><TERM><![CDATA[cholesterol biosynthesis]]></TERM><TERM><![CDATA[cholesterol-binding protein]]></TERM><TERM><![CDATA[Clustered Regularly Interspaced Short Palindromic Repeats]]></TERM><TERM><![CDATA[Confocal Microscopy]]></TERM><TERM><![CDATA[cytokine]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Environment]]></TERM><TERM><![CDATA[Enzyme Induction]]></TERM><TERM><![CDATA[Enzymes]]></TERM><TERM><![CDATA[extracellular]]></TERM><TERM><![CDATA[Family]]></TERM><TERM><![CDATA[Family member]]></TERM><TERM><![CDATA[fatty acid biosynthesis]]></TERM><TERM><![CDATA[Gene Targeting]]></TERM><TERM><![CDATA[Genes]]></TERM><TERM><![CDATA[Genetic Transcription]]></TERM><TERM><![CDATA[Immune response]]></TERM><TERM><![CDATA[immunopathology]]></TERM><TERM><![CDATA[Immunosuppressive Agents]]></TERM><TERM><![CDATA[Infection]]></TERM><TERM><![CDATA[Inflammation]]></TERM><TERM><![CDATA[Inflammation Mediators]]></TERM><TERM><![CDATA[Inflammatory]]></TERM><TERM><![CDATA[Interferon Type I]]></TERM><TERM><![CDATA[Interferons]]></TERM><TERM><![CDATA[Interleukin-1]]></TERM><TERM><![CDATA[Intracellular Membranes]]></TERM><TERM><![CDATA[Link]]></TERM><TERM><![CDATA[lipid biosynthesis]]></TERM><TERM><![CDATA[Lipids]]></TERM><TERM><![CDATA[Lipopolysaccharides]]></TERM><TERM><![CDATA[macrophage]]></TERM><TERM><![CDATA[Mass Spectrum Analysis]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[Membrane]]></TERM><TERM><![CDATA[Messenger RNA]]></TERM><TERM><![CDATA[Metabolic]]></TERM><TERM><![CDATA[Metabolic syndrome]]></TERM><TERM><![CDATA[Mixed Function Oxygenases]]></TERM><TERM><![CDATA[Molecular Chaperones]]></TERM><TERM><![CDATA[Morbidity - disease rate]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[Myeloid Cells]]></TERM><TERM><![CDATA[Nuclear]]></TERM><TERM><![CDATA[pathogen]]></TERM><TERM><![CDATA[Pathway interactions]]></TERM><TERM><![CDATA[Peptide Hydrolases]]></TERM><TERM><![CDATA[Phenotype]]></TERM><TERM><![CDATA[Play]]></TERM><TERM><![CDATA[prevent]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[Production]]></TERM><TERM><![CDATA[protein activation]]></TERM><TERM><![CDATA[protein complex]]></TERM><TERM><![CDATA[Proteins]]></TERM><TERM><![CDATA[public health relevance]]></TERM><TERM><![CDATA[receptor]]></TERM><TERM><![CDATA[reconstitution]]></TERM><TERM><![CDATA[Recruitment Activity]]></TERM><TERM><![CDATA[Regulation]]></TERM><TERM><![CDATA[Repression]]></TERM><TERM><![CDATA[research study]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[Response Elements]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[sensor]]></TERM><TERM><![CDATA[Sterols]]></TERM><TERM><![CDATA[System]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[therapy development]]></TERM><TERM><![CDATA[Toll-like receptors]]></TERM><TERM><![CDATA[transcription factor]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Dissecting the contribution of SREBPs and lipid biosynthesis to inflammasome function]]></PROJECT_TITLE><SERIAL_NUMBER>120527</SERIAL_NUMBER><STUDY_SECTION>ZRG1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>01</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>35005</DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>35005</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8986882</APPLICATION_ID><ACTIVITY>F31</ACTIVITY><ADMINISTERING_IC>NS</ADMINISTERING_IC><APPLICATION_TYPE>1</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>07/14/2015</AWARD_NOTICE_DATE><BUDGET_START>08/01/2015</BUDGET_START><BUDGET_END>07/31/2016</BUDGET_END><CFDA_CODE>853</CFDA_CODE><CORE_PROJECT_NUM>F31NS093960</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-14-148</FOA_NUMBER><FULL_PROJECT_NUM>1F31NS093960-01</FULL_PROJECT_NUM><FUNDING_ICs>NINDS:35520\</FUNDING_ICs><FUNDING_MECHANISM>TRAINING, INDIVIDUAL</FUNDING_MECHANISM><FY>2015</FY><IC_NAME>NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE</IC_NAME><NIH_SPENDING_CATS><CATEGORY><![CDATA[Brain Disorders]]></CATEGORY><CATEGORY><![CDATA[Neurosciences]]></CATEGORY></NIH_SPENDING_CATS><ORG_CITY>BIRMINGHAM</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[NEUROSCIENCES]]></ORG_DEPT><ORG_DISTRICT>07</ORG_DISTRICT><ORG_DUNS>063690705</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIVERSITY OF ALABAMA AT BIRMINGHAM]]></ORG_NAME><ORG_STATE>AL</ORG_STATE><ORG_ZIPCODE>352940004</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: The cerebellum is a brain region that is critical for coordinated movement. The experiments proposed here will investigate an unusual form of synaptic connectivity within the cerebellar cortex that results from neurotransmitter spillover in the absence of anatomically defined synapses. The results of these experiments will help to expand understanding of spillover neurotransmission and elucidate how the cerebellar cortex processes sensory information to enable coordination of movement.   
   
      

]]></PHR><PIS><PI><PI_NAME>NIETZ, ANGELA K</PI_NAME><PI_ID>12049551</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>STEWART, RANDALL R</PROGRAM_OFFICER_NAME><PROJECT_START>08/01/2015</PROJECT_START><PROJECT_END>07/31/2019</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[Alzheimer's Disease]]></TERM><TERM><![CDATA[Axon]]></TERM><TERM><![CDATA[Biological Assay]]></TERM><TERM><![CDATA[Brain]]></TERM><TERM><![CDATA[Brain region]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Cerebellar cortex structure]]></TERM><TERM><![CDATA[Cerebellum]]></TERM><TERM><![CDATA[Coupled]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Disinhibition]]></TERM><TERM><![CDATA[Electrophysiology (science)]]></TERM><TERM><![CDATA[Ensure]]></TERM><TERM><![CDATA[Epilepsy]]></TERM><TERM><![CDATA[Ethics]]></TERM><TERM><![CDATA[excitotoxicity]]></TERM><TERM><![CDATA[Feedback]]></TERM><TERM><![CDATA[feeding]]></TERM><TERM><![CDATA[Fiber]]></TERM><TERM><![CDATA[flexibility]]></TERM><TERM><![CDATA[gamma-Aminobutyric Acid]]></TERM><TERM><![CDATA[Glutamate Receptor]]></TERM><TERM><![CDATA[Glutamate Transporter]]></TERM><TERM><![CDATA[Glutamates]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Golgi Apparatus]]></TERM><TERM><![CDATA[granule cell]]></TERM><TERM><![CDATA[information processing]]></TERM><TERM><![CDATA[insight]]></TERM><TERM><![CDATA[Interneurons]]></TERM><TERM><![CDATA[inward rectifier potassium channel]]></TERM><TERM><![CDATA[Journals]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[Measures]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[meetings]]></TERM><TERM><![CDATA[Mental disorders]]></TERM><TERM><![CDATA[Mentors]]></TERM><TERM><![CDATA[metabotropic glutamate receptor 2]]></TERM><TERM><![CDATA[Metabotropic Glutamate Receptors]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[mossy fiber]]></TERM><TERM><![CDATA[Motor]]></TERM><TERM><![CDATA[Movement]]></TERM><TERM><![CDATA[Neuraxis]]></TERM><TERM><![CDATA[Neurodegenerative Disorders]]></TERM><TERM><![CDATA[Neurons]]></TERM><TERM><![CDATA[neurotransmission]]></TERM><TERM><![CDATA[Neurotransmitters]]></TERM><TERM><![CDATA[optogenetics]]></TERM><TERM><![CDATA[Output]]></TERM><TERM><![CDATA[Pathology]]></TERM><TERM><![CDATA[Play]]></TERM><TERM><![CDATA[postsynaptic]]></TERM><TERM><![CDATA[prevent]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[public health relevance]]></TERM><TERM><![CDATA[Purkinje Cells]]></TERM><TERM><![CDATA[receptor]]></TERM><TERM><![CDATA[research study]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Sensory]]></TERM><TERM><![CDATA[Sensory Process]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[spatiotemporal]]></TERM><TERM><![CDATA[Specificity]]></TERM><TERM><![CDATA[Spinocerebellar Ataxias]]></TERM><TERM><![CDATA[Staging]]></TERM><TERM><![CDATA[Structure of molecular layer of cerebellar cortex]]></TERM><TERM><![CDATA[Supervision]]></TERM><TERM><![CDATA[Synapses]]></TERM><TERM><![CDATA[synaptic inhibition]]></TERM><TERM><![CDATA[Synaptic plasticity]]></TERM><TERM><![CDATA[Synaptic Transmission]]></TERM><TERM><![CDATA[Techniques]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Training]]></TERM><TERM><![CDATA[transmission process]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Extrasynaptic Signaling to Interneuron Networks]]></PROJECT_TITLE><SERIAL_NUMBER>093960</SERIAL_NUMBER><STUDY_SECTION>ZRG1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>01</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>35520</DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>35520</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8990887</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>MH</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/31/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>242</CFDA_CODE><CORE_PROJECT_NUM>R01MH103253</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF ARTS AND SCIENCES]]></ED_INST_TYPE><FOA_NUMBER>PA-13-302</FOA_NUMBER><FULL_PROJECT_NUM>5R01MH103253-02</FULL_PROJECT_NUM><FUNDING_ICs>NIMH:567199\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF MENTAL HEALTH</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>COLLEGE PARK</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[PSYCHOLOGY]]></ORG_DEPT><ORG_DISTRICT>05</ORG_DISTRICT><ORG_DUNS>790934285</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIV OF MARYLAND, COLLEGE PARK]]></ORG_NAME><ORG_STATE>MD</ORG_STATE><ORG_ZIPCODE>207425141</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Stable, early behavioral inhibition (BI)/social reticence (RET) is a risk factor for the development of later social anxiety disorder, and overly directive/controlling parenting moderates this risk. Pilot data obtained from our NIMH-funded R34 provides preliminary efficacy data for the Turtle Program, a developmentally-grounded, multi-component early intervention program which combines an adaptation of Parent-Child Interaction Therapy and a social skills program to simultaneously address child BI/RET and parenting. The proposed randomized controlled trial aims to evaluate the Turtle Program compared to the best available treatment for preschool BI, Cool Little Kids, a parent psychoeducation group, and to examine mediators and moderators of intervention effects.]]></PHR><PIS><PI><PI_NAME>CHRONIS-TUSCANO, ANDREA  (contact)</PI_NAME><PI_ID>7748338 (contact)</PI_ID></PI><PI><PI_NAME>RUBIN, KENNETH H</PI_NAME><PI_ID>2100169</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>SHERRILL, JOEL </PROGRAM_OFFICER_NAME><PROJECT_START>12/25/2014</PROJECT_START><PROJECT_END>10/31/2019</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[Adolescence]]></TERM><TERM><![CDATA[Adolescent]]></TERM><TERM><![CDATA[Adult]]></TERM><TERM><![CDATA[Aftercare]]></TERM><TERM><![CDATA[Age]]></TERM><TERM><![CDATA[aged]]></TERM><TERM><![CDATA[Amination]]></TERM><TERM><![CDATA[Anxiety]]></TERM><TERM><![CDATA[Anxiety Disorders]]></TERM><TERM><![CDATA[approach behavior]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Behavior]]></TERM><TERM><![CDATA[Behavioral]]></TERM><TERM><![CDATA[Behavioral inhibition]]></TERM><TERM><![CDATA[Biological]]></TERM><TERM><![CDATA[Characteristics]]></TERM><TERM><![CDATA[Child]]></TERM><TERM><![CDATA[Child Rearing]]></TERM><TERM><![CDATA[Childhood]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Early Intervention]]></TERM><TERM><![CDATA[emotion regulation]]></TERM><TERM><![CDATA[Emotional]]></TERM><TERM><![CDATA[Experimental Designs]]></TERM><TERM><![CDATA[follow-up]]></TERM><TERM><![CDATA[Funding]]></TERM><TERM><![CDATA[Grant]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Heart Rate]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[indexing]]></TERM><TERM><![CDATA[interest]]></TERM><TERM><![CDATA[Intervention]]></TERM><TERM><![CDATA[intervention effect]]></TERM><TERM><![CDATA[intervention program]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[Learning]]></TERM><TERM><![CDATA[Longitudinal Studies]]></TERM><TERM><![CDATA[Maintenance]]></TERM><TERM><![CDATA[Manuals]]></TERM><TERM><![CDATA[Measures]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[Mediator of activation protein]]></TERM><TERM><![CDATA[Modification]]></TERM><TERM><![CDATA[multi-component intervention]]></TERM><TERM><![CDATA[National Institute of Mental Health (U.S.)]]></TERM><TERM><![CDATA[Nature]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[Nursery Schools]]></TERM><TERM><![CDATA[Outcome]]></TERM><TERM><![CDATA[Outcome Measure]]></TERM><TERM><![CDATA[Parent-Child Relations]]></TERM><TERM><![CDATA[Parents]]></TERM><TERM><![CDATA[peer]]></TERM><TERM><![CDATA[Peer Group]]></TERM><TERM><![CDATA[Physiological]]></TERM><TERM><![CDATA[Physiology]]></TERM><TERM><![CDATA[Play]]></TERM><TERM><![CDATA[Population]]></TERM><TERM><![CDATA[Preschool Child]]></TERM><TERM><![CDATA[primary outcome]]></TERM><TERM><![CDATA[Procedures]]></TERM><TERM><![CDATA[programs]]></TERM><TERM><![CDATA[prospective]]></TERM><TERM><![CDATA[Protocols documentation]]></TERM><TERM><![CDATA[psychoeducation]]></TERM><TERM><![CDATA[Psychologist]]></TERM><TERM><![CDATA[Psychopathology]]></TERM><TERM><![CDATA[Questionnaires]]></TERM><TERM><![CDATA[Randomized]]></TERM><TERM><![CDATA[Randomized Controlled Trials]]></TERM><TERM><![CDATA[Regulation]]></TERM><TERM><![CDATA[Relative (related person)]]></TERM><TERM><![CDATA[Reporting]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Research Personnel]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[Rest]]></TERM><TERM><![CDATA[Risk]]></TERM><TERM><![CDATA[Risk Factors]]></TERM><TERM><![CDATA[Sampling]]></TERM><TERM><![CDATA[Severities]]></TERM><TERM><![CDATA[skills]]></TERM><TERM><![CDATA[social]]></TERM><TERM><![CDATA[Social Behavior]]></TERM><TERM><![CDATA[Social Environment]]></TERM><TERM><![CDATA[Social Functioning]]></TERM><TERM><![CDATA[Social Phobia]]></TERM><TERM><![CDATA[social skills]]></TERM><TERM><![CDATA[teacher]]></TERM><TERM><![CDATA[Temperament]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[theories]]></TERM><TERM><![CDATA[therapy development]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[Training]]></TERM><TERM><![CDATA[treatment effect]]></TERM><TERM><![CDATA[treatment response]]></TERM><TERM><![CDATA[Turtles]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Multi-Component Early Intervention for Socially Inhibited Preschool Children]]></PROJECT_TITLE><SERIAL_NUMBER>103253</SERIAL_NUMBER><STUDY_SECTION>ITVC</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Interventions Committee for Disorders Involving Children and Their Families ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>386929</DIRECT_COST_AMT><INDIRECT_COST_AMT>180270</INDIRECT_COST_AMT><TOTAL_COST>567199</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9005950</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>AI</ADMINISTERING_IC><APPLICATION_TYPE>1</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/04/2015</AWARD_NOTICE_DATE><BUDGET_START>11/05/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>855</CFDA_CODE><CORE_PROJECT_NUM>R01AI121124</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF VETERINARY MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-13-302</FOA_NUMBER><FULL_PROJECT_NUM>1R01AI121124-01</FULL_PROJECT_NUM><FUNDING_ICs>NIAID:385000\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>COLUMBUS</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[VETERINARY SCIENCES]]></ORG_DEPT><ORG_DISTRICT>03</ORG_DISTRICT><ORG_DUNS>832127323</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[OHIO STATE UNIVERSITY]]></ORG_NAME><ORG_STATE>OH</ORG_STATE><ORG_ZIPCODE>432101016</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: The application is important to public health because understanding how Ehrlichia chaffeensis enters inside human leukocytes to replicate is ultimately expected to provide new targets for prophylactic and therapeutic intervention of human monocytic ehrlichiosis, and what is learned will contribute to broader understanding of how human cell surface and cytoplasmic proteins can be coordinated to deliver particles inside human cells. Thus, the proposed research is relevant to the part of NIH's mission that pertains to developing fundamental knowledge that will reduce the burden of human disease.   
      

]]></PHR><PIS><PI><PI_NAME>RIKIHISA, YASUKO </PI_NAME><PI_ID>1894305</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>PERDUE, SAMUEL S.</PROGRAM_OFFICER_NAME><PROJECT_START>11/05/2015</PROJECT_START><PROJECT_END>10/31/2020</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Actins]]></TERM><TERM><![CDATA[Affinity Chromatography]]></TERM><TERM><![CDATA[Anaplasma phagocytophilum]]></TERM><TERM><![CDATA[Animals]]></TERM><TERM><![CDATA[Antibodies]]></TERM><TERM><![CDATA[axenic culture]]></TERM><TERM><![CDATA[Bacteria]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Binding (Molecular Function)]]></TERM><TERM><![CDATA[Binding Sites]]></TERM><TERM><![CDATA[Biological Assay]]></TERM><TERM><![CDATA[C-terminal]]></TERM><TERM><![CDATA[Cell surface]]></TERM><TERM><![CDATA[Cell Surface Proteins]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[cellular imaging]]></TERM><TERM><![CDATA[Chlamydia]]></TERM><TERM><![CDATA[Complex]]></TERM><TERM><![CDATA[Cre-LoxP]]></TERM><TERM><![CDATA[Cytoplasmic Protein]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Deoxyribonuclease I]]></TERM><TERM><![CDATA[Deoxyribonucleases]]></TERM><TERM><![CDATA[Dependence]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[DNA]]></TERM><TERM><![CDATA[Ehrlichia]]></TERM><TERM><![CDATA[Ehrlichia chaffeensis]]></TERM><TERM><![CDATA[Ehrlichiosis]]></TERM><TERM><![CDATA[Endotoxins]]></TERM><TERM><![CDATA[Exotoxins]]></TERM><TERM><![CDATA[F-Actin]]></TERM><TERM><![CDATA[Filopodia]]></TERM><TERM><![CDATA[Fluorescence]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[granulocyte]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Heterogeneous-Nuclear Ribonucleoprotein K]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[human disease]]></TERM><TERM><![CDATA[In Vitro]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[Infection]]></TERM><TERM><![CDATA[Inositol]]></TERM><TERM><![CDATA[Integral Membrane Protein]]></TERM><TERM><![CDATA[intravital fluorescence microscopy]]></TERM><TERM><![CDATA[Kinetics]]></TERM><TERM><![CDATA[Knock-out]]></TERM><TERM><![CDATA[Knowledge]]></TERM><TERM><![CDATA[Latex Bead]]></TERM><TERM><![CDATA[Learning]]></TERM><TERM><![CDATA[Leukocytes]]></TERM><TERM><![CDATA[Life]]></TERM><TERM><![CDATA[macrophage]]></TERM><TERM><![CDATA[Mammalian Cell]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[Membrane Proteins]]></TERM><TERM><![CDATA[Mission]]></TERM><TERM><![CDATA[monocyte]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[mutant]]></TERM><TERM><![CDATA[Neoplasm Metastasis]]></TERM><TERM><![CDATA[neuromechanism]]></TERM><TERM><![CDATA[neurotensin mimic 1]]></TERM><TERM><![CDATA[neutrophil]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[Outcome]]></TERM><TERM><![CDATA[Parasites]]></TERM><TERM><![CDATA[particle]]></TERM><TERM><![CDATA[pathogen]]></TERM><TERM><![CDATA[Pathway interactions]]></TERM><TERM><![CDATA[Phagocytes]]></TERM><TERM><![CDATA[Plasmodium]]></TERM><TERM><![CDATA[polymerization]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[prophylactic]]></TERM><TERM><![CDATA[protein activation]]></TERM><TERM><![CDATA[protein complex]]></TERM><TERM><![CDATA[Proteins]]></TERM><TERM><![CDATA[public health medicine (field)]]></TERM><TERM><![CDATA[Publishing]]></TERM><TERM><![CDATA[receptor]]></TERM><TERM><![CDATA[Recruitment (Neurology)]]></TERM><TERM><![CDATA[Recruitment Activity]]></TERM><TERM><![CDATA[relating to nervous system]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[rho GTP-Binding Proteins]]></TERM><TERM><![CDATA[Rickettsia]]></TERM><TERM><![CDATA[Route]]></TERM><TERM><![CDATA[Scanning]]></TERM><TERM><![CDATA[Small Interfering RNA]]></TERM><TERM><![CDATA[spatiotemporal]]></TERM><TERM><![CDATA[Staging]]></TERM><TERM><![CDATA[Surface]]></TERM><TERM><![CDATA[Technology]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Therapeutic]]></TERM><TERM><![CDATA[Therapeutic Intervention]]></TERM><TERM><![CDATA[Ticks]]></TERM><TERM><![CDATA[transmission process]]></TERM><TERM><![CDATA[Tropism]]></TERM><TERM><![CDATA[uptake]]></TERM><TERM><![CDATA[Virulence Factors]]></TERM><TERM><![CDATA[Wiskott-Aldrich Syndrome]]></TERM><TERM><![CDATA[Work]]></TERM><TERM><![CDATA[Wound Healing]]></TERM><TERM><![CDATA[Zoonoses]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Infectious Entry Mechanisms of Obligatory Intracellular Pathogen]]></PROJECT_TITLE><SERIAL_NUMBER>121124</SERIAL_NUMBER><STUDY_SECTION>HIBP</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Host Interactions with Bacterial Pathogens Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>01</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>250000</DIRECT_COST_AMT><INDIRECT_COST_AMT>135000</INDIRECT_COST_AMT><TOTAL_COST>385000</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9054632</APPLICATION_ID><ACTIVITY>U54</ACTIVITY><ADMINISTERING_IC>HD</ADMINISTERING_IC><APPLICATION_TYPE>1</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/30/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>U54HD086984</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-HD-15-033</FOA_NUMBER><FULL_PROJECT_NUM>1U54HD086984-01</FULL_PROJECT_NUM><FUNDING_ICs>NICHD:157763\</FUNDING_ICs><FUNDING_MECHANISM>RESEARCH CENTERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &amp; HUMAN DEVELOPMENT</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>PHILADELPHIA</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>02</ORG_DISTRICT><ORG_DUNS>073757627</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[CHILDREN'S HOSP OF PHILADELPHIA]]></ORG_NAME><ORG_STATE>PA</ORG_STATE><ORG_ZIPCODE>191044318</ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>PUTT, MARY E.</PI_NAME><PI_ID>1939737</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>11/01/2015</PROJECT_START><PROJECT_END>05/31/2020</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Attention]]></TERM><TERM><![CDATA[Attention deficit hyperactivity disorder]]></TERM><TERM><![CDATA[Auditory]]></TERM><TERM><![CDATA[authority]]></TERM><TERM><![CDATA[Autistic Disorder]]></TERM><TERM><![CDATA[Basic Science]]></TERM><TERM><![CDATA[Behavior]]></TERM><TERM><![CDATA[biobank]]></TERM><TERM><![CDATA[Biochemical]]></TERM><TERM><![CDATA[Bioenergetics]]></TERM><TERM><![CDATA[Bioinformatics]]></TERM><TERM><![CDATA[Biological Assay]]></TERM><TERM><![CDATA[biomedical informatics]]></TERM><TERM><![CDATA[Biomedical Research]]></TERM><TERM><![CDATA[Biometry]]></TERM><TERM><![CDATA[brain behavior]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Child]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[Clinical Trials]]></TERM><TERM><![CDATA[Clinical Trials Design]]></TERM><TERM><![CDATA[college]]></TERM><TERM><![CDATA[Communication]]></TERM><TERM><![CDATA[Consultations]]></TERM><TERM><![CDATA[Copy Number Polymorphism]]></TERM><TERM><![CDATA[cost effective]]></TERM><TERM><![CDATA[Critiques]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Data Analyses]]></TERM><TERM><![CDATA[Data Set]]></TERM><TERM><![CDATA[Databases]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Developmental Disabilities]]></TERM><TERM><![CDATA[DNA analysis]]></TERM><TERM><![CDATA[DNA Sequence]]></TERM><TERM><![CDATA[DNA Sequence Alteration]]></TERM><TERM><![CDATA[Doctor of Philosophy]]></TERM><TERM><![CDATA[Documentation]]></TERM><TERM><![CDATA[Eligibility Determination]]></TERM><TERM><![CDATA[Ensure]]></TERM><TERM><![CDATA[Epidemiology]]></TERM><TERM><![CDATA[epigenomics]]></TERM><TERM><![CDATA[Epilepsy]]></TERM><TERM><![CDATA[Ethics]]></TERM><TERM><![CDATA[experimental analysis]]></TERM><TERM><![CDATA[Experimental Designs]]></TERM><TERM><![CDATA[Foundations]]></TERM><TERM><![CDATA[Genes]]></TERM><TERM><![CDATA[Genetic]]></TERM><TERM><![CDATA[genetic analysis]]></TERM><TERM><![CDATA[Genetic Research]]></TERM><TERM><![CDATA[Genome]]></TERM><TERM><![CDATA[genome wide association study]]></TERM><TERM><![CDATA[genome-wide]]></TERM><TERM><![CDATA[Genomics]]></TERM><TERM><![CDATA[Genotype]]></TERM><TERM><![CDATA[Glutamate Transporter]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Hand]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[human disease]]></TERM><TERM><![CDATA[In Vitro]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[Intellectual functioning disability]]></TERM><TERM><![CDATA[Investigation]]></TERM><TERM><![CDATA[Journals]]></TERM><TERM><![CDATA[Leadership]]></TERM><TERM><![CDATA[Left]]></TERM><TERM><![CDATA[Maps]]></TERM><TERM><![CDATA[Medicine]]></TERM><TERM><![CDATA[member]]></TERM><TERM><![CDATA[Mental Retardation and Developmental Disabilities Research Centers]]></TERM><TERM><![CDATA[Methods]]></TERM><TERM><![CDATA[Mission]]></TERM><TERM><![CDATA[Mitochondria]]></TERM><TERM><![CDATA[Mitochondrial Diseases]]></TERM><TERM><![CDATA[Mitochondrial DNA]]></TERM><TERM><![CDATA[mitochondrial genome]]></TERM><TERM><![CDATA[Mutation]]></TERM><TERM><![CDATA[National Academy of Sciences (U.S.)]]></TERM><TERM><![CDATA[Nature]]></TERM><TERM><![CDATA[neurochemistry]]></TERM><TERM><![CDATA[neuroimaging]]></TERM><TERM><![CDATA[neuronal patterning]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[Nuclear]]></TERM><TERM><![CDATA[Online Systems]]></TERM><TERM><![CDATA[operation]]></TERM><TERM><![CDATA[Pediatric Hospitals]]></TERM><TERM><![CDATA[Phenotype]]></TERM><TERM><![CDATA[Philadelphia]]></TERM><TERM><![CDATA[Play]]></TERM><TERM><![CDATA[preference]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[programs]]></TERM><TERM><![CDATA[Publications]]></TERM><TERM><![CDATA[Quality Control]]></TERM><TERM><![CDATA[Recruitment Activity]]></TERM><TERM><![CDATA[Reproducibility of Results]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Research Design]]></TERM><TERM><![CDATA[Research Personnel]]></TERM><TERM><![CDATA[Research Project Grants]]></TERM><TERM><![CDATA[research study]]></TERM><TERM><![CDATA[Resources]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[RNA]]></TERM><TERM><![CDATA[Sample Size]]></TERM><TERM><![CDATA[Sampling]]></TERM><TERM><![CDATA[Science]]></TERM><TERM><![CDATA[Seminal]]></TERM><TERM><![CDATA[Services]]></TERM><TERM><![CDATA[Solid]]></TERM><TERM><![CDATA[Staging]]></TERM><TERM><![CDATA[Statistical Methods]]></TERM><TERM><![CDATA[Surveys]]></TERM><TERM><![CDATA[System]]></TERM><TERM><![CDATA[Technology]]></TERM><TERM><![CDATA[tool]]></TERM><TERM><![CDATA[translational medicine]]></TERM><TERM><![CDATA[Trust]]></TERM><TERM><![CDATA[United States National Institutes of Health]]></TERM><TERM><![CDATA[Universities]]></TERM><TERM><![CDATA[Variant]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Biostatistics and Bioinformatics: Core C]]></PROJECT_TITLE><SERIAL_NUMBER>086984</SERIAL_NUMBER><STUDY_SECTION>ZHD1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID>8060</SUBPROJECT_ID><SUPPORT_YEAR>01</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>119309</DIRECT_COST_AMT><INDIRECT_COST_AMT>60683</INDIRECT_COST_AMT><TOTAL_COST /><TOTAL_COST_SUB_PROJECT>157763</TOTAL_COST_SUB_PROJECT></row>
<row><APPLICATION_ID>9056018</APPLICATION_ID><ACTIVITY>U54</ACTIVITY><ADMINISTERING_IC>HD</ADMINISTERING_IC><APPLICATION_TYPE>1</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/30/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>U54HD087101</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-HD-15-033</FOA_NUMBER><FULL_PROJECT_NUM>1U54HD087101-01</FULL_PROJECT_NUM><FUNDING_ICs>NICHD:222807\</FUNDING_ICs><FUNDING_MECHANISM>RESEARCH CENTERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &amp; HUMAN DEVELOPMENT</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>LOS ANGELES</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>33</ORG_DISTRICT><ORG_DUNS>092530369</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIVERSITY OF CALIFORNIA LOS ANGELES]]></ORG_NAME><ORG_STATE>CA</ORG_STATE><ORG_ZIPCODE>900952000</ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>BUTLER, SAMANTHA J</PI_NAME><PI_ID>8142141</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>11/01/2015</PROJECT_START><PROJECT_END>05/31/2020</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[abstracting]]></TERM><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[Animal Model]]></TERM><TERM><![CDATA[Animals]]></TERM><TERM><![CDATA[Basic Science]]></TERM><TERM><![CDATA[Biological]]></TERM><TERM><![CDATA[Biological Models]]></TERM><TERM><![CDATA[Biological Process]]></TERM><TERM><![CDATA[Brain]]></TERM><TERM><![CDATA[Brain region]]></TERM><TERM><![CDATA[Cell Culture Techniques]]></TERM><TERM><![CDATA[Cell physiology]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Cellular biology]]></TERM><TERM><![CDATA[cellular imaging]]></TERM><TERM><![CDATA[Center for Translational Science Activities]]></TERM><TERM><![CDATA[cognitive neuroscience]]></TERM><TERM><![CDATA[Communities]]></TERM><TERM><![CDATA[Complex]]></TERM><TERM><![CDATA[Confocal Microscopy]]></TERM><TERM><![CDATA[Coupled]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Developmental Disabilities]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[fluorescence microscope]]></TERM><TERM><![CDATA[Fluorescence Microscopy]]></TERM><TERM><![CDATA[Gene Expression]]></TERM><TERM><![CDATA[Generations]]></TERM><TERM><![CDATA[Genetic]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[holistic approach]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[Image]]></TERM><TERM><![CDATA[Image Analysis]]></TERM><TERM><![CDATA[Imagery]]></TERM><TERM><![CDATA[Imaging technology]]></TERM><TERM><![CDATA[Implant]]></TERM><TERM><![CDATA[In Vitro]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[indexing]]></TERM><TERM><![CDATA[innovation]]></TERM><TERM><![CDATA[Laboratories]]></TERM><TERM><![CDATA[Life]]></TERM><TERM><![CDATA[Light Microscope]]></TERM><TERM><![CDATA[light microscopy]]></TERM><TERM><![CDATA[Lipids]]></TERM><TERM><![CDATA[Magnetic Resonance Imaging]]></TERM><TERM><![CDATA[meetings]]></TERM><TERM><![CDATA[member]]></TERM><TERM><![CDATA[Mental Retardation and Developmental Disabilities Research Centers]]></TERM><TERM><![CDATA[Methodology]]></TERM><TERM><![CDATA[Methods]]></TERM><TERM><![CDATA[Microscope]]></TERM><TERM><![CDATA[Microscopy]]></TERM><TERM><![CDATA[miniaturize]]></TERM><TERM><![CDATA[Modality]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Molecular Probes]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[nervous system development]]></TERM><TERM><![CDATA[Nervous System Physiology]]></TERM><TERM><![CDATA[neural circuit]]></TERM><TERM><![CDATA[neurodevelopment]]></TERM><TERM><![CDATA[Neurons]]></TERM><TERM><![CDATA[new technology]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[open source]]></TERM><TERM><![CDATA[optic imaging]]></TERM><TERM><![CDATA[optogenetics]]></TERM><TERM><![CDATA[Organoids]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Pattern]]></TERM><TERM><![CDATA[Photons]]></TERM><TERM><![CDATA[Population]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[Protocols documentation]]></TERM><TERM><![CDATA[Reagent]]></TERM><TERM><![CDATA[Recording of previous events]]></TERM><TERM><![CDATA[Refractory]]></TERM><TERM><![CDATA[relating to nervous system]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Research Personnel]]></TERM><TERM><![CDATA[Research Support]]></TERM><TERM><![CDATA[Resolution]]></TERM><TERM><![CDATA[Resources]]></TERM><TERM><![CDATA[Rodent]]></TERM><TERM><![CDATA[Rodent Model]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Sampling]]></TERM><TERM><![CDATA[Scientist]]></TERM><TERM><![CDATA[Services]]></TERM><TERM><![CDATA[Spectrum Analysis]]></TERM><TERM><![CDATA[Stem Cell Research]]></TERM><TERM><![CDATA[Stem cells]]></TERM><TERM><![CDATA[Structure]]></TERM><TERM><![CDATA[Structure of thyroid parafollicular cell]]></TERM><TERM><![CDATA[submicron]]></TERM><TERM><![CDATA[Syndrome]]></TERM><TERM><![CDATA[System]]></TERM><TERM><![CDATA[Techniques]]></TERM><TERM><![CDATA[Therapeutic Intervention]]></TERM><TERM><![CDATA[Tissues]]></TERM><TERM><![CDATA[Translating]]></TERM><TERM><![CDATA[translational neuroscience]]></TERM><TERM><![CDATA[Translational Research]]></TERM><TERM><![CDATA[Visual]]></TERM><TERM><![CDATA[Visual Acuity]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[UCLA Center for Translational Research in Neurodevelopment (UC-TRaN): Functional Visual Core (Core E)]]></PROJECT_TITLE><SERIAL_NUMBER>087101</SERIAL_NUMBER><STUDY_SECTION>ZHD1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID>8268</SUBPROJECT_ID><SUPPORT_YEAR>01</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>144680</DIRECT_COST_AMT><INDIRECT_COST_AMT>78127</INDIRECT_COST_AMT><TOTAL_COST /><TOTAL_COST_SUB_PROJECT>222807</TOTAL_COST_SUB_PROJECT></row>
<row><APPLICATION_ID>9056020</APPLICATION_ID><ACTIVITY>U54</ACTIVITY><ADMINISTERING_IC>HD</ADMINISTERING_IC><APPLICATION_TYPE>1</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/30/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>U54HD087101</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-HD-15-033</FOA_NUMBER><FULL_PROJECT_NUM>1U54HD087101-01</FULL_PROJECT_NUM><FUNDING_ICs>NICHD:167411\</FUNDING_ICs><FUNDING_MECHANISM>RESEARCH CENTERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &amp; HUMAN DEVELOPMENT</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>LOS ANGELES</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>33</ORG_DISTRICT><ORG_DUNS>092530369</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIVERSITY OF CALIFORNIA LOS ANGELES]]></ORG_NAME><ORG_STATE>CA</ORG_STATE><ORG_ZIPCODE>900952000</ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>MCCRACKEN, JAMES T.</PI_NAME><PI_ID>1908544</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>11/01/2015</PROJECT_START><PROJECT_END>05/31/2020</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[abstracting]]></TERM><TERM><![CDATA[autism spectrum disorder]]></TERM><TERM><![CDATA[Autistic Disorder]]></TERM><TERM><![CDATA[Basic Science]]></TERM><TERM><![CDATA[Behavior]]></TERM><TERM><![CDATA[Behavioral]]></TERM><TERM><![CDATA[Biology]]></TERM><TERM><![CDATA[Center for Translational Science Activities]]></TERM><TERM><![CDATA[Clinic]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[Clinical Research]]></TERM><TERM><![CDATA[Clinical Trials]]></TERM><TERM><![CDATA[Cognitive]]></TERM><TERM><![CDATA[Communication]]></TERM><TERM><![CDATA[Consultations]]></TERM><TERM><![CDATA[data management]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Diagnosis]]></TERM><TERM><![CDATA[Dimensions]]></TERM><TERM><![CDATA[Disability phenotype]]></TERM><TERM><![CDATA[Elements]]></TERM><TERM><![CDATA[emotion regulation]]></TERM><TERM><![CDATA[Evaluation]]></TERM><TERM><![CDATA[Expectancy]]></TERM><TERM><![CDATA[Fragile X Syndrome]]></TERM><TERM><![CDATA[Hyperactive behavior]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[Intellectual functioning disability]]></TERM><TERM><![CDATA[interest]]></TERM><TERM><![CDATA[Intervention]]></TERM><TERM><![CDATA[joint attention]]></TERM><TERM><![CDATA[Knowledge]]></TERM><TERM><![CDATA[Literature]]></TERM><TERM><![CDATA[Measurement]]></TERM><TERM><![CDATA[Measures]]></TERM><TERM><![CDATA[Mental Retardation and Developmental Disabilities Research Centers]]></TERM><TERM><![CDATA[Methods]]></TERM><TERM><![CDATA[Methylphenidate]]></TERM><TERM><![CDATA[Mission]]></TERM><TERM><![CDATA[Modification]]></TERM><TERM><![CDATA[National Institute of Mental Health (U.S.)]]></TERM><TERM><![CDATA[neurodevelopment]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[outreach]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[pediatric pharmacology]]></TERM><TERM><![CDATA[Performance]]></TERM><TERM><![CDATA[Pervasive Development Disorder]]></TERM><TERM><![CDATA[Pharmaceutical Preparations]]></TERM><TERM><![CDATA[Phenotype]]></TERM><TERM><![CDATA[Placebo Effect]]></TERM><TERM><![CDATA[preclinical study]]></TERM><TERM><![CDATA[Prevention]]></TERM><TERM><![CDATA[Quality of life]]></TERM><TERM><![CDATA[Randomized Clinical Trials]]></TERM><TERM><![CDATA[Registries]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Research Design]]></TERM><TERM><![CDATA[Research Personnel]]></TERM><TERM><![CDATA[Scientific Advances and Accomplishments]]></TERM><TERM><![CDATA[social]]></TERM><TERM><![CDATA[Social Behavior]]></TERM><TERM><![CDATA[social communication]]></TERM><TERM><![CDATA[Social Functioning]]></TERM><TERM><![CDATA[Socialization]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[tool]]></TERM><TERM><![CDATA[Training]]></TERM><TERM><![CDATA[translational study]]></TERM><TERM><![CDATA[Translations]]></TERM><TERM><![CDATA[treatment effect]]></TERM><TERM><![CDATA[Withdrawal]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[UCLA Center for Translational Research in Neurodevelopment (UCTRaN)Translational Core (Core B)]]></PROJECT_TITLE><SERIAL_NUMBER>087101</SERIAL_NUMBER><STUDY_SECTION>ZHD1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID>8270</SUBPROJECT_ID><SUPPORT_YEAR>01</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>108709</DIRECT_COST_AMT><INDIRECT_COST_AMT>58702</INDIRECT_COST_AMT><TOTAL_COST /><TOTAL_COST_SUB_PROJECT>167411</TOTAL_COST_SUB_PROJECT></row>
<row><APPLICATION_ID>9098904</APPLICATION_ID><ACTIVITY>R03</ACTIVITY><ADMINISTERING_IC>HD</ADMINISTERING_IC><APPLICATION_TYPE>7</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/05/2015</AWARD_NOTICE_DATE><BUDGET_START>11/05/2015</BUDGET_START><BUDGET_END>03/31/2016</BUDGET_END><CFDA_CODE>865</CFDA_CODE><CORE_PROJECT_NUM>R03HD081290</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>PA-14-078</FOA_NUMBER><FULL_PROJECT_NUM>7R03HD081290-02</FULL_PROJECT_NUM><FUNDING_ICs>NICHD:39086\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2015</FY><IC_NAME>EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &amp; HUMAN DEVELOPMENT</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>LANCASTER</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>16</ORG_DISTRICT><ORG_DUNS>069773646</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[FRANKLIN AND MARSHALL COLLEGE]]></ORG_NAME><ORG_STATE>PA</ORG_STATE><ORG_ZIPCODE>176043003</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Women who have children at younger ages and their children are often at a disadvantage in terms of education, income, and other resources. Understanding how and why young women have children at young ages is important for population health, since attempts to address these disadvantages require better understanding of the processes that produce them. This study will provide new information about how attitudes about motherhood, contraception, timing of childbearing, education, career, and other topics are related to young women's decisions to have children by identifying cultural groups with similar ways of thinking about childbearing, then showing which patterns of attitudes are associated with a fertility-related behavior, contraception use, giving insight into possible sites of intervention.]]></PHR><PIS><PI><PI_NAME>MARSHALL, EMILY ANN (contact)</PI_NAME><PI_ID>11194994 (contact)</PI_ID></PI><PI><PI_NAME>SHEPHERD, HANA RAE</PI_NAME><PI_ID>12006406</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>KING, ROSALIND B</PROGRAM_OFFICER_NAME><PROJECT_START>11/05/2015</PROJECT_START><PROJECT_END>03/31/2017</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[Age]]></TERM><TERM><![CDATA[Attitude]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Behavior]]></TERM><TERM><![CDATA[Belief]]></TERM><TERM><![CDATA[career]]></TERM><TERM><![CDATA[Characteristics]]></TERM><TERM><![CDATA[Child]]></TERM><TERM><![CDATA[child bearing]]></TERM><TERM><![CDATA[Cognition]]></TERM><TERM><![CDATA[Cognitive]]></TERM><TERM><![CDATA[Cognitive Science]]></TERM><TERM><![CDATA[Contraception Behavior]]></TERM><TERM><![CDATA[Contraceptive methods]]></TERM><TERM><![CDATA[Contraceptive Usage]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Data Sources]]></TERM><TERM><![CDATA[Demographer]]></TERM><TERM><![CDATA[Dimensions]]></TERM><TERM><![CDATA[Disadvantaged]]></TERM><TERM><![CDATA[Educational aspects]]></TERM><TERM><![CDATA[Factor Analysis]]></TERM><TERM><![CDATA[Fertility]]></TERM><TERM><![CDATA[Future]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[Income]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[innovation]]></TERM><TERM><![CDATA[insight]]></TERM><TERM><![CDATA[Intervention]]></TERM><TERM><![CDATA[Knowledge]]></TERM><TERM><![CDATA[Life]]></TERM><TERM><![CDATA[Literature]]></TERM><TERM><![CDATA[Longitudinal Surveys]]></TERM><TERM><![CDATA[Measurement]]></TERM><TERM><![CDATA[Measures]]></TERM><TERM><![CDATA[member]]></TERM><TERM><![CDATA[Methods]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Morphologic artifacts]]></TERM><TERM><![CDATA[motherhood]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[Outcome]]></TERM><TERM><![CDATA[Pattern]]></TERM><TERM><![CDATA[Population]]></TERM><TERM><![CDATA[population based]]></TERM><TERM><![CDATA[population health]]></TERM><TERM><![CDATA[Predictive Value]]></TERM><TERM><![CDATA[Probability]]></TERM><TERM><![CDATA[Procedures]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[prototype]]></TERM><TERM><![CDATA[Proxy]]></TERM><TERM><![CDATA[Psychology]]></TERM><TERM><![CDATA[Reporting]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Resources]]></TERM><TERM><![CDATA[Respondent]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Sampling]]></TERM><TERM><![CDATA[Series]]></TERM><TERM><![CDATA[Site]]></TERM><TERM><![CDATA[social]]></TERM><TERM><![CDATA[socioeconomics]]></TERM><TERM><![CDATA[Sorting - Cell Movement]]></TERM><TERM><![CDATA[statistics]]></TERM><TERM><![CDATA[Structure]]></TERM><TERM><![CDATA[Subgroup]]></TERM><TERM><![CDATA[Surveys]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[theories]]></TERM><TERM><![CDATA[Thinking, function]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[Woman]]></TERM><TERM><![CDATA[young woman]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Using Innovative Analyses of Attitudes to Predict Fertility-Related Behavior]]></PROJECT_TITLE><SERIAL_NUMBER>081290</SERIAL_NUMBER><STUDY_SECTION>CHHD</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Pediatrics Subcommittee ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>34875</DIRECT_COST_AMT><INDIRECT_COST_AMT>4211</INDIRECT_COST_AMT><TOTAL_COST>39086</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9134516</APPLICATION_ID><ACTIVITY>Y01</ACTIVITY><ADMINISTERING_IC>HL</ADMINISTERING_IC><APPLICATION_TYPE></APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE></AWARD_NOTICE_DATE><BUDGET_START></BUDGET_START><BUDGET_END></BUDGET_END><CFDA_CODE>837</CFDA_CODE><CORE_PROJECT_NUM>Y01HL120040</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER></FOA_NUMBER><FULL_PROJECT_NUM>AHL12004001-1-0-1</FULL_PROJECT_NUM><FUNDING_ICs>NHLBI:1698396\</FUNDING_ICs><FUNDING_MECHANISM>INTERAGENCY AGREEMENTS</FUNDING_MECHANISM><FY>2015</FY><IC_NAME>NATIONAL HEART, LUNG, AND BLOOD INSTITUTE</IC_NAME><NIH_SPENDING_CATS><CATEGORY><![CDATA[Cardiovascular]]></CATEGORY><CATEGORY><![CDATA[Heart Disease]]></CATEGORY><CATEGORY><![CDATA[Hematology]]></CATEGORY><CATEGORY><![CDATA[Prevention]]></CATEGORY></NIH_SPENDING_CATS><ORG_CITY></ORG_CITY><ORG_COUNTRY></ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT></ORG_DISTRICT><ORG_DUNS></ORG_DUNS><ORG_FIPS></ORG_FIPS><ORG_NAME><![CDATA[NATIONAL HEART, LUNG, AND BLOOD INSTITUTE]]></ORG_NAME><ORG_STATE></ORG_STATE><ORG_ZIPCODE></ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>,  </PI_NAME><PI_ID></PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START></PROJECT_START><PROJECT_END></PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Adherence (attribute)]]></TERM><TERM><![CDATA[Clinic]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[Consumption]]></TERM><TERM><![CDATA[Country]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[disability]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Glean]]></TERM><TERM><![CDATA[Guidelines]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Heart]]></TERM><TERM><![CDATA[Heart Diseases]]></TERM><TERM><![CDATA[Hematological Disease]]></TERM><TERM><![CDATA[high risk]]></TERM><TERM><![CDATA[Hypotension]]></TERM><TERM><![CDATA[Institutes]]></TERM><TERM><![CDATA[Lung]]></TERM><TERM><![CDATA[Lung diseases]]></TERM><TERM><![CDATA[Monitor]]></TERM><TERM><![CDATA[Morbidity - disease rate]]></TERM><TERM><![CDATA[Mortality Vital Statistics]]></TERM><TERM><![CDATA[NHANES]]></TERM><TERM><![CDATA[Penetration]]></TERM><TERM><![CDATA[Population]]></TERM><TERM><![CDATA[Prevalence]]></TERM><TERM><![CDATA[Prevention education]]></TERM><TERM><![CDATA[Risk Factors]]></TERM><TERM><![CDATA[Sleep Disorders]]></TERM><TERM><![CDATA[Sodium]]></TERM><TERM><![CDATA[Source]]></TERM><TERM><![CDATA[standardize measure]]></TERM><TERM><![CDATA[Subgroup]]></TERM><TERM><![CDATA[success]]></TERM><TERM><![CDATA[Surveys]]></TERM><TERM><![CDATA[Travel]]></TERM><TERM><![CDATA[trend]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[NHANES]]></PROJECT_TITLE><SERIAL_NUMBER></SERIAL_NUMBER><STUDY_SECTION></STUDY_SECTION><STUDY_SECTION_NAME xsi:nil='true' /><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR></SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>1698396</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9135757</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>DK</ADMINISTERING_IC><APPLICATION_TYPE>6</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/06/2015</AWARD_NOTICE_DATE><BUDGET_START>09/01/2015</BUDGET_START><BUDGET_END>07/31/2016</BUDGET_END><CFDA_CODE>847</CFDA_CODE><CORE_PROJECT_NUM>R01DK097096</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>PAR-10-038</FOA_NUMBER><FULL_PROJECT_NUM>6R01DK097096-04</FULL_PROJECT_NUM><FUNDING_ICs>NIDDK:618330\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2015</FY><IC_NAME>NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>BRONX</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>14</ORG_DISTRICT><ORG_DUNS>079783367</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[ALBERT EINSTEIN COLLEGE OF MEDICINE]]></ORG_NAME><ORG_STATE>NY</ORG_STATE><ORG_ZIPCODE>104611975</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: The Participatory Implementation Model for School Wellness Planning. This study will introduce and evaluate a participatory implementation model to address barriers and improve school-based programming to achieve obesity-related health recommendations. This approach engages students, teachers, school staff members, and community members in the decision making process. Barriers will be addressed at both the school and student level. This study will be conducted in New York City high schools in partnership with HealthCorps, a nationwide non-profit agency. This study will assess the impact of wellness programming on student health behaviors, in relation to their school environment, and will use simulation modeling to evaluate the process by which wellness programming is adapted and sustained over time.]]></PHR><PIS><PI><PI_NAME>WYLIE-ROSETT, JUDITH </PI_NAME><PI_ID>1876554</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>KUCZMARSKI, ROBERT J</PROGRAM_OFFICER_NAME><PROJECT_START>09/01/2013</PROJECT_START><PROJECT_END>07/31/2017</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Achievement]]></TERM><TERM><![CDATA[Action Research]]></TERM><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[Adolescence]]></TERM><TERM><![CDATA[Adolescent]]></TERM><TERM><![CDATA[Adoption]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Behavior]]></TERM><TERM><![CDATA[Behavioral]]></TERM><TERM><![CDATA[Beverages]]></TERM><TERM><![CDATA[Body mass index]]></TERM><TERM><![CDATA[Chronic Disease]]></TERM><TERM><![CDATA[Communities]]></TERM><TERM><![CDATA[Complex]]></TERM><TERM><![CDATA[cost]]></TERM><TERM><![CDATA[Crowding]]></TERM><TERM><![CDATA[Decision Making]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Diet]]></TERM><TERM><![CDATA[Educational aspects]]></TERM><TERM><![CDATA[Educational Curriculum]]></TERM><TERM><![CDATA[Effectiveness]]></TERM><TERM><![CDATA[Electronic Mail]]></TERM><TERM><![CDATA[Elements]]></TERM><TERM><![CDATA[empowered]]></TERM><TERM><![CDATA[Enrollment]]></TERM><TERM><![CDATA[Ensure]]></TERM><TERM><![CDATA[Environment]]></TERM><TERM><![CDATA[Equipment]]></TERM><TERM><![CDATA[Evaluation]]></TERM><TERM><![CDATA[evidence base]]></TERM><TERM><![CDATA[Exercise]]></TERM><TERM><![CDATA[fast food]]></TERM><TERM><![CDATA[Food Services]]></TERM><TERM><![CDATA[Foundations]]></TERM><TERM><![CDATA[Frequencies (time pattern)]]></TERM><TERM><![CDATA[Fruit]]></TERM><TERM><![CDATA[fruits and vegetables]]></TERM><TERM><![CDATA[Generations]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Guidelines]]></TERM><TERM><![CDATA[Habits]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Health behavior]]></TERM><TERM><![CDATA[Healthy People 2020]]></TERM><TERM><![CDATA[high school]]></TERM><TERM><![CDATA[High School Student]]></TERM><TERM><![CDATA[Home environment]]></TERM><TERM><![CDATA[Hour]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[Institutes]]></TERM><TERM><![CDATA[Intake]]></TERM><TERM><![CDATA[Intervention]]></TERM><TERM><![CDATA[Life Style]]></TERM><TERM><![CDATA[Maintenance]]></TERM><TERM><![CDATA[member]]></TERM><TERM><![CDATA[Methods]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[models and simulation]]></TERM><TERM><![CDATA[Motivation]]></TERM><TERM><![CDATA[New York City]]></TERM><TERM><![CDATA[nutrition]]></TERM><TERM><![CDATA[Obesity]]></TERM><TERM><![CDATA[obesity prevention]]></TERM><TERM><![CDATA[Outcome]]></TERM><TERM><![CDATA[Output]]></TERM><TERM><![CDATA[Pattern]]></TERM><TERM><![CDATA[Physical activity]]></TERM><TERM><![CDATA[Physical Education]]></TERM><TERM><![CDATA[Policies]]></TERM><TERM><![CDATA[prevent]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[programs]]></TERM><TERM><![CDATA[Randomized]]></TERM><TERM><![CDATA[Recommendation]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Resources]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[School Teachers]]></TERM><TERM><![CDATA[Schools]]></TERM><TERM><![CDATA[sedentary]]></TERM><TERM><![CDATA[Self Efficacy]]></TERM><TERM><![CDATA[simulation]]></TERM><TERM><![CDATA[social]]></TERM><TERM><![CDATA[Students]]></TERM><TERM><![CDATA[System]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Text]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[Training Programs]]></TERM><TERM><![CDATA[Underrepresented Minority]]></TERM><TERM><![CDATA[Weight Gain]]></TERM><TERM><![CDATA[Wellness Program]]></TERM><TERM><![CDATA[Youth]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Wellness Program Implementation: School & Student Toolkits]]></PROJECT_TITLE><SERIAL_NUMBER>097096</SERIAL_NUMBER><STUDY_SECTION>DIRH</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Dissemination and Implementation Research in Health Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>04</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>423290</DIRECT_COST_AMT><INDIRECT_COST_AMT>195040</INDIRECT_COST_AMT><TOTAL_COST>618330</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9136279</APPLICATION_ID><ACTIVITY>P30</ACTIVITY><ADMINISTERING_IC>DK</ADMINISTERING_IC><APPLICATION_TYPE>6</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/03/2015</AWARD_NOTICE_DATE><BUDGET_START>09/01/2015</BUDGET_START><BUDGET_END>03/31/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>P30DK020541</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-DK-13-004</FOA_NUMBER><FULL_PROJECT_NUM>6P30DK020541-39</FULL_PROJECT_NUM><FUNDING_ICs>NIDDK:118666\</FUNDING_ICs><FUNDING_MECHANISM>RESEARCH CENTERS</FUNDING_MECHANISM><FY>2015</FY><IC_NAME>NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES</IC_NAME><NIH_SPENDING_CATS><CATEGORY><![CDATA[Clinical Research]]></CATEGORY><CATEGORY><![CDATA[Diabetes]]></CATEGORY><CATEGORY><![CDATA[Nutrition]]></CATEGORY><CATEGORY><![CDATA[Prevention]]></CATEGORY></NIH_SPENDING_CATS><ORG_CITY>BRONX</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>14</ORG_DISTRICT><ORG_DUNS>079783367</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[ALBERT EINSTEIN COLLEGE OF MEDICINE]]></ORG_NAME><ORG_STATE>NY</ORG_STATE><ORG_ZIPCODE>104611975</ORG_ZIPCODE><PHR><![CDATA[The Translational Research Core provides cost effective, thoughtful design and implementation of human- 
based clinical and population based studies with Einstein-Mount Sinai Diabetes Research Center members to 
improve our understanding and treatment of patients with diabetes.]]></PHR><PIS><PI><PI_NAME>CRANDALL, JILL P</PI_NAME><PI_ID>6421719</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START></PROJECT_START><PROJECT_END></PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Award]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Basic Science]]></TERM><TERM><![CDATA[Behavioral]]></TERM><TERM><![CDATA[bench to bedside]]></TERM><TERM><![CDATA[Biological Models]]></TERM><TERM><![CDATA[Biopsy]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[Clinical Investigator]]></TERM><TERM><![CDATA[Clinical Research]]></TERM><TERM><![CDATA[Clinical Sciences]]></TERM><TERM><![CDATA[Clinical Trials]]></TERM><TERM><![CDATA[Cohort Studies]]></TERM><TERM><![CDATA[Collaborations]]></TERM><TERM><![CDATA[college]]></TERM><TERM><![CDATA[Communities]]></TERM><TERM><![CDATA[comparative effectiveness]]></TERM><TERM><![CDATA[Consultations]]></TERM><TERM><![CDATA[cost effective]]></TERM><TERM><![CDATA[Defect]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[diabetes control]]></TERM><TERM><![CDATA[Diabetes Mellitus]]></TERM><TERM><![CDATA[Diabetes prevention]]></TERM><TERM><![CDATA[effectiveness research]]></TERM><TERM><![CDATA[Faculty]]></TERM><TERM><![CDATA[Fatty acid glycerol esters]]></TERM><TERM><![CDATA[Growth]]></TERM><TERM><![CDATA[high risk]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[Human Resources]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[Infusion procedures]]></TERM><TERM><![CDATA[innovation]]></TERM><TERM><![CDATA[Institutes]]></TERM><TERM><![CDATA[Laboratories]]></TERM><TERM><![CDATA[medical schools]]></TERM><TERM><![CDATA[Medicine]]></TERM><TERM><![CDATA[member]]></TERM><TERM><![CDATA[Mentors]]></TERM><TERM><![CDATA[Metabolic]]></TERM><TERM><![CDATA[Metabolism]]></TERM><TERM><![CDATA[Methodology]]></TERM><TERM><![CDATA[Mission]]></TERM><TERM><![CDATA[Muscle]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[Obesity]]></TERM><TERM><![CDATA[Outcomes Research]]></TERM><TERM><![CDATA[Patient-Focused Outcomes]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Physiological]]></TERM><TERM><![CDATA[Physiology]]></TERM><TERM><![CDATA[population based]]></TERM><TERM><![CDATA[Positioning Attribute]]></TERM><TERM><![CDATA[Prevention]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[programs]]></TERM><TERM><![CDATA[Protocols documentation]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Research Design]]></TERM><TERM><![CDATA[Research Infrastructure]]></TERM><TERM><![CDATA[Research Methodology]]></TERM><TERM><![CDATA[Research Personnel]]></TERM><TERM><![CDATA[Research Priority]]></TERM><TERM><![CDATA[Research Project Grants]]></TERM><TERM><![CDATA[research study]]></TERM><TERM><![CDATA[Resources]]></TERM><TERM><![CDATA[Scientist]]></TERM><TERM><![CDATA[Services]]></TERM><TERM><![CDATA[Techniques]]></TERM><TERM><![CDATA[Tracer]]></TERM><TERM><![CDATA[Training]]></TERM><TERM><![CDATA[Training and Education]]></TERM><TERM><![CDATA[Training and Infrastructure]]></TERM><TERM><![CDATA[Training Support]]></TERM><TERM><![CDATA[Translational Research]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Translational Research Core]]></PROJECT_TITLE><SERIAL_NUMBER>020541</SERIAL_NUMBER><STUDY_SECTION>ZDK1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID>7656</SUBPROJECT_ID><SUPPORT_YEAR>39</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>75509</DIRECT_COST_AMT><INDIRECT_COST_AMT>43157</INDIRECT_COST_AMT><TOTAL_COST /><TOTAL_COST_SUB_PROJECT>118666</TOTAL_COST_SUB_PROJECT></row>
<row><APPLICATION_ID>9138202</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>NS</ADMINISTERING_IC><APPLICATION_TYPE>7</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/02/2015</AWARD_NOTICE_DATE><BUDGET_START>09/05/2015</BUDGET_START><BUDGET_END>05/31/2016</BUDGET_END><CFDA_CODE>853</CFDA_CODE><CORE_PROJECT_NUM>R01NS087227</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>PA-14-078</FOA_NUMBER><FULL_PROJECT_NUM>7R01NS087227-03</FULL_PROJECT_NUM><FUNDING_ICs>NINDS:245226\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2015</FY><IC_NAME>NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>BOSTON</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>08</ORG_DISTRICT><ORG_DUNS>073130411</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[MASSACHUSETTS GENERAL HOSPITAL]]></ORG_NAME><ORG_STATE>MA</ORG_STATE><ORG_ZIPCODE>021142696</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: The most frequent cause of two devastating neurodegenerative diseases amyotrophic lateral sclerosis (ALS) (also called Lou Gehrig's disease) and frontotemporal dementia (FTD) has recently been identified in the uncharacterized C9orf72 gene. We will use state of the art sequencing approaches to identify disease mechanisms and screen therapeutic compounds.]]></PHR><PIS><PI><PI_NAME>LAGIER-TOURENNE, CLOTILDE </PI_NAME><PI_ID>14241626</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>GUBITZ, AMELIE </PROGRAM_OFFICER_NAME><PROJECT_START>09/05/2015</PROJECT_START><PROJECT_END>05/31/2019</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[Amyotrophic Lateral Sclerosis]]></TERM><TERM><![CDATA[Antisense Oligonucleotides]]></TERM><TERM><![CDATA[Binding (Molecular Function)]]></TERM><TERM><![CDATA[C9orf72]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Chemicals]]></TERM><TERM><![CDATA[Clinical Trials]]></TERM><TERM><![CDATA[Collaborations]]></TERM><TERM><![CDATA[Consensus]]></TERM><TERM><![CDATA[cost effective]]></TERM><TERM><![CDATA[cytotoxic]]></TERM><TERM><![CDATA[cytotoxicity]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[Dipeptides]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[drug efficacy]]></TERM><TERM><![CDATA[Employee Strikes]]></TERM><TERM><![CDATA[Engineering]]></TERM><TERM><![CDATA[Familial Amyotrophic Lateral Sclerosis]]></TERM><TERM><![CDATA[FDA approved]]></TERM><TERM><![CDATA[Fibroblasts]]></TERM><TERM><![CDATA[Frontotemporal Dementia]]></TERM><TERM><![CDATA[gain of function]]></TERM><TERM><![CDATA[Genes]]></TERM><TERM><![CDATA[Genetic]]></TERM><TERM><![CDATA[Genetic Transcription]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[high throughput screening]]></TERM><TERM><![CDATA[High-Throughput Nucleotide Sequencing]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[In Vitro]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[induced pluripotent stem cell]]></TERM><TERM><![CDATA[innovation]]></TERM><TERM><![CDATA[Link]]></TERM><TERM><![CDATA[loss of function]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[Messenger RNA]]></TERM><TERM><![CDATA[Methods]]></TERM><TERM><![CDATA[Molecular Profiling]]></TERM><TERM><![CDATA[Motor Cortex]]></TERM><TERM><![CDATA[Motor Neurons]]></TERM><TERM><![CDATA[Nerve Degeneration]]></TERM><TERM><![CDATA[Neurodegenerative Disorders]]></TERM><TERM><![CDATA[Neurons]]></TERM><TERM><![CDATA[novel therapeutics]]></TERM><TERM><![CDATA[Pathogenesis]]></TERM><TERM><![CDATA[Pathway interactions]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Pharmaceutical Preparations]]></TERM><TERM><![CDATA[Play]]></TERM><TERM><![CDATA[Preclinical Drug Evaluation]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[Production]]></TERM><TERM><![CDATA[Property]]></TERM><TERM><![CDATA[Proteins]]></TERM><TERM><![CDATA[Reporting]]></TERM><TERM><![CDATA[RNA]]></TERM><TERM><![CDATA[RNA Processing]]></TERM><TERM><![CDATA[RNA Splicing]]></TERM><TERM><![CDATA[RNA-Binding Proteins]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[screening]]></TERM><TERM><![CDATA[Seminal]]></TERM><TERM><![CDATA[small molecule]]></TERM><TERM><![CDATA[Spinal]]></TERM><TERM><![CDATA[System]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Therapeutic]]></TERM><TERM><![CDATA[therapeutic development]]></TERM><TERM><![CDATA[therapy development]]></TERM><TERM><![CDATA[Toxic effect]]></TERM><TERM><![CDATA[Transcript]]></TERM><TERM><![CDATA[Translating]]></TERM><TERM><![CDATA[Translations]]></TERM><TERM><![CDATA[Untranslated RNA]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Using RNA signatures for therapy development in neurodegeneration due to C9orf72 expansions]]></PROJECT_TITLE><SERIAL_NUMBER>087227</SERIAL_NUMBER><STUDY_SECTION>CMND</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Cellular and Molecular Biology of Neurodegeneration Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>03</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>140935</DIRECT_COST_AMT><INDIRECT_COST_AMT>104291</INDIRECT_COST_AMT><TOTAL_COST>245226</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9146907</APPLICATION_ID><ACTIVITY>U51</ACTIVITY><ADMINISTERING_IC>PS</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/26/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>U51PS004030</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-PS-13-303</FOA_NUMBER><FULL_PROJECT_NUM>5U51PS004030-04</FULL_PROJECT_NUM><FUNDING_ICs>NCHHSTP:271652\</FUNDING_ICs><FUNDING_MECHANISM>OTHERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP)</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>LANSING</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>08</ORG_DISTRICT><ORG_DUNS>113704139</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[MICHIGAN STATE DEPT OF COMMUNITY HEALTH]]></ORG_NAME><ORG_STATE>MI</ORG_STATE><ORG_ZIPCODE>489331617</ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>MACOMBER, KATHRYN EMERY</PI_NAME><PI_ID>11933199</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>11/01/2012</PROJECT_START><PROJECT_END>10/31/2016</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[MICHIGAN DEPT. OF COMMUNITY HEALTH VIRAL HEPATITIS PREVENTION]]></PROJECT_TITLE><SERIAL_NUMBER>004030</SERIAL_NUMBER><STUDY_SECTION>ZPS1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>04</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>271652</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9146916</APPLICATION_ID><ACTIVITY>U51</ACTIVITY><ADMINISTERING_IC>PS</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/23/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>U51PS004046</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-PS-13-303</FOA_NUMBER><FULL_PROJECT_NUM>5U51PS004046-04</FULL_PROJECT_NUM><FUNDING_ICs>NCHHSTP:41452\</FUNDING_ICs><FUNDING_MECHANISM>OTHERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP)</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>HONOLULU</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>01</ORG_DISTRICT><ORG_DUNS>809935679</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[HAWAII STATE DEPARTMENT OF HEALTH]]></ORG_NAME><ORG_STATE>HI</ORG_STATE><ORG_ZIPCODE>968132416</ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>PARK, SARAH </PI_NAME><PI_ID>10806129</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>11/01/2012</PROJECT_START><PROJECT_END>10/31/2016</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[Hawaii Department of Health Category A, Part 1 and Category B Project for Viral H]]></PROJECT_TITLE><SERIAL_NUMBER>004046</SERIAL_NUMBER><STUDY_SECTION>ZPS1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>04</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>41452</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9146924</APPLICATION_ID><ACTIVITY>U51</ACTIVITY><ADMINISTERING_IC>PS</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/23/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>U51PS004052</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-PS-13-303</FOA_NUMBER><FULL_PROJECT_NUM>5U51PS004052-04</FULL_PROJECT_NUM><FUNDING_ICs>NCHHSTP:55035\</FUNDING_ICs><FUNDING_MECHANISM>OTHERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP)</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>DES MOINES</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>03</ORG_DISTRICT><ORG_DUNS>808345920</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[IOWA STATE DEPT OF PUBLIC HEALTH]]></ORG_NAME><ORG_STATE>IA</ORG_STATE><ORG_ZIPCODE>503191002</ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>STONE, KATHY T</PI_NAME><PI_ID>12085596</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>11/01/2012</PROJECT_START><PROJECT_END>10/31/2016</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[VIRAL HEPATITIS - PREVENTION AND SURVEILLANCE]]></PROJECT_TITLE><SERIAL_NUMBER>004052</SERIAL_NUMBER><STUDY_SECTION>ZPS1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>04</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>55035</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9146925</APPLICATION_ID><ACTIVITY>U51</ACTIVITY><ADMINISTERING_IC>PS</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/23/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>U51PS004054</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-PS-13-303</FOA_NUMBER><FULL_PROJECT_NUM>5U51PS004054-04</FULL_PROJECT_NUM><FUNDING_ICs>NCHHSTP:31384\</FUNDING_ICs><FUNDING_MECHANISM>OTHERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP)</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>RALEIGH</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>04</ORG_DISTRICT><ORG_DUNS>809785363</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[NC STATE DEPT/HLTH & HUMAN SERVICES]]></ORG_NAME><ORG_STATE>NC</ORG_STATE><ORG_ZIPCODE>276032040</ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>CLYMORE, JACQUELYN </PI_NAME><PI_ID>14306730</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>11/01/2012</PROJECT_START><PROJECT_END>10/31/2016</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[NORTH CAROLINA VIRAL HEPATITIS PREVENTION ]]></PROJECT_TITLE><SERIAL_NUMBER>004054</SERIAL_NUMBER><STUDY_SECTION>ZPS1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>04</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>31384</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9149051</APPLICATION_ID><ACTIVITY>U51</ACTIVITY><ADMINISTERING_IC>PS</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/23/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>U51PS004064</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-PS-13-303</FOA_NUMBER><FULL_PROJECT_NUM>5U51PS004064-04</FULL_PROJECT_NUM><FUNDING_ICs>NCHHSTP:31215\</FUNDING_ICs><FUNDING_MECHANISM>OTHERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP)</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>BISMARCK</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>00</ORG_DISTRICT><ORG_DUNS>067976824</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[NORTH DAKOTA STATE DEPARTMENT OF HEALTH]]></ORG_NAME><ORG_STATE>ND</ORG_STATE><ORG_ZIPCODE>585050200</ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>KRUGER, KIRBY J</PI_NAME><PI_ID>9142976</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>11/01/2012</PROJECT_START><PROJECT_END>10/31/2016</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[VIRAL HEPATITIS - PREVENTION AND SURVEILLANCE]]></PROJECT_TITLE><SERIAL_NUMBER>004064</SERIAL_NUMBER><STUDY_SECTION>ZPS1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>04</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>31215</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9149053</APPLICATION_ID><ACTIVITY>U51</ACTIVITY><ADMINISTERING_IC>PS</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/23/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>U51PS004067</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-PS-13-303</FOA_NUMBER><FULL_PROJECT_NUM>5U51PS004067-04</FULL_PROJECT_NUM><FUNDING_ICs>NCHHSTP:55195\</FUNDING_ICs><FUNDING_MECHANISM>OTHERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP)</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>LINCOLN</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>01</ORG_DISTRICT><ORG_DUNS>808819957</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[NEBRASKA ST DEPT OF HEALTH & HUMAN SERVS]]></ORG_NAME><ORG_STATE>NE</ORG_STATE><ORG_ZIPCODE>685082529</ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>DEAN, JUDE </PI_NAME><PI_ID>11477739</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>11/01/2012</PROJECT_START><PROJECT_END>10/31/2016</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[NEBRASKA VIRAL HEPATITIS PREVENTION AND SURVEILLANCE PROGRAM]]></PROJECT_TITLE><SERIAL_NUMBER>004067</SERIAL_NUMBER><STUDY_SECTION>ZPS1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>04</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>55195</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9172327</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>ES</ADMINISTERING_IC><APPLICATION_TYPE>7</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/05/2015</AWARD_NOTICE_DATE><BUDGET_START>09/25/2015</BUDGET_START><BUDGET_END>05/31/2016</BUDGET_END><CFDA_CODE>113</CFDA_CODE><CORE_PROJECT_NUM>R01ES021800</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF PHARMACY]]></ED_INST_TYPE><FOA_NUMBER>PA-11-260</FOA_NUMBER><FULL_PROJECT_NUM>7R01ES021800-03</FULL_PROJECT_NUM><FUNDING_ICs>NIEHS:250149\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2015</FY><IC_NAME>NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>ROOTSTOWN</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[PHARMACOLOGY]]></ORG_DEPT><ORG_DISTRICT>16</ORG_DISTRICT><ORG_DUNS>077779882</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[NORTHEAST OHIO MEDICAL UNIVERSITY]]></ORG_NAME><ORG_STATE>OH</ORG_STATE><ORG_ZIPCODE>442720095</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: This project will provide a mechanistic insight into the associations between pesticide exposure, MDR1 genetic variation, and neurodegeneration. By studying the interaction of genetic variation, inflammation, and environmental exposure, we will likely demonstrate the convergence of multiple pathways previously implicated in the pathogenesis of Parkinson's disease. This, in turn, could lead to new avenues in identifying individuals most susceptible to pesticides-induced neurotoxicity and potentially lead to therapeutic interventions to increase clearance of pesticides from the brain.]]></PHR><PIS><PI><PI_NAME>ALEKSUNES, LAUREN M</PI_NAME><PI_ID>8924186</PI_ID></PI><PI><PI_NAME>RICHARDSON, JASON R (contact)</PI_NAME><PI_ID>7536679 (contact)</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>HOLLANDER, JONATHAN </PROGRAM_OFFICER_NAME><PROJECT_START>09/01/2014</PROJECT_START><PROJECT_END>05/31/2019</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[ABCB1 gene]]></TERM><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[Applications Grants]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Blood - brain barrier anatomy]]></TERM><TERM><![CDATA[Brain]]></TERM><TERM><![CDATA[Capillary Endothelial Cell]]></TERM><TERM><![CDATA[Catalytic Domain]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Chemicals]]></TERM><TERM><![CDATA[Chronic]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[Complement]]></TERM><TERM><![CDATA[Complex]]></TERM><TERM><![CDATA[Cultured Cells]]></TERM><TERM><![CDATA[cytokine]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Degenerative Disorder]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[dopaminergic neuron]]></TERM><TERM><![CDATA[Dose]]></TERM><TERM><![CDATA[Down-Regulation]]></TERM><TERM><![CDATA[Engineering]]></TERM><TERM><![CDATA[Environmental Exposure]]></TERM><TERM><![CDATA[Environmental Risk Factor]]></TERM><TERM><![CDATA[Epidemiologic Studies]]></TERM><TERM><![CDATA[Epidemiology]]></TERM><TERM><![CDATA[Etiology]]></TERM><TERM><![CDATA[Event]]></TERM><TERM><![CDATA[Exhibits]]></TERM><TERM><![CDATA[Exposure to]]></TERM><TERM><![CDATA[gene environment interaction]]></TERM><TERM><![CDATA[Genes]]></TERM><TERM><![CDATA[Genetic]]></TERM><TERM><![CDATA[Genetic Polymorphism]]></TERM><TERM><![CDATA[genetic variant]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Herbicides]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[immortalized cell]]></TERM><TERM><![CDATA[In Vitro]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[in vivo Model]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[Inflammation]]></TERM><TERM><![CDATA[Inflammatory]]></TERM><TERM><![CDATA[inhibitor/antagonist]]></TERM><TERM><![CDATA[insight]]></TERM><TERM><![CDATA[Killings]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[Link]]></TERM><TERM><![CDATA[Lipopolysaccharides]]></TERM><TERM><![CDATA[loss of function]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[Messenger RNA]]></TERM><TERM><![CDATA[Microglia]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[NADPH Oxidase]]></TERM><TERM><![CDATA[Nerve Degeneration]]></TERM><TERM><![CDATA[nervous system disorder]]></TERM><TERM><![CDATA[neuroinflammation]]></TERM><TERM><![CDATA[Neurons]]></TERM><TERM><![CDATA[neurotoxicity]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[Orthologous Gene]]></TERM><TERM><![CDATA[overexpression]]></TERM><TERM><![CDATA[P-Glycoprotein]]></TERM><TERM><![CDATA[Paraquat]]></TERM><TERM><![CDATA[Parkinson Disease]]></TERM><TERM><![CDATA[Pathogenesis]]></TERM><TERM><![CDATA[Pathway interactions]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[pesticide exposure]]></TERM><TERM><![CDATA[pesticide induced neurotoxicity]]></TERM><TERM><![CDATA[Pesticides]]></TERM><TERM><![CDATA[Predisposition]]></TERM><TERM><![CDATA[prevent]]></TERM><TERM><![CDATA[Proteins]]></TERM><TERM><![CDATA[Regulation]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Risk]]></TERM><TERM><![CDATA[Risk Factors]]></TERM><TERM><![CDATA[Rodent]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Small Interfering RNA]]></TERM><TERM><![CDATA[Substantia nigra structure]]></TERM><TERM><![CDATA[Techniques]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Therapeutic Intervention]]></TERM><TERM><![CDATA[Toxic effect]]></TERM><TERM><![CDATA[Transgenic Mice]]></TERM><TERM><![CDATA[translational study]]></TERM><TERM><![CDATA[Tumor Necrosis Factor Receptor]]></TERM><TERM><![CDATA[Up-Regulation (Physiology)]]></TERM><TERM><![CDATA[Variation (Genetics)]]></TERM><TERM><![CDATA[Xenobiotics]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Gene-Environment Interactions in Neurodegeneration: Role of Efflux Transporters]]></PROJECT_TITLE><SERIAL_NUMBER>021800</SERIAL_NUMBER><STUDY_SECTION>NAL</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Neurotoxicology and Alcohol Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>03</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>165006</DIRECT_COST_AMT><INDIRECT_COST_AMT>85143</INDIRECT_COST_AMT><TOTAL_COST>250149</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9172438</APPLICATION_ID><ACTIVITY>U01</ACTIVITY><ADMINISTERING_IC>HL</ADMINISTERING_IC><APPLICATION_TYPE>6</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/05/2015</AWARD_NOTICE_DATE><BUDGET_START>11/05/2015</BUDGET_START><BUDGET_END>04/30/2016</BUDGET_END><CFDA_CODE>837</CFDA_CODE><CORE_PROJECT_NUM>U01HL101456</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-HL-10-007</FOA_NUMBER><FULL_PROJECT_NUM>6U01HL101456-06</FULL_PROJECT_NUM><FUNDING_ICs>NHLBI:485429\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2014</FY><IC_NAME>NATIONAL HEART, LUNG, AND BLOOD INSTITUTE</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>BRONX</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>14</ORG_DISTRICT><ORG_DUNS>079783367</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[ALBERT EINSTEIN COLLEGE OF MEDICINE]]></ORG_NAME><ORG_STATE>NY</ORG_STATE><ORG_ZIPCODE>104611975</ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>ASCHNER, JUDY LYNN</PI_NAME><PI_ID>1916235</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>BLAISDELL, CAROL J</PROGRAM_OFFICER_NAME><PROJECT_START>05/01/2010</PROJECT_START><PROJECT_END>04/30/2016</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[Improving Prematurity-related Respiratory Outcomes at Vanderbilt (IMPROV)]]></PROJECT_TITLE><SERIAL_NUMBER>101456</SERIAL_NUMBER><STUDY_SECTION>ZHL1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>06</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>317480</DIRECT_COST_AMT><INDIRECT_COST_AMT>167949</INDIRECT_COST_AMT><TOTAL_COST>485429</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9172448</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>HL</ADMINISTERING_IC><APPLICATION_TYPE>6</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/05/2015</AWARD_NOTICE_DATE><BUDGET_START>11/05/2015</BUDGET_START><BUDGET_END>06/30/2016</BUDGET_END><CFDA_CODE>837</CFDA_CODE><CORE_PROJECT_NUM>R01HL111770</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>PA-11-260</FOA_NUMBER><FULL_PROJECT_NUM>6R01HL111770-05</FULL_PROJECT_NUM><FUNDING_ICs>NHLBI:490539\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2015</FY><IC_NAME>NATIONAL HEART, LUNG, AND BLOOD INSTITUTE</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>BRONX</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>14</ORG_DISTRICT><ORG_DUNS>079783367</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[ALBERT EINSTEIN COLLEGE OF MEDICINE]]></ORG_NAME><ORG_STATE>NY</ORG_STATE><ORG_ZIPCODE>104611975</ORG_ZIPCODE><PHR><![CDATA[The goal of this project is to study cellular and molecular mechanisms of calcific aortic valve stenosis by using newly generated mouse models of the disease. Completion of the project will provide critical information on the underlying pathogenesis of human calcific aortic valve stenosis thereby helping develop new therapeutic and preventive strategies for this devastating human disease.]]></PHR><PIS><PI><PI_NAME>ZHOU, BIN </PI_NAME><PI_ID>7929369</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>EVANS, FRANK </PROGRAM_OFFICER_NAME><PROJECT_START>08/03/2012</PROJECT_START><PROJECT_END>06/30/2016</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Adult]]></TERM><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[Age]]></TERM><TERM><![CDATA[aortic valve]]></TERM><TERM><![CDATA[Aortic Valve Stenosis]]></TERM><TERM><![CDATA[bicuspid aortic valve]]></TERM><TERM><![CDATA[Biology]]></TERM><TERM><![CDATA[bone]]></TERM><TERM><![CDATA[cardiovascular risk factor]]></TERM><TERM><![CDATA[Cell physiology]]></TERM><TERM><![CDATA[ChIP-seq]]></TERM><TERM><![CDATA[Complex]]></TERM><TERM><![CDATA[Congenital Heart Defects]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Degenerative Disorder]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Diet]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Embryo]]></TERM><TERM><![CDATA[Endothelial Cells]]></TERM><TERM><![CDATA[Enhancers]]></TERM><TERM><![CDATA[Essential Genes]]></TERM><TERM><![CDATA[feeding]]></TERM><TERM><![CDATA[Gender]]></TERM><TERM><![CDATA[Genes]]></TERM><TERM><![CDATA[Genetic]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Homeostasis]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[Human Characteristics]]></TERM><TERM><![CDATA[human disease]]></TERM><TERM><![CDATA[Human Genetics]]></TERM><TERM><![CDATA[human old age (65+)]]></TERM><TERM><![CDATA[Hypertension]]></TERM><TERM><![CDATA[Injury]]></TERM><TERM><![CDATA[insight]]></TERM><TERM><![CDATA[interstitial cell]]></TERM><TERM><![CDATA[lipoprotein cholesterol]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[Mesenchymal]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[mouse model]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[mutant]]></TERM><TERM><![CDATA[Mutation]]></TERM><TERM><![CDATA[Non-Insulin-Dependent Diabetes Mellitus]]></TERM><TERM><![CDATA[Notch Signaling Pathway]]></TERM><TERM><![CDATA[NOTCH1 gene]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[novel therapeutics]]></TERM><TERM><![CDATA[osteogenic]]></TERM><TERM><![CDATA[Outcome]]></TERM><TERM><![CDATA[Pathogenesis]]></TERM><TERM><![CDATA[Pathologic]]></TERM><TERM><![CDATA[Pathology]]></TERM><TERM><![CDATA[Pathway interactions]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Population]]></TERM><TERM><![CDATA[prevent]]></TERM><TERM><![CDATA[Prevention strategy]]></TERM><TERM><![CDATA[Principal Investigator]]></TERM><TERM><![CDATA[programs]]></TERM><TERM><![CDATA[Risk]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Sclerosis]]></TERM><TERM><![CDATA[semilunar valve]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[Staging]]></TERM><TERM><![CDATA[Surgical Valves]]></TERM><TERM><![CDATA[Syndrome]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[transcriptome sequencing]]></TERM><TERM><![CDATA[valve replacement]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Molecular and Cellular Mechanisms of Calcific Aortic Stenosis]]></PROJECT_TITLE><SERIAL_NUMBER>111770</SERIAL_NUMBER><STUDY_SECTION>AICS</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Atherosclerosis and Inflammation of the Cardiovascular System Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>05</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>293736</DIRECT_COST_AMT><INDIRECT_COST_AMT>196803</INDIRECT_COST_AMT><TOTAL_COST>490539</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9172470</APPLICATION_ID><ACTIVITY>R21</ACTIVITY><ADMINISTERING_IC>HL</ADMINISTERING_IC><APPLICATION_TYPE>6</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/05/2015</AWARD_NOTICE_DATE><BUDGET_START>11/05/2015</BUDGET_START><BUDGET_END>04/30/2016</BUDGET_END><CFDA_CODE>837</CFDA_CODE><CORE_PROJECT_NUM>R21HL118637</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>PAR-09-219</FOA_NUMBER><FULL_PROJECT_NUM>6R21HL118637-03</FULL_PROJECT_NUM><FUNDING_ICs>NHLBI:168860\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2014</FY><IC_NAME>NATIONAL HEART, LUNG, AND BLOOD INSTITUTE</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>BRONX</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>14</ORG_DISTRICT><ORG_DUNS>079783367</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[ALBERT EINSTEIN COLLEGE OF MEDICINE]]></ORG_NAME><ORG_STATE>NY</ORG_STATE><ORG_ZIPCODE>104611975</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Genome-wide association studies have produced over a thousand significant associations but these findings only explain a small proportion of the heritability for most common diseases and traits. Genetic heterogeneity is one of the major reasons for failure to identify associations. Our projects will provide a new statistical tool to tackle this important question to facilitate the efforts of finding important genes of complex diseases. Using the developed approach to analyze a large dataset of structural cardiovascular malformations, this project has the potential to produce novel genetic variants, genes and pathways, providing an insight into biological mechanisms.]]></PHR><PIS><PI><PI_NAME>WANG, TAO </PI_NAME><PI_ID>9233539</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>KALTMAN, JONATHAN R</PROGRAM_OFFICER_NAME><PROJECT_START>08/01/2013</PROJECT_START><PROJECT_END>04/30/2016</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[Statistical Method for Identifying Genetic Modifiers of Conotruncal Heart De]]></PROJECT_TITLE><SERIAL_NUMBER>118637</SERIAL_NUMBER><STUDY_SECTION>CASE</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Cardiovascular and Sleep Epidemiology ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>03</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>101114</DIRECT_COST_AMT><INDIRECT_COST_AMT>67746</INDIRECT_COST_AMT><TOTAL_COST>168860</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9172485</APPLICATION_ID><ACTIVITY>UH3</ACTIVITY><ADMINISTERING_IC>HL</ADMINISTERING_IC><APPLICATION_TYPE>6</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/06/2015</AWARD_NOTICE_DATE><BUDGET_START>11/06/2015</BUDGET_START><BUDGET_END>07/31/2016</BUDGET_END><CFDA_CODE>837</CFDA_CODE><CORE_PROJECT_NUM>UH3HL125119</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-HL-14-019</FOA_NUMBER><FULL_PROJECT_NUM>6UH3HL125119-03</FULL_PROJECT_NUM><FUNDING_ICs>NHLBI:457591\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2015</FY><IC_NAME>NATIONAL HEART, LUNG, AND BLOOD INSTITUTE</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>BRONX</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>14</ORG_DISTRICT><ORG_DUNS>079783367</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[ALBERT EINSTEIN COLLEGE OF MEDICINE]]></ORG_NAME><ORG_STATE>NY</ORG_STATE><ORG_ZIPCODE>104611975</ORG_ZIPCODE><PHR><![CDATA[RELEVANCE
Severe acute respiratory failure with prolonged mechanical ventilation is a common and morbid
condition with high mortality. By intervening in high risk patients early in their hospital course,
before organ damage is established, by alerting providers to their patient's risk and prompting
them towards greater adherence to proven therapies, this project aims to change the paradigm
of how acute respiratory failure is managed and improve short and long term survival in a large
proportion of patients admitted to the hospital.]]></PHR><PIS><PI><PI_NAME>GAJIC, OGNJEN </PI_NAME><PI_ID>7924601</PI_ID></PI><PI><PI_NAME>GONG, MICHELLE NG (contact)</PI_NAME><PI_ID>6271418 (contact)</PI_ID></PI><PI><PI_NAME>TALMOR, DANIEL STUART</PI_NAME><PI_ID>9535238</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>REINECK, LORA A</PROGRAM_OFFICER_NAME><PROJECT_START>09/19/2014</PROJECT_START><PROJECT_END>07/31/2019</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Acute]]></TERM><TERM><![CDATA[Acute respiratory failure]]></TERM><TERM><![CDATA[Adherence (attribute)]]></TERM><TERM><![CDATA[Admission activity]]></TERM><TERM><![CDATA[Adult Respiratory Distress Syndrome]]></TERM><TERM><![CDATA[Adverse event]]></TERM><TERM><![CDATA[Area]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Caring]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[Clinical Trials]]></TERM><TERM><![CDATA[Clinical Trials Data Monitoring Committees]]></TERM><TERM><![CDATA[Communities]]></TERM><TERM><![CDATA[Computerized Medical Record]]></TERM><TERM><![CDATA[cost]]></TERM><TERM><![CDATA[Critical Care]]></TERM><TERM><![CDATA[Critical Illness]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Data Collection]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Early identification]]></TERM><TERM><![CDATA[Electronics]]></TERM><TERM><![CDATA[Ensure]]></TERM><TERM><![CDATA[Environmental air flow]]></TERM><TERM><![CDATA[Etiology]]></TERM><TERM><![CDATA[Event]]></TERM><TERM><![CDATA[Foundations]]></TERM><TERM><![CDATA[functional disability]]></TERM><TERM><![CDATA[Functional disorder]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Healthcare]]></TERM><TERM><![CDATA[high risk]]></TERM><TERM><![CDATA[Home environment]]></TERM><TERM><![CDATA[Hospital Mortality]]></TERM><TERM><![CDATA[Hospitals]]></TERM><TERM><![CDATA[Hour]]></TERM><TERM><![CDATA[Impaired cognition]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[Injury]]></TERM><TERM><![CDATA[Institutional Review Boards]]></TERM><TERM><![CDATA[Intensive Care Units]]></TERM><TERM><![CDATA[Intervention]]></TERM><TERM><![CDATA[knowledge translation]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[Length of Stay]]></TERM><TERM><![CDATA[lung injury]]></TERM><TERM><![CDATA[Mechanical ventilation]]></TERM><TERM><![CDATA[member]]></TERM><TERM><![CDATA[Methodology]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Monitor]]></TERM><TERM><![CDATA[Morbidity - disease rate]]></TERM><TERM><![CDATA[Mortality Vital Statistics]]></TERM><TERM><![CDATA[multidisciplinary]]></TERM><TERM><![CDATA[Multiple Organ Failure]]></TERM><TERM><![CDATA[Organ]]></TERM><TERM><![CDATA[Organ failure]]></TERM><TERM><![CDATA[Outcome]]></TERM><TERM><![CDATA[Patient Care]]></TERM><TERM><![CDATA[patient oriented]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Phase]]></TERM><TERM><![CDATA[pragmatic trial]]></TERM><TERM><![CDATA[prevent]]></TERM><TERM><![CDATA[Prevention]]></TERM><TERM><![CDATA[primary outcome]]></TERM><TERM><![CDATA[Principal Investigator]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[Provider]]></TERM><TERM><![CDATA[Randomized Clinical Trials]]></TERM><TERM><![CDATA[Randomized Controlled Trials]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Research Infrastructure]]></TERM><TERM><![CDATA[Sample Size]]></TERM><TERM><![CDATA[secondary outcome]]></TERM><TERM><![CDATA[Secondary Prevention]]></TERM><TERM><![CDATA[tool]]></TERM><TERM><![CDATA[United States]]></TERM><TERM><![CDATA[Ventilator]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Prevention of Severe Acute Respiratory Failure in Patients with PROOFCheck - an E]]></PROJECT_TITLE><SERIAL_NUMBER>125119</SERIAL_NUMBER><STUDY_SECTION>ZHL1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>03</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>274007</DIRECT_COST_AMT><INDIRECT_COST_AMT>183584</INDIRECT_COST_AMT><TOTAL_COST>457591</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9172492</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>HL</ADMINISTERING_IC><APPLICATION_TYPE>6</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/06/2015</AWARD_NOTICE_DATE><BUDGET_START>11/06/2015</BUDGET_START><BUDGET_END>02/29/2016</BUDGET_END><CFDA_CODE>837</CFDA_CODE><CORE_PROJECT_NUM>R01HL128066</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>PA-13-302</FOA_NUMBER><FULL_PROJECT_NUM>6R01HL128066-02</FULL_PROJECT_NUM><FUNDING_ICs>NHLBI:275344\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2015</FY><IC_NAME>NATIONAL HEART, LUNG, AND BLOOD INSTITUTE</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>BRONX</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>14</ORG_DISTRICT><ORG_DUNS>079783367</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[ALBERT EINSTEIN COLLEGE OF MEDICINE]]></ORG_NAME><ORG_STATE>NY</ORG_STATE><ORG_ZIPCODE>104611975</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE:  Atherosclerosis is the leading cause of death and disability in Western-style societies, with rapidly increasing incidence worldwide. The most serious consequences of atherosclerosis are caused by blood clots that form at sites of partial arterial narrowing called plaques. These plaques, which contain deposits of excess cholesterol and dead cells, expand and weaken the lining of the arterial wall; with progressive weakening, the plaques can rupture, and these sudden rupture events cause local clot formation, which can completely occlude the artery and block blood flow to vital organs. The goal of this project is to find new ways to prevent plaque expansion and weakening, and so to decrease the catastrophic end results of atherosclerosis, including unstable angina, myocardial infarction, and stroke.   
      

]]></PHR><PIS><PI><PI_NAME>SIBINGA, NICHOLAS E</PI_NAME><PI_ID>1939506</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>OLIVE, MICHELLE </PROGRAM_OFFICER_NAME><PROJECT_START>03/16/2015</PROJECT_START><PROJECT_END>02/28/2019</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Abbreviations]]></TERM><TERM><![CDATA[Actins]]></TERM><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[allograft inflammatory factor-1]]></TERM><TERM><![CDATA[Apolipoprotein E]]></TERM><TERM><![CDATA[Arterial Fatty Streak]]></TERM><TERM><![CDATA[Arterial Lines]]></TERM><TERM><![CDATA[Arteries]]></TERM><TERM><![CDATA[atherogenesis]]></TERM><TERM><![CDATA[Atherosclerosis]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Binding (Molecular Function)]]></TERM><TERM><![CDATA[Blood coagulation]]></TERM><TERM><![CDATA[Blood flow]]></TERM><TERM><![CDATA[Blood Vessels]]></TERM><TERM><![CDATA[Bone Marrow]]></TERM><TERM><![CDATA[Bundling]]></TERM><TERM><![CDATA[Cause of Death]]></TERM><TERM><![CDATA[Cell Cycle]]></TERM><TERM><![CDATA[Cell Death]]></TERM><TERM><![CDATA[Cell physiology]]></TERM><TERM><![CDATA[Cell Surface Receptors]]></TERM><TERM><![CDATA[cell type]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Cessation of life]]></TERM><TERM><![CDATA[Characteristics]]></TERM><TERM><![CDATA[Cholesterol]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[Coagulation Process]]></TERM><TERM><![CDATA[cytokine]]></TERM><TERM><![CDATA[Cytoplasm]]></TERM><TERM><![CDATA[Deposition]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Diet]]></TERM><TERM><![CDATA[disability]]></TERM><TERM><![CDATA[Event]]></TERM><TERM><![CDATA[extracellular]]></TERM><TERM><![CDATA[Fatty acid glycerol esters]]></TERM><TERM><![CDATA[feeding]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Growth]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[In Vitro]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[Incidence]]></TERM><TERM><![CDATA[Inflammation]]></TERM><TERM><![CDATA[Inflammatory]]></TERM><TERM><![CDATA[insight]]></TERM><TERM><![CDATA[Interleukins]]></TERM><TERM><![CDATA[Intervention]]></TERM><TERM><![CDATA[Knock-out]]></TERM><TERM><![CDATA[Left]]></TERM><TERM><![CDATA[macrophage]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[migration]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[monocyte]]></TERM><TERM><![CDATA[mouse model]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[Myocardial Infarction]]></TERM><TERM><![CDATA[Necrosis]]></TERM><TERM><![CDATA[NF-kappa B]]></TERM><TERM><![CDATA[novel therapeutics]]></TERM><TERM><![CDATA[Organ]]></TERM><TERM><![CDATA[overexpression]]></TERM><TERM><![CDATA[paracrine]]></TERM><TERM><![CDATA[Pathway interactions]]></TERM><TERM><![CDATA[Phagocytosis]]></TERM><TERM><![CDATA[Physiological]]></TERM><TERM><![CDATA[Play]]></TERM><TERM><![CDATA[prevent]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[Production]]></TERM><TERM><![CDATA[Proteins]]></TERM><TERM><![CDATA[public health medicine (field)]]></TERM><TERM><![CDATA[public health relevance]]></TERM><TERM><![CDATA[Recombinants]]></TERM><TERM><![CDATA[Relative (related person)]]></TERM><TERM><![CDATA[Reporting]]></TERM><TERM><![CDATA[response to injury]]></TERM><TERM><![CDATA[restoration]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Rupture]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[Site]]></TERM><TERM><![CDATA[Small Interfering RNA]]></TERM><TERM><![CDATA[Smooth Muscle Myocytes]]></TERM><TERM><![CDATA[Societies]]></TERM><TERM><![CDATA[Staging]]></TERM><TERM><![CDATA[stroke]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[theories]]></TERM><TERM><![CDATA[Therapeutic]]></TERM><TERM><![CDATA[therapeutic target]]></TERM><TERM><![CDATA[Transgenic Mice]]></TERM><TERM><![CDATA[Unstable angina]]></TERM><TERM><![CDATA[Vascular remodeling]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Allograft inflammatory factor-1 in atherosclerosis]]></PROJECT_TITLE><SERIAL_NUMBER>128066</SERIAL_NUMBER><STUDY_SECTION>ZRG1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>165881</DIRECT_COST_AMT><INDIRECT_COST_AMT>109463</INDIRECT_COST_AMT><TOTAL_COST>275344</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9172493</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>HL</ADMINISTERING_IC><APPLICATION_TYPE>6</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/06/2015</AWARD_NOTICE_DATE><BUDGET_START>11/06/2015</BUDGET_START><BUDGET_END>02/29/2016</BUDGET_END><CFDA_CODE>837</CFDA_CODE><CORE_PROJECT_NUM>R01HL128071</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>PA-13-302</FOA_NUMBER><FULL_PROJECT_NUM>6R01HL128071-02</FULL_PROJECT_NUM><FUNDING_ICs>NHLBI:267969\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2015</FY><IC_NAME>NATIONAL HEART, LUNG, AND BLOOD INSTITUTE</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>BRONX</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>14</ORG_DISTRICT><ORG_DUNS>079783367</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[ALBERT EINSTEIN COLLEGE OF MEDICINE]]></ORG_NAME><ORG_STATE>NY</ORG_STATE><ORG_ZIPCODE>104611975</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: This project connects two fundamental mitochondrial processes in the heart - cell death and mitophagy - through molecular connections and bi-directional antagonism between Bax (a central mediator of cardiomyocyte apoptosis and necrosis) and Parkin (a critical inducer of cardiomyocyte mitophagy). The resulting information will prompt a rethinking of the mechanistic and functional relationships between mitophagy and cell death and a reconsideration of the primary mechanism by which Parkin protects the heart.   
   
      

]]></PHR><PIS><PI><PI_NAME>DORN, GERALD W.</PI_NAME><PI_ID>1869126</PI_ID></PI><PI><PI_NAME>KITSIS, RICHARD N (contact)</PI_NAME><PI_ID>1912286 (contact)</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>WONG, RENEE P.</PROGRAM_OFFICER_NAME><PROJECT_START>04/01/2015</PROJECT_START><PROJECT_END>02/28/2019</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Acute]]></TERM><TERM><![CDATA[Adult]]></TERM><TERM><![CDATA[Animals]]></TERM><TERM><![CDATA[Apoptosis]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Binding (Molecular Function)]]></TERM><TERM><![CDATA[Biogenesis]]></TERM><TERM><![CDATA[Biology]]></TERM><TERM><![CDATA[Blood Circulation]]></TERM><TERM><![CDATA[Cardiac]]></TERM><TERM><![CDATA[Cardiac Myocytes]]></TERM><TERM><![CDATA[Cell Death]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Cessation of life]]></TERM><TERM><![CDATA[Collaborations]]></TERM><TERM><![CDATA[Complex]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[experience]]></TERM><TERM><![CDATA[Figs - dietary]]></TERM><TERM><![CDATA[genetic manipulation]]></TERM><TERM><![CDATA[Heart]]></TERM><TERM><![CDATA[heart cell]]></TERM><TERM><![CDATA[Heart Diseases]]></TERM><TERM><![CDATA[Heart failure]]></TERM><TERM><![CDATA[In Vitro]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[Infarction]]></TERM><TERM><![CDATA[Injury]]></TERM><TERM><![CDATA[innovation]]></TERM><TERM><![CDATA[Ischemia]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[Link]]></TERM><TERM><![CDATA[Literature]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[Mediator of activation protein]]></TERM><TERM><![CDATA[Mitochondria]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[Molecular Conformation]]></TERM><TERM><![CDATA[Mortality Vital Statistics]]></TERM><TERM><![CDATA[Necrosis]]></TERM><TERM><![CDATA[parkin gene/protein]]></TERM><TERM><![CDATA[Pathogenesis]]></TERM><TERM><![CDATA[Physiological]]></TERM><TERM><![CDATA[Postdoctoral Fellow]]></TERM><TERM><![CDATA[prevent]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[Production]]></TERM><TERM><![CDATA[professor]]></TERM><TERM><![CDATA[public health relevance]]></TERM><TERM><![CDATA[Quality Control]]></TERM><TERM><![CDATA[Reperfusion Therapy]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[research study]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[Structure]]></TERM><TERM><![CDATA[System]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Linking cell death and mitochondrial quality control mechanisms in heart disease]]></PROJECT_TITLE><SERIAL_NUMBER>128071</SERIAL_NUMBER><STUDY_SECTION>MIM</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Myocardial Ischemia and Metabolism Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>205158</DIRECT_COST_AMT><INDIRECT_COST_AMT>62811</INDIRECT_COST_AMT><TOTAL_COST>267969</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9173548</APPLICATION_ID><ACTIVITY>Y01</ACTIVITY><ADMINISTERING_IC>HL</ADMINISTERING_IC><APPLICATION_TYPE></APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE></AWARD_NOTICE_DATE><BUDGET_START></BUDGET_START><BUDGET_END></BUDGET_END><CFDA_CODE>837</CFDA_CODE><CORE_PROJECT_NUM>Y01HL130020</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER></FOA_NUMBER><FULL_PROJECT_NUM>AHL13002001-1-0-1</FULL_PROJECT_NUM><FUNDING_ICs>NHLBI:3131663\</FUNDING_ICs><FUNDING_MECHANISM>INTERAGENCY AGREEMENTS</FUNDING_MECHANISM><FY>2015</FY><IC_NAME>NATIONAL HEART, LUNG, AND BLOOD INSTITUTE</IC_NAME><NIH_SPENDING_CATS><CATEGORY><![CDATA[Acquired Cognitive Impairment]]></CATEGORY><CATEGORY><![CDATA[Aging]]></CATEGORY><CATEGORY><![CDATA[Atherosclerosis]]></CATEGORY><CATEGORY><![CDATA[Brain Disorders]]></CATEGORY><CATEGORY><![CDATA[Clinical Research]]></CATEGORY><CATEGORY><![CDATA[Clinical Trials and Supportive Activities]]></CATEGORY><CATEGORY><![CDATA[Dementia]]></CATEGORY><CATEGORY><![CDATA[Kidney Disease]]></CATEGORY><CATEGORY><![CDATA[Prevention]]></CATEGORY></NIH_SPENDING_CATS><ORG_CITY></ORG_CITY><ORG_COUNTRY></ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT></ORG_DISTRICT><ORG_DUNS></ORG_DUNS><ORG_FIPS></ORG_FIPS><ORG_NAME><![CDATA[NATIONAL HEART, LUNG, AND BLOOD INSTITUTE]]></ORG_NAME><ORG_STATE></ORG_STATE><ORG_ZIPCODE></ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>,  </PI_NAME><PI_ID></PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START></PROJECT_START><PROJECT_END></PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Age-associated memory impairment]]></TERM><TERM><![CDATA[Agreement]]></TERM><TERM><![CDATA[Blood Pressure]]></TERM><TERM><![CDATA[cardiovascular disorder risk]]></TERM><TERM><![CDATA[Chronic Kidney Failure]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[Clinical Trials]]></TERM><TERM><![CDATA[Dementia]]></TERM><TERM><![CDATA[High Density Lipoproteins]]></TERM><TERM><![CDATA[high risk]]></TERM><TERM><![CDATA[Intervention Trial]]></TERM><TERM><![CDATA[Low-Density Lipoproteins]]></TERM><TERM><![CDATA[National Heart, Lung, and Blood Institute]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Recommendation]]></TERM><TERM><![CDATA[Risk Factors]]></TERM><TERM><![CDATA[Smoking]]></TERM><TERM><![CDATA[Staging]]></TERM><TERM><![CDATA[stroke]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Systolic Blood Pressure Intervention Trial (SPRINT) ? Clinical Center Network (CCN)]]></PROJECT_TITLE><SERIAL_NUMBER></SERIAL_NUMBER><STUDY_SECTION></STUDY_SECTION><STUDY_SECTION_NAME xsi:nil='true' /><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR></SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>3131663</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9174622</APPLICATION_ID><ACTIVITY>U2G</ACTIVITY><ADMINISTERING_IC>PS</ADMINISTERING_IC><APPLICATION_TYPE>3</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/04/2015</AWARD_NOTICE_DATE><BUDGET_START>09/30/2014</BUDGET_START><BUDGET_END>09/29/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>U2GPS002853</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-PS-10-060</FOA_NUMBER><FULL_PROJECT_NUM>3U2GPS002853-05S2</FULL_PROJECT_NUM><FUNDING_ICs>COGH:1873297\</FUNDING_ICs><FUNDING_MECHANISM>OTHERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP)</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>DODOMA</ORG_CITY><ORG_COUNTRY>TANZANIA U REP</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT></ORG_DISTRICT><ORG_DUNS></ORG_DUNS><ORG_FIPS>TZ</ORG_FIPS><ORG_NAME><![CDATA[CHRISTIAN COUNCIL OF TANZANIA]]></ORG_NAME><ORG_STATE></ORG_STATE><ORG_ZIPCODE></ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>NYAMOGA, JUSTIN LAZARO</PI_NAME><PI_ID>10026146</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>09/30/2010</PROJECT_START><PROJECT_END>09/29/2016</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[EFFECTIVE HIV PREVENTION AND ENHANCED HIV/AIDS COMMUNITY CARE THROUGH TANZANIAN I]]></PROJECT_TITLE><SERIAL_NUMBER>002853</SERIAL_NUMBER><STUDY_SECTION>ZPS1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>05</SUPPORT_YEAR><SUFFIX>S2</SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>1873297</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8957406</APPLICATION_ID><ACTIVITY>K23</ACTIVITY><ADMINISTERING_IC>ES</ADMINISTERING_IC><APPLICATION_TYPE>4</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/04/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>113</CFDA_CODE><CORE_PROJECT_NUM>K23ES022242</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>PA-11-194</FOA_NUMBER><FULL_PROJECT_NUM>4K23ES022242-04</FULL_PROJECT_NUM><FUNDING_ICs>NIEHS:158322\</FUNDING_ICs><FUNDING_MECHANISM>OTHER RESEARCH-RELATED</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>BOSTON</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>07</ORG_DISTRICT><ORG_DUNS>071723621</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[BETH ISRAEL DEACONESS MEDICAL CENTER]]></ORG_NAME><ORG_STATE>MA</ORG_STATE><ORG_ZIPCODE>022155400</ORG_ZIPCODE><PHR><![CDATA[Public Health Relevance: Poor fetal growth is associated with short-term perinatal morbidity and mortality as well as long-term poor health later in life. Arsenic exposure during pregnancy has been shown to potentially inhibit fetal growth in animals and to be associated with low birth weights in humans. Understanding the biology of arsenic toxicity and its effect on fetal growth may ultimately spurn tighter environmental regulation policies, trigger clean-up efforts and allow for targeted therapies during pregnancies affected by high arsenic exposure.]]></PHR><PIS><PI><PI_NAME>BURRIS, HEATHER HERSON</PI_NAME><PI_ID>9837141</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>CHADWICK, LISA </PROGRAM_OFFICER_NAME><PROJECT_START>12/01/2012</PROJECT_START><PROJECT_END>10/31/2017</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[Animals]]></TERM><TERM><![CDATA[Arsenic]]></TERM><TERM><![CDATA[Biology]]></TERM><TERM><![CDATA[Birth]]></TERM><TERM><![CDATA[Birth Weight]]></TERM><TERM><![CDATA[Blood]]></TERM><TERM><![CDATA[career]]></TERM><TERM><![CDATA[catalyst]]></TERM><TERM><![CDATA[Center for Translational Science Activities]]></TERM><TERM><![CDATA[Chemicals]]></TERM><TERM><![CDATA[Child health care]]></TERM><TERM><![CDATA[Childhood]]></TERM><TERM><![CDATA[Chronic]]></TERM><TERM><![CDATA[Cities]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[Clinical Sciences]]></TERM><TERM><![CDATA[cohort]]></TERM><TERM><![CDATA[Cohort Studies]]></TERM><TERM><![CDATA[cost]]></TERM><TERM><![CDATA[cytokine]]></TERM><TERM><![CDATA[Cytokine Gene]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[developmental disease/disorder]]></TERM><TERM><![CDATA[DNA]]></TERM><TERM><![CDATA[DNA Methylation]]></TERM><TERM><![CDATA[DNA Sequence]]></TERM><TERM><![CDATA[Doctor of Philosophy]]></TERM><TERM><![CDATA[Environment]]></TERM><TERM><![CDATA[Environmental Exposure]]></TERM><TERM><![CDATA[Environmental Health]]></TERM><TERM><![CDATA[Environmental Impact]]></TERM><TERM><![CDATA[environmental toxicology]]></TERM><TERM><![CDATA[Epidemiology]]></TERM><TERM><![CDATA[Epigenetic Process]]></TERM><TERM><![CDATA[experience]]></TERM><TERM><![CDATA[Faculty]]></TERM><TERM><![CDATA[Fellowship]]></TERM><TERM><![CDATA[Fetal Growth]]></TERM><TERM><![CDATA[Fetal Growth Retardation]]></TERM><TERM><![CDATA[Funding]]></TERM><TERM><![CDATA[Gene Expression]]></TERM><TERM><![CDATA[Gene Expression Regulation]]></TERM><TERM><![CDATA[Genes]]></TERM><TERM><![CDATA[Genetic]]></TERM><TERM><![CDATA[Gestational Age]]></TERM><TERM><![CDATA[Glucocorticoid Receptor]]></TERM><TERM><![CDATA[Glucocorticoids]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[human disease]]></TERM><TERM><![CDATA[IL6 gene]]></TERM><TERM><![CDATA[IL8 gene]]></TERM><TERM><![CDATA[in utero]]></TERM><TERM><![CDATA[In Vitro]]></TERM><TERM><![CDATA[Infant]]></TERM><TERM><![CDATA[Infant Mortality]]></TERM><TERM><![CDATA[Inflammation]]></TERM><TERM><![CDATA[Inflammatory]]></TERM><TERM><![CDATA[instructor]]></TERM><TERM><![CDATA[Israel]]></TERM><TERM><![CDATA[Learning]]></TERM><TERM><![CDATA[Leukocytes]]></TERM><TERM><![CDATA[Life]]></TERM><TERM><![CDATA[Link]]></TERM><TERM><![CDATA[Low Birth Weight Infant]]></TERM><TERM><![CDATA[Measures]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[Mediation]]></TERM><TERM><![CDATA[Medical center]]></TERM><TERM><![CDATA[medical schools]]></TERM><TERM><![CDATA[Medicine]]></TERM><TERM><![CDATA[member]]></TERM><TERM><![CDATA[Mentored Patient-Oriented Research Career Development Award]]></TERM><TERM><![CDATA[Mentors]]></TERM><TERM><![CDATA[Metabolic Diseases]]></TERM><TERM><![CDATA[Metabolism]]></TERM><TERM><![CDATA[Metal exposure]]></TERM><TERM><![CDATA[Mexico]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Morbidity - disease rate]]></TERM><TERM><![CDATA[Mortality Vital Statistics]]></TERM><TERM><![CDATA[Mothers]]></TERM><TERM><![CDATA[Neonatology]]></TERM><TERM><![CDATA[Newborn Infant]]></TERM><TERM><![CDATA[NR3C1 gene]]></TERM><TERM><![CDATA[offspring]]></TERM><TERM><![CDATA[Outcome]]></TERM><TERM><![CDATA[Pediatrics]]></TERM><TERM><![CDATA[Perinatal]]></TERM><TERM><![CDATA[Phenotype]]></TERM><TERM><![CDATA[Play]]></TERM><TERM><![CDATA[Poisons]]></TERM><TERM><![CDATA[Policies]]></TERM><TERM><![CDATA[Positioning Attribute]]></TERM><TERM><![CDATA[Pregnancy]]></TERM><TERM><![CDATA[Pregnancy Trimesters]]></TERM><TERM><![CDATA[prenatal]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[professor]]></TERM><TERM><![CDATA[programs]]></TERM><TERM><![CDATA[prospective]]></TERM><TERM><![CDATA[public health relevance]]></TERM><TERM><![CDATA[Public Health Schools]]></TERM><TERM><![CDATA[Receptor Gene]]></TERM><TERM><![CDATA[Regulation]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Research Activity]]></TERM><TERM><![CDATA[Research Personnel]]></TERM><TERM><![CDATA[Resources]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Running]]></TERM><TERM><![CDATA[Shapes]]></TERM><TERM><![CDATA[skills]]></TERM><TERM><![CDATA[Small for Gestational Age Infant]]></TERM><TERM><![CDATA[social]]></TERM><TERM><![CDATA[Structure]]></TERM><TERM><![CDATA[success]]></TERM><TERM><![CDATA[Survivors]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[Tissues]]></TERM><TERM><![CDATA[TNF gene]]></TERM><TERM><![CDATA[Toxic effect]]></TERM><TERM><![CDATA[toxic metal]]></TERM><TERM><![CDATA[Training]]></TERM><TERM><![CDATA[Training Activity]]></TERM><TERM><![CDATA[Umbilical Cord Blood]]></TERM><TERM><![CDATA[Woman]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[The Toxic Environment and the Epigenetics of Fetal Growth]]></PROJECT_TITLE><SERIAL_NUMBER>022242</SERIAL_NUMBER><STUDY_SECTION>ZES1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>04</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>146594</DIRECT_COST_AMT><INDIRECT_COST_AMT>11728</INDIRECT_COST_AMT><TOTAL_COST>158322</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8958770</APPLICATION_ID><ACTIVITY>I01</ACTIVITY><ADMINISTERING_IC>VA</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/03/2015</AWARD_NOTICE_DATE><BUDGET_START>10/01/2015</BUDGET_START><BUDGET_END>09/30/2016</BUDGET_END><CFDA_CODE>999</CFDA_CODE><CORE_PROJECT_NUM>I01CX000139</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-CX-12-001</FOA_NUMBER><FULL_PROJECT_NUM>5I01CX000139-06</FULL_PROJECT_NUM><FUNDING_ICs>VA:150000\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>Veterans Affairs</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>INDIANAPOLIS</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>07</ORG_DISTRICT><ORG_DUNS>608434697</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[RLR VA MEDICAL CENTER]]></ORG_NAME><ORG_STATE>IN</ORG_STATE><ORG_ZIPCODE>462022803</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE:   
   
Project Narrative Objective molecular correlates (biomarkers) of illness and response to treatment would make a significant difference in our ability to diagnose and treat patients with psychiatric disorders, eliminating subjectivity and reliance on patient's self-report of symptoms. Blood gene expression studies have emerged as a particularly interesting area of research in the search for peripheral biomarkers. We propose to conduct such studies in human subjects with schizophrenia, as a way of accelerating the discovery of biomarkers for psychosis symptoms. Moreover, we propose to study how much of an overlap there is between mood disorders and psychosis, at a biomarker level.]]></PHR><PIS><PI><PI_NAME>NICULESCU, ALEXANDER B</PI_NAME><PI_ID>8138693</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>04/01/2008</PROJECT_START><PROJECT_END>09/30/2017</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[Adverse effects]]></TERM><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[Animal Model]]></TERM><TERM><![CDATA[Animals]]></TERM><TERM><![CDATA[Anxiety]]></TERM><TERM><![CDATA[Area]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Biological Markers]]></TERM><TERM><![CDATA[Biology]]></TERM><TERM><![CDATA[Bipolar Disorder]]></TERM><TERM><![CDATA[Blood]]></TERM><TERM><![CDATA[Blood Tests]]></TERM><TERM><![CDATA[Brain]]></TERM><TERM><![CDATA[Candidate Disease Gene]]></TERM><TERM><![CDATA[Caring]]></TERM><TERM><![CDATA[Clinic]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[Clinical assessments]]></TERM><TERM><![CDATA[Clinical Treatment]]></TERM><TERM><![CDATA[Clozapine]]></TERM><TERM><![CDATA[cohort]]></TERM><TERM><![CDATA[Complex]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Diagnosis]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[disease classification]]></TERM><TERM><![CDATA[drug development]]></TERM><TERM><![CDATA[Early Intervention]]></TERM><TERM><![CDATA[follow-up]]></TERM><TERM><![CDATA[functional genomics]]></TERM><TERM><![CDATA[Future]]></TERM><TERM><![CDATA[Gene Chips]]></TERM><TERM><![CDATA[Gene Expression]]></TERM><TERM><![CDATA[Gene Expression Profiling]]></TERM><TERM><![CDATA[Genes]]></TERM><TERM><![CDATA[Genetic]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Hallucinations]]></TERM><TERM><![CDATA[Harvest]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Health Care Costs]]></TERM><TERM><![CDATA[Healthcare]]></TERM><TERM><![CDATA[Hospitalization]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[human data]]></TERM><TERM><![CDATA[human subject]]></TERM><TERM><![CDATA[immune activation]]></TERM><TERM><![CDATA[impression]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[Inflammatory]]></TERM><TERM><![CDATA[information gathering]]></TERM><TERM><![CDATA[interest]]></TERM><TERM><![CDATA[Interview]]></TERM><TERM><![CDATA[Laboratories]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[lymphoblastoid cell line]]></TERM><TERM><![CDATA[Lymphocyte]]></TERM><TERM><![CDATA[male]]></TERM><TERM><![CDATA[Measurement]]></TERM><TERM><![CDATA[Measures]]></TERM><TERM><![CDATA[Mental Depression]]></TERM><TERM><![CDATA[Mental disorders]]></TERM><TERM><![CDATA[Meta-Analysis]]></TERM><TERM><![CDATA[Modality]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[Mood Disorders]]></TERM><TERM><![CDATA[Moods]]></TERM><TERM><![CDATA[Nature]]></TERM><TERM><![CDATA[Paper]]></TERM><TERM><![CDATA[Pathway interactions]]></TERM><TERM><![CDATA[Patient Self-Report]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Peripheral]]></TERM><TERM><![CDATA[peripheral blood]]></TERM><TERM><![CDATA[Personal Satisfaction]]></TERM><TERM><![CDATA[Pharmaceutical Preparations]]></TERM><TERM><![CDATA[Phencyclidine]]></TERM><TERM><![CDATA[Post-Traumatic Stress Disorders]]></TERM><TERM><![CDATA[Predictive Value]]></TERM><TERM><![CDATA[prevent]]></TERM><TERM><![CDATA[Probability]]></TERM><TERM><![CDATA[Psychiatry]]></TERM><TERM><![CDATA[Psychotic Disorders]]></TERM><TERM><![CDATA[psychotic symptoms]]></TERM><TERM><![CDATA[Publishing]]></TERM><TERM><![CDATA[Quality of life]]></TERM><TERM><![CDATA[Recruitment Activity]]></TERM><TERM><![CDATA[Relapse]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[Risk]]></TERM><TERM><![CDATA[Running]]></TERM><TERM><![CDATA[Safety]]></TERM><TERM><![CDATA[Sampling]]></TERM><TERM><![CDATA[Schizoaffective Disorders]]></TERM><TERM><![CDATA[Schizophrenia]]></TERM><TERM><![CDATA[Series]]></TERM><TERM><![CDATA[Severities]]></TERM><TERM><![CDATA[Solid]]></TERM><TERM><![CDATA[Source]]></TERM><TERM><![CDATA[Specificity]]></TERM><TERM><![CDATA[Study Subject]]></TERM><TERM><![CDATA[Symptoms]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[trait]]></TERM><TERM><![CDATA[translational approach]]></TERM><TERM><![CDATA[Validation]]></TERM><TERM><![CDATA[Veterans]]></TERM><TERM><![CDATA[Visit]]></TERM><TERM><![CDATA[Whole Blood]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Blood Biomarkers for Psychosis: Specificity vs Overlap with Mood Disorders]]></PROJECT_TITLE><SERIAL_NUMBER>000139</SERIAL_NUMBER><STUDY_SECTION>EPID</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Epidemiology ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>06</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST></TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8960323</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>AI</ADMINISTERING_IC><APPLICATION_TYPE>4</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/27/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>855</CFDA_CODE><CORE_PROJECT_NUM>R01AI092305</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>PA-10-067</FOA_NUMBER><FULL_PROJECT_NUM>4R01AI092305-05</FULL_PROJECT_NUM><FUNDING_ICs>NIAID:666124\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>BOSTON</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>07</ORG_DISTRICT><ORG_DUNS>076593722</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[CHILDREN'S HOSPITAL CORPORATION]]></ORG_NAME><ORG_STATE>MA</ORG_STATE><ORG_ZIPCODE>021155737</ORG_ZIPCODE><PHR><![CDATA[Organ transplantation is a life saving therapy for individuals with end stage organ failure, but all transplants eventually fail due to a process called chronic allograft rejection. We have identified that Vascular Endothelial Growth Factor (VEGF) facilitates the recruitment and activation of T cells. In this research proposal, we plan to perform mechanistic studies addressing questions about the molecular basis for VEGF receptor interactions in T cells, and how overexpressed VEGF within transplanted organs may result in chronic rejection.]]></PHR><PIS><PI><PI_NAME>BRISCOE, DAVID M.</PI_NAME><PI_ID>1874250</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>KEHN, PATRICIA J.</PROGRAM_OFFICER_NAME><PROJECT_START>11/17/2011</PROJECT_START><PROJECT_END>10/31/2016</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Acute]]></TERM><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[allograft rejection]]></TERM><TERM><![CDATA[Allografting]]></TERM><TERM><![CDATA[Angiogenic Factor]]></TERM><TERM><![CDATA[Area]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Binding (Molecular Function)]]></TERM><TERM><![CDATA[Biology]]></TERM><TERM><![CDATA[cell motility]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Chemotaxis]]></TERM><TERM><![CDATA[Chronic]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[clinically relevant]]></TERM><TERM><![CDATA[cytokine]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Effector Cell]]></TERM><TERM><![CDATA[end-stage organ failure]]></TERM><TERM><![CDATA[Endothelial Cells]]></TERM><TERM><![CDATA[Evolution]]></TERM><TERM><![CDATA[Family]]></TERM><TERM><![CDATA[Graft Survival]]></TERM><TERM><![CDATA[Humoral Immunities]]></TERM><TERM><![CDATA[Immune]]></TERM><TERM><![CDATA[Immune response]]></TERM><TERM><![CDATA[Immunity]]></TERM><TERM><![CDATA[immunoregulation]]></TERM><TERM><![CDATA[In Vitro]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[in vivo Model]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[Inflammation]]></TERM><TERM><![CDATA[Inflammatory]]></TERM><TERM><![CDATA[inhibitor/antagonist]]></TERM><TERM><![CDATA[Investigation]]></TERM><TERM><![CDATA[Ischemia]]></TERM><TERM><![CDATA[Isoantibodies]]></TERM><TERM><![CDATA[isoimmunity]]></TERM><TERM><![CDATA[Knockout Mice]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[Life]]></TERM><TERM><![CDATA[Ligands]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[Mediator of activation protein]]></TERM><TERM><![CDATA[Memory]]></TERM><TERM><![CDATA[Methods]]></TERM><TERM><![CDATA[migration]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[Mononuclear]]></TERM><TERM><![CDATA[Neuropilin-1]]></TERM><TERM><![CDATA[Neuropilins]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[novel strategies]]></TERM><TERM><![CDATA[novel therapeutics]]></TERM><TERM><![CDATA[Organ Transplantation]]></TERM><TERM><![CDATA[Outcome]]></TERM><TERM><![CDATA[overexpression]]></TERM><TERM><![CDATA[Oxidative Stress]]></TERM><TERM><![CDATA[Physiological]]></TERM><TERM><![CDATA[Population]]></TERM><TERM><![CDATA[prevent]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[receptor]]></TERM><TERM><![CDATA[Regulatory T-Lymphocyte]]></TERM><TERM><![CDATA[Reperfusion Injury]]></TERM><TERM><![CDATA[Reperfusion Therapy]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Research Proposals]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Semaphorin-3]]></TERM><TERM><![CDATA[Semaphorin-3A]]></TERM><TERM><![CDATA[Semaphorins]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[T-Cell Activation]]></TERM><TERM><![CDATA[T-Lymphocyte]]></TERM><TERM><![CDATA[T-Lymphocyte Subsets]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Transgenic Mice]]></TERM><TERM><![CDATA[Translating]]></TERM><TERM><![CDATA[Transplantation]]></TERM><TERM><![CDATA[Vascular Endothelial Growth Factor Receptor]]></TERM><TERM><![CDATA[Vascular Endothelial Growth Factor Receptor-1]]></TERM><TERM><![CDATA[Vascular Endothelial Growth Factor Receptor-2]]></TERM><TERM><![CDATA[Vascular Endothelial Growth Factors]]></TERM><TERM><![CDATA[Vascular remodeling]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Vascular Endothelial Growth Factor Receptor Interactions and Allograft Rejection]]></PROJECT_TITLE><SERIAL_NUMBER>092305</SERIAL_NUMBER><STUDY_SECTION>TTT</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Transplantation, Tolerance, and Tumor Immunology ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>05</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>381612</DIRECT_COST_AMT><INDIRECT_COST_AMT>284512</INDIRECT_COST_AMT><TOTAL_COST>666124</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8960855</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>AI</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/29/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>855</CFDA_CODE><CORE_PROJECT_NUM>R01AI114543</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-13-302</FOA_NUMBER><FULL_PROJECT_NUM>5R01AI114543-02</FULL_PROJECT_NUM><FUNDING_ICs>NIAID:378750\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>IOWA CITY</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[MICROBIOLOGY/IMMUN/VIROLOGY]]></ORG_DEPT><ORG_DISTRICT>02</ORG_DISTRICT><ORG_DUNS>062761671</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIVERSITY OF IOWA]]></ORG_NAME><ORG_STATE>IA</ORG_STATE><ORG_ZIPCODE>522463111</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Influenza virus infections have a major impact on human health and the threat of pandemic infections remains imminent. Due to the ability of influenza to mutate and reassert, protection antibody inducting vaccines has limitations. Here, we will identify properties of memory CD8 T cells with the capacity to induce subtype transcending protection, information that will be crucial for the design of broadly protective vaccines.]]></PHR><PIS><PI><PI_NAME>BADOVINAC, VLADIMIR P</PI_NAME><PI_ID>8241183</PI_ID></PI><PI><PI_NAME>HARTY, JOHN T. (contact)</PI_NAME><PI_ID>1888864 (contact)</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>HAUGUEL, TERESA M.</PROGRAM_OFFICER_NAME><PROJECT_START>11/01/2014</PROJECT_START><PROJECT_END>10/31/2019</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[Antibodies]]></TERM><TERM><![CDATA[Antigens]]></TERM><TERM><![CDATA[CD4 Positive T Lymphocytes]]></TERM><TERM><![CDATA[CD8B1 gene]]></TERM><TERM><![CDATA[Cell Count]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Characteristics]]></TERM><TERM><![CDATA[Collaborations]]></TERM><TERM><![CDATA[cross immunity]]></TERM><TERM><![CDATA[CXCR3 gene]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Epitopes]]></TERM><TERM><![CDATA[Exposure to]]></TERM><TERM><![CDATA[Gene Expression]]></TERM><TERM><![CDATA[Generations]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Hemagglutinin]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[Immunity]]></TERM><TERM><![CDATA[Infection]]></TERM><TERM><![CDATA[Influenza]]></TERM><TERM><![CDATA[Influenza A Virus, H1N1 Subtype]]></TERM><TERM><![CDATA[influenzavirus]]></TERM><TERM><![CDATA[Influenzavirus A]]></TERM><TERM><![CDATA[Information Protection]]></TERM><TERM><![CDATA[Interleukin-12]]></TERM><TERM><![CDATA[Location]]></TERM><TERM><![CDATA[Longitudinal Studies]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[Memory]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[Mutate]]></TERM><TERM><![CDATA[Mutation]]></TERM><TERM><![CDATA[Neuraminidase]]></TERM><TERM><![CDATA[neutralizing antibody]]></TERM><TERM><![CDATA[novel strategies]]></TERM><TERM><![CDATA[Nucleoproteins]]></TERM><TERM><![CDATA[pandemic disease]]></TERM><TERM><![CDATA[Paper]]></TERM><TERM><![CDATA[Pathway interactions]]></TERM><TERM><![CDATA[Polymerase]]></TERM><TERM><![CDATA[Population]]></TERM><TERM><![CDATA[Population Heterogeneity]]></TERM><TERM><![CDATA[Productivity]]></TERM><TERM><![CDATA[Property]]></TERM><TERM><![CDATA[Proteins]]></TERM><TERM><![CDATA[Publishing]]></TERM><TERM><![CDATA[Relative (related person)]]></TERM><TERM><![CDATA[Reporting]]></TERM><TERM><![CDATA[Research Personnel]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[STAT4 gene]]></TERM><TERM><![CDATA[Surveys]]></TERM><TERM><![CDATA[T memory cell]]></TERM><TERM><![CDATA[T-Cell Activation]]></TERM><TERM><![CDATA[T-Lymphocyte]]></TERM><TERM><![CDATA[Tissues]]></TERM><TERM><![CDATA[Transcend]]></TERM><TERM><![CDATA[Vaccination]]></TERM><TERM><![CDATA[Vaccines]]></TERM><TERM><![CDATA[Viral Proteins]]></TERM><TERM><![CDATA[Virus Diseases]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Memory CD8 T cell localization and protection from influenza]]></PROJECT_TITLE><SERIAL_NUMBER>114543</SERIAL_NUMBER><STUDY_SECTION>IHD</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Immunity and Host Defense Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>250000</DIRECT_COST_AMT><INDIRECT_COST_AMT>128750</INDIRECT_COST_AMT><TOTAL_COST>378750</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8960920</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>AI</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/26/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>855</CFDA_CODE><CORE_PROJECT_NUM>R01AI105097</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-13-302</FOA_NUMBER><FULL_PROJECT_NUM>5R01AI105097-02</FULL_PROJECT_NUM><FUNDING_ICs>NIAID:416250\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>NEW HAVEN</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[VETERINARY SCIENCES]]></ORG_DEPT><ORG_DISTRICT>03</ORG_DISTRICT><ORG_DUNS>043207562</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[YALE UNIVERSITY]]></ORG_NAME><ORG_STATE>CT</ORG_STATE><ORG_ZIPCODE>065113572</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Thymus produces infection and cancer fighting immune cells called as T-lymphocytes. However, with progressive aging, thymus is replaced with fat cells and its ability to produce T-lymphocytes is dramatically diminished. This research project is designed to understand the origin of fat cells in aging thymus and to determine the causes and consequences of thymic adiposity during aging. The aim of this project is to unravel underlying process of thymic dysfunction that impacts immune function in aging with a long-term goal of developing novel therapeutic approaches to strengthen immunity and enhance health-span of elderly.]]></PHR><PIS><PI><PI_NAME>DIXIT, VISHWA DEEP</PI_NAME><PI_ID>8836931</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>PRABHUDAS, MERCY R.</PROGRAM_OFFICER_NAME><PROJECT_START>11/01/2014</PROJECT_START><PROJECT_END>10/31/2018</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Ablation]]></TERM><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[adipocyte differentiation]]></TERM><TERM><![CDATA[Adipocytes]]></TERM><TERM><![CDATA[Adipose tissue]]></TERM><TERM><![CDATA[Adult]]></TERM><TERM><![CDATA[Age]]></TERM><TERM><![CDATA[age related]]></TERM><TERM><![CDATA[Aging]]></TERM><TERM><![CDATA[Aging-Related Process]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Biological Models]]></TERM><TERM><![CDATA[Blood capillaries]]></TERM><TERM><![CDATA[Calories]]></TERM><TERM><![CDATA[capillary]]></TERM><TERM><![CDATA[Cell Lineage]]></TERM><TERM><![CDATA[Cell physiology]]></TERM><TERM><![CDATA[cell type]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[chemokine]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[Cues]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[Deterioration]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Elderly]]></TERM><TERM><![CDATA[Emigrations]]></TERM><TERM><![CDATA[Employee Strikes]]></TERM><TERM><![CDATA[Endothelial Cells]]></TERM><TERM><![CDATA[Environment]]></TERM><TERM><![CDATA[Epithelial]]></TERM><TERM><![CDATA[Etiology]]></TERM><TERM><![CDATA[Event]]></TERM><TERM><![CDATA[Excision]]></TERM><TERM><![CDATA[Fatty Change]]></TERM><TERM><![CDATA[Fibroblasts]]></TERM><TERM><![CDATA[fibrogenesis]]></TERM><TERM><![CDATA[fighting]]></TERM><TERM><![CDATA[Functional disorder]]></TERM><TERM><![CDATA[Generations]]></TERM><TERM><![CDATA[Genes]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Hematopoietic]]></TERM><TERM><![CDATA[Homeostasis]]></TERM><TERM><![CDATA[Immune]]></TERM><TERM><![CDATA[immune function]]></TERM><TERM><![CDATA[Immune System Diseases]]></TERM><TERM><![CDATA[Immunity]]></TERM><TERM><![CDATA[Immunology]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[Infection]]></TERM><TERM><![CDATA[Label]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[Life]]></TERM><TERM><![CDATA[lipid biosynthesis]]></TERM><TERM><![CDATA[Lipids]]></TERM><TERM><![CDATA[Lymphopoiesis]]></TERM><TERM><![CDATA[Malignant Neoplasms]]></TERM><TERM><![CDATA[Membrane]]></TERM><TERM><![CDATA[Mesenchymal]]></TERM><TERM><![CDATA[middle age]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[novel strategies]]></TERM><TERM><![CDATA[novel therapeutic intervention]]></TERM><TERM><![CDATA[Obesity]]></TERM><TERM><![CDATA[Peroxisome Proliferator-Activated Receptors]]></TERM><TERM><![CDATA[prevent]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[Production]]></TERM><TERM><![CDATA[progenitor]]></TERM><TERM><![CDATA[Proteins]]></TERM><TERM><![CDATA[Reporter]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Research Project Grants]]></TERM><TERM><![CDATA[research study]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[Stromal Cells]]></TERM><TERM><![CDATA[T-Cell Development]]></TERM><TERM><![CDATA[T-Lymphocyte]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Thymic epithelial cell]]></TERM><TERM><![CDATA[thymocyte]]></TERM><TERM><![CDATA[Thymus Gland]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[Tracer]]></TERM><TERM><![CDATA[transcription factor]]></TERM><TERM><![CDATA[Transgenic Organisms]]></TERM><TERM><![CDATA[Vacuole]]></TERM><TERM><![CDATA[venule]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Thymic adipogenesis and age-related thymic demise]]></PROJECT_TITLE><SERIAL_NUMBER>105097</SERIAL_NUMBER><STUDY_SECTION>CMIB</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Cellular and Molecular Immunology - B Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>250000</DIRECT_COST_AMT><INDIRECT_COST_AMT>166250</INDIRECT_COST_AMT><TOTAL_COST>416250</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8962154</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>HL</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/04/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>837</CFDA_CODE><CORE_PROJECT_NUM>R01HL067724</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-13-302</FOA_NUMBER><FULL_PROJECT_NUM>5R01HL067724-16</FULL_PROJECT_NUM><FUNDING_ICs>NHLBI:321975\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL HEART, LUNG, AND BLOOD INSTITUTE</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>NEWARK</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[ANATOMY/CELL BIOLOGY]]></ORG_DEPT><ORG_DISTRICT>10</ORG_DISTRICT><ORG_DUNS>078795851</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[RBHS-NEW JERSEY MEDICAL SCHOOL]]></ORG_NAME><ORG_STATE>NJ</ORG_STATE><ORG_ZIPCODE>071032757</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Our study will elucidate a novel mechanism of posttranslational modification of PPAR?y GSK-3?ediating the metabolic derangement and diastolic dysfunction in the heart in response to obesity and insulin resistance. The study will provide an important clue to alleviating cardiac dysfunction in patients with metabolic syndrome.]]></PHR><PIS><PI><PI_NAME>SADOSHIMA, JUNICHI </PI_NAME><PI_ID>6354902</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>BUXTON, DENIS B</PROGRAM_OFFICER_NAME><PROJECT_START>09/30/2000</PROJECT_START><PROJECT_END>10/31/2018</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Agonist]]></TERM><TERM><![CDATA[Attenuated]]></TERM><TERM><![CDATA[Autophagocytosis]]></TERM><TERM><![CDATA[Birds]]></TERM><TERM><![CDATA[Cardiac]]></TERM><TERM><![CDATA[Cardiomyopathies]]></TERM><TERM><![CDATA[CD36 gene]]></TERM><TERM><![CDATA[Cell Nucleus]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Cessation of life]]></TERM><TERM><![CDATA[Consumption]]></TERM><TERM><![CDATA[coronary fibrosis]]></TERM><TERM><![CDATA[Cytoplasm]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Diet]]></TERM><TERM><![CDATA[Fatty acid glycerol esters]]></TERM><TERM><![CDATA[fatty acid metabolism]]></TERM><TERM><![CDATA[fatty acid oxidation]]></TERM><TERM><![CDATA[Fatty Acids]]></TERM><TERM><![CDATA[feeding]]></TERM><TERM><![CDATA[Fenofibrate]]></TERM><TERM><![CDATA[Fibrosis]]></TERM><TERM><![CDATA[Functional disorder]]></TERM><TERM><![CDATA[Genetic Transcription]]></TERM><TERM><![CDATA[Glucose]]></TERM><TERM><![CDATA[glucose metabolism]]></TERM><TERM><![CDATA[Glycogen Synthase Kinase 3]]></TERM><TERM><![CDATA[Glycogen Synthase Kinases]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Growth]]></TERM><TERM><![CDATA[Heart]]></TERM><TERM><![CDATA[Heart Hypertrophy]]></TERM><TERM><![CDATA[Heterodimerization]]></TERM><TERM><![CDATA[Hypertrophy]]></TERM><TERM><![CDATA[Insulin Resistance]]></TERM><TERM><![CDATA[Intervention]]></TERM><TERM><![CDATA[Ischemia]]></TERM><TERM><![CDATA[Knock-in Mouse]]></TERM><TERM><![CDATA[Knowledge]]></TERM><TERM><![CDATA[Ligand Binding Domain]]></TERM><TERM><![CDATA[Ligands]]></TERM><TERM><![CDATA[Link]]></TERM><TERM><![CDATA[Lipids]]></TERM><TERM><![CDATA[Liver]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[Metabolic]]></TERM><TERM><![CDATA[Metabolic syndrome]]></TERM><TERM><![CDATA[Metabolism]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[mutant]]></TERM><TERM><![CDATA[Myocardial]]></TERM><TERM><![CDATA[Myocardial dysfunction]]></TERM><TERM><![CDATA[N-terminal]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[Nuclear]]></TERM><TERM><![CDATA[Nuclear Receptors]]></TERM><TERM><![CDATA[Obese Mice]]></TERM><TERM><![CDATA[Obesity]]></TERM><TERM><![CDATA[oxidation]]></TERM><TERM><![CDATA[Pathogenesis]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Peroxisome Proliferator-Activated Receptors]]></TERM><TERM><![CDATA[Phosphorylation]]></TERM><TERM><![CDATA[Play]]></TERM><TERM><![CDATA[Post-Translational Protein Processing]]></TERM><TERM><![CDATA[pressure]]></TERM><TERM><![CDATA[Protein Isoforms]]></TERM><TERM><![CDATA[Protein Kinase]]></TERM><TERM><![CDATA[Proteomics]]></TERM><TERM><![CDATA[public health relevance]]></TERM><TERM><![CDATA[Regulation]]></TERM><TERM><![CDATA[Reperfusion Therapy]]></TERM><TERM><![CDATA[Resistance]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[RXR]]></TERM><TERM><![CDATA[Serine]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[therapeutic target]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Regulation of myocardial growth and death by GSK-3]]></PROJECT_TITLE><SERIAL_NUMBER>067724</SERIAL_NUMBER><STUDY_SECTION>CCHF</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Cardiac Contractility, Hypertrophy, and Failure Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>16</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>202500</DIRECT_COST_AMT><INDIRECT_COST_AMT>119475</INDIRECT_COST_AMT><TOTAL_COST>321975</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8962161</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>HL</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/04/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>837</CFDA_CODE><CORE_PROJECT_NUM>R01HL119830</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-13-302</FOA_NUMBER><FULL_PROJECT_NUM>5R01HL119830-02</FULL_PROJECT_NUM><FUNDING_ICs>NHLBI:360000\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL HEART, LUNG, AND BLOOD INSTITUTE</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>NEW YORK</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[INTERNAL MEDICINE/MEDICINE]]></ORG_DEPT><ORG_DISTRICT>13</ORG_DISTRICT><ORG_DUNS>621889815</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[COLUMBIA UNIVERSITY HEALTH SCIENCES]]></ORG_NAME><ORG_STATE>NY</ORG_STATE><ORG_ZIPCODE>100320049</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Recent human genome wide association studies have identified TTC39B as a novel gene associated with changes in HDL levels. We have confirmed the role of TTC39B in HDL metabolism in knockout mice. Deficiency of TTC39B leads to increased levels of the oxysterol activated transcription factor LXR in liver and small intestine. The proposal will further evaluate the functions of TTC39B in mouse models, and evaluate the hypothesis that deficiency results in beneficial lipoprotein changes, reduced steatohepatitis and reduced atherosclerosis.]]></PHR><PIS><PI><PI_NAME>TALL, ALAN RICHARD</PI_NAME><PI_ID>1962373</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>LIU, LIJUAN </PROGRAM_OFFICER_NAME><PROJECT_START>11/04/2014</PROJECT_START><PROJECT_END>10/31/2018</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[activating transcription factor]]></TERM><TERM><![CDATA[ADD-1 protein]]></TERM><TERM><![CDATA[Alleles]]></TERM><TERM><![CDATA[Atherosclerosis]]></TERM><TERM><![CDATA[ATP binding cassette transporter 1]]></TERM><TERM><![CDATA[bile salts]]></TERM><TERM><![CDATA[Binding (Molecular Function)]]></TERM><TERM><![CDATA[bone marrow hyperplasia]]></TERM><TERM><![CDATA[Breeding]]></TERM><TERM><![CDATA[Cell Nucleus]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Cessation of life]]></TERM><TERM><![CDATA[Cholesterol]]></TERM><TERM><![CDATA[cholesterol control]]></TERM><TERM><![CDATA[Chylomicrons]]></TERM><TERM><![CDATA[Databases]]></TERM><TERM><![CDATA[Desmosterol]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Diet]]></TERM><TERM><![CDATA[Enterocytes]]></TERM><TERM><![CDATA[Family member]]></TERM><TERM><![CDATA[Fatty acid glycerol esters]]></TERM><TERM><![CDATA[Fatty Acids]]></TERM><TERM><![CDATA[Fatty Liver]]></TERM><TERM><![CDATA[feeding]]></TERM><TERM><![CDATA[Figs - dietary]]></TERM><TERM><![CDATA[Gene Expression]]></TERM><TERM><![CDATA[Gene Targeting]]></TERM><TERM><![CDATA[Genes]]></TERM><TERM><![CDATA[Genetic Transcription]]></TERM><TERM><![CDATA[genome wide association study]]></TERM><TERM><![CDATA[Golgi Apparatus]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Hematopoietic]]></TERM><TERM><![CDATA[Hepatic]]></TERM><TERM><![CDATA[Hepatitis]]></TERM><TERM><![CDATA[Hepatocyte]]></TERM><TERM><![CDATA[High Density Lipoprotein Cholesterol]]></TERM><TERM><![CDATA[High Density Lipoproteins]]></TERM><TERM><![CDATA[human disease]]></TERM><TERM><![CDATA[Human Genome]]></TERM><TERM><![CDATA[Infiltration]]></TERM><TERM><![CDATA[Inflammatory]]></TERM><TERM><![CDATA[Intestines]]></TERM><TERM><![CDATA[Knock-in Mouse]]></TERM><TERM><![CDATA[Knockout Mice]]></TERM><TERM><![CDATA[LDL Cholesterol Lipoproteins]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[Ligands]]></TERM><TERM><![CDATA[Ligase]]></TERM><TERM><![CDATA[lipid biosynthesis]]></TERM><TERM><![CDATA[Lipids]]></TERM><TERM><![CDATA[Lipoproteins]]></TERM><TERM><![CDATA[liquid chromatography mass spectrometry]]></TERM><TERM><![CDATA[Liver]]></TERM><TERM><![CDATA[liver cell proliferation]]></TERM><TERM><![CDATA[macrophage]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[Messenger RNA]]></TERM><TERM><![CDATA[Metabolism]]></TERM><TERM><![CDATA[Minor]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Modification]]></TERM><TERM><![CDATA[monocyte]]></TERM><TERM><![CDATA[mouse model]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[neutrophil]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[Nuclear]]></TERM><TERM><![CDATA[Orthologous Gene]]></TERM><TERM><![CDATA[prevent]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[Proteins]]></TERM><TERM><![CDATA[Repression]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[scaffold]]></TERM><TERM><![CDATA[Scaffolding Protein]]></TERM><TERM><![CDATA[Small Interfering RNA]]></TERM><TERM><![CDATA[Small Intestines]]></TERM><TERM><![CDATA[Spleen]]></TERM><TERM><![CDATA[Steatohepatitis]]></TERM><TERM><![CDATA[Tertiary Protein Structure]]></TERM><TERM><![CDATA[Tissues]]></TERM><TERM><![CDATA[transcription factor]]></TERM><TERM><![CDATA[Transplantation]]></TERM><TERM><![CDATA[Triglycerides]]></TERM><TERM><![CDATA[Ubiquitin]]></TERM><TERM><![CDATA[ubiquitin-protein ligase]]></TERM><TERM><![CDATA[Ubiquitination]]></TERM><TERM><![CDATA[Western World]]></TERM><TERM><![CDATA[Yeasts]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[TTC39B in Metabolism]]></PROJECT_TITLE><SERIAL_NUMBER>119830</SERIAL_NUMBER><STUDY_SECTION>INMP</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Integrative Nutrition and Metabolic Processes Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>225000</DIRECT_COST_AMT><INDIRECT_COST_AMT>135000</INDIRECT_COST_AMT><TOTAL_COST>360000</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8963415</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>AI</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/28/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>855</CFDA_CODE><CORE_PROJECT_NUM>R01AI085596</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-13-302</FOA_NUMBER><FULL_PROJECT_NUM>5R01AI085596-06</FULL_PROJECT_NUM><FUNDING_ICs>NIAID:400000\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>PHILADELPHIA</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[PHARMACOLOGY]]></ORG_DEPT><ORG_DISTRICT>02</ORG_DISTRICT><ORG_DUNS>042250712</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIVERSITY OF PENNSYLVANIA]]></ORG_NAME><ORG_STATE>PA</ORG_STATE><ORG_ZIPCODE>191046205</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: This project uses a mouse model to study what causes and how to treat a rare human disease called dense deposit disease (DDD). Patients with DDD often develop kidney failure and vision loss and currently no treatment is available. The proposed studies will help the development of highly specific and effective drugs for these patients.]]></PHR><PIS><PI><PI_NAME>SONG, WENCHAO </PI_NAME><PI_ID>1870363</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>NASSERI, M. FARAZ </PROGRAM_OFFICER_NAME><PROJECT_START>04/01/2010</PROJECT_START><PROJECT_END>10/31/2019</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Age related macular degeneration]]></TERM><TERM><![CDATA[Alternative Complement Pathway]]></TERM><TERM><![CDATA[Animal Model]]></TERM><TERM><![CDATA[Blindness]]></TERM><TERM><![CDATA[C-terminal]]></TERM><TERM><![CDATA[cell injury]]></TERM><TERM><![CDATA[Complement]]></TERM><TERM><![CDATA[Complement 5a]]></TERM><TERM><![CDATA[Complement Activation]]></TERM><TERM><![CDATA[Complement Factor D]]></TERM><TERM><![CDATA[Complement Factor H]]></TERM><TERM><![CDATA[Complement Membrane Attack Complex]]></TERM><TERM><![CDATA[Consumption]]></TERM><TERM><![CDATA[Deposition]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Drusen]]></TERM><TERM><![CDATA[Electrons]]></TERM><TERM><![CDATA[End stage renal failure]]></TERM><TERM><![CDATA[Eye]]></TERM><TERM><![CDATA[glomerular basement membrane]]></TERM><TERM><![CDATA[Glomerulonephritis]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Host Defense]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[human disease]]></TERM><TERM><![CDATA[Human Pathology]]></TERM><TERM><![CDATA[Immunoglobulin Deposition]]></TERM><TERM><![CDATA[Inflammation]]></TERM><TERM><![CDATA[Inflammatory]]></TERM><TERM><![CDATA[Injury]]></TERM><TERM><![CDATA[Kidney]]></TERM><TERM><![CDATA[Kidney Diseases]]></TERM><TERM><![CDATA[Kidney Failure]]></TERM><TERM><![CDATA[Light]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[Membranoproliferative Glomerulonephritis]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[mouse model]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[Mutation]]></TERM><TERM><![CDATA[Natural Immunity]]></TERM><TERM><![CDATA[neutralizing monoclonal antibodies]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[Oligonucleotides]]></TERM><TERM><![CDATA[outcome forecast]]></TERM><TERM><![CDATA[Pathogenesis]]></TERM><TERM><![CDATA[Pathology]]></TERM><TERM><![CDATA[Pathway interactions]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Pharmaceutical Preparations]]></TERM><TERM><![CDATA[Phenotype]]></TERM><TERM><![CDATA[Play]]></TERM><TERM><![CDATA[prevent]]></TERM><TERM><![CDATA[Properdin]]></TERM><TERM><![CDATA[Replacement Therapy]]></TERM><TERM><![CDATA[Retinal]]></TERM><TERM><![CDATA[Retinal Degeneration]]></TERM><TERM><![CDATA[RNA]]></TERM><TERM><![CDATA[Signal Pathway]]></TERM><TERM><![CDATA[Structure of retinal pigment epithelium]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Therapeutic Agents]]></TERM><TERM><![CDATA[Therapeutic Studies]]></TERM><TERM><![CDATA[Tissues]]></TERM><TERM><![CDATA[Vision]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Pathogenesis and therapy of dense deposit disease in a mouse model]]></PROJECT_TITLE><SERIAL_NUMBER>085596</SERIAL_NUMBER><STUDY_SECTION>III</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Innate Immunity and Inflammation Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>06</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>250000</DIRECT_COST_AMT><INDIRECT_COST_AMT>150000</INDIRECT_COST_AMT><TOTAL_COST>400000</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8963425</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>AI</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/27/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>855</CFDA_CODE><CORE_PROJECT_NUM>R01AI110703</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PAR-13-137</FOA_NUMBER><FULL_PROJECT_NUM>5R01AI110703-02</FULL_PROJECT_NUM><FUNDING_ICs>NIAID:394281\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>NEW YORK</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[INTERNAL MEDICINE/MEDICINE]]></ORG_DEPT><ORG_DISTRICT>13</ORG_DISTRICT><ORG_DUNS>078861598</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI]]></ORG_NAME><ORG_STATE>NY</ORG_STATE><ORG_ZIPCODE>100296574</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Quantifying Environmental Variables Affecting Airborne Influenza Transmission This project addresses questions of critical importance in understanding the circulation of influenza viruses in the human population. Our main scientific goal is to perform experiments that explain how environmental variables - such as temperature, humidity, and airflow - affect the ability of influenza viruses to spread among experimental guinea pigs; these results can then be analyzed mathematically so that we can better appreciate the cumulative effect of each individual variable on influenza transmission as a whole. Improved understanding of these variables will aid in designing public health interventions designed to interrupt the spread of influenza viruses among people, which has an enormous economic and health impact on populations worldwide.]]></PHR><PIS><PI><PI_NAME>BOUVIER, NICOLE M.</PI_NAME><PI_ID>10244533</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>HAUGUEL, TERESA M.</PROGRAM_OFFICER_NAME><PROJECT_START>11/05/2014</PROJECT_START><PROJECT_END>10/31/2019</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[Aerosols]]></TERM><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[Air]]></TERM><TERM><![CDATA[Animal Model]]></TERM><TERM><![CDATA[Animal Viruses]]></TERM><TERM><![CDATA[Animals]]></TERM><TERM><![CDATA[authority]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Blood Circulation]]></TERM><TERM><![CDATA[California]]></TERM><TERM><![CDATA[Cavia]]></TERM><TERM><![CDATA[Climate]]></TERM><TERM><![CDATA[Complex]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Data Set]]></TERM><TERM><![CDATA[Dependence]]></TERM><TERM><![CDATA[Deposition]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[Disease Outbreaks]]></TERM><TERM><![CDATA[Dryness]]></TERM><TERM><![CDATA[Engineering]]></TERM><TERM><![CDATA[Environment]]></TERM><TERM><![CDATA[Epidemiology]]></TERM><TERM><![CDATA[Exhalation]]></TERM><TERM><![CDATA[experience]]></TERM><TERM><![CDATA[flu transmission]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[health economics]]></TERM><TERM><![CDATA[Housing]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[Humidity]]></TERM><TERM><![CDATA[Image]]></TERM><TERM><![CDATA[Imaging technology]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[Influenza]]></TERM><TERM><![CDATA[influenzavirus]]></TERM><TERM><![CDATA[innovation]]></TERM><TERM><![CDATA[Investigation]]></TERM><TERM><![CDATA[Laboratories]]></TERM><TERM><![CDATA[Laboratory Study]]></TERM><TERM><![CDATA[Liquid substance]]></TERM><TERM><![CDATA[Mechanics]]></TERM><TERM><![CDATA[medical schools]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[pandemic influenza]]></TERM><TERM><![CDATA[particle]]></TERM><TERM><![CDATA[physical science]]></TERM><TERM><![CDATA[Physicians]]></TERM><TERM><![CDATA[Physiology]]></TERM><TERM><![CDATA[Population]]></TERM><TERM><![CDATA[Positioning Attribute]]></TERM><TERM><![CDATA[Precipitation]]></TERM><TERM><![CDATA[Probability]]></TERM><TERM><![CDATA[Production]]></TERM><TERM><![CDATA[public health medicine (field)]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Research Design]]></TERM><TERM><![CDATA[Research Personnel]]></TERM><TERM><![CDATA[research study]]></TERM><TERM><![CDATA[Resolution]]></TERM><TERM><![CDATA[respiratory]]></TERM><TERM><![CDATA[Respiratory System]]></TERM><TERM><![CDATA[Respiratory tract structure]]></TERM><TERM><![CDATA[respiratory virus]]></TERM><TERM><![CDATA[Risk]]></TERM><TERM><![CDATA[Rodent]]></TERM><TERM><![CDATA[Science]]></TERM><TERM><![CDATA[Scientist]]></TERM><TERM><![CDATA[seasonal influenza]]></TERM><TERM><![CDATA[Site]]></TERM><TERM><![CDATA[skills]]></TERM><TERM><![CDATA[Social Behavior]]></TERM><TERM><![CDATA[Source]]></TERM><TERM><![CDATA[Speed (motion)]]></TERM><TERM><![CDATA[System]]></TERM><TERM><![CDATA[Techniques]]></TERM><TERM><![CDATA[Temperature]]></TERM><TERM><![CDATA[Theoretical model]]></TERM><TERM><![CDATA[therapy design]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[transmission process]]></TERM><TERM><![CDATA[Universities]]></TERM><TERM><![CDATA[Viral]]></TERM><TERM><![CDATA[Viral Load result]]></TERM><TERM><![CDATA[virology]]></TERM><TERM><![CDATA[Virus]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Quantifying Environmental Variables Affecting Airborne Influenza Transmission]]></PROJECT_TITLE><SERIAL_NUMBER>110703</SERIAL_NUMBER><STUDY_SECTION>VIRB</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Virology - B Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>307406</DIRECT_COST_AMT><INDIRECT_COST_AMT>86875</INDIRECT_COST_AMT><TOTAL_COST>394281</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8963427</APPLICATION_ID><ACTIVITY>R21</ACTIVITY><ADMINISTERING_IC>AI</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/27/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>855</CFDA_CODE><CORE_PROJECT_NUM>R21AI111125</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF VETERINARY MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-13-303</FOA_NUMBER><FULL_PROJECT_NUM>5R21AI111125-02</FULL_PROJECT_NUM><FUNDING_ICs>NIAID:231000\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>COLUMBUS</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[VETERINARY SCIENCES]]></ORG_DEPT><ORG_DISTRICT>03</ORG_DISTRICT><ORG_DUNS>832127323</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[OHIO STATE UNIVERSITY]]></ORG_NAME><ORG_STATE>OH</ORG_STATE><ORG_ZIPCODE>432101016</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE:  Human T-cell leukemia virus type 1 (HTLV-1) infects approximately 15 to 25 million people worldwide and is the causative infectious agent of adult T-cell leukemia/ lymphoma (ATL). ATL arises after an extensive clinical latency period; however the detailed mechanism(s) of ATL development remain poorly defined. Here we focus on PRMT5 (protein arginine methyltransferase 5), an epigenetic player involved in cellular transformation and silencing tumor suppressor gene expression. Understanding the role of PRMT5 during HTLV-1-driven cellular transformation and leukemia will have significant implications for therapeutic targeting of this protein and towards understanding the genetic and epigenetic changes that arise during ATL development.]]></PHR><PIS><PI><PI_NAME>GREEN, PATRICK LEE</PI_NAME><PI_ID>1866427</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>PARK, EUN-CHUNG </PROGRAM_OFFICER_NAME><PROJECT_START>11/05/2014</PROJECT_START><PROJECT_END>10/31/2016</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Adult T-Cell Leukemia/Lymphoma]]></TERM><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[Arginine]]></TERM><TERM><![CDATA[Astrocytoma]]></TERM><TERM><![CDATA[B-Lymphocytes]]></TERM><TERM><![CDATA[Biological Assay]]></TERM><TERM><![CDATA[Biology]]></TERM><TERM><![CDATA[CD34 gene]]></TERM><TERM><![CDATA[CD4 Positive T Lymphocytes]]></TERM><TERM><![CDATA[Cell Culture Techniques]]></TERM><TERM><![CDATA[Cell Line]]></TERM><TERM><![CDATA[cell transformation]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[chemotherapy]]></TERM><TERM><![CDATA[chromatin immunoprecipitation]]></TERM><TERM><![CDATA[Chromatin Remodeling Factor]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[Coculture Techniques]]></TERM><TERM><![CDATA[Complex]]></TERM><TERM><![CDATA[Coupled]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Disease Resistance]]></TERM><TERM><![CDATA[DNA Modification Methylases]]></TERM><TERM><![CDATA[effective therapy]]></TERM><TERM><![CDATA[Enzymes]]></TERM><TERM><![CDATA[Epigenetic Process]]></TERM><TERM><![CDATA[Event]]></TERM><TERM><![CDATA[falls]]></TERM><TERM><![CDATA[Future]]></TERM><TERM><![CDATA[Gene Chips]]></TERM><TERM><![CDATA[Gene Expression]]></TERM><TERM><![CDATA[Gene Targeting]]></TERM><TERM><![CDATA[Genes]]></TERM><TERM><![CDATA[Genetic Transcription]]></TERM><TERM><![CDATA[Grant]]></TERM><TERM><![CDATA[Growth]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Herpesviridae]]></TERM><TERM><![CDATA[Histones]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[Human Herpesvirus 4]]></TERM><TERM><![CDATA[Human T-lymphotropic virus 1]]></TERM><TERM><![CDATA[In Vitro]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[Incidence]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[Infectious Agent]]></TERM><TERM><![CDATA[inhibitor/antagonist]]></TERM><TERM><![CDATA[insight]]></TERM><TERM><![CDATA[Kinetics]]></TERM><TERM><![CDATA[leukemia]]></TERM><TERM><![CDATA[Lymphoma]]></TERM><TERM><![CDATA[Malignant Neoplasms]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[melanoma]]></TERM><TERM><![CDATA[metaplastic cell transformation]]></TERM><TERM><![CDATA[Methylation]]></TERM><TERM><![CDATA[Molecular Profiling]]></TERM><TERM><![CDATA[Monitor]]></TERM><TERM><![CDATA[mouse model]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[Mutation]]></TERM><TERM><![CDATA[Nature]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[Pathogenesis]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Pattern]]></TERM><TERM><![CDATA[Pharmaceutical Preparations]]></TERM><TERM><![CDATA[Play]]></TERM><TERM><![CDATA[Positioning Attribute]]></TERM><TERM><![CDATA[pre-clinical]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[Promotor (Genetics)]]></TERM><TERM><![CDATA[Protein-Arginine N-Methyltransferase]]></TERM><TERM><![CDATA[Proteins]]></TERM><TERM><![CDATA[reconstitution]]></TERM><TERM><![CDATA[Regulator Genes]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Rest]]></TERM><TERM><![CDATA[Retroviridae]]></TERM><TERM><![CDATA[Reverse Transcriptase Polymerase Chain Reaction]]></TERM><TERM><![CDATA[RNA]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[small hairpin RNA]]></TERM><TERM><![CDATA[small molecule]]></TERM><TERM><![CDATA[Solid Neoplasm]]></TERM><TERM><![CDATA[Stem cells]]></TERM><TERM><![CDATA[System]]></TERM><TERM><![CDATA[T-Cell Transformation]]></TERM><TERM><![CDATA[T-Lymphocyte]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Therapeutic]]></TERM><TERM><![CDATA[Therapeutic Effect]]></TERM><TERM><![CDATA[therapeutic target]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[tissue culture]]></TERM><TERM><![CDATA[Treatment Efficacy]]></TERM><TERM><![CDATA[Treatment Protocols]]></TERM><TERM><![CDATA[tumor]]></TERM><TERM><![CDATA[Tumor Suppressor Genes]]></TERM><TERM><![CDATA[Tumor Suppressor Proteins]]></TERM><TERM><![CDATA[tumorigenic]]></TERM><TERM><![CDATA[Viral]]></TERM><TERM><![CDATA[Viral Genes]]></TERM><TERM><![CDATA[Viral Genome]]></TERM><TERM><![CDATA[Virus]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Role of PRMT5 in HTLV-1 transformation and disease]]></PROJECT_TITLE><SERIAL_NUMBER>111125</SERIAL_NUMBER><STUDY_SECTION>VIRA</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Virology - A Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>150000</DIRECT_COST_AMT><INDIRECT_COST_AMT>81000</INDIRECT_COST_AMT><TOTAL_COST>231000</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8965517</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>HL</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/03/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>837</CFDA_CODE><CORE_PROJECT_NUM>R01HL123064</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-13-302</FOA_NUMBER><FULL_PROJECT_NUM>5R01HL123064-02</FULL_PROJECT_NUM><FUNDING_ICs>NHLBI:566931\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL HEART, LUNG, AND BLOOD INSTITUTE</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>LOS ANGELES</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[INTERNAL MEDICINE/MEDICINE]]></ORG_DEPT><ORG_DISTRICT>33</ORG_DISTRICT><ORG_DUNS>092530369</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIVERSITY OF CALIFORNIA LOS ANGELES]]></ORG_NAME><ORG_STATE>CA</ORG_STATE><ORG_ZIPCODE>900952000</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Cardiovascular disease (CVD) is the leading killer of patients with rheumatoid arthritis (RA). Traditional CV risk factors do not accurately predict CVD in RA patients, and therefore adequate primary prevention strategies are lacking. The current project investigates molecular mechanisms through which inflammation from active RA may predispose patients to CVD, which may identify new markers for risk assessment and specific targets for intervention.]]></PHR><PIS><PI><PI_NAME>CHARLES-SCHOEMAN, CHRISTINA </PI_NAME><PI_ID>9381559</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>KIRBY, RUTH </PROGRAM_OFFICER_NAME><PROJECT_START>11/15/2014</PROJECT_START><PROJECT_END>10/31/2019</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Animal Model]]></TERM><TERM><![CDATA[Antiatherogenic]]></TERM><TERM><![CDATA[Antioxidants]]></TERM><TERM><![CDATA[Arthritis]]></TERM><TERM><![CDATA[Atherosclerosis]]></TERM><TERM><![CDATA[Biological Assay]]></TERM><TERM><![CDATA[Cardiovascular Diseases]]></TERM><TERM><![CDATA[cardiovascular risk factor]]></TERM><TERM><![CDATA[Cardiovascular system]]></TERM><TERM><![CDATA[Carotid Artery Plaques]]></TERM><TERM><![CDATA[Carotid Atherosclerotic Disease]]></TERM><TERM><![CDATA[Cholesterol]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[Clinical Research]]></TERM><TERM><![CDATA[Clinical Trials]]></TERM><TERM><![CDATA[cohort]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Discipline of Nuclear Medicine]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[fluorodeoxyglucose]]></TERM><TERM><![CDATA[follow-up]]></TERM><TERM><![CDATA[Functional disorder]]></TERM><TERM><![CDATA[Gene Deletion]]></TERM><TERM><![CDATA[General Population]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[High Density Lipoproteins]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[in vitro Assay]]></TERM><TERM><![CDATA[Inflammation]]></TERM><TERM><![CDATA[Intervention]]></TERM><TERM><![CDATA[intimal medial thickening]]></TERM><TERM><![CDATA[Joints]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[Lectin]]></TERM><TERM><![CDATA[Link]]></TERM><TERM><![CDATA[Low Density Lipoprotein oxidation]]></TERM><TERM><![CDATA[Low Density Lipoprotein Receptor]]></TERM><TERM><![CDATA[Master's Degree]]></TERM><TERM><![CDATA[Measures]]></TERM><TERM><![CDATA[member]]></TERM><TERM><![CDATA[mimetics]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[Morbidity - disease rate]]></TERM><TERM><![CDATA[Mortality Vital Statistics]]></TERM><TERM><![CDATA[mouse model]]></TERM><TERM><![CDATA[Myocardial Infarction]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[novel marker]]></TERM><TERM><![CDATA[overexpression]]></TERM><TERM><![CDATA[oxidized low density lipoprotein]]></TERM><TERM><![CDATA[Paraoxonase 1]]></TERM><TERM><![CDATA[Pathogenesis]]></TERM><TERM><![CDATA[Pathway interactions]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Peptides]]></TERM><TERM><![CDATA[Positron-Emission Tomography]]></TERM><TERM><![CDATA[prevent]]></TERM><TERM><![CDATA[Prevention strategy]]></TERM><TERM><![CDATA[Primary Prevention]]></TERM><TERM><![CDATA[prospective]]></TERM><TERM><![CDATA[Proteins]]></TERM><TERM><![CDATA[Proteomics]]></TERM><TERM><![CDATA[Research Personnel]]></TERM><TERM><![CDATA[Research Project Grants]]></TERM><TERM><![CDATA[Rheumatoid Arthritis]]></TERM><TERM><![CDATA[Rheumatology]]></TERM><TERM><![CDATA[Risk]]></TERM><TERM><![CDATA[Risk Assessment]]></TERM><TERM><![CDATA[Rosa]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[Staging]]></TERM><TERM><![CDATA[Synovial Membrane]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Therapeutic]]></TERM><TERM><![CDATA[Translational Research]]></TERM><TERM><![CDATA[Ultrasonography]]></TERM><TERM><![CDATA[United States National Institutes of Health]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Mechanisms Linking Joint Inflammation and Atherosclerosis in Rheumatoid Arthritis]]></PROJECT_TITLE><SERIAL_NUMBER>123064</SERIAL_NUMBER><STUDY_SECTION>ACTS</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Arthritis, Connective Tissue and Skin Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>368137</DIRECT_COST_AMT><INDIRECT_COST_AMT>198794</INDIRECT_COST_AMT><TOTAL_COST>566931</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8966039</APPLICATION_ID><ACTIVITY>R21</ACTIVITY><ADMINISTERING_IC>HL</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/02/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>837</CFDA_CODE><CORE_PROJECT_NUM>R21HL122881</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-12-284</FOA_NUMBER><FULL_PROJECT_NUM>5R21HL122881-02</FULL_PROJECT_NUM><FUNDING_ICs>NHLBI:182250\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL HEART, LUNG, AND BLOOD INSTITUTE</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>BALTIMORE</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[BIOMEDICAL ENGINEERING]]></ORG_DEPT><ORG_DISTRICT>07</ORG_DISTRICT><ORG_DUNS>001910777</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[JOHNS HOPKINS UNIVERSITY]]></ORG_NAME><ORG_STATE>MD</ORG_STATE><ORG_ZIPCODE>212051832</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Exciting progress has been made in the creation of human cardiomyocytes from stem cell sources, and they are known to develop into the major subtypes found in the heart. However, quantitative and automated measures of their relative proportions are lacking, and will be developed in this project using optical measurements and advanced computational algorithms. This information is vital in determining the suitability of the cells for
any given application.]]></PHR><PIS><PI><PI_NAME>TUNG, LESLIE  (contact)</PI_NAME><PI_ID>1918405 (contact)</PI_ID></PI><PI><PI_NAME>VIDAL, RENE </PI_NAME><PI_ID>8366795</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>WANG, LAN-HSIANG </PROGRAM_OFFICER_NAME><PROJECT_START>11/15/2014</PROJECT_START><PROJECT_END>10/31/2016</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Action Potentials]]></TERM><TERM><![CDATA[Algorithms]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Biological Metamorphosis]]></TERM><TERM><![CDATA[Cardiac]]></TERM><TERM><![CDATA[Cardiac Myocytes]]></TERM><TERM><![CDATA[Cell Line]]></TERM><TERM><![CDATA[Cell Maturation]]></TERM><TERM><![CDATA[cell type]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Classification]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[Computational algorithm]]></TERM><TERM><![CDATA[Computer Simulation]]></TERM><TERM><![CDATA[Computing Methodologies]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Data Set]]></TERM><TERM><![CDATA[Descriptor]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[drug testing]]></TERM><TERM><![CDATA[Electrophysiology (science)]]></TERM><TERM><![CDATA[Embryo]]></TERM><TERM><![CDATA[Engraftment]]></TERM><TERM><![CDATA[Evaluation]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Gold]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Heart]]></TERM><TERM><![CDATA[Heart Atrium]]></TERM><TERM><![CDATA[heart cell]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[human embryonic stem cell]]></TERM><TERM><![CDATA[human stem cells]]></TERM><TERM><![CDATA[Image Analysis]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[indexing]]></TERM><TERM><![CDATA[innovation]]></TERM><TERM><![CDATA[interest]]></TERM><TERM><![CDATA[ion channel blocker]]></TERM><TERM><![CDATA[Label]]></TERM><TERM><![CDATA[Location]]></TERM><TERM><![CDATA[Machine Learning]]></TERM><TERM><![CDATA[Maps]]></TERM><TERM><![CDATA[Measurement]]></TERM><TERM><![CDATA[Measures]]></TERM><TERM><![CDATA[Methods]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[monolayer]]></TERM><TERM><![CDATA[Nodal]]></TERM><TERM><![CDATA[Ontology]]></TERM><TERM><![CDATA[Optics]]></TERM><TERM><![CDATA[Phenotype]]></TERM><TERM><![CDATA[Pluripotent Stem Cells]]></TERM><TERM><![CDATA[Population]]></TERM><TERM><![CDATA[Procedures]]></TERM><TERM><![CDATA[Regenerative Medicine]]></TERM><TERM><![CDATA[Relative (related person)]]></TERM><TERM><![CDATA[Reporting]]></TERM><TERM><![CDATA[Reproducibility]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Research Personnel]]></TERM><TERM><![CDATA[Resolution]]></TERM><TERM><![CDATA[Resources]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[Shapes]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[Site]]></TERM><TERM><![CDATA[Source]]></TERM><TERM><![CDATA[spatiotemporal]]></TERM><TERM><![CDATA[Staging]]></TERM><TERM><![CDATA[Stem cells]]></TERM><TERM><![CDATA[Techniques]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[tissue repair]]></TERM><TERM><![CDATA[Transplantation]]></TERM><TERM><![CDATA[Ventricular]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Computational Classification of Human Stem Cell-Derived Cardiomyocytes]]></PROJECT_TITLE><SERIAL_NUMBER>122881</SERIAL_NUMBER><STUDY_SECTION>BDMA</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Biodata Management and Analysis Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>112500</DIRECT_COST_AMT><INDIRECT_COST_AMT>69750</INDIRECT_COST_AMT><TOTAL_COST>182250</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8966617</APPLICATION_ID><ACTIVITY>I01</ACTIVITY><ADMINISTERING_IC>VA</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/03/2015</AWARD_NOTICE_DATE><BUDGET_START>10/01/2015</BUDGET_START><BUDGET_END>09/30/2016</BUDGET_END><CFDA_CODE>999</CFDA_CODE><CORE_PROJECT_NUM>I01BX000605</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-BX-13-002</FOA_NUMBER><FULL_PROJECT_NUM>5I01BX000605-07</FULL_PROJECT_NUM><FUNDING_ICs>VA:149358\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>Veterans Affairs</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>WEST HAVEN</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>03</ORG_DISTRICT><ORG_DUNS>039624291</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[VA CONNECTICUT HEALTHCARE SYSTEM]]></ORG_NAME><ORG_STATE>CT</ORG_STATE><ORG_ZIPCODE>065162770</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE:    
   
Chronic pain resulting from injury to peripheral nerves, and spasticity due to spinal cord injury (SCI), are major health concerns within the VA. Clinically significant pain and spasticity affects approximately 50-80% of patients with nerve injuries. Currently available treatments for pain and spasticity due to nerve injuries are often not effective or are only partially effective, and thus represent an unmet medical need within the VA. The goal of our research is to explore novel therapies and delineate underlying mechanisms of neuronal hyperexcitability associated with chronic pain and spasticity.]]></PHR><PIS><PI><PI_NAME>WAXMAN, STEPHEN </PI_NAME><PI_ID>9097316</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>10/01/2009</PROJECT_START><PROJECT_END>09/30/2017</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Action Potentials]]></TERM><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[Architecture]]></TERM><TERM><![CDATA[Attenuated]]></TERM><TERM><![CDATA[attenuation]]></TERM><TERM><![CDATA[Automobile Driving]]></TERM><TERM><![CDATA[Axon]]></TERM><TERM><![CDATA[Axotomy]]></TERM><TERM><![CDATA[biophysical properties]]></TERM><TERM><![CDATA[Caliber]]></TERM><TERM><![CDATA[cell body (neuron)]]></TERM><TERM><![CDATA[chronic pain]]></TERM><TERM><![CDATA[clinically significant]]></TERM><TERM><![CDATA[Computer Simulation]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[effective therapy]]></TERM><TERM><![CDATA[Equilibrium]]></TERM><TERM><![CDATA[Experimental Autoimmune Encephalomyelitis]]></TERM><TERM><![CDATA[Face]]></TERM><TERM><![CDATA[gain of function]]></TERM><TERM><![CDATA[gene therapy]]></TERM><TERM><![CDATA[Generations]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[In Vitro]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[injured]]></TERM><TERM><![CDATA[Injury]]></TERM><TERM><![CDATA[limb amputation]]></TERM><TERM><![CDATA[Link]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[Medical]]></TERM><TERM><![CDATA[Methods]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[Motor Neurons]]></TERM><TERM><![CDATA[multiple neuroma]]></TERM><TERM><![CDATA[Multiple Sclerosis]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[Nerve Fibers]]></TERM><TERM><![CDATA[nerve injury]]></TERM><TERM><![CDATA[Neurites]]></TERM><TERM><![CDATA[Neuroma]]></TERM><TERM><![CDATA[Neurons]]></TERM><TERM><![CDATA[Nociception]]></TERM><TERM><![CDATA[Nociceptors]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[novel therapeutics]]></TERM><TERM><![CDATA[Pain]]></TERM><TERM><![CDATA[painful neuropathy]]></TERM><TERM><![CDATA[patch clamp]]></TERM><TERM><![CDATA[Pathway interactions]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Peripheral]]></TERM><TERM><![CDATA[Peripheral Nerves]]></TERM><TERM><![CDATA[Pharmaceutical Preparations]]></TERM><TERM><![CDATA[Physiology]]></TERM><TERM><![CDATA[Posterior Horn Cells]]></TERM><TERM><![CDATA[Presynaptic Terminals]]></TERM><TERM><![CDATA[Protein Isoforms]]></TERM><TERM><![CDATA[Rattus]]></TERM><TERM><![CDATA[Reporting]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Research Personnel]]></TERM><TERM><![CDATA[Research Proposals]]></TERM><TERM><![CDATA[Route]]></TERM><TERM><![CDATA[Site]]></TERM><TERM><![CDATA[small hairpin RNA]]></TERM><TERM><![CDATA[Sodium]]></TERM><TERM><![CDATA[Sodium Channel]]></TERM><TERM><![CDATA[Spinal]]></TERM><TERM><![CDATA[Spinal cord injury]]></TERM><TERM><![CDATA[spinal reflex]]></TERM><TERM><![CDATA[Synaptic Transmission]]></TERM><TERM><![CDATA[Syndrome]]></TERM><TERM><![CDATA[System]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Traumatic Nerve Injury]]></TERM><TERM><![CDATA[Variant]]></TERM><TERM><![CDATA[Veterans]]></TERM><TERM><![CDATA[Viral]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Sodium Channels in Spinal Cord Injury, Nerve Injury and Neuropathic Pain]]></PROJECT_TITLE><SERIAL_NUMBER>000605</SERIAL_NUMBER><STUDY_SECTION>NURC</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Neurobiology C ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>07</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST></TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8968264</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>HL</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/04/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>837</CFDA_CODE><CORE_PROJECT_NUM>R01HL123301</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-13-302</FOA_NUMBER><FULL_PROJECT_NUM>5R01HL123301-02</FULL_PROJECT_NUM><FUNDING_ICs>NHLBI:340124\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL HEART, LUNG, AND BLOOD INSTITUTE</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>ALBUQUERQUE</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[ANATOMY/CELL BIOLOGY]]></ORG_DEPT><ORG_DISTRICT>01</ORG_DISTRICT><ORG_DUNS>829868723</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR]]></ORG_NAME><ORG_STATE>NM</ORG_STATE><ORG_ZIPCODE>871310001</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: It is estimated that up to 20% of the American adult population suffers from sleep apnea and that one third suffer from peripheral vascular disease. Both conditions increase the risk for renal failure, myocardial infarction, cardiac ischemia and death from cardiovascular causes. This study uses laboratory rats to investigate basic vascular control mechanisms that appear to be deranged in many vascular disease states including sleep apnea and which appear to contribute to increased vascular disease in rats with simulated sleep apnea. The proposed studies examine potential mechanisms causing vascular disease in this model of sleep apnea and investigate prospective pharmacological interventions to prevent or reverse vascular disease caused by sleep apnea and other forms of hypertension.]]></PHR><PIS><PI><PI_NAME>KANAGY, NANCY L</PI_NAME><PI_ID>1912014</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>CHARETTE, MARC F</PROGRAM_OFFICER_NAME><PROJECT_START>11/15/2014</PROJECT_START><PROJECT_END>10/31/2018</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Adult]]></TERM><TERM><![CDATA[American]]></TERM><TERM><![CDATA[Animals]]></TERM><TERM><![CDATA[Arteries]]></TERM><TERM><![CDATA[autocrine]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Beds]]></TERM><TERM><![CDATA[Blood]]></TERM><TERM><![CDATA[Blood flow]]></TERM><TERM><![CDATA[Blood gas]]></TERM><TERM><![CDATA[Blood Pressure]]></TERM><TERM><![CDATA[Blood Vessels]]></TERM><TERM><![CDATA[Calcium]]></TERM><TERM><![CDATA[Cardiac Death]]></TERM><TERM><![CDATA[cardiovascular risk factor]]></TERM><TERM><![CDATA[Cardiovascular system]]></TERM><TERM><![CDATA[Chronic]]></TERM><TERM><![CDATA[Cysteine Desulfhydrase]]></TERM><TERM><![CDATA[Cytochrome P450]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Dilator]]></TERM><TERM><![CDATA[Down-Regulation]]></TERM><TERM><![CDATA[Endothelial Cells]]></TERM><TERM><![CDATA[endothelial dysfunction]]></TERM><TERM><![CDATA[Endothelium]]></TERM><TERM><![CDATA[experience]]></TERM><TERM><![CDATA[Exposure to]]></TERM><TERM><![CDATA[falls]]></TERM><TERM><![CDATA[Future]]></TERM><TERM><![CDATA[Generations]]></TERM><TERM><![CDATA[Genetic]]></TERM><TERM><![CDATA[Genetic Transcription]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Hydrogen Sulfide]]></TERM><TERM><![CDATA[Hypertension]]></TERM><TERM><![CDATA[Hypotension]]></TERM><TERM><![CDATA[Hypoxia]]></TERM><TERM><![CDATA[iberiotoxin]]></TERM><TERM><![CDATA[Incidence]]></TERM><TERM><![CDATA[Intervention]]></TERM><TERM><![CDATA[Kidney]]></TERM><TERM><![CDATA[Kidney Failure]]></TERM><TERM><![CDATA[Knockout Mice]]></TERM><TERM><![CDATA[Knowledge]]></TERM><TERM><![CDATA[Laboratory Rat]]></TERM><TERM><![CDATA[Left]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[Mesentery]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[Morbidity - disease rate]]></TERM><TERM><![CDATA[Mortality Vital Statistics]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[Myocardial Infarction]]></TERM><TERM><![CDATA[Myocardial Ischemia]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[Oxygen]]></TERM><TERM><![CDATA[Pathway interactions]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Peripheral Vascular Diseases]]></TERM><TERM><![CDATA[Pilot Projects]]></TERM><TERM><![CDATA[Population]]></TERM><TERM><![CDATA[Potassium]]></TERM><TERM><![CDATA[Potassium Channel]]></TERM><TERM><![CDATA[pressure]]></TERM><TERM><![CDATA[prevent]]></TERM><TERM><![CDATA[Production]]></TERM><TERM><![CDATA[prospective]]></TERM><TERM><![CDATA[Rattus]]></TERM><TERM><![CDATA[receptor]]></TERM><TERM><![CDATA[Regulation]]></TERM><TERM><![CDATA[Risk]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Signal Pathway]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[Sleep]]></TERM><TERM><![CDATA[Sleep Apnea Syndromes]]></TERM><TERM><![CDATA[Smooth Muscle Myocytes]]></TERM><TERM><![CDATA[Source]]></TERM><TERM><![CDATA[Therapeutic]]></TERM><TERM><![CDATA[therapy development]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[Tissues]]></TERM><TERM><![CDATA[transcription factor]]></TERM><TERM><![CDATA[transcription factor NF-AT c3]]></TERM><TERM><![CDATA[vascular bed]]></TERM><TERM><![CDATA[Vascular Diseases]]></TERM><TERM><![CDATA[Vascular resistance]]></TERM><TERM><![CDATA[Vasodilation]]></TERM><TERM><![CDATA[Vasodilator Agents]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Hydrogen sulfide regulation of vascular tone and blood pressure]]></PROJECT_TITLE><SERIAL_NUMBER>123301</SERIAL_NUMBER><STUDY_SECTION>HM</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Hypertension and Microcirculation Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>225000</DIRECT_COST_AMT><INDIRECT_COST_AMT>115124</INDIRECT_COST_AMT><TOTAL_COST>340124</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8968265</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>HL</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/02/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>837</CFDA_CODE><CORE_PROJECT_NUM>R01HL125228</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-13-302</FOA_NUMBER><FULL_PROJECT_NUM>5R01HL125228-02</FULL_PROJECT_NUM><FUNDING_ICs>NHLBI:467656\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL HEART, LUNG, AND BLOOD INSTITUTE</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>LEXINGTON</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[PHYSIOLOGY]]></ORG_DEPT><ORG_DISTRICT>06</ORG_DISTRICT><ORG_DUNS>939017877</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIVERSITY OF KENTUCKY]]></ORG_NAME><ORG_STATE>KY</ORG_STATE><ORG_ZIPCODE>405060057</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Abdominal aortic aneurysm (AAA) is defined as a permanent localized dilations of aorta, affect 4 to 8% of men and 0.5 to 1.5% of women over the age of 60, and account for about 2% of all deaths in Western countries. AAA is a vascular disease with rising prevalence and a high mortality rate (65% to 85%) related to AAA rupture. Currently, surgery is the only option for treatment of AAA and no drug has been approved for the treatment of this devastating disease. The goals of this application are to elucidate the mechanisms responsible for AAA and thereby identify new therapeutic targets to develop new drugs to treat AAA.]]></PHR><PIS><PI><PI_NAME>GONG, MING C (contact)</PI_NAME><PI_ID>6625920 (contact)</PI_ID></PI><PI><PI_NAME>GUO, ZHENHENG </PI_NAME><PI_ID>8664760</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>TOLUNAY, ESER </PROGRAM_OFFICER_NAME><PROJECT_START>11/15/2014</PROJECT_START><PROJECT_END>10/31/2018</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[2,2,6,6-tetramethyl-4-piperidinol-N-oxyl]]></TERM><TERM><![CDATA[Abdomen]]></TERM><TERM><![CDATA[abdominal aorta]]></TERM><TERM><![CDATA[Abdominal Aortic Aneurysm]]></TERM><TERM><![CDATA[Accounting]]></TERM><TERM><![CDATA[Acetates]]></TERM><TERM><![CDATA[Actins]]></TERM><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[Age]]></TERM><TERM><![CDATA[age related]]></TERM><TERM><![CDATA[Agonist]]></TERM><TERM><![CDATA[Aldosterone]]></TERM><TERM><![CDATA[Aldosterone Antagonists]]></TERM><TERM><![CDATA[Animal Model]]></TERM><TERM><![CDATA[Aorta]]></TERM><TERM><![CDATA[Aortic Aneurysm]]></TERM><TERM><![CDATA[Attenuated]]></TERM><TERM><![CDATA[Basic Science]]></TERM><TERM><![CDATA[Binding (Molecular Function)]]></TERM><TERM><![CDATA[Biochemical]]></TERM><TERM><![CDATA[Cardiovascular Diseases]]></TERM><TERM><![CDATA[Cardiovascular system]]></TERM><TERM><![CDATA[Cessation of life]]></TERM><TERM><![CDATA[Clinic]]></TERM><TERM><![CDATA[clinical practice]]></TERM><TERM><![CDATA[Country]]></TERM><TERM><![CDATA[Deoxycorticosterone]]></TERM><TERM><![CDATA[Diagnosis]]></TERM><TERM><![CDATA[diagnosis evaluation]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[effective therapy]]></TERM><TERM><![CDATA[Elastin]]></TERM><TERM><![CDATA[Endothelial Cells]]></TERM><TERM><![CDATA[eplerenone]]></TERM><TERM><![CDATA[Etiology]]></TERM><TERM><![CDATA[Free Radical Scavengers]]></TERM><TERM><![CDATA[Genetic]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Heart failure]]></TERM><TERM><![CDATA[Hospitalization]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[Hypertension]]></TERM><TERM><![CDATA[insight]]></TERM><TERM><![CDATA[Intake]]></TERM><TERM><![CDATA[Kidney]]></TERM><TERM><![CDATA[Knockout Mice]]></TERM><TERM><![CDATA[Left Ventricular Hypertrophy]]></TERM><TERM><![CDATA[Link]]></TERM><TERM><![CDATA[loss of function]]></TERM><TERM><![CDATA[male]]></TERM><TERM><![CDATA[Matrix Metalloproteinases]]></TERM><TERM><![CDATA[Medial]]></TERM><TERM><![CDATA[Membrane]]></TERM><TERM><![CDATA[men]]></TERM><TERM><![CDATA[Messenger RNA]]></TERM><TERM><![CDATA[Metalloproteases]]></TERM><TERM><![CDATA[Mineralocorticoid Receptor]]></TERM><TERM><![CDATA[MMP2 gene]]></TERM><TERM><![CDATA[MMP9 gene]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[Mortality Vital Statistics]]></TERM><TERM><![CDATA[mouse model]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[Myocardial Infarction]]></TERM><TERM><![CDATA[NADPH Oxidase]]></TERM><TERM><![CDATA[new therapeutic target]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[novel therapeutics]]></TERM><TERM><![CDATA[Operative Surgical Procedures]]></TERM><TERM><![CDATA[Oxidative Stress]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Pharmaceutical Preparations]]></TERM><TERM><![CDATA[Plasma]]></TERM><TERM><![CDATA[Prevalence]]></TERM><TERM><![CDATA[prevent]]></TERM><TERM><![CDATA[Procedures]]></TERM><TERM><![CDATA[Promotor (Genetics)]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Rupture]]></TERM><TERM><![CDATA[Ruptured Abdominal Aortic Aneurysm]]></TERM><TERM><![CDATA[salt intake]]></TERM><TERM><![CDATA[Scheme]]></TERM><TERM><![CDATA[Smooth Muscle Myocytes]]></TERM><TERM><![CDATA[Sodium]]></TERM><TERM><![CDATA[Sodium Chloride]]></TERM><TERM><![CDATA[Spironolactone]]></TERM><TERM><![CDATA[Stress]]></TERM><TERM><![CDATA[stroke]]></TERM><TERM><![CDATA[Tamoxifen]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[Vascular Diseases]]></TERM><TERM><![CDATA[vascular inflammation]]></TERM><TERM><![CDATA[Withdrawal]]></TERM><TERM><![CDATA[Woman]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Mineralocorticoid receptor and abdominal aortic aneurysm]]></PROJECT_TITLE><SERIAL_NUMBER>125228</SERIAL_NUMBER><STUDY_SECTION>ZRG1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>310735</DIRECT_COST_AMT><INDIRECT_COST_AMT>156921</INDIRECT_COST_AMT><TOTAL_COST>467656</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8970554</APPLICATION_ID><ACTIVITY>I01</ACTIVITY><ADMINISTERING_IC>VA</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/03/2015</AWARD_NOTICE_DATE><BUDGET_START>10/01/2015</BUDGET_START><BUDGET_END>09/30/2016</BUDGET_END><CFDA_CODE>999</CFDA_CODE><CORE_PROJECT_NUM>I01CX000584</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-CX-11-001</FOA_NUMBER><FULL_PROJECT_NUM>5I01CX000584-04</FULL_PROJECT_NUM><FUNDING_ICs>VA:150000\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>Veterans Affairs</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>PALO ALTO</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>18</ORG_DISTRICT><ORG_DUNS>046017455</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[VETERANS ADMIN PALO ALTO HEALTH CARE SYS]]></ORG_NAME><ORG_STATE>CA</ORG_STATE><ORG_ZIPCODE>943041207</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE:   
  
 Each year, over 350,000 veterans within the VA are diagnosed with Alcohol Abuse or Dependence (AUD) and approximately 2/3 of these veterans are between 40 and 60 years of age. Clearly, increased knowledge of mid-to-later life alcoholism is essential for the development of more efficient and effective interventions tailored to this population. The current project will contribute to this knowledge base by identifying predictors of successful remission, differentiating those with AUD in terms of differences in the developmental course of the disorder, and identifying barriers to treatment and alternative treatment interventions that are more likely to engage the large number of veterans with AUD who do not seek out conventional treatment.]]></PHR><PIS><PI><PI_NAME>JACOB, THEODORE </PI_NAME><PI_ID>1861279</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>10/01/2012</PROJECT_START><PROJECT_END>09/30/2016</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Accidents]]></TERM><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[Age]]></TERM><TERM><![CDATA[age group]]></TERM><TERM><![CDATA[Age-Years]]></TERM><TERM><![CDATA[Aging]]></TERM><TERM><![CDATA[Alcohol abuse]]></TERM><TERM><![CDATA[Alcohol dependence]]></TERM><TERM><![CDATA[alcohol use disorder]]></TERM><TERM><![CDATA[Alcoholism]]></TERM><TERM><![CDATA[Alcohols]]></TERM><TERM><![CDATA[alternative treatment]]></TERM><TERM><![CDATA[Attention]]></TERM><TERM><![CDATA[Automobile Driving]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Characteristics]]></TERM><TERM><![CDATA[Chronic]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[clinically relevant]]></TERM><TERM><![CDATA[Consumption]]></TERM><TERM><![CDATA[conventional therapy]]></TERM><TERM><![CDATA[coping]]></TERM><TERM><![CDATA[Country]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[data registry]]></TERM><TERM><![CDATA[Data Set]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Diagnosis]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Disease remission]]></TERM><TERM><![CDATA[drinking]]></TERM><TERM><![CDATA[drinking onset]]></TERM><TERM><![CDATA[effective intervention]]></TERM><TERM><![CDATA[Elderly]]></TERM><TERM><![CDATA[Event]]></TERM><TERM><![CDATA[Evidence based treatment]]></TERM><TERM><![CDATA[falls]]></TERM><TERM><![CDATA[Family]]></TERM><TERM><![CDATA[Foundations]]></TERM><TERM><![CDATA[Future]]></TERM><TERM><![CDATA[Generations]]></TERM><TERM><![CDATA[Genetic]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Grant]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[health administration]]></TERM><TERM><![CDATA[Health Personnel]]></TERM><TERM><![CDATA[Healthcare Systems]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[Intervention]]></TERM><TERM><![CDATA[Knowledge]]></TERM><TERM><![CDATA[knowledge base]]></TERM><TERM><![CDATA[Life Cycle Stages]]></TERM><TERM><![CDATA[Measures]]></TERM><TERM><![CDATA[Medical]]></TERM><TERM><![CDATA[medical specialties]]></TERM><TERM><![CDATA[Mental disorders]]></TERM><TERM><![CDATA[middle age]]></TERM><TERM><![CDATA[Occupational]]></TERM><TERM><![CDATA[Outcome]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Pattern]]></TERM><TERM><![CDATA[Personality Character]]></TERM><TERM><![CDATA[Phase]]></TERM><TERM><![CDATA[Planning Techniques]]></TERM><TERM><![CDATA[Population]]></TERM><TERM><![CDATA[Primary Health Care]]></TERM><TERM><![CDATA[Principal Investigator]]></TERM><TERM><![CDATA[Procedures]]></TERM><TERM><![CDATA[Progress Reports]]></TERM><TERM><![CDATA[prospective]]></TERM><TERM><![CDATA[Recording of previous events]]></TERM><TERM><![CDATA[Registries]]></TERM><TERM><![CDATA[Relapse]]></TERM><TERM><![CDATA[Reporting]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Sampling]]></TERM><TERM><![CDATA[Severities]]></TERM><TERM><![CDATA[social]]></TERM><TERM><![CDATA[socioeconomics]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[Twin Multiple Birth]]></TERM><TERM><![CDATA[Twin Studies]]></TERM><TERM><![CDATA[Veterans]]></TERM><TERM><![CDATA[Vietnam]]></TERM><TERM><![CDATA[Work]]></TERM><TERM><![CDATA[young adult]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Alcoholism Course From Drinking Onset to Late Life]]></PROJECT_TITLE><SERIAL_NUMBER>000584</SERIAL_NUMBER><STUDY_SECTION>EPID</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Epidemiology ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>04</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST></TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8976623</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>MH</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/03/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>242</CFDA_CODE><CORE_PROJECT_NUM>R01MH105527</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PAR-13-392</FOA_NUMBER><FULL_PROJECT_NUM>5R01MH105527-02</FULL_PROJECT_NUM><FUNDING_ICs>NIMH:343767\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF MENTAL HEALTH</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>IOWA CITY</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[PSYCHIATRY]]></ORG_DEPT><ORG_DISTRICT>02</ORG_DISTRICT><ORG_DUNS>062761671</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIVERSITY OF IOWA]]></ORG_NAME><ORG_STATE>IA</ORG_STATE><ORG_ZIPCODE>522463111</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Non-protein coding sequence accounts for about 97% of the human genome, and genetic variants in these regions can contribute to diseases and other traits. Our proposed computer algorithms and methods will make it easier for scientists and clinicians to focus on the non-coding variants that are most likely to play a role in disease.]]></PHR><PIS><PI><PI_NAME>MICHAELSON, JACOB JAMES</PI_NAME><PI_ID>10923497</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>ADDINGTON, ANJENE M</PROGRAM_OFFICER_NAME><PROJECT_START>12/01/2014</PROJECT_START><PROJECT_END>10/31/2017</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Accounting]]></TERM><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[Alleles]]></TERM><TERM><![CDATA[Autistic Disorder]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Binding (Molecular Function)]]></TERM><TERM><![CDATA[Bioinformatics]]></TERM><TERM><![CDATA[Bipolar Disorder]]></TERM><TERM><![CDATA[Brain]]></TERM><TERM><![CDATA[brain tissue]]></TERM><TERM><![CDATA[case control]]></TERM><TERM><![CDATA[Chromatin]]></TERM><TERM><![CDATA[Clinic]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[Code]]></TERM><TERM><![CDATA[Computational algorithm]]></TERM><TERM><![CDATA[Computing Methodologies]]></TERM><TERM><![CDATA[cost]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Data Set]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Diagnosis]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[epigenomics]]></TERM><TERM><![CDATA[exome]]></TERM><TERM><![CDATA[experience]]></TERM><TERM><![CDATA[falls]]></TERM><TERM><![CDATA[Foundations]]></TERM><TERM><![CDATA[Gene Cluster]]></TERM><TERM><![CDATA[Gene Expression]]></TERM><TERM><![CDATA[Gene Expression Profile]]></TERM><TERM><![CDATA[Genes]]></TERM><TERM><![CDATA[Genetic]]></TERM><TERM><![CDATA[genetic variant]]></TERM><TERM><![CDATA[Genome]]></TERM><TERM><![CDATA[genome sequencing]]></TERM><TERM><![CDATA[genome-wide]]></TERM><TERM><![CDATA[Genomics]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[Human Genome]]></TERM><TERM><![CDATA[Human Genome Project]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[insight]]></TERM><TERM><![CDATA[Learning]]></TERM><TERM><![CDATA[Light]]></TERM><TERM><![CDATA[loss of function]]></TERM><TERM><![CDATA[Measures]]></TERM><TERM><![CDATA[Medical]]></TERM><TERM><![CDATA[Methods]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[Mutation]]></TERM><TERM><![CDATA[Neurologic]]></TERM><TERM><![CDATA[neuropsychiatry]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[Open Reading Frames]]></TERM><TERM><![CDATA[Other Genetics]]></TERM><TERM><![CDATA[Phenotype]]></TERM><TERM><![CDATA[Play]]></TERM><TERM><![CDATA[Potassium Hydroxide]]></TERM><TERM><![CDATA[Probability]]></TERM><TERM><![CDATA[Promotor (Genetics)]]></TERM><TERM><![CDATA[Proteins]]></TERM><TERM><![CDATA[psychogenetics]]></TERM><TERM><![CDATA[Reading]]></TERM><TERM><![CDATA[Reporting]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[research study]]></TERM><TERM><![CDATA[Resources]]></TERM><TERM><![CDATA[Risk]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Scientist]]></TERM><TERM><![CDATA[Shapes]]></TERM><TERM><![CDATA[spatiotemporal]]></TERM><TERM><![CDATA[Specificity]]></TERM><TERM><![CDATA[Staging]]></TERM><TERM><![CDATA[Sum]]></TERM><TERM><![CDATA[System]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[Tissues]]></TERM><TERM><![CDATA[tool]]></TERM><TERM><![CDATA[Training]]></TERM><TERM><![CDATA[trait]]></TERM><TERM><![CDATA[transcription factor]]></TERM><TERM><![CDATA[Untranslated RNA]]></TERM><TERM><![CDATA[Variant]]></TERM><TERM><![CDATA[Variation (Genetics)]]></TERM><TERM><![CDATA[Weight]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Estimating the impact of genetic variants on the brain in space and time]]></PROJECT_TITLE><SERIAL_NUMBER>105527</SERIAL_NUMBER><STUDY_SECTION>ZRG1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>231264</DIRECT_COST_AMT><INDIRECT_COST_AMT>112503</INDIRECT_COST_AMT><TOTAL_COST>343767</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8990852</APPLICATION_ID><ACTIVITY>I01</ACTIVITY><ADMINISTERING_IC>VA</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/02/2015</AWARD_NOTICE_DATE><BUDGET_START>10/01/2015</BUDGET_START><BUDGET_END>09/30/2016</BUDGET_END><CFDA_CODE>999</CFDA_CODE><CORE_PROJECT_NUM>I01RX000844</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-RX-13-001</FOA_NUMBER><FULL_PROJECT_NUM>5I01RX000844-03</FULL_PROJECT_NUM><FUNDING_ICs>VA:285200\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>Veterans Affairs</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>CHARLESTON</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>01</ORG_DISTRICT><ORG_DUNS>039807318</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[RALPH H JOHNSON VA MEDICAL CENTER]]></ORG_NAME><ORG_STATE>SC</ORG_STATE><ORG_ZIPCODE>294015703</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE:    
Hemiparesis, strictly defined as (muscular) weakness affecting one side of the body, is seen in three-quarters of individuals following stroke. Weakness in this population results from both neural and muscular factors which include, respectively, the ability of the central nervous system to activate skeletal muscle as well as the force generating capacity of the muscle. Our overall goal is to improve walking in persons post-stroke by training subjects with an intervention
that specifically targets existing neural and muscular impairments, thereby facilitating locomotor recovery.]]></PHR><PIS><PI><PI_NAME>GREGORY, CHRIS </PI_NAME><PI_ID>7339945</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>10/01/2013</PROJECT_START><PROJECT_END>09/30/2017</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[3-Dimensional]]></TERM><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[aging population]]></TERM><TERM><![CDATA[Area]]></TERM><TERM><![CDATA[Attenuated]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Belief]]></TERM><TERM><![CDATA[Bioenergetics]]></TERM><TERM><![CDATA[Biomechanics]]></TERM><TERM><![CDATA[Biomedical Research]]></TERM><TERM><![CDATA[Body Weight]]></TERM><TERM><![CDATA[Characteristics]]></TERM><TERM><![CDATA[Chronic]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[cohort]]></TERM><TERM><![CDATA[Communities]]></TERM><TERM><![CDATA[Complex]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[disability]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Educational Intervention]]></TERM><TERM><![CDATA[Effectiveness]]></TERM><TERM><![CDATA[Elements]]></TERM><TERM><![CDATA[Equilibrium]]></TERM><TERM><![CDATA[Equipment]]></TERM><TERM><![CDATA[Exercise]]></TERM><TERM><![CDATA[Failure (biologic function)]]></TERM><TERM><![CDATA[fall risk]]></TERM><TERM><![CDATA[functional disability]]></TERM><TERM><![CDATA[Functional disorder]]></TERM><TERM><![CDATA[functional improvement]]></TERM><TERM><![CDATA[Funding]]></TERM><TERM><![CDATA[Future]]></TERM><TERM><![CDATA[Gait]]></TERM><TERM><![CDATA[Generations]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Hemipareses]]></TERM><TERM><![CDATA[Image]]></TERM><TERM><![CDATA[Impairment]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[innovation]]></TERM><TERM><![CDATA[inorganic phosphate]]></TERM><TERM><![CDATA[Intervention]]></TERM><TERM><![CDATA[Joints]]></TERM><TERM><![CDATA[kinematics]]></TERM><TERM><![CDATA[Leg]]></TERM><TERM><![CDATA[Level of Evidence]]></TERM><TERM><![CDATA[Life]]></TERM><TERM><![CDATA[Limb structure]]></TERM><TERM><![CDATA[Locomotor Recovery]]></TERM><TERM><![CDATA[Locomotor training]]></TERM><TERM><![CDATA[Lower Extremity]]></TERM><TERM><![CDATA[Magnetic Resonance]]></TERM><TERM><![CDATA[Magnetic Resonance Imaging]]></TERM><TERM><![CDATA[Magnetic Resonance Spectroscopy]]></TERM><TERM><![CDATA[Measures]]></TERM><TERM><![CDATA[Morphology]]></TERM><TERM><![CDATA[Motor]]></TERM><TERM><![CDATA[motor control]]></TERM><TERM><![CDATA[Muscle]]></TERM><TERM><![CDATA[Muscle function]]></TERM><TERM><![CDATA[muscle strength]]></TERM><TERM><![CDATA[Muscle Weakness]]></TERM><TERM><![CDATA[Neuraxis]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[Paresis]]></TERM><TERM><![CDATA[Performance]]></TERM><TERM><![CDATA[Peripheral]]></TERM><TERM><![CDATA[Persons]]></TERM><TERM><![CDATA[Physiological]]></TERM><TERM><![CDATA[Population]]></TERM><TERM><![CDATA[post stroke]]></TERM><TERM><![CDATA[prevent]]></TERM><TERM><![CDATA[Property]]></TERM><TERM><![CDATA[Recovery of Function]]></TERM><TERM><![CDATA[Rehabilitation Outcome]]></TERM><TERM><![CDATA[Rehabilitation therapy]]></TERM><TERM><![CDATA[relating to nervous system]]></TERM><TERM><![CDATA[remediation]]></TERM><TERM><![CDATA[Reporting]]></TERM><TERM><![CDATA[Residual state]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[Rest]]></TERM><TERM><![CDATA[Side]]></TERM><TERM><![CDATA[skeletal muscle plasticity]]></TERM><TERM><![CDATA[Skeletal muscle structure]]></TERM><TERM><![CDATA[Speed (motion)]]></TERM><TERM><![CDATA[strength training]]></TERM><TERM><![CDATA[stroke]]></TERM><TERM><![CDATA[Support System]]></TERM><TERM><![CDATA[Survivors]]></TERM><TERM><![CDATA[Task Performances]]></TERM><TERM><![CDATA[Techniques]]></TERM><TERM><![CDATA[Therapeutic]]></TERM><TERM><![CDATA[Therapeutic Intervention]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[Training]]></TERM><TERM><![CDATA[Treatment Efficacy]]></TERM><TERM><![CDATA[United States]]></TERM><TERM><![CDATA[Walking]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Skeletal Muscle Plasticity As An Indicator of Functional Performance Post-Stroke]]></PROJECT_TITLE><SERIAL_NUMBER>000844</SERIAL_NUMBER><STUDY_SECTION>RRD1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Brain Injury: TBI & Stroke  ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>03</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST></TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8990858</APPLICATION_ID><ACTIVITY>I01</ACTIVITY><ADMINISTERING_IC>VA</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/03/2015</AWARD_NOTICE_DATE><BUDGET_START>10/01/2015</BUDGET_START><BUDGET_END>09/30/2016</BUDGET_END><CFDA_CODE>999</CFDA_CODE><CORE_PROJECT_NUM>I01RX000924</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-RX-13-001</FOA_NUMBER><FULL_PROJECT_NUM>5I01RX000924-03</FULL_PROJECT_NUM><FUNDING_ICs>VA:253980\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>Veterans Affairs</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>PALO ALTO</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>18</ORG_DISTRICT><ORG_DUNS>046017455</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[VETERANS ADMIN PALO ALTO HEALTH CARE SYS]]></ORG_NAME><ORG_STATE>CA</ORG_STATE><ORG_ZIPCODE>943041207</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE:    
   
Arthroscopic meniscectomy is among the most commonly performed orthopedic surgical procedures in the VA system. There remains substantial uncertainty, however, regarding the short term benefits and the long term consequences of arthroscopic meniscectomy in patients with degenerative meniscus tears. Of major concern is the fact that degenerative meniscus tears are associated with osteoarthritis, and it is known that within two years of surgery, arthroscopic debridement for osteoarthritis is no better than placebo in relieving pain and restoring function (Moseley et al., 2002). Longer term, meniscectomy has been shown to be associated with elevated risk of osteoarthritis development, raising the concern that meniscectomy can actually be harmful (Englund et al., 2003). We aim to determine whether meniscectomy in the setting of a degenerative meniscus tear is of any clinical value. Determining this would either justify the expenses associated with arthroscopic meniscectomy on a large number of patients, or would identify an area of significant potential cost savings.]]></PHR><PIS><PI><PI_NAME>GIORI, NICHOLAS </PI_NAME><PI_ID>9822003</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>10/01/2013</PROJECT_START><PROJECT_END>09/30/2017</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[Age]]></TERM><TERM><![CDATA[age group]]></TERM><TERM><![CDATA[Area]]></TERM><TERM><![CDATA[Arthritis]]></TERM><TERM><![CDATA[Arthroscopic Surgical Procedures]]></TERM><TERM><![CDATA[Arthroscopy]]></TERM><TERM><![CDATA[articular cartilage]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Biological]]></TERM><TERM><![CDATA[Blinded]]></TERM><TERM><![CDATA[Cartilage]]></TERM><TERM><![CDATA[Cartilage Matrix]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[Clinical Trials]]></TERM><TERM><![CDATA[Complement]]></TERM><TERM><![CDATA[complement system]]></TERM><TERM><![CDATA[Control Groups]]></TERM><TERM><![CDATA[Controlled Study]]></TERM><TERM><![CDATA[cost]]></TERM><TERM><![CDATA[Cost Savings]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Debridement]]></TERM><TERM><![CDATA[Degenerative polyarthritis]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Diffusion Magnetic Resonance Imaging]]></TERM><TERM><![CDATA[functional outcomes]]></TERM><TERM><![CDATA[functional restoration]]></TERM><TERM><![CDATA[Future]]></TERM><TERM><![CDATA[gait examination]]></TERM><TERM><![CDATA[Gene Expression Alteration]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Healthcare Systems]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[Inferior]]></TERM><TERM><![CDATA[insight]]></TERM><TERM><![CDATA[Irrigation]]></TERM><TERM><![CDATA[Joints]]></TERM><TERM><![CDATA[Knee]]></TERM><TERM><![CDATA[Magnetic Resonance Imaging]]></TERM><TERM><![CDATA[Maps]]></TERM><TERM><![CDATA[Measures]]></TERM><TERM><![CDATA[Medial]]></TERM><TERM><![CDATA[Meniscus structure of joint]]></TERM><TERM><![CDATA[Motion]]></TERM><TERM><![CDATA[Muscle]]></TERM><TERM><![CDATA[Operative Surgical Procedures]]></TERM><TERM><![CDATA[Orthopedic Surgical Procedures]]></TERM><TERM><![CDATA[Pain]]></TERM><TERM><![CDATA[Patient Care]]></TERM><TERM><![CDATA[Patient Self-Report]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Placebos]]></TERM><TERM><![CDATA[Positioning Attribute]]></TERM><TERM><![CDATA[Procedures]]></TERM><TERM><![CDATA[prospective]]></TERM><TERM><![CDATA[Published Comment]]></TERM><TERM><![CDATA[Randomized]]></TERM><TERM><![CDATA[Relative (related person)]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[Risk]]></TERM><TERM><![CDATA[Rotation]]></TERM><TERM><![CDATA[Sodium]]></TERM><TERM><![CDATA[soft tissue]]></TERM><TERM><![CDATA[Surgical Flaps]]></TERM><TERM><![CDATA[System]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Thick]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[treatment planning]]></TERM><TERM><![CDATA[Uncertainty]]></TERM><TERM><![CDATA[Walking]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Prospective Trial of Arthroscopic Meniscectomy for Degenerative Meniscus Tears]]></PROJECT_TITLE><SERIAL_NUMBER>000924</SERIAL_NUMBER><STUDY_SECTION>RRD2</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Musculoskeletal/Orthopedic Rehabilitation  ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>03</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST></TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9001064</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>AI</ADMINISTERING_IC><APPLICATION_TYPE>1</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/30/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>855</CFDA_CODE><CORE_PROJECT_NUM>R01AI120987</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF ARTS AND SCIENCES]]></ED_INST_TYPE><FOA_NUMBER>PA-13-302</FOA_NUMBER><FULL_PROJECT_NUM>1R01AI120987-01</FULL_PROJECT_NUM><FUNDING_ICs>NIAID:361600\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>COLUMBIA</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[CHEMISTRY]]></ORG_DEPT><ORG_DISTRICT>06</ORG_DISTRICT><ORG_DUNS>041387846</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA]]></ORG_NAME><ORG_STATE>SC</ORG_STATE><ORG_ZIPCODE>292080001</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE:  The ever-increasing emergence of bacteria resistance to traditional antibiotics is a puzzling issue in battling infectious diseases. We propose to develop  new paradigm of metallopolymers to reinstate vitality of conventional antibiotics. The proposed research will have a significant impact on advancing the development of novel antimicrobial agents for the success of bacteria- associated infections.   
   
      

]]></PHR><PIS><PI><PI_NAME>TANG, CHUANBING </PI_NAME><PI_ID>11121680</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>XU, ZUOYU </PROGRAM_OFFICER_NAME><PROJECT_START>11/01/2015</PROJECT_START><PROJECT_END>10/31/2019</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[absorption]]></TERM><TERM><![CDATA[Acylation]]></TERM><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[Adsorption]]></TERM><TERM><![CDATA[Advanced Development]]></TERM><TERM><![CDATA[Amino Acids]]></TERM><TERM><![CDATA[Amoxicillin]]></TERM><TERM><![CDATA[Amoxicillin-Potassium Clavulanate Combination]]></TERM><TERM><![CDATA[Ampicillin]]></TERM><TERM><![CDATA[Anions]]></TERM><TERM><![CDATA[Antibiotic Therapy]]></TERM><TERM><![CDATA[Antibiotics]]></TERM><TERM><![CDATA[antimicrobial]]></TERM><TERM><![CDATA[antimicrobial drug]]></TERM><TERM><![CDATA[antimicrobial peptide]]></TERM><TERM><![CDATA[Bacteria]]></TERM><TERM><![CDATA[Bacterial Infections]]></TERM><TERM><![CDATA[bacterial resistance]]></TERM><TERM><![CDATA[Bacterial Typing]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[carboxylate]]></TERM><TERM><![CDATA[Cefazolin]]></TERM><TERM><![CDATA[Cell Culture Techniques]]></TERM><TERM><![CDATA[Cell membrane]]></TERM><TERM><![CDATA[Cell surface]]></TERM><TERM><![CDATA[Cell Wall]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Cessation of life]]></TERM><TERM><![CDATA[Charge]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[Communicable Diseases]]></TERM><TERM><![CDATA[Complex]]></TERM><TERM><![CDATA[Cytolysis]]></TERM><TERM><![CDATA[cytotoxic]]></TERM><TERM><![CDATA[deacylation]]></TERM><TERM><![CDATA[Defense Mechanisms]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[disability]]></TERM><TERM><![CDATA[Drug resistance]]></TERM><TERM><![CDATA[Enzymes]]></TERM><TERM><![CDATA[Eukaryotic Cell]]></TERM><TERM><![CDATA[Excretory function]]></TERM><TERM><![CDATA[Exhibits]]></TERM><TERM><![CDATA[fighting]]></TERM><TERM><![CDATA[Frequencies (time pattern)]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Gram-Positive Bacterial Infections]]></TERM><TERM><![CDATA[Health Care Costs]]></TERM><TERM><![CDATA[Healthcare]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[Hydrolysis]]></TERM><TERM><![CDATA[In Vitro]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[Infection]]></TERM><TERM><![CDATA[innovation]]></TERM><TERM><![CDATA[Ions]]></TERM><TERM><![CDATA[Killings]]></TERM><TERM><![CDATA[Lactamase]]></TERM><TERM><![CDATA[Lactams]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[Mammalian Cell]]></TERM><TERM><![CDATA[Metabolism]]></TERM><TERM><![CDATA[metal poisoning]]></TERM><TERM><![CDATA[Metals]]></TERM><TERM><![CDATA[Methicillin]]></TERM><TERM><![CDATA[methicillin resistant Staphylococcus aureus (organism)]]></TERM><TERM><![CDATA[Methods]]></TERM><TERM><![CDATA[Microbiology]]></TERM><TERM><![CDATA[Modern Medicine]]></TERM><TERM><![CDATA[Monobactams]]></TERM><TERM><![CDATA[Morbidity - disease rate]]></TERM><TERM><![CDATA[Multi-Drug Resistance]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[Natural regeneration]]></TERM><TERM><![CDATA[Nosocomial Infections]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[pathogen]]></TERM><TERM><![CDATA[Pathway interactions]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Penicillin G]]></TERM><TERM><![CDATA[Penicillin Resistance]]></TERM><TERM><![CDATA[Polymer Chemistry]]></TERM><TERM><![CDATA[Polymers]]></TERM><TERM><![CDATA[Predisposition]]></TERM><TERM><![CDATA[prevent]]></TERM><TERM><![CDATA[Production]]></TERM><TERM><![CDATA[public health relevance]]></TERM><TERM><![CDATA[Recurrence]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Residual state]]></TERM><TERM><![CDATA[Resistance development]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[scaffold]]></TERM><TERM><![CDATA[structural biology]]></TERM><TERM><![CDATA[Structure]]></TERM><TERM><![CDATA[success]]></TERM><TERM><![CDATA[System]]></TERM><TERM><![CDATA[Techniques]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Tissues]]></TERM><TERM><![CDATA[Toxic effect]]></TERM><TERM><![CDATA[Vancomycin]]></TERM><TERM><![CDATA[Work]]></TERM><TERM><![CDATA[X-Ray Crystallography]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Metallopolymer and Antibiotic Bioconjugates against Multidrug Resistant Bacteria]]></PROJECT_TITLE><SERIAL_NUMBER>120987</SERIAL_NUMBER><STUDY_SECTION>BMBI</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Biomaterials and Biointerfaces Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>01</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>250000</DIRECT_COST_AMT><INDIRECT_COST_AMT>111600</INDIRECT_COST_AMT><TOTAL_COST>361600</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9026120</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>AI</ADMINISTERING_IC><APPLICATION_TYPE>1</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/03/2015</AWARD_NOTICE_DATE><BUDGET_START>11/04/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>855</CFDA_CODE><CORE_PROJECT_NUM>R01AI114780</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-13-302</FOA_NUMBER><FULL_PROJECT_NUM>1R01AI114780-01A1</FULL_PROJECT_NUM><FUNDING_ICs>NIAID:104271\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>NEW HAVEN</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[NEUROLOGY]]></ORG_DEPT><ORG_DISTRICT>03</ORG_DISTRICT><ORG_DUNS>043207562</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[YALE UNIVERSITY]]></ORG_NAME><ORG_STATE>CT</ORG_STATE><ORG_ZIPCODE>065113572</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Myasthenia gravis (MG) is a chronic, disabling autoimmune neurological disease for which current treatments are ineffective in many patients. We will perform a mechanistic study linked to a clinical trial that will determine whether B cell depletion affected by the drug rituximab, is an effective treatment for MG. The mechanistic study will define the immunological events that both initiate and propagate this disease, thereby providing fundamental insight into the mechanisms of MG pathology and how the treatment affects clinical improvement.   
      

]]></PHR><PIS><PI><PI_NAME>O'CONNOR, KEVIN C</PI_NAME><PI_ID>6277821</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>ESCH, THOMAS R.</PROGRAM_OFFICER_NAME><PROJECT_START>11/04/2015</PROJECT_START><PROJECT_END>10/31/2020</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[Adverse effects]]></TERM><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[Aftercare]]></TERM><TERM><![CDATA[Antibodies]]></TERM><TERM><![CDATA[Antibody Repertoire]]></TERM><TERM><![CDATA[Antigen Presentation]]></TERM><TERM><![CDATA[Antigens]]></TERM><TERM><![CDATA[Autoantibodies]]></TERM><TERM><![CDATA[Autoantigens]]></TERM><TERM><![CDATA[Autoimmune Diseases]]></TERM><TERM><![CDATA[Autoimmune Process]]></TERM><TERM><![CDATA[Autoimmunity]]></TERM><TERM><![CDATA[autoreactive B cell]]></TERM><TERM><![CDATA[autoreactive T cell]]></TERM><TERM><![CDATA[B cell repertoire]]></TERM><TERM><![CDATA[B-Lymphocyte Subsets]]></TERM><TERM><![CDATA[B-Lymphocytes]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Biological Assay]]></TERM><TERM><![CDATA[CD4 Positive T Lymphocytes]]></TERM><TERM><![CDATA[Cell Lineage]]></TERM><TERM><![CDATA[Cell physiology]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Cellular Immunity]]></TERM><TERM><![CDATA[central tolerance]]></TERM><TERM><![CDATA[Characteristics]]></TERM><TERM><![CDATA[Cholinergic Receptors]]></TERM><TERM><![CDATA[Chronic]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[Clinical Trials]]></TERM><TERM><![CDATA[Collection]]></TERM><TERM><![CDATA[Controlled Clinical Trials]]></TERM><TERM><![CDATA[Coupled]]></TERM><TERM><![CDATA[cytokine]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Defect]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Double-Blind Method]]></TERM><TERM><![CDATA[effective therapy]]></TERM><TERM><![CDATA[Enzyme-Linked Immunosorbent Assay]]></TERM><TERM><![CDATA[Evaluation]]></TERM><TERM><![CDATA[Event]]></TERM><TERM><![CDATA[Exhibits]]></TERM><TERM><![CDATA[experience]]></TERM><TERM><![CDATA[Feeds]]></TERM><TERM><![CDATA[Frequencies (time pattern)]]></TERM><TERM><![CDATA[Functional disorder]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Granulocyte-Macrophage Colony-Stimulating Factor]]></TERM><TERM><![CDATA[High-Throughput Nucleotide Sequencing]]></TERM><TERM><![CDATA[Homeostasis]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[human disease]]></TERM><TERM><![CDATA[Immune]]></TERM><TERM><![CDATA[Immunoglobulin G]]></TERM><TERM><![CDATA[Immunoglobulin-Secreting Cells]]></TERM><TERM><![CDATA[immunopathology]]></TERM><TERM><![CDATA[Immunotherapy]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[Inflammatory]]></TERM><TERM><![CDATA[innovation]]></TERM><TERM><![CDATA[insight]]></TERM><TERM><![CDATA[Interferon Type II]]></TERM><TERM><![CDATA[Interleukin-10]]></TERM><TERM><![CDATA[Interleukin-17]]></TERM><TERM><![CDATA[Investigation]]></TERM><TERM><![CDATA[Life]]></TERM><TERM><![CDATA[Link]]></TERM><TERM><![CDATA[Maps]]></TERM><TERM><![CDATA[Mature B-Lymphocyte]]></TERM><TERM><![CDATA[Measures]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[Mediator of activation protein]]></TERM><TERM><![CDATA[Memory]]></TERM><TERM><![CDATA[Memory B-Lymphocyte]]></TERM><TERM><![CDATA[Methods]]></TERM><TERM><![CDATA[Mission]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Monitor]]></TERM><TERM><![CDATA[Myasthenia Gravis]]></TERM><TERM><![CDATA[National Institute of Neurological Disorders and Stroke]]></TERM><TERM><![CDATA[nervous system disorder]]></TERM><TERM><![CDATA[Neuromuscular Junction]]></TERM><TERM><![CDATA[neuromuscular transmission]]></TERM><TERM><![CDATA[new technology]]></TERM><TERM><![CDATA[next generation]]></TERM><TERM><![CDATA[next generation sequencing]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[Pathogenesis]]></TERM><TERM><![CDATA[Pathology]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[peripheral tolerance]]></TERM><TERM><![CDATA[Pharmaceutical Preparations]]></TERM><TERM><![CDATA[Phase II Clinical Trials]]></TERM><TERM><![CDATA[Phenotype]]></TERM><TERM><![CDATA[Placebo Control]]></TERM><TERM><![CDATA[Play]]></TERM><TERM><![CDATA[Population]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[Production]]></TERM><TERM><![CDATA[programs]]></TERM><TERM><![CDATA[prospective]]></TERM><TERM><![CDATA[public health relevance]]></TERM><TERM><![CDATA[Randomized]]></TERM><TERM><![CDATA[Recombinants]]></TERM><TERM><![CDATA[Refractory]]></TERM><TERM><![CDATA[Relative (related person)]]></TERM><TERM><![CDATA[rituximab]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Services]]></TERM><TERM><![CDATA[Specimen]]></TERM><TERM><![CDATA[Staining method]]></TERM><TERM><![CDATA[Stains]]></TERM><TERM><![CDATA[T-Lymphocyte]]></TERM><TERM><![CDATA[T-Lymphocyte Subsets]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Therapeutic Effect]]></TERM><TERM><![CDATA[Translational Research]]></TERM><TERM><![CDATA[United States National Institutes of Health]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Mechanisms of autoantibody production in myasthenia gravis]]></PROJECT_TITLE><SERIAL_NUMBER>114780</SERIAL_NUMBER><STUDY_SECTION>CNBT</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Clinical Neuroimmunology and Brain Tumors Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>01</SUPPORT_YEAR><SUFFIX>A1</SUFFIX><DIRECT_COST_AMT>62500</DIRECT_COST_AMT><INDIRECT_COST_AMT>41771</INDIRECT_COST_AMT><TOTAL_COST>104271</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9050490</APPLICATION_ID><ACTIVITY>F31</ACTIVITY><ADMINISTERING_IC>NS</ADMINISTERING_IC><APPLICATION_TYPE>1</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>09/18/2015</AWARD_NOTICE_DATE><BUDGET_START>09/30/2015</BUDGET_START><BUDGET_END>09/29/2016</BUDGET_END><CFDA_CODE>853</CFDA_CODE><CORE_PROJECT_NUM>F31NS095568</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-14-147</FOA_NUMBER><FULL_PROJECT_NUM>1F31NS095568-01</FULL_PROJECT_NUM><FUNDING_ICs>NINDS:33870\</FUNDING_ICs><FUNDING_MECHANISM>TRAINING, INDIVIDUAL</FUNDING_MECHANISM><FY>2015</FY><IC_NAME>NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE</IC_NAME><NIH_SPENDING_CATS><CATEGORY><![CDATA[Brain Disorders]]></CATEGORY><CATEGORY><![CDATA[Epilepsy]]></CATEGORY><CATEGORY><![CDATA[Neurodegenerative]]></CATEGORY><CATEGORY><![CDATA[Neurosciences]]></CATEGORY></NIH_SPENDING_CATS><ORG_CITY>BIRMINGHAM</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[ANATOMY/CELL BIOLOGY]]></ORG_DEPT><ORG_DISTRICT>07</ORG_DISTRICT><ORG_DUNS>063690705</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIVERSITY OF ALABAMA AT BIRMINGHAM]]></ORG_NAME><ORG_STATE>AL</ORG_STATE><ORG_ZIPCODE>352940004</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: A novel form of synaptic depression has been identified, associated with pharmacologically increased O- GlcNAc levels on synaptic proteins. This proposal seeks to provide further characterize the molecular mechanisms underlying this synaptic depression and test this phenomenon as a possible therapeutic target with which to combat seizure activity in the brain.   
   
      

]]></PHR><PIS><PI><PI_NAME>STEWART, LUKE THOMAS</PI_NAME><PI_ID>12597189</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>WHITTEMORE, VICKY R</PROGRAM_OFFICER_NAME><PROJECT_START>09/30/2015</PROJECT_START><PROJECT_END>09/29/2017</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Acetylglucosamine]]></TERM><TERM><![CDATA[Acute]]></TERM><TERM><![CDATA[AMPA Receptors]]></TERM><TERM><![CDATA[Animals]]></TERM><TERM><![CDATA[Area]]></TERM><TERM><![CDATA[awake]]></TERM><TERM><![CDATA[Biological Assay]]></TERM><TERM><![CDATA[Brain]]></TERM><TERM><![CDATA[Cancer Biology]]></TERM><TERM><![CDATA[Cardiac]]></TERM><TERM><![CDATA[Cellular Stress]]></TERM><TERM><![CDATA[combat]]></TERM><TERM><![CDATA[conditioned fear]]></TERM><TERM><![CDATA[Convulsants]]></TERM><TERM><![CDATA[CREB1 gene]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Dendrites]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[Diabetes Mellitus]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Dominant-Negative Mutation]]></TERM><TERM><![CDATA[Electroencephalography]]></TERM><TERM><![CDATA[Ensure]]></TERM><TERM><![CDATA[Enzymes]]></TERM><TERM><![CDATA[Epilepsy]]></TERM><TERM><![CDATA[Excision]]></TERM><TERM><![CDATA[Exhibits]]></TERM><TERM><![CDATA[Frequencies (time pattern)]]></TERM><TERM><![CDATA[genetic regulatory protein]]></TERM><TERM><![CDATA[Glucosamine]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Hexosamines]]></TERM><TERM><![CDATA[hippocampal pyramidal neuron]]></TERM><TERM><![CDATA[Hippocampus (Brain)]]></TERM><TERM><![CDATA[Homeostasis]]></TERM><TERM><![CDATA[Hyperactive behavior]]></TERM><TERM><![CDATA[In Vitro]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[Injury]]></TERM><TERM><![CDATA[Laboratories]]></TERM><TERM><![CDATA[Literature]]></TERM><TERM><![CDATA[Long-Term Depression (Physiology)]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[Metabolic]]></TERM><TERM><![CDATA[Metabolism]]></TERM><TERM><![CDATA[Modification]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[Monosaccharides]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[N-Methylaspartate]]></TERM><TERM><![CDATA[Nervous system structure]]></TERM><TERM><![CDATA[Neurons]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[O-GlcNAc transferase]]></TERM><TERM><![CDATA[object recognition]]></TERM><TERM><![CDATA[overexpression]]></TERM><TERM><![CDATA[Pathway interactions]]></TERM><TERM><![CDATA[Pentylenetetrazole]]></TERM><TERM><![CDATA[peptide O-linked N-acetylglucosamine-beta-N-acetylglucosaminidase]]></TERM><TERM><![CDATA[Performance]]></TERM><TERM><![CDATA[Phosphorylation]]></TERM><TERM><![CDATA[Picrotoxin]]></TERM><TERM><![CDATA[Play]]></TERM><TERM><![CDATA[Post-Translational Protein Processing]]></TERM><TERM><![CDATA[postsynaptic]]></TERM><TERM><![CDATA[protective effect]]></TERM><TERM><![CDATA[protein function]]></TERM><TERM><![CDATA[Proteins]]></TERM><TERM><![CDATA[public health relevance]]></TERM><TERM><![CDATA[Publications]]></TERM><TERM><![CDATA[Rattus]]></TERM><TERM><![CDATA[receptor internalization]]></TERM><TERM><![CDATA[relating to nervous system]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[research study]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Seizures]]></TERM><TERM><![CDATA[Serine]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[Site]]></TERM><TERM><![CDATA[Slice]]></TERM><TERM><![CDATA[Synapses]]></TERM><TERM><![CDATA[synaptic depression]]></TERM><TERM><![CDATA[Synaptic Transmission]]></TERM><TERM><![CDATA[System]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[therapeutic target]]></TERM><TERM><![CDATA[Threonine]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[O-GlcNAcylation dampens hyper-excitability in hippocampus during acute epileptiform activity]]></PROJECT_TITLE><SERIAL_NUMBER>095568</SERIAL_NUMBER><STUDY_SECTION>ZRG1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>01</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>33870</DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>33870</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9054637</APPLICATION_ID><ACTIVITY>U54</ACTIVITY><ADMINISTERING_IC>HD</ADMINISTERING_IC><APPLICATION_TYPE>1</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/30/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>U54HD086984</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-HD-15-033</FOA_NUMBER><FULL_PROJECT_NUM>1U54HD086984-01</FULL_PROJECT_NUM><FUNDING_ICs>NICHD:121174\</FUNDING_ICs><FUNDING_MECHANISM>RESEARCH CENTERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &amp; HUMAN DEVELOPMENT</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>PHILADELPHIA</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>02</ORG_DISTRICT><ORG_DUNS>073757627</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[CHILDREN'S HOSP OF PHILADELPHIA]]></ORG_NAME><ORG_STATE>PA</ORG_STATE><ORG_ZIPCODE>191044318</ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>SCHULTZ, ROBERT THOMAS</PI_NAME><PI_ID>1907666</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>11/01/2015</PROJECT_START><PROJECT_END>05/31/2020</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Accounting]]></TERM><TERM><![CDATA[Acute]]></TERM><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[Architecture]]></TERM><TERM><![CDATA[Autistic Disorder]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Behavior]]></TERM><TERM><![CDATA[Behavioral]]></TERM><TERM><![CDATA[Biological]]></TERM><TERM><![CDATA[Biological Markers]]></TERM><TERM><![CDATA[Brain]]></TERM><TERM><![CDATA[brain behavior]]></TERM><TERM><![CDATA[Caring]]></TERM><TERM><![CDATA[Catchment Area]]></TERM><TERM><![CDATA[Categories]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[Clinical and Translational Science Awards]]></TERM><TERM><![CDATA[Clinical Research]]></TERM><TERM><![CDATA[Clinical Trials]]></TERM><TERM><![CDATA[Collaborations]]></TERM><TERM><![CDATA[Collection]]></TERM><TERM><![CDATA[Consent]]></TERM><TERM><![CDATA[Consultations]]></TERM><TERM><![CDATA[cost effective]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Data Set]]></TERM><TERM><![CDATA[Databases]]></TERM><TERM><![CDATA[Diagnosis]]></TERM><TERM><![CDATA[Diagnostic]]></TERM><TERM><![CDATA[Dimensions]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Effectiveness]]></TERM><TERM><![CDATA[Electronic Health Record]]></TERM><TERM><![CDATA[Eligibility Determination]]></TERM><TERM><![CDATA[Environment]]></TERM><TERM><![CDATA[Eye]]></TERM><TERM><![CDATA[Fostering]]></TERM><TERM><![CDATA[Foundations]]></TERM><TERM><![CDATA[Functional disorder]]></TERM><TERM><![CDATA[Future]]></TERM><TERM><![CDATA[Genes]]></TERM><TERM><![CDATA[Genetic]]></TERM><TERM><![CDATA[Genomics]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Gold]]></TERM><TERM><![CDATA[Health Services Research]]></TERM><TERM><![CDATA[Heterogeneity]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[Informatics]]></TERM><TERM><![CDATA[innovation]]></TERM><TERM><![CDATA[Institution]]></TERM><TERM><![CDATA[Institutional Review Boards]]></TERM><TERM><![CDATA[instrumentation]]></TERM><TERM><![CDATA[Intellectual functioning disability]]></TERM><TERM><![CDATA[Interdisciplinary Study]]></TERM><TERM><![CDATA[Knowledge]]></TERM><TERM><![CDATA[Libraries]]></TERM><TERM><![CDATA[Light]]></TERM><TERM><![CDATA[Literature]]></TERM><TERM><![CDATA[medical specialties]]></TERM><TERM><![CDATA[Mental Retardation and Developmental Disabilities Research Centers]]></TERM><TERM><![CDATA[Methodology]]></TERM><TERM><![CDATA[Methods]]></TERM><TERM><![CDATA[Mining]]></TERM><TERM><![CDATA[Mission]]></TERM><TERM><![CDATA[Motion]]></TERM><TERM><![CDATA[National Institute of Child Health and Human Development]]></TERM><TERM><![CDATA[new technology]]></TERM><TERM><![CDATA[Online Systems]]></TERM><TERM><![CDATA[Outcome]]></TERM><TERM><![CDATA[Participant]]></TERM><TERM><![CDATA[Pathogenesis]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Phenotype]]></TERM><TERM><![CDATA[Population]]></TERM><TERM><![CDATA[Population Study]]></TERM><TERM><![CDATA[Prevention]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[Productivity]]></TERM><TERM><![CDATA[Questionnaires]]></TERM><TERM><![CDATA[Recruitment Activity]]></TERM><TERM><![CDATA[Registries]]></TERM><TERM><![CDATA[relating to nervous system]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Research Infrastructure]]></TERM><TERM><![CDATA[Research Personnel]]></TERM><TERM><![CDATA[Resources]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Sample Size]]></TERM><TERM><![CDATA[Sampling]]></TERM><TERM><![CDATA[Services]]></TERM><TERM><![CDATA[Sister]]></TERM><TERM><![CDATA[Source]]></TERM><TERM><![CDATA[Support System]]></TERM><TERM><![CDATA[Syndrome]]></TERM><TERM><![CDATA[System]]></TERM><TERM><![CDATA[Talents]]></TERM><TERM><![CDATA[Technology]]></TERM><TERM><![CDATA[tertiary care]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[therapy development]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[tool]]></TERM><TERM><![CDATA[Translational Research]]></TERM><TERM><![CDATA[Translations]]></TERM><TERM><![CDATA[web site]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Clinical Translational: Core B]]></PROJECT_TITLE><SERIAL_NUMBER>086984</SERIAL_NUMBER><STUDY_SECTION>ZHD1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID>8065</SUBPROJECT_ID><SUPPORT_YEAR>01</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>81124</DIRECT_COST_AMT><INDIRECT_COST_AMT>55164</INDIRECT_COST_AMT><TOTAL_COST /><TOTAL_COST_SUB_PROJECT>121174</TOTAL_COST_SUB_PROJECT></row>
<row><APPLICATION_ID>9056019</APPLICATION_ID><ACTIVITY>U54</ACTIVITY><ADMINISTERING_IC>HD</ADMINISTERING_IC><APPLICATION_TYPE>1</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/30/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>U54HD087101</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-HD-15-033</FOA_NUMBER><FULL_PROJECT_NUM>1U54HD087101-01</FULL_PROJECT_NUM><FUNDING_ICs>NICHD:309029\</FUNDING_ICs><FUNDING_MECHANISM>RESEARCH CENTERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &amp; HUMAN DEVELOPMENT</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>LOS ANGELES</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>33</ORG_DISTRICT><ORG_DUNS>092530369</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIVERSITY OF CALIFORNIA LOS ANGELES]]></ORG_NAME><ORG_STATE>CA</ORG_STATE><ORG_ZIPCODE>900952000</ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>JESTE, SHAFALI SPURLING</PI_NAME><PI_ID>10521132</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>11/01/2015</PROJECT_START><PROJECT_END>05/31/2020</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[15q]]></TERM><TERM><![CDATA[abstracting]]></TERM><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[Agonist]]></TERM><TERM><![CDATA[Animal Model]]></TERM><TERM><![CDATA[Animals]]></TERM><TERM><![CDATA[Attention]]></TERM><TERM><![CDATA[awake]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Basic Science]]></TERM><TERM><![CDATA[Behavior]]></TERM><TERM><![CDATA[Behavior assessment]]></TERM><TERM><![CDATA[Behavioral]]></TERM><TERM><![CDATA[Bioinformatics]]></TERM><TERM><![CDATA[Biological Markers]]></TERM><TERM><![CDATA[Calcium]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Center for Translational Science Activities]]></TERM><TERM><![CDATA[Child]]></TERM><TERM><![CDATA[Clinic]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[Clinical Research]]></TERM><TERM><![CDATA[Cognition]]></TERM><TERM><![CDATA[Cognitive]]></TERM><TERM><![CDATA[cognitive function]]></TERM><TERM><![CDATA[cognitive performance]]></TERM><TERM><![CDATA[cohort]]></TERM><TERM><![CDATA[Complex]]></TERM><TERM><![CDATA[Copy Number Polymorphism]]></TERM><TERM><![CDATA[Custom]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Data Set]]></TERM><TERM><![CDATA[Decision Making]]></TERM><TERM><![CDATA[density]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[effective therapy]]></TERM><TERM><![CDATA[efficacy testing]]></TERM><TERM><![CDATA[Electroencephalography]]></TERM><TERM><![CDATA[Electrophysiology (science)]]></TERM><TERM><![CDATA[Environment]]></TERM><TERM><![CDATA[Equilibrium]]></TERM><TERM><![CDATA[Evidence based treatment]]></TERM><TERM><![CDATA[excitatory neuron]]></TERM><TERM><![CDATA[flexibility]]></TERM><TERM><![CDATA[Future]]></TERM><TERM><![CDATA[GABA Receptor]]></TERM><TERM><![CDATA[Gene Expression]]></TERM><TERM><![CDATA[Generations]]></TERM><TERM><![CDATA[Genes]]></TERM><TERM><![CDATA[Genetic]]></TERM><TERM><![CDATA[Genetic Predisposition to Disease]]></TERM><TERM><![CDATA[genetic profiling]]></TERM><TERM><![CDATA[Heterogeneity]]></TERM><TERM><![CDATA[Hippocampus (Brain)]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[Human Genetics]]></TERM><TERM><![CDATA[Image]]></TERM><TERM><![CDATA[Imagery]]></TERM><TERM><![CDATA[Imaging Device]]></TERM><TERM><![CDATA[Impaired cognition]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[Individual Differences]]></TERM><TERM><![CDATA[innovation]]></TERM><TERM><![CDATA[Intellectual functioning disability]]></TERM><TERM><![CDATA[Interneurons]]></TERM><TERM><![CDATA[interstitial]]></TERM><TERM><![CDATA[Intervention]]></TERM><TERM><![CDATA[Investigation]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[Learning]]></TERM><TERM><![CDATA[learning extinction]]></TERM><TERM><![CDATA[Link]]></TERM><TERM><![CDATA[Measurable]]></TERM><TERM><![CDATA[Measurement]]></TERM><TERM><![CDATA[Measures]]></TERM><TERM><![CDATA[Methods]]></TERM><TERM><![CDATA[Microscope]]></TERM><TERM><![CDATA[miniaturize]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[mouse model]]></TERM><TERM><![CDATA[mTOR Inhibitor]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[N-Methyl-D-Aspartate Receptors]]></TERM><TERM><![CDATA[neurodevelopment]]></TERM><TERM><![CDATA[Neurodevelopmental Disorder]]></TERM><TERM><![CDATA[Neurons]]></TERM><TERM><![CDATA[neurophysiology]]></TERM><TERM><![CDATA[outcome forecast]]></TERM><TERM><![CDATA[Parietal]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Pattern]]></TERM><TERM><![CDATA[Pharmacological Treatment]]></TERM><TERM><![CDATA[Plant Roots]]></TERM><TERM><![CDATA[Population]]></TERM><TERM><![CDATA[Population Dynamics]]></TERM><TERM><![CDATA[protein degradation]]></TERM><TERM><![CDATA[receptor]]></TERM><TERM><![CDATA[Receptor Gene]]></TERM><TERM><![CDATA[Relative (related person)]]></TERM><TERM><![CDATA[Research Personnel]]></TERM><TERM><![CDATA[research study]]></TERM><TERM><![CDATA[Rest]]></TERM><TERM><![CDATA[Serine]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[Silicon]]></TERM><TERM><![CDATA[Sirolimus]]></TERM><TERM><![CDATA[skills]]></TERM><TERM><![CDATA[standardize measure]]></TERM><TERM><![CDATA[Study models]]></TERM><TERM><![CDATA[Syndrome]]></TERM><TERM><![CDATA[System]]></TERM><TERM><![CDATA[Task Performances]]></TERM><TERM><![CDATA[Techniques]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[tool]]></TERM><TERM><![CDATA[Translating]]></TERM><TERM><![CDATA[translational study]]></TERM><TERM><![CDATA[treatment response]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[UCLA Center for Translational Neurodevelopment (UC-TRaN): Neurophysiological biomarkers of cognition in Dup15 syndrome: From mouse models to patients (Project)]]></PROJECT_TITLE><SERIAL_NUMBER>087101</SERIAL_NUMBER><STUDY_SECTION>ZHD1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID>8269</SUBPROJECT_ID><SUPPORT_YEAR>01</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>200668</DIRECT_COST_AMT><INDIRECT_COST_AMT>108361</INDIRECT_COST_AMT><TOTAL_COST /><TOTAL_COST_SUB_PROJECT>309029</TOTAL_COST_SUB_PROJECT></row>
<row><APPLICATION_ID>9146909</APPLICATION_ID><ACTIVITY>U51</ACTIVITY><ADMINISTERING_IC>PS</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/22/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>U51PS004034</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-PS-13-303</FOA_NUMBER><FULL_PROJECT_NUM>5U51PS004034-04</FULL_PROJECT_NUM><FUNDING_ICs>NCHHSTP:75000\</FUNDING_ICs><FUNDING_MECHANISM>OTHERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP)</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>HARTFORD</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>01</ORG_DISTRICT><ORG_DUNS>807853791</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[CONNECTICUT STATE DEPT OF PUBLIC HEALTH]]></ORG_NAME><ORG_STATE>CT</ORG_STATE><ORG_ZIPCODE>061061367</ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>LOMBARD, ANDREA </PI_NAME><PI_ID>12046631</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>11/01/2012</PROJECT_START><PROJECT_END>10/31/2016</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[VIRAL HEPATITIS PREVENTION AND SURVEILLANCE]]></PROJECT_TITLE><SERIAL_NUMBER>004034</SERIAL_NUMBER><STUDY_SECTION>ZPS1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>04</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>75000</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9146915</APPLICATION_ID><ACTIVITY>U51</ACTIVITY><ADMINISTERING_IC>PS</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/23/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>U51PS004044</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-PS-13-303</FOA_NUMBER><FULL_PROJECT_NUM>5U51PS004044-04</FULL_PROJECT_NUM><FUNDING_ICs>NCHHSTP:35686\</FUNDING_ICs><FUNDING_MECHANISM>OTHERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP)</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>TOPEKA</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>02</ORG_DISTRICT><ORG_DUNS>175941483</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[KANSAS STATE DEPT OF HLTH AND ENVIRONMNT]]></ORG_NAME><ORG_STATE>KS</ORG_STATE><ORG_ZIPCODE>666121371</ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>VANDEVELDE, JENNNIFER L</PI_NAME><PI_ID>11907592</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>11/01/2012</PROJECT_START><PROJECT_END>10/31/2016</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[KDHE VIRAL HEPATITIS PREVENTION & SURVEILLANCE]]></PROJECT_TITLE><SERIAL_NUMBER>004044</SERIAL_NUMBER><STUDY_SECTION>ZPS1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>04</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>35686</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9146927</APPLICATION_ID><ACTIVITY>U51</ACTIVITY><ADMINISTERING_IC>PS</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/23/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>U51PS004055</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-PS-13-303</FOA_NUMBER><FULL_PROJECT_NUM>5U51PS004055-04</FULL_PROJECT_NUM><FUNDING_ICs>NCHHSTP:9952\</FUNDING_ICs><FUNDING_MECHANISM>OTHERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP)</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>BOISE</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>02</ORG_DISTRICT><ORG_DUNS>825201486</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[IDAHO STATE DEPT OF HEALTH AND WELFARE]]></ORG_NAME><ORG_STATE>ID</ORG_STATE><ORG_ZIPCODE>837200003</ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>HEWETT, RAFE </PI_NAME><PI_ID>11536070</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>11/01/2012</PROJECT_START><PROJECT_END>10/31/2016</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[HEPATITIS VIRAL PREVENTION COORDINATOR-IMPROVE THE DELIVERY OF VIRAL HEP PREVENT]]></PROJECT_TITLE><SERIAL_NUMBER>004055</SERIAL_NUMBER><STUDY_SECTION>ZPS1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>04</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>9952</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9146933</APPLICATION_ID><ACTIVITY>U51</ACTIVITY><ADMINISTERING_IC>PS</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/26/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>U51PS004060</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-PS-13-303</FOA_NUMBER><FULL_PROJECT_NUM>5U51PS004060-04</FULL_PROJECT_NUM><FUNDING_ICs>NCHHSTP:259973\</FUNDING_ICs><FUNDING_MECHANISM>OTHERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP)</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>SAN FRANCISCO</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>12</ORG_DISTRICT><ORG_DUNS>103717336</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[SAN FRANCISCO DEPT OF PUBLIC HEALTH]]></ORG_NAME><ORG_STATE>CA</ORG_STATE><ORG_ZIPCODE>941032651</ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>SANCHEZ, MELISSA </PI_NAME><PI_ID>10944897</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>11/01/2012</PROJECT_START><PROJECT_END>10/31/2016</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[Active, Enhanced Surveillance for Viral Hepatitis in San Francisco, California]]></PROJECT_TITLE><SERIAL_NUMBER>004060</SERIAL_NUMBER><STUDY_SECTION>ZPS1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>04</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>259973</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9146938</APPLICATION_ID><ACTIVITY>U51</ACTIVITY><ADMINISTERING_IC>PS</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/23/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>U51PS004072</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-PS-13-303</FOA_NUMBER><FULL_PROJECT_NUM>5U51PS004072-04</FULL_PROJECT_NUM><FUNDING_ICs>NCHHSTP:50725\</FUNDING_ICs><FUNDING_MECHANISM>OTHERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP)</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>FRANKFORT</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>06</ORG_DISTRICT><ORG_DUNS>927049767</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[KY ST CABINET/HEALTH/FAMILY SERVICES]]></ORG_NAME><ORG_STATE>KY</ORG_STATE><ORG_ZIPCODE>406012321</ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>BRAWLEY, MD, ROBERT L.</PI_NAME><PI_ID>9201771</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>11/01/2012</PROJECT_START><PROJECT_END>10/31/2016</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[KENTUCKY VIRAL HEPATITIS PREVENTION AND CONTROL PROGRAM]]></PROJECT_TITLE><SERIAL_NUMBER>004072</SERIAL_NUMBER><STUDY_SECTION>ZPS1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>04</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>50725</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9146941</APPLICATION_ID><ACTIVITY>U51</ACTIVITY><ADMINISTERING_IC>PS</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/26/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>U51PS004076</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-PS-13-303</FOA_NUMBER><FULL_PROJECT_NUM>5U51PS004076-04</FULL_PROJECT_NUM><FUNDING_ICs>NCHHSTP:67956\</FUNDING_ICs><FUNDING_MECHANISM>OTHERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP)</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>NEW YORK</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>12</ORG_DISTRICT><ORG_DUNS>083489737</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[NEW YORK CITY HEALTH/MENTAL HYGIENE]]></ORG_NAME><ORG_STATE>NY</ORG_STATE><ORG_ZIPCODE>111014130</ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>LAYTON, MARCELLE CAROL</PI_NAME><PI_ID>8994562</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>11/01/2012</PROJECT_START><PROJECT_END>10/31/2016</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[NY CITY DEPT OF HEALTH & MENTAL HYGIENE APP FOR VIRAL HEPATITIS PREVENTION & SURV]]></PROJECT_TITLE><SERIAL_NUMBER>004076</SERIAL_NUMBER><STUDY_SECTION>ZPS1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>04</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>67956</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9146945</APPLICATION_ID><ACTIVITY>U51</ACTIVITY><ADMINISTERING_IC>PS</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/23/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>U51PS004084</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-PS-13-303</FOA_NUMBER><FULL_PROJECT_NUM>5U51PS004084-04</FULL_PROJECT_NUM><FUNDING_ICs>NCHHSTP:48873\</FUNDING_ICs><FUNDING_MECHANISM>OTHERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP)</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>DOVER</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>00</ORG_DISTRICT><ORG_DUNS>103989187</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[DELAWARE DIVISION OF PUBLIC HEALTH]]></ORG_NAME><ORG_STATE>DE</ORG_STATE><ORG_ZIPCODE>199013635</ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>RODMAN, JEANNETTE </PI_NAME><PI_ID>12498807</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>11/01/2012</PROJECT_START><PROJECT_END>10/31/2016</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[ADULT VIRAL HEPATITIS PREVENTION AND CONTROL]]></PROJECT_TITLE><SERIAL_NUMBER>004084</SERIAL_NUMBER><STUDY_SECTION>ZPS1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>04</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>48873</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9149045</APPLICATION_ID><ACTIVITY>U51</ACTIVITY><ADMINISTERING_IC>PS</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/23/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>U51PS004045</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-PS-13-303</FOA_NUMBER><FULL_PROJECT_NUM>5U51PS004045-04</FULL_PROJECT_NUM><FUNDING_ICs>NCHHSTP:235821\</FUNDING_ICs><FUNDING_MECHANISM>OTHERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP)</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>PHILADELPHIA</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>01</ORG_DISTRICT><ORG_DUNS>140533410</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[PHILADELPHIA DEPARTMENTOF PUBLIC HEALTH]]></ORG_NAME><ORG_STATE>PA</ORG_STATE><ORG_ZIPCODE>191021617</ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>JOHNSON, CAROLINE CARLSON</PI_NAME><PI_ID>9038869</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>11/01/2012</PROJECT_START><PROJECT_END>10/31/2016</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[PHILADELPHIA VIRAL HEPT PREVENTION & SURVEILLANCE - CATEGORY A & B]]></PROJECT_TITLE><SERIAL_NUMBER>004045</SERIAL_NUMBER><STUDY_SECTION>ZPS1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>04</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>235821</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9149058</APPLICATION_ID><ACTIVITY>U51</ACTIVITY><ADMINISTERING_IC>PS</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/28/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>U51PS004080</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-PS-13-303</FOA_NUMBER><FULL_PROJECT_NUM>5U51PS004080-04</FULL_PROJECT_NUM><FUNDING_ICs>NCHHSTP:24550\</FUNDING_ICs><FUNDING_MECHANISM>OTHERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP)</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>RICHMOND</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>03</ORG_DISTRICT><ORG_DUNS>809740459</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[VIRGINIA STATE DEPT OF HEALTH]]></ORG_NAME><ORG_STATE>VA</ORG_STATE><ORG_ZIPCODE>232193623</ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>JORDAN, DIANA </PI_NAME><PI_ID>11263695</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>11/01/2012</PROJECT_START><PROJECT_END>10/31/2016</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[VIRAL HEPATITIS PREVENTION AND SURVEILLANCE]]></PROJECT_TITLE><SERIAL_NUMBER>004080</SERIAL_NUMBER><STUDY_SECTION>ZPS1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>04</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>24550</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9149062</APPLICATION_ID><ACTIVITY>U51</ACTIVITY><ADMINISTERING_IC>PS</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/28/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>U51PS004082</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-PS-13-303</FOA_NUMBER><FULL_PROJECT_NUM>5U51PS004082-04</FULL_PROJECT_NUM><FUNDING_ICs>NCHHSTP:60842\</FUNDING_ICs><FUNDING_MECHANISM>OTHERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP)</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>MADISON</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>02</ORG_DISTRICT><ORG_DUNS>036448835</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[WISCONSIN DEPARTMENT OF HEALTH SERVICES]]></ORG_NAME><ORG_STATE>WI</ORG_STATE><ORG_ZIPCODE>537033445</ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>GUILFOYLE, SHEILA </PI_NAME><PI_ID>14308251</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>11/01/2012</PROJECT_START><PROJECT_END>10/31/2016</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[WISCONSIN VIRAL HEPATITIS PREVENTION GRANT: VIRAL HEPATITIS PREVENTION COORDINATO]]></PROJECT_TITLE><SERIAL_NUMBER>004082</SERIAL_NUMBER><STUDY_SECTION>ZPS1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>04</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>60842</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9170802</APPLICATION_ID><ACTIVITY>R44</ACTIVITY><ADMINISTERING_IC>MH</ADMINISTERING_IC><APPLICATION_TYPE>3</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/27/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>06/30/2016</BUDGET_END><CFDA_CODE>242</CFDA_CODE><CORE_PROJECT_NUM>R44MH110161</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>PA-14-071</FOA_NUMBER><FULL_PROJECT_NUM>3R44MH110161-05S1</FULL_PROJECT_NUM><FUNDING_ICs>NIMH:447022\</FUNDING_ICs><FUNDING_MECHANISM>SBIR-STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF MENTAL HEALTH</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>PASADENA</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>27</ORG_DISTRICT><ORG_DUNS>148679884</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[AURITEC PHARMACEUTICALS, INC.]]></ORG_NAME><ORG_STATE>CA</ORG_STATE><ORG_ZIPCODE>911073658</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: The broad long term goal of this work is to empower women in the developing world to protect themselves against HIV infection through the use of an HIV microbicide intravaginal ring. In this Phase IIB program we propose to develop the capacity for cost effective manufacture of commercial lots of HIV microbicide intravaginal rings through automation of the manufacturing process. The successful completion of this project will allow cost-effective provision of microbicide rings to the developing world.]]></PHR><PIS><PI><PI_NAME>SMITH, THOMAS J.</PI_NAME><PI_ID>8200105</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>DELCARMEN-WIGGINS, REBECCA </PROGRAM_OFFICER_NAME><PROJECT_START>03/01/2009</PROJECT_START><PROJECT_END>06/30/2017</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Adherence (attribute)]]></TERM><TERM><![CDATA[Agreement]]></TERM><TERM><![CDATA[Animals]]></TERM><TERM><![CDATA[Antiviral Agents]]></TERM><TERM><![CDATA[aqueous]]></TERM><TERM><![CDATA[Automation]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[cGMP production]]></TERM><TERM><![CDATA[Chemistry]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[Clinical Trials]]></TERM><TERM><![CDATA[Collaborations]]></TERM><TERM><![CDATA[controlled release]]></TERM><TERM><![CDATA[cost effective]]></TERM><TERM><![CDATA[Cyclic GMP]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Devices]]></TERM><TERM><![CDATA[Drug Delivery Systems]]></TERM><TERM><![CDATA[drug development]]></TERM><TERM><![CDATA[Drug Formulations]]></TERM><TERM><![CDATA[Drug Kinetics]]></TERM><TERM><![CDATA[empowered]]></TERM><TERM><![CDATA[Engineering]]></TERM><TERM><![CDATA[Environment]]></TERM><TERM><![CDATA[Equipment]]></TERM><TERM><![CDATA[experience]]></TERM><TERM><![CDATA[FDA approved]]></TERM><TERM><![CDATA[Feasibility Studies]]></TERM><TERM><![CDATA[Gel]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[HIV]]></TERM><TERM><![CDATA[HIV Infections]]></TERM><TERM><![CDATA[Hormones]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[Infection]]></TERM><TERM><![CDATA[Infection prevention]]></TERM><TERM><![CDATA[innovation]]></TERM><TERM><![CDATA[Licensing]]></TERM><TERM><![CDATA[lot production]]></TERM><TERM><![CDATA[Macaca]]></TERM><TERM><![CDATA[manufacturing process]]></TERM><TERM><![CDATA[Marketing]]></TERM><TERM><![CDATA[material transfer agreement]]></TERM><TERM><![CDATA[Methods]]></TERM><TERM><![CDATA[microbicide]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Oryctolagus cuniculus]]></TERM><TERM><![CDATA[Pharmaceutical Preparations]]></TERM><TERM><![CDATA[Pharmacologic Substance]]></TERM><TERM><![CDATA[Phase]]></TERM><TERM><![CDATA[Pilot Projects]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[Production]]></TERM><TERM><![CDATA[programs]]></TERM><TERM><![CDATA[Prophylactic treatment]]></TERM><TERM><![CDATA[Qualifying]]></TERM><TERM><![CDATA[Research Personnel]]></TERM><TERM><![CDATA[Safety]]></TERM><TERM><![CDATA[Sheep]]></TERM><TERM><![CDATA[Simplexvirus]]></TERM><TERM><![CDATA[Solubility]]></TERM><TERM><![CDATA[System]]></TERM><TERM><![CDATA[Technology]]></TERM><TERM><![CDATA[Tenofovir]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Vaginal Ring]]></TERM><TERM><![CDATA[Validation]]></TERM><TERM><![CDATA[Woman]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Automation of GMP manufacturing of HIV microbicide rings]]></PROJECT_TITLE><SERIAL_NUMBER>110161</SERIAL_NUMBER><STUDY_SECTION>ADDT</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[AIDS Discovery and Development of Therapeutics Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>05</SUPPORT_YEAR><SUFFIX>S1</SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>447022</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9171342</APPLICATION_ID><ACTIVITY>U51</ACTIVITY><ADMINISTERING_IC>PS</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/26/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>U51PS004043</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-PS-13-303</FOA_NUMBER><FULL_PROJECT_NUM>5U51PS004043-04</FULL_PROJECT_NUM><FUNDING_ICs>NCHHSTP:45600\</FUNDING_ICs><FUNDING_MECHANISM>OTHERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP)</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>WILLISTON</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>00</ORG_DISTRICT><ORG_DUNS>809376155</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[VERMONT STATE AGENCY OF HUMAN SERVICES]]></ORG_NAME><ORG_STATE>VT</ORG_STATE><ORG_ZIPCODE>054952069</ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>DALTRY, DANIEL JOSEPH</PI_NAME><PI_ID>9141505</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>11/01/2012</PROJECT_START><PROJECT_END>10/31/2016</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[VIRAL HEPATITIS-PREVENTION AND SURVEILLANCE]]></PROJECT_TITLE><SERIAL_NUMBER>004043</SERIAL_NUMBER><STUDY_SECTION>ZPS1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>04</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>45600</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9172456</APPLICATION_ID><ACTIVITY>F30</ACTIVITY><ADMINISTERING_IC>HL</ADMINISTERING_IC><APPLICATION_TYPE>6</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/05/2015</AWARD_NOTICE_DATE><BUDGET_START>11/05/2015</BUDGET_START><BUDGET_END>01/31/2016</BUDGET_END><CFDA_CODE>837</CFDA_CODE><CORE_PROJECT_NUM>F30HL117545</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>PA-11-125</FOA_NUMBER><FULL_PROJECT_NUM>6F30HL117545-04</FULL_PROJECT_NUM><FUNDING_ICs>NHLBI:20050\</FUNDING_ICs><FUNDING_MECHANISM>TRAINING, INDIVIDUAL</FUNDING_MECHANISM><FY>2015</FY><IC_NAME>NATIONAL HEART, LUNG, AND BLOOD INSTITUTE</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>BRONX</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>14</ORG_DISTRICT><ORG_DUNS>079783367</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[ALBERT EINSTEIN COLLEGE OF MEDICINE]]></ORG_NAME><ORG_STATE>NY</ORG_STATE><ORG_ZIPCODE>104611975</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: The goal of this project is to understand the functions of the non-clustered homeobox protein Hlx in healthy hematopoiesis and in leukemia pathogenesis. To characterize the roles of Hlx in lineage commitment of stem and progenitor cells, as well as in myeloid differentiation and acute myeloid leukemia cells, we will utilize genetic murine models, stem cell transplantation assays and targeted reduction of Hlx levels in vivo and in vitro.
To elucidate the mechanism of action of Hlx, we will study downstream pathways we have identified by transcriptional profiling and perform chromatin-immunoprecipitation to establish Hlx as a transcription factor capable of directly regulating its target genes.]]></PHR><PIS><PI><PI_NAME>PANDOLFI, ASHLEY MARIE</PI_NAME><PI_ID>10321642</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>WELNIAK, LISBETH A</PROGRAM_OFFICER_NAME><PROJECT_START>02/01/2013</PROJECT_START><PROJECT_END>01/31/2016</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[Adopted]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Biological Assay]]></TERM><TERM><![CDATA[Biology]]></TERM><TERM><![CDATA[Blood]]></TERM><TERM><![CDATA[Blood Cells]]></TERM><TERM><![CDATA[Cell Cycle Regulation]]></TERM><TERM><![CDATA[Cell Line]]></TERM><TERM><![CDATA[Cell Lineage]]></TERM><TERM><![CDATA[Cell physiology]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Characteristics]]></TERM><TERM><![CDATA[ChIP-seq]]></TERM><TERM><![CDATA[chromatin immunoprecipitation]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Disease remission]]></TERM><TERM><![CDATA[Down-Regulation]]></TERM><TERM><![CDATA[FLT3 gene]]></TERM><TERM><![CDATA[Gene Expression Profiling]]></TERM><TERM><![CDATA[Gene Targeting]]></TERM><TERM><![CDATA[Genes]]></TERM><TERM><![CDATA[Genetic]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Growth]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Hematopoiesis]]></TERM><TERM><![CDATA[Hematopoietic]]></TERM><TERM><![CDATA[Hematopoietic stem cells]]></TERM><TERM><![CDATA[Homeobox]]></TERM><TERM><![CDATA[Homeobox Genes]]></TERM><TERM><![CDATA[Homeodomain Proteins]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[In Vitro]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[leukemia]]></TERM><TERM><![CDATA[Leukemia, Myelocytic, Acute]]></TERM><TERM><![CDATA[leukemogenesis]]></TERM><TERM><![CDATA[Malignant - descriptor]]></TERM><TERM><![CDATA[Malignant Neoplasms]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[Mediator of activation protein]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Molecular Mechanisms of Action]]></TERM><TERM><![CDATA[mouse model]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[Mutate]]></TERM><TERM><![CDATA[Mutation]]></TERM><TERM><![CDATA[Myelogenous]]></TERM><TERM><![CDATA[Myeloid Cells]]></TERM><TERM><![CDATA[Myeloid Leukemia]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[novel strategies]]></TERM><TERM><![CDATA[Outcome]]></TERM><TERM><![CDATA[overexpression]]></TERM><TERM><![CDATA[Pathogenesis]]></TERM><TERM><![CDATA[Pathway interactions]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Play]]></TERM><TERM><![CDATA[Population]]></TERM><TERM><![CDATA[precursor cell]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[progenitor]]></TERM><TERM><![CDATA[programs]]></TERM><TERM><![CDATA[Regulation]]></TERM><TERM><![CDATA[research study]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[self-renewal]]></TERM><TERM><![CDATA[Signaling Protein]]></TERM><TERM><![CDATA[stem]]></TERM><TERM><![CDATA[stem cell biology]]></TERM><TERM><![CDATA[Stem cell transplant]]></TERM><TERM><![CDATA[Stem cells]]></TERM><TERM><![CDATA[Therapeutic Intervention]]></TERM><TERM><![CDATA[transcription factor]]></TERM><TERM><![CDATA[Transcriptional Regulation]]></TERM><TERM><![CDATA[Transplantation]]></TERM><TERM><![CDATA[Treatment Protocols]]></TERM><TERM><![CDATA[Up-Regulation (Physiology)]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Unraveling crucial roles of homeobox gene Hlx in hematopoiesis and leukemogenesis]]></PROJECT_TITLE><SERIAL_NUMBER>117545</SERIAL_NUMBER><STUDY_SECTION>ZRG1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>04</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>20050</DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>20050</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9173552</APPLICATION_ID><ACTIVITY>Y01</ACTIVITY><ADMINISTERING_IC>HL</ADMINISTERING_IC><APPLICATION_TYPE></APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE></AWARD_NOTICE_DATE><BUDGET_START></BUDGET_START><BUDGET_END></BUDGET_END><CFDA_CODE>837</CFDA_CODE><CORE_PROJECT_NUM>Y01HL150080</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER></FOA_NUMBER><FULL_PROJECT_NUM>AHL15008001-1-0-1</FULL_PROJECT_NUM><FUNDING_ICs>NHLBI:6777\</FUNDING_ICs><FUNDING_MECHANISM>INTERAGENCY AGREEMENTS</FUNDING_MECHANISM><FY>2015</FY><IC_NAME>NATIONAL HEART, LUNG, AND BLOOD INSTITUTE</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY></ORG_CITY><ORG_COUNTRY></ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT></ORG_DISTRICT><ORG_DUNS></ORG_DUNS><ORG_FIPS></ORG_FIPS><ORG_NAME><![CDATA[NATIONAL HEART, LUNG, AND BLOOD INSTITUTE]]></ORG_NAME><ORG_STATE></ORG_STATE><ORG_ZIPCODE></ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>,  </PI_NAME><PI_ID></PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START></PROJECT_START><PROJECT_END></PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Age-Years]]></TERM><TERM><![CDATA[Centers for Disease Control and Prevention (U.S.)]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[Communication]]></TERM><TERM><![CDATA[Communities]]></TERM><TERM><![CDATA[Data Collection]]></TERM><TERM><![CDATA[data registry]]></TERM><TERM><![CDATA[DNA]]></TERM><TERM><![CDATA[Funding]]></TERM><TERM><![CDATA[Grant]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[Monitor]]></TERM><TERM><![CDATA[National Heart, Lung, and Blood Institute]]></TERM><TERM><![CDATA[Performance]]></TERM><TERM><![CDATA[Phase]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[programs]]></TERM><TERM><![CDATA[Progress Reports]]></TERM><TERM><![CDATA[Registries]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Research Personnel]]></TERM><TERM><![CDATA[Resources]]></TERM><TERM><![CDATA[Running]]></TERM><TERM><![CDATA[Sampling]]></TERM><TERM><![CDATA[Specimen]]></TERM><TERM><![CDATA[Sudden Death]]></TERM><TERM><![CDATA[System]]></TERM><TERM><![CDATA[Training]]></TERM><TERM><![CDATA[United States National Institutes of Health]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Sudden Death in Young (SDY)]]></PROJECT_TITLE><SERIAL_NUMBER></SERIAL_NUMBER><STUDY_SECTION></STUDY_SECTION><STUDY_SECTION_NAME xsi:nil='true' /><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR></SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>6777</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8821660</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>HL</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/30/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>837</CFDA_CODE><CORE_PROJECT_NUM>R01HL114933</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-14-078</FOA_NUMBER><FULL_PROJECT_NUM>5R01HL114933-03</FULL_PROJECT_NUM><FUNDING_ICs>NHLBI:326092\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL HEART, LUNG, AND BLOOD INSTITUTE</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>BIRMINGHAM</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[ANESTHESIOLOGY]]></ORG_DEPT><ORG_DISTRICT>07</ORG_DISTRICT><ORG_DUNS>063690705</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIVERSITY OF ALABAMA AT BIRMINGHAM]]></ORG_NAME><ORG_STATE>AL</ORG_STATE><ORG_ZIPCODE>352940004</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Severe pulmonary hypertension is an irreversible disease that causes morbidity and mortality. The project investigates the role of a hypoxic factor, HIF-2alpha in causing pulmonary hypertension and proposes to block this factor and associated pathway as a therapeutic intervention. Proposed studies could lead to new targets for therapy of pulmonary hypertension and a better understanding of the disease process.]]></PHR><PIS><PI><PI_NAME>AHMAD, AFTAB </PI_NAME><PI_ID>10808503</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>XIAO, LEI </PROGRAM_OFFICER_NAME><PROJECT_START>04/01/2014</PROJECT_START><PROJECT_END>10/31/2018</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Adenosine]]></TERM><TERM><![CDATA[ADORA2A gene]]></TERM><TERM><![CDATA[Altitude]]></TERM><TERM><![CDATA[autocrine]]></TERM><TERM><![CDATA[Binding (Molecular Function)]]></TERM><TERM><![CDATA[blocking factor]]></TERM><TERM><![CDATA[Blood Vessels]]></TERM><TERM><![CDATA[Cell Proliferation]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Chronic]]></TERM><TERM><![CDATA[constriction]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[DNA]]></TERM><TERM><![CDATA[Elements]]></TERM><TERM><![CDATA[Endothelial Cells]]></TERM><TERM><![CDATA[Endothelium]]></TERM><TERM><![CDATA[Fibroblasts]]></TERM><TERM><![CDATA[Figs - dietary]]></TERM><TERM><![CDATA[gain of function mutation]]></TERM><TERM><![CDATA[Genes]]></TERM><TERM><![CDATA[Genetic Polymorphism]]></TERM><TERM><![CDATA[Glycolysis]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Growth]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Heart failure]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[human disease]]></TERM><TERM><![CDATA[Hypoxemia]]></TERM><TERM><![CDATA[Hypoxia]]></TERM><TERM><![CDATA[Hypoxia Inducible Factor]]></TERM><TERM><![CDATA[Hypoxia Pathway]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[insight]]></TERM><TERM><![CDATA[Investigation]]></TERM><TERM><![CDATA[Knock-out]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[loss of function mutation]]></TERM><TERM><![CDATA[Lung]]></TERM><TERM><![CDATA[Lung diseases]]></TERM><TERM><![CDATA[Medial]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[Mediator of activation protein]]></TERM><TERM><![CDATA[Metabolic Pathway]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[Morbidity - disease rate]]></TERM><TERM><![CDATA[Mortality Vital Statistics]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[Oxidative Phosphorylation]]></TERM><TERM><![CDATA[paracrine]]></TERM><TERM><![CDATA[Pathogenesis]]></TERM><TERM><![CDATA[Pathway interactions]]></TERM><TERM><![CDATA[Pattern]]></TERM><TERM><![CDATA[Pentosephosphate Pathway]]></TERM><TERM><![CDATA[Phenotype]]></TERM><TERM><![CDATA[Play]]></TERM><TERM><![CDATA[Polycythemia]]></TERM><TERM><![CDATA[pressure]]></TERM><TERM><![CDATA[Prevention]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[pulmonary arterial hypertension]]></TERM><TERM><![CDATA[Pulmonary artery structure]]></TERM><TERM><![CDATA[Pulmonary Hypertension]]></TERM><TERM><![CDATA[Rattus]]></TERM><TERM><![CDATA[receptor]]></TERM><TERM><![CDATA[Receptor Inhibition]]></TERM><TERM><![CDATA[Reporting]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[small hairpin RNA]]></TERM><TERM><![CDATA[Small Interfering RNA]]></TERM><TERM><![CDATA[Smooth muscle (tissue)]]></TERM><TERM><![CDATA[Smooth Muscle Myocytes]]></TERM><TERM><![CDATA[SU 5416]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Therapeutic Intervention]]></TERM><TERM><![CDATA[therapeutic target]]></TERM><TERM><![CDATA[Tissues]]></TERM><TERM><![CDATA[transcription factor]]></TERM><TERM><![CDATA[Vascular Endothelial Growth Factors]]></TERM><TERM><![CDATA[Vascular remodeling]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Hypoxic factors in pulmonary hypertension]]></PROJECT_TITLE><SERIAL_NUMBER>114933</SERIAL_NUMBER><STUDY_SECTION>ZRG1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>03</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>225000</DIRECT_COST_AMT><INDIRECT_COST_AMT>101092</INDIRECT_COST_AMT><TOTAL_COST>326092</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8929225</APPLICATION_ID><ACTIVITY>F32</ACTIVITY><ADMINISTERING_IC>DK</ADMINISTERING_IC><APPLICATION_TYPE>4</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/05/2015</AWARD_NOTICE_DATE><BUDGET_START>10/07/2015</BUDGET_START><BUDGET_END>10/06/2016</BUDGET_END><CFDA_CODE>847</CFDA_CODE><CORE_PROJECT_NUM>F32DK097893</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-11-113</FOA_NUMBER><FULL_PROJECT_NUM>4F32DK097893-03</FULL_PROJECT_NUM><FUNDING_ICs>NIDDK:57962\</FUNDING_ICs><FUNDING_MECHANISM>TRAINING, INDIVIDUAL</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>SAINT LOUIS</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[INTERNAL MEDICINE/MEDICINE]]></ORG_DEPT><ORG_DISTRICT>01</ORG_DISTRICT><ORG_DUNS>068552207</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[WASHINGTON UNIVERSITY]]></ORG_NAME><ORG_STATE>MO</ORG_STATE><ORG_ZIPCODE>631304862</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Tolerance to the luminal bacteria is imperative for good digestive health, as seen in digestive diseases such as Crohn's disease and ulcerative colitis when the intestinal immune system responds inappropriately to the luminal contents. Specific epithelial cells can contribute to intestinal homeostasis by delivering bacterial and dietary antigen from the lumen of the gut and promoting tolerogenic responses. We will study the contribution of the intestinal epithelium to antigen delivery with the hope to better understand how systemic signals and the enteric micro flora can regulate antigen delivery and therefore intestinal homeostasis.]]></PHR><PIS><PI><PI_NAME>KNOOP, KATHRYN </PI_NAME><PI_ID>11335126</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>DENSMORE, CHRISTINE L</PROGRAM_OFFICER_NAME><PROJECT_START>09/05/2013</PROJECT_START><PROJECT_END>10/06/2016</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Acetylcholine]]></TERM><TERM><![CDATA[acetylcholine receptor agonist]]></TERM><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[Adult]]></TERM><TERM><![CDATA[Aftercare]]></TERM><TERM><![CDATA[Antibiotics]]></TERM><TERM><![CDATA[Antigens]]></TERM><TERM><![CDATA[Bacteria]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Calcium]]></TERM><TERM><![CDATA[Carbamoylcholine]]></TERM><TERM><![CDATA[Cell Culture Techniques]]></TERM><TERM><![CDATA[Cell secretion]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Colon]]></TERM><TERM><![CDATA[Crohn's disease]]></TERM><TERM><![CDATA[Dendritic Cells]]></TERM><TERM><![CDATA[Diet]]></TERM><TERM><![CDATA[Digestive System Disorders]]></TERM><TERM><![CDATA[Enteral]]></TERM><TERM><![CDATA[Epithelial]]></TERM><TERM><![CDATA[Epithelial Cells]]></TERM><TERM><![CDATA[Epithelium]]></TERM><TERM><![CDATA[Exocytosis]]></TERM><TERM><![CDATA[germ free condition]]></TERM><TERM><![CDATA[Germ-Free]]></TERM><TERM><![CDATA[Goblet Cells]]></TERM><TERM><![CDATA[Grant]]></TERM><TERM><![CDATA[Growth]]></TERM><TERM><![CDATA[Growth Factor Receptors]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Homeostasis]]></TERM><TERM><![CDATA[House mice]]></TERM><TERM><![CDATA[Housing]]></TERM><TERM><![CDATA[Immune response]]></TERM><TERM><![CDATA[Immune system]]></TERM><TERM><![CDATA[In Vitro]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[Infection]]></TERM><TERM><![CDATA[Inflammatory Response]]></TERM><TERM><![CDATA[inhibitor/antagonist]]></TERM><TERM><![CDATA[intestinal epithelium]]></TERM><TERM><![CDATA[intestinal homeostasis]]></TERM><TERM><![CDATA[Intestines]]></TERM><TERM><![CDATA[Lamina Propria]]></TERM><TERM><![CDATA[Ligands]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[microbial]]></TERM><TERM><![CDATA[Microscopy]]></TERM><TERM><![CDATA[Mitogen-Activated Protein Kinases]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[Muscarinic Acetylcholine Receptor]]></TERM><TERM><![CDATA[Neonatal]]></TERM><TERM><![CDATA[neonate]]></TERM><TERM><![CDATA[Pathway interactions]]></TERM><TERM><![CDATA[Phosphorylation]]></TERM><TERM><![CDATA[prevent]]></TERM><TERM><![CDATA[Receptor Activation]]></TERM><TERM><![CDATA[receptor expression]]></TERM><TERM><![CDATA[Receptor Signaling]]></TERM><TERM><![CDATA[Regulation]]></TERM><TERM><![CDATA[research study]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Salmonella typhimurium]]></TERM><TERM><![CDATA[Sampling]]></TERM><TERM><![CDATA[sensor]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[Small Intestinal Goblet Cell]]></TERM><TERM><![CDATA[Small Intestines]]></TERM><TERM><![CDATA[Specific Pathogen Frees]]></TERM><TERM><![CDATA[Stimulus]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Tissues]]></TERM><TERM><![CDATA[Trans-Activation (Genetics)]]></TERM><TERM><![CDATA[two-photon]]></TERM><TERM><![CDATA[Ulcerative Colitis]]></TERM><TERM><![CDATA[Villous]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Goblet Cell Secretion and Antigen Delivery]]></PROJECT_TITLE><SERIAL_NUMBER>097893</SERIAL_NUMBER><STUDY_SECTION>ZDK1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>03</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>57962</DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>57962</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8957380</APPLICATION_ID><ACTIVITY>F32</ACTIVITY><ADMINISTERING_IC>GM</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/29/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>859</CFDA_CODE><CORE_PROJECT_NUM>F32GM110984</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>PA-11-113</FOA_NUMBER><FULL_PROJECT_NUM>5F32GM110984-02</FULL_PROJECT_NUM><FUNDING_ICs>NIGMS:54194\</FUNDING_ICs><FUNDING_MECHANISM>TRAINING, INDIVIDUAL</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>BOSTON</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>07</ORG_DISTRICT><ORG_DUNS>076593722</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[CHILDREN'S HOSPITAL CORPORATION]]></ORG_NAME><ORG_STATE>MA</ORG_STATE><ORG_ZIPCODE>021155737</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Deficiencies in axonal microtubule-based transport have been implicated in neuro- developmental and neuro-degenerative diseases. The goal of this project is to develop, validate and optimize a novel tool for light-controlled regulation of target proteins, and use it to probe the molecular machinery that underlies this process in living cells. Additionally, we believe this new method will prove a valuable tool for the study of many other cell biology questions underlying a broad range of health-related topics.   
      

]]></PHR><PIS><PI><PI_NAME>GUTNICK, AMOS </PI_NAME><PI_ID>11910184</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>MAAS, STEFAN </PROGRAM_OFFICER_NAME><PROJECT_START>11/01/2014</PROJECT_START><PROJECT_END>10/31/2016</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Acute]]></TERM><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[Aspergillus nidulans]]></TERM><TERM><![CDATA[Automobile Driving]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Behavior]]></TERM><TERM><![CDATA[Binding (Molecular Function)]]></TERM><TERM><![CDATA[Biological]]></TERM><TERM><![CDATA[Biological Assay]]></TERM><TERM><![CDATA[Catalytic Domain]]></TERM><TERM><![CDATA[Cell Culture Techniques]]></TERM><TERM><![CDATA[Cell membrane]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Cellular biology]]></TERM><TERM><![CDATA[Chemicals]]></TERM><TERM><![CDATA[Cleaved cell]]></TERM><TERM><![CDATA[Complex]]></TERM><TERM><![CDATA[Couples]]></TERM><TERM><![CDATA[Degenerative Disorder]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[DHFR gene]]></TERM><TERM><![CDATA[Dimerization]]></TERM><TERM><![CDATA[Discipline]]></TERM><TERM><![CDATA[Dynein ATPase]]></TERM><TERM><![CDATA[Engineering]]></TERM><TERM><![CDATA[Enzymes]]></TERM><TERM><![CDATA[Eukaryotic Cell]]></TERM><TERM><![CDATA[Excision]]></TERM><TERM><![CDATA[Exposure to]]></TERM><TERM><![CDATA[Financial compensation]]></TERM><TERM><![CDATA[fluorophore]]></TERM><TERM><![CDATA[Genes]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Hippocampus (Brain)]]></TERM><TERM><![CDATA[Image]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[in vivo Model]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[interest]]></TERM><TERM><![CDATA[Intracellular Transport]]></TERM><TERM><![CDATA[Kinesin]]></TERM><TERM><![CDATA[Lasers]]></TERM><TERM><![CDATA[Life]]></TERM><TERM><![CDATA[Light]]></TERM><TERM><![CDATA[Lighting]]></TERM><TERM><![CDATA[Measures]]></TERM><TERM><![CDATA[Messenger RNA]]></TERM><TERM><![CDATA[Methods]]></TERM><TERM><![CDATA[Microtubules]]></TERM><TERM><![CDATA[Mitochondria]]></TERM><TERM><![CDATA[Modality]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Molds]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[Molecular Motors]]></TERM><TERM><![CDATA[Molecular Probes]]></TERM><TERM><![CDATA[Motor]]></TERM><TERM><![CDATA[Movement]]></TERM><TERM><![CDATA[Mutation]]></TERM><TERM><![CDATA[Names]]></TERM><TERM><![CDATA[Neurons]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[novel strategies]]></TERM><TERM><![CDATA[Organelles]]></TERM><TERM><![CDATA[Peptides]]></TERM><TERM><![CDATA[peroxisome]]></TERM><TERM><![CDATA[Pharmaceutical Preparations]]></TERM><TERM><![CDATA[Photochemistry]]></TERM><TERM><![CDATA[photolysis]]></TERM><TERM><![CDATA[Positioning Attribute]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[Property]]></TERM><TERM><![CDATA[Protein Engineering]]></TERM><TERM><![CDATA[Proteins]]></TERM><TERM><![CDATA[public health relevance]]></TERM><TERM><![CDATA[Rattus]]></TERM><TERM><![CDATA[receptor]]></TERM><TERM><![CDATA[Recombinant Proteins]]></TERM><TERM><![CDATA[Recombinants]]></TERM><TERM><![CDATA[Regulation]]></TERM><TERM><![CDATA[Research Personnel]]></TERM><TERM><![CDATA[research study]]></TERM><TERM><![CDATA[RNA Interference]]></TERM><TERM><![CDATA[Side]]></TERM><TERM><![CDATA[small molecule]]></TERM><TERM><![CDATA[Specificity]]></TERM><TERM><![CDATA[Speed (motion)]]></TERM><TERM><![CDATA[Structure]]></TERM><TERM><![CDATA[Synapses]]></TERM><TERM><![CDATA[Tacrolimus Binding Proteins]]></TERM><TERM><![CDATA[Techniques]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[theories]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[tool]]></TERM><TERM><![CDATA[transcription factor]]></TERM><TERM><![CDATA[Variant]]></TERM><TERM><![CDATA[Vesicle]]></TERM><TERM><![CDATA[War]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Testing the Tug-of-War Model In Vivo with a Novel Method for Protein Photolysis]]></PROJECT_TITLE><SERIAL_NUMBER>110984</SERIAL_NUMBER><STUDY_SECTION>ZRG1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>54194</DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>54194</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8957400</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>AI</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/22/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>855</CFDA_CODE><CORE_PROJECT_NUM>R01AI105191</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-11-260</FOA_NUMBER><FULL_PROJECT_NUM>5R01AI105191-03</FULL_PROJECT_NUM><FUNDING_ICs>NIAID:381250\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>BURLINGTON</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[MICROBIOLOGY/IMMUN/VIROLOGY]]></ORG_DEPT><ORG_DISTRICT>00</ORG_DISTRICT><ORG_DUNS>066811191</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIVERSITY OF VERMONT & ST AGRIC COLLEGE]]></ORG_NAME><ORG_STATE>VT</ORG_STATE><ORG_ZIPCODE>054051704</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Toxoplasma gondii is an important human pathogen and a valuable model organism for the closely related parasites that cause malaria and cryptosporidiosis. This work will increase our understanding of how a critical protein named AMA1 on the surface of these parasites functions during host cell invasion, thereby providing new opportunities for the development of drugs to treat the devastating diseases these parasites cause.]]></PHR><PIS><PI><PI_NAME>WARD, GARY E</PI_NAME><PI_ID>1872902</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>MCGUGAN, GLEN C</PROGRAM_OFFICER_NAME><PROJECT_START>11/15/2013</PROJECT_START><PROJECT_END>10/31/2018</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Acquired Immunodeficiency Syndrome]]></TERM><TERM><![CDATA[Acute]]></TERM><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[Aldehyde-Lyases]]></TERM><TERM><![CDATA[American]]></TERM><TERM><![CDATA[Animal Model]]></TERM><TERM><![CDATA[Antigens]]></TERM><TERM><![CDATA[Apical]]></TERM><TERM><![CDATA[apical membrane]]></TERM><TERM><![CDATA[Attention]]></TERM><TERM><![CDATA[Binding (Molecular Function)]]></TERM><TERM><![CDATA[Binding Proteins]]></TERM><TERM><![CDATA[Biological Assay]]></TERM><TERM><![CDATA[Biological Process]]></TERM><TERM><![CDATA[C-terminal]]></TERM><TERM><![CDATA[Cause of Death]]></TERM><TERM><![CDATA[Cell membrane]]></TERM><TERM><![CDATA[Cell surface]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Cleaved cell]]></TERM><TERM><![CDATA[cost]]></TERM><TERM><![CDATA[Cryptosporidiosis]]></TERM><TERM><![CDATA[Cytosol]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[drug development]]></TERM><TERM><![CDATA[Event]]></TERM><TERM><![CDATA[Experimental Models]]></TERM><TERM><![CDATA[Extracellular Domain]]></TERM><TERM><![CDATA[foodborne illness]]></TERM><TERM><![CDATA[genetic analysis]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[Hybrids]]></TERM><TERM><![CDATA[Immunocompromised Host]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[Infection]]></TERM><TERM><![CDATA[Integral Membrane Protein]]></TERM><TERM><![CDATA[Invaded]]></TERM><TERM><![CDATA[knowledge of results]]></TERM><TERM><![CDATA[Life]]></TERM><TERM><![CDATA[Life Cycle Stages]]></TERM><TERM><![CDATA[Ligands]]></TERM><TERM><![CDATA[Link]]></TERM><TERM><![CDATA[Malaria]]></TERM><TERM><![CDATA[Malaria Vaccines]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[Mutation]]></TERM><TERM><![CDATA[Names]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[novel strategies]]></TERM><TERM><![CDATA[Organelles]]></TERM><TERM><![CDATA[Parasites]]></TERM><TERM><![CDATA[pathogen]]></TERM><TERM><![CDATA[Pathogenesis]]></TERM><TERM><![CDATA[Phosphorylation]]></TERM><TERM><![CDATA[Play]]></TERM><TERM><![CDATA[Population]]></TERM><TERM><![CDATA[Pregnancy]]></TERM><TERM><![CDATA[prevent]]></TERM><TERM><![CDATA[Protein Binding]]></TERM><TERM><![CDATA[protein function]]></TERM><TERM><![CDATA[Proteins]]></TERM><TERM><![CDATA[receptor]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[research study]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Signal Pathway]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[Staging]]></TERM><TERM><![CDATA[Surface]]></TERM><TERM><![CDATA[Tail]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Toxoplasma gondii]]></TERM><TERM><![CDATA[Toxoplasmosis]]></TERM><TERM><![CDATA[Transmembrane Domain]]></TERM><TERM><![CDATA[vaccine candidate]]></TERM><TERM><![CDATA[vaccine development]]></TERM><TERM><![CDATA[Work]]></TERM><TERM><![CDATA[Yeasts]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Functional Analysis of the T. gondii AMA1 Cytosolic Tail]]></PROJECT_TITLE><SERIAL_NUMBER>105191</SERIAL_NUMBER><STUDY_SECTION>PTHE</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Pathogenic Eukaryotes Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>03</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>250000</DIRECT_COST_AMT><INDIRECT_COST_AMT>131250</INDIRECT_COST_AMT><TOTAL_COST>381250</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8960335</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>AI</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/23/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>855</CFDA_CODE><CORE_PROJECT_NUM>R01AI107121</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-13-302</FOA_NUMBER><FULL_PROJECT_NUM>5R01AI107121-02</FULL_PROJECT_NUM><FUNDING_ICs>NIAID:396690\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>HERSHEY</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[INTERNAL MEDICINE/MEDICINE]]></ORG_DEPT><ORG_DISTRICT>15</ORG_DISTRICT><ORG_DUNS>129348186</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[PENNSYLVANIA STATE UNIV HERSHEY MED CTR]]></ORG_NAME><ORG_STATE>PA</ORG_STATE><ORG_ZIPCODE>170332360</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE:  Enteroviruses cause a wide spectrum of acute disease, ranging from mild upper respiratory illness to aseptic meningitis, encephalitis and acute flaccid paralysis. In addition to acute infections, enteroviuses, especially coxsackieviruses of the B group, have also been associated with severe myocarditis and type 1 diabetes mellitus. This study will investigate the mechanisms of entry beginning with receptor recognition by coxsackievirus B3. Binding of receptor is a critical first step as it sets in motion events that promote host entry as well as initiating conformational changes to the virus capsid that are necessary for release of the viral genome.]]></PHR><PIS><PI><PI_NAME>HAFENSTEIN, SUSAN </PI_NAME><PI_ID>9256454</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>PARK, EUN-CHUNG </PROGRAM_OFFICER_NAME><PROJECT_START>11/01/2014</PROJECT_START><PROJECT_END>10/31/2019</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[3-Dimensional]]></TERM><TERM><![CDATA[Acute]]></TERM><TERM><![CDATA[Acute Disease]]></TERM><TERM><![CDATA[adenovirus receptor]]></TERM><TERM><![CDATA[Affinity]]></TERM><TERM><![CDATA[Aseptic Meningitis]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Binding (Molecular Function)]]></TERM><TERM><![CDATA[Biological Assay]]></TERM><TERM><![CDATA[Capsid]]></TERM><TERM><![CDATA[CAR receptor]]></TERM><TERM><![CDATA[CD55 Antigens]]></TERM><TERM><![CDATA[Cell membrane]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Cleaved cell]]></TERM><TERM><![CDATA[Collaborations]]></TERM><TERM><![CDATA[Communicable Diseases]]></TERM><TERM><![CDATA[Complex]]></TERM><TERM><![CDATA[Coxsackie B Viruses]]></TERM><TERM><![CDATA[Coxsackie Viruses]]></TERM><TERM><![CDATA[Cryoelectron Microscopy]]></TERM><TERM><![CDATA[Crystallography]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[density]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[Encephalitis]]></TERM><TERM><![CDATA[endosome membrane]]></TERM><TERM><![CDATA[Enterovirus]]></TERM><TERM><![CDATA[Epithelial]]></TERM><TERM><![CDATA[Event]]></TERM><TERM><![CDATA[factor A]]></TERM><TERM><![CDATA[Genome]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Heating]]></TERM><TERM><![CDATA[Hour]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[In Situ]]></TERM><TERM><![CDATA[Infection]]></TERM><TERM><![CDATA[innovation]]></TERM><TERM><![CDATA[insulin dependent diabetes mellitus onset]]></TERM><TERM><![CDATA[Insulin-Dependent Diabetes Mellitus]]></TERM><TERM><![CDATA[interest]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[Length]]></TERM><TERM><![CDATA[Lipid Bilayers]]></TERM><TERM><![CDATA[Location]]></TERM><TERM><![CDATA[Mass Spectrum Analysis]]></TERM><TERM><![CDATA[Membrane]]></TERM><TERM><![CDATA[Methods]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[Motion]]></TERM><TERM><![CDATA[Myocarditis]]></TERM><TERM><![CDATA[nanodisk]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[Pancreatitis]]></TERM><TERM><![CDATA[Paralysed]]></TERM><TERM><![CDATA[particle]]></TERM><TERM><![CDATA[pathogen]]></TERM><TERM><![CDATA[Pediatric Hospitals]]></TERM><TERM><![CDATA[Peptides]]></TERM><TERM><![CDATA[Pharmaceutical Preparations]]></TERM><TERM><![CDATA[Philadelphia]]></TERM><TERM><![CDATA[Physiological]]></TERM><TERM><![CDATA[Play]]></TERM><TERM><![CDATA[Proteins]]></TERM><TERM><![CDATA[Proteolysis]]></TERM><TERM><![CDATA[receptor]]></TERM><TERM><![CDATA[receptor binding]]></TERM><TERM><![CDATA[recombinant virus]]></TERM><TERM><![CDATA[reconstruction]]></TERM><TERM><![CDATA[research study]]></TERM><TERM><![CDATA[Resolution]]></TERM><TERM><![CDATA[respiratory]]></TERM><TERM><![CDATA[RNA]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[Solutions]]></TERM><TERM><![CDATA[Staging]]></TERM><TERM><![CDATA[Stimulus]]></TERM><TERM><![CDATA[Structure]]></TERM><TERM><![CDATA[Surface Plasmon Resonance]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Tight Junctions]]></TERM><TERM><![CDATA[trafficking]]></TERM><TERM><![CDATA[Transmembrane Domain]]></TERM><TERM><![CDATA[Viral Genome]]></TERM><TERM><![CDATA[Virus]]></TERM><TERM><![CDATA[Virus Receptors]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Mechanisms of Enterovirus Entry]]></PROJECT_TITLE><SERIAL_NUMBER>107121</SERIAL_NUMBER><STUDY_SECTION>VIRA</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Virology - A Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>262029</DIRECT_COST_AMT><INDIRECT_COST_AMT>134661</INDIRECT_COST_AMT><TOTAL_COST>396690</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8960341</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>AI</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/23/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>855</CFDA_CODE><CORE_PROJECT_NUM>R01AI114699</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>PA-13-302</FOA_NUMBER><FULL_PROJECT_NUM>5R01AI114699-02</FULL_PROJECT_NUM><FUNDING_ICs>NIAID:472500\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>SEATTLE</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>07</ORG_DISTRICT><ORG_DUNS>070967955</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[SEATTLE BIOMEDICAL RESEARCH INSTITUTE]]></ORG_NAME><ORG_STATE>WA</ORG_STATE><ORG_ZIPCODE>981095240</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Malaria remains a devastating disease with global impact and an effective vaccine to prevent malaria is urgently needed. Immunizations with whole attenuated parasites that target the liver stage of development are effective at preventing subsequent infection, however the innate immune responses generated to parasites at this stage of infection remain unknown. This proposal seeks to identify and delineate the innate immune responses generated against malaria parasite liver stage infection, and will assess how these innate responses shape the adaptive immune response during whole parasite immunization.]]></PHR><PIS><PI><PI_NAME>KAPPE, STEFAN H.I.</PI_NAME><PI_ID>7043665</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>MO, ANNIE X. Y.</PROGRAM_OFFICER_NAME><PROJECT_START>11/01/2014</PROJECT_START><PROJECT_END>10/31/2019</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[adaptive immunity]]></TERM><TERM><![CDATA[Antigen Presentation]]></TERM><TERM><![CDATA[Attenuated]]></TERM><TERM><![CDATA[Biological Assay]]></TERM><TERM><![CDATA[Bite]]></TERM><TERM><![CDATA[Blood]]></TERM><TERM><![CDATA[cell type]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[chemokine]]></TERM><TERM><![CDATA[chemokine receptor]]></TERM><TERM><![CDATA[Child]]></TERM><TERM><![CDATA[Collaborations]]></TERM><TERM><![CDATA[Complex]]></TERM><TERM><![CDATA[Culicidae]]></TERM><TERM><![CDATA[cytokine]]></TERM><TERM><![CDATA[Cytokine Receptors]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Erythrocytes]]></TERM><TERM><![CDATA[extracellular]]></TERM><TERM><![CDATA[Gene Expression Profiling]]></TERM><TERM><![CDATA[Generations]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Hepatocyte]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[IFNAR1 gene]]></TERM><TERM><![CDATA[Immune]]></TERM><TERM><![CDATA[Immune response]]></TERM><TERM><![CDATA[Immune system]]></TERM><TERM><![CDATA[Immunity]]></TERM><TERM><![CDATA[Immunization]]></TERM><TERM><![CDATA[Infection]]></TERM><TERM><![CDATA[Infiltration]]></TERM><TERM><![CDATA[Interferon Receptor]]></TERM><TERM><![CDATA[Interferon Type I]]></TERM><TERM><![CDATA[Interferon Type II]]></TERM><TERM><![CDATA[Interferons]]></TERM><TERM><![CDATA[Intervention]]></TERM><TERM><![CDATA[Invaded]]></TERM><TERM><![CDATA[IRF3 gene]]></TERM><TERM><![CDATA[Killings]]></TERM><TERM><![CDATA[Life Cycle Stages]]></TERM><TERM><![CDATA[Link]]></TERM><TERM><![CDATA[Liver]]></TERM><TERM><![CDATA[liver infection]]></TERM><TERM><![CDATA[Lymphocyte]]></TERM><TERM><![CDATA[Malaria]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[Morbidity - disease rate]]></TERM><TERM><![CDATA[Mortality Vital Statistics]]></TERM><TERM><![CDATA[mouse model]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[Natural Immunity]]></TERM><TERM><![CDATA[Nature]]></TERM><TERM><![CDATA[Parasites]]></TERM><TERM><![CDATA[pathogen]]></TERM><TERM><![CDATA[Pathology]]></TERM><TERM><![CDATA[Pathway interactions]]></TERM><TERM><![CDATA[Pattern recognition receptor]]></TERM><TERM><![CDATA[Plasmodium]]></TERM><TERM><![CDATA[Plasmodium falciparum]]></TERM><TERM><![CDATA[Play]]></TERM><TERM><![CDATA[prevent]]></TERM><TERM><![CDATA[receptor]]></TERM><TERM><![CDATA[research study]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[Rodent]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Shapes]]></TERM><TERM><![CDATA[Signal Pathway]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[Signaling Molecule]]></TERM><TERM><![CDATA[Sporozoites]]></TERM><TERM><![CDATA[Staging]]></TERM><TERM><![CDATA[T-Lymphocyte]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[Tissues]]></TERM><TERM><![CDATA[Vaccination]]></TERM><TERM><![CDATA[Vaccines]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Innate immune responses to malaria liver stage infection]]></PROJECT_TITLE><SERIAL_NUMBER>114699</SERIAL_NUMBER><STUDY_SECTION>IHD</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Immunity and Host Defense Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>250000</DIRECT_COST_AMT><INDIRECT_COST_AMT>222500</INDIRECT_COST_AMT><TOTAL_COST>472500</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8960342</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>AI</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/28/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>855</CFDA_CODE><CORE_PROJECT_NUM>R01AI116276</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-13-302</FOA_NUMBER><FULL_PROJECT_NUM>5R01AI116276-02</FULL_PROJECT_NUM><FUNDING_ICs>NIAID:613909\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>PITTSBURGH</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[INTERNAL MEDICINE/MEDICINE]]></ORG_DEPT><ORG_DISTRICT>14</ORG_DISTRICT><ORG_DUNS>004514360</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIVERSITY OF PITTSBURGH AT PITTSBURGH]]></ORG_NAME><ORG_STATE>PA</ORG_STATE><ORG_ZIPCODE>152132303</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: This proposal compares the efficacy of Truvada and long-acting Rilpivirine prophylaxis against intravaginal transmission of WT HIV-1 and prevalent drug-resistant mutants. In addition, this proposal uses a novel imaging system to visualize HIV-1 infection and dissemination in humanized mice. We believe that this innovative technology will allow us to better understand inhibition of mucosal HIV-1 transmission by reverse transcriptase inhibitors.]]></PHR><PIS><PI><PI_NAME>AMBROSE, ZANDREA </PI_NAME><PI_ID>9260720</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>PORTER, KRISTEN A.</PROGRAM_OFFICER_NAME><PROJECT_START>11/01/2014</PROJECT_START><PROJECT_END>10/31/2019</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[Adherence (attribute)]]></TERM><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[Animal Model]]></TERM><TERM><![CDATA[Anti-Retroviral Agents]]></TERM><TERM><![CDATA[antiretroviral therapy]]></TERM><TERM><![CDATA[Biology]]></TERM><TERM><![CDATA[Blood]]></TERM><TERM><![CDATA[Bone Marrow]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Clinical Trials]]></TERM><TERM><![CDATA[clinically relevant]]></TERM><TERM><![CDATA[comparative efficacy]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Dose]]></TERM><TERM><![CDATA[Drug Kinetics]]></TERM><TERM><![CDATA[Drug resistance]]></TERM><TERM><![CDATA[Failure (biologic function)]]></TERM><TERM><![CDATA[Female]]></TERM><TERM><![CDATA[Focal Infection]]></TERM><TERM><![CDATA[Genital system]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Health Personnel]]></TERM><TERM><![CDATA[high risk]]></TERM><TERM><![CDATA[HIV]]></TERM><TERM><![CDATA[HIV-1]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[Imagery]]></TERM><TERM><![CDATA[Imaging technology]]></TERM><TERM><![CDATA[In Vitro]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[Infection]]></TERM><TERM><![CDATA[Injectable]]></TERM><TERM><![CDATA[innovation]]></TERM><TERM><![CDATA[innovative technologies]]></TERM><TERM><![CDATA[Intramuscular]]></TERM><TERM><![CDATA[Kinetics]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[Liver]]></TERM><TERM><![CDATA[Macaca]]></TERM><TERM><![CDATA[macrophage]]></TERM><TERM><![CDATA[Methods]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[mouse model]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[mutant]]></TERM><TERM><![CDATA[Mutation]]></TERM><TERM><![CDATA[nanoparticle]]></TERM><TERM><![CDATA[non-nucleoside reverse transcriptase inhibitors]]></TERM><TERM><![CDATA[nonhuman primate]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[Oral]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Pharmaceutical Preparations]]></TERM><TERM><![CDATA[Plasma]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[Prophylactic treatment]]></TERM><TERM><![CDATA[Regimen]]></TERM><TERM><![CDATA[Reporter]]></TERM><TERM><![CDATA[Resistance]]></TERM><TERM><![CDATA[Resistance development]]></TERM><TERM><![CDATA[resistance mutation]]></TERM><TERM><![CDATA[Resistance profile]]></TERM><TERM><![CDATA[Reverse Transcriptase Inhibitors]]></TERM><TERM><![CDATA[Route]]></TERM><TERM><![CDATA[simian human immunodeficiency virus]]></TERM><TERM><![CDATA[SIV]]></TERM><TERM><![CDATA[success]]></TERM><TERM><![CDATA[System]]></TERM><TERM><![CDATA[Technology]]></TERM><TERM><![CDATA[Tenofovir]]></TERM><TERM><![CDATA[Therapeutic]]></TERM><TERM><![CDATA[Thymus Gland]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[Tissues]]></TERM><TERM><![CDATA[transmission process]]></TERM><TERM><![CDATA[Treatment outcome]]></TERM><TERM><![CDATA[truvada]]></TERM><TERM><![CDATA[Vaccines]]></TERM><TERM><![CDATA[vaginal transmission]]></TERM><TERM><![CDATA[Variant]]></TERM><TERM><![CDATA[Viral]]></TERM><TERM><![CDATA[Virus]]></TERM><TERM><![CDATA[Woman]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Visualization of in vivo HIV-1 vaginal transmission in the presence and absence of PrEP]]></PROJECT_TITLE><SERIAL_NUMBER>116276</SERIAL_NUMBER><STUDY_SECTION>ADDT</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[AIDS Discovery and Development of Therapeutics Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>424643</DIRECT_COST_AMT><INDIRECT_COST_AMT>189266</INDIRECT_COST_AMT><TOTAL_COST>613909</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8960921</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>AI</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/28/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>855</CFDA_CODE><CORE_PROJECT_NUM>R01AI106007</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-11-260</FOA_NUMBER><FULL_PROJECT_NUM>5R01AI106007-03</FULL_PROJECT_NUM><FUNDING_ICs>NIAID:760936\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>SEATTLE</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[MICROBIOLOGY/IMMUN/VIROLOGY]]></ORG_DEPT><ORG_DISTRICT>07</ORG_DISTRICT><ORG_DUNS>605799469</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIVERSITY OF WASHINGTON]]></ORG_NAME><ORG_STATE>WA</ORG_STATE><ORG_ZIPCODE>981959472</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE:  In practical terms, accomplishment of the proposed studies will advance at the molecular level our understanding of the pathogenicity and epidemiology of UPEC strains and will provide information on possible targets for vaccines, antibiotics, or other therapeutics.]]></PHR><PIS><PI><PI_NAME>SOKURENKO, EVGENI VENIAMINOVIC</PI_NAME><PI_ID>1874984</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>ERNST, NANCY LEWIS</PROGRAM_OFFICER_NAME><PROJECT_START>11/19/2013</PROJECT_START><PROJECT_END>10/31/2018</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Acute]]></TERM><TERM><![CDATA[Antibiotics]]></TERM><TERM><![CDATA[Bacterial Infections]]></TERM><TERM><![CDATA[bacterial resistance]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Bioinformatics]]></TERM><TERM><![CDATA[Biological Assay]]></TERM><TERM><![CDATA[capsule (pharmacologic)]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[Clonality]]></TERM><TERM><![CDATA[Code]]></TERM><TERM><![CDATA[colanic acid]]></TERM><TERM><![CDATA[Collection]]></TERM><TERM><![CDATA[Communities]]></TERM><TERM><![CDATA[comparative]]></TERM><TERM><![CDATA[Cystitis]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Data Analyses]]></TERM><TERM><![CDATA[Databases]]></TERM><TERM><![CDATA[DNA Sequence Alteration]]></TERM><TERM><![CDATA[Epidemic]]></TERM><TERM><![CDATA[Epidemiology]]></TERM><TERM><![CDATA[Escherichia coli]]></TERM><TERM><![CDATA[expectation]]></TERM><TERM><![CDATA[Experimental Models]]></TERM><TERM><![CDATA[Fimbrial Adhesins]]></TERM><TERM><![CDATA[Gene Transfer]]></TERM><TERM><![CDATA[Genes]]></TERM><TERM><![CDATA[Genetic]]></TERM><TERM><![CDATA[Genetic Transcription]]></TERM><TERM><![CDATA[Genome]]></TERM><TERM><![CDATA[genome analysis]]></TERM><TERM><![CDATA[genome sequencing]]></TERM><TERM><![CDATA[genome-wide]]></TERM><TERM><![CDATA[genome-wide analysis]]></TERM><TERM><![CDATA[Genomics]]></TERM><TERM><![CDATA[Genotype]]></TERM><TERM><![CDATA[Geographic Locations]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Health Personnel]]></TERM><TERM><![CDATA[High-Throughput Nucleotide Sequencing]]></TERM><TERM><![CDATA[Horizontal Gene Transfer]]></TERM><TERM><![CDATA[Housekeeping]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[In Vitro]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[Infection]]></TERM><TERM><![CDATA[insertion/deletion mutation]]></TERM><TERM><![CDATA[Investigation]]></TERM><TERM><![CDATA[Killings]]></TERM><TERM><![CDATA[Maps]]></TERM><TERM><![CDATA[Measures]]></TERM><TERM><![CDATA[Microbial Biofilms]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[Molecular Epidemiology]]></TERM><TERM><![CDATA[mouse model]]></TERM><TERM><![CDATA[mucoid]]></TERM><TERM><![CDATA[Mutation]]></TERM><TERM><![CDATA[neutrophil]]></TERM><TERM><![CDATA[nosocomial UTI]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[Pathogenesis]]></TERM><TERM><![CDATA[Pathogenicity]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Phylogenetic Analysis]]></TERM><TERM><![CDATA[Population]]></TERM><TERM><![CDATA[Preventive]]></TERM><TERM><![CDATA[Primary Health Care]]></TERM><TERM><![CDATA[Prophylactic treatment]]></TERM><TERM><![CDATA[public health medicine (field)]]></TERM><TERM><![CDATA[public health relevance]]></TERM><TERM><![CDATA[Recurrence]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Research Personnel]]></TERM><TERM><![CDATA[research study]]></TERM><TERM><![CDATA[Resistance]]></TERM><TERM><![CDATA[Resources]]></TERM><TERM><![CDATA[Sampling]]></TERM><TERM><![CDATA[Single Nucleotide Polymorphism]]></TERM><TERM><![CDATA[Stratification]]></TERM><TERM><![CDATA[Structure]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Therapeutic]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[tool]]></TERM><TERM><![CDATA[trait]]></TERM><TERM><![CDATA[Universities]]></TERM><TERM><![CDATA[Untranslated RNA]]></TERM><TERM><![CDATA[Urinary tract infection]]></TERM><TERM><![CDATA[Uropathogen]]></TERM><TERM><![CDATA[Uropathogenic E. coli]]></TERM><TERM><![CDATA[Vaccine Therapy]]></TERM><TERM><![CDATA[Vaccines]]></TERM><TERM><![CDATA[Variation (Genetics)]]></TERM><TERM><![CDATA[Virulence]]></TERM><TERM><![CDATA[Washington]]></TERM><TERM><![CDATA[Woman]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Molecular Clonality of Uropathogenic E. Coli]]></PROJECT_TITLE><SERIAL_NUMBER>106007</SERIAL_NUMBER><STUDY_SECTION>UGPP</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>03</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>551655</DIRECT_COST_AMT><INDIRECT_COST_AMT>209281</INDIRECT_COST_AMT><TOTAL_COST>760936</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8960922</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>AI</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/27/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>855</CFDA_CODE><CORE_PROJECT_NUM>R01AI106874</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-13-302</FOA_NUMBER><FULL_PROJECT_NUM>5R01AI106874-02</FULL_PROJECT_NUM><FUNDING_ICs>NIAID:416080\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>LA JOLLA</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[INTERNAL MEDICINE/MEDICINE]]></ORG_DEPT><ORG_DISTRICT>52</ORG_DISTRICT><ORG_DUNS>804355790</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIVERSITY OF CALIFORNIA SAN DIEGO]]></ORG_NAME><ORG_STATE>CA</ORG_STATE><ORG_ZIPCODE>920930934</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: The concept of microbiome, being part of the human organism, also implies the recognition that the immune system has co-evolved with the commensal microbes, and developed a system of mutual identification and cooperation; this applies to skin microbiome and mast cells (MCs). We provide evidence that the presence of bacterial products at the skin surface participates in the regulation of MC antimicrobial function,
drives them to the skin, helps their survival, and most important, creates an anti-inflammatory environment. Our work will reveal significant new aspects of MC function with important implications for diseases such as atopic dermatitis and psoriasis, in which mast cells are key players. .]]></PHR><PIS><PI><PI_NAME>DI NARDO, ANNA </PI_NAME><PI_ID>8763174</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>DONG, GANG </PROGRAM_OFFICER_NAME><PROJECT_START>11/01/2014</PROJECT_START><PROJECT_END>10/31/2019</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[acquired immunity]]></TERM><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[Animals]]></TERM><TERM><![CDATA[Anti-inflammatory]]></TERM><TERM><![CDATA[Anti-Inflammatory Agents]]></TERM><TERM><![CDATA[Antibiotics]]></TERM><TERM><![CDATA[antimicrobial]]></TERM><TERM><![CDATA[antimicrobial peptide]]></TERM><TERM><![CDATA[Atopic Dermatitis]]></TERM><TERM><![CDATA[Bacteria]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Biochemical]]></TERM><TERM><![CDATA[Biological Assay]]></TERM><TERM><![CDATA[Biological Models]]></TERM><TERM><![CDATA[Cell Communication]]></TERM><TERM><![CDATA[Cell Maturation]]></TERM><TERM><![CDATA[Cell Migration Pathway]]></TERM><TERM><![CDATA[cell motility]]></TERM><TERM><![CDATA[Cell physiology]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[commensal microbes]]></TERM><TERM><![CDATA[Communication]]></TERM><TERM><![CDATA[cytokine]]></TERM><TERM><![CDATA[Cytoplasmic Granules]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Defect]]></TERM><TERM><![CDATA[Dermal]]></TERM><TERM><![CDATA[Dermis]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Endothelial Cells]]></TERM><TERM><![CDATA[Environment]]></TERM><TERM><![CDATA[Epithelial]]></TERM><TERM><![CDATA[fighting]]></TERM><TERM><![CDATA[Foundations]]></TERM><TERM><![CDATA[Future]]></TERM><TERM><![CDATA[Germ-Free]]></TERM><TERM><![CDATA[Growth Factor]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Homeostasis]]></TERM><TERM><![CDATA[Homing]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[Immune response]]></TERM><TERM><![CDATA[Immune system]]></TERM><TERM><![CDATA[In Vitro]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[Incidence]]></TERM><TERM><![CDATA[Infection]]></TERM><TERM><![CDATA[Inflammation]]></TERM><TERM><![CDATA[Inflammatory]]></TERM><TERM><![CDATA[Interleukin-1]]></TERM><TERM><![CDATA[keratinocyte]]></TERM><TERM><![CDATA[Life]]></TERM><TERM><![CDATA[Ligands]]></TERM><TERM><![CDATA[lipoteichoic acid]]></TERM><TERM><![CDATA[mast cell]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[Methods]]></TERM><TERM><![CDATA[microbiome]]></TERM><TERM><![CDATA[MicroRNAs]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[mouse model]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[Natural Immunity]]></TERM><TERM><![CDATA[NF-kappa B]]></TERM><TERM><![CDATA[Organism]]></TERM><TERM><![CDATA[Pathway interactions]]></TERM><TERM><![CDATA[Phenotype]]></TERM><TERM><![CDATA[Play]]></TERM><TERM><![CDATA[Positioning Attribute]]></TERM><TERM><![CDATA[Production]]></TERM><TERM><![CDATA[Psoriasis]]></TERM><TERM><![CDATA[receptor]]></TERM><TERM><![CDATA[Receptor Signaling]]></TERM><TERM><![CDATA[reconstitution]]></TERM><TERM><![CDATA[Recruitment Activity]]></TERM><TERM><![CDATA[Regulation]]></TERM><TERM><![CDATA[Relative (related person)]]></TERM><TERM><![CDATA[research study]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Shapes]]></TERM><TERM><![CDATA[Signal Pathway]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[Skin]]></TERM><TERM><![CDATA[Surface]]></TERM><TERM><![CDATA[System]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Toll-Like Receptor 2]]></TERM><TERM><![CDATA[trafficking]]></TERM><TERM><![CDATA[Translating]]></TERM><TERM><![CDATA[Translational Research]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[The Microbiome Drives Masts Cell Recruitment in the Skin]]></PROJECT_TITLE><SERIAL_NUMBER>106874</SERIAL_NUMBER><STUDY_SECTION>ACTS</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Arthritis, Connective Tissue and Skin Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>268439</DIRECT_COST_AMT><INDIRECT_COST_AMT>147641</INDIRECT_COST_AMT><TOTAL_COST>416080</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8960925</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>AI</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/27/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>855</CFDA_CODE><CORE_PROJECT_NUM>R01AI115471</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-13-302</FOA_NUMBER><FULL_PROJECT_NUM>5R01AI115471-02</FULL_PROJECT_NUM><FUNDING_ICs>NIAID:389432\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>CHICAGO</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[INTERNAL MEDICINE/MEDICINE]]></ORG_DEPT><ORG_DISTRICT>01</ORG_DISTRICT><ORG_DUNS>005421136</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIVERSITY OF CHICAGO]]></ORG_NAME><ORG_STATE>IL</ORG_STATE><ORG_ZIPCODE>606375418</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE:  Gamma delta T cells are a T cell population of emerging importance in human health yet information is limited on the molecular signals that these cells, through their T cell receptor (TCR), respond to. We seek to characterize the repertoire of ligands. Combined, our aims strive to elucidate the molecular signals that lead to gamma delta T cell stimulation and understand how these responses are involved in human disease.]]></PHR><PIS><PI><PI_NAME>ADAMS, ERIN JUNE</PI_NAME><PI_ID>8532838</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>MOAYERI, MAHTAB </PROGRAM_OFFICER_NAME><PROJECT_START>11/03/2014</PROJECT_START><PROJECT_END>10/31/2019</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Actins]]></TERM><TERM><![CDATA[Adopted]]></TERM><TERM><![CDATA[Agonist]]></TERM><TERM><![CDATA[Anabolism]]></TERM><TERM><![CDATA[Antibodies]]></TERM><TERM><![CDATA[Antigens]]></TERM><TERM><![CDATA[Applications Grants]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Binding (Molecular Function)]]></TERM><TERM><![CDATA[Blood]]></TERM><TERM><![CDATA[butyrophilin]]></TERM><TERM><![CDATA[Cell membrane]]></TERM><TERM><![CDATA[Cell surface]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Cellular Stress]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[Complement]]></TERM><TERM><![CDATA[Coupled]]></TERM><TERM><![CDATA[crosslink]]></TERM><TERM><![CDATA[Crystallography]]></TERM><TERM><![CDATA[Cytoskeleton]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Detection]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Energy Transfer]]></TERM><TERM><![CDATA[Event]]></TERM><TERM><![CDATA[extracellular]]></TERM><TERM><![CDATA[Extracellular Domain]]></TERM><TERM><![CDATA[Fluorescence]]></TERM><TERM><![CDATA[genome-wide]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[human disease]]></TERM><TERM><![CDATA[Immobilization]]></TERM><TERM><![CDATA[Immunity]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[Infection]]></TERM><TERM><![CDATA[isoprenoid]]></TERM><TERM><![CDATA[Laboratories]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[Leprosy]]></TERM><TERM><![CDATA[Ligands]]></TERM><TERM><![CDATA[Link]]></TERM><TERM><![CDATA[Maps]]></TERM><TERM><![CDATA[Mass Spectrum Analysis]]></TERM><TERM><![CDATA[Measurement]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[Mediator of activation protein]]></TERM><TERM><![CDATA[member]]></TERM><TERM><![CDATA[Membrane]]></TERM><TERM><![CDATA[mevalonate]]></TERM><TERM><![CDATA[Microbe]]></TERM><TERM><![CDATA[microbial]]></TERM><TERM><![CDATA[Microscopy]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[Molecular Conformation]]></TERM><TERM><![CDATA[Mycobacterium leprae]]></TERM><TERM><![CDATA[Mycobacterium tuberculosis]]></TERM><TERM><![CDATA[neoplastic cell]]></TERM><TERM><![CDATA[pathogen]]></TERM><TERM><![CDATA[Pathway interactions]]></TERM><TERM><![CDATA[Play]]></TERM><TERM><![CDATA[Population]]></TERM><TERM><![CDATA[Primates]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[Production]]></TERM><TERM><![CDATA[Protein Engineering]]></TERM><TERM><![CDATA[Protein Family]]></TERM><TERM><![CDATA[Proteins]]></TERM><TERM><![CDATA[Publications]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[research study]]></TERM><TERM><![CDATA[Resolution]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[RNA Interference]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[sensor]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[Sirolimus]]></TERM><TERM><![CDATA[Structure]]></TERM><TERM><![CDATA[Surface]]></TERM><TERM><![CDATA[T cell response]]></TERM><TERM><![CDATA[T-Cell Activation]]></TERM><TERM><![CDATA[T-Cell Receptor]]></TERM><TERM><![CDATA[T-Lymphocyte]]></TERM><TERM><![CDATA[T-Lymphocyte Subsets]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Translating]]></TERM><TERM><![CDATA[Tuberculosis]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Gamma Delta T cell surveillance of metabolites as signals of cellular stress]]></PROJECT_TITLE><SERIAL_NUMBER>115471</SERIAL_NUMBER><STUDY_SECTION>ZRG1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>250000</DIRECT_COST_AMT><INDIRECT_COST_AMT>139432</INDIRECT_COST_AMT><TOTAL_COST>389432</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8960941</APPLICATION_ID><ACTIVITY>P01</ACTIVITY><ADMINISTERING_IC>HL</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/26/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>P01HL029582</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>PAR-13-316</FOA_NUMBER><FULL_PROJECT_NUM>5P01HL029582-32</FULL_PROJECT_NUM><FUNDING_ICs>NHLBI:433904\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL HEART, LUNG, AND BLOOD INSTITUTE</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>CLEVELAND</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>11</ORG_DISTRICT><ORG_DUNS>135781701</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[CLEVELAND CLINIC LERNER COM-CWRU]]></ORG_NAME><ORG_STATE>OH</ORG_STATE><ORG_ZIPCODE>441950001</ORG_ZIPCODE><PHR><![CDATA[Project 1 (P1). Project Narrative
Our proposed study will provide novel mechanistic insights into IL-1R/TLR-mediated inflammatory response,
initiation and pathogenesis of obesity-associated inflammatory diseases. The elucidation of the detailed
signaling mechanisms will not only establish the molecular basis for future anti-inflammatory drug design and
development of new therapies for metabolic diseases, but will also advance our knowledge about innate
immune signal transduction in general.]]></PHR><PIS><PI><PI_NAME>LI, XIAOXIA </PI_NAME><PI_ID>7919432</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START></PROJECT_START><PROJECT_END></PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[abstracting]]></TERM><TERM><![CDATA[Adipocytes]]></TERM><TERM><![CDATA[Adipose tissue]]></TERM><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[Anti-inflammatory]]></TERM><TERM><![CDATA[Anti-Inflammatory Agents]]></TERM><TERM><![CDATA[Atherosclerosis]]></TERM><TERM><![CDATA[Attenuated]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Biochemical]]></TERM><TERM><![CDATA[Cardiovascular Diseases]]></TERM><TERM><![CDATA[chemokine]]></TERM><TERM><![CDATA[Complex]]></TERM><TERM><![CDATA[Coupling]]></TERM><TERM><![CDATA[cytokine]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Diet]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Dissociation]]></TERM><TERM><![CDATA[Doctor of Philosophy]]></TERM><TERM><![CDATA[Drug Design]]></TERM><TERM><![CDATA[drug development]]></TERM><TERM><![CDATA[Endothelial Cells]]></TERM><TERM><![CDATA[Fatty acid glycerol esters]]></TERM><TERM><![CDATA[Future]]></TERM><TERM><![CDATA[Gene Expression]]></TERM><TERM><![CDATA[Genetic]]></TERM><TERM><![CDATA[Genetic Transcription]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[human FRAP1 protein]]></TERM><TERM><![CDATA[human IRAK3 protein]]></TERM><TERM><![CDATA[Immune]]></TERM><TERM><![CDATA[Incidence]]></TERM><TERM><![CDATA[Inflammation]]></TERM><TERM><![CDATA[Inflammatory]]></TERM><TERM><![CDATA[Inflammatory Response]]></TERM><TERM><![CDATA[insight]]></TERM><TERM><![CDATA[Insulin Resistance]]></TERM><TERM><![CDATA[Interleukin-1]]></TERM><TERM><![CDATA[interleukin-1 receptor-associated kinase]]></TERM><TERM><![CDATA[Interleukin-1 Receptors]]></TERM><TERM><![CDATA[IRAK1 gene]]></TERM><TERM><![CDATA[IRAK2 gene]]></TERM><TERM><![CDATA[IRAK4 gene]]></TERM><TERM><![CDATA[Knowledge]]></TERM><TERM><![CDATA[Ligands]]></TERM><TERM><![CDATA[Link]]></TERM><TERM><![CDATA[macrophage]]></TERM><TERM><![CDATA[MAP Kinase Kinase Kinase 3]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[Mediator of activation protein]]></TERM><TERM><![CDATA[Messenger RNA]]></TERM><TERM><![CDATA[Metabolic]]></TERM><TERM><![CDATA[Metabolic Diseases]]></TERM><TERM><![CDATA[Metabolic syndrome]]></TERM><TERM><![CDATA[Metabolism]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[monocyte]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[Myeloid Cells]]></TERM><TERM><![CDATA[new therapeutic target]]></TERM><TERM><![CDATA[Nonesterified Fatty Acids]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[null mutation]]></TERM><TERM><![CDATA[Obesity]]></TERM><TERM><![CDATA[Obesity associated disease]]></TERM><TERM><![CDATA[oxidized low density lipoprotein]]></TERM><TERM><![CDATA[Pathogenesis]]></TERM><TERM><![CDATA[Pathway interactions]]></TERM><TERM><![CDATA[Permeability]]></TERM><TERM><![CDATA[Pharmaceutical Preparations]]></TERM><TERM><![CDATA[Phenotype]]></TERM><TERM><![CDATA[Phosphotransferases]]></TERM><TERM><![CDATA[Play]]></TERM><TERM><![CDATA[Population]]></TERM><TERM><![CDATA[prevent]]></TERM><TERM><![CDATA[Production]]></TERM><TERM><![CDATA[Proteins]]></TERM><TERM><![CDATA[public health medicine (field)]]></TERM><TERM><![CDATA[receptor]]></TERM><TERM><![CDATA[Receptor Activation]]></TERM><TERM><![CDATA[Receptor Signaling]]></TERM><TERM><![CDATA[receptor-mediated signaling]]></TERM><TERM><![CDATA[Reducing diet]]></TERM><TERM><![CDATA[Regulation]]></TERM><TERM><![CDATA[Reporting]]></TERM><TERM><![CDATA[Risk]]></TERM><TERM><![CDATA[RNA-Binding Proteins]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Sclerosis]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[Signaling Molecule]]></TERM><TERM><![CDATA[small molecule]]></TERM><TERM><![CDATA[Stimulus]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[TLR2 gene]]></TERM><TERM><![CDATA[TLR4 gene]]></TERM><TERM><![CDATA[Toll-Like Receptor 1]]></TERM><TERM><![CDATA[Toll-like receptors]]></TERM><TERM><![CDATA[transcription factor]]></TERM><TERM><![CDATA[Transcriptional Activation]]></TERM><TERM><![CDATA[Translations]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Signaling mechanisms of toll-like and interleukin-1 recepters in inflammation -Pr]]></PROJECT_TITLE><SERIAL_NUMBER>029582</SERIAL_NUMBER><STUDY_SECTION>ZHL1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID>7865</SUBPROJECT_ID><SUPPORT_YEAR>32</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>273757</DIRECT_COST_AMT><INDIRECT_COST_AMT>160147</INDIRECT_COST_AMT><TOTAL_COST /><TOTAL_COST_SUB_PROJECT>433904</TOTAL_COST_SUB_PROJECT></row>
<row><APPLICATION_ID>8960942</APPLICATION_ID><ACTIVITY>P01</ACTIVITY><ADMINISTERING_IC>HL</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/26/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>P01HL029582</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>PAR-13-316</FOA_NUMBER><FULL_PROJECT_NUM>5P01HL029582-32</FULL_PROJECT_NUM><FUNDING_ICs>NHLBI:424318\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL HEART, LUNG, AND BLOOD INSTITUTE</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>CLEVELAND</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>11</ORG_DISTRICT><ORG_DUNS>135781701</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[CLEVELAND CLINIC LERNER COM-CWRU]]></ORG_NAME><ORG_STATE>OH</ORG_STATE><ORG_ZIPCODE>441950001</ORG_ZIPCODE><PHR><![CDATA[Project 2 (P2). Project Narrative
The proposed studies address a significant health concern, coronary artery disease, and will yield insight into
the mechanisms that modify atherosclerosis susceptibility. The discovery of novel pathways and proteins that
regulate atherosclerosis and foam cell cholesterol ester turnover offers hope for new modes of risk assessment,
prevention, and therapy.]]></PHR><PIS><PI><PI_NAME>SMITH, JONATHAN D</PI_NAME><PI_ID>1916685</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START></PROJECT_START><PROJECT_END></PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[abstracting]]></TERM><TERM><![CDATA[Accounting]]></TERM><TERM><![CDATA[acetyl-LDL]]></TERM><TERM><![CDATA[Acid Lipase]]></TERM><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[Alleles]]></TERM><TERM><![CDATA[Antiatherogenic]]></TERM><TERM><![CDATA[Apolipoprotein E]]></TERM><TERM><![CDATA[apolipoprotein E-2]]></TERM><TERM><![CDATA[Area]]></TERM><TERM><![CDATA[atherogenesis]]></TERM><TERM><![CDATA[atheroprotective]]></TERM><TERM><![CDATA[Atherosclerosis]]></TERM><TERM><![CDATA[Autophagocytosis]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Bioinformatics]]></TERM><TERM><![CDATA[Bone Marrow]]></TERM><TERM><![CDATA[Breeding]]></TERM><TERM><![CDATA[Candidate Disease Gene]]></TERM><TERM><![CDATA[Cardiovascular Diseases]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Cessation of life]]></TERM><TERM><![CDATA[Cholesterol]]></TERM><TERM><![CDATA[Cholesterol Esters]]></TERM><TERM><![CDATA[Cholesterol Homeostasis]]></TERM><TERM><![CDATA[Chromosomes, Human, Pair 2]]></TERM><TERM><![CDATA[Complement]]></TERM><TERM><![CDATA[Congenic Mice]]></TERM><TERM><![CDATA[Congenic Strain]]></TERM><TERM><![CDATA[Coronary Arteriosclerosis]]></TERM><TERM><![CDATA[Defect]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[disorder risk]]></TERM><TERM><![CDATA[Doctor of Philosophy]]></TERM><TERM><![CDATA[Drug effect disorder]]></TERM><TERM><![CDATA[Drug Targeting]]></TERM><TERM><![CDATA[embryonic stem cell]]></TERM><TERM><![CDATA[Event]]></TERM><TERM><![CDATA[extracellular]]></TERM><TERM><![CDATA[feeding]]></TERM><TERM><![CDATA[Foam Cells]]></TERM><TERM><![CDATA[Funding]]></TERM><TERM><![CDATA[Genes]]></TERM><TERM><![CDATA[Genetic]]></TERM><TERM><![CDATA[genetic variant]]></TERM><TERM><![CDATA[genome wide association study]]></TERM><TERM><![CDATA[Genomics]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Gold]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[healthy aging]]></TERM><TERM><![CDATA[Heart Diseases]]></TERM><TERM><![CDATA[High Density Lipoproteins]]></TERM><TERM><![CDATA[Human Genome]]></TERM><TERM><![CDATA[Hydrolysis]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[Inbred Strain]]></TERM><TERM><![CDATA[Incidence]]></TERM><TERM><![CDATA[Inflammation]]></TERM><TERM><![CDATA[inhibitor/antagonist]]></TERM><TERM><![CDATA[insight]]></TERM><TERM><![CDATA[Knock-out]]></TERM><TERM><![CDATA[Knowledge]]></TERM><TERM><![CDATA[LDL Cholesterol Lipoproteins]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[Lesion]]></TERM><TERM><![CDATA[Link]]></TERM><TERM><![CDATA[Lipids]]></TERM><TERM><![CDATA[Lysosomes]]></TERM><TERM><![CDATA[macrophage]]></TERM><TERM><![CDATA[Maps]]></TERM><TERM><![CDATA[Measures]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[men]]></TERM><TERM><![CDATA[Metabolism]]></TERM><TERM><![CDATA[Methods]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Modification]]></TERM><TERM><![CDATA[mTOR Inhibitor]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[novel therapeutics]]></TERM><TERM><![CDATA[Pathway interactions]]></TERM><TERM><![CDATA[Pharmaceutical Preparations]]></TERM><TERM><![CDATA[Pharmacotherapy]]></TERM><TERM><![CDATA[Phenotype]]></TERM><TERM><![CDATA[Plant Roots]]></TERM><TERM><![CDATA[Play]]></TERM><TERM><![CDATA[Predisposition]]></TERM><TERM><![CDATA[prevent]]></TERM><TERM><![CDATA[Prevention therapy]]></TERM><TERM><![CDATA[Proteins]]></TERM><TERM><![CDATA[Proteomics]]></TERM><TERM><![CDATA[Quantitative Trait Loci]]></TERM><TERM><![CDATA[Regulation]]></TERM><TERM><![CDATA[Resistance]]></TERM><TERM><![CDATA[reverse cholesterol transport]]></TERM><TERM><![CDATA[Risk]]></TERM><TERM><![CDATA[Risk Assessment]]></TERM><TERM><![CDATA[Risk Factors]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Sterol O-Acyltransferase]]></TERM><TERM><![CDATA[success]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[transcriptomics]]></TERM><TERM><![CDATA[United States]]></TERM><TERM><![CDATA[Validation]]></TERM><TERM><![CDATA[Variation (Genetics)]]></TERM><TERM><![CDATA[Woman]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Genetic Modifiers of atherosclerosis and foam cell lipid droplet metabolism-Proje]]></PROJECT_TITLE><SERIAL_NUMBER>029582</SERIAL_NUMBER><STUDY_SECTION>ZHL1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID>7866</SUBPROJECT_ID><SUPPORT_YEAR>32</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>267709</DIRECT_COST_AMT><INDIRECT_COST_AMT>156609</INDIRECT_COST_AMT><TOTAL_COST /><TOTAL_COST_SUB_PROJECT>424318</TOTAL_COST_SUB_PROJECT></row>
<row><APPLICATION_ID>8962141</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>AI</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/27/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>855</CFDA_CODE><CORE_PROJECT_NUM>R01AI095499</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-10-213</FOA_NUMBER><FULL_PROJECT_NUM>5R01AI095499-03</FULL_PROJECT_NUM><FUNDING_ICs>NIAID:349821\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>BOSTON</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[MICROBIOLOGY/IMMUN/VIROLOGY]]></ORG_DEPT><ORG_DISTRICT>07</ORG_DISTRICT><ORG_DUNS>047006379</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[HARVARD MEDICAL SCHOOL]]></ORG_NAME><ORG_STATE>MA</ORG_STATE><ORG_ZIPCODE>021156027</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Dengue virus is the most widespread mosquito-borne virus in the world today and the cause of significant human disease; however, there currently are no vaccines or specific antiviral therapies to prevent or to treat dengue virus infection. The proposed experiments will develop assays to identify small molecules that inhibit dengue virus by preventing the entry of dengue virus into a host cell.]]></PHR><PIS><PI><PI_NAME>GRAY, NATHANAEL SCHIANDER</PI_NAME><PI_ID>8122521</PI_ID></PI><PI><PI_NAME>YANG, PRISCILLA LI-NING (contact)</PI_NAME><PI_ID>6467011 (contact)</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>CASSETTI, CRISTINA </PROGRAM_OFFICER_NAME><PROJECT_START>09/30/2011</PROJECT_START><PROJECT_END>10/31/2016</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[Affinity]]></TERM><TERM><![CDATA[Antiviral Agents]]></TERM><TERM><![CDATA[Antiviral Therapy]]></TERM><TERM><![CDATA[Binding (Molecular Function)]]></TERM><TERM><![CDATA[Binding Sites]]></TERM><TERM><![CDATA[Biochemical]]></TERM><TERM><![CDATA[Biological Assay]]></TERM><TERM><![CDATA[Cell Culture Techniques]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Characteristics]]></TERM><TERM><![CDATA[Chemicals]]></TERM><TERM><![CDATA[Clathrin]]></TERM><TERM><![CDATA[combat]]></TERM><TERM><![CDATA[Computer Simulation]]></TERM><TERM><![CDATA[Culicidae]]></TERM><TERM><![CDATA[cytotoxic]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Dengue]]></TERM><TERM><![CDATA[Dengue Virus]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[dimer]]></TERM><TERM><![CDATA[drug discovery]]></TERM><TERM><![CDATA[env Gene Products]]></TERM><TERM><![CDATA[Exposure to]]></TERM><TERM><![CDATA[Flavivirus]]></TERM><TERM><![CDATA[Fluorescence Polarization]]></TERM><TERM><![CDATA[fluorophore]]></TERM><TERM><![CDATA[Future]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[high throughput screening]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[human disease]]></TERM><TERM><![CDATA[In Vitro]]></TERM><TERM><![CDATA[inhibitor/antagonist]]></TERM><TERM><![CDATA[Knowledge]]></TERM><TERM><![CDATA[Label]]></TERM><TERM><![CDATA[Laboratories]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[Libraries]]></TERM><TERM><![CDATA[Ligand Binding]]></TERM><TERM><![CDATA[Ligands]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[Membrane]]></TERM><TERM><![CDATA[membrane model]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[Molecular Probes]]></TERM><TERM><![CDATA[Molecular Target]]></TERM><TERM><![CDATA[Monitor]]></TERM><TERM><![CDATA[mutant]]></TERM><TERM><![CDATA[novel therapeutics]]></TERM><TERM><![CDATA[particle]]></TERM><TERM><![CDATA[Pathogenesis]]></TERM><TERM><![CDATA[Pharmaceutical Preparations]]></TERM><TERM><![CDATA[pre-clinical]]></TERM><TERM><![CDATA[prevent]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[protein E]]></TERM><TERM><![CDATA[public health medicine (field)]]></TERM><TERM><![CDATA[Pyrimidine]]></TERM><TERM><![CDATA[Pyrimidines]]></TERM><TERM><![CDATA[receptor]]></TERM><TERM><![CDATA[Reporting]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[research study]]></TERM><TERM><![CDATA[Resistance]]></TERM><TERM><![CDATA[Resolution]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[RNA Interference]]></TERM><TERM><![CDATA[scaffold]]></TERM><TERM><![CDATA[screening]]></TERM><TERM><![CDATA[Series]]></TERM><TERM><![CDATA[Serotyping]]></TERM><TERM><![CDATA[Site]]></TERM><TERM><![CDATA[small molecule]]></TERM><TERM><![CDATA[Specificity]]></TERM><TERM><![CDATA[Structure]]></TERM><TERM><![CDATA[Structure-Activity Relationship]]></TERM><TERM><![CDATA[Surface]]></TERM><TERM><![CDATA[surface coating]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Therapeutic]]></TERM><TERM><![CDATA[tool]]></TERM><TERM><![CDATA[Tracer]]></TERM><TERM><![CDATA[Vaccines]]></TERM><TERM><![CDATA[Viral]]></TERM><TERM><![CDATA[Virion]]></TERM><TERM><![CDATA[Virus]]></TERM><TERM><![CDATA[Virus Diseases]]></TERM><TERM><![CDATA[virus envelope]]></TERM><TERM><![CDATA[Virus Inhibitors]]></TERM><TERM><![CDATA[Virus Replication]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Chemical Tools for the Study of Dengue Virus Entry]]></PROJECT_TITLE><SERIAL_NUMBER>095499</SERIAL_NUMBER><STUDY_SECTION>ZRG1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>03</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>251384</DIRECT_COST_AMT><INDIRECT_COST_AMT>98437</INDIRECT_COST_AMT><TOTAL_COST>349821</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8962163</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>HL</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/29/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>837</CFDA_CODE><CORE_PROJECT_NUM>R01HL121796</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>PA-13-302</FOA_NUMBER><FULL_PROJECT_NUM>5R01HL121796-02</FULL_PROJECT_NUM><FUNDING_ICs>NHLBI:397500\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL HEART, LUNG, AND BLOOD INSTITUTE</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>PROVIDENCE</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>01</ORG_DISTRICT><ORG_DUNS>075710996</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[RHODE ISLAND HOSPITAL]]></ORG_NAME><ORG_STATE>RI</ORG_STATE><ORG_ZIPCODE>029034923</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: MicroRNAs, recently discovered class of posttranscriptional regulators of gene expression, have been implicated in cardiac pathology including malignant cardiac arrhythmia and heart failure. MicroRNAs are thought to have a significant therapeutic potential due to their ability to regulate multiple functionally associated genes. These studies into modulation of cardiomyocyte function by a group of microRNAs specific to muscle tissue called myomiRs should contribute important insights into mechanisms of arrhythmia and contractile dysfunction associated with acquired cardiac disorders and assist in development of informed microRNA-based therapeutic strategies.]]></PHR><PIS><PI><PI_NAME>TERENTYEV, DMITRY A</PI_NAME><PI_ID>10634176</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>ADHIKARI, BISHOW B.</PROGRAM_OFFICER_NAME><PROJECT_START>11/14/2014</PROJECT_START><PROJECT_END>10/31/2019</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Adult]]></TERM><TERM><![CDATA[Anti-Arrhythmia Agents]]></TERM><TERM><![CDATA[Arrhythmia]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Base Pairing]]></TERM><TERM><![CDATA[Ca(2+)-Transporting ATPase]]></TERM><TERM><![CDATA[calcineurin phosphatase]]></TERM><TERM><![CDATA[Calcium]]></TERM><TERM><![CDATA[Calmodulin]]></TERM><TERM><![CDATA[Cardiac]]></TERM><TERM><![CDATA[Cardiac Myocytes]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Characteristics]]></TERM><TERM><![CDATA[Code]]></TERM><TERM><![CDATA[Complex]]></TERM><TERM><![CDATA[Coupling]]></TERM><TERM><![CDATA[Cyclic AMP-Dependent Protein Kinases]]></TERM><TERM><![CDATA[Death, Sudden, Cardiac]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Electrophysiology (science)]]></TERM><TERM><![CDATA[Enzymes]]></TERM><TERM><![CDATA[Experimental Models]]></TERM><TERM><![CDATA[Family]]></TERM><TERM><![CDATA[Functional disorder]]></TERM><TERM><![CDATA[Gene Expression]]></TERM><TERM><![CDATA[Genes]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Heart]]></TERM><TERM><![CDATA[Heart Diseases]]></TERM><TERM><![CDATA[Heart failure]]></TERM><TERM><![CDATA[Homeostasis]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[Hypertrophy]]></TERM><TERM><![CDATA[Image]]></TERM><TERM><![CDATA[In Vitro]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[Inbred SHR Rats]]></TERM><TERM><![CDATA[insight]]></TERM><TERM><![CDATA[Introns]]></TERM><TERM><![CDATA[Investigation]]></TERM><TERM><![CDATA[Laser Scanning Confocal Microscopy]]></TERM><TERM><![CDATA[Macromolecular Complexes]]></TERM><TERM><![CDATA[Malignant - descriptor]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[Messenger RNA]]></TERM><TERM><![CDATA[MicroRNAs]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[Mortality Vital Statistics]]></TERM><TERM><![CDATA[Muscle]]></TERM><TERM><![CDATA[Muscle Cells]]></TERM><TERM><![CDATA[Myosin Heavy Chains]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[Nucleotides]]></TERM><TERM><![CDATA[Pathogenesis]]></TERM><TERM><![CDATA[Pathology]]></TERM><TERM><![CDATA[Pattern]]></TERM><TERM><![CDATA[Phenotype]]></TERM><TERM><![CDATA[phosphodiesterase 4D]]></TERM><TERM><![CDATA[Phosphorylation]]></TERM><TERM><![CDATA[Photons]]></TERM><TERM><![CDATA[Play]]></TERM><TERM><![CDATA[Porifera]]></TERM><TERM><![CDATA[Post-Translational Protein Processing]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[protein function]]></TERM><TERM><![CDATA[Protein phosphatase]]></TERM><TERM><![CDATA[Proteins]]></TERM><TERM><![CDATA[Rattus]]></TERM><TERM><![CDATA[Regulation]]></TERM><TERM><![CDATA[Regulator Genes]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Ryanodine Receptor Calcium Release Channel]]></TERM><TERM><![CDATA[Ryanodine Receptors]]></TERM><TERM><![CDATA[RyR2]]></TERM><TERM><![CDATA[Sarcoplasmic Reticulum]]></TERM><TERM><![CDATA[Staging]]></TERM><TERM><![CDATA[Structure]]></TERM><TERM><![CDATA[Techniques]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Therapeutic]]></TERM><TERM><![CDATA[Tissues]]></TERM><TERM><![CDATA[Transcript]]></TERM><TERM><![CDATA[Translational Repression]]></TERM><TERM><![CDATA[Translations]]></TERM><TERM><![CDATA[Untranslated RNA]]></TERM><TERM><![CDATA[Ventricular]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Regulation of Calcium Homeostasis by MyomiRs in Heart Failure]]></PROJECT_TITLE><SERIAL_NUMBER>121796</SERIAL_NUMBER><STUDY_SECTION>CCHF</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Cardiac Contractility, Hypertrophy, and Failure Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>250000</DIRECT_COST_AMT><INDIRECT_COST_AMT>147500</INDIRECT_COST_AMT><TOTAL_COST>397500</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8963428</APPLICATION_ID><ACTIVITY>R21</ACTIVITY><ADMINISTERING_IC>AI</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/27/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>855</CFDA_CODE><CORE_PROJECT_NUM>R21AI111286</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF ARTS AND SCIENCES]]></ED_INST_TYPE><FOA_NUMBER>PA-13-303</FOA_NUMBER><FULL_PROJECT_NUM>5R21AI111286-02</FULL_PROJECT_NUM><FUNDING_ICs>NIAID:190000\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>NOTRE DAME</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[BIOLOGY]]></ORG_DEPT><ORG_DISTRICT>02</ORG_DISTRICT><ORG_DUNS>824910376</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIVERSITY OF NOTRE DAME]]></ORG_NAME><ORG_STATE>IN</ORG_STATE><ORG_ZIPCODE>465565708</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: The emergence of artemisinin resistant malaria in Southeast Asia portends a global health crisis. Association studies have identified a key marker for resistance, a kelch-domain gene, but its function remains unknown. We develop a systems biology method that first constructs a comprehensive reference network of gene interactions and then uses it to optimally connect experimentally-determined gene sets through network nodes to identify high-priority genes and functions controlling drug resistance.]]></PHR><PIS><PI><PI_NAME>FERDIG, MICHAEL T</PI_NAME><PI_ID>7153301</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>JOY, DEIRDRE A.</PROGRAM_OFFICER_NAME><PROJECT_START>11/06/2014</PROJECT_START><PROJECT_END>10/31/2016</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Alleles]]></TERM><TERM><![CDATA[artemisinine]]></TERM><TERM><![CDATA[Artemisinins]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[biological systems]]></TERM><TERM><![CDATA[Candidate Disease Gene]]></TERM><TERM><![CDATA[Chloroquine resistance]]></TERM><TERM><![CDATA[Chloroquinoxaline Sulfonamide]]></TERM><TERM><![CDATA[Chromosomes, Human, Pair 13]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[Combined Modality Therapy]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Drug resistance]]></TERM><TERM><![CDATA[Evolution]]></TERM><TERM><![CDATA[Exhibits]]></TERM><TERM><![CDATA[fitness]]></TERM><TERM><![CDATA[gene function]]></TERM><TERM><![CDATA[gene interaction]]></TERM><TERM><![CDATA[Genes]]></TERM><TERM><![CDATA[Genetic]]></TERM><TERM><![CDATA[Genome]]></TERM><TERM><![CDATA[genome wide association study]]></TERM><TERM><![CDATA[genome-wide]]></TERM><TERM><![CDATA[Genotype]]></TERM><TERM><![CDATA[global health]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Gold]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[In Vitro]]></TERM><TERM><![CDATA[innovation]]></TERM><TERM><![CDATA[Intervention]]></TERM><TERM><![CDATA[Killings]]></TERM><TERM><![CDATA[Knowledge]]></TERM><TERM><![CDATA[Libraries]]></TERM><TERM><![CDATA[Link]]></TERM><TERM><![CDATA[Malaria]]></TERM><TERM><![CDATA[Maps]]></TERM><TERM><![CDATA[Measures]]></TERM><TERM><![CDATA[Methods]]></TERM><TERM><![CDATA[Molecular Profiling]]></TERM><TERM><![CDATA[Monitor]]></TERM><TERM><![CDATA[Mutagenesis]]></TERM><TERM><![CDATA[mutant]]></TERM><TERM><![CDATA[Mutation]]></TERM><TERM><![CDATA[Myanmar]]></TERM><TERM><![CDATA[Network-based]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[novel strategies]]></TERM><TERM><![CDATA[Parasite resistance]]></TERM><TERM><![CDATA[Parasites]]></TERM><TERM><![CDATA[Pathway Analysis]]></TERM><TERM><![CDATA[Pharmaceutical Preparations]]></TERM><TERM><![CDATA[Phenotype]]></TERM><TERM><![CDATA[Physiology]]></TERM><TERM><![CDATA[Plasmodium falciparum]]></TERM><TERM><![CDATA[Population]]></TERM><TERM><![CDATA[Population Genetics]]></TERM><TERM><![CDATA[Predisposition]]></TERM><TERM><![CDATA[pressure]]></TERM><TERM><![CDATA[Relative (related person)]]></TERM><TERM><![CDATA[Resistance]]></TERM><TERM><![CDATA[resistance mechanism]]></TERM><TERM><![CDATA[resistance mutation]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[screening]]></TERM><TERM><![CDATA[Southeastern Asia]]></TERM><TERM><![CDATA[Staging]]></TERM><TERM><![CDATA[Systems Biology]]></TERM><TERM><![CDATA[Tertiary Protein Structure]]></TERM><TERM><![CDATA[Thailand]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[tool]]></TERM><TERM><![CDATA[Transcript]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[A network-based method for predicting gene interactions in artemisinin resistance]]></PROJECT_TITLE><SERIAL_NUMBER>111286</SERIAL_NUMBER><STUDY_SECTION>ZRG1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>125000</DIRECT_COST_AMT><INDIRECT_COST_AMT>65000</INDIRECT_COST_AMT><TOTAL_COST>190000</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8966557</APPLICATION_ID><ACTIVITY>R21</ACTIVITY><ADMINISTERING_IC>HL</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/29/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>837</CFDA_CODE><CORE_PROJECT_NUM>R21HL123012</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-12-284</FOA_NUMBER><FULL_PROJECT_NUM>5R21HL123012-02</FULL_PROJECT_NUM><FUNDING_ICs>NHLBI:178312\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL HEART, LUNG, AND BLOOD INSTITUTE</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>CLEVELAND</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[INTERNAL MEDICINE/MEDICINE]]></ORG_DEPT><ORG_DISTRICT>11</ORG_DISTRICT><ORG_DUNS>077758407</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[CASE WESTERN RESERVE UNIVERSITY]]></ORG_NAME><ORG_STATE>OH</ORG_STATE><ORG_ZIPCODE>441067000</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: A major public health concern in recent years has been increasing reports of adverse cardiac events, including arrhythmias and sudden cardiac death that have been associated with the use of non-cardiac drugs. To reduce the incidence of adverse events, we will develop a novel, fully optical platform that leverages recent advances in infrared light stimulation with fluorescent indicators of cellular function that is suitable for a igh throughput screening format. Our long term goal to advance the safe use of effective therapeutic drug compounds.]]></PHR><PIS><PI><PI_NAME>LAURITA, KENNETH </PI_NAME><PI_ID>6800833</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>DANTHI, NARASIMHAN </PROGRAM_OFFICER_NAME><PROJECT_START>11/14/2014</PROJECT_START><PROJECT_END>10/31/2016</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Action Potentials]]></TERM><TERM><![CDATA[Adverse event]]></TERM><TERM><![CDATA[Animals]]></TERM><TERM><![CDATA[Arrhythmia]]></TERM><TERM><![CDATA[Biological Assay]]></TERM><TERM><![CDATA[Biological Markers]]></TERM><TERM><![CDATA[Calcium]]></TERM><TERM><![CDATA[Cardiac]]></TERM><TERM><![CDATA[Cardiac Myocytes]]></TERM><TERM><![CDATA[cell injury]]></TERM><TERM><![CDATA[Cell physiology]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[cellular engineering]]></TERM><TERM><![CDATA[Communities]]></TERM><TERM><![CDATA[Complex]]></TERM><TERM><![CDATA[cost]]></TERM><TERM><![CDATA[Death, Sudden, Cardiac]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Drug Compounding]]></TERM><TERM><![CDATA[Drug Industry]]></TERM><TERM><![CDATA[drug testing]]></TERM><TERM><![CDATA[Electric Stimulation]]></TERM><TERM><![CDATA[Electrodes]]></TERM><TERM><![CDATA[Electrophysiology (science)]]></TERM><TERM><![CDATA[Event]]></TERM><TERM><![CDATA[Fluorescence]]></TERM><TERM><![CDATA[fluorescence imaging]]></TERM><TERM><![CDATA[genetically modified cells]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Gold]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Heart]]></TERM><TERM><![CDATA[heart rhythm]]></TERM><TERM><![CDATA[high throughput screening]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[Imaging Techniques]]></TERM><TERM><![CDATA[Incidence]]></TERM><TERM><![CDATA[induced pluripotent stem cell]]></TERM><TERM><![CDATA[innovation]]></TERM><TERM><![CDATA[Investigation]]></TERM><TERM><![CDATA[Ion Channel]]></TERM><TERM><![CDATA[Light]]></TERM><TERM><![CDATA[Link]]></TERM><TERM><![CDATA[Marketing]]></TERM><TERM><![CDATA[Measurement]]></TERM><TERM><![CDATA[Measures]]></TERM><TERM><![CDATA[Membrane Potentials]]></TERM><TERM><![CDATA[Methods]]></TERM><TERM><![CDATA[monolayer]]></TERM><TERM><![CDATA[Morphologic artifacts]]></TERM><TERM><![CDATA[Necrosis]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[novel strategies]]></TERM><TERM><![CDATA[Optics]]></TERM><TERM><![CDATA[Pharmaceutical Preparations]]></TERM><TERM><![CDATA[Physiologic pulse]]></TERM><TERM><![CDATA[Physiological]]></TERM><TERM><![CDATA[Preparation]]></TERM><TERM><![CDATA[public health medicine (field)]]></TERM><TERM><![CDATA[Reporting]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[Risk]]></TERM><TERM><![CDATA[Safety]]></TERM><TERM><![CDATA[safety testing]]></TERM><TERM><![CDATA[screening]]></TERM><TERM><![CDATA[Specificity]]></TERM><TERM><![CDATA[Technology]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Therapeutic]]></TERM><TERM><![CDATA[Tissues]]></TERM><TERM><![CDATA[virtual]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Fully optical high throughput screening platform for drug induced arrhythmias]]></PROJECT_TITLE><SERIAL_NUMBER>123012</SERIAL_NUMBER><STUDY_SECTION>BMIT</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Biomedical Imaging Technology Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>112500</DIRECT_COST_AMT><INDIRECT_COST_AMT>65812</INDIRECT_COST_AMT><TOTAL_COST>178312</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8967221</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>HL</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/29/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>837</CFDA_CODE><CORE_PROJECT_NUM>R01HL126186</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-13-302</FOA_NUMBER><FULL_PROJECT_NUM>5R01HL126186-02</FULL_PROJECT_NUM><FUNDING_ICs>NHLBI:351000\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL HEART, LUNG, AND BLOOD INSTITUTE</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>PHILADELPHIA</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[INTERNAL MEDICINE/MEDICINE]]></ORG_DEPT><ORG_DISTRICT>01</ORG_DISTRICT><ORG_DUNS>057123192</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[TEMPLE UNIV OF THE COMMONWEALTH]]></ORG_NAME><ORG_STATE>PA</ORG_STATE><ORG_ZIPCODE>191226003</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Heart disease is a leading cause of morbidity and mortality amongst Americans. Adult stem cells including autologous cardiac progenitor cells (CPC) are currently used in the clinical trials to enhance the repair and regeneration of the diseased heart and have shown significant improvement in patients with ischemic heart disease. The available results however show modest gain in improved heart functions in patients treated with stem cells. Part of the reasons that limit the full benefits of such therapies is poor survival of transplanted cells and inefficient activation of tissue residing stem cells. Studies proposed in ths application provide a novel approach to enhance the survival and function of CPC. Most importantly, our results may significantly improve the benefits of an existing cellular therapy and
improve the lives of the over 16 million patients in the United States living with coronary heart disease.]]></PHR><PIS><PI><PI_NAME>KISHORE, RAJ </PI_NAME><PI_ID>7117773</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>WONG, RENEE P.</PROGRAM_OFFICER_NAME><PROJECT_START>11/11/2014</PROJECT_START><PROJECT_END>10/31/2018</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Adoptive Cell Transfers]]></TERM><TERM><![CDATA[Adoptive Transfer]]></TERM><TERM><![CDATA[Adult]]></TERM><TERM><![CDATA[adult stem cell]]></TERM><TERM><![CDATA[Adverse effects]]></TERM><TERM><![CDATA[American]]></TERM><TERM><![CDATA[angiogenesis]]></TERM><TERM><![CDATA[Area]]></TERM><TERM><![CDATA[Autologous]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Cardiac]]></TERM><TERM><![CDATA[Cardiac Myocytes]]></TERM><TERM><![CDATA[Cell Communication]]></TERM><TERM><![CDATA[Cell Count]]></TERM><TERM><![CDATA[Cell Cycle]]></TERM><TERM><![CDATA[Cell physiology]]></TERM><TERM><![CDATA[Cell Proliferation]]></TERM><TERM><![CDATA[Cell Survival]]></TERM><TERM><![CDATA[Cell Therapy]]></TERM><TERM><![CDATA[Cell Transplants]]></TERM><TERM><![CDATA[Cell-Free System]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Chronic]]></TERM><TERM><![CDATA[Clinical Research]]></TERM><TERM><![CDATA[Clinical Trials]]></TERM><TERM><![CDATA[Coronary heart disease]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Embryo]]></TERM><TERM><![CDATA[embryonic stem cell]]></TERM><TERM><![CDATA[Engraftment]]></TERM><TERM><![CDATA[Environment]]></TERM><TERM><![CDATA[Face]]></TERM><TERM><![CDATA[gain of function]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Heart]]></TERM><TERM><![CDATA[Heart Diseases]]></TERM><TERM><![CDATA[heart function]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[In Vitro]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[induced pluripotent stem cell]]></TERM><TERM><![CDATA[Infarction]]></TERM><TERM><![CDATA[Inflammation]]></TERM><TERM><![CDATA[Injection of therapeutic agent]]></TERM><TERM><![CDATA[injured]]></TERM><TERM><![CDATA[Injury]]></TERM><TERM><![CDATA[intercellular communication]]></TERM><TERM><![CDATA[Life]]></TERM><TERM><![CDATA[Link]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[Mediator of activation protein]]></TERM><TERM><![CDATA[Messenger RNA]]></TERM><TERM><![CDATA[MicroRNAs]]></TERM><TERM><![CDATA[Morbidity - disease rate]]></TERM><TERM><![CDATA[Mortality Vital Statistics]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[Muscle Cells]]></TERM><TERM><![CDATA[Myocardial]]></TERM><TERM><![CDATA[Myocardial Ischemia]]></TERM><TERM><![CDATA[Myocardium]]></TERM><TERM><![CDATA[Natural regeneration]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[novel strategies]]></TERM><TERM><![CDATA[oxidative damage]]></TERM><TERM><![CDATA[Parents]]></TERM><TERM><![CDATA[Pathologic]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Physiological]]></TERM><TERM><![CDATA[Play]]></TERM><TERM><![CDATA[Pluripotent Stem Cells]]></TERM><TERM><![CDATA[Population]]></TERM><TERM><![CDATA[pre-clinical]]></TERM><TERM><![CDATA[preclinical study]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[Proto-Oncogene Protein c-kit]]></TERM><TERM><![CDATA[regenerative]]></TERM><TERM><![CDATA[Regimen]]></TERM><TERM><![CDATA[repaired]]></TERM><TERM><![CDATA[research study]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[restoration]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Solutions]]></TERM><TERM><![CDATA[Source]]></TERM><TERM><![CDATA[stem]]></TERM><TERM><![CDATA[Stem cells]]></TERM><TERM><![CDATA[success]]></TERM><TERM><![CDATA[Teratoma]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Therapeutic]]></TERM><TERM><![CDATA[Tissues]]></TERM><TERM><![CDATA[Transplantation]]></TERM><TERM><![CDATA[Treatment Efficacy]]></TERM><TERM><![CDATA[United States]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Pluripotent cell-derived exosomes as mediators of myocardial regeneration]]></PROJECT_TITLE><SERIAL_NUMBER>126186</SERIAL_NUMBER><STUDY_SECTION>MIM</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Myocardial Ischemia and Metabolism Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>225000</DIRECT_COST_AMT><INDIRECT_COST_AMT>126000</INDIRECT_COST_AMT><TOTAL_COST>351000</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8968859</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>HL</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/30/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>837</CFDA_CODE><CORE_PROJECT_NUM>R01HL125224</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-13-302</FOA_NUMBER><FULL_PROJECT_NUM>5R01HL125224-02</FULL_PROJECT_NUM><FUNDING_ICs>NHLBI:418393\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL HEART, LUNG, AND BLOOD INSTITUTE</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>STANFORD</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[SURGERY]]></ORG_DEPT><ORG_DISTRICT>18</ORG_DISTRICT><ORG_DUNS>009214214</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[STANFORD UNIVERSITY]]></ORG_NAME><ORG_STATE>CA</ORG_STATE><ORG_ZIPCODE>943041222</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Scientists do not yet understand how genetic variation causes cardiovascular disease. Recent studies have identified chromosome 9 and the cell-regulating gene, CDKN2B, as possible sources of inherited risk for disease. Understanding how these pathways function might lead to new therapies for heart and blood vessel disorders- currently the leading killers in the United States.]]></PHR><PIS><PI><PI_NAME>LEEPER, NICHOLAS JAMES</PI_NAME><PI_ID>8833018</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>OLIVE, MICHELLE </PROGRAM_OFFICER_NAME><PROJECT_START>11/15/2014</PROJECT_START><PROJECT_END>10/31/2019</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[9p21]]></TERM><TERM><![CDATA[Accounting]]></TERM><TERM><![CDATA[angiogenesis]]></TERM><TERM><![CDATA[Animals]]></TERM><TERM><![CDATA[Apoptosis]]></TERM><TERM><![CDATA[Arterial Fatty Streak]]></TERM><TERM><![CDATA[atherogenesis]]></TERM><TERM><![CDATA[Atherosclerosis]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Biological Assay]]></TERM><TERM><![CDATA[Biology]]></TERM><TERM><![CDATA[Blood Vessels]]></TERM><TERM><![CDATA[Candidate Disease Gene]]></TERM><TERM><![CDATA[Cardiovascular Diseases]]></TERM><TERM><![CDATA[cardiovascular risk factor]]></TERM><TERM><![CDATA[Cardiovascular system]]></TERM><TERM><![CDATA[Cause of Death]]></TERM><TERM><![CDATA[CDKN2B gene]]></TERM><TERM><![CDATA[cell behavior]]></TERM><TERM><![CDATA[cell type]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Chromosomes]]></TERM><TERM><![CDATA[Chromosomes, Human, Pair 9]]></TERM><TERM><![CDATA[Coculture Techniques]]></TERM><TERM><![CDATA[Cohort Studies]]></TERM><TERM><![CDATA[Collaborations]]></TERM><TERM><![CDATA[Coronary Arteriosclerosis]]></TERM><TERM><![CDATA[Defect]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[disorder risk]]></TERM><TERM><![CDATA[Dominant-Negative Mutation]]></TERM><TERM><![CDATA[Endothelial Cells]]></TERM><TERM><![CDATA[Enrollment]]></TERM><TERM><![CDATA[Event]]></TERM><TERM><![CDATA[femoral artery]]></TERM><TERM><![CDATA[Figs - dietary]]></TERM><TERM><![CDATA[Genes]]></TERM><TERM><![CDATA[Genetic]]></TERM><TERM><![CDATA[Genetic Polymorphism]]></TERM><TERM><![CDATA[Genetic Risk]]></TERM><TERM><![CDATA[genome wide association study]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Heart]]></TERM><TERM><![CDATA[Hemorrhage]]></TERM><TERM><![CDATA[Hindlimb]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[human tissue]]></TERM><TERM><![CDATA[Hyperlipidemia]]></TERM><TERM><![CDATA[Hypertension]]></TERM><TERM><![CDATA[Hypoxia]]></TERM><TERM><![CDATA[In Vitro]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[Inherited]]></TERM><TERM><![CDATA[insight]]></TERM><TERM><![CDATA[Intramuscular]]></TERM><TERM><![CDATA[Ischemia]]></TERM><TERM><![CDATA[knockout animal]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[Lifetime Risk]]></TERM><TERM><![CDATA[Ligation]]></TERM><TERM><![CDATA[Limb structure]]></TERM><TERM><![CDATA[Link]]></TERM><TERM><![CDATA[macrophage]]></TERM><TERM><![CDATA[man]]></TERM><TERM><![CDATA[Maps]]></TERM><TERM><![CDATA[matrigel]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[Mission]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[Molecular Genetics]]></TERM><TERM><![CDATA[mouse model]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[Myocardial Infarction]]></TERM><TERM><![CDATA[neovascularization]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[Operative Surgical Procedures]]></TERM><TERM><![CDATA[Pathologic]]></TERM><TERM><![CDATA[Pathway interactions]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Pericytes]]></TERM><TERM><![CDATA[Peripheral arterial disease]]></TERM><TERM><![CDATA[Phagocytosis]]></TERM><TERM><![CDATA[Phenotype]]></TERM><TERM><![CDATA[Phosphorylation]]></TERM><TERM><![CDATA[Physiology]]></TERM><TERM><![CDATA[pleiotropism]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[Publishing]]></TERM><TERM><![CDATA[Quantitative Trait Loci]]></TERM><TERM><![CDATA[Research Personnel]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[Risk]]></TERM><TERM><![CDATA[Risk Factors]]></TERM><TERM><![CDATA[risk variant]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Rupture]]></TERM><TERM><![CDATA[Sampling]]></TERM><TERM><![CDATA[Scientist]]></TERM><TERM><![CDATA[Secondary to]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[Smoking]]></TERM><TERM><![CDATA[Smooth Muscle Myocytes]]></TERM><TERM><![CDATA[Source]]></TERM><TERM><![CDATA[Tissue Sample]]></TERM><TERM><![CDATA[Transfection]]></TERM><TERM><![CDATA[Transgenic Organisms]]></TERM><TERM><![CDATA[Translating]]></TERM><TERM><![CDATA[Tube]]></TERM><TERM><![CDATA[Tumor Suppressor Proteins]]></TERM><TERM><![CDATA[United States]]></TERM><TERM><![CDATA[United States National Institutes of Health]]></TERM><TERM><![CDATA[Variant]]></TERM><TERM><![CDATA[Variation (Genetics)]]></TERM><TERM><![CDATA[Vascular Diseases]]></TERM><TERM><![CDATA[Vascular Endothelial Growth Factors]]></TERM><TERM><![CDATA[Western World]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[The paradoxical role of CDKN2B in blood vessel sprouting and maturation]]></PROJECT_TITLE><SERIAL_NUMBER>125224</SERIAL_NUMBER><STUDY_SECTION>VCMB</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Vascular Cell and Molecular Biology Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>259312</DIRECT_COST_AMT><INDIRECT_COST_AMT>159081</INDIRECT_COST_AMT><TOTAL_COST>418393</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8978204</APPLICATION_ID><ACTIVITY>F32</ACTIVITY><ADMINISTERING_IC>HD</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/05/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>865</CFDA_CODE><CORE_PROJECT_NUM>F32HD081957</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF ARTS AND SCIENCES]]></ED_INST_TYPE><FOA_NUMBER>PA-11-113</FOA_NUMBER><FULL_PROJECT_NUM>5F32HD081957-02</FULL_PROJECT_NUM><FUNDING_ICs>NICHD:56042\</FUNDING_ICs><FUNDING_MECHANISM>TRAINING, INDIVIDUAL</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &amp; HUMAN DEVELOPMENT</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>BERKELEY</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[PSYCHOLOGY]]></ORG_DEPT><ORG_DISTRICT>13</ORG_DISTRICT><ORG_DUNS>124726725</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIVERSITY OF CALIFORNIA BERKELEY]]></ORG_NAME><ORG_STATE>CA</ORG_STATE><ORG_ZIPCODE>947045940</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Although it well-established that stable circadian (daily) rhythms are important for adult health and disease prevention, little is known about the impact of disruptions to circadian rhythms on early life development. Artificial lights and shift work negatively impact body and brain rhythms, with lasting health impacts, suggesting that daily disruptions of this sort during fetal and early life development can lead to life-long damage. This
proposal seeks to understand the role of daily stability in early development, identify the risks o early life instability, and test interventions and preventions to mollify these risks when daily instability is unavoidable.]]></PHR><PIS><PI><PI_NAME>SMARR, BENJAMIN LEE</PI_NAME><PI_ID>9394351</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>FREUND, LISA S</PROGRAM_OFFICER_NAME><PROJECT_START>11/16/2014</PROJECT_START><PROJECT_END>10/31/2017</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Acute]]></TERM><TERM><![CDATA[Adrenal Glands]]></TERM><TERM><![CDATA[Adult]]></TERM><TERM><![CDATA[Adult Children]]></TERM><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[Agreement]]></TERM><TERM><![CDATA[Bacteria]]></TERM><TERM><![CDATA[Behavior]]></TERM><TERM><![CDATA[Behavioral]]></TERM><TERM><![CDATA[Brain]]></TERM><TERM><![CDATA[Caring]]></TERM><TERM><![CDATA[Child]]></TERM><TERM><![CDATA[Chronic]]></TERM><TERM><![CDATA[circadian pacemaker]]></TERM><TERM><![CDATA[Circadian Rhythms]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[Cues]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[disorder prevention]]></TERM><TERM><![CDATA[Epigenetic Process]]></TERM><TERM><![CDATA[Event]]></TERM><TERM><![CDATA[Exercise]]></TERM><TERM><![CDATA[Eye]]></TERM><TERM><![CDATA[fetal]]></TERM><TERM><![CDATA[Fetus]]></TERM><TERM><![CDATA[Genetic]]></TERM><TERM><![CDATA[Glucocorticoids]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Health behavior]]></TERM><TERM><![CDATA[Heart Diseases]]></TERM><TERM><![CDATA[Hormones]]></TERM><TERM><![CDATA[Hour]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[Hypothalamic structure]]></TERM><TERM><![CDATA[Impaired cognition]]></TERM><TERM><![CDATA[Impairment]]></TERM><TERM><![CDATA[Intervention]]></TERM><TERM><![CDATA[Jet Lag Syndrome]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[Learning]]></TERM><TERM><![CDATA[Life]]></TERM><TERM><![CDATA[Light]]></TERM><TERM><![CDATA[Malignant Neoplasms]]></TERM><TERM><![CDATA[Mammals]]></TERM><TERM><![CDATA[Maternal Physiology]]></TERM><TERM><![CDATA[maternal stress]]></TERM><TERM><![CDATA[Mental Depression]]></TERM><TERM><![CDATA[Mental Health]]></TERM><TERM><![CDATA[Methylation]]></TERM><TERM><![CDATA[Modification]]></TERM><TERM><![CDATA[Morphology]]></TERM><TERM><![CDATA[Mothers]]></TERM><TERM><![CDATA[Neonatal]]></TERM><TERM><![CDATA[neonate]]></TERM><TERM><![CDATA[neurobehavioral]]></TERM><TERM><![CDATA[neurobiological mechanism]]></TERM><TERM><![CDATA[Neurobiology]]></TERM><TERM><![CDATA[neurogenesis]]></TERM><TERM><![CDATA[Neurons]]></TERM><TERM><![CDATA[offspring]]></TERM><TERM><![CDATA[Organ]]></TERM><TERM><![CDATA[Organism]]></TERM><TERM><![CDATA[Paris, France]]></TERM><TERM><![CDATA[Pattern]]></TERM><TERM><![CDATA[Peripheral]]></TERM><TERM><![CDATA[physical conditioning]]></TERM><TERM><![CDATA[Physiological]]></TERM><TERM><![CDATA[Physiology]]></TERM><TERM><![CDATA[Pituitary Gland]]></TERM><TERM><![CDATA[Pregnancy]]></TERM><TERM><![CDATA[pregnant]]></TERM><TERM><![CDATA[prenatal]]></TERM><TERM><![CDATA[prevent]]></TERM><TERM><![CDATA[Prevention]]></TERM><TERM><![CDATA[Prevention strategy]]></TERM><TERM><![CDATA[Preventive Intervention]]></TERM><TERM><![CDATA[Regulation]]></TERM><TERM><![CDATA[relating to nervous system]]></TERM><TERM><![CDATA[Relative (related person)]]></TERM><TERM><![CDATA[Retina]]></TERM><TERM><![CDATA[Risk]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Rotation]]></TERM><TERM><![CDATA[shift work]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[Sleep]]></TERM><TERM><![CDATA[Sorting - Cell Movement]]></TERM><TERM><![CDATA[Stress]]></TERM><TERM><![CDATA[suprachiasmatic nucleus]]></TERM><TERM><![CDATA[Surface]]></TERM><TERM><![CDATA[System]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[Tissues]]></TERM><TERM><![CDATA[Travel]]></TERM><TERM><![CDATA[Ulcer]]></TERM><TERM><![CDATA[Weaning]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[The role of circadian stability during development in adult health and behavior]]></PROJECT_TITLE><SERIAL_NUMBER>081957</SERIAL_NUMBER><STUDY_SECTION>ZRG1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>56042</DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>56042</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9030801</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>AI</ADMINISTERING_IC><APPLICATION_TYPE>2</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/30/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>855</CFDA_CODE><CORE_PROJECT_NUM>R01AI040215</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>PA-13-302</FOA_NUMBER><FULL_PROJECT_NUM>2R01AI040215-16A1</FULL_PROJECT_NUM><FUNDING_ICs>NIAID:473750\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>LA JOLLA</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>49</ORG_DISTRICT><ORG_DUNS>781613492</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[SCRIPPS RESEARCH INSTITUTE]]></ORG_NAME><ORG_STATE>CA</ORG_STATE><ORG_ZIPCODE>920371000</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Vaccines rely on antibodies to protect us for long periods against infection. We know a lot about how antibody molecules function but very little about the memory cells that quality control their production. In order to design better vaccines, we need to understand how memory T cells work to improve the quality of antibody produced at the vaccine boost.   
   
      

]]></PHR><PIS><PI><PI_NAME>MCHEYZER-WILLIAMS, MICHAEL G.</PI_NAME><PI_ID>2404682</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>FERGUSON, STACY E.</PROGRAM_OFFICER_NAME><PROJECT_START>09/30/1996</PROJECT_START><PROJECT_END>10/31/2020</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[adaptive immunity]]></TERM><TERM><![CDATA[Adjuvant]]></TERM><TERM><![CDATA[Affinity]]></TERM><TERM><![CDATA[Antibodies]]></TERM><TERM><![CDATA[Antibody Affinity]]></TERM><TERM><![CDATA[Antigens]]></TERM><TERM><![CDATA[Area]]></TERM><TERM><![CDATA[B-Cell Activation]]></TERM><TERM><![CDATA[B-Cell Development]]></TERM><TERM><![CDATA[B-Lymphocytes]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Behavior]]></TERM><TERM><![CDATA[Binding (Molecular Function)]]></TERM><TERM><![CDATA[Biological Assay]]></TERM><TERM><![CDATA[Biological Response Modifiers]]></TERM><TERM><![CDATA[BLR1 gene]]></TERM><TERM><![CDATA[CD4 Positive T Lymphocytes]]></TERM><TERM><![CDATA[Cell Differentiation process]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Chimera organism]]></TERM><TERM><![CDATA[Clonal Evolution]]></TERM><TERM><![CDATA[Complex]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[directed evolution]]></TERM><TERM><![CDATA[Equilibrium]]></TERM><TERM><![CDATA[Evolution]]></TERM><TERM><![CDATA[feeding]]></TERM><TERM><![CDATA[Generations]]></TERM><TERM><![CDATA[Genetic Transcription]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Helper-Inducer T-Lymphocyte]]></TERM><TERM><![CDATA[Immune]]></TERM><TERM><![CDATA[immune function]]></TERM><TERM><![CDATA[Immunity]]></TERM><TERM><![CDATA[Immunoglobulin Class Switching]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[In Situ]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[Infection]]></TERM><TERM><![CDATA[Label]]></TERM><TERM><![CDATA[Memory]]></TERM><TERM><![CDATA[Memory B-Lymphocyte]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[pathogen]]></TERM><TERM><![CDATA[Pathway interactions]]></TERM><TERM><![CDATA[Peptides]]></TERM><TERM><![CDATA[plasma cell differentiation]]></TERM><TERM><![CDATA[Plasma Cells]]></TERM><TERM><![CDATA[Production]]></TERM><TERM><![CDATA[programs]]></TERM><TERM><![CDATA[Proteins]]></TERM><TERM><![CDATA[public health relevance]]></TERM><TERM><![CDATA[Quality Control]]></TERM><TERM><![CDATA[Regulation]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Resolution]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[single cell analysis]]></TERM><TERM><![CDATA[Staging]]></TERM><TERM><![CDATA[Structure of germinal center of lymph node]]></TERM><TERM><![CDATA[Study models]]></TERM><TERM><![CDATA[T memory cell]]></TERM><TERM><![CDATA[T-Lymphocyte]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Transcription Repressor/Corepressor]]></TERM><TERM><![CDATA[transcriptome sequencing]]></TERM><TERM><![CDATA[uptake]]></TERM><TERM><![CDATA[Vaccination]]></TERM><TERM><![CDATA[Vaccine Antigen]]></TERM><TERM><![CDATA[vaccine development]]></TERM><TERM><![CDATA[Vaccine Research]]></TERM><TERM><![CDATA[Vaccines]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Development of antigen-specific helper T cell memory]]></PROJECT_TITLE><SERIAL_NUMBER>040215</SERIAL_NUMBER><STUDY_SECTION>CMIB</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Cellular and Molecular Immunology - B Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>16</SUPPORT_YEAR><SUFFIX>A1</SUFFIX><DIRECT_COST_AMT>250000</DIRECT_COST_AMT><INDIRECT_COST_AMT>223750</INDIRECT_COST_AMT><TOTAL_COST>473750</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9042732</APPLICATION_ID><ACTIVITY>R13</ACTIVITY><ADMINISTERING_IC>AA</ADMINISTERING_IC><APPLICATION_TYPE>1</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/26/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>273</CFDA_CODE><CORE_PROJECT_NUM>R13AA024639</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>PA-13-347</FOA_NUMBER><FULL_PROJECT_NUM>1R13AA024639-01</FULL_PROJECT_NUM><FUNDING_ICs>NIAAA:24000\</FUNDING_ICs><FUNDING_MECHANISM>OTHER RESEARCH-RELATED</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>WEST KINGSTON</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>02</ORG_DISTRICT><ORG_DUNS>075712877</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[GORDON RESEARCH CONFERENCES]]></ORG_NAME><ORG_STATE>RI</ORG_STATE><ORG_ZIPCODE>028921502</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE   
The Gordon Research Conference (GRC) on Alcohol and the Nervous System will provide a unique forum to bring together a diverse range of young and established alcohol researchers, and experts in complementary fields, to discuss groundbreaking advances in alcohol neuroscience research. The innovative GRC format will promote deep and open discussions, build bridges in interdisciplinary neuroscience research between preclinical and clinical researchers, and foster the development of the next generation of alcohol researchers. We envision that this conference will stimulate cutting edge research in the field, and eventually contribute to the development of new approaches for the prevention and treatment of alcoholism and fetal alcohol spectrum disorders.      

]]></PHR><PIS><PI><PI_NAME>WEINER, JEFFREY L</PI_NAME><PI_ID>1902086</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>CUI, CHANGHAI </PROGRAM_OFFICER_NAME><PROJECT_START>11/01/2015</PROJECT_START><PROJECT_END>10/31/2017</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[addiction]]></TERM><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[Alcohol abuse]]></TERM><TERM><![CDATA[Alcohol consumption]]></TERM><TERM><![CDATA[Alcohol dependence]]></TERM><TERM><![CDATA[alcohol effect]]></TERM><TERM><![CDATA[alcohol exposure]]></TERM><TERM><![CDATA[alcohol research]]></TERM><TERM><![CDATA[alcohol response]]></TERM><TERM><![CDATA[alcohol use disorder]]></TERM><TERM><![CDATA[Alcoholism]]></TERM><TERM><![CDATA[alcoholism therapy]]></TERM><TERM><![CDATA[Alcohols]]></TERM><TERM><![CDATA[Area]]></TERM><TERM><![CDATA[Automobile Driving]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Brain]]></TERM><TERM><![CDATA[career]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[Clinical Research]]></TERM><TERM><![CDATA[Collaborations]]></TERM><TERM><![CDATA[Communication]]></TERM><TERM><![CDATA[Communities]]></TERM><TERM><![CDATA[Custom]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Discipline]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Drug Formulations]]></TERM><TERM><![CDATA[Ensure]]></TERM><TERM><![CDATA[Exposure to]]></TERM><TERM><![CDATA[Fetal Alcohol Spectrum Disorder]]></TERM><TERM><![CDATA[Fostering]]></TERM><TERM><![CDATA[frontier]]></TERM><TERM><![CDATA[Functional disorder]]></TERM><TERM><![CDATA[Future]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Growth]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[innovation]]></TERM><TERM><![CDATA[International]]></TERM><TERM><![CDATA[Longevity]]></TERM><TERM><![CDATA[meetings]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[Nervous system structure]]></TERM><TERM><![CDATA[Neurobiology]]></TERM><TERM><![CDATA[Neurosciences]]></TERM><TERM><![CDATA[Neurosciences Research]]></TERM><TERM><![CDATA[next generation]]></TERM><TERM><![CDATA[novel strategies]]></TERM><TERM><![CDATA[Postdoctoral Fellow]]></TERM><TERM><![CDATA[posters]]></TERM><TERM><![CDATA[pre-clinical]]></TERM><TERM><![CDATA[Prevention]]></TERM><TERM><![CDATA[public health relevance]]></TERM><TERM><![CDATA[relating to nervous system]]></TERM><TERM><![CDATA[Request for Applications]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[research and development]]></TERM><TERM><![CDATA[Research Personnel]]></TERM><TERM><![CDATA[Scientific Advances and Accomplishments]]></TERM><TERM><![CDATA[Scientist]]></TERM><TERM><![CDATA[Shapes]]></TERM><TERM><![CDATA[Staging]]></TERM><TERM><![CDATA[Structure]]></TERM><TERM><![CDATA[Students]]></TERM><TERM><![CDATA[success]]></TERM><TERM><![CDATA[symposium]]></TERM><TERM><![CDATA[Techniques]]></TERM><TERM><![CDATA[Technology]]></TERM><TERM><![CDATA[Therapeutic]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[Ursidae Family]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[2016 and 2018 Alcohol and the Nervous System GRC]]></PROJECT_TITLE><SERIAL_NUMBER>024639</SERIAL_NUMBER><STUDY_SECTION>ZAA1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>01</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>24000</DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>24000</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9065323</APPLICATION_ID><ACTIVITY>R13</ACTIVITY><ADMINISTERING_IC>AI</ADMINISTERING_IC><APPLICATION_TYPE>1</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/27/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>855</CFDA_CODE><CORE_PROJECT_NUM>R13AI123007</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF VETERINARY MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-13-347</FOA_NUMBER><FULL_PROJECT_NUM>1R13AI123007-01</FULL_PROJECT_NUM><FUNDING_ICs>NIAID:7500\</FUNDING_ICs><FUNDING_MECHANISM>OTHER RESEARCH-RELATED</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>AMES</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[VETERINARY SCIENCES]]></ORG_DEPT><ORG_DISTRICT>04</ORG_DISTRICT><ORG_DUNS>005309844</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[IOWA STATE UNIVERSITY]]></ORG_NAME><ORG_STATE>IA</ORG_STATE><ORG_ZIPCODE>500112207</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Antigenic variation is a defensive strategy commonly exploited by many viruses to hide from the body's immune system. Antigenically variable viruses (AVV) are responsible for many human as well as veterinary diseases with high morbidity/mortality and significant economic losses worldwide. Viruses such as HIV-1, influenza virus and PRRSV (Porcine Reproductive and Respiratory Syndrome Virus) are notorious examples. Despite many decades of research, there is still no vaccine against HIV-1 and those against influenza virus and PRRSV are only partially effective against similar virus strains. In June 2014, Iowa State University hosted and financed the first symposium on Vaccines Against Antigenically Variable Viruses (VAAVV) to promote and facilitate highly integrative, cooperative, interdisciplinary research. The symposium was highly successful and funding is requested to continue this effort. This proposal is highly unique and innovative in that the   
symposium seeks to bring together investigators from different disciplines to address a problem common to many viruses and poses enormous scientific challenges in developing effective vaccines.      

]]></PHR><PIS><PI><PI_NAME>CHO, MICHAEL W (contact)</PI_NAME><PI_ID>1926709 (contact)</PI_ID></PI><PI><PI_NAME>VERHOEVEN, DAVID E</PI_NAME><PI_ID>9163551</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>MULACH, BARBARA L.</PROGRAM_OFFICER_NAME><PROJECT_START>11/01/2015</PROJECT_START><PROJECT_END>10/31/2016</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Academia]]></TERM><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[antigen processing]]></TERM><TERM><![CDATA[Antigenic Variation]]></TERM><TERM><![CDATA[Antigens]]></TERM><TERM><![CDATA[Biomedical Engineering]]></TERM><TERM><![CDATA[Cellular Immunology]]></TERM><TERM><![CDATA[Collaborations]]></TERM><TERM><![CDATA[Communicable Diseases]]></TERM><TERM><![CDATA[cost effective]]></TERM><TERM><![CDATA[Defense Mechanisms]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[Discipline]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Economics]]></TERM><TERM><![CDATA[Epidemiologist]]></TERM><TERM><![CDATA[Epitopes]]></TERM><TERM><![CDATA[Face]]></TERM><TERM><![CDATA[Family]]></TERM><TERM><![CDATA[fight against]]></TERM><TERM><![CDATA[Fostering]]></TERM><TERM><![CDATA[Foundations]]></TERM><TERM><![CDATA[Funding]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Government]]></TERM><TERM><![CDATA[HIV Envelope Protein gp120]]></TERM><TERM><![CDATA[HIV-1]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[Immune]]></TERM><TERM><![CDATA[Immune response]]></TERM><TERM><![CDATA[Immune system]]></TERM><TERM><![CDATA[Immunization]]></TERM><TERM><![CDATA[Immunoassay]]></TERM><TERM><![CDATA[immunogenicity]]></TERM><TERM><![CDATA[Immunologist]]></TERM><TERM><![CDATA[Industry]]></TERM><TERM><![CDATA[Influenza]]></TERM><TERM><![CDATA[influenzavirus]]></TERM><TERM><![CDATA[innovation]]></TERM><TERM><![CDATA[insight]]></TERM><TERM><![CDATA[interdisciplinary collaboration]]></TERM><TERM><![CDATA[Interdisciplinary Study]]></TERM><TERM><![CDATA[International]]></TERM><TERM><![CDATA[Iowa]]></TERM><TERM><![CDATA[Knowledge]]></TERM><TERM><![CDATA[Measles]]></TERM><TERM><![CDATA[meetings]]></TERM><TERM><![CDATA[Morbidity - disease rate]]></TERM><TERM><![CDATA[Mortality Vital Statistics]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[novel strategies]]></TERM><TERM><![CDATA[novel vaccines]]></TERM><TERM><![CDATA[Participant]]></TERM><TERM><![CDATA[Play]]></TERM><TERM><![CDATA[Poliomyelitis]]></TERM><TERM><![CDATA[Porcine respiratory and reproductive syndrome virus]]></TERM><TERM><![CDATA[public health relevance]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Research Personnel]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Smallpox]]></TERM><TERM><![CDATA[Speed (motion)]]></TERM><TERM><![CDATA[Structural Biologist]]></TERM><TERM><![CDATA[structural biology]]></TERM><TERM><![CDATA[symposium]]></TERM><TERM><![CDATA[Systems Biology]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[United States National Institutes of Health]]></TERM><TERM><![CDATA[Universities]]></TERM><TERM><![CDATA[Update]]></TERM><TERM><![CDATA[Vaccination]]></TERM><TERM><![CDATA[vaccine delivery]]></TERM><TERM><![CDATA[vaccine development]]></TERM><TERM><![CDATA[Vaccines]]></TERM><TERM><![CDATA[vaccinology]]></TERM><TERM><![CDATA[virology]]></TERM><TERM><![CDATA[Virus]]></TERM><TERM><![CDATA[web site]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Vaccines Against Antigenically Variable Viruses Symposium]]></PROJECT_TITLE><SERIAL_NUMBER>123007</SERIAL_NUMBER><STUDY_SECTION>ZAI1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>01</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>7500</DIRECT_COST_AMT><INDIRECT_COST_AMT>0</INDIRECT_COST_AMT><TOTAL_COST>7500</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9083212</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>AI</ADMINISTERING_IC><APPLICATION_TYPE>2</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/04/2015</AWARD_NOTICE_DATE><BUDGET_START>11/05/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>855</CFDA_CODE><CORE_PROJECT_NUM>R01AI062520</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF PHARMACY]]></ED_INST_TYPE><FOA_NUMBER>PA-13-302</FOA_NUMBER><FULL_PROJECT_NUM>2R01AI062520-10A1</FULL_PROJECT_NUM><FUNDING_ICs>NIAID:412060\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>COLUMBUS</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[OTHER HEALTH PROFESSIONS]]></ORG_DEPT><ORG_DISTRICT>03</ORG_DISTRICT><ORG_DUNS>832127323</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[OHIO STATE UNIVERSITY]]></ORG_NAME><ORG_STATE>OH</ORG_STATE><ORG_ZIPCODE>432101016</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: HIV-1 integrase plays an essential role in viral replication and serves as an important therapeutic target. We propose to investigate structural interactions and multifunctional role of HIV-1 integrase in the virus lifecycle. The findings of our studies will hep us to better understand the mechanism of action of allosteric HIV-1 integrase inhibitors, which are currently in clinical trials, as well as to develop new antiretroviral therapies.      

]]></PHR><PIS><PI><PI_NAME>KVARATSKHELIA, MAMUKA </PI_NAME><PI_ID>7597193</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>SHARMA, OPENDRA K.</PROGRAM_OFFICER_NAME><PROJECT_START>07/01/2004</PROJECT_START><PROJECT_END>10/31/2020</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[Affinity]]></TERM><TERM><![CDATA[antiretroviral therapy]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Binding (Molecular Function)]]></TERM><TERM><![CDATA[Binding Sites]]></TERM><TERM><![CDATA[Biochemical]]></TERM><TERM><![CDATA[Biological]]></TERM><TERM><![CDATA[Biological Assay]]></TERM><TERM><![CDATA[Biology]]></TERM><TERM><![CDATA[biophysical techniques]]></TERM><TERM><![CDATA[Capsid]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Chromatin]]></TERM><TERM><![CDATA[Chromosomes]]></TERM><TERM><![CDATA[Clinical Trials]]></TERM><TERM><![CDATA[Code]]></TERM><TERM><![CDATA[Complementary DNA]]></TERM><TERM><![CDATA[Complex]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[DNA]]></TERM><TERM><![CDATA[Electron Microscopy]]></TERM><TERM><![CDATA[Elements]]></TERM><TERM><![CDATA[Engineering]]></TERM><TERM><![CDATA[Epigenetic Process]]></TERM><TERM><![CDATA[Fractionation]]></TERM><TERM><![CDATA[Funding]]></TERM><TERM><![CDATA[Gagging]]></TERM><TERM><![CDATA[Genes]]></TERM><TERM><![CDATA[Genome]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Histone H3]]></TERM><TERM><![CDATA[HIV-1]]></TERM><TERM><![CDATA[In Vitro]]></TERM><TERM><![CDATA[inhibitor/antagonist]]></TERM><TERM><![CDATA[Integrase]]></TERM><TERM><![CDATA[Integrase Inhibitors]]></TERM><TERM><![CDATA[Knowledge]]></TERM><TERM><![CDATA[Length]]></TERM><TERM><![CDATA[Link]]></TERM><TERM><![CDATA[Mass Spectrum Analysis]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[Membrane]]></TERM><TERM><![CDATA[Morphogenesis]]></TERM><TERM><![CDATA[Mutagenesis]]></TERM><TERM><![CDATA[Mutation]]></TERM><TERM><![CDATA[Nucleoproteins]]></TERM><TERM><![CDATA[Nucleosome Core Particle]]></TERM><TERM><![CDATA[particle]]></TERM><TERM><![CDATA[Phenotype]]></TERM><TERM><![CDATA[Play]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[Protein Footprinting]]></TERM><TERM><![CDATA[Proteins]]></TERM><TERM><![CDATA[public health relevance]]></TERM><TERM><![CDATA[PWWP Domain]]></TERM><TERM><![CDATA[Recombinants]]></TERM><TERM><![CDATA[research study]]></TERM><TERM><![CDATA[Ribonucleoproteins]]></TERM><TERM><![CDATA[RNA]]></TERM><TERM><![CDATA[RNA Binding]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Site]]></TERM><TERM><![CDATA[Site-Directed Mutagenesis]]></TERM><TERM><![CDATA[Solutions]]></TERM><TERM><![CDATA[Staging]]></TERM><TERM><![CDATA[Structural Models]]></TERM><TERM><![CDATA[Structure]]></TERM><TERM><![CDATA[Sucrose]]></TERM><TERM><![CDATA[Surface]]></TERM><TERM><![CDATA[Tail]]></TERM><TERM><![CDATA[Technology]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[therapeutic target]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[transcriptional coactivator p75]]></TERM><TERM><![CDATA[Viral]]></TERM><TERM><![CDATA[viral DNA]]></TERM><TERM><![CDATA[viral RNA]]></TERM><TERM><![CDATA[Virion]]></TERM><TERM><![CDATA[virology]]></TERM><TERM><![CDATA[Virus]]></TERM><TERM><![CDATA[Virus Replication]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Structure and function of HIV-1 integrase]]></PROJECT_TITLE><SERIAL_NUMBER>062520</SERIAL_NUMBER><STUDY_SECTION>ZRG1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>10</SUPPORT_YEAR><SUFFIX>A1</SUFFIX><DIRECT_COST_AMT>269500</DIRECT_COST_AMT><INDIRECT_COST_AMT>142560</INDIRECT_COST_AMT><TOTAL_COST>412060</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9136276</APPLICATION_ID><ACTIVITY>P30</ACTIVITY><ADMINISTERING_IC>DK</ADMINISTERING_IC><APPLICATION_TYPE>6</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/03/2015</AWARD_NOTICE_DATE><BUDGET_START>09/01/2015</BUDGET_START><BUDGET_END>03/31/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>P30DK020541</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-DK-13-004</FOA_NUMBER><FULL_PROJECT_NUM>6P30DK020541-39</FULL_PROJECT_NUM><FUNDING_ICs>NIDDK:163009\</FUNDING_ICs><FUNDING_MECHANISM>RESEARCH CENTERS</FUNDING_MECHANISM><FY>2015</FY><IC_NAME>NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES</IC_NAME><NIH_SPENDING_CATS><CATEGORY><![CDATA[Bioengineering]]></CATEGORY><CATEGORY><![CDATA[Diabetes]]></CATEGORY><CATEGORY><![CDATA[Diagnostic Radiology]]></CATEGORY><CATEGORY><![CDATA[Digestive Diseases]]></CATEGORY><CATEGORY><![CDATA[Neurosciences]]></CATEGORY><CATEGORY><![CDATA[Nutrition]]></CATEGORY><CATEGORY><![CDATA[Obesity]]></CATEGORY></NIH_SPENDING_CATS><ORG_CITY>BRONX</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>14</ORG_DISTRICT><ORG_DUNS>079783367</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[ALBERT EINSTEIN COLLEGE OF MEDICINE]]></ORG_NAME><ORG_STATE>NY</ORG_STATE><ORG_ZIPCODE>104611975</ORG_ZIPCODE><PHR><![CDATA[The Animal Physiology Core provides cost effective, high quality resources that facilitate the scientific progress 
made by a large group of scientists committed to improving our understanding of the integrative physiology of 
diabetes in order to improve the treatment of patients with diabetes.]]></PHR><PIS><PI><PI_NAME>SCHWARTZ, GARY J</PI_NAME><PI_ID>6361245</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START></PROJECT_START><PROJECT_END></PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Adipose tissue]]></TERM><TERM><![CDATA[Animals]]></TERM><TERM><![CDATA[Awareness]]></TERM><TERM><![CDATA[bariatric surgery]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Behavior]]></TERM><TERM><![CDATA[Behavioral]]></TERM><TERM><![CDATA[blood glucose regulation]]></TERM><TERM><![CDATA[Brain]]></TERM><TERM><![CDATA[Carbohydrates]]></TERM><TERM><![CDATA[Cardiac]]></TERM><TERM><![CDATA[Circadian Rhythms]]></TERM><TERM><![CDATA[Complications of Diabetes Mellitus]]></TERM><TERM><![CDATA[Core Facility]]></TERM><TERM><![CDATA[cost effective]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Denervation]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[detection of nutrient]]></TERM><TERM><![CDATA[Diabetes Mellitus]]></TERM><TERM><![CDATA[Diet]]></TERM><TERM><![CDATA[diet and exercise]]></TERM><TERM><![CDATA[Drug or chemical Tissue Distribution]]></TERM><TERM><![CDATA[Eating]]></TERM><TERM><![CDATA[energy balance]]></TERM><TERM><![CDATA[Energy Metabolism]]></TERM><TERM><![CDATA[Exercise]]></TERM><TERM><![CDATA[Experimental Animal Model]]></TERM><TERM><![CDATA[Experimental Models]]></TERM><TERM><![CDATA[fatty acid metabolism]]></TERM><TERM><![CDATA[fatty acid oxidation]]></TERM><TERM><![CDATA[Feeding behaviors]]></TERM><TERM><![CDATA[Functional Magnetic Resonance Imaging]]></TERM><TERM><![CDATA[Gastric Bypass]]></TERM><TERM><![CDATA[gastrointestinal]]></TERM><TERM><![CDATA[Gastrointestinal tract structure]]></TERM><TERM><![CDATA[Glucose]]></TERM><TERM><![CDATA[glucose metabolism]]></TERM><TERM><![CDATA[glucose tolerance]]></TERM><TERM><![CDATA[Glycogen]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Homeostasis]]></TERM><TERM><![CDATA[Hyperglycemia]]></TERM><TERM><![CDATA[Image Analysis]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[Indirect Calorimetry]]></TERM><TERM><![CDATA[innovation]]></TERM><TERM><![CDATA[Instruction]]></TERM><TERM><![CDATA[Insulin]]></TERM><TERM><![CDATA[insulin sensitivity]]></TERM><TERM><![CDATA[intrahepatic]]></TERM><TERM><![CDATA[Laboratories]]></TERM><TERM><![CDATA[Light]]></TERM><TERM><![CDATA[Lipids]]></TERM><TERM><![CDATA[Liver]]></TERM><TERM><![CDATA[Magnetic Resonance Spectroscopy]]></TERM><TERM><![CDATA[Measurement]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[Metabolic]]></TERM><TERM><![CDATA[metabolic abnormality assessment]]></TERM><TERM><![CDATA[Metabolism]]></TERM><TERM><![CDATA[Methodology]]></TERM><TERM><![CDATA[Mission]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[Motor Activity]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[Muscle]]></TERM><TERM><![CDATA[Mutation]]></TERM><TERM><![CDATA[Neuraxis]]></TERM><TERM><![CDATA[NMR Spectroscopy]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[Obesity]]></TERM><TERM><![CDATA[Operative Surgical Procedures]]></TERM><TERM><![CDATA[Pancreas]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Performance]]></TERM><TERM><![CDATA[Phenotype]]></TERM><TERM><![CDATA[Physiological]]></TERM><TERM><![CDATA[Physiology]]></TERM><TERM><![CDATA[Play]]></TERM><TERM><![CDATA[Postdoctoral Fellow]]></TERM><TERM><![CDATA[Procedures]]></TERM><TERM><![CDATA[Productivity]]></TERM><TERM><![CDATA[Rattus]]></TERM><TERM><![CDATA[Recording of previous events]]></TERM><TERM><![CDATA[Regulation]]></TERM><TERM><![CDATA[relating to nervous system]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Research Methodology]]></TERM><TERM><![CDATA[Research Personnel]]></TERM><TERM><![CDATA[Resources]]></TERM><TERM><![CDATA[Rodent]]></TERM><TERM><![CDATA[Rodent Model]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Scanning]]></TERM><TERM><![CDATA[Schedule]]></TERM><TERM><![CDATA[Scientist]]></TERM><TERM><![CDATA[Services]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[Skeletal muscle structure]]></TERM><TERM><![CDATA[Students]]></TERM><TERM><![CDATA[Surgical Models]]></TERM><TERM><![CDATA[Systems Biology]]></TERM><TERM><![CDATA[Techniques]]></TERM><TERM><![CDATA[Temperature]]></TERM><TERM><![CDATA[Thermogenesis]]></TERM><TERM><![CDATA[Tissues]]></TERM><TERM><![CDATA[tool]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Animal Physiology Core]]></PROJECT_TITLE><SERIAL_NUMBER>020541</SERIAL_NUMBER><STUDY_SECTION>ZDK1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID>7652</SUBPROJECT_ID><SUPPORT_YEAR>39</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>97610</DIRECT_COST_AMT><INDIRECT_COST_AMT>65399</INDIRECT_COST_AMT><TOTAL_COST /><TOTAL_COST_SUB_PROJECT>163009</TOTAL_COST_SUB_PROJECT></row>
<row><APPLICATION_ID>9146699</APPLICATION_ID><ACTIVITY>U51</ACTIVITY><ADMINISTERING_IC>PS</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/22/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>U51PS004031</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-PS-13-303</FOA_NUMBER><FULL_PROJECT_NUM>5U51PS004031-04</FULL_PROJECT_NUM><FUNDING_ICs>NCHHSTP:47383\</FUNDING_ICs><FUNDING_MECHANISM>OTHERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP)</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>MONTGOMERY</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>02</ORG_DISTRICT><ORG_DUNS>613842061</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[ALABAMA STATE DEPT OF PUBLIC HEALTH]]></ORG_NAME><ORG_STATE>AL</ORG_STATE><ORG_ZIPCODE>361043735</ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>MCINTYRE, MARY </PI_NAME><PI_ID>11412862</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>11/01/2012</PROJECT_START><PROJECT_END>10/31/2016</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[ALABAMA ADULT VIRAL HEPATITIS PREVENTION AND CONTROL PROJECT]]></PROJECT_TITLE><SERIAL_NUMBER>004031</SERIAL_NUMBER><STUDY_SECTION>ZPS1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>04</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>47383</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9146914</APPLICATION_ID><ACTIVITY>U51</ACTIVITY><ADMINISTERING_IC>PS</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/23/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>U51PS004042</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-PS-13-303</FOA_NUMBER><FULL_PROJECT_NUM>5U51PS004042-04</FULL_PROJECT_NUM><FUNDING_ICs>NCHHSTP:250750\</FUNDING_ICs><FUNDING_MECHANISM>OTHERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP)</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>TALLAHASSEE</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>02</ORG_DISTRICT><ORG_DUNS>364215061</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[FLORIDA STATE DEPARTMENT OF HEALTH]]></ORG_NAME><ORG_STATE>FL</ORG_STATE><ORG_ZIPCODE>323997017</ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>REICHERT, PHILIP </PI_NAME><PI_ID>11535416</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>11/01/2012</PROJECT_START><PROJECT_END>10/31/2016</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[FLORIDA ADULT VIRAL HEPATITIS PREVENTION & SURVEILLANCE PROJECY=T]]></PROJECT_TITLE><SERIAL_NUMBER>004042</SERIAL_NUMBER><STUDY_SECTION>ZPS1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>04</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>250750</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9146934</APPLICATION_ID><ACTIVITY>U51</ACTIVITY><ADMINISTERING_IC>PS</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/23/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>U51PS004069</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-PS-13-303</FOA_NUMBER><FULL_PROJECT_NUM>5U51PS004069-04</FULL_PROJECT_NUM><FUNDING_ICs>NCHHSTP:15750\</FUNDING_ICs><FUNDING_MECHANISM>OTHERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP)</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>HELENA</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>00</ORG_DISTRICT><ORG_DUNS>051659352</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[MONTANA STATE DEPT/PUB HLTH & HUMAN SRVS]]></ORG_NAME><ORG_STATE>MT</ORG_STATE><ORG_ZIPCODE>596014520</ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>NIELSEN, JUDY </PI_NAME><PI_ID>12479578</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>11/01/2012</PROJECT_START><PROJECT_END>10/31/2016</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[Viral Hepatitis - Prevention and Surveillance]]></PROJECT_TITLE><SERIAL_NUMBER>004069</SERIAL_NUMBER><STUDY_SECTION>ZPS1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>04</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>15750</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9146935</APPLICATION_ID><ACTIVITY>U51</ACTIVITY><ADMINISTERING_IC>PS</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/23/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>U51PS004070</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-PS-13-303</FOA_NUMBER><FULL_PROJECT_NUM>5U51PS004070-04</FULL_PROJECT_NUM><FUNDING_ICs>NCHHSTP:55695\</FUNDING_ICs><FUNDING_MECHANISM>OTHERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP)</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>JACKSON</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>02</ORG_DISTRICT><ORG_DUNS>809399892</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[MISSISSIPPI STATE DEPARTMENT OF HEALTH]]></ORG_NAME><ORG_STATE>MS</ORG_STATE><ORG_ZIPCODE>392164538</ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>SENNETT, DEBORAH JOY</PI_NAME><PI_ID>9160505</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>11/01/2012</PROJECT_START><PROJECT_END>10/31/2016</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[VIRAL HEPATITIS - PREVENTION AND SURVEILLANCE]]></PROJECT_TITLE><SERIAL_NUMBER>004070</SERIAL_NUMBER><STUDY_SECTION>ZPS1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>04</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>55695</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9148091</APPLICATION_ID><ACTIVITY>U51</ACTIVITY><ADMINISTERING_IC>PS</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/26/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>U51PS004098</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-PS-13-303</FOA_NUMBER><FULL_PROJECT_NUM>5U51PS004098-04</FULL_PROJECT_NUM><FUNDING_ICs>NCHHSTP:32579\</FUNDING_ICs><FUNDING_MECHANISM>OTHERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP)</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>COLUMBIA</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>06</ORG_DISTRICT><ORG_DUNS>808385892</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[SC STATE DEPT/HEALTH/ENVIRONMENTAL CONTR]]></ORG_NAME><ORG_STATE>SC</ORG_STATE><ORG_ZIPCODE>292011708</ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>DAGUISE, VIRGINIE </PI_NAME><PI_ID>14251732</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>11/01/2012</PROJECT_START><PROJECT_END>10/31/2016</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[Viral Hepatitis - Prevention and Surveillance]]></PROJECT_TITLE><SERIAL_NUMBER>004098</SERIAL_NUMBER><STUDY_SECTION>ZPS1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>04</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>32579</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9149056</APPLICATION_ID><ACTIVITY>U51</ACTIVITY><ADMINISTERING_IC>PS</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/26/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>U51PS004073</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-PS-13-303</FOA_NUMBER><FULL_PROJECT_NUM>5U51PS004073-04</FULL_PROJECT_NUM><FUNDING_ICs>NCHHSTP:70878\</FUNDING_ICs><FUNDING_MECHANISM>OTHERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP)</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>HARRISBURG</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>04</ORG_DISTRICT><ORG_DUNS>614489839</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[PENNSYLVANIA STATE DEPT OF HEALTH]]></ORG_NAME><ORG_STATE>PA</ORG_STATE><ORG_ZIPCODE>171200701</ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>NAMBIAR, ATMARAM M.</PI_NAME><PI_ID>12679342</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>11/01/2012</PROJECT_START><PROJECT_END>10/31/2016</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[VIRAL HEPATITIS PREVENTION AND SURVEILLANCE]]></PROJECT_TITLE><SERIAL_NUMBER>004073</SERIAL_NUMBER><STUDY_SECTION>ZPS1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>04</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>70878</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9149059</APPLICATION_ID><ACTIVITY>U51</ACTIVITY><ADMINISTERING_IC>PS</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/26/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>U51PS004081</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-PS-13-303</FOA_NUMBER><FULL_PROJECT_NUM>5U51PS004081-04</FULL_PROJECT_NUM><FUNDING_ICs>NCHHSTP:28951\</FUNDING_ICs><FUNDING_MECHANISM>OTHERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP)</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>CHARLESTON</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>02</ORG_DISTRICT><ORG_DUNS>140779708</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[WEST VIRGINIA STATE DEPT HLTH/HUMAN RSCS]]></ORG_NAME><ORG_STATE>WV</ORG_STATE><ORG_ZIPCODE>253011745</ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>HADDY, LORETTA </PI_NAME><PI_ID>11518710</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>11/01/2012</PROJECT_START><PROJECT_END>10/31/2016</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[VIRAL HEPATITIS - PREVENTION AND SURVEILLANCE]]></PROJECT_TITLE><SERIAL_NUMBER>004081</SERIAL_NUMBER><STUDY_SECTION>ZPS1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>04</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>28951</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9149065</APPLICATION_ID><ACTIVITY>U51</ACTIVITY><ADMINISTERING_IC>PS</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/28/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>U51PS004091</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-PS-13-303</FOA_NUMBER><FULL_PROJECT_NUM>5U51PS004091-04</FULL_PROJECT_NUM><FUNDING_ICs>NCHHSTP:288855\</FUNDING_ICs><FUNDING_MECHANISM>OTHERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP)</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>TUMWATER</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>10</ORG_DISTRICT><ORG_DUNS>808883128</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[WASHINGTON STATE DEPARTMENT OF HEALTH]]></ORG_NAME><ORG_STATE>WA</ORG_STATE><ORG_ZIPCODE>985015570</ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>STOCKTON, JON </PI_NAME><PI_ID>14169403</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>11/01/2012</PROJECT_START><PROJECT_END>10/31/2016</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[VIRAL HEPATITIS-PREVENTION & SURVEILLANCE]]></PROJECT_TITLE><SERIAL_NUMBER>004091</SERIAL_NUMBER><STUDY_SECTION>ZPS1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>04</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>288855</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9170045</APPLICATION_ID><ACTIVITY>R43</ACTIVITY><ADMINISTERING_IC>AT</ADMINISTERING_IC><APPLICATION_TYPE>3</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/06/2015</AWARD_NOTICE_DATE><BUDGET_START>09/30/2006</BUDGET_START><BUDGET_END>11/30/2015</BUDGET_END><CFDA_CODE>213</CFDA_CODE><CORE_PROJECT_NUM>R43AT004071</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-AT-06-003</FOA_NUMBER><FULL_PROJECT_NUM>3R43AT004071-01S3</FULL_PROJECT_NUM><FUNDING_ICs>NCCIH:76099\</FUNDING_ICs><FUNDING_MECHANISM>SBIR-STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL CENTER FOR COMPLEMENTARY &amp; INTEGRATIVE HEALTH</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>Boston</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>07</ORG_DISTRICT><ORG_DUNS>111487588</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[METIS DESIGN CORPORATION]]></ORG_NAME><ORG_STATE>MA</ORG_STATE><ORG_ZIPCODE>02114</ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>NARAYANASWAMI, RANGA </PI_NAME><PI_ID>8232573</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>KHALSA, PARTAP SINGH</PROGRAM_OFFICER_NAME><PROJECT_START>09/30/2006</PROJECT_START><PROJECT_END>11/30/2015</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Affective]]></TERM><TERM><![CDATA[alternative treatment]]></TERM><TERM><![CDATA[American]]></TERM><TERM><![CDATA[Attention]]></TERM><TERM><![CDATA[Clinical Research]]></TERM><TERM><![CDATA[Clinical Trials]]></TERM><TERM><![CDATA[Computer Assisted]]></TERM><TERM><![CDATA[cost]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Data Collection]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[Devices]]></TERM><TERM><![CDATA[diaries]]></TERM><TERM><![CDATA[Dimensions]]></TERM><TERM><![CDATA[Electronics]]></TERM><TERM><![CDATA[experience]]></TERM><TERM><![CDATA[forest]]></TERM><TERM><![CDATA[Frequencies (time pattern)]]></TERM><TERM><![CDATA[Future]]></TERM><TERM><![CDATA[Galvanic Skin Response]]></TERM><TERM><![CDATA[Genitourinary system]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Hot flushes]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[instrument]]></TERM><TERM><![CDATA[Interview]]></TERM><TERM><![CDATA[Life]]></TERM><TERM><![CDATA[Measures]]></TERM><TERM><![CDATA[medical schools]]></TERM><TERM><![CDATA[Menopausal Symptom]]></TERM><TERM><![CDATA[menopausal symptomatology]]></TERM><TERM><![CDATA[Menopause]]></TERM><TERM><![CDATA[Monitor]]></TERM><TERM><![CDATA[Night Sweating]]></TERM><TERM><![CDATA[Patient Self-Report]]></TERM><TERM><![CDATA[Questionnaires]]></TERM><TERM><![CDATA[Records]]></TERM><TERM><![CDATA[Science]]></TERM><TERM><![CDATA[Symptoms]]></TERM><TERM><![CDATA[System]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[time use]]></TERM><TERM><![CDATA[United States National Institutes of Health]]></TERM><TERM><![CDATA[Universities]]></TERM><TERM><![CDATA[Vasomotor]]></TERM><TERM><![CDATA[Woman]]></TERM><TERM><![CDATA[Women's Health]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[WHFM/MS-DIARY: An Integrated Wearable Hot Flash Monitor and Portable Electronic D]]></PROJECT_TITLE><SERIAL_NUMBER>004071</SERIAL_NUMBER><STUDY_SECTION>ZAT1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>01</SUPPORT_YEAR><SUFFIX>S3</SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>76099</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9172469</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>HL</ADMINISTERING_IC><APPLICATION_TYPE>6</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/05/2015</AWARD_NOTICE_DATE><BUDGET_START>11/05/2015</BUDGET_START><BUDGET_END>03/31/2016</BUDGET_END><CFDA_CODE>837</CFDA_CODE><CORE_PROJECT_NUM>R01HL118437</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>PA-11-260</FOA_NUMBER><FULL_PROJECT_NUM>6R01HL118437-03</FULL_PROJECT_NUM><FUNDING_ICs>NHLBI:239888\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2015</FY><IC_NAME>NATIONAL HEART, LUNG, AND BLOOD INSTITUTE</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>BRONX</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>14</ORG_DISTRICT><ORG_DUNS>079783367</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[ALBERT EINSTEIN COLLEGE OF MEDICINE]]></ORG_NAME><ORG_STATE>NY</ORG_STATE><ORG_ZIPCODE>104611975</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Malfunction of hERG ion channels through mutations or drug interactions is a common cause of heart rhythm disturbances with risk for sudden cardiac death. The hERG channel has unique properties that seem to make it susceptible to malfunction that are not completely understood. We hypothesize that some of these properties come from information hidden within the DNA and RNA that has been unexplored. We propose to explore and understand this information and test whether it contributes to malfunction of the channel and risk for heart rhythm disturbance.]]></PHR><PIS><PI><PI_NAME>MCDONALD, THOMAS V</PI_NAME><PI_ID>1858348</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>WANG, LAN-HSIANG </PROGRAM_OFFICER_NAME><PROJECT_START>04/01/2014</PROJECT_START><PROJECT_END>03/31/2018</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[Amino Acid Sequence]]></TERM><TERM><![CDATA[Amino Acids]]></TERM><TERM><![CDATA[Anabolism]]></TERM><TERM><![CDATA[Area]]></TERM><TERM><![CDATA[Arrhythmia]]></TERM><TERM><![CDATA[Biochemical]]></TERM><TERM><![CDATA[Cell surface]]></TERM><TERM><![CDATA[Characteristics]]></TERM><TERM><![CDATA[Code]]></TERM><TERM><![CDATA[Codon Nucleotides]]></TERM><TERM><![CDATA[Complementary DNA]]></TERM><TERM><![CDATA[Complex]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Death, Sudden, Cardiac]]></TERM><TERM><![CDATA[deep sequencing]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[Diagnostic]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[DNA]]></TERM><TERM><![CDATA[Drug Interactions]]></TERM><TERM><![CDATA[Elements]]></TERM><TERM><![CDATA[Employee Strikes]]></TERM><TERM><![CDATA[Exhibits]]></TERM><TERM><![CDATA[Gene Expression]]></TERM><TERM><![CDATA[genetic variant]]></TERM><TERM><![CDATA[Guanine + Cytosine Composition]]></TERM><TERM><![CDATA[heart rhythm]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[Inherited]]></TERM><TERM><![CDATA[Investigation]]></TERM><TERM><![CDATA[Ion Channel]]></TERM><TERM><![CDATA[Kinetics]]></TERM><TERM><![CDATA[Knowledge]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[Light]]></TERM><TERM><![CDATA[Link]]></TERM><TERM><![CDATA[Locales]]></TERM><TERM><![CDATA[Long QT Syndrome]]></TERM><TERM><![CDATA[Messenger RNA]]></TERM><TERM><![CDATA[Missense Mutation]]></TERM><TERM><![CDATA[Modification]]></TERM><TERM><![CDATA[Molecular Chaperones]]></TERM><TERM><![CDATA[mutant]]></TERM><TERM><![CDATA[Mutation]]></TERM><TERM><![CDATA[Nature]]></TERM><TERM><![CDATA[Pathogenesis]]></TERM><TERM><![CDATA[Pharmaceutical Preparations]]></TERM><TERM><![CDATA[Play]]></TERM><TERM><![CDATA[Potassium Channel]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[Property]]></TERM><TERM><![CDATA[Protein Biosynthesis]]></TERM><TERM><![CDATA[protein folding]]></TERM><TERM><![CDATA[Proteins]]></TERM><TERM><![CDATA[public health relevance]]></TERM><TERM><![CDATA[Regulation]]></TERM><TERM><![CDATA[Reporting]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Risk]]></TERM><TERM><![CDATA[RNA]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[stem]]></TERM><TERM><![CDATA[Stress]]></TERM><TERM><![CDATA[Structure]]></TERM><TERM><![CDATA[Syndrome]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Therapeutic]]></TERM><TERM><![CDATA[trafficking]]></TERM><TERM><![CDATA[Translations]]></TERM><TERM><![CDATA[Untranslated Regions]]></TERM><TERM><![CDATA[Untranslated RNA]]></TERM><TERM><![CDATA[Variant]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Functional Implications of non-coding data in HERG-mRNA]]></PROJECT_TITLE><SERIAL_NUMBER>118437</SERIAL_NUMBER><STUDY_SECTION>ESTA</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Electrical Signaling, Ion Transport, and Arrhythmias Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>03</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>143646</DIRECT_COST_AMT><INDIRECT_COST_AMT>96242</INDIRECT_COST_AMT><TOTAL_COST>239888</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9172478</APPLICATION_ID><ACTIVITY>F30</ACTIVITY><ADMINISTERING_IC>HL</ADMINISTERING_IC><APPLICATION_TYPE>6</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/05/2015</AWARD_NOTICE_DATE><BUDGET_START>11/05/2015</BUDGET_START><BUDGET_END>07/14/2016</BUDGET_END><CFDA_CODE>837</CFDA_CODE><CORE_PROJECT_NUM>F30HL122085</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>PA-11-110</FOA_NUMBER><FULL_PROJECT_NUM>6F30HL122085-03</FULL_PROJECT_NUM><FUNDING_ICs>NHLBI:42105\</FUNDING_ICs><FUNDING_MECHANISM>TRAINING, INDIVIDUAL</FUNDING_MECHANISM><FY>2015</FY><IC_NAME>NATIONAL HEART, LUNG, AND BLOOD INSTITUTE</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>BRONX</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>14</ORG_DISTRICT><ORG_DUNS>079783367</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[ALBERT EINSTEIN COLLEGE OF MEDICINE]]></ORG_NAME><ORG_STATE>NY</ORG_STATE><ORG_ZIPCODE>104611975</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: The goal of this project is to understand the functions of the apoptosis repressor with caspase recruitment domain (ARC) in normal hematopoietic differentiation and the pathogenesis of myeloproliferative neoplasms. To characterize the roles of ARC in lineage commitment of stem and progenitor cells, as well as in myeloid differentiation and myeloproliferative neoplasms, we will utilize genetic murine models, stem cell transplantation assays and restoration of ARC levels in in vitro and in vivo functional assays. To elucidate the molecular consequences of ARC-deficiency in hematopoietic stem cells we will use gene expression arrays to identify pathways and genes altered in the absence of ARC.]]></PHR><PIS><PI><PI_NAME>STANLEY, ROBERT </PI_NAME><PI_ID>10603069</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>WELNIAK, LISBETH A</PROGRAM_OFFICER_NAME><PROJECT_START>07/15/2014</PROJECT_START><PROJECT_END>07/14/2016</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[aged]]></TERM><TERM><![CDATA[Anemia]]></TERM><TERM><![CDATA[Apoptosis]]></TERM><TERM><![CDATA[Biological]]></TERM><TERM><![CDATA[Biological Assay]]></TERM><TERM><![CDATA[Blood]]></TERM><TERM><![CDATA[Blood Cells]]></TERM><TERM><![CDATA[Bone Marrow]]></TERM><TERM><![CDATA[Bone Marrow Aspiration]]></TERM><TERM><![CDATA[caspase]]></TERM><TERM><![CDATA[Cell Count]]></TERM><TERM><![CDATA[Cell Death]]></TERM><TERM><![CDATA[Cell Differentiation process]]></TERM><TERM><![CDATA[Cell Line]]></TERM><TERM><![CDATA[Cell Lineage]]></TERM><TERM><![CDATA[Cell physiology]]></TERM><TERM><![CDATA[Cell Proliferation]]></TERM><TERM><![CDATA[Cell Survival]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Characteristics]]></TERM><TERM><![CDATA[congenic]]></TERM><TERM><![CDATA[Critical Pathways]]></TERM><TERM><![CDATA[Cytotoxic Chemotherapy]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Dose]]></TERM><TERM><![CDATA[Exhibits]]></TERM><TERM><![CDATA[Extramedullary Hematopoiesis]]></TERM><TERM><![CDATA[Fibrosis]]></TERM><TERM><![CDATA[Gene Expression]]></TERM><TERM><![CDATA[Genes]]></TERM><TERM><![CDATA[Genetic]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Hematopoiesis]]></TERM><TERM><![CDATA[Hematopoietic]]></TERM><TERM><![CDATA[Hematopoietic Stem Cell Transplantation]]></TERM><TERM><![CDATA[Hematopoietic stem cells]]></TERM><TERM><![CDATA[Hematopoietic System]]></TERM><TERM><![CDATA[Hemorrhagic Thrombocythemia]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[Hyperplasia]]></TERM><TERM><![CDATA[In Vitro]]></TERM><TERM><![CDATA[in vitro Assay]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[Investigation]]></TERM><TERM><![CDATA[Leukemia, Myelocytic, Acute]]></TERM><TERM><![CDATA[Maintenance]]></TERM><TERM><![CDATA[Malignant - descriptor]]></TERM><TERM><![CDATA[Malignant Neoplasms]]></TERM><TERM><![CDATA[Marrow]]></TERM><TERM><![CDATA[Megakaryocytes]]></TERM><TERM><![CDATA[Methylcellulose]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[Mortality Vital Statistics]]></TERM><TERM><![CDATA[mouse model]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[Mutate]]></TERM><TERM><![CDATA[Mutation]]></TERM><TERM><![CDATA[Myelogenous]]></TERM><TERM><![CDATA[Myeloid Cells]]></TERM><TERM><![CDATA[Myeloid Progenitor Cells]]></TERM><TERM><![CDATA[Myeloproliferation]]></TERM><TERM><![CDATA[Myeloproliferative disease]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[Pathogenesis]]></TERM><TERM><![CDATA[Pathway interactions]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Philadelphia Chromosome]]></TERM><TERM><![CDATA[Play]]></TERM><TERM><![CDATA[Polycythemia Vera]]></TERM><TERM><![CDATA[Primary Myelofibrosis]]></TERM><TERM><![CDATA[protein expression]]></TERM><TERM><![CDATA[Regulation]]></TERM><TERM><![CDATA[Regulation of Apoptosis Pathway]]></TERM><TERM><![CDATA[Relapse]]></TERM><TERM><![CDATA[Relative (related person)]]></TERM><TERM><![CDATA[restoration]]></TERM><TERM><![CDATA[Reticulin]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Sampling]]></TERM><TERM><![CDATA[Spleen]]></TERM><TERM><![CDATA[Splenomegaly]]></TERM><TERM><![CDATA[Staining method]]></TERM><TERM><![CDATA[Stains]]></TERM><TERM><![CDATA[stem]]></TERM><TERM><![CDATA[stem cell differentiation]]></TERM><TERM><![CDATA[Stem cell transplant]]></TERM><TERM><![CDATA[Stem cells]]></TERM><TERM><![CDATA[Therapeutic Intervention]]></TERM><TERM><![CDATA[Thrombocytopenia]]></TERM><TERM><![CDATA[Ursidae Family]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Investigating the role of ARC in hematopoiesis and myeloproliferative neoplasms]]></PROJECT_TITLE><SERIAL_NUMBER>122085</SERIAL_NUMBER><STUDY_SECTION>ZRG1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>03</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>42105</DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>42105</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9172481</APPLICATION_ID><ACTIVITY>U01</ACTIVITY><ADMINISTERING_IC>HL</ADMINISTERING_IC><APPLICATION_TYPE>6</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/06/2015</AWARD_NOTICE_DATE><BUDGET_START>11/06/2015</BUDGET_START><BUDGET_END>04/30/2016</BUDGET_END><CFDA_CODE>837</CFDA_CODE><CORE_PROJECT_NUM>U01HL122998</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-HL-14-014</FOA_NUMBER><FULL_PROJECT_NUM>6U01HL122998-03</FULL_PROJECT_NUM><FUNDING_ICs>NHLBI:183939\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2015</FY><IC_NAME>NATIONAL HEART, LUNG, AND BLOOD INSTITUTE</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>BRONX</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>14</ORG_DISTRICT><ORG_DUNS>079783367</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[ALBERT EINSTEIN COLLEGE OF MEDICINE]]></ORG_NAME><ORG_STATE>NY</ORG_STATE><ORG_ZIPCODE>104611975</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: PETAL represents the first instrumental step towards prevention of acute organ failure that may significantly reduce both the mortality and the comorbidities associated with acute critical illness. The two proposed clinical trials, if proven effective, are cheap and readily available for rapid implementation to improve outcomes for large populations of injured patients. Einstein-PETAL is uniquely and optimally well suited to conduct PETAL trials in a diverse population of patients.]]></PHR><PIS><PI><PI_NAME>GONG, MICHELLE NG (contact)</PI_NAME><PI_ID>6271418 (contact)</PI_ID></PI><PI><PI_NAME>RICHARDSON, LYNNE D</PI_NAME><PI_ID>2414371</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>HARABIN, ANDREA L</PROGRAM_OFFICER_NAME><PROJECT_START>06/17/2014</PROJECT_START><PROJECT_END>04/30/2021</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Accident and Emergency department]]></TERM><TERM><![CDATA[Acute]]></TERM><TERM><![CDATA[Adult]]></TERM><TERM><![CDATA[Adult Respiratory Distress Syndrome]]></TERM><TERM><![CDATA[Aspiration Pneumonia]]></TERM><TERM><![CDATA[Aspirin]]></TERM><TERM><![CDATA[Beds]]></TERM><TERM><![CDATA[Caring]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[Clinical Nurse Specialists]]></TERM><TERM><![CDATA[Clinical Research]]></TERM><TERM><![CDATA[Clinical Services]]></TERM><TERM><![CDATA[Clinical Trials]]></TERM><TERM><![CDATA[Collaborations]]></TERM><TERM><![CDATA[college]]></TERM><TERM><![CDATA[Communication]]></TERM><TERM><![CDATA[Comorbidity]]></TERM><TERM><![CDATA[Complication]]></TERM><TERM><![CDATA[Computerized Medical Record]]></TERM><TERM><![CDATA[Country]]></TERM><TERM><![CDATA[Coupled]]></TERM><TERM><![CDATA[Critical Care]]></TERM><TERM><![CDATA[Critical Illness]]></TERM><TERM><![CDATA[Data Collection]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Discipline]]></TERM><TERM><![CDATA[Double-Blind Method]]></TERM><TERM><![CDATA[Early identification]]></TERM><TERM><![CDATA[Early Intervention]]></TERM><TERM><![CDATA[Electronics]]></TERM><TERM><![CDATA[Emergency Medicine]]></TERM><TERM><![CDATA[Emergency Situation]]></TERM><TERM><![CDATA[Enrollment]]></TERM><TERM><![CDATA[experience]]></TERM><TERM><![CDATA[functional outcomes]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[high risk]]></TERM><TERM><![CDATA[Hospitals]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[Informatics]]></TERM><TERM><![CDATA[injured]]></TERM><TERM><![CDATA[Injury]]></TERM><TERM><![CDATA[injury prevention]]></TERM><TERM><![CDATA[Institutes]]></TERM><TERM><![CDATA[Institution]]></TERM><TERM><![CDATA[Intensive Care Units]]></TERM><TERM><![CDATA[Leadership]]></TERM><TERM><![CDATA[lung injury]]></TERM><TERM><![CDATA[Medical]]></TERM><TERM><![CDATA[Medical center]]></TERM><TERM><![CDATA[Medicine]]></TERM><TERM><![CDATA[Monitor]]></TERM><TERM><![CDATA[Mortality Vital Statistics]]></TERM><TERM><![CDATA[multidisciplinary]]></TERM><TERM><![CDATA[New York City]]></TERM><TERM><![CDATA[operation]]></TERM><TERM><![CDATA[Operative Surgical Procedures]]></TERM><TERM><![CDATA[Organ failure]]></TERM><TERM><![CDATA[Outcome]]></TERM><TERM><![CDATA[Pancreatitis]]></TERM><TERM><![CDATA[Patient Recruitments]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Phase]]></TERM><TERM><![CDATA[Placebo Control]]></TERM><TERM><![CDATA[Pneumonia]]></TERM><TERM><![CDATA[Population]]></TERM><TERM><![CDATA[Population Heterogeneity]]></TERM><TERM><![CDATA[Population Study]]></TERM><TERM><![CDATA[prevent]]></TERM><TERM><![CDATA[Prevention]]></TERM><TERM><![CDATA[Prevention Research]]></TERM><TERM><![CDATA[Procedures]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[public health relevance]]></TERM><TERM><![CDATA[Randomized Controlled Trials]]></TERM><TERM><![CDATA[Research Infrastructure]]></TERM><TERM><![CDATA[Research Support]]></TERM><TERM><![CDATA[Resources]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[Risk]]></TERM><TERM><![CDATA[sample collection]]></TERM><TERM><![CDATA[screening]]></TERM><TERM><![CDATA[Sepsis]]></TERM><TERM><![CDATA[Services]]></TERM><TERM><![CDATA[Site]]></TERM><TERM><![CDATA[Standardization]]></TERM><TERM><![CDATA[success]]></TERM><TERM><![CDATA[Surgical Intensive Care]]></TERM><TERM><![CDATA[Survivors]]></TERM><TERM><![CDATA[System]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Transfusion]]></TERM><TERM><![CDATA[Translational Research]]></TERM><TERM><![CDATA[University Hospitals]]></TERM><TERM><![CDATA[Visit]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Einstein PETAL: Clinical Center for the PETAL Network]]></PROJECT_TITLE><SERIAL_NUMBER>122998</SERIAL_NUMBER><STUDY_SECTION>ZHL1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>03</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>128960</DIRECT_COST_AMT><INDIRECT_COST_AMT>54979</INDIRECT_COST_AMT><TOTAL_COST>183939</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8959619</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>AI</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/27/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>855</CFDA_CODE><CORE_PROJECT_NUM>R01AI116059</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-13-302</FOA_NUMBER><FULL_PROJECT_NUM>5R01AI116059-02</FULL_PROJECT_NUM><FUNDING_ICs>NIAID:399847\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>STANFORD</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[MICROBIOLOGY/IMMUN/VIROLOGY]]></ORG_DEPT><ORG_DISTRICT>18</ORG_DISTRICT><ORG_DUNS>009214214</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[STANFORD UNIVERSITY]]></ORG_NAME><ORG_STATE>CA</ORG_STATE><ORG_ZIPCODE>943041222</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: The proposed research is relevant to public health. An increased understanding of the mechanisms that lead to persistent Salmonella infections within macrophages and the gastrointestinal tract will lead to novel therapeutic avenues. Thus, the proposed research is relevant to NIH's mission that pertains to developing fundamental knowledge to reduce the burdens of human infectious disease.]]></PHR><PIS><PI><PI_NAME>MONACK, DENISE </PI_NAME><PI_ID>3124667</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>ALEXANDER, WILLIAM A.</PROGRAM_OFFICER_NAME><PROJECT_START>11/01/2014</PROJECT_START><PROJECT_END>10/31/2019</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Automobile Driving]]></TERM><TERM><![CDATA[Bacterial Infections]]></TERM><TERM><![CDATA[Binding (Molecular Function)]]></TERM><TERM><![CDATA[Biochemical]]></TERM><TERM><![CDATA[Carrier State]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Chronic]]></TERM><TERM><![CDATA[commensal microbes]]></TERM><TERM><![CDATA[Communicable Diseases]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Disease Reservoirs]]></TERM><TERM><![CDATA[Environment]]></TERM><TERM><![CDATA[Epithelial Cells]]></TERM><TERM><![CDATA[fatty acid metabolism]]></TERM><TERM><![CDATA[Fatty Acids]]></TERM><TERM><![CDATA[Gastrointestinal tract structure]]></TERM><TERM><![CDATA[Gene Expression]]></TERM><TERM><![CDATA[Genes]]></TERM><TERM><![CDATA[Genetic]]></TERM><TERM><![CDATA[Germ-Free]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[Immune]]></TERM><TERM><![CDATA[Immunity]]></TERM><TERM><![CDATA[Infection]]></TERM><TERM><![CDATA[Inflammation]]></TERM><TERM><![CDATA[Inflammatory]]></TERM><TERM><![CDATA[Integration Host Factors]]></TERM><TERM><![CDATA[Intestines]]></TERM><TERM><![CDATA[Knowledge]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[Ligands]]></TERM><TERM><![CDATA[macrophage]]></TERM><TERM><![CDATA[Measures]]></TERM><TERM><![CDATA[member]]></TERM><TERM><![CDATA[Messenger RNA]]></TERM><TERM><![CDATA[Metabolic]]></TERM><TERM><![CDATA[Metabolic Pathway]]></TERM><TERM><![CDATA[microbial]]></TERM><TERM><![CDATA[Mission]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[mouse model]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[Nature]]></TERM><TERM><![CDATA[novel therapeutics]]></TERM><TERM><![CDATA[Nuclear]]></TERM><TERM><![CDATA[pathogen]]></TERM><TERM><![CDATA[Pathogenesis]]></TERM><TERM><![CDATA[Pathway interactions]]></TERM><TERM><![CDATA[Peroxisome Proliferator-Activated Receptors]]></TERM><TERM><![CDATA[Physiological]]></TERM><TERM><![CDATA[Play]]></TERM><TERM><![CDATA[PPAR delta]]></TERM><TERM><![CDATA[Preventive]]></TERM><TERM><![CDATA[Preventive Intervention]]></TERM><TERM><![CDATA[programs]]></TERM><TERM><![CDATA[Proteins]]></TERM><TERM><![CDATA[public health medicine (field)]]></TERM><TERM><![CDATA[Relative (related person)]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Research Proposals]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Salmonella]]></TERM><TERM><![CDATA[Salmonella enterica]]></TERM><TERM><![CDATA[Salmonella infections]]></TERM><TERM><![CDATA[Salmonella typhi]]></TERM><TERM><![CDATA[Salmonella typhimurium]]></TERM><TERM><![CDATA[Signal Pathway]]></TERM><TERM><![CDATA[Systemic infection]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Therapeutic]]></TERM><TERM><![CDATA[Therapeutic Intervention]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[transmission process]]></TERM><TERM><![CDATA[Transplantation]]></TERM><TERM><![CDATA[Up-Regulation (Physiology)]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Mechanisms of persistent Salmonella infection]]></PROJECT_TITLE><SERIAL_NUMBER>116059</SERIAL_NUMBER><STUDY_SECTION>ZRG1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>250000</DIRECT_COST_AMT><INDIRECT_COST_AMT>149847</INDIRECT_COST_AMT><TOTAL_COST>399847</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8959920</APPLICATION_ID><ACTIVITY>R21</ACTIVITY><ADMINISTERING_IC>AI</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/27/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>855</CFDA_CODE><CORE_PROJECT_NUM>R21AI115194</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>PA-13-303</FOA_NUMBER><FULL_PROJECT_NUM>5R21AI115194-02</FULL_PROJECT_NUM><FUNDING_ICs>NIAID:211960\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>SEATTLE</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>07</ORG_DISTRICT><ORG_DUNS>070967955</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[SEATTLE BIOMEDICAL RESEARCH INSTITUTE]]></ORG_NAME><ORG_STATE>WA</ORG_STATE><ORG_ZIPCODE>981095240</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: We have developed a human-liver chimeric mouse model that can be utilized to perform experimental Plasmodium falciparum genetic crosses. Crosses are a methodology used to determine the genetic basis of observed phenotypes and this model could place high throughput malaria genetic research within reach.]]></PHR><PIS><PI><PI_NAME>VAUGHAN, ASHLEY MICHAEL</PI_NAME><PI_ID>8871487</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>JOY, DEIRDRE A.</PROGRAM_OFFICER_NAME><PROJECT_START>11/01/2014</PROJECT_START><PROJECT_END>10/31/2016</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Anopheles Genus]]></TERM><TERM><![CDATA[Anti-malarial drug resistance]]></TERM><TERM><![CDATA[Antimalarials]]></TERM><TERM><![CDATA[artemisinine]]></TERM><TERM><![CDATA[Artemisinins]]></TERM><TERM><![CDATA[asexual]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Biomedical Research]]></TERM><TERM><![CDATA[Blood]]></TERM><TERM><![CDATA[Chloroquine]]></TERM><TERM><![CDATA[Chloroquine resistance]]></TERM><TERM><![CDATA[Chromosome Mapping]]></TERM><TERM><![CDATA[Chromosomes, Human, Pair 7]]></TERM><TERM><![CDATA[Combined Modality Therapy]]></TERM><TERM><![CDATA[Communities]]></TERM><TERM><![CDATA[Culicidae]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Drug resistance]]></TERM><TERM><![CDATA[drug standard]]></TERM><TERM><![CDATA[Erythrocytes]]></TERM><TERM><![CDATA[Exhibits]]></TERM><TERM><![CDATA[Experimental Genetics]]></TERM><TERM><![CDATA[Female]]></TERM><TERM><![CDATA[Frequencies (time pattern)]]></TERM><TERM><![CDATA[Future]]></TERM><TERM><![CDATA[Generations]]></TERM><TERM><![CDATA[Genes]]></TERM><TERM><![CDATA[Genetic]]></TERM><TERM><![CDATA[genetic analysis]]></TERM><TERM><![CDATA[Genetic Crosses]]></TERM><TERM><![CDATA[Genetic Determinism]]></TERM><TERM><![CDATA[genetic manipulation]]></TERM><TERM><![CDATA[Genetic Population Study]]></TERM><TERM><![CDATA[Genetic Recombination]]></TERM><TERM><![CDATA[Genetic Research]]></TERM><TERM><![CDATA[Genotype]]></TERM><TERM><![CDATA[Growth]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Hepatocyte]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[Infection]]></TERM><TERM><![CDATA[Ingestion]]></TERM><TERM><![CDATA[Insecticide Resistance]]></TERM><TERM><![CDATA[Intervention]]></TERM><TERM><![CDATA[Killings]]></TERM><TERM><![CDATA[Liver]]></TERM><TERM><![CDATA[Maintenance]]></TERM><TERM><![CDATA[Malaria]]></TERM><TERM><![CDATA[Maps]]></TERM><TERM><![CDATA[Methodology]]></TERM><TERM><![CDATA[Modality]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Morbidity - disease rate]]></TERM><TERM><![CDATA[Mortality Vital Statistics]]></TERM><TERM><![CDATA[mouse model]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[Pan Genus]]></TERM><TERM><![CDATA[Parasites]]></TERM><TERM><![CDATA[Partner in relationship]]></TERM><TERM><![CDATA[pathogen]]></TERM><TERM><![CDATA[Pharmaceutical Preparations]]></TERM><TERM><![CDATA[Phenotype]]></TERM><TERM><![CDATA[Plasmodium]]></TERM><TERM><![CDATA[Plasmodium falciparum]]></TERM><TERM><![CDATA[Point Mutation]]></TERM><TERM><![CDATA[Predisposition]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[Production]]></TERM><TERM><![CDATA[programs]]></TERM><TERM><![CDATA[Publishing]]></TERM><TERM><![CDATA[Quantitative Trait Loci]]></TERM><TERM><![CDATA[Recombinants]]></TERM><TERM><![CDATA[Recovery]]></TERM><TERM><![CDATA[Reproduction]]></TERM><TERM><![CDATA[Resistance]]></TERM><TERM><![CDATA[resistant strain]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[Salivary Glands]]></TERM><TERM><![CDATA[Sporozoites]]></TERM><TERM><![CDATA[Staging]]></TERM><TERM><![CDATA[System]]></TERM><TERM><![CDATA[Technology]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[tool]]></TERM><TERM><![CDATA[trait]]></TERM><TERM><![CDATA[Transgenic Organisms]]></TERM><TERM><![CDATA[United States National Institutes of Health]]></TERM><TERM><![CDATA[Validation]]></TERM><TERM><![CDATA[Variant]]></TERM><TERM><![CDATA[vector mosquito]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Experimental Plasmodium falciparum crosses using human-liver chimeric mice]]></PROJECT_TITLE><SERIAL_NUMBER>115194</SERIAL_NUMBER><STUDY_SECTION>DDR</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Drug Discovery and Mechanisms of Antimicrobial Resistance Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>159138</DIRECT_COST_AMT><INDIRECT_COST_AMT>52822</INDIRECT_COST_AMT><TOTAL_COST>211960</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8960324</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>AI</ADMINISTERING_IC><APPLICATION_TYPE>4</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/27/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>855</CFDA_CODE><CORE_PROJECT_NUM>R01AI095098</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-10-067</FOA_NUMBER><FULL_PROJECT_NUM>4R01AI095098-06</FULL_PROJECT_NUM><FUNDING_ICs>NIAID:587424\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>MADISON</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[PATHOLOGY]]></ORG_DEPT><ORG_DISTRICT>02</ORG_DISTRICT><ORG_DUNS>161202122</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIVERSITY OF WISCONSIN-MADISON]]></ORG_NAME><ORG_STATE>WI</ORG_STATE><ORG_ZIPCODE>537151218</ORG_ZIPCODE><PHR><![CDATA[We have identified an interaction between an inhibitory killer immunoglobulin-like receptor (KIR) on natural killer (NK) cells and a common MHC class I molecule in the rhesus macaque that is modulated by simian immunodeficiency virus (SIV) peptides. We will use KIR- and MHC class I-defined rhesus macaques to determine how this interaction affects the outcome of immunodeficiency virus infection, and to specifically address the role of viral peptides in modulating NK cell activation as a mechanism of immune evasion.]]></PHR><PIS><PI><PI_NAME>EVANS, DAVID T</PI_NAME><PI_ID>6155054</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>SANDERS, BRIGITTE E.</PROGRAM_OFFICER_NAME><PROJECT_START>11/14/2011</PROJECT_START><PROJECT_END>10/31/2016</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[Alleles]]></TERM><TERM><![CDATA[Animal Experiments]]></TERM><TERM><![CDATA[Animals]]></TERM><TERM><![CDATA[Antibodies]]></TERM><TERM><![CDATA[Avidity]]></TERM><TERM><![CDATA[Binding (Molecular Function)]]></TERM><TERM><![CDATA[Biological Assay]]></TERM><TERM><![CDATA[Biology]]></TERM><TERM><![CDATA[CD8B1 gene]]></TERM><TERM><![CDATA[Cell Count]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[Drug or chemical Tissue Distribution]]></TERM><TERM><![CDATA[Epitopes]]></TERM><TERM><![CDATA[Foundations]]></TERM><TERM><![CDATA[Frequencies (time pattern)]]></TERM><TERM><![CDATA[Genes]]></TERM><TERM><![CDATA[Genetic Polymorphism]]></TERM><TERM><![CDATA[Genome]]></TERM><TERM><![CDATA[Gut associated lymphoid tissue]]></TERM><TERM><![CDATA[Histocompatibility Antigens Class I]]></TERM><TERM><![CDATA[HIV]]></TERM><TERM><![CDATA[HIV-1]]></TERM><TERM><![CDATA[Immune]]></TERM><TERM><![CDATA[Immunogenetics]]></TERM><TERM><![CDATA[Immunologic Deficiency Syndromes]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[Infection]]></TERM><TERM><![CDATA[Jurkat Cells]]></TERM><TERM><![CDATA[killer immunoglobulin-like receptor]]></TERM><TERM><![CDATA[Ligands]]></TERM><TERM><![CDATA[lymph nodes]]></TERM><TERM><![CDATA[Macaca]]></TERM><TERM><![CDATA[Macaca mulatta]]></TERM><TERM><![CDATA[Mamu-A 02 antigen]]></TERM><TERM><![CDATA[Memory]]></TERM><TERM><![CDATA[MHC Class I Genes]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Monitor]]></TERM><TERM><![CDATA[mutant]]></TERM><TERM><![CDATA[Mutation]]></TERM><TERM><![CDATA[Natural Killer Cells]]></TERM><TERM><![CDATA[NK Cell Activation]]></TERM><TERM><![CDATA[nonhuman primate]]></TERM><TERM><![CDATA[Outcome]]></TERM><TERM><![CDATA[Pathogenesis]]></TERM><TERM><![CDATA[Peptides]]></TERM><TERM><![CDATA[Phenotype]]></TERM><TERM><![CDATA[Play]]></TERM><TERM><![CDATA[Population]]></TERM><TERM><![CDATA[prevent]]></TERM><TERM><![CDATA[Property]]></TERM><TERM><![CDATA[Reagent]]></TERM><TERM><![CDATA[receptor]]></TERM><TERM><![CDATA[Regulation]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[SIV]]></TERM><TERM><![CDATA[Staining method]]></TERM><TERM><![CDATA[Stains]]></TERM><TERM><![CDATA[T cell response]]></TERM><TERM><![CDATA[T-Lymphocyte]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Tissues]]></TERM><TERM><![CDATA[Up-Regulation (Physiology)]]></TERM><TERM><![CDATA[Viral]]></TERM><TERM><![CDATA[Virus]]></TERM><TERM><![CDATA[Virus Diseases]]></TERM><TERM><![CDATA[Virus Replication]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[KIR and MHC Class I Immunogenetics in SIV Infection]]></PROJECT_TITLE><SERIAL_NUMBER>095098</SERIAL_NUMBER><STUDY_SECTION>AIP</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[AIDS Immunology and Pathogenesis Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>06</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>391201</DIRECT_COST_AMT><INDIRECT_COST_AMT>196223</INDIRECT_COST_AMT><TOTAL_COST>587424</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8960340</APPLICATION_ID><ACTIVITY>R21</ACTIVITY><ADMINISTERING_IC>AI</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/26/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>855</CFDA_CODE><CORE_PROJECT_NUM>R21AI114277</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-13-303</FOA_NUMBER><FULL_PROJECT_NUM>5R21AI114277-02</FULL_PROJECT_NUM><FUNDING_ICs>NIAID:225260\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>MADISON</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[MICROBIOLOGY/IMMUN/VIROLOGY]]></ORG_DEPT><ORG_DISTRICT>02</ORG_DISTRICT><ORG_DUNS>161202122</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIVERSITY OF WISCONSIN-MADISON]]></ORG_NAME><ORG_STATE>WI</ORG_STATE><ORG_ZIPCODE>537151218</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE:    
Toxoplasma gondii is a serious pathogen in persons immunocompromised by AIDS. The work in this proposal will determine the importance of developmentally regulated CCCH1 zinc finger proteins for the establishment and maintenance of chronic infection.]]></PHR><PIS><PI><PI_NAME>KNOLL, LAURA J</PI_NAME><PI_ID>1932387</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>JOY, DEIRDRE A.</PROGRAM_OFFICER_NAME><PROJECT_START>11/01/2014</PROJECT_START><PROJECT_END>10/31/2016</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[3' Untranslated Regions]]></TERM><TERM><![CDATA[Acquired Immunodeficiency Syndrome]]></TERM><TERM><![CDATA[Acute]]></TERM><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[Animal Model]]></TERM><TERM><![CDATA[Animals]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Binding (Molecular Function)]]></TERM><TERM><![CDATA[Biochemistry]]></TERM><TERM><![CDATA[Biological]]></TERM><TERM><![CDATA[biological systems]]></TERM><TERM><![CDATA[Brain]]></TERM><TERM><![CDATA[Cellular biology]]></TERM><TERM><![CDATA[Chelating Agents]]></TERM><TERM><![CDATA[Chronic]]></TERM><TERM><![CDATA[Cyst]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Data Set]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[DNA-Binding Proteins]]></TERM><TERM><![CDATA[drug development]]></TERM><TERM><![CDATA[Drug Targeting]]></TERM><TERM><![CDATA[effective therapy]]></TERM><TERM><![CDATA[Encephalitis]]></TERM><TERM><![CDATA[Ensure]]></TERM><TERM><![CDATA[Epitopes]]></TERM><TERM><![CDATA[Felis catus]]></TERM><TERM><![CDATA[foodborne]]></TERM><TERM><![CDATA[Foundations]]></TERM><TERM><![CDATA[Funding]]></TERM><TERM><![CDATA[Future]]></TERM><TERM><![CDATA[Gene Expression Profile]]></TERM><TERM><![CDATA[Genes]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[high risk]]></TERM><TERM><![CDATA[homologous recombination]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[Immunocompromised Host]]></TERM><TERM><![CDATA[Immunologic Surveillance]]></TERM><TERM><![CDATA[Immunoprecipitation]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[Infection]]></TERM><TERM><![CDATA[Ingestion]]></TERM><TERM><![CDATA[Intervention]]></TERM><TERM><![CDATA[Knowledge]]></TERM><TERM><![CDATA[Maintenance]]></TERM><TERM><![CDATA[Meat]]></TERM><TERM><![CDATA[Messenger RNA]]></TERM><TERM><![CDATA[Methods]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[Molecular Analysis]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[mutant]]></TERM><TERM><![CDATA[next generation sequencing]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[Oocysts]]></TERM><TERM><![CDATA[overexpression]]></TERM><TERM><![CDATA[Parasites]]></TERM><TERM><![CDATA[pathogen]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Persons]]></TERM><TERM><![CDATA[Pharmaceutical Preparations]]></TERM><TERM><![CDATA[Pharmacologic Substance]]></TERM><TERM><![CDATA[Poly A]]></TERM><TERM><![CDATA[Poly C]]></TERM><TERM><![CDATA[Poly G]]></TERM><TERM><![CDATA[Poly U]]></TERM><TERM><![CDATA[prevent]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[Promotor (Genetics)]]></TERM><TERM><![CDATA[Protein Binding]]></TERM><TERM><![CDATA[Proteins]]></TERM><TERM><![CDATA[Reading]]></TERM><TERM><![CDATA[Reagent]]></TERM><TERM><![CDATA[Refractory]]></TERM><TERM><![CDATA[Regulation]]></TERM><TERM><![CDATA[research study]]></TERM><TERM><![CDATA[Resolution]]></TERM><TERM><![CDATA[RNA]]></TERM><TERM><![CDATA[RNA Binding]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Staging]]></TERM><TERM><![CDATA[stem]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Therapeutic]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[tissue culture]]></TERM><TERM><![CDATA[Tissue-Specific Gene Expression]]></TERM><TERM><![CDATA[Tissues]]></TERM><TERM><![CDATA[Toxoplasma]]></TERM><TERM><![CDATA[Toxoplasma gondii]]></TERM><TERM><![CDATA[Toxoplasmosis]]></TERM><TERM><![CDATA[Transcript]]></TERM><TERM><![CDATA[transcriptome sequencing]]></TERM><TERM><![CDATA[Trypanosoma brucei brucei]]></TERM><TERM><![CDATA[Tubulin]]></TERM><TERM><![CDATA[Vaccines]]></TERM><TERM><![CDATA[web site]]></TERM><TERM><![CDATA[Work]]></TERM><TERM><![CDATA[Zinc]]></TERM><TERM><![CDATA[Zinc Fingers]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Mechanisms of RNA regulation in the persistence of the AIDS pathogen Toxoplasma]]></PROJECT_TITLE><SERIAL_NUMBER>114277</SERIAL_NUMBER><STUDY_SECTION>AOIC</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[AIDS-associated Opportunistic Infections and Cancer Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>150000</DIRECT_COST_AMT><INDIRECT_COST_AMT>75260</INDIRECT_COST_AMT><TOTAL_COST>225260</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8960945</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>HL</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/28/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>837</CFDA_CODE><CORE_PROJECT_NUM>R01HL122975</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-13-302</FOA_NUMBER><FULL_PROJECT_NUM>5R01HL122975-02</FULL_PROJECT_NUM><FUNDING_ICs>NHLBI:330750\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL HEART, LUNG, AND BLOOD INSTITUTE</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>BIRMINGHAM</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[PATHOLOGY]]></ORG_DEPT><ORG_DISTRICT>07</ORG_DISTRICT><ORG_DUNS>063690705</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIVERSITY OF ALABAMA AT BIRMINGHAM]]></ORG_NAME><ORG_STATE>AL</ORG_STATE><ORG_ZIPCODE>352940004</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: The risk for heart failure increases significantly in patients with diabetes; however the molecular mechanisms underlying the effects of diabetes on the heart are not well understood. Therefore, the goal of this study is to determine the role of abnormalities in time-of-day-dependent rhythms in cardiomyocyte function, growth and metabolism in the development of diabetes-related heart disease. We anticipate that the successful outcome of these studies will help identify new approaches for reducing the risk of developing heart failure in the patients with diabetes.]]></PHR><PIS><PI><PI_NAME>CHATHAM, JOHN C (contact)</PI_NAME><PI_ID>1901048 (contact)</PI_ID></PI><PI><PI_NAME>YOUNG, MARTIN ELLIOT</PI_NAME><PI_ID>6676909</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>WONG, RENEE P.</PROGRAM_OFFICER_NAME><PROJECT_START>11/03/2014</PROJECT_START><PROJECT_END>10/31/2018</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Acute]]></TERM><TERM><![CDATA[Adverse effects]]></TERM><TERM><![CDATA[Age of Onset]]></TERM><TERM><![CDATA[ARNT gene]]></TERM><TERM><![CDATA[Attenuated]]></TERM><TERM><![CDATA[Brain]]></TERM><TERM><![CDATA[Cardiac]]></TERM><TERM><![CDATA[Cardiac Myocytes]]></TERM><TERM><![CDATA[Cardiomyopathies]]></TERM><TERM><![CDATA[Cardiovascular Diseases]]></TERM><TERM><![CDATA[cardiovascular disorder risk]]></TERM><TERM><![CDATA[Cardiovascular Physiology]]></TERM><TERM><![CDATA[Cardiovascular system]]></TERM><TERM><![CDATA[Cause of Death]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[circadian pacemaker]]></TERM><TERM><![CDATA[Circadian Rhythms]]></TERM><TERM><![CDATA[Clinical Treatment]]></TERM><TERM><![CDATA[clinically relevant]]></TERM><TERM><![CDATA[Dependence]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Diabetes Mellitus]]></TERM><TERM><![CDATA[diabetic]]></TERM><TERM><![CDATA[diabetic cardiomyopathy]]></TERM><TERM><![CDATA[diabetic patient]]></TERM><TERM><![CDATA[Disease Progression]]></TERM><TERM><![CDATA[Etiology]]></TERM><TERM><![CDATA[Event]]></TERM><TERM><![CDATA[Exhibits]]></TERM><TERM><![CDATA[Functional disorder]]></TERM><TERM><![CDATA[Gap Junctions]]></TERM><TERM><![CDATA[Genetic]]></TERM><TERM><![CDATA[Genetic Transcription]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Growth]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Heart]]></TERM><TERM><![CDATA[Heart Diseases]]></TERM><TERM><![CDATA[Heart failure]]></TERM><TERM><![CDATA[Heart Hypertrophy]]></TERM><TERM><![CDATA[infancy]]></TERM><TERM><![CDATA[insight]]></TERM><TERM><![CDATA[Ischemia]]></TERM><TERM><![CDATA[Knock-out]]></TERM><TERM><![CDATA[Knockout Mice]]></TERM><TERM><![CDATA[Knowledge]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[Link]]></TERM><TERM><![CDATA[Longevity]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[Metabolism]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[mouse model]]></TERM><TERM><![CDATA[multicatalytic endopeptidase complex]]></TERM><TERM><![CDATA[Muscle]]></TERM><TERM><![CDATA[mutant]]></TERM><TERM><![CDATA[Myocardial dysfunction]]></TERM><TERM><![CDATA[Myocardium]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[novel strategies]]></TERM><TERM><![CDATA[Organ]]></TERM><TERM><![CDATA[Outcome Study]]></TERM><TERM><![CDATA[Output]]></TERM><TERM><![CDATA[Pathologic]]></TERM><TERM><![CDATA[Pathology]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Phase]]></TERM><TERM><![CDATA[Phosphorylation]]></TERM><TERM><![CDATA[Physiology]]></TERM><TERM><![CDATA[Play]]></TERM><TERM><![CDATA[Post-Translational Protein Processing]]></TERM><TERM><![CDATA[Protein Biosynthesis]]></TERM><TERM><![CDATA[protein degradation]]></TERM><TERM><![CDATA[protein function]]></TERM><TERM><![CDATA[Proteins]]></TERM><TERM><![CDATA[Publishing]]></TERM><TERM><![CDATA[repaired]]></TERM><TERM><![CDATA[Reperfusion Therapy]]></TERM><TERM><![CDATA[Reporting]]></TERM><TERM><![CDATA[Risk]]></TERM><TERM><![CDATA[Risk Factors]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[Stimulus]]></TERM><TERM><![CDATA[stressor]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[transcription factor]]></TERM><TERM><![CDATA[Translations]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Disruption of the Clock O-GlcNAc axis in diabetic cardiomyopathy]]></PROJECT_TITLE><SERIAL_NUMBER>122975</SERIAL_NUMBER><STUDY_SECTION>MIM</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Myocardial Ischemia and Metabolism Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>225000</DIRECT_COST_AMT><INDIRECT_COST_AMT>105750</INDIRECT_COST_AMT><TOTAL_COST>330750</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8962094</APPLICATION_ID><ACTIVITY>P60</ACTIVITY><ADMINISTERING_IC>MD</ADMINISTERING_IC><APPLICATION_TYPE>4</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/30/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>P60MD000538</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-MD-11-003</FOA_NUMBER><FULL_PROJECT_NUM>4P60MD000538-13</FULL_PROJECT_NUM><FUNDING_ICs>NIMHD:400362\</FUNDING_ICs><FUNDING_MECHANISM>RESEARCH CENTERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE ON MINORITY HEALTH AND HEALTH DISPARITIES</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>NEW YORK</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>12</ORG_DISTRICT><ORG_DUNS>121911077</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[NEW YORK UNIVERSITY SCHOOL OF MEDICINE]]></ORG_NAME><ORG_STATE>NY</ORG_STATE><ORG_ZIPCODE>100165802</ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>REY, MARIANO J</PI_NAME><PI_ID>7704072</PI_ID></PI><PI><PI_NAME>TRINH-SHEVRIN, CHAU  (contact)</PI_NAME><PI_ID>7860791 (contact)</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START></PROJECT_START><PROJECT_END></PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Ally]]></TERM><TERM><![CDATA[ARHGEF5 gene]]></TERM><TERM><![CDATA[Asian Americans]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[career]]></TERM><TERM><![CDATA[Clinical Sciences]]></TERM><TERM><![CDATA[college]]></TERM><TERM><![CDATA[Communities]]></TERM><TERM><![CDATA[community based participatory research]]></TERM><TERM><![CDATA[Community Health]]></TERM><TERM><![CDATA[Community Health Centers]]></TERM><TERM><![CDATA[Competence]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Educational Activities]]></TERM><TERM><![CDATA[Faculty]]></TERM><TERM><![CDATA[Fostering]]></TERM><TERM><![CDATA[Foundations]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[graduate student]]></TERM><TERM><![CDATA[Growth]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[health disparity]]></TERM><TERM><![CDATA[Health Personnel]]></TERM><TERM><![CDATA[Health Professional]]></TERM><TERM><![CDATA[Health Promotion]]></TERM><TERM><![CDATA[high school]]></TERM><TERM><![CDATA[Hospitals]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[Institutes]]></TERM><TERM><![CDATA[interest]]></TERM><TERM><![CDATA[Internships]]></TERM><TERM><![CDATA[Leadership]]></TERM><TERM><![CDATA[Medicine]]></TERM><TERM><![CDATA[Mentors]]></TERM><TERM><![CDATA[minority health]]></TERM><TERM><![CDATA[next generation]]></TERM><TERM><![CDATA[Population]]></TERM><TERM><![CDATA[Postdoctoral Fellow]]></TERM><TERM><![CDATA[Prevention Research]]></TERM><TERM><![CDATA[programs]]></TERM><TERM><![CDATA[Provider]]></TERM><TERM><![CDATA[public health medicine (field)]]></TERM><TERM><![CDATA[Recording of previous events]]></TERM><TERM><![CDATA[Recruitment Activity]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[research and development]]></TERM><TERM><![CDATA[Research Infrastructure]]></TERM><TERM><![CDATA[Research Personnel]]></TERM><TERM><![CDATA[Research Training]]></TERM><TERM><![CDATA[Resources]]></TERM><TERM><![CDATA[Risk]]></TERM><TERM><![CDATA[Series]]></TERM><TERM><![CDATA[skills]]></TERM><TERM><![CDATA[Structure]]></TERM><TERM><![CDATA[Students]]></TERM><TERM><![CDATA[tool]]></TERM><TERM><![CDATA[Training Activity]]></TERM><TERM><![CDATA[Training and Education]]></TERM><TERM><![CDATA[Training Programs]]></TERM><TERM><![CDATA[Translational Research]]></TERM><TERM><![CDATA[Trust]]></TERM><TERM><![CDATA[Veins]]></TERM><TERM><![CDATA[Visit]]></TERM><TERM><![CDATA[Work]]></TERM><TERM><![CDATA[Youth]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Research Training and Education Core]]></PROJECT_TITLE><SERIAL_NUMBER>000538</SERIAL_NUMBER><STUDY_SECTION>ZMD1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID>6308</SUBPROJECT_ID><SUPPORT_YEAR>13</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>244745</DIRECT_COST_AMT><INDIRECT_COST_AMT>155617</INDIRECT_COST_AMT><TOTAL_COST /><TOTAL_COST_SUB_PROJECT>400362</TOTAL_COST_SUB_PROJECT></row>
<row><APPLICATION_ID>8962095</APPLICATION_ID><ACTIVITY>P60</ACTIVITY><ADMINISTERING_IC>MD</ADMINISTERING_IC><APPLICATION_TYPE>4</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/30/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>P60MD000538</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-MD-11-003</FOA_NUMBER><FULL_PROJECT_NUM>4P60MD000538-13</FULL_PROJECT_NUM><FUNDING_ICs>NIMHD:121649\</FUNDING_ICs><FUNDING_MECHANISM>RESEARCH CENTERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE ON MINORITY HEALTH AND HEALTH DISPARITIES</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>NEW YORK</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>12</ORG_DISTRICT><ORG_DUNS>121911077</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[NEW YORK UNIVERSITY SCHOOL OF MEDICINE]]></ORG_NAME><ORG_STATE>NY</ORG_STATE><ORG_ZIPCODE>100165802</ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>REY, MARIANO J</PI_NAME><PI_ID>7704072</PI_ID></PI><PI><PI_NAME>TRINH-SHEVRIN, CHAU  (contact)</PI_NAME><PI_ID>7860791 (contact)</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START></PROJECT_START><PROJECT_END></PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Academic Medical Centers]]></TERM><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[Area]]></TERM><TERM><![CDATA[Asian Americans]]></TERM><TERM><![CDATA[Award]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Chronic Disease]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[Clinical Trials]]></TERM><TERM><![CDATA[Communities]]></TERM><TERM><![CDATA[community based participatory research]]></TERM><TERM><![CDATA[Community Health Centers]]></TERM><TERM><![CDATA[community organizations]]></TERM><TERM><![CDATA[Country]]></TERM><TERM><![CDATA[disorder prevention]]></TERM><TERM><![CDATA[Education and Outreach]]></TERM><TERM><![CDATA[Educational aspects]]></TERM><TERM><![CDATA[ethnic minority population]]></TERM><TERM><![CDATA[evidence base]]></TERM><TERM><![CDATA[Fostering]]></TERM><TERM><![CDATA[Foundations]]></TERM><TERM><![CDATA[Fright]]></TERM><TERM><![CDATA[Funding]]></TERM><TERM><![CDATA[Government]]></TERM><TERM><![CDATA[graduate student]]></TERM><TERM><![CDATA[Grant]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[health disparity]]></TERM><TERM><![CDATA[Health Priorities]]></TERM><TERM><![CDATA[Health Promotion]]></TERM><TERM><![CDATA[Health Services Accessibility]]></TERM><TERM><![CDATA[Health Status]]></TERM><TERM><![CDATA[Healthcare]]></TERM><TERM><![CDATA[Healthcare Systems]]></TERM><TERM><![CDATA[high school]]></TERM><TERM><![CDATA[Hospitals]]></TERM><TERM><![CDATA[Institutes]]></TERM><TERM><![CDATA[Investments]]></TERM><TERM><![CDATA[Linguistics]]></TERM><TERM><![CDATA[literacy]]></TERM><TERM><![CDATA[minority health]]></TERM><TERM><![CDATA[New York]]></TERM><TERM><![CDATA[outreach]]></TERM><TERM><![CDATA[Outreach Research]]></TERM><TERM><![CDATA[patient population]]></TERM><TERM><![CDATA[Population]]></TERM><TERM><![CDATA[Prevention program]]></TERM><TERM><![CDATA[Prevention strategy]]></TERM><TERM><![CDATA[Primary Health Care]]></TERM><TERM><![CDATA[Provider]]></TERM><TERM><![CDATA[Recording of previous events]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Research Infrastructure]]></TERM><TERM><![CDATA[Research Training]]></TERM><TERM><![CDATA[Risk]]></TERM><TERM><![CDATA[Schools]]></TERM><TERM><![CDATA[science education]]></TERM><TERM><![CDATA[Series]]></TERM><TERM><![CDATA[Services]]></TERM><TERM><![CDATA[Site]]></TERM><TERM><![CDATA[Students]]></TERM><TERM><![CDATA[symposium]]></TERM><TERM><![CDATA[Target Populations]]></TERM><TERM><![CDATA[Training]]></TERM><TERM><![CDATA[United States National Institutes of Health]]></TERM><TERM><![CDATA[Universities]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Community Engagement and Outreach Core]]></PROJECT_TITLE><SERIAL_NUMBER>000538</SERIAL_NUMBER><STUDY_SECTION>ZMD1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID>6309</SUBPROJECT_ID><SUPPORT_YEAR>13</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>74366</DIRECT_COST_AMT><INDIRECT_COST_AMT>47283</INDIRECT_COST_AMT><TOTAL_COST /><TOTAL_COST_SUB_PROJECT>121649</TOTAL_COST_SUB_PROJECT></row>
<row><APPLICATION_ID>8963423</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>AI</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/22/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>855</CFDA_CODE><CORE_PROJECT_NUM>R01AI110482</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>PAR-13-055</FOA_NUMBER><FULL_PROJECT_NUM>5R01AI110482-02</FULL_PROJECT_NUM><FUNDING_ICs>NIAID:785845\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>ATLANTA</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>05</ORG_DISTRICT><ORG_DUNS>066469933</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[EMORY UNIVERSITY]]></ORG_NAME><ORG_STATE>GA</ORG_STATE><ORG_ZIPCODE>303224250</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Vaccination of pregnant women can impart health benefits on the unborn and infant child, and increased acceptance of maternal vaccination may lead to increase in acceptability of childhood vaccination. However, maternal vaccination rates are low, and new comprehensive, evidence-based interventions are needed to increase vaccination uptake among pregnant women and their children. We will build off of a prior intervention at the practice, provider, and patient-levels (P3) to develop, implement and evaluate an enhanced intervention (P3+) to improve vaccination uptake among pregnant women, and later, their children.]]></PHR><PIS><PI><PI_NAME>OMER, SAAD B. (contact)</PI_NAME><PI_ID>9085924 (contact)</PI_ID></PI><PI><PI_NAME>SALMON, DANIEL A</PI_NAME><PI_ID>6579177</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>GU, XIN-XING </PROGRAM_OFFICER_NAME><PROJECT_START>11/05/2014</PROJECT_START><PROJECT_END>10/31/2019</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Accounting]]></TERM><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[Age-Months]]></TERM><TERM><![CDATA[Age-Years]]></TERM><TERM><![CDATA[Area]]></TERM><TERM><![CDATA[Attitude]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Belief]]></TERM><TERM><![CDATA[Cessation of life]]></TERM><TERM><![CDATA[Characteristics]]></TERM><TERM><![CDATA[Child]]></TERM><TERM><![CDATA[Childhood]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[Colorado]]></TERM><TERM><![CDATA[Communities]]></TERM><TERM><![CDATA[community based practice]]></TERM><TERM><![CDATA[Complex]]></TERM><TERM><![CDATA[Contracts]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Discipline of obstetrics]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Disease Outbreaks]]></TERM><TERM><![CDATA[early childhood]]></TERM><TERM><![CDATA[Educational aspects]]></TERM><TERM><![CDATA[Educational Materials]]></TERM><TERM><![CDATA[Evaluation]]></TERM><TERM><![CDATA[evidence base]]></TERM><TERM><![CDATA[Evidence based intervention]]></TERM><TERM><![CDATA[experience]]></TERM><TERM><![CDATA[Feedback]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Gynecologist]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Health Benefit]]></TERM><TERM><![CDATA[Health Expenditures]]></TERM><TERM><![CDATA[Healthcare]]></TERM><TERM><![CDATA[high risk infant]]></TERM><TERM><![CDATA[Hospitalization]]></TERM><TERM><![CDATA[Immunization]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[Infant]]></TERM><TERM><![CDATA[Influenza]]></TERM><TERM><![CDATA[innovation]]></TERM><TERM><![CDATA[Intervention]]></TERM><TERM><![CDATA[Knowledge]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[Learning]]></TERM><TERM><![CDATA[Left]]></TERM><TERM><![CDATA[Logistics]]></TERM><TERM><![CDATA[Managed Care]]></TERM><TERM><![CDATA[Medical]]></TERM><TERM><![CDATA[meetings]]></TERM><TERM><![CDATA[Mothers]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[Parents]]></TERM><TERM><![CDATA[Patient Care]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[peer]]></TERM><TERM><![CDATA[Pertussis]]></TERM><TERM><![CDATA[Physicians]]></TERM><TERM><![CDATA[Pilot Projects]]></TERM><TERM><![CDATA[posters]]></TERM><TERM><![CDATA[Pregnancy]]></TERM><TERM><![CDATA[pregnant]]></TERM><TERM><![CDATA[Pregnant Women]]></TERM><TERM><![CDATA[prenatal]]></TERM><TERM><![CDATA[prevent]]></TERM><TERM><![CDATA[Provider]]></TERM><TERM><![CDATA[public health medicine (field)]]></TERM><TERM><![CDATA[Qualitative Research]]></TERM><TERM><![CDATA[Questionnaires]]></TERM><TERM><![CDATA[Recommendation]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Research Design]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[Risk]]></TERM><TERM><![CDATA[secondary outcome]]></TERM><TERM><![CDATA[Series]]></TERM><TERM><![CDATA[success]]></TERM><TERM><![CDATA[System]]></TERM><TERM><![CDATA[Tablet Computer]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[tool]]></TERM><TERM><![CDATA[Training]]></TERM><TERM><![CDATA[United States]]></TERM><TERM><![CDATA[uptake]]></TERM><TERM><![CDATA[Vaccinated]]></TERM><TERM><![CDATA[Vaccination]]></TERM><TERM><![CDATA[Vaccines]]></TERM><TERM><![CDATA[Visit]]></TERM><TERM><![CDATA[Woman]]></TERM><TERM><![CDATA[Writing]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[A Comprehensive Pre-Natal Intervention to Increase Vaccine Coverage]]></PROJECT_TITLE><SERIAL_NUMBER>110482</SERIAL_NUMBER><STUDY_SECTION>DIRH</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Dissemination and Implementation Research in Health Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>701713</DIRECT_COST_AMT><INDIRECT_COST_AMT>84132</INDIRECT_COST_AMT><TOTAL_COST>785845</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8963426</APPLICATION_ID><ACTIVITY>R21</ACTIVITY><ADMINISTERING_IC>AI</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/29/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>855</CFDA_CODE><CORE_PROJECT_NUM>R21AI110777</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-13-303</FOA_NUMBER><FULL_PROJECT_NUM>5R21AI110777-02</FULL_PROJECT_NUM><FUNDING_ICs>NIAID:233250\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>AURORA</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[MICROBIOLOGY/IMMUN/VIROLOGY]]></ORG_DEPT><ORG_DISTRICT>06</ORG_DISTRICT><ORG_DUNS>041096314</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIVERSITY OF COLORADO DENVER]]></ORG_NAME><ORG_STATE>CO</ORG_STATE><ORG_ZIPCODE>800452570</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Our proposed studies will provide major new insights into the regulation of activation induced deaminase (AID) targeting to immunoglobulin (Ig) loci, a fundamental question in basic immunology. Better understanding of these mechanisms will increase our knowledge of AID-directed somatic hypermutation (SHM) and class switch recombination (CSR), as well as genomic instability. Besides the fundamental relevance to immunological control mechanisms, elucidation of SHM and CSR is required to generate effective antibody-mediated immune responses to fight against pathogens. Conversely, abnormal SHM/CSR can underlie immunological diseases such as infection, immunodeficiency, and autoimmunity, and contribute to oncogenic chromosomal translocations.]]></PHR><PIS><PI><PI_NAME>WANG, JING HONG</PI_NAME><PI_ID>9969182</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>NASSERI, M. FARAZ </PROGRAM_OFFICER_NAME><PROJECT_START>11/06/2014</PROJECT_START><PROJECT_END>10/31/2016</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[activation-induced cytidine deaminase]]></TERM><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[Affinity]]></TERM><TERM><![CDATA[Antibodies]]></TERM><TERM><![CDATA[Antibody Affinity]]></TERM><TERM><![CDATA[Antibody Diversity]]></TERM><TERM><![CDATA[Antigens]]></TERM><TERM><![CDATA[Autoimmunity]]></TERM><TERM><![CDATA[B-Cell Lymphomas]]></TERM><TERM><![CDATA[B-Lymphocytes]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Base Sequence]]></TERM><TERM><![CDATA[Binding (Molecular Function)]]></TERM><TERM><![CDATA[Biological Assay]]></TERM><TERM><![CDATA[Chromatin]]></TERM><TERM><![CDATA[chromatin immunoprecipitation]]></TERM><TERM><![CDATA[Chromosomal translocation]]></TERM><TERM><![CDATA[Chromosome Fragile Sites]]></TERM><TERM><![CDATA[Cytidine Deaminase]]></TERM><TERM><![CDATA[Cytosine]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Deamination]]></TERM><TERM><![CDATA[Defect]]></TERM><TERM><![CDATA[density]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[DNA]]></TERM><TERM><![CDATA[DNA Double Strand Break]]></TERM><TERM><![CDATA[DNA lesion]]></TERM><TERM><![CDATA[DNA Repair Pathway]]></TERM><TERM><![CDATA[DNA Sequence]]></TERM><TERM><![CDATA[DNA Sequence Alteration]]></TERM><TERM><![CDATA[Enhancing Antibodies]]></TERM><TERM><![CDATA[Exons]]></TERM><TERM><![CDATA[fight against]]></TERM><TERM><![CDATA[Frequencies (time pattern)]]></TERM><TERM><![CDATA[Generations]]></TERM><TERM><![CDATA[Genome]]></TERM><TERM><![CDATA[Genomic Instability]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Heavy-Chain Immunoglobulins]]></TERM><TERM><![CDATA[Higher Order Chromatin Structure]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[IGH@ gene cluster]]></TERM><TERM><![CDATA[Immune response]]></TERM><TERM><![CDATA[Immune System Diseases]]></TERM><TERM><![CDATA[Immunoglobulin Class Switching]]></TERM><TERM><![CDATA[Immunoglobulin Genes]]></TERM><TERM><![CDATA[Immunoglobulin M]]></TERM><TERM><![CDATA[Immunoglobulin Somatic Hypermutation]]></TERM><TERM><![CDATA[Immunoglobulin Switch Recombination]]></TERM><TERM><![CDATA[Immunoglobulins]]></TERM><TERM><![CDATA[Immunologic Deficiency Syndromes]]></TERM><TERM><![CDATA[Immunology]]></TERM><TERM><![CDATA[In Vitro]]></TERM><TERM><![CDATA[Infection]]></TERM><TERM><![CDATA[insight]]></TERM><TERM><![CDATA[interest]]></TERM><TERM><![CDATA[Knock-in Mouse]]></TERM><TERM><![CDATA[Knowledge]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[Lesion]]></TERM><TERM><![CDATA[Link]]></TERM><TERM><![CDATA[Lymphomagenesis]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[Mismatch Repair]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[mouse model]]></TERM><TERM><![CDATA[MSH2 gene]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[Mutation]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[Oncogenic]]></TERM><TERM><![CDATA[Outcome]]></TERM><TERM><![CDATA[pathogen]]></TERM><TERM><![CDATA[Pathway interactions]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Pattern]]></TERM><TERM><![CDATA[Physiological]]></TERM><TERM><![CDATA[Play]]></TERM><TERM><![CDATA[Point Mutation]]></TERM><TERM><![CDATA[Predisposition]]></TERM><TERM><![CDATA[preference]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[Recruitment Activity]]></TERM><TERM><![CDATA[Regulation]]></TERM><TERM><![CDATA[repaired]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[RNA]]></TERM><TERM><![CDATA[RNA Processing]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Syndrome]]></TERM><TERM><![CDATA[System]]></TERM><TERM><![CDATA[Techniques]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Transcript]]></TERM><TERM><![CDATA[Uracil]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Role of Target DNA sequences in mutation and DNA Break Generation]]></PROJECT_TITLE><SERIAL_NUMBER>110777</SERIAL_NUMBER><STUDY_SECTION>CMIB</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Cellular and Molecular Immunology - B Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>150000</DIRECT_COST_AMT><INDIRECT_COST_AMT>83250</INDIRECT_COST_AMT><TOTAL_COST>233250</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8965514</APPLICATION_ID><ACTIVITY>R21</ACTIVITY><ADMINISTERING_IC>HL</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/27/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>837</CFDA_CODE><CORE_PROJECT_NUM>R21HL121130</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-12-284</FOA_NUMBER><FULL_PROJECT_NUM>5R21HL121130-02</FULL_PROJECT_NUM><FUNDING_ICs>NHLBI:205024\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL HEART, LUNG, AND BLOOD INSTITUTE</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>CLEVELAND</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[RADIATION-DIAGNOSTIC/ONCOLOGY]]></ORG_DEPT><ORG_DISTRICT>11</ORG_DISTRICT><ORG_DUNS>077758407</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[CASE WESTERN RESERVE UNIVERSITY]]></ORG_NAME><ORG_STATE>OH</ORG_STATE><ORG_ZIPCODE>441067000</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE:   Cardiovascular disease is the number one cause of death and hospitalization. Reperfusion therapy with fibrinolytic agents has significantly reduced early mortality from acute myocardial infarction and disability from stroke. Nevertheless, fibrinolytic agents bear a high risk of bleeding complications and death. We propose a drug delivery system to deliver fibrinolytic therapies in a tissue-specific manner to the injured vessel wall, therefore increasing therapy success while minimizing adverse effects, leading to an improved net clinical benefit.]]></PHR><PIS><PI><PI_NAME>STEINMETZ, NICOLE FRANZISKA</PI_NAME><PI_ID>9346940</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>DANTHI, NARASIMHAN </PROGRAM_OFFICER_NAME><PROJECT_START>11/14/2014</PROJECT_START><PROJECT_END>10/31/2016</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Acids]]></TERM><TERM><![CDATA[Acute myocardial infarction]]></TERM><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[Adverse effects]]></TERM><TERM><![CDATA[Alteplase]]></TERM><TERM><![CDATA[Antibodies]]></TERM><TERM><![CDATA[arm]]></TERM><TERM><![CDATA[artery occlusion]]></TERM><TERM><![CDATA[atherothrombosis]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Biodistribution]]></TERM><TERM><![CDATA[Biological Assay]]></TERM><TERM><![CDATA[Bleeding time procedure]]></TERM><TERM><![CDATA[Blood Platelets]]></TERM><TERM><![CDATA[Cardiovascular Diseases]]></TERM><TERM><![CDATA[Cardiovascular system]]></TERM><TERM><![CDATA[Carotid Arteries]]></TERM><TERM><![CDATA[Cause of Death]]></TERM><TERM><![CDATA[Cerebral hemisphere hemorrhage]]></TERM><TERM><![CDATA[Cessation of life]]></TERM><TERM><![CDATA[Chemistry]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[Coagulation Process]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[density]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Devices]]></TERM><TERM><![CDATA[disability]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Dose]]></TERM><TERM><![CDATA[Drug Carriers]]></TERM><TERM><![CDATA[Drug Combinations]]></TERM><TERM><![CDATA[Drug Delivery Systems]]></TERM><TERM><![CDATA[Drug Formulations]]></TERM><TERM><![CDATA[Drug Kinetics]]></TERM><TERM><![CDATA[Elements]]></TERM><TERM><![CDATA[Engineering]]></TERM><TERM><![CDATA[Environment]]></TERM><TERM><![CDATA[Fibrin]]></TERM><TERM><![CDATA[Fibrinogen]]></TERM><TERM><![CDATA[Fibrinolysis]]></TERM><TERM><![CDATA[Fibrinolytic Agents]]></TERM><TERM><![CDATA[Genetic Engineering]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Growth]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Hemorrhage]]></TERM><TERM><![CDATA[Hemostatic function]]></TERM><TERM><![CDATA[high risk]]></TERM><TERM><![CDATA[Home environment]]></TERM><TERM><![CDATA[Hospitalization]]></TERM><TERM><![CDATA[Image]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[In Vitro]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[inhibitor/antagonist]]></TERM><TERM><![CDATA[injured]]></TERM><TERM><![CDATA[Injury]]></TERM><TERM><![CDATA[insight]]></TERM><TERM><![CDATA[intravital microscopy]]></TERM><TERM><![CDATA[Lasers]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Mortality Vital Statistics]]></TERM><TERM><![CDATA[mouse model]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[nanomedicine]]></TERM><TERM><![CDATA[nanoparticle]]></TERM><TERM><![CDATA[nanotherapy]]></TERM><TERM><![CDATA[next generation]]></TERM><TERM><![CDATA[Penetration]]></TERM><TERM><![CDATA[Peptides]]></TERM><TERM><![CDATA[Pharmaceutical Preparations]]></TERM><TERM><![CDATA[Physiological]]></TERM><TERM><![CDATA[Physiology]]></TERM><TERM><![CDATA[Plant Viruses]]></TERM><TERM><![CDATA[Plasminogen Activator Inhibitor 1]]></TERM><TERM><![CDATA[Pre-Clinical Model]]></TERM><TERM><![CDATA[Protease Inhibitor]]></TERM><TERM><![CDATA[Reactive Oxygen Species]]></TERM><TERM><![CDATA[Reperfusion Therapy]]></TERM><TERM><![CDATA[Research Institute]]></TERM><TERM><![CDATA[Research Personnel]]></TERM><TERM><![CDATA[restenosis]]></TERM><TERM><![CDATA[Risk]]></TERM><TERM><![CDATA[Rodent]]></TERM><TERM><![CDATA[Safety]]></TERM><TERM><![CDATA[Secondary to]]></TERM><TERM><![CDATA[Serpins]]></TERM><TERM><![CDATA[Serum]]></TERM><TERM><![CDATA[Site]]></TERM><TERM><![CDATA[small molecule]]></TERM><TERM><![CDATA[Specificity]]></TERM><TERM><![CDATA[stroke]]></TERM><TERM><![CDATA[Structure]]></TERM><TERM><![CDATA[success]]></TERM><TERM><![CDATA[System]]></TERM><TERM><![CDATA[Tail]]></TERM><TERM><![CDATA[targeted delivery]]></TERM><TERM><![CDATA[Technology]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Therapeutic]]></TERM><TERM><![CDATA[Thromboembolism]]></TERM><TERM><![CDATA[Thrombolytic Therapy]]></TERM><TERM><![CDATA[Thrombosis]]></TERM><TERM><![CDATA[Thrombus]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[Tissues]]></TERM><TERM><![CDATA[Tobacco Mosaic Virus]]></TERM><TERM><![CDATA[Transplantation]]></TERM><TERM><![CDATA[Treatment Efficacy]]></TERM><TERM><![CDATA[Ursidae Family]]></TERM><TERM><![CDATA[Vascular Diseases]]></TERM><TERM><![CDATA[Venous]]></TERM><TERM><![CDATA[Virus]]></TERM><TERM><![CDATA[Western World]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Drug Delivery to Thrombotic Cardiovascular Disease]]></PROJECT_TITLE><SERIAL_NUMBER>121130</SERIAL_NUMBER><STUDY_SECTION>GDD</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Gene and Drug Delivery Systems Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>135000</DIRECT_COST_AMT><INDIRECT_COST_AMT>70024</INDIRECT_COST_AMT><TOTAL_COST>205024</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8965515</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>HL</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/30/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>837</CFDA_CODE><CORE_PROJECT_NUM>R01HL122352</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-13-302</FOA_NUMBER><FULL_PROJECT_NUM>5R01HL122352-02</FULL_PROJECT_NUM><FUNDING_ICs>NHLBI:427129\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL HEART, LUNG, AND BLOOD INSTITUTE</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>ANN ARBOR</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[INTERNAL MEDICINE/MEDICINE]]></ORG_DEPT><ORG_DISTRICT>12</ORG_DISTRICT><ORG_DUNS>073133571</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIVERSITY OF MICHIGAN]]></ORG_NAME><ORG_STATE>MI</ORG_STATE><ORG_ZIPCODE>481091276</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: The work proposed has strong implications for understanding the regulation of cardiac ion channels in health, as well as in heart failure and acquired and inheritable ion channel diseases. Posttranslational modifications and protein-protein interactions in macromolecular complexes may play critical roles in ion channel dysfunction and life-threatening arrhythmias, and may great potential to improved medical care.]]></PHR><PIS><PI><PI_NAME>JALIFE, JOSE S</PI_NAME><PI_ID>1878886</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>LATHROP, DAVID A.</PROGRAM_OFFICER_NAME><PROJECT_START>11/14/2014</PROJECT_START><PROJECT_END>10/31/2018</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Action Potentials]]></TERM><TERM><![CDATA[Acute]]></TERM><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[Arrhythmia]]></TERM><TERM><![CDATA[Atrial Fibrillation]]></TERM><TERM><![CDATA[Barium]]></TERM><TERM><![CDATA[Binding (Molecular Function)]]></TERM><TERM><![CDATA[C-terminal]]></TERM><TERM><![CDATA[Cardiac]]></TERM><TERM><![CDATA[Cardiac Myocytes]]></TERM><TERM><![CDATA[Caring]]></TERM><TERM><![CDATA[Cell membrane]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[cellular imaging]]></TERM><TERM><![CDATA[Code]]></TERM><TERM><![CDATA[Complex]]></TERM><TERM><![CDATA[Computer Simulation]]></TERM><TERM><![CDATA[Confocal Microscopy]]></TERM><TERM><![CDATA[Consensus Sequence]]></TERM><TERM><![CDATA[density]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Dissection]]></TERM><TERM><![CDATA[DLG1 gene]]></TERM><TERM><![CDATA[domain mapping]]></TERM><TERM><![CDATA[Dystrophin-Associated Protein Complex]]></TERM><TERM><![CDATA[Electrophysiology (science)]]></TERM><TERM><![CDATA[Endocytosis]]></TERM><TERM><![CDATA[Endoplasmic Reticulum]]></TERM><TERM><![CDATA[Fluorescence]]></TERM><TERM><![CDATA[fluorescence imaging]]></TERM><TERM><![CDATA[Fluorescence Recovery After Photobleaching]]></TERM><TERM><![CDATA[Functional disorder]]></TERM><TERM><![CDATA[Gene Silencing]]></TERM><TERM><![CDATA[Gene Transfer]]></TERM><TERM><![CDATA[Genes]]></TERM><TERM><![CDATA[Genetic]]></TERM><TERM><![CDATA[genetic variant]]></TERM><TERM><![CDATA[Golgi Apparatus]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Heart Diseases]]></TERM><TERM><![CDATA[Heart failure]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[immunocytochemistry]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[induced pluripotent stem cell]]></TERM><TERM><![CDATA[Inherited]]></TERM><TERM><![CDATA[intermolecular interaction]]></TERM><TERM><![CDATA[inward rectifier potassium channel]]></TERM><TERM><![CDATA[Ion Channel]]></TERM><TERM><![CDATA[Ion Channel Protein]]></TERM><TERM><![CDATA[Joints]]></TERM><TERM><![CDATA[Life]]></TERM><TERM><![CDATA[Link]]></TERM><TERM><![CDATA[loss of function mutation]]></TERM><TERM><![CDATA[Macromolecular Complexes]]></TERM><TERM><![CDATA[Maps]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[Medical]]></TERM><TERM><![CDATA[Membrane]]></TERM><TERM><![CDATA[Membrane Protein Traffic]]></TERM><TERM><![CDATA[membrane-associated guanylate kinase]]></TERM><TERM><![CDATA[Modification]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[monolayer]]></TERM><TERM><![CDATA[Mutagenesis]]></TERM><TERM><![CDATA[mutant]]></TERM><TERM><![CDATA[Mutation]]></TERM><TERM><![CDATA[Optics]]></TERM><TERM><![CDATA[patch clamp]]></TERM><TERM><![CDATA[Pathway interactions]]></TERM><TERM><![CDATA[Phenotype]]></TERM><TERM><![CDATA[Play]]></TERM><TERM><![CDATA[Population]]></TERM><TERM><![CDATA[Post-Translational Protein Processing]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[Property]]></TERM><TERM><![CDATA[protein protein interaction]]></TERM><TERM><![CDATA[protein purification]]></TERM><TERM><![CDATA[protein transport]]></TERM><TERM><![CDATA[Proteins]]></TERM><TERM><![CDATA[Proteomics]]></TERM><TERM><![CDATA[Publishing]]></TERM><TERM><![CDATA[Recycling]]></TERM><TERM><![CDATA[Regulation]]></TERM><TERM><![CDATA[research study]]></TERM><TERM><![CDATA[Rest]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[scaffold]]></TERM><TERM><![CDATA[Scaffolding Protein]]></TERM><TERM><![CDATA[Sick Sinus Syndrome]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[simulation]]></TERM><TERM><![CDATA[Sodium Channel]]></TERM><TERM><![CDATA[Sudden infant death syndrome]]></TERM><TERM><![CDATA[Surface]]></TERM><TERM><![CDATA[Syndrome]]></TERM><TERM><![CDATA[syntrophin]]></TERM><TERM><![CDATA[System]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[tool]]></TERM><TERM><![CDATA[trafficking]]></TERM><TERM><![CDATA[Two-Hybrid System Techniques]]></TERM><TERM><![CDATA[Ventricular]]></TERM><TERM><![CDATA[Viral]]></TERM><TERM><![CDATA[virtual]]></TERM><TERM><![CDATA[voltage]]></TERM><TERM><![CDATA[Work]]></TERM><TERM><![CDATA[Yeasts]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Intermolecular Interactions of NaV1.5 and Kir2.1 In Ion Channel Diseases]]></PROJECT_TITLE><SERIAL_NUMBER>122352</SERIAL_NUMBER><STUDY_SECTION>ESTA</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Electrical Signaling, Ion Transport, and Arrhythmias Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>311636</DIRECT_COST_AMT><INDIRECT_COST_AMT>115493</INDIRECT_COST_AMT><TOTAL_COST>427129</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8966040</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>HL</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/05/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>837</CFDA_CODE><CORE_PROJECT_NUM>R01HL123605</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>PA-13-302</FOA_NUMBER><FULL_PROJECT_NUM>5R01HL123605-03</FULL_PROJECT_NUM><FUNDING_ICs>NHLBI:385875\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL HEART, LUNG, AND BLOOD INSTITUTE</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>OKLAHOMA CITY</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>05</ORG_DISTRICT><ORG_DUNS>077333797</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[OKLAHOMA MEDICAL RESEARCH FOUNDATION]]></ORG_NAME><ORG_STATE>OK</ORG_STATE><ORG_ZIPCODE>731045005</ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>AHAMED, JASIMUDDIN </PI_NAME><PI_ID>9425980</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>GAO, YUNLING </PROGRAM_OFFICER_NAME><PROJECT_START>11/07/2014</PROJECT_START><PROJECT_END>10/31/2018</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[Animal Model]]></TERM><TERM><![CDATA[aorta constriction]]></TERM><TERM><![CDATA[aortic valve]]></TERM><TERM><![CDATA[Aortic Valve Stenosis]]></TERM><TERM><![CDATA[ascending aorta]]></TERM><TERM><![CDATA[Biochemical]]></TERM><TERM><![CDATA[Biological Markers]]></TERM><TERM><![CDATA[Blood Circulation]]></TERM><TERM><![CDATA[Blood Platelets]]></TERM><TERM><![CDATA[Breeding]]></TERM><TERM><![CDATA[Cessation of life]]></TERM><TERM><![CDATA[Cholesterol]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[Complex]]></TERM><TERM><![CDATA[constriction]]></TERM><TERM><![CDATA[coronary fibrosis]]></TERM><TERM><![CDATA[cytokine]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Diagnostic]]></TERM><TERM><![CDATA[Disease model]]></TERM><TERM><![CDATA[disulfide bond]]></TERM><TERM><![CDATA[Disulfides]]></TERM><TERM><![CDATA[Elderly]]></TERM><TERM><![CDATA[Event]]></TERM><TERM><![CDATA[Fibrosis]]></TERM><TERM><![CDATA[Functional disorder]]></TERM><TERM><![CDATA[Genes]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Heart]]></TERM><TERM><![CDATA[Heart failure]]></TERM><TERM><![CDATA[Heart Transplantation]]></TERM><TERM><![CDATA[Hemorrhage]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[human TGFB1 protein]]></TERM><TERM><![CDATA[Hyperlipidemia]]></TERM><TERM><![CDATA[Implant]]></TERM><TERM><![CDATA[implantation]]></TERM><TERM><![CDATA[In Vitro]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[Intervention]]></TERM><TERM><![CDATA[Isomerase]]></TERM><TERM><![CDATA[Label]]></TERM><TERM><![CDATA[latency-associated protein]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[Left]]></TERM><TERM><![CDATA[Mass Spectrum Analysis]]></TERM><TERM><![CDATA[Measures]]></TERM><TERM><![CDATA[Medical]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[Molecular Conformation]]></TERM><TERM><![CDATA[Molecular Weight]]></TERM><TERM><![CDATA[Monitor]]></TERM><TERM><![CDATA[mouse model]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[Mutagenesis]]></TERM><TERM><![CDATA[mutant]]></TERM><TERM><![CDATA[Mutation]]></TERM><TERM><![CDATA[neutralizing antibody]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[novel diagnostics]]></TERM><TERM><![CDATA[Operative Surgical Procedures]]></TERM><TERM><![CDATA[Pathology]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Phosphorylation]]></TERM><TERM><![CDATA[Plasma]]></TERM><TERM><![CDATA[Plasminogen Activator Inhibitor 1]]></TERM><TERM><![CDATA[Platelet Activation]]></TERM><TERM><![CDATA[pressure]]></TERM><TERM><![CDATA[prevent]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[Proteins]]></TERM><TERM><![CDATA[Proteomics]]></TERM><TERM><![CDATA[Recombinant Proteins]]></TERM><TERM><![CDATA[Recombinant Transforming Growth Factor]]></TERM><TERM><![CDATA[Recombinants]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[Risk]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[shear stress]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[Source]]></TERM><TERM><![CDATA[Sulfhydryl Compounds]]></TERM><TERM><![CDATA[Surrogate Markers]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Thrombosis]]></TERM><TERM><![CDATA[Thrombospondin 1]]></TERM><TERM><![CDATA[tool]]></TERM><TERM><![CDATA[Transforming Growth Factor beta]]></TERM><TERM><![CDATA[Transforming Growth Factors]]></TERM><TERM><![CDATA[valve replacement]]></TERM><TERM><![CDATA[ventricular assist device]]></TERM><TERM><![CDATA[von Willebrand Factor]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[The Mechanism of Shear-Induced Release and Activation of TGF-beta1]]></PROJECT_TITLE><SERIAL_NUMBER>123605</SERIAL_NUMBER><STUDY_SECTION>HT</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Hemostasis and Thrombosis Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>03</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>225000</DIRECT_COST_AMT><INDIRECT_COST_AMT>160875</INDIRECT_COST_AMT><TOTAL_COST>385875</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8966701</APPLICATION_ID><ACTIVITY>R21</ACTIVITY><ADMINISTERING_IC>MH</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/05/2015</AWARD_NOTICE_DATE><BUDGET_START>11/05/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>242</CFDA_CODE><CORE_PROJECT_NUM>R21MH103963</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-13-303</FOA_NUMBER><FULL_PROJECT_NUM>5R21MH103963-02</FULL_PROJECT_NUM><FUNDING_ICs>NIMH:180000\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF MENTAL HEALTH</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>PHILADELPHIA</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[GENETICS]]></ORG_DEPT><ORG_DISTRICT>02</ORG_DISTRICT><ORG_DUNS>042250712</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIVERSITY OF PENNSYLVANIA]]></ORG_NAME><ORG_STATE>PA</ORG_STATE><ORG_ZIPCODE>191046205</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Sleep abnormalities are seen in virtually all psychiatric disorders. Given the important need for effective basic and translational RDoC-based research across these complex and common diseases, we believe that application of novel rest: activity monitoring methods combined with genomic characterization and diagnostic measures make the timing ideal for this pilot project.]]></PHR><PIS><PI><PI_NAME>BUCAN, MAJA </PI_NAME><PI_ID>1880195</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>KOESTER, SUSAN E</PROGRAM_OFFICER_NAME><PROJECT_START>11/10/2014</PROJECT_START><PROJECT_END>10/31/2016</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[actigraphy]]></TERM><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[Architecture]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Basic Science]]></TERM><TERM><![CDATA[Bipolar Disorder]]></TERM><TERM><![CDATA[Categories]]></TERM><TERM><![CDATA[Childhood]]></TERM><TERM><![CDATA[circadian pacemaker]]></TERM><TERM><![CDATA[Circadian Rhythms]]></TERM><TERM><![CDATA[Clinic]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[Complex]]></TERM><TERM><![CDATA[Consensus]]></TERM><TERM><![CDATA[cost]]></TERM><TERM><![CDATA[cost effective]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[depressive symptoms]]></TERM><TERM><![CDATA[Devices]]></TERM><TERM><![CDATA[Diagnostic]]></TERM><TERM><![CDATA[Dimensions]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Dissection]]></TERM><TERM><![CDATA[Dizygotic Twins]]></TERM><TERM><![CDATA[endophenotype]]></TERM><TERM><![CDATA[Environment]]></TERM><TERM><![CDATA[Environmental Risk Factor]]></TERM><TERM><![CDATA[Evaluation]]></TERM><TERM><![CDATA[exome sequencing]]></TERM><TERM><![CDATA[Functional disorder]]></TERM><TERM><![CDATA[Genetic]]></TERM><TERM><![CDATA[Genetic Heterogeneity]]></TERM><TERM><![CDATA[genome sequencing]]></TERM><TERM><![CDATA[Genomics]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Heritability]]></TERM><TERM><![CDATA[Heterogeneity]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[Individual Differences]]></TERM><TERM><![CDATA[insight]]></TERM><TERM><![CDATA[Manic]]></TERM><TERM><![CDATA[Measurable]]></TERM><TERM><![CDATA[Measures]]></TERM><TERM><![CDATA[Mental Depression]]></TERM><TERM><![CDATA[Mental disorders]]></TERM><TERM><![CDATA[Methodology]]></TERM><TERM><![CDATA[Methods]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[Monitor]]></TERM><TERM><![CDATA[Monozygotic Twinning]]></TERM><TERM><![CDATA[Monozygotic twins]]></TERM><TERM><![CDATA[Mood Disorders]]></TERM><TERM><![CDATA[Moods]]></TERM><TERM><![CDATA[National Institute of Mental Health (U.S.)]]></TERM><TERM><![CDATA[Neurodegenerative Disorders]]></TERM><TERM><![CDATA[neuropsychiatry]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[Outpatients]]></TERM><TERM><![CDATA[Pathway interactions]]></TERM><TERM><![CDATA[Patient Self-Report]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Pattern]]></TERM><TERM><![CDATA[Pennsylvania]]></TERM><TERM><![CDATA[Phenotype]]></TERM><TERM><![CDATA[Physical activity]]></TERM><TERM><![CDATA[Pilot Projects]]></TERM><TERM><![CDATA[Polysomnography]]></TERM><TERM><![CDATA[Population]]></TERM><TERM><![CDATA[Protocols documentation]]></TERM><TERM><![CDATA[Psychiatrist]]></TERM><TERM><![CDATA[psychogenetics]]></TERM><TERM><![CDATA[Psychologist]]></TERM><TERM><![CDATA[Psychopathology]]></TERM><TERM><![CDATA[rare variant]]></TERM><TERM><![CDATA[Recruitment Activity]]></TERM><TERM><![CDATA[Registries]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Research Domain Criteria]]></TERM><TERM><![CDATA[Rest]]></TERM><TERM><![CDATA[Sampling]]></TERM><TERM><![CDATA[Series]]></TERM><TERM><![CDATA[Severities]]></TERM><TERM><![CDATA[Sleep]]></TERM><TERM><![CDATA[sleep abnormalities]]></TERM><TERM><![CDATA[Sleep disturbances]]></TERM><TERM><![CDATA[sleep regulation]]></TERM><TERM><![CDATA[Subgroup]]></TERM><TERM><![CDATA[Symptoms]]></TERM><TERM><![CDATA[Syndrome]]></TERM><TERM><![CDATA[Technology]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[trait]]></TERM><TERM><![CDATA[Translating]]></TERM><TERM><![CDATA[Translational Research]]></TERM><TERM><![CDATA[Treadmill Tests]]></TERM><TERM><![CDATA[treatment program]]></TERM><TERM><![CDATA[Twin Multiple Birth]]></TERM><TERM><![CDATA[Twin Studies]]></TERM><TERM><![CDATA[Variation (Genetics)]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Activity as an endophenotype for genetic studies]]></PROJECT_TITLE><SERIAL_NUMBER>103963</SERIAL_NUMBER><STUDY_SECTION>BGES</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Behavioral Genetics and Epidemiology Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>112500</DIRECT_COST_AMT><INDIRECT_COST_AMT>67500</INDIRECT_COST_AMT><TOTAL_COST>180000</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8967583</APPLICATION_ID><ACTIVITY>R21</ACTIVITY><ADMINISTERING_IC>HL</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/03/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>837</CFDA_CODE><CORE_PROJECT_NUM>R21HL125998</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF ARTS AND SCIENCES]]></ED_INST_TYPE><FOA_NUMBER>PA-12-284</FOA_NUMBER><FULL_PROJECT_NUM>5R21HL125998-02</FULL_PROJECT_NUM><FUNDING_ICs>NHLBI:199884\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL HEART, LUNG, AND BLOOD INSTITUTE</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>ROCHESTER</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[NONE]]></ORG_DEPT><ORG_DISTRICT>25</ORG_DISTRICT><ORG_DUNS>002223642</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[ROCHESTER INSTITUTE OF TECHNOLOGY]]></ORG_NAME><ORG_STATE>NY</ORG_STATE><ORG_ZIPCODE>146235603</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Catheter ablation is an important therapy that treats ventricular arrhythmia by destroying the culprit tissue causing arrhythmia. However, the current paradigm of VT ablation is associated with low success and high complication rates due to the lack of a technology to effectively and safely locate ablation targets prior to the therapy. We wil develop a new noninvasive, transmural, and high-resolution imaging technology to map the substrate and dynamics of ventricular arrhythmia, which will improve the clinical outcomes of VT ablation by providing better pre-procedural planning and targeting.]]></PHR><PIS><PI><PI_NAME>WANG, LINWEI </PI_NAME><PI_ID>9889988</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>LATHROP, DAVID A.</PROGRAM_OFFICER_NAME><PROJECT_START>11/12/2014</PROJECT_START><PROJECT_END>10/31/2016</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Ablation]]></TERM><TERM><![CDATA[Algorithms]]></TERM><TERM><![CDATA[Anatomy]]></TERM><TERM><![CDATA[Animal Model]]></TERM><TERM><![CDATA[Animals]]></TERM><TERM><![CDATA[Arrhythmia]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Body Surface]]></TERM><TERM><![CDATA[Body Surface Potential Mapping]]></TERM><TERM><![CDATA[Cardiac ablation]]></TERM><TERM><![CDATA[Catheters]]></TERM><TERM><![CDATA[Cicatrix]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[clinical practice]]></TERM><TERM><![CDATA[Clinical Research]]></TERM><TERM><![CDATA[Clinical Trials]]></TERM><TERM><![CDATA[Collaborations]]></TERM><TERM><![CDATA[Complication]]></TERM><TERM><![CDATA[Computational algorithm]]></TERM><TERM><![CDATA[Coronary]]></TERM><TERM><![CDATA[cost]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Death, Sudden, Cardiac]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Electrocardiogram]]></TERM><TERM><![CDATA[Family suidae]]></TERM><TERM><![CDATA[Fruit]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Heart]]></TERM><TERM><![CDATA[Heart Diseases]]></TERM><TERM><![CDATA[heart rhythm]]></TERM><TERM><![CDATA[Histology]]></TERM><TERM><![CDATA[Hospitals]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[Image]]></TERM><TERM><![CDATA[Imaging Device]]></TERM><TERM><![CDATA[Imaging technology]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[Infarction]]></TERM><TERM><![CDATA[Institutes]]></TERM><TERM><![CDATA[Investigation]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[Life]]></TERM><TERM><![CDATA[Magnetic Resonance Imaging]]></TERM><TERM><![CDATA[Maps]]></TERM><TERM><![CDATA[Modality]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Morbidity - disease rate]]></TERM><TERM><![CDATA[Morphology]]></TERM><TERM><![CDATA[Mortality Vital Statistics]]></TERM><TERM><![CDATA[Outcome]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Performance]]></TERM><TERM><![CDATA[Physicians]]></TERM><TERM><![CDATA[Procedures]]></TERM><TERM><![CDATA[Recurrence]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Resolution]]></TERM><TERM><![CDATA[Safety]]></TERM><TERM><![CDATA[Scientist]]></TERM><TERM><![CDATA[Sinus]]></TERM><TERM><![CDATA[Site]]></TERM><TERM><![CDATA[standard of care]]></TERM><TERM><![CDATA[success]]></TERM><TERM><![CDATA[Surface]]></TERM><TERM><![CDATA[Technology]]></TERM><TERM><![CDATA[Therapeutic]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[Tissues]]></TERM><TERM><![CDATA[United States]]></TERM><TERM><![CDATA[Universities]]></TERM><TERM><![CDATA[Ventricular]]></TERM><TERM><![CDATA[Ventricular Arrhythmia]]></TERM><TERM><![CDATA[Ventricular Tachycardia]]></TERM><TERM><![CDATA[voltage]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Transmural Electrophysiological Imaging to Guide Catheter Ablation of Arrhythmias]]></PROJECT_TITLE><SERIAL_NUMBER>125998</SERIAL_NUMBER><STUDY_SECTION>BMIT</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Biomedical Imaging Technology Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>175224</DIRECT_COST_AMT><INDIRECT_COST_AMT>24660</INDIRECT_COST_AMT><TOTAL_COST>199884</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8968266</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>HL</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/05/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>837</CFDA_CODE><CORE_PROJECT_NUM>R01HL125303</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-13-302</FOA_NUMBER><FULL_PROJECT_NUM>5R01HL125303-02</FULL_PROJECT_NUM><FUNDING_ICs>NHLBI:508902\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL HEART, LUNG, AND BLOOD INSTITUTE</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>STANFORD</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[INTERNAL MEDICINE/MEDICINE]]></ORG_DEPT><ORG_DISTRICT>18</ORG_DISTRICT><ORG_DUNS>009214214</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[STANFORD UNIVERSITY]]></ORG_NAME><ORG_STATE>CA</ORG_STATE><ORG_ZIPCODE>943041222</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: The proposed research will provide evidence-based strategies for the evaluation and acceptance of donor hearts for transplantation. This is relevant to public health because judicious expansion of donor hearts used for transplantation will make this life-saving procedure available to a larger number of patients living with end- stage heart disease.]]></PHR><PIS><PI><PI_NAME>KHUSH, KIRAN KAUR</PI_NAME><PI_ID>8866950</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>SHAH, MONICA R</PROGRAM_OFFICER_NAME><PROJECT_START>11/15/2014</PROJECT_START><PROJECT_END>10/31/2019</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[adjudicate]]></TERM><TERM><![CDATA[adverse outcome]]></TERM><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[Age]]></TERM><TERM><![CDATA[Allografting]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Biological Markers]]></TERM><TERM><![CDATA[Brain Death]]></TERM><TERM><![CDATA[Brain natriuretic peptide]]></TERM><TERM><![CDATA[Cardiac]]></TERM><TERM><![CDATA[Cause of Death]]></TERM><TERM><![CDATA[Characteristics]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[Collection]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Data Collection]]></TERM><TERM><![CDATA[Databases]]></TERM><TERM><![CDATA[Decision Making]]></TERM><TERM><![CDATA[Echocardiography]]></TERM><TERM><![CDATA[Electrocardiogram]]></TERM><TERM><![CDATA[Evaluation]]></TERM><TERM><![CDATA[evidence base]]></TERM><TERM><![CDATA[Functional disorder]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[graft function]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Heart]]></TERM><TERM><![CDATA[heart allograft]]></TERM><TERM><![CDATA[Heart Diseases]]></TERM><TERM><![CDATA[heart function]]></TERM><TERM><![CDATA[Heart Transplantation]]></TERM><TERM><![CDATA[Hospitalization]]></TERM><TERM><![CDATA[Human Resources]]></TERM><TERM><![CDATA[Hypertension]]></TERM><TERM><![CDATA[innovation]]></TERM><TERM><![CDATA[Investigation]]></TERM><TERM><![CDATA[Left Ventricular Dysfunction]]></TERM><TERM><![CDATA[Left Ventricular Ejection Fraction]]></TERM><TERM><![CDATA[Left Ventricular Hypertrophy]]></TERM><TERM><![CDATA[Length]]></TERM><TERM><![CDATA[Life]]></TERM><TERM><![CDATA[Myocardial dysfunction]]></TERM><TERM><![CDATA[Organ]]></TERM><TERM><![CDATA[Organ Donor]]></TERM><TERM><![CDATA[Organ Procurements]]></TERM><TERM><![CDATA[Outcome]]></TERM><TERM><![CDATA[Pathology]]></TERM><TERM><![CDATA[patient population]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Population]]></TERM><TERM><![CDATA[Procedures]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[public health medicine (field)]]></TERM><TERM><![CDATA[Recording of previous events]]></TERM><TERM><![CDATA[Reporting]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[Risk]]></TERM><TERM><![CDATA[Staging]]></TERM><TERM><![CDATA[Surveys]]></TERM><TERM><![CDATA[System]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[tool]]></TERM><TERM><![CDATA[Transplant Recipients]]></TERM><TERM><![CDATA[Transplantation]]></TERM><TERM><![CDATA[Troponin I]]></TERM><TERM><![CDATA[United States]]></TERM><TERM><![CDATA[Variant]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Evidence Based Evaluation and Acceptance of Donor Hearts for Transplantation]]></PROJECT_TITLE><SERIAL_NUMBER>125303</SERIAL_NUMBER><STUDY_SECTION>CICS</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Clinical and Integrative Cardiovascular Sciences Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>415954</DIRECT_COST_AMT><INDIRECT_COST_AMT>92948</INDIRECT_COST_AMT><TOTAL_COST>508902</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8984895</APPLICATION_ID><ACTIVITY>IK2</ACTIVITY><ADMINISTERING_IC>VA</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/05/2015</AWARD_NOTICE_DATE><BUDGET_START>10/01/2015</BUDGET_START><BUDGET_END>09/30/2016</BUDGET_END><CFDA_CODE>999</CFDA_CODE><CORE_PROJECT_NUM>IK2RX000709</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-RX-11-020</FOA_NUMBER><FULL_PROJECT_NUM>5IK2RX000709-03</FULL_PROJECT_NUM><FUNDING_ICs>VA:159760\</FUNDING_ICs><FUNDING_MECHANISM>OTHERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>Veterans Affairs</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>MINNEAPOLIS</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>05</ORG_DISTRICT><ORG_DUNS>071774624</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[MINNEAPOLIS VA  MEDICAL CENTER]]></ORG_NAME><ORG_STATE>MN</ORG_STATE><ORG_ZIPCODE>554172309</ORG_ZIPCODE><PHR><![CDATA[The proposed research addresses potential neurological disruptions associated with mild traumatic brain  injury (mTBI), or concussion, that results from exposure to an explosive blast. This condition is among the  major sources of injury in veterans of recent conflicts and represents a substantial cost in terms of disability  and treatment. One of the goals of the proposed research is to establish a biological basis for identifying  damage associated with this condition, which would have dramatic implications for diagnosis and differentiation  from other conditions such as post-traumatic stress disorder. The other major goal of the proposed research is  to characterize the neurological effects of deployment stress and its interaction with
blast-related mTBI. The  results of these investigations have the potential to contribute valuable information to discussions of how best  to protect service members and prevent long-term brain injury.]]></PHR><PIS><PI><PI_NAME>DAVENPORT, NICHOLAS DAVID</PI_NAME><PI_ID>10516934</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>10/01/2013</PROJECT_START><PROJECT_END>09/30/2018</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[Attention]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[behavior measurement]]></TERM><TERM><![CDATA[Behavioral]]></TERM><TERM><![CDATA[Biological]]></TERM><TERM><![CDATA[Blast Cell]]></TERM><TERM><![CDATA[Brain]]></TERM><TERM><![CDATA[Brain Concussion]]></TERM><TERM><![CDATA[Brain Injuries]]></TERM><TERM><![CDATA[Brain region]]></TERM><TERM><![CDATA[career]]></TERM><TERM><![CDATA[career development]]></TERM><TERM><![CDATA[Caring]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[Clinical assessments]]></TERM><TERM><![CDATA[Clinical Services]]></TERM><TERM><![CDATA[Cognition]]></TERM><TERM><![CDATA[Cognitive]]></TERM><TERM><![CDATA[cognitive function]]></TERM><TERM><![CDATA[cognitive performance]]></TERM><TERM><![CDATA[cognitive reserve]]></TERM><TERM><![CDATA[Collection]]></TERM><TERM><![CDATA[combat]]></TERM><TERM><![CDATA[Conflict (Psychology)]]></TERM><TERM><![CDATA[cost]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Diagnosis]]></TERM><TERM><![CDATA[disability]]></TERM><TERM><![CDATA[Distant]]></TERM><TERM><![CDATA[Educational aspects]]></TERM><TERM><![CDATA[Elements]]></TERM><TERM><![CDATA[Emotional]]></TERM><TERM><![CDATA[Ensure]]></TERM><TERM><![CDATA[experience]]></TERM><TERM><![CDATA[Exposure to]]></TERM><TERM><![CDATA[Funding]]></TERM><TERM><![CDATA[Future]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Healthcare Systems]]></TERM><TERM><![CDATA[Impaired cognition]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[Injury]]></TERM><TERM><![CDATA[Institutional Review Boards]]></TERM><TERM><![CDATA[Investigation]]></TERM><TERM><![CDATA[Leadership]]></TERM><TERM><![CDATA[Magnetic Resonance Imaging]]></TERM><TERM><![CDATA[Measures]]></TERM><TERM><![CDATA[meetings]]></TERM><TERM><![CDATA[member]]></TERM><TERM><![CDATA[Mental Depression]]></TERM><TERM><![CDATA[Mentors]]></TERM><TERM><![CDATA[Methods]]></TERM><TERM><![CDATA[Military Personnel]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Nature]]></TERM><TERM><![CDATA[neuroimaging]]></TERM><TERM><![CDATA[Neurologic]]></TERM><TERM><![CDATA[neuropsychological]]></TERM><TERM><![CDATA[Neuropsychological Tests]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Performance]]></TERM><TERM><![CDATA[Physiological]]></TERM><TERM><![CDATA[Population]]></TERM><TERM><![CDATA[Post-Traumatic Stress Disorders]]></TERM><TERM><![CDATA[prevent]]></TERM><TERM><![CDATA[psychologic]]></TERM><TERM><![CDATA[Psychological Stress]]></TERM><TERM><![CDATA[Recording of previous events]]></TERM><TERM><![CDATA[Rehabilitation Centers]]></TERM><TERM><![CDATA[relating to nervous system]]></TERM><TERM><![CDATA[Relative (related person)]]></TERM><TERM><![CDATA[Reporting]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Resources]]></TERM><TERM><![CDATA[Services]]></TERM><TERM><![CDATA[skills]]></TERM><TERM><![CDATA[Soldier]]></TERM><TERM><![CDATA[Source]]></TERM><TERM><![CDATA[Stress]]></TERM><TERM><![CDATA[Surveys]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[Training]]></TERM><TERM><![CDATA[Training Activity]]></TERM><TERM><![CDATA[Veterans]]></TERM><TERM><![CDATA[white matter]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Structural & Functional Connectivity Disruptions Associated with Blast TBI]]></PROJECT_TITLE><SERIAL_NUMBER>000709</SERIAL_NUMBER><STUDY_SECTION>RRD8</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Blank ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>03</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST></TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8988598</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>MH</ADMINISTERING_IC><APPLICATION_TYPE>4</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/20/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>242</CFDA_CODE><CORE_PROJECT_NUM>R01MH080225</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF ARTS AND SCIENCES]]></ED_INST_TYPE><FOA_NUMBER>PA-11-260</FOA_NUMBER><FULL_PROJECT_NUM>4R01MH080225-09</FULL_PROJECT_NUM><FUNDING_ICs>NIMH:338625\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF MENTAL HEALTH</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>MADISON</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[ZOOLOGY]]></ORG_DEPT><ORG_DISTRICT>02</ORG_DISTRICT><ORG_DUNS>161202122</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIVERSITY OF WISCONSIN-MADISON]]></ORG_NAME><ORG_STATE>WI</ORG_STATE><ORG_ZIPCODE>537151218</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Deficits in social communication are a hallmark of several mental disorders, including autism spectrum disorders, depression, and anxiety. Such disorders are characterized by social withdrawal and deficits in the ability to communicate appropriately in distinct social contexts. The proposed research will identify manipulations that stimulate context-appropriate social interactions, which can be used in the design of clinical interventions in humans with context-specific deficits in social communication.]]></PHR><PIS><PI><PI_NAME>RITERS, LAUREN V</PI_NAME><PI_ID>1890382</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>SIMMONS, JANINE M</PROGRAM_OFFICER_NAME><PROJECT_START>12/10/2007</PROJECT_START><PROJECT_END>10/31/2017</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[Affective]]></TERM><TERM><![CDATA[Anxiety]]></TERM><TERM><![CDATA[Apple]]></TERM><TERM><![CDATA[Area]]></TERM><TERM><![CDATA[autism spectrum disorder]]></TERM><TERM><![CDATA[Autistic Disorder]]></TERM><TERM><![CDATA[Back]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[behavior influence]]></TERM><TERM><![CDATA[Behavioral]]></TERM><TERM><![CDATA[Biological Models]]></TERM><TERM><![CDATA[Cations]]></TERM><TERM><![CDATA[Characteristics]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[Communication]]></TERM><TERM><![CDATA[Communications Media]]></TERM><TERM><![CDATA[Copulation]]></TERM><TERM><![CDATA[Coupled]]></TERM><TERM><![CDATA[Courtship]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Dopamine]]></TERM><TERM><![CDATA[emotional stimulus]]></TERM><TERM><![CDATA[Food]]></TERM><TERM><![CDATA[Functional disorder]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Heart]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[Individual Differences]]></TERM><TERM><![CDATA[innovation]]></TERM><TERM><![CDATA[insight]]></TERM><TERM><![CDATA[interest]]></TERM><TERM><![CDATA[Intervention]]></TERM><TERM><![CDATA[Link]]></TERM><TERM><![CDATA[male]]></TERM><TERM><![CDATA[Measures]]></TERM><TERM><![CDATA[medial preoptic nucleus]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[Mental Depression]]></TERM><TERM><![CDATA[Mental disorders]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Motivation]]></TERM><TERM><![CDATA[Narcotic Antagonists]]></TERM><TERM><![CDATA[neurochemistry]]></TERM><TERM><![CDATA[neuromechanism]]></TERM><TERM><![CDATA[Neuropeptides]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[Opioid]]></TERM><TERM><![CDATA[Outcome]]></TERM><TERM><![CDATA[Play]]></TERM><TERM><![CDATA[pleasure]]></TERM><TERM><![CDATA[preference]]></TERM><TERM><![CDATA[Principal Investigator]]></TERM><TERM><![CDATA[Psychological reinforcement]]></TERM><TERM><![CDATA[Receptors, Opioid, delta]]></TERM><TERM><![CDATA[Receptors, Opioid, mu]]></TERM><TERM><![CDATA[Regulation]]></TERM><TERM><![CDATA[relating to nervous system]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[Rewards]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Shapes]]></TERM><TERM><![CDATA[Site]]></TERM><TERM><![CDATA[skills]]></TERM><TERM><![CDATA[social]]></TERM><TERM><![CDATA[Social Behavior]]></TERM><TERM><![CDATA[social communication]]></TERM><TERM><![CDATA[Social Environment]]></TERM><TERM><![CDATA[social group]]></TERM><TERM><![CDATA[Social Interaction]]></TERM><TERM><![CDATA[Songbirds]]></TERM><TERM><![CDATA[standard measure]]></TERM><TERM><![CDATA[Stimulus]]></TERM><TERM><![CDATA[Sturnus vulgaris]]></TERM><TERM><![CDATA[System]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[United States National Institutes of Health]]></TERM><TERM><![CDATA[ward]]></TERM><TERM><![CDATA[Western Blotting]]></TERM><TERM><![CDATA[Withdrawal]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Opioids and individual differences in social communication]]></PROJECT_TITLE><SERIAL_NUMBER>080225</SERIAL_NUMBER><STUDY_SECTION>BRLE</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Biobehavioral Regulation, Learning and Ethology Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>09</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>225000</DIRECT_COST_AMT><INDIRECT_COST_AMT>113625</INDIRECT_COST_AMT><TOTAL_COST>338625</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8990864</APPLICATION_ID><ACTIVITY>IK2</ACTIVITY><ADMINISTERING_IC>VA</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/05/2015</AWARD_NOTICE_DATE><BUDGET_START>10/01/2015</BUDGET_START><BUDGET_END>09/30/2016</BUDGET_END><CFDA_CODE>999</CFDA_CODE><CORE_PROJECT_NUM>IK2RX000974</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-RX-13-009</FOA_NUMBER><FULL_PROJECT_NUM>5IK2RX000974-03</FULL_PROJECT_NUM><FUNDING_ICs>VA:101773\</FUNDING_ICs><FUNDING_MECHANISM>OTHERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>Veterans Affairs</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>MATHER</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>07</ORG_DISTRICT><ORG_DUNS>127349889</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[VA NORTHERN CALIFORNIA HEALTH CARE SYS]]></ORG_NAME><ORG_STATE>CA</ORG_STATE><ORG_ZIPCODE>956554200</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE:    
   
 1 The main objective of this study is to improve rehabilitation methods for Veterans with traumatic brain injury  2 (TBI). Current treatments methods, such as Cognitive Rehabilitation Therapy, show some promise, but  3 evaluations of the shortcomings of current rehabilitation methods suggest that characterizing the specific  4 cognitive impairments of TBI patients is a crucial component of improving treatment. This project will do so by  5 investigating speech perception and memory deficits in Veterans with TBI. This project will also characterize  6 the structural abnormalities in the brain associated with these different deficits and differences in functional  7 brain activation in TBI patients compared to controls. Successful completion of the study will provide a set of  8 tools to direct rehabilitation methods in TBI patients. Instead of te current method of broad-based treatment,  9 this more detailed diagnosis of deficits can direct clinicians to instead direct focus on memory training or 10 speech perception training (American Speech-Language-Hearing Association, 1994; Jaeggi et al., 2008).]]></PHR><PIS><PI><PI_NAME>ETTLINGER, MARC </PI_NAME><PI_ID>9291662</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>10/01/2013</PROJECT_START><PROJECT_END>09/30/2016</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Accounting]]></TERM><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[American Speech-Language-Hearing Association]]></TERM><TERM><![CDATA[Area]]></TERM><TERM><![CDATA[Attention]]></TERM><TERM><![CDATA[Audiometry]]></TERM><TERM><![CDATA[Auditory]]></TERM><TERM><![CDATA[Auditory area]]></TERM><TERM><![CDATA[auditory comprehension]]></TERM><TERM><![CDATA[Auditory Perception]]></TERM><TERM><![CDATA[Auditory system]]></TERM><TERM><![CDATA[Award]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Behavior]]></TERM><TERM><![CDATA[behavior test]]></TERM><TERM><![CDATA[Blast Cell]]></TERM><TERM><![CDATA[Brain]]></TERM><TERM><![CDATA[Brain imaging]]></TERM><TERM><![CDATA[Brain region]]></TERM><TERM><![CDATA[career]]></TERM><TERM><![CDATA[Cognition]]></TERM><TERM><![CDATA[Cognitive]]></TERM><TERM><![CDATA[Cognitive deficits]]></TERM><TERM><![CDATA[cognitive function]]></TERM><TERM><![CDATA[cognitive rehabilitation]]></TERM><TERM><![CDATA[Complex]]></TERM><TERM><![CDATA[Comprehension]]></TERM><TERM><![CDATA[Conflict (Psychology)]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Diagnosis]]></TERM><TERM><![CDATA[Elderly]]></TERM><TERM><![CDATA[Evaluation]]></TERM><TERM><![CDATA[Executive Dysfunction]]></TERM><TERM><![CDATA[executive function]]></TERM><TERM><![CDATA[Exhibits]]></TERM><TERM><![CDATA[Freedom]]></TERM><TERM><![CDATA[frontal lobe]]></TERM><TERM><![CDATA[Functional Magnetic Resonance Imaging]]></TERM><TERM><![CDATA[Future]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Grant]]></TERM><TERM><![CDATA[Hearing]]></TERM><TERM><![CDATA[Hearing Aids]]></TERM><TERM><![CDATA[hearing impairment]]></TERM><TERM><![CDATA[Hearing problem]]></TERM><TERM><![CDATA[Hearing Tests]]></TERM><TERM><![CDATA[Image]]></TERM><TERM><![CDATA[Impaired cognition]]></TERM><TERM><![CDATA[Impairment]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[Incidence]]></TERM><TERM><![CDATA[innovation]]></TERM><TERM><![CDATA[Language]]></TERM><TERM><![CDATA[Magnetic Resonance Imaging]]></TERM><TERM><![CDATA[Memory]]></TERM><TERM><![CDATA[Memory impairment]]></TERM><TERM><![CDATA[Mentors]]></TERM><TERM><![CDATA[Methods]]></TERM><TERM><![CDATA[Multimodal Imaging]]></TERM><TERM><![CDATA[neuroimaging]]></TERM><TERM><![CDATA[Neurology]]></TERM><TERM><![CDATA[Neuropsychology]]></TERM><TERM><![CDATA[operation]]></TERM><TERM><![CDATA[Participant]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Pattern]]></TERM><TERM><![CDATA[Perception]]></TERM><TERM><![CDATA[Performance]]></TERM><TERM><![CDATA[Peripheral]]></TERM><TERM><![CDATA[Phonetics]]></TERM><TERM><![CDATA[phonology]]></TERM><TERM><![CDATA[Plant Roots]]></TERM><TERM><![CDATA[Play]]></TERM><TERM><![CDATA[Population]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[Property]]></TERM><TERM><![CDATA[public health relevance]]></TERM><TERM><![CDATA[Publishing]]></TERM><TERM><![CDATA[Rehabilitation therapy]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Research Personnel]]></TERM><TERM><![CDATA[Resources]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Scanning]]></TERM><TERM><![CDATA[screening]]></TERM><TERM><![CDATA[Short-Term Memory]]></TERM><TERM><![CDATA[Speech]]></TERM><TERM><![CDATA[Speech Perception]]></TERM><TERM><![CDATA[Structure]]></TERM><TERM><![CDATA[TBI Patients]]></TERM><TERM><![CDATA[Techniques]]></TERM><TERM><![CDATA[Tinnitus]]></TERM><TERM><![CDATA[Tissues]]></TERM><TERM><![CDATA[tool]]></TERM><TERM><![CDATA[Training]]></TERM><TERM><![CDATA[Traumatic Brain Injury]]></TERM><TERM><![CDATA[Veterans]]></TERM><TERM><![CDATA[Wood material]]></TERM><TERM><![CDATA[Work]]></TERM><TERM><![CDATA[wound]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Auditory perception and cognition following TBI]]></PROJECT_TITLE><SERIAL_NUMBER>000974</SERIAL_NUMBER><STUDY_SECTION>RRD8</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Blank ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>03</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST></TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8996546</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>AI</ADMINISTERING_IC><APPLICATION_TYPE>4</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/22/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>855</CFDA_CODE><CORE_PROJECT_NUM>R01AI056234</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-10-067</FOA_NUMBER><FULL_PROJECT_NUM>4R01AI056234-13</FULL_PROJECT_NUM><FUNDING_ICs>NIAID:412500\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>BOSTON</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[PATHOLOGY]]></ORG_DEPT><ORG_DISTRICT>07</ORG_DISTRICT><ORG_DUNS>039318308</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[TUFTS UNIVERSITY BOSTON]]></ORG_NAME><ORG_STATE>MA</ORG_STATE><ORG_ZIPCODE>021111901</ORG_ZIPCODE><PHR><![CDATA[Mechanisms of control of septic shock and human responses to G(-) infections and lipopolysaccharide (LPS), are poorly understood. The proposal is concerned with identification of genes that confer resistance to LPS and its main effector TNF (tumor necrosis factor). The identification of these genes could lead to diagnostics or even open new opportunities for therapeutic intervention. Importantly, targeting the TNF-activation pathway, a relatively late event in the progression of septic shock, will likely be more beneficial than therapies currently explored by several pharmaceutical companies.]]></PHR><PIS><PI><PI_NAME>POLTORAK, ALEXANDER </PI_NAME><PI_ID>6714175</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>DAVIDSON, WENDY F.</PROGRAM_OFFICER_NAME><PROJECT_START>09/01/2003</PROJECT_START><PROJECT_END>10/31/2016</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Acute]]></TERM><TERM><![CDATA[Alleles]]></TERM><TERM><![CDATA[Apoptosis]]></TERM><TERM><![CDATA[Area]]></TERM><TERM><![CDATA[Autoimmunity]]></TERM><TERM><![CDATA[Bioinformatics]]></TERM><TERM><![CDATA[C57BL/6 Mouse]]></TERM><TERM><![CDATA[Candidate Disease Gene]]></TERM><TERM><![CDATA[caspase]]></TERM><TERM><![CDATA[Cell Death]]></TERM><TERM><![CDATA[Cell Survival]]></TERM><TERM><![CDATA[Cessation of life]]></TERM><TERM><![CDATA[Chromosome Mapping]]></TERM><TERM><![CDATA[Chronic]]></TERM><TERM><![CDATA[clinically relevant]]></TERM><TERM><![CDATA[clinically significant]]></TERM><TERM><![CDATA[Cloning]]></TERM><TERM><![CDATA[Complex]]></TERM><TERM><![CDATA[Congenic Mice]]></TERM><TERM><![CDATA[Couples]]></TERM><TERM><![CDATA[Coupling]]></TERM><TERM><![CDATA[cytotoxic]]></TERM><TERM><![CDATA[cytotoxicity]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Defect]]></TERM><TERM><![CDATA[Diagnostic]]></TERM><TERM><![CDATA[Dose]]></TERM><TERM><![CDATA[Equilibrium]]></TERM><TERM><![CDATA[Event]]></TERM><TERM><![CDATA[Family member]]></TERM><TERM><![CDATA[Funding]]></TERM><TERM><![CDATA[Gene Expression Profiling]]></TERM><TERM><![CDATA[Generations]]></TERM><TERM><![CDATA[Genes]]></TERM><TERM><![CDATA[Genetic]]></TERM><TERM><![CDATA[genetic analysis]]></TERM><TERM><![CDATA[Genomic Segment]]></TERM><TERM><![CDATA[Genotype]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[human TNF protein]]></TERM><TERM><![CDATA[Immune response]]></TERM><TERM><![CDATA[Immune system]]></TERM><TERM><![CDATA[immunopathology]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[Inbred Mouse]]></TERM><TERM><![CDATA[Inbred Strain]]></TERM><TERM><![CDATA[Inbred Strains Mice]]></TERM><TERM><![CDATA[Inbreeding]]></TERM><TERM><![CDATA[Infection]]></TERM><TERM><![CDATA[Inflammation]]></TERM><TERM><![CDATA[Inflammatory]]></TERM><TERM><![CDATA[Inflammatory Response]]></TERM><TERM><![CDATA[insight]]></TERM><TERM><![CDATA[Interleukin-1]]></TERM><TERM><![CDATA[Interleukin-6]]></TERM><TERM><![CDATA[Investigation]]></TERM><TERM><![CDATA[IRAK1 gene]]></TERM><TERM><![CDATA[IRAK2 gene]]></TERM><TERM><![CDATA[Laboratory mice]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[Link]]></TERM><TERM><![CDATA[Lipopolysaccharides]]></TERM><TERM><![CDATA[Liver]]></TERM><TERM><![CDATA[Liver Disease Shock Liver]]></TERM><TERM><![CDATA[Liver Failure]]></TERM><TERM><![CDATA[macrophage]]></TERM><TERM><![CDATA[MAP Kinase Gene]]></TERM><TERM><![CDATA[MAP3K7 gene]]></TERM><TERM><![CDATA[MAPK14 gene]]></TERM><TERM><![CDATA[Maps]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[Mediator of activation protein]]></TERM><TERM><![CDATA[men who have sex with men]]></TERM><TERM><![CDATA[mitogen-activated protein kinase p38]]></TERM><TERM><![CDATA[Mitogen-Activated Protein Kinases]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[Mutation]]></TERM><TERM><![CDATA[Natural Selections]]></TERM><TERM><![CDATA[Necrosis]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[Organ]]></TERM><TERM><![CDATA[Outcome]]></TERM><TERM><![CDATA[Pathology]]></TERM><TERM><![CDATA[Pathway interactions]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Pharmacologic Substance]]></TERM><TERM><![CDATA[Phase]]></TERM><TERM><![CDATA[Phenotype]]></TERM><TERM><![CDATA[Phosphotransferases]]></TERM><TERM><![CDATA[Play]]></TERM><TERM><![CDATA[positional cloning]]></TERM><TERM><![CDATA[pressure]]></TERM><TERM><![CDATA[Principal Investigator]]></TERM><TERM><![CDATA[programs]]></TERM><TERM><![CDATA[Progress Reports]]></TERM><TERM><![CDATA[receptor]]></TERM><TERM><![CDATA[Receptor Activation]]></TERM><TERM><![CDATA[receptor function]]></TERM><TERM><![CDATA[Regulation]]></TERM><TERM><![CDATA[Reporting]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Resistance]]></TERM><TERM><![CDATA[Resolution]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Schistosomiasis]]></TERM><TERM><![CDATA[Sepsis]]></TERM><TERM><![CDATA[Septic Shock]]></TERM><TERM><![CDATA[Serine]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[Therapeutic Intervention]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[trait]]></TERM><TERM><![CDATA[Tumor Necrosis Factor Activation]]></TERM><TERM><![CDATA[Tumor Necrosis Factor Receptor]]></TERM><TERM><![CDATA[Tumor Necrosis Factor-alpha]]></TERM><TERM><![CDATA[Ursidae Family]]></TERM><TERM><![CDATA[Variation (Genetics)]]></TERM><TERM><![CDATA[Vertebrates]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Genetic analysis of inflammatory responses in wild-derived mice]]></PROJECT_TITLE><SERIAL_NUMBER>056234</SERIAL_NUMBER><STUDY_SECTION>IHD</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Immunity and Host Defense Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>13</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>250000</DIRECT_COST_AMT><INDIRECT_COST_AMT>162500</INDIRECT_COST_AMT><TOTAL_COST>412500</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9026897</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>AI</ADMINISTERING_IC><APPLICATION_TYPE>1</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/28/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>855</CFDA_CODE><CORE_PROJECT_NUM>R01AI116575</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-13-302</FOA_NUMBER><FULL_PROJECT_NUM>1R01AI116575-01A1</FULL_PROJECT_NUM><FUNDING_ICs>NIAID:308000\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>PITTSBURGH</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[INTERNAL MEDICINE/MEDICINE]]></ORG_DEPT><ORG_DISTRICT>14</ORG_DISTRICT><ORG_DUNS>004514360</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIVERSITY OF PITTSBURGH AT PITTSBURGH]]></ORG_NAME><ORG_STATE>PA</ORG_STATE><ORG_ZIPCODE>152132303</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Pneumococcal disease continues to be an important public health problem, particularly in underserved minorities. This project will evaluate vaccination strategies to improve vaccination protection in this group   
      

]]></PHR><PIS><PI><PI_NAME>SMITH, KENNETH J</PI_NAME><PI_ID>6986300</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>LU, KRISTINA </PROGRAM_OFFICER_NAME><PROJECT_START>11/01/2015</PROJECT_START><PROJECT_END>10/31/2019</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[Adult]]></TERM><TERM><![CDATA[Age]]></TERM><TERM><![CDATA[Area]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Caring]]></TERM><TERM><![CDATA[Centers for Disease Control and Prevention (U.S.)]]></TERM><TERM><![CDATA[Cessation of life]]></TERM><TERM><![CDATA[Characteristics]]></TERM><TERM><![CDATA[Childhood]]></TERM><TERM><![CDATA[Chronic]]></TERM><TERM><![CDATA[Clinical Trials]]></TERM><TERM><![CDATA[cohort]]></TERM><TERM><![CDATA[Combined Vaccines]]></TERM><TERM><![CDATA[Comorbidity]]></TERM><TERM><![CDATA[Complex]]></TERM><TERM><![CDATA[cost]]></TERM><TERM><![CDATA[cost effectiveness]]></TERM><TERM><![CDATA[Cost Effectiveness Analysis]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Decision Making]]></TERM><TERM><![CDATA[Decision Modeling]]></TERM><TERM><![CDATA[disorder risk]]></TERM><TERM><![CDATA[Economics]]></TERM><TERM><![CDATA[epidemiologic data]]></TERM><TERM><![CDATA[Epidemiology]]></TERM><TERM><![CDATA[Evaluation]]></TERM><TERM><![CDATA[evidence base]]></TERM><TERM><![CDATA[Future]]></TERM><TERM><![CDATA[Healthcare]]></TERM><TERM><![CDATA[Herd Immunity]]></TERM><TERM><![CDATA[high risk]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[innovation]]></TERM><TERM><![CDATA[Insurance]]></TERM><TERM><![CDATA[Insurance Coverage]]></TERM><TERM><![CDATA[Intervention]]></TERM><TERM><![CDATA[markov model]]></TERM><TERM><![CDATA[Medical]]></TERM><TERM><![CDATA[Minority]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[models and simulation]]></TERM><TERM><![CDATA[outreach]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Persons]]></TERM><TERM><![CDATA[Pneumococcal conjugate vaccine]]></TERM><TERM><![CDATA[Pneumococcal Infections]]></TERM><TERM><![CDATA[Pneumococcal vaccine]]></TERM><TERM><![CDATA[Policies]]></TERM><TERM><![CDATA[Polyvalent pneumococcal vaccine]]></TERM><TERM><![CDATA[Population]]></TERM><TERM><![CDATA[prevent]]></TERM><TERM><![CDATA[programs]]></TERM><TERM><![CDATA[public health medicine (field)]]></TERM><TERM><![CDATA[public health relevance]]></TERM><TERM><![CDATA[Race]]></TERM><TERM><![CDATA[Recommendation]]></TERM><TERM><![CDATA[Regimen]]></TERM><TERM><![CDATA[Relative (related person)]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Resource Allocation]]></TERM><TERM><![CDATA[Resources]]></TERM><TERM><![CDATA[Risk]]></TERM><TERM><![CDATA[routine care]]></TERM><TERM><![CDATA[Serotyping]]></TERM><TERM><![CDATA[Subgroup]]></TERM><TERM><![CDATA[Techniques]]></TERM><TERM><![CDATA[theories]]></TERM><TERM><![CDATA[To specify]]></TERM><TERM><![CDATA[trial comparing]]></TERM><TERM><![CDATA[Uncertainty]]></TERM><TERM><![CDATA[Underrepresented Minority]]></TERM><TERM><![CDATA[uptake]]></TERM><TERM><![CDATA[Vaccinated]]></TERM><TERM><![CDATA[Vaccination]]></TERM><TERM><![CDATA[vaccination strategy]]></TERM><TERM><![CDATA[vaccine effectiveness]]></TERM><TERM><![CDATA[vaccine efficacy]]></TERM><TERM><![CDATA[Vaccines]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Analyzing Adult Pneumococcal Vaccination Implementation in the Underserved]]></PROJECT_TITLE><SERIAL_NUMBER>116575</SERIAL_NUMBER><STUDY_SECTION>HSOD</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Health Services Organization and Delivery Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>01</SUPPORT_YEAR><SUFFIX>A1</SUFFIX><DIRECT_COST_AMT>200000</DIRECT_COST_AMT><INDIRECT_COST_AMT>108000</INDIRECT_COST_AMT><TOTAL_COST>308000</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9040017</APPLICATION_ID><ACTIVITY>I01</ACTIVITY><ADMINISTERING_IC>VA</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/03/2015</AWARD_NOTICE_DATE><BUDGET_START>10/01/2015</BUDGET_START><BUDGET_END>09/30/2016</BUDGET_END><CFDA_CODE>999</CFDA_CODE><CORE_PROJECT_NUM>I01RX001450</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-RX-14-001</FOA_NUMBER><FULL_PROJECT_NUM>5I01RX001450-02</FULL_PROJECT_NUM><FUNDING_ICs>VA:273400\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>Veterans Affairs</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>CHARLESTON</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>01</ORG_DISTRICT><ORG_DUNS>039807318</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[RALPH H JOHNSON VA MEDICAL CENTER]]></ORG_NAME><ORG_STATE>SC</ORG_STATE><ORG_ZIPCODE>294015703</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE:    
Secondary neuronal injury in stroke results in massive neuronal death days to weeks after the primary insult. Few treatment options are available to alleviate effects of the free radical-induce damage to brain. One recently discovered possibility is treatment by antioxidant enzymes or their artificial mimetics, which can serve as highly efficient free radical scavengers at the site f injury. However, these agents alone are unable to reach the site of injury because brain is separated from the blood stream by the blood-brain barrier. The goal of this project is to improve delivery of highly reactive antioxidant AEOL 10150 to central nervous system. If successful, this research can lead to considerable improvement of stroke outcomes and therefore enhance long-term quality of life for the stroke survivors. Here, we propose to test this approach using a mouse stroke model. Once established, the proposed approach can be further extended to improve outcomes of other neurological conditions that involve secondary injury, such as traumatic brain injury and spinal cord injury.    
   
      

]]></PHR><PIS><PI><PI_NAME>KINDY, MARK S.</PI_NAME><PI_ID>1867302</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>10/01/2014</PROJECT_START><PROJECT_END>09/30/2018</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Achievement]]></TERM><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[Adverse effects]]></TERM><TERM><![CDATA[Animal Experiments]]></TERM><TERM><![CDATA[Animal Model]]></TERM><TERM><![CDATA[Animals]]></TERM><TERM><![CDATA[Antibodies]]></TERM><TERM><![CDATA[Antioxidants]]></TERM><TERM><![CDATA[Attention]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Behavior assessment]]></TERM><TERM><![CDATA[Binding (Molecular Function)]]></TERM><TERM><![CDATA[Biodistribution]]></TERM><TERM><![CDATA[Blood]]></TERM><TERM><![CDATA[Blood - brain barrier anatomy]]></TERM><TERM><![CDATA[Brain]]></TERM><TERM><![CDATA[brain tissue]]></TERM><TERM><![CDATA[Carotid Arteries]]></TERM><TERM><![CDATA[caspase-3]]></TERM><TERM><![CDATA[catalase]]></TERM><TERM><![CDATA[Cause of Death]]></TERM><TERM><![CDATA[Cell Culture Techniques]]></TERM><TERM><![CDATA[central nervous system injury]]></TERM><TERM><![CDATA[Cerebral Ischemia]]></TERM><TERM><![CDATA[Cerebrum]]></TERM><TERM><![CDATA[Cessation of life]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[Continuous Infusion]]></TERM><TERM><![CDATA[cytotoxicity]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[disability]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[dosage]]></TERM><TERM><![CDATA[Dose]]></TERM><TERM><![CDATA[Doxorubicin Hydrochloride Liposome]]></TERM><TERM><![CDATA[drug candidate]]></TERM><TERM><![CDATA[Drug Carriers]]></TERM><TERM><![CDATA[Drug Delivery Systems]]></TERM><TERM><![CDATA[drug distribution]]></TERM><TERM><![CDATA[drug efficacy]]></TERM><TERM><![CDATA[efficacy evaluation]]></TERM><TERM><![CDATA[Ensure]]></TERM><TERM><![CDATA[Enzymes]]></TERM><TERM><![CDATA[EUK-134]]></TERM><TERM><![CDATA[Fc Receptor]]></TERM><TERM><![CDATA[FDA approved]]></TERM><TERM><![CDATA[Free Radical Scavengers]]></TERM><TERM><![CDATA[Free Radicals]]></TERM><TERM><![CDATA[Generations]]></TERM><TERM><![CDATA[Glycolic-Lactic Acid Polyester]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[immunogenicity]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[In Vitro]]></TERM><TERM><![CDATA[in vitro testing]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[Infarction]]></TERM><TERM><![CDATA[injured]]></TERM><TERM><![CDATA[Injury]]></TERM><TERM><![CDATA[intravenous administration]]></TERM><TERM><![CDATA[Ischemia]]></TERM><TERM><![CDATA[Ischemic Stroke]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[Ligands]]></TERM><TERM><![CDATA[Lipids]]></TERM><TERM><![CDATA[Liposomes]]></TERM><TERM><![CDATA[Measures]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[Microspheres]]></TERM><TERM><![CDATA[Middle Cerebral Artery Occlusion]]></TERM><TERM><![CDATA[mimetics]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Molecular Weight]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[N-Methyl-D-Aspartate Receptors]]></TERM><TERM><![CDATA[nanoparticle]]></TERM><TERM><![CDATA[nanoparticulate]]></TERM><TERM><![CDATA[nanoscale]]></TERM><TERM><![CDATA[Neuraxis]]></TERM><TERM><![CDATA[Neurologic]]></TERM><TERM><![CDATA[Neuronal Injury]]></TERM><TERM><![CDATA[Neurons]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[NR1 gene]]></TERM><TERM><![CDATA[Outcome]]></TERM><TERM><![CDATA[Outcome Measure]]></TERM><TERM><![CDATA[oxidation]]></TERM><TERM><![CDATA[Oxygen]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Peroxides]]></TERM><TERM><![CDATA[Pharmaceutical Preparations]]></TERM><TERM><![CDATA[Pharmacologic Substance]]></TERM><TERM><![CDATA[Phase I Clinical Trials]]></TERM><TERM><![CDATA[preclinical study]]></TERM><TERM><![CDATA[prevent]]></TERM><TERM><![CDATA[Price]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[Production]]></TERM><TERM><![CDATA[Prophylactic treatment]]></TERM><TERM><![CDATA[public health relevance]]></TERM><TERM><![CDATA[Quality of life]]></TERM><TERM><![CDATA[Rattus]]></TERM><TERM><![CDATA[Reactive Oxygen Species]]></TERM><TERM><![CDATA[receptor]]></TERM><TERM><![CDATA[Reperfusion Therapy]]></TERM><TERM><![CDATA[Reporting]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[research study]]></TERM><TERM><![CDATA[Rodent Model]]></TERM><TERM><![CDATA[Safety]]></TERM><TERM><![CDATA[safety study]]></TERM><TERM><![CDATA[Secondary to]]></TERM><TERM><![CDATA[Series]]></TERM><TERM><![CDATA[Serious Adverse Event]]></TERM><TERM><![CDATA[Site]]></TERM><TERM><![CDATA[Spinal cord injury]]></TERM><TERM><![CDATA[Stream]]></TERM><TERM><![CDATA[stroke]]></TERM><TERM><![CDATA[Superoxide Dismutase]]></TERM><TERM><![CDATA[Superoxides]]></TERM><TERM><![CDATA[Survivors]]></TERM><TERM><![CDATA[System]]></TERM><TERM><![CDATA[targeted delivery]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Therapeutic]]></TERM><TERM><![CDATA[Therapeutic Agents]]></TERM><TERM><![CDATA[Therapeutic Effect]]></TERM><TERM><![CDATA[Therapeutic Uses]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[Toxic effect]]></TERM><TERM><![CDATA[Translations]]></TERM><TERM><![CDATA[Traumatic Brain Injury]]></TERM><TERM><![CDATA[United States]]></TERM><TERM><![CDATA[vector]]></TERM><TERM><![CDATA[Vitamin E]]></TERM><TERM><![CDATA[Water]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Targeted Delivery of Antioxidant Drugs Following Cerebral Ischemic Injury]]></PROJECT_TITLE><SERIAL_NUMBER>001450</SERIAL_NUMBER><STUDY_SECTION>RRD1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Brain Injury: TBI & Stroke  ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST></TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9077835</APPLICATION_ID><ACTIVITY>R21</ACTIVITY><ADMINISTERING_IC>AI</ADMINISTERING_IC><APPLICATION_TYPE>7</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/05/2015</AWARD_NOTICE_DATE><BUDGET_START>08/01/2015</BUDGET_START><BUDGET_END>11/30/2016</BUDGET_END><CFDA_CODE>855</CFDA_CODE><CORE_PROJECT_NUM>R21AI105656</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF ARTS AND SCIENCES]]></ED_INST_TYPE><FOA_NUMBER>PA-14-078</FOA_NUMBER><FULL_PROJECT_NUM>7R21AI105656-03</FULL_PROJECT_NUM><FUNDING_ICs>NIAID:183936\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2015</FY><IC_NAME>NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>PROVO</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[CHEMISTRY]]></ORG_DEPT><ORG_DISTRICT>03</ORG_DISTRICT><ORG_DUNS>009094012</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[BRIGHAM YOUNG UNIVERSITY]]></ORG_NAME><ORG_STATE>UT</ORG_STATE><ORG_ZIPCODE>846021001</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Glucose metabolism is the sole source of ATP for the infectious lifecycle stage of the African trypanosome, Trypanosoma brucei, and occurs exclusively in the glycosome. The proposed research would use both recombinant protein-based probes and peptide-bearing small molecule sensors to quantitatively observe intraglycosomal pH and glucose levels in live parasites, as a means to probe the mechanism of ATP production and reveal regulatory mechanisms suitable for therapeutic targeting of glucose metabolism. This work is a necessary first step in the design of mechanism-based therapeutics that target glycosomal pathways and is therefore relevant to NIH's mission to promote public health.]]></PHR><PIS><PI><PI_NAME>CHRISTENSEN, KENNETH A (contact)</PI_NAME><PI_ID>2436302 (contact)</PI_ID></PI><PI><PI_NAME>MORRIS, JAMES CULVIN</PI_NAME><PI_ID>7727272</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>MCGUGAN, GLEN C</PROGRAM_OFFICER_NAME><PROJECT_START>12/12/2013</PROJECT_START><PROJECT_END>11/30/2016</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[Africa South of the Sahara]]></TERM><TERM><![CDATA[African]]></TERM><TERM><![CDATA[African Trypanosomiasis]]></TERM><TERM><![CDATA[Area]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Biology]]></TERM><TERM><![CDATA[Blood Circulation]]></TERM><TERM><![CDATA[Calcium Signaling]]></TERM><TERM><![CDATA[Carbon]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Cessation of life]]></TERM><TERM><![CDATA[Chagas Disease]]></TERM><TERM><![CDATA[Consumption]]></TERM><TERM><![CDATA[Cues]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[deprivation]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Drug Design]]></TERM><TERM><![CDATA[Drug resistance]]></TERM><TERM><![CDATA[economic cost]]></TERM><TERM><![CDATA[Endoplasmic Reticulum]]></TERM><TERM><![CDATA[Environment]]></TERM><TERM><![CDATA[environmental change]]></TERM><TERM><![CDATA[enzyme activity]]></TERM><TERM><![CDATA[enzyme mechanism]]></TERM><TERM><![CDATA[Enzymes]]></TERM><TERM><![CDATA[extracellular]]></TERM><TERM><![CDATA[Failure (biologic function)]]></TERM><TERM><![CDATA[Fluorescent Probes]]></TERM><TERM><![CDATA[Foundations]]></TERM><TERM><![CDATA[Glucose]]></TERM><TERM><![CDATA[glucose metabolism]]></TERM><TERM><![CDATA[glucose sensor]]></TERM><TERM><![CDATA[Glycolysis]]></TERM><TERM><![CDATA[Glycosome]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Golgi Apparatus]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[hexokinase]]></TERM><TERM><![CDATA[HIV]]></TERM><TERM><![CDATA[Housing]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[Killings]]></TERM><TERM><![CDATA[Leishmania (genus)]]></TERM><TERM><![CDATA[Leishmaniasis]]></TERM><TERM><![CDATA[Life]]></TERM><TERM><![CDATA[Measurement]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[Metabolic]]></TERM><TERM><![CDATA[Metabolic Pathway]]></TERM><TERM><![CDATA[Metabolism]]></TERM><TERM><![CDATA[Methodology]]></TERM><TERM><![CDATA[Mission]]></TERM><TERM><![CDATA[Mitochondria]]></TERM><TERM><![CDATA[Monitor]]></TERM><TERM><![CDATA[Morbidity - disease rate]]></TERM><TERM><![CDATA[Mortality Vital Statistics]]></TERM><TERM><![CDATA[novel strategies]]></TERM><TERM><![CDATA[Nutrient]]></TERM><TERM><![CDATA[Organelles]]></TERM><TERM><![CDATA[Organism]]></TERM><TERM><![CDATA[Parasites]]></TERM><TERM><![CDATA[Parasitic Diseases]]></TERM><TERM><![CDATA[Pathway interactions]]></TERM><TERM><![CDATA[Peptides]]></TERM><TERM><![CDATA[peroxisome]]></TERM><TERM><![CDATA[Pharmaceutical Preparations]]></TERM><TERM><![CDATA[Pharmacotherapy]]></TERM><TERM><![CDATA[Production]]></TERM><TERM><![CDATA[Proteins]]></TERM><TERM><![CDATA[public health medicine (field)]]></TERM><TERM><![CDATA[Quantitative Evaluations]]></TERM><TERM><![CDATA[ratiometric]]></TERM><TERM><![CDATA[Recombinant Proteins]]></TERM><TERM><![CDATA[Recombinants]]></TERM><TERM><![CDATA[Regulation]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[sensor]]></TERM><TERM><![CDATA[Sepsis]]></TERM><TERM><![CDATA[Series]]></TERM><TERM><![CDATA[small molecule]]></TERM><TERM><![CDATA[social]]></TERM><TERM><![CDATA[Sodium Chloride]]></TERM><TERM><![CDATA[solute]]></TERM><TERM><![CDATA[Solutions]]></TERM><TERM><![CDATA[Source]]></TERM><TERM><![CDATA[Staging]]></TERM><TERM><![CDATA[sugar]]></TERM><TERM><![CDATA[Techniques]]></TERM><TERM><![CDATA[Temperature]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[therapeutic target]]></TERM><TERM><![CDATA[Toxic effect]]></TERM><TERM><![CDATA[Treatment Failure]]></TERM><TERM><![CDATA[Trypanosoma]]></TERM><TERM><![CDATA[Trypanosoma brucei brucei]]></TERM><TERM><![CDATA[Trypanosoma cruzi]]></TERM><TERM><![CDATA[Trypanosomiasis]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[pH and glucose sensing in Trypanosoma brucei glycosomes]]></PROJECT_TITLE><SERIAL_NUMBER>105656</SERIAL_NUMBER><STUDY_SECTION>PTHE</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Pathogenic Eukaryotes Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>03</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>151834</DIRECT_COST_AMT><INDIRECT_COST_AMT>32102</INDIRECT_COST_AMT><TOTAL_COST>183936</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9110753</APPLICATION_ID><ACTIVITY>I21</ACTIVITY><ADMINISTERING_IC>VA</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/02/2015</AWARD_NOTICE_DATE><BUDGET_START>10/01/2015</BUDGET_START><BUDGET_END>09/30/2016</BUDGET_END><CFDA_CODE>999</CFDA_CODE><CORE_PROJECT_NUM>I21RX001382</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-RX-13-011</FOA_NUMBER><FULL_PROJECT_NUM>5I21RX001382-02</FULL_PROJECT_NUM><FUNDING_ICs>VA:97390\</FUNDING_ICs><FUNDING_MECHANISM>RESEARCH CENTERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>Veterans Affairs</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>BRONX</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>13</ORG_DISTRICT><ORG_DUNS>040077133</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[JAMES J PETERS VA  MEDICAL CENTER]]></ORG_NAME><ORG_STATE>NY</ORG_STATE><ORG_ZIPCODE>104683904</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE:    
   
We have found that the incidence of hypotension is increased 2.5-fold in veterans with spinal cord injury (SCI) compared to age-matched veterans without SCI. Although many chronically hypotensive individuals with SCI remain overtly asymptomatic, we have reported evidence of impaired memory and reduced attention and processing speed in a hypotensive SCI cohort compared to a normotensive SCI cohort. Increase in systemic blood pressure (BP), secondary to administration of an anti-hypotensive agent (midodrine), has been shown to increase cerebral blood flow (CBF) at rest and in response to cognitive testing, which was associated with improved test performance in hypotensive controls. In a relatively small group of hypotensive individuals with SCI we have demonstrated that midodrine significantly increases BP and CBF, which may improve cognitive function. Therefore, we aim to determine the long term benefit of sustained elevation in BP following midodrine administration on CBF, cognitive performance, mood and quality of life in persons with SCI.   
      

]]></PHR><PIS><PI><PI_NAME>WECHT, JILL M.</PI_NAME><PI_ID>9673190</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>10/01/2014</PROJECT_START><PROJECT_END>09/30/2016</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Acute]]></TERM><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[adrenergic]]></TERM><TERM><![CDATA[Adrenergic Agents]]></TERM><TERM><![CDATA[Adrenergic alpha-Agonists]]></TERM><TERM><![CDATA[Adverse event]]></TERM><TERM><![CDATA[Age]]></TERM><TERM><![CDATA[Antihypertensive Agents]]></TERM><TERM><![CDATA[Anxiety]]></TERM><TERM><![CDATA[Attention]]></TERM><TERM><![CDATA[Autonomic Dysreflexia]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Belief]]></TERM><TERM><![CDATA[Benign]]></TERM><TERM><![CDATA[Blood Flow Velocity]]></TERM><TERM><![CDATA[Blood Pressure]]></TERM><TERM><![CDATA[Cardiovascular system]]></TERM><TERM><![CDATA[cerebrovascular]]></TERM><TERM><![CDATA[Cerebrovascular Circulation]]></TERM><TERM><![CDATA[Cervical]]></TERM><TERM><![CDATA[Chronic]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[Clinical Management]]></TERM><TERM><![CDATA[Clinical Trials]]></TERM><TERM><![CDATA[Cognition]]></TERM><TERM><![CDATA[Cognitive]]></TERM><TERM><![CDATA[Cognitive deficits]]></TERM><TERM><![CDATA[cognitive function]]></TERM><TERM><![CDATA[cognitive performance]]></TERM><TERM><![CDATA[cohort]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Digit structure]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Double-Blind Method]]></TERM><TERM><![CDATA[Emotional]]></TERM><TERM><![CDATA[Etiology]]></TERM><TERM><![CDATA[experience]]></TERM><TERM><![CDATA[Face]]></TERM><TERM><![CDATA[falls]]></TERM><TERM><![CDATA[Fatigue]]></TERM><TERM><![CDATA[Head]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Hour]]></TERM><TERM><![CDATA[Hydrochloride Salt]]></TERM><TERM><![CDATA[Hypertension]]></TERM><TERM><![CDATA[hypertension treatment]]></TERM><TERM><![CDATA[Hypotension]]></TERM><TERM><![CDATA[Impaired cognition]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[Incidence]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[Intervention]]></TERM><TERM><![CDATA[Laboratories]]></TERM><TERM><![CDATA[Lesion]]></TERM><TERM><![CDATA[Limb structure]]></TERM><TERM><![CDATA[Literature]]></TERM><TERM><![CDATA[Longitudinal Studies]]></TERM><TERM><![CDATA[Medical]]></TERM><TERM><![CDATA[Memory]]></TERM><TERM><![CDATA[Mental Depression]]></TERM><TERM><![CDATA[middle cerebral artery]]></TERM><TERM><![CDATA[Midodrine]]></TERM><TERM><![CDATA[Moods]]></TERM><TERM><![CDATA[Mortality Vital Statistics]]></TERM><TERM><![CDATA[Nature]]></TERM><TERM><![CDATA[normotensive]]></TERM><TERM><![CDATA[Orthostasis]]></TERM><TERM><![CDATA[Orthostatic Hypotension]]></TERM><TERM><![CDATA[Outpatients]]></TERM><TERM><![CDATA[Paper]]></TERM><TERM><![CDATA[Perception]]></TERM><TERM><![CDATA[performance tests]]></TERM><TERM><![CDATA[Persons]]></TERM><TERM><![CDATA[Pilot Projects]]></TERM><TERM><![CDATA[Placebo Control]]></TERM><TERM><![CDATA[Placebos]]></TERM><TERM><![CDATA[Population]]></TERM><TERM><![CDATA[Prevalence]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[processing speed]]></TERM><TERM><![CDATA[Psyche structure]]></TERM><TERM><![CDATA[public health relevance]]></TERM><TERM><![CDATA[Quality of life]]></TERM><TERM><![CDATA[Randomized]]></TERM><TERM><![CDATA[Reaction Time]]></TERM><TERM><![CDATA[Reporting]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[Rest]]></TERM><TERM><![CDATA[Risk]]></TERM><TERM><![CDATA[Sampling]]></TERM><TERM><![CDATA[Secondary to]]></TERM><TERM><![CDATA[Severities]]></TERM><TERM><![CDATA[social]]></TERM><TERM><![CDATA[Speed (motion)]]></TERM><TERM><![CDATA[Spinal cord injury]]></TERM><TERM><![CDATA[Test Result]]></TERM><TERM><![CDATA[Veterans]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Increase in Blood Pressure: Effects on Cognition, Mood and Life Quality in SCI]]></PROJECT_TITLE><SERIAL_NUMBER>001382</SERIAL_NUMBER><STUDY_SECTION>RRDS</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST></TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9121219</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>AR</ADMINISTERING_IC><APPLICATION_TYPE>7</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>09/17/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>03/31/2016</BUDGET_END><CFDA_CODE>846</CFDA_CODE><CORE_PROJECT_NUM>R01AR047442</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-14-078</FOA_NUMBER><FULL_PROJECT_NUM>7R01AR047442-15</FULL_PROJECT_NUM><FUNDING_ICs>NIAMS:246914\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2015</FY><IC_NAME>NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES</IC_NAME><NIH_SPENDING_CATS><CATEGORY><![CDATA[Complementary and Alternative Medicine]]></CATEGORY><CATEGORY><![CDATA[Neurodegenerative]]></CATEGORY><CATEGORY><![CDATA[Neurosciences]]></CATEGORY><CATEGORY><![CDATA[Pain Conditions - Chronic]]></CATEGORY><CATEGORY><![CDATA[Pain Research]]></CATEGORY><CATEGORY><![CDATA[Peripheral Neuropathy]]></CATEGORY><CATEGORY><![CDATA[Rehabilitation]]></CATEGORY></NIH_SPENDING_CATS><ORG_CITY>SAINT LOUIS</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[NONE]]></ORG_DEPT><ORG_DISTRICT>01</ORG_DISTRICT><ORG_DUNS>068552207</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[WASHINGTON UNIVERSITY]]></ORG_NAME><ORG_STATE>MO</ORG_STATE><ORG_ZIPCODE>631304862</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: This project will synthesize injectable and in situ-forming perineural depots that provide for sustained release of small molecule antagonists of inflammation in radiculopathy. Sustained release of a model small molecule, curcumin, will be studied and compared against findings for a bolus delivery of a standard-of-care corticosteroid, triamcinolone acetonide, to test for an ability of the drug depot to modify pain sensitivity and gait characteristics in a rat model of lumbar radiculopathy.]]></PHR><PIS><PI><PI_NAME>SETTON, LORI A.</PI_NAME><PI_ID>2091970</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>TYREE, BERNADETTE </PROGRAM_OFFICER_NAME><PROJECT_START>11/01/2015</PROJECT_START><PROJECT_END>03/31/2016</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Adrenal Cortex Hormones]]></TERM><TERM><![CDATA[allodynia]]></TERM><TERM><![CDATA[Amines]]></TERM><TERM><![CDATA[Animal Model]]></TERM><TERM><![CDATA[Attenuated]]></TERM><TERM><![CDATA[Autologous]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Blocking Antibodies]]></TERM><TERM><![CDATA[Body Temperature]]></TERM><TERM><![CDATA[Bolus Infusion]]></TERM><TERM><![CDATA[Caring]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Characteristics]]></TERM><TERM><![CDATA[Chemicals]]></TERM><TERM><![CDATA[Clinical Treatment]]></TERM><TERM><![CDATA[Clinical Trials]]></TERM><TERM><![CDATA[cohort]]></TERM><TERM><![CDATA[Coupling]]></TERM><TERM><![CDATA[crosslink]]></TERM><TERM><![CDATA[Curcumin]]></TERM><TERM><![CDATA[cytokine]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Degenerative polyarthritis]]></TERM><TERM><![CDATA[Delayed-Action Preparations]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Dose]]></TERM><TERM><![CDATA[Drug Exposure]]></TERM><TERM><![CDATA[Drug Formulations]]></TERM><TERM><![CDATA[Drug usage]]></TERM><TERM><![CDATA[Elastin]]></TERM><TERM><![CDATA[Etanercept]]></TERM><TERM><![CDATA[experience]]></TERM><TERM><![CDATA[Frequencies (time pattern)]]></TERM><TERM><![CDATA[functional loss]]></TERM><TERM><![CDATA[functional restoration]]></TERM><TERM><![CDATA[Gait]]></TERM><TERM><![CDATA[Gait abnormality]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[In Situ]]></TERM><TERM><![CDATA[In Vitro]]></TERM><TERM><![CDATA[in vitro testing]]></TERM><TERM><![CDATA[Inflammation]]></TERM><TERM><![CDATA[Inflammation Mediators]]></TERM><TERM><![CDATA[Inflammatory]]></TERM><TERM><![CDATA[infliximab]]></TERM><TERM><![CDATA[inhibitor/antagonist]]></TERM><TERM><![CDATA[Injectable]]></TERM><TERM><![CDATA[Interleukin-1]]></TERM><TERM><![CDATA[Intervertebral disc structure]]></TERM><TERM><![CDATA[Kinetics]]></TERM><TERM><![CDATA[Measures]]></TERM><TERM><![CDATA[mechanical allodynia]]></TERM><TERM><![CDATA[Mechanical Stimulation]]></TERM><TERM><![CDATA[Mechanics]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[motor deficit]]></TERM><TERM><![CDATA[nanoparticle]]></TERM><TERM><![CDATA[Nerve]]></TERM><TERM><![CDATA[Nerve Root Compressions]]></TERM><TERM><![CDATA[neuroinflammation]]></TERM><TERM><![CDATA[neuropathology]]></TERM><TERM><![CDATA[neurotrophic factor]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[nucleus pulposus]]></TERM><TERM><![CDATA[Operative Surgical Procedures]]></TERM><TERM><![CDATA[Pain]]></TERM><TERM><![CDATA[Particle Size]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[perineural]]></TERM><TERM><![CDATA[Pharmaceutical Preparations]]></TERM><TERM><![CDATA[Phase Transition]]></TERM><TERM><![CDATA[polypeptide]]></TERM><TERM><![CDATA[polyphenol]]></TERM><TERM><![CDATA[Postoperative Period]]></TERM><TERM><![CDATA[protein expression]]></TERM><TERM><![CDATA[Proteins]]></TERM><TERM><![CDATA[Radiculopathy]]></TERM><TERM><![CDATA[Rattus]]></TERM><TERM><![CDATA[Sciatica]]></TERM><TERM><![CDATA[Serum]]></TERM><TERM><![CDATA[small molecule]]></TERM><TERM><![CDATA[Source]]></TERM><TERM><![CDATA[Spinal Cord]]></TERM><TERM><![CDATA[Spinal Ganglia]]></TERM><TERM><![CDATA[Spinal nerve root structure]]></TERM><TERM><![CDATA[Staining method]]></TERM><TERM><![CDATA[Stains]]></TERM><TERM><![CDATA[Symptoms]]></TERM><TERM><![CDATA[System]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Therapeutic]]></TERM><TERM><![CDATA[Therapeutic Effect]]></TERM><TERM><![CDATA[Thermal Hyperalgesias]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[Tissues]]></TERM><TERM><![CDATA[Triamcinolone Acetonide]]></TERM><TERM><![CDATA[Tumor Necrosis Factor Receptor]]></TERM><TERM><![CDATA[Tumor Necrosis Factor-alpha]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Mechanical Stimulation of IVD Cells]]></PROJECT_TITLE><SERIAL_NUMBER>047442</SERIAL_NUMBER><STUDY_SECTION>MTE</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Musculoskeletal Tissue Engineering Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>15</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>161911</DIRECT_COST_AMT><INDIRECT_COST_AMT>85003</INDIRECT_COST_AMT><TOTAL_COST>246914</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9135810</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>DK</ADMINISTERING_IC><APPLICATION_TYPE>6</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/06/2015</AWARD_NOTICE_DATE><BUDGET_START>09/01/2015</BUDGET_START><BUDGET_END>03/31/2016</BUDGET_END><CFDA_CODE>847</CFDA_CODE><CORE_PROJECT_NUM>R01DK079974</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>PA-11-260</FOA_NUMBER><FULL_PROJECT_NUM>6R01DK079974-09</FULL_PROJECT_NUM><FUNDING_ICs>NIDDK:214825\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2015</FY><IC_NAME>NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>BRONX</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>14</ORG_DISTRICT><ORG_DUNS>079783367</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[ALBERT EINSTEIN COLLEGE OF MEDICINE]]></ORG_NAME><ORG_STATE>NY</ORG_STATE><ORG_ZIPCODE>104611975</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Patients with type 1 diabetes mellitus (T1DM) on intensive insulin treatment suffer from recurrent episodes of low glucose (hypoglycemia), with severe consequences: 1) a tendency to maintain suboptimal glycemic control, which results in increased risk for vascular complications, and 2) recurrent morbidity that is associated with hypoglycemia which may be fatal (6 to 10% of deaths in patients with T1DM are directly related to hypoglycemic events). Hypoglycemia associated autonomic failure (HAAF) represents a defect in the capacity to recover from hypoglycemia after recurrent previous episodes of hypoglycemia, but its mechanism is not established. In this project we propose to elucidate the defect responsible for HAAF in T1DM patients and to explore the possibility of treating patients with a drug that may reverse this defect.]]></PHR><PIS><PI><PI_NAME>HAWKINS, MEREDITH A</PI_NAME><PI_ID>6488817</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>TEFF, KAREN L</PROGRAM_OFFICER_NAME><PROJECT_START>02/01/2008</PROJECT_START><PROJECT_END>03/31/2018</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Acute]]></TERM><TERM><![CDATA[adrenergic]]></TERM><TERM><![CDATA[Adrenergic Agents]]></TERM><TERM><![CDATA[Adrenergic Receptor]]></TERM><TERM><![CDATA[analog]]></TERM><TERM><![CDATA[Awareness]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[beta-adrenergic receptor]]></TERM><TERM><![CDATA[biological adaptation to stress]]></TERM><TERM><![CDATA[Biomedical Engineering]]></TERM><TERM><![CDATA[Biosensor]]></TERM><TERM><![CDATA[blood glucose regulation]]></TERM><TERM><![CDATA[Blood Vessels]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Cessation of life]]></TERM><TERM><![CDATA[Chronic]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[Clinical Research]]></TERM><TERM><![CDATA[Clinical Trials]]></TERM><TERM><![CDATA[counterregulation]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Defect]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Devices]]></TERM><TERM><![CDATA[Dose]]></TERM><TERM><![CDATA[Eating]]></TERM><TERM><![CDATA[effective therapy]]></TERM><TERM><![CDATA[Epinephrine]]></TERM><TERM><![CDATA[Event]]></TERM><TERM><![CDATA[Exercise]]></TERM><TERM><![CDATA[Failure (biologic function)]]></TERM><TERM><![CDATA[Glucagon]]></TERM><TERM><![CDATA[Glucose]]></TERM><TERM><![CDATA[glucose monitor]]></TERM><TERM><![CDATA[glycemic control]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Health Benefit]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[Hypoglycemia]]></TERM><TERM><![CDATA[hypoglycemia unawareness]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[Incidence]]></TERM><TERM><![CDATA[Infusion procedures]]></TERM><TERM><![CDATA[Insulin]]></TERM><TERM><![CDATA[Insulin-Dependent Diabetes Mellitus]]></TERM><TERM><![CDATA[islet]]></TERM><TERM><![CDATA[Islets of Langerhans Transplantation]]></TERM><TERM><![CDATA[Laboratories]]></TERM><TERM><![CDATA[Link]]></TERM><TERM><![CDATA[Methods]]></TERM><TERM><![CDATA[Morbidity - disease rate]]></TERM><TERM><![CDATA[Morphine]]></TERM><TERM><![CDATA[Naloxone]]></TERM><TERM><![CDATA[Naltrexone]]></TERM><TERM><![CDATA[non-diabetic]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[novel strategies]]></TERM><TERM><![CDATA[Opioid]]></TERM><TERM><![CDATA[Opioid Receptor]]></TERM><TERM><![CDATA[Oral Administration]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Pattern]]></TERM><TERM><![CDATA[Pharmaceutical Preparations]]></TERM><TERM><![CDATA[Phentolamine]]></TERM><TERM><![CDATA[Play]]></TERM><TERM><![CDATA[prevent]]></TERM><TERM><![CDATA[Propranolol]]></TERM><TERM><![CDATA[Publishing]]></TERM><TERM><![CDATA[Pump]]></TERM><TERM><![CDATA[Recurrence]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[Risk]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[Solutions]]></TERM><TERM><![CDATA[Stress]]></TERM><TERM><![CDATA[Symptoms]]></TERM><TERM><![CDATA[System]]></TERM><TERM><![CDATA[Therapeutic]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[Translating]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Mechanisms of hypoglycemia-associated authonomic failure]]></PROJECT_TITLE><SERIAL_NUMBER>079974</SERIAL_NUMBER><STUDY_SECTION>CIDO</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Clinical and Integrative Diabetes and Obesity Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>09</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>128638</DIRECT_COST_AMT><INDIRECT_COST_AMT>86187</INDIRECT_COST_AMT><TOTAL_COST>214825</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9146923</APPLICATION_ID><ACTIVITY>U51</ACTIVITY><ADMINISTERING_IC>PS</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/22/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>U51PS004051</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-PS-13-303</FOA_NUMBER><FULL_PROJECT_NUM>5U51PS004051-04</FULL_PROJECT_NUM><FUNDING_ICs>NCHHSTP:50568\</FUNDING_ICs><FUNDING_MECHANISM>OTHERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP)</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>PHOENIX</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>07</ORG_DISTRICT><ORG_DUNS>804745420</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[ARIZONA STATE DEPARTMENT OF HLTH SRVCS]]></ORG_NAME><ORG_STATE>AZ</ORG_STATE><ORG_ZIPCODE>850072641</ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>TSANG, CLARISSE </PI_NAME><PI_ID>12105577</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>11/01/2012</PROJECT_START><PROJECT_END>10/31/2016</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[Arizona Viral Hepatitis - Prevention and Surveillance]]></PROJECT_TITLE><SERIAL_NUMBER>004051</SERIAL_NUMBER><STUDY_SECTION>ZPS1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>04</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>50568</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9171972</APPLICATION_ID><ACTIVITY>R13</ACTIVITY><ADMINISTERING_IC>AI</ADMINISTERING_IC><APPLICATION_TYPE>4</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/05/2015</AWARD_NOTICE_DATE><BUDGET_START>11/05/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>855</CFDA_CODE><CORE_PROJECT_NUM>R13AI108234</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-12-212</FOA_NUMBER><FULL_PROJECT_NUM>4R13AI108234-02</FULL_PROJECT_NUM><FUNDING_ICs>NIAID:8000\</FUNDING_ICs><FUNDING_MECHANISM>OTHER RESEARCH-RELATED</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>LEXINGTON</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[MICROBIOLOGY/IMMUN/VIROLOGY]]></ORG_DEPT><ORG_DISTRICT>06</ORG_DISTRICT><ORG_DUNS>939017877</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIVERSITY OF KENTUCKY]]></ORG_NAME><ORG_STATE>KY</ORG_STATE><ORG_ZIPCODE>405060057</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: High quality scientific conferences are vital to the public health mission of the NIH. This application requests funding for an annual scientific conference called the Autumn Immunology Conference. The purpose of this meeting is to exchange and disseminate information, and to explore contemporary problems in the field of Immunology. Thus it is consistent with the fiscal and programmatic priorities of the National Institutes of Allergy and Infectious Diseases (NIAID), which is to conduct and support basic and applied research to better understand, treat, and ultimately prevent infectious, immunologic, and allergic diseases.]]></PHR><PIS><PI><PI_NAME>WOODWARD, JEROLD G</PI_NAME><PI_ID>1863468</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>MILLER, LARA R.</PROGRAM_OFFICER_NAME><PROJECT_START>07/01/2013</PROJECT_START><PROJECT_END>10/31/2016</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[Allergic Disease]]></TERM><TERM><![CDATA[Applied Research]]></TERM><TERM><![CDATA[Autoimmunity]]></TERM><TERM><![CDATA[Award]]></TERM><TERM><![CDATA[Basic Science]]></TERM><TERM><![CDATA[Cancer Biology]]></TERM><TERM><![CDATA[career]]></TERM><TERM><![CDATA[career development]]></TERM><TERM><![CDATA[Collaborations]]></TERM><TERM><![CDATA[Communicable Diseases]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[Discipline]]></TERM><TERM><![CDATA[Educational aspects]]></TERM><TERM><![CDATA[Educational workshop]]></TERM><TERM><![CDATA[Equilibrium]]></TERM><TERM><![CDATA[Feedback]]></TERM><TERM><![CDATA[Fostering]]></TERM><TERM><![CDATA[Funding]]></TERM><TERM><![CDATA[Gender]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Grant]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Immune System Diseases]]></TERM><TERM><![CDATA[Immunology]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[Inflammation]]></TERM><TERM><![CDATA[Institution]]></TERM><TERM><![CDATA[interest]]></TERM><TERM><![CDATA[meetings]]></TERM><TERM><![CDATA[Mentors]]></TERM><TERM><![CDATA[Minority]]></TERM><TERM><![CDATA[Minority Groups]]></TERM><TERM><![CDATA[Mission]]></TERM><TERM><![CDATA[National Institute of Allergy and Infectious Disease]]></TERM><TERM><![CDATA[Oral]]></TERM><TERM><![CDATA[Participant]]></TERM><TERM><![CDATA[Pathogenesis]]></TERM><TERM><![CDATA[posters]]></TERM><TERM><![CDATA[pre-doctoral]]></TERM><TERM><![CDATA[Preparation]]></TERM><TERM><![CDATA[prevent]]></TERM><TERM><![CDATA[programs]]></TERM><TERM><![CDATA[public health medicine (field)]]></TERM><TERM><![CDATA[Recruitment Activity]]></TERM><TERM><![CDATA[Request for Applications]]></TERM><TERM><![CDATA[Request for Proposals]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Research Personnel]]></TERM><TERM><![CDATA[Scholarship]]></TERM><TERM><![CDATA[Science]]></TERM><TERM><![CDATA[Scientist]]></TERM><TERM><![CDATA[Staging]]></TERM><TERM><![CDATA[symposium]]></TERM><TERM><![CDATA[Travel]]></TERM><TERM><![CDATA[Underrepresented Minority]]></TERM><TERM><![CDATA[United States]]></TERM><TERM><![CDATA[United States National Institutes of Health]]></TERM><TERM><![CDATA[vaccine development]]></TERM><TERM><![CDATA[Vendor]]></TERM><TERM><![CDATA[Woman]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Autumn Immunology Conference]]></PROJECT_TITLE><SERIAL_NUMBER>108234</SERIAL_NUMBER><STUDY_SECTION>ZAI1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>8000</DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>8000</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9171997</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>HL</ADMINISTERING_IC><APPLICATION_TYPE>6</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/05/2015</AWARD_NOTICE_DATE><BUDGET_START>11/05/2015</BUDGET_START><BUDGET_END>06/30/2016</BUDGET_END><CFDA_CODE>837</CFDA_CODE><CORE_PROJECT_NUM>R01HL069438</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>PA-11-260</FOA_NUMBER><FULL_PROJECT_NUM>6R01HL069438-14</FULL_PROJECT_NUM><FUNDING_ICs>NHLBI:342697\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2015</FY><IC_NAME>NATIONAL HEART, LUNG, AND BLOOD INSTITUTE</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>BRONX</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>14</ORG_DISTRICT><ORG_DUNS>079783367</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[ALBERT EINSTEIN COLLEGE OF MEDICINE]]></ORG_NAME><ORG_STATE>NY</ORG_STATE><ORG_ZIPCODE>104611975</ORG_ZIPCODE><PHR><![CDATA[Studies conducted under this project have uncovered an important role for polymorphonuclearneutrophils (PMNs) in vaso-occlusion of sickle cell disease. Here, we will characterize a pro-inflammatory PMN subset and investigate the contributions of the autonomic nervous system in leukocyte migration, activation and disease outcome.]]></PHR><PIS><PI><PI_NAME>FRENETTE, PAUL S</PI_NAME><PI_ID>2085323</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>QASBA, PANKAJ </PROGRAM_OFFICER_NAME><PROJECT_START>09/30/2001</PROJECT_START><PROJECT_END>06/30/2017</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Acute]]></TERM><TERM><![CDATA[adhesion receptor]]></TERM><TERM><![CDATA[Adhesions]]></TERM><TERM><![CDATA[adrenergic]]></TERM><TERM><![CDATA[Adrenergic Agents]]></TERM><TERM><![CDATA[Adrenergic Receptor]]></TERM><TERM><![CDATA[Aging]]></TERM><TERM><![CDATA[Applications Grants]]></TERM><TERM><![CDATA[arteriole]]></TERM><TERM><![CDATA[Autonomic nervous system]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Behavior]]></TERM><TERM><![CDATA[Biological Models]]></TERM><TERM><![CDATA[Blood]]></TERM><TERM><![CDATA[Blood Circulation]]></TERM><TERM><![CDATA[Blood Vessels]]></TERM><TERM><![CDATA[bone]]></TERM><TERM><![CDATA[Bone Marrow]]></TERM><TERM><![CDATA[Brain]]></TERM><TERM><![CDATA[Calcium Oscillations]]></TERM><TERM><![CDATA[CD18 Antigens]]></TERM><TERM><![CDATA[Cell Adhesion Molecules]]></TERM><TERM><![CDATA[Cell physiology]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[cholinergic]]></TERM><TERM><![CDATA[Circadian Rhythms]]></TERM><TERM><![CDATA[Collaborations]]></TERM><TERM><![CDATA[Connexins]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Disease Outcome]]></TERM><TERM><![CDATA[E-Selectin]]></TERM><TERM><![CDATA[Endothelial Cells]]></TERM><TERM><![CDATA[Erythrocytes]]></TERM><TERM><![CDATA[Fluorescence]]></TERM><TERM><![CDATA[Functional disorder]]></TERM><TERM><![CDATA[Funding]]></TERM><TERM><![CDATA[genetic analysis]]></TERM><TERM><![CDATA[Heterogeneity]]></TERM><TERM><![CDATA[Image]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[Inflammation]]></TERM><TERM><![CDATA[Inflammatory]]></TERM><TERM><![CDATA[Inflammatory Response]]></TERM><TERM><![CDATA[insight]]></TERM><TERM><![CDATA[Institutes]]></TERM><TERM><![CDATA[Integrins]]></TERM><TERM><![CDATA[intravital fluorescence microscopy]]></TERM><TERM><![CDATA[L-Selectin]]></TERM><TERM><![CDATA[Laboratories]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[leukocyte activation]]></TERM><TERM><![CDATA[Leukocyte Trafficking]]></TERM><TERM><![CDATA[Leukocytes]]></TERM><TERM><![CDATA[Ligands]]></TERM><TERM><![CDATA[Liver]]></TERM><TERM><![CDATA[loss of function]]></TERM><TERM><![CDATA[macrophage]]></TERM><TERM><![CDATA[Macrophage-1 Antigen]]></TERM><TERM><![CDATA[Marrow]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[Medical Research]]></TERM><TERM><![CDATA[migration]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[mouse model]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[Muscarinic Acetylcholine Receptor]]></TERM><TERM><![CDATA[Muscarinics]]></TERM><TERM><![CDATA[Nerve]]></TERM><TERM><![CDATA[nestin protein]]></TERM><TERM><![CDATA[neural stimulation]]></TERM><TERM><![CDATA[neurotransmission]]></TERM><TERM><![CDATA[neutrophil]]></TERM><TERM><![CDATA[Neutrophil Infiltration]]></TERM><TERM><![CDATA[Nicotinic Receptors]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[Outcome]]></TERM><TERM><![CDATA[Parasympathetic Nervous System]]></TERM><TERM><![CDATA[Pathogenesis]]></TERM><TERM><![CDATA[Pericytes]]></TERM><TERM><![CDATA[Peripheral]]></TERM><TERM><![CDATA[Phenotype]]></TERM><TERM><![CDATA[Play]]></TERM><TERM><![CDATA[programs]]></TERM><TERM><![CDATA[Radiation Chimera]]></TERM><TERM><![CDATA[receptor]]></TERM><TERM><![CDATA[Receptor Signaling]]></TERM><TERM><![CDATA[Recruitment Activity]]></TERM><TERM><![CDATA[relating to nervous system]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[SELL gene]]></TERM><TERM><![CDATA[senescence]]></TERM><TERM><![CDATA[Sepsis]]></TERM><TERM><![CDATA[Sickle Cell]]></TERM><TERM><![CDATA[Sickle Cell Anemia]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[Spleen]]></TERM><TERM><![CDATA[Sympathetic Nervous System]]></TERM><TERM><![CDATA[System]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Tissues]]></TERM><TERM><![CDATA[TNF gene]]></TERM><TERM><![CDATA[transmission process]]></TERM><TERM><![CDATA[vagus nerve stimulation]]></TERM><TERM><![CDATA[Vagus nerve structure]]></TERM><TERM><![CDATA[venule]]></TERM><TERM><![CDATA[Video Microscopy]]></TERM><TERM><![CDATA[White Blood Cell Count procedure]]></TERM><TERM><![CDATA[Wild Type Mouse]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Adhesion Mechanisms Mediating Sickle Cell Vasooclusion In Vivo]]></PROJECT_TITLE><SERIAL_NUMBER>069438</SERIAL_NUMBER><STUDY_SECTION>MCH</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Molecular and Cellular Hematology ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>14</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>205208</DIRECT_COST_AMT><INDIRECT_COST_AMT>137489</INDIRECT_COST_AMT><TOTAL_COST>342697</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9172455</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>HL</ADMINISTERING_IC><APPLICATION_TYPE>6</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/05/2015</AWARD_NOTICE_DATE><BUDGET_START>11/05/2015</BUDGET_START><BUDGET_END>06/30/2016</BUDGET_END><CFDA_CODE>837</CFDA_CODE><CORE_PROJECT_NUM>R01HL116997</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>PA-11-260</FOA_NUMBER><FULL_PROJECT_NUM>6R01HL116997-04</FULL_PROJECT_NUM><FUNDING_ICs>NHLBI:342697\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2015</FY><IC_NAME>NATIONAL HEART, LUNG, AND BLOOD INSTITUTE</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>BRONX</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>14</ORG_DISTRICT><ORG_DUNS>079783367</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[ALBERT EINSTEIN COLLEGE OF MEDICINE]]></ORG_NAME><ORG_STATE>NY</ORG_STATE><ORG_ZIPCODE>104611975</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: This project investigates the mechanisms of coronary ostium formation and patterning. Completion of this project will help to understand the etiology of coronary anomalies and developmental basis of coronary regeneration.]]></PHR><PIS><PI><PI_NAME>ZHOU, BIN </PI_NAME><PI_ID>7929369</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>SCHRAMM, CHARLENE A.</PROGRAM_OFFICER_NAME><PROJECT_START>08/01/2013</PROJECT_START><PROJECT_END>06/30/2017</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Ablation]]></TERM><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[Anatomy]]></TERM><TERM><![CDATA[Aorta]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Binding (Molecular Function)]]></TERM><TERM><![CDATA[Blood]]></TERM><TERM><![CDATA[Blood Circulation]]></TERM><TERM><![CDATA[Blood Vessels]]></TERM><TERM><![CDATA[Candidate Disease Gene]]></TERM><TERM><![CDATA[Cardiac Myocytes]]></TERM><TERM><![CDATA[cell behavior]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[chromatin immunoprecipitation]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[Color]]></TERM><TERM><![CDATA[Coronary]]></TERM><TERM><![CDATA[Coronary artery]]></TERM><TERM><![CDATA[Coronary Circulation]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Defect]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Diffusion]]></TERM><TERM><![CDATA[Embryo]]></TERM><TERM><![CDATA[Embryonic Development]]></TERM><TERM><![CDATA[Endocardium]]></TERM><TERM><![CDATA[Endothelial Cells]]></TERM><TERM><![CDATA[Endothelium]]></TERM><TERM><![CDATA[Enhancers]]></TERM><TERM><![CDATA[Etiology]]></TERM><TERM><![CDATA[Genes]]></TERM><TERM><![CDATA[Genetic]]></TERM><TERM><![CDATA[Genetic Transcription]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Growth]]></TERM><TERM><![CDATA[Growth Factor]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Heart]]></TERM><TERM><![CDATA[heart circulation]]></TERM><TERM><![CDATA[Hypoxia]]></TERM><TERM><![CDATA[hypoxia inducible factor 1]]></TERM><TERM><![CDATA[Immunofluorescence Immunologic]]></TERM><TERM><![CDATA[Location]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[Molecular Analysis]]></TERM><TERM><![CDATA[mouse model]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[Muscle Cells]]></TERM><TERM><![CDATA[Mutant Strains Mice]]></TERM><TERM><![CDATA[Myocardial]]></TERM><TERM><![CDATA[Myocardium]]></TERM><TERM><![CDATA[Names]]></TERM><TERM><![CDATA[Natural regeneration]]></TERM><TERM><![CDATA[Nuclear]]></TERM><TERM><![CDATA[nuclear factors of activated T-cells]]></TERM><TERM><![CDATA[Nutrient]]></TERM><TERM><![CDATA[Outcome]]></TERM><TERM><![CDATA[Oxygen]]></TERM><TERM><![CDATA[Pathway interactions]]></TERM><TERM><![CDATA[Pattern]]></TERM><TERM><![CDATA[Pattern Formation]]></TERM><TERM><![CDATA[Phase]]></TERM><TERM><![CDATA[Phenotype]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[receptor]]></TERM><TERM><![CDATA[Reporter Genes]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[Site]]></TERM><TERM><![CDATA[spatiotemporal]]></TERM><TERM><![CDATA[stem]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[transcription factor]]></TERM><TERM><![CDATA[transcriptome sequencing]]></TERM><TERM><![CDATA[Valsalva sinus]]></TERM><TERM><![CDATA[Vascular Endothelial Growth Factor Receptor]]></TERM><TERM><![CDATA[Vascular Endothelial Growth Factors]]></TERM><TERM><![CDATA[Vegf gene]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Mechanisms of Coronary Ostium Formation and Coronary Artery Patterning]]></PROJECT_TITLE><SERIAL_NUMBER>116997</SERIAL_NUMBER><STUDY_SECTION>CDD</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Cardiovascular Differentiation and Development Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>04</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>205208</DIRECT_COST_AMT><INDIRECT_COST_AMT>137489</INDIRECT_COST_AMT><TOTAL_COST>342697</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9172479</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>HL</ADMINISTERING_IC><APPLICATION_TYPE>6</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/06/2015</AWARD_NOTICE_DATE><BUDGET_START>11/06/2015</BUDGET_START><BUDGET_END>03/31/2016</BUDGET_END><CFDA_CODE>837</CFDA_CODE><CORE_PROJECT_NUM>R01HL122866</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>PA-13-302</FOA_NUMBER><FULL_PROJECT_NUM>6R01HL122866-02</FULL_PROJECT_NUM><FUNDING_ICs>NHLBI:243541\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2015</FY><IC_NAME>NATIONAL HEART, LUNG, AND BLOOD INSTITUTE</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>BRONX</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>14</ORG_DISTRICT><ORG_DUNS>079783367</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[ALBERT EINSTEIN COLLEGE OF MEDICINE]]></ORG_NAME><ORG_STATE>NY</ORG_STATE><ORG_ZIPCODE>104611975</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Low Density Lipoprotein receptor (LDLr) and cholesterol play a major role in the mechanism of Trypanosoma cruzi invasion and progression of Chagas disease. Chagas disease is a neglected tropical disease characterized by myocarditis and cardiomyopathy. It is estimated that 15 million people are infected with or carriers of the disease
in Latin and South America. Obesity and diabetes have become more prevalent in Chagas-endemic area. Chronically infected immigrants in the United States estimated at 300,000. T. cruzi utilizes LDLr for invasion and infection results in accumulation of cholesterol in cells/tissues, contributing to the pathogenesis of adipose tissue and liver dysfunction and cardiomyopathy. The studies proposed in this application will establish link between infection induced intracellular cholesterol/fatty acid levels, metabolic dysfunction and cardiomyopathy, which offers the best chance for early intervention strategies aimed at preventing this devastating heart disease and to understand the interactions of the epidemics of diabetes and obesity with Chagas disease.]]></PHR><PIS><PI><PI_NAME>NAGAJYOTHI, JYOTHI FALGUNI</PI_NAME><PI_ID>10188975</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>BURNS, KRISTIN </PROGRAM_OFFICER_NAME><PROJECT_START>04/01/2015</PROJECT_START><PROJECT_END>03/31/2019</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Acute]]></TERM><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[Adipocytes]]></TERM><TERM><![CDATA[adiponectin]]></TERM><TERM><![CDATA[Adipose tissue]]></TERM><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[apolipoprotein B-100]]></TERM><TERM><![CDATA[Apolipoproteins B]]></TERM><TERM><![CDATA[Area]]></TERM><TERM><![CDATA[Australia]]></TERM><TERM><![CDATA[Autopsy]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[burden of illness]]></TERM><TERM><![CDATA[Cardiac]]></TERM><TERM><![CDATA[Cardiac Myocytes]]></TERM><TERM><![CDATA[Cardiomyopathies]]></TERM><TERM><![CDATA[Case Study]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Chagas Disease]]></TERM><TERM><![CDATA[Cholesterol]]></TERM><TERM><![CDATA[cholesterol biosynthesis]]></TERM><TERM><![CDATA[Cholesterol Homeostasis]]></TERM><TERM><![CDATA[Chronic]]></TERM><TERM><![CDATA[Country]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Developed Countries]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Diabetes Mellitus]]></TERM><TERM><![CDATA[Diet]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Drug Targeting]]></TERM><TERM><![CDATA[Dyslipidemias]]></TERM><TERM><![CDATA[Early Intervention]]></TERM><TERM><![CDATA[Economic Burden]]></TERM><TERM><![CDATA[Endoplasmic Reticulum]]></TERM><TERM><![CDATA[Epidemic]]></TERM><TERM><![CDATA[Epidemiology]]></TERM><TERM><![CDATA[Europe]]></TERM><TERM><![CDATA[exhaust]]></TERM><TERM><![CDATA[Fat necrosis]]></TERM><TERM><![CDATA[Fatty acid glycerol esters]]></TERM><TERM><![CDATA[fatty acid metabolism]]></TERM><TERM><![CDATA[Fatty Acids]]></TERM><TERM><![CDATA[Fatty Liver]]></TERM><TERM><![CDATA[Frequencies (time pattern)]]></TERM><TERM><![CDATA[Functional disorder]]></TERM><TERM><![CDATA[glucose metabolism]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Healthcare Systems]]></TERM><TERM><![CDATA[Heart]]></TERM><TERM><![CDATA[Heart Diseases]]></TERM><TERM><![CDATA[heart function]]></TERM><TERM><![CDATA[Hepatocyte]]></TERM><TERM><![CDATA[Homeostasis]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[Human Development]]></TERM><TERM><![CDATA[Immigrant]]></TERM><TERM><![CDATA[Immunofluorescence Immunologic]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[In-Migration]]></TERM><TERM><![CDATA[Incubated]]></TERM><TERM><![CDATA[Infection]]></TERM><TERM><![CDATA[Inflammation]]></TERM><TERM><![CDATA[Intervention]]></TERM><TERM><![CDATA[Invaded]]></TERM><TERM><![CDATA[Latin America]]></TERM><TERM><![CDATA[LDL Cholesterol Lipoproteins]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[Link]]></TERM><TERM><![CDATA[lipid biosynthesis]]></TERM><TERM><![CDATA[lipid metabolism]]></TERM><TERM><![CDATA[Lipids]]></TERM><TERM><![CDATA[Lipolysis]]></TERM><TERM><![CDATA[Lipoproteins]]></TERM><TERM><![CDATA[Liver]]></TERM><TERM><![CDATA[Liver Dysfunction]]></TERM><TERM><![CDATA[low density lipoprotein inhibitor]]></TERM><TERM><![CDATA[Low Density Lipoprotein Receptor]]></TERM><TERM><![CDATA[Lysosomes]]></TERM><TERM><![CDATA[Mammalian Cell]]></TERM><TERM><![CDATA[Manuscripts]]></TERM><TERM><![CDATA[Metabolic]]></TERM><TERM><![CDATA[Metabolism]]></TERM><TERM><![CDATA[Mitochondria]]></TERM><TERM><![CDATA[Morbidity - disease rate]]></TERM><TERM><![CDATA[Mortality Vital Statistics]]></TERM><TERM><![CDATA[mouse model]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[Myocardial dysfunction]]></TERM><TERM><![CDATA[Myocarditis]]></TERM><TERM><![CDATA[Myocardium]]></TERM><TERM><![CDATA[North America]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[novel strategies]]></TERM><TERM><![CDATA[Obesity]]></TERM><TERM><![CDATA[Organ]]></TERM><TERM><![CDATA[overexpression]]></TERM><TERM><![CDATA[parasite invasion]]></TERM><TERM><![CDATA[Parasites]]></TERM><TERM><![CDATA[pathogen]]></TERM><TERM><![CDATA[Pathogenesis]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Pharmaceutical Preparations]]></TERM><TERM><![CDATA[Phase]]></TERM><TERM><![CDATA[Play]]></TERM><TERM><![CDATA[Preparation]]></TERM><TERM><![CDATA[prevent]]></TERM><TERM><![CDATA[Publishing]]></TERM><TERM><![CDATA[Risk]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Sampling]]></TERM><TERM><![CDATA[Sarcomeres]]></TERM><TERM><![CDATA[Serum]]></TERM><TERM><![CDATA[Signal Pathway]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[South America]]></TERM><TERM><![CDATA[Staging]]></TERM><TERM><![CDATA[Stress]]></TERM><TERM><![CDATA[Survival Rate]]></TERM><TERM><![CDATA[Therapeutic Intervention]]></TERM><TERM><![CDATA[Tissues]]></TERM><TERM><![CDATA[Transgenic Mice]]></TERM><TERM><![CDATA[Transgenic Organisms]]></TERM><TERM><![CDATA[Transmission Electron Microscopy]]></TERM><TERM><![CDATA[Triglycerides]]></TERM><TERM><![CDATA[Trypanosoma cruzi]]></TERM><TERM><![CDATA[United States]]></TERM><TERM><![CDATA[Up-Regulation (Physiology)]]></TERM><TERM><![CDATA[Vaccines]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Pathogenic contribution of lipid homeostasis to chagasic Cardiomyopathy]]></PROJECT_TITLE><SERIAL_NUMBER>122866</SERIAL_NUMBER><STUDY_SECTION>AICS</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Atherosclerosis and Inflammation of the Cardiovascular System Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>145833</DIRECT_COST_AMT><INDIRECT_COST_AMT>97708</INDIRECT_COST_AMT><TOTAL_COST>243541</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9172491</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>HL</ADMINISTERING_IC><APPLICATION_TYPE>6</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/06/2015</AWARD_NOTICE_DATE><BUDGET_START>11/06/2015</BUDGET_START><BUDGET_END>04/30/2016</BUDGET_END><CFDA_CODE>837</CFDA_CODE><CORE_PROJECT_NUM>R01HL127700</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>PA-13-302</FOA_NUMBER><FULL_PROJECT_NUM>6R01HL127700-02</FULL_PROJECT_NUM><FUNDING_ICs>NHLBI:349817\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2015</FY><IC_NAME>NATIONAL HEART, LUNG, AND BLOOD INSTITUTE</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>BRONX</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>14</ORG_DISTRICT><ORG_DUNS>079783367</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[ALBERT EINSTEIN COLLEGE OF MEDICINE]]></ORG_NAME><ORG_STATE>NY</ORG_STATE><ORG_ZIPCODE>104611975</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Transplantation of hearts and kidneys is a proven life-saving intervention for patients suffering from end stage heart and renal failure. Unfortunately, the long
term effectiveness of these procedures is limited by arteriosclerotic vascular disease that occurs in within the circulation of the transplanted organ. This problem affects almost all transplant recipients and is the major cause of eventual graft failure. There are currently no proven therapies that can prevent or reverse this vascular disease. Our studies address the role in this process of a cellular growth factor called CSF-1, and will evaluate the possibility that inhibitionof this factor may provide a novel strategy to decrease transplant vascular disease and prolong transplanted organ function.   
      

]]></PHR><PIS><PI><PI_NAME>SIBINGA, NICHOLAS E</PI_NAME><PI_ID>1939506</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>ADHIKARI, BISHOW B.</PROGRAM_OFFICER_NAME><PROJECT_START>07/06/2015</PROJECT_START><PROJECT_END>04/30/2019</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Abbreviations]]></TERM><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[Allografting]]></TERM><TERM><![CDATA[Antibodies]]></TERM><TERM><![CDATA[Arteriosclerosis]]></TERM><TERM><![CDATA[autocrine]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Biological Assay]]></TERM><TERM><![CDATA[Biology]]></TERM><TERM><![CDATA[Biopsy]]></TERM><TERM><![CDATA[Blood Circulation]]></TERM><TERM><![CDATA[Blood Vessels]]></TERM><TERM><![CDATA[c-fms Proto-Oncogenes]]></TERM><TERM><![CDATA[Cardiac]]></TERM><TERM><![CDATA[cell growth]]></TERM><TERM><![CDATA[Cell Proliferation]]></TERM><TERM><![CDATA[Cell surface]]></TERM><TERM><![CDATA[Cell Survival]]></TERM><TERM><![CDATA[cell type]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[cellular targeting]]></TERM><TERM><![CDATA[Chronic]]></TERM><TERM><![CDATA[Clinic]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[clinical practice]]></TERM><TERM><![CDATA[Coronary artery]]></TERM><TERM><![CDATA[cytokine]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Disease model]]></TERM><TERM><![CDATA[Effectiveness]]></TERM><TERM><![CDATA[Extracellular Matrix]]></TERM><TERM><![CDATA[Failure (biologic function)]]></TERM><TERM><![CDATA[Gene Transfer Techniques]]></TERM><TERM><![CDATA[graft failure]]></TERM><TERM><![CDATA[Growth Factor]]></TERM><TERM><![CDATA[Heart failure]]></TERM><TERM><![CDATA[Heart Transplantation]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[human MYH11 protein]]></TERM><TERM><![CDATA[Hyperplasia]]></TERM><TERM><![CDATA[In Situ Hybridization]]></TERM><TERM><![CDATA[In Vitro]]></TERM><TERM><![CDATA[inhibitor/antagonist]]></TERM><TERM><![CDATA[Interferons]]></TERM><TERM><![CDATA[Interleukins]]></TERM><TERM><![CDATA[Intervention]]></TERM><TERM><![CDATA[Ischemia]]></TERM><TERM><![CDATA[Kidney]]></TERM><TERM><![CDATA[Kidney Failure]]></TERM><TERM><![CDATA[Lesion]]></TERM><TERM><![CDATA[Life]]></TERM><TERM><![CDATA[Ligands]]></TERM><TERM><![CDATA[Ligation]]></TERM><TERM><![CDATA[macrophage]]></TERM><TERM><![CDATA[Macrophage Colony-Stimulating Factor]]></TERM><TERM><![CDATA[Macrophage Colony-Stimulating Factor Receptor]]></TERM><TERM><![CDATA[Major Histocompatibility Complex]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[Mediator of activation protein]]></TERM><TERM><![CDATA[migration]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[mouse model]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[Myosin Heavy Chains]]></TERM><TERM><![CDATA[neointima formation]]></TERM><TERM><![CDATA[Nitric Oxide Synthase]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[novel strategies]]></TERM><TERM><![CDATA[Obstruction]]></TERM><TERM><![CDATA[Oncogenes]]></TERM><TERM><![CDATA[Organ Transplantation]]></TERM><TERM><![CDATA[Pathogenesis]]></TERM><TERM><![CDATA[Pathway interactions]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Platelet-Derived Growth Factor]]></TERM><TERM><![CDATA[pre-clinical]]></TERM><TERM><![CDATA[Pre-Clinical Model]]></TERM><TERM><![CDATA[prevent]]></TERM><TERM><![CDATA[Prevention]]></TERM><TERM><![CDATA[Procedures]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[Protein Isoforms]]></TERM><TERM><![CDATA[public health relevance]]></TERM><TERM><![CDATA[receptor]]></TERM><TERM><![CDATA[reconstitution]]></TERM><TERM><![CDATA[Relative (related person)]]></TERM><TERM><![CDATA[Risk]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Signal Pathway]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[Smooth muscle (tissue)]]></TERM><TERM><![CDATA[Smooth Muscle Myocytes]]></TERM><TERM><![CDATA[Smooth Muscle Myosins]]></TERM><TERM><![CDATA[Solid]]></TERM><TERM><![CDATA[Source]]></TERM><TERM><![CDATA[Staging]]></TERM><TERM><![CDATA[success]]></TERM><TERM><![CDATA[Surface]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Therapeutic]]></TERM><TERM><![CDATA[therapeutic target]]></TERM><TERM><![CDATA[Tissue Donors]]></TERM><TERM><![CDATA[TNF gene]]></TERM><TERM><![CDATA[transdifferentiation]]></TERM><TERM><![CDATA[Transforming Growth Factors]]></TERM><TERM><![CDATA[Translating]]></TERM><TERM><![CDATA[Transplant Recipients]]></TERM><TERM><![CDATA[Transplantation]]></TERM><TERM><![CDATA[Transplanted tissue]]></TERM><TERM><![CDATA[Tumor Necrosis Factor-alpha]]></TERM><TERM><![CDATA[Vascular Diseases]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Colony stimulating factor-1 in graft vascular disease]]></PROJECT_TITLE><SERIAL_NUMBER>127700</SERIAL_NUMBER><STUDY_SECTION>AICS</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Atherosclerosis and Inflammation of the Cardiovascular System Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>211611</DIRECT_COST_AMT><INDIRECT_COST_AMT>138206</INDIRECT_COST_AMT><TOTAL_COST>349817</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9174733</APPLICATION_ID><ACTIVITY>U2G</ACTIVITY><ADMINISTERING_IC>PS</ADMINISTERING_IC><APPLICATION_TYPE>3</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/04/2015</AWARD_NOTICE_DATE><BUDGET_START>09/01/2014</BUDGET_START><BUDGET_END>08/31/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>U2GPS001975</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-PS-09-973</FOA_NUMBER><FULL_PROJECT_NUM>3U2GPS001975-05S2</FULL_PROJECT_NUM><FUNDING_ICs>COGH:2292108\</FUNDING_ICs><FUNDING_MECHANISM>OTHERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP)</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>DAR ES SALAAM</ORG_CITY><ORG_COUNTRY>TANZANIA U REP</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT></ORG_DISTRICT><ORG_DUNS></ORG_DUNS><ORG_FIPS>TZ</ORG_FIPS><ORG_NAME><![CDATA[TANZANIA YOUTH ALLIANCE (TAYOA)]]></ORG_NAME><ORG_STATE></ORG_STATE><ORG_ZIPCODE></ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>MASIKA, PETER </PI_NAME><PI_ID>9539289</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>09/01/2010</PROJECT_START><PROJECT_END>08/31/2016</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[IMPLEMENTATION OF PROGRAMS FOR THE PREVENTION CARE AND TREATMENT OF HIV/AIDS]]></PROJECT_TITLE><SERIAL_NUMBER>001975</SERIAL_NUMBER><STUDY_SECTION>ZPS1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>05</SUPPORT_YEAR><SUFFIX>S2</SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>2292108</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8959921</APPLICATION_ID><ACTIVITY>R21</ACTIVITY><ADMINISTERING_IC>AI</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/29/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>855</CFDA_CODE><CORE_PROJECT_NUM>R21AI115449</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-13-303</FOA_NUMBER><FULL_PROJECT_NUM>5R21AI115449-02</FULL_PROJECT_NUM><FUNDING_ICs>NIAID:190384\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>GALVESTON</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[PATHOLOGY]]></ORG_DEPT><ORG_DISTRICT>14</ORG_DISTRICT><ORG_DUNS>800771149</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIVERSITY OF TEXAS MEDICAL BR GALVESTON]]></ORG_NAME><ORG_STATE>TX</ORG_STATE><ORG_ZIPCODE>775555302</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE:  Ehrlichia chaffeensis is the etiologic agent of the life-threatening disease human monocytotropic ehrlichiosis. E chaffeensis selectively invades mammalian mononuclear phagocytes and establishes intracellular infection through effector-mediated mechanisms that manipulate host cellular functions and evade innate immune responses. Molecular characterization of these processes provides insight into mechanisms through which microbes exploit host cellular functions, and identifies novel pharmacological targets in the host organism for antimicrobial therapeutics.]]></PHR><PIS><PI><PI_NAME>MCBRIDE, JERE W</PI_NAME><PI_ID>6807366</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>PERDUE, SAMUEL S.</PROGRAM_OFFICER_NAME><PROJECT_START>11/01/2014</PROJECT_START><PROJECT_END>10/31/2016</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[antimicrobial]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Binding (Molecular Function)]]></TERM><TERM><![CDATA[Biological Models]]></TERM><TERM><![CDATA[Cell membrane]]></TERM><TERM><![CDATA[Cell physiology]]></TERM><TERM><![CDATA[cell type]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Cellular biology]]></TERM><TERM><![CDATA[Chromatin]]></TERM><TERM><![CDATA[Complex]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Down-Regulation]]></TERM><TERM><![CDATA[Ehrlichia]]></TERM><TERM><![CDATA[Ehrlichia chaffeensis]]></TERM><TERM><![CDATA[Ehrlichiosis]]></TERM><TERM><![CDATA[Enzymes]]></TERM><TERM><![CDATA[Epigenetic Process]]></TERM><TERM><![CDATA[Family]]></TERM><TERM><![CDATA[Feasibility Studies]]></TERM><TERM><![CDATA[Gene Expression]]></TERM><TERM><![CDATA[Gene Expression Profile]]></TERM><TERM><![CDATA[Gene Expression Regulation]]></TERM><TERM><![CDATA[Gene Targeting]]></TERM><TERM><![CDATA[Genes]]></TERM><TERM><![CDATA[Genetic Transcription]]></TERM><TERM><![CDATA[Global Change]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Gram-Negative Bacteria]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[histone modification]]></TERM><TERM><![CDATA[Histones]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[human disease]]></TERM><TERM><![CDATA[Immune]]></TERM><TERM><![CDATA[Immune response]]></TERM><TERM><![CDATA[Infection]]></TERM><TERM><![CDATA[insight]]></TERM><TERM><![CDATA[Invaded]]></TERM><TERM><![CDATA[Investigation]]></TERM><TERM><![CDATA[Knowledge]]></TERM><TERM><![CDATA[Life]]></TERM><TERM><![CDATA[Ligase]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[member]]></TERM><TERM><![CDATA[Microbe]]></TERM><TERM><![CDATA[Modification]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[monocyte]]></TERM><TERM><![CDATA[Mononuclear]]></TERM><TERM><![CDATA[nanomachine]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[novel therapeutics]]></TERM><TERM><![CDATA[Organism]]></TERM><TERM><![CDATA[pathogen]]></TERM><TERM><![CDATA[pathogenic bacteria]]></TERM><TERM><![CDATA[Pathway interactions]]></TERM><TERM><![CDATA[Pattern]]></TERM><TERM><![CDATA[Phagocytes]]></TERM><TERM><![CDATA[Polycomb]]></TERM><TERM><![CDATA[Post-Translational Protein Processing]]></TERM><TERM><![CDATA[PRC1 Protein]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[programs]]></TERM><TERM><![CDATA[protein complex]]></TERM><TERM><![CDATA[protein degradation]]></TERM><TERM><![CDATA[protein E]]></TERM><TERM><![CDATA[protein expression]]></TERM><TERM><![CDATA[Protein Isoforms]]></TERM><TERM><![CDATA[protein protein interaction]]></TERM><TERM><![CDATA[Proteins]]></TERM><TERM><![CDATA[Recruitment Activity]]></TERM><TERM><![CDATA[Regulation]]></TERM><TERM><![CDATA[Reporting]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Ring Finger Domain]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[Tandem Repeat Sequences]]></TERM><TERM><![CDATA[Tertiary Protein Structure]]></TERM><TERM><![CDATA[Therapeutic]]></TERM><TERM><![CDATA[therapeutic target]]></TERM><TERM><![CDATA[transcription factor]]></TERM><TERM><![CDATA[Transcription Repressor/Corepressor]]></TERM><TERM><![CDATA[Transcriptional Regulation]]></TERM><TERM><![CDATA[Vacuole]]></TERM><TERM><![CDATA[Zoonoses]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Ehrlichia modulation of polycomb group-dependent epigenetic regulation]]></PROJECT_TITLE><SERIAL_NUMBER>115449</SERIAL_NUMBER><STUDY_SECTION>ZRG1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>125000</DIRECT_COST_AMT><INDIRECT_COST_AMT>65384</INDIRECT_COST_AMT><TOTAL_COST>190384</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8960339</APPLICATION_ID><ACTIVITY>R21</ACTIVITY><ADMINISTERING_IC>AI</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/23/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>855</CFDA_CODE><CORE_PROJECT_NUM>R21AI111201</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF ARTS AND SCIENCES]]></ED_INST_TYPE><FOA_NUMBER>PA-13-303</FOA_NUMBER><FULL_PROJECT_NUM>5R21AI111201-02</FULL_PROJECT_NUM><FUNDING_ICs>NIAID:146000\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>CORVALLIS</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[ZOOLOGY]]></ORG_DEPT><ORG_DISTRICT>04</ORG_DISTRICT><ORG_DUNS>053599908</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[OREGON STATE UNIVERSITY]]></ORG_NAME><ORG_STATE>OR</ORG_STATE><ORG_ZIPCODE>973318517</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Schistosomes are water-borne blood-flukes that are transmitted by snails (infecting over 200 million people in more than 70 countries, and causing severe and chronic disability). We will use tens of thousands of genetic markers to create a linkage map for the sequenced genome of the snail host. This resource will allow us and others to find genes involved in snail-parasite interactions, which can be targeted to block parasite transmission.]]></PHR><PIS><PI><PI_NAME>BLOUIN, MICHAEL S</PI_NAME><PI_ID>9114736</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>COSTERO-SAINT DENIS, ADRIANA </PROGRAM_OFFICER_NAME><PROJECT_START>11/01/2014</PROJECT_START><PROJECT_END>10/31/2016</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Binding (Molecular Function)]]></TERM><TERM><![CDATA[Biochemical]]></TERM><TERM><![CDATA[Biomphalaria]]></TERM><TERM><![CDATA[Candidate Disease Gene]]></TERM><TERM><![CDATA[Chromosome Mapping]]></TERM><TERM><![CDATA[Chromosomes]]></TERM><TERM><![CDATA[Chronic]]></TERM><TERM><![CDATA[Chronic Disease]]></TERM><TERM><![CDATA[Communities]]></TERM><TERM><![CDATA[Complement]]></TERM><TERM><![CDATA[Country]]></TERM><TERM><![CDATA[Culicidae]]></TERM><TERM><![CDATA[density]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[disability]]></TERM><TERM><![CDATA[disability-adjusted life years]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[DNA]]></TERM><TERM><![CDATA[Dose]]></TERM><TERM><![CDATA[Drug resistance]]></TERM><TERM><![CDATA[effective therapy]]></TERM><TERM><![CDATA[Elements]]></TERM><TERM><![CDATA[Epidemiology]]></TERM><TERM><![CDATA[Evolution]]></TERM><TERM><![CDATA[Foundations]]></TERM><TERM><![CDATA[functional genomics]]></TERM><TERM><![CDATA[gene discovery]]></TERM><TERM><![CDATA[Genes]]></TERM><TERM><![CDATA[Genetic Markers]]></TERM><TERM><![CDATA[Genome]]></TERM><TERM><![CDATA[genome sequencing]]></TERM><TERM><![CDATA[genome wide association study]]></TERM><TERM><![CDATA[Genomic Segment]]></TERM><TERM><![CDATA[Genomics]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Helminths]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[immune function]]></TERM><TERM><![CDATA[Immune response]]></TERM><TERM><![CDATA[Immune system]]></TERM><TERM><![CDATA[Immunity]]></TERM><TERM><![CDATA[Infection]]></TERM><TERM><![CDATA[innovation]]></TERM><TERM><![CDATA[interest]]></TERM><TERM><![CDATA[Link]]></TERM><TERM><![CDATA[Malaria]]></TERM><TERM><![CDATA[Maps]]></TERM><TERM><![CDATA[Methods]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[novel strategies]]></TERM><TERM><![CDATA[Outcome]]></TERM><TERM><![CDATA[Parasites]]></TERM><TERM><![CDATA[Parasitic Diseases]]></TERM><TERM><![CDATA[Pharmaceutical Preparations]]></TERM><TERM><![CDATA[Phenotype]]></TERM><TERM><![CDATA[Plasmodium]]></TERM><TERM><![CDATA[Population]]></TERM><TERM><![CDATA[Population Genetics]]></TERM><TERM><![CDATA[Population Study]]></TERM><TERM><![CDATA[Praziquantel]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Research Personnel]]></TERM><TERM><![CDATA[Resistance]]></TERM><TERM><![CDATA[resistance gene]]></TERM><TERM><![CDATA[Resources]]></TERM><TERM><![CDATA[Schistosoma]]></TERM><TERM><![CDATA[Schistosomatidae]]></TERM><TERM><![CDATA[Schistosomiasis]]></TERM><TERM><![CDATA[Snails]]></TERM><TERM><![CDATA[Staging]]></TERM><TERM><![CDATA[success]]></TERM><TERM><![CDATA[System]]></TERM><TERM><![CDATA[Therapeutic]]></TERM><TERM><![CDATA[therapeutic target]]></TERM><TERM><![CDATA[trait]]></TERM><TERM><![CDATA[transmission process]]></TERM><TERM><![CDATA[Vaccines]]></TERM><TERM><![CDATA[Variant]]></TERM><TERM><![CDATA[Variation (Genetics)]]></TERM><TERM><![CDATA[Water]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[High-density linkage map to find snail genes that block schistosome transmission]]></PROJECT_TITLE><SERIAL_NUMBER>111201</SERIAL_NUMBER><STUDY_SECTION>VB</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Vector Biology Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>100000</DIRECT_COST_AMT><INDIRECT_COST_AMT>46000</INDIRECT_COST_AMT><TOTAL_COST>146000</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8960926</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>AI</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/23/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>855</CFDA_CODE><CORE_PROJECT_NUM>R01AI115716</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-13-302</FOA_NUMBER><FULL_PROJECT_NUM>5R01AI115716-02</FULL_PROJECT_NUM><FUNDING_ICs>NIAID:389432\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>CHICAGO</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[INTERNAL MEDICINE/MEDICINE]]></ORG_DEPT><ORG_DISTRICT>01</ORG_DISTRICT><ORG_DUNS>005421136</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIVERSITY OF CHICAGO]]></ORG_NAME><ORG_STATE>IL</ORG_STATE><ORG_ZIPCODE>606375418</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Our preliminary results indicate that the complex communities of commensal microbes that inhabit the body, collectively called the microbiota, contribute to activate the immune system following solid organ transplantation and promote transplant rejection. In this application, we propose to investigate the mechanisms by which the microbiota enhances the anti-transplant immune response and explore approaches to manipulate the microbiota to promote graft survival. Because the microbiota is very amenable to therapeutic manipulation by antibiotics or probiotics, results from this research can be translated to the clinc to improve the health of transplanted patients and the outcome of transplanted organs.]]></PHR><PIS><PI><PI_NAME>ALEGRE, MARIA-LUISA </PI_NAME><PI_ID>6411448</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>KEHN, PATRICIA J.</PROGRAM_OFFICER_NAME><PROJECT_START>11/03/2014</PROJECT_START><PROJECT_END>10/31/2019</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Acute]]></TERM><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[allograft rejection]]></TERM><TERM><![CDATA[Allografting]]></TERM><TERM><![CDATA[Antibiotics]]></TERM><TERM><![CDATA[antimicrobial]]></TERM><TERM><![CDATA[antimicrobial drug]]></TERM><TERM><![CDATA[Bacteria]]></TERM><TERM><![CDATA[Bacterial Infections]]></TERM><TERM><![CDATA[Body Surface]]></TERM><TERM><![CDATA[Chronic]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[commensal microbes]]></TERM><TERM><![CDATA[Communities]]></TERM><TERM><![CDATA[Complex]]></TERM><TERM><![CDATA[Control Animal]]></TERM><TERM><![CDATA[Cutaneous]]></TERM><TERM><![CDATA[Dendritic Cells]]></TERM><TERM><![CDATA[Dependence]]></TERM><TERM><![CDATA[Diet]]></TERM><TERM><![CDATA[Distal]]></TERM><TERM><![CDATA[end-stage organ failure]]></TERM><TERM><![CDATA[Environmental Risk Factor]]></TERM><TERM><![CDATA[Follow-Up Studies]]></TERM><TERM><![CDATA[Generations]]></TERM><TERM><![CDATA[Genetic]]></TERM><TERM><![CDATA[Germ-Free]]></TERM><TERM><![CDATA[Graft Rejection]]></TERM><TERM><![CDATA[Graft Survival]]></TERM><TERM><![CDATA[gut microbiota]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Heart]]></TERM><TERM><![CDATA[Heart Transplantation]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[Immune response]]></TERM><TERM><![CDATA[Immune system]]></TERM><TERM><![CDATA[Immunity]]></TERM><TERM><![CDATA[Immunosuppressive Agents]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[Infection]]></TERM><TERM><![CDATA[Inflammation]]></TERM><TERM><![CDATA[Intervention]]></TERM><TERM><![CDATA[Intestines]]></TERM><TERM><![CDATA[Ischemia]]></TERM><TERM><![CDATA[isoimmunity]]></TERM><TERM><![CDATA[ITGAX gene]]></TERM><TERM><![CDATA[Kidney]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[Life]]></TERM><TERM><![CDATA[Lung]]></TERM><TERM><![CDATA[lymph nodes]]></TERM><TERM><![CDATA[Metabolism]]></TERM><TERM><![CDATA[microbial]]></TERM><TERM><![CDATA[microbial community]]></TERM><TERM><![CDATA[migration]]></TERM><TERM><![CDATA[Minor]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[mouse model]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[Natural immunosuppression]]></TERM><TERM><![CDATA[Organ]]></TERM><TERM><![CDATA[Organ Transplantation]]></TERM><TERM><![CDATA[Outcome]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Pattern]]></TERM><TERM><![CDATA[Pharmaceutical Preparations]]></TERM><TERM><![CDATA[Phase]]></TERM><TERM><![CDATA[Phenotype]]></TERM><TERM><![CDATA[prebiotics]]></TERM><TERM><![CDATA[Probiotics]]></TERM><TERM><![CDATA[Procedures]]></TERM><TERM><![CDATA[prophylactic]]></TERM><TERM><![CDATA[Prophylactic treatment]]></TERM><TERM><![CDATA[Regulatory T-Lymphocyte]]></TERM><TERM><![CDATA[Reperfusion Therapy]]></TERM><TERM><![CDATA[Reporting]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[research study]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[Rest]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Secondary to]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[Skin]]></TERM><TERM><![CDATA[Skin graft]]></TERM><TERM><![CDATA[Skin Transplantation]]></TERM><TERM><![CDATA[Solid]]></TERM><TERM><![CDATA[Sterility]]></TERM><TERM><![CDATA[Surface]]></TERM><TERM><![CDATA[T-Lymphocyte]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Therapeutic]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[Tissues]]></TERM><TERM><![CDATA[Toll-like receptors]]></TERM><TERM><![CDATA[Translating]]></TERM><TERM><![CDATA[Transplant Recipients]]></TERM><TERM><![CDATA[Transplantation]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Impact of Microbiota on Alloimmune Responses in Transplantation]]></PROJECT_TITLE><SERIAL_NUMBER>115716</SERIAL_NUMBER><STUDY_SECTION>TTT</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Transplantation, Tolerance, and Tumor Immunology ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>250000</DIRECT_COST_AMT><INDIRECT_COST_AMT>139432</INDIRECT_COST_AMT><TOTAL_COST>389432</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8960940</APPLICATION_ID><ACTIVITY>P01</ACTIVITY><ADMINISTERING_IC>HL</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/26/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>P01HL029582</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>PAR-13-316</FOA_NUMBER><FULL_PROJECT_NUM>5P01HL029582-32</FULL_PROJECT_NUM><FUNDING_ICs>NHLBI:119059\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL HEART, LUNG, AND BLOOD INSTITUTE</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>CLEVELAND</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>11</ORG_DISTRICT><ORG_DUNS>135781701</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[CLEVELAND CLINIC LERNER COM-CWRU]]></ORG_NAME><ORG_STATE>OH</ORG_STATE><ORG_ZIPCODE>441950001</ORG_ZIPCODE><PHR><![CDATA[Macromolecular Interaction Core (Core D). Project Narrative
The principal objective of Core D is to make available robust, state-of-the-art techniques for accurate and
reproducible measurement of macromolecular interactions, particularly protein-protein and protein-RNA
interactions. Such measurements are essential for understanding the signaling pathways and metabolic
relationships of molecules. Often, defects in these interactions can have pathological consequences. The
Macromolecular Interaction Core will provide a diversity of services including provision of reagents, assistance
in probe design and construction, design and performance of experiments, and data analysis and interpretation
of results. An educational component is a major strength of this Core. All of the methods provided by Core D
require technical expertise and experience not generally available in a modern cell or molecular biology
laboratory; additionally, some methods require unfamiliar computational analysis methods.]]></PHR><PIS><PI><PI_NAME>FOX, PAUL L</PI_NAME><PI_ID>1891116</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START></PROJECT_START><PROJECT_END></PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[abstracting]]></TERM><TERM><![CDATA[Amino Acid Sequence]]></TERM><TERM><![CDATA[Antibodies]]></TERM><TERM><![CDATA[Atherosclerosis]]></TERM><TERM><![CDATA[Biochemical]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Cellular biology]]></TERM><TERM><![CDATA[Circular Dichroism]]></TERM><TERM><![CDATA[Co-Immunoprecipitations]]></TERM><TERM><![CDATA[Complex]]></TERM><TERM><![CDATA[Computer Analysis]]></TERM><TERM><![CDATA[Confocal Microscopy]]></TERM><TERM><![CDATA[Data Analyses]]></TERM><TERM><![CDATA[Defect]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[design and construction]]></TERM><TERM><![CDATA[Detection]]></TERM><TERM><![CDATA[Disadvantaged]]></TERM><TERM><![CDATA[DNA]]></TERM><TERM><![CDATA[Doctor of Philosophy]]></TERM><TERM><![CDATA[Effectiveness]]></TERM><TERM><![CDATA[Endothelial Cells]]></TERM><TERM><![CDATA[Energy Transfer]]></TERM><TERM><![CDATA[experience]]></TERM><TERM><![CDATA[Foxes]]></TERM><TERM><![CDATA[Gene Expression]]></TERM><TERM><![CDATA[Human Resources]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[Inflammation]]></TERM><TERM><![CDATA[Inflammatory]]></TERM><TERM><![CDATA[instrumentation]]></TERM><TERM><![CDATA[Investigation]]></TERM><TERM><![CDATA[Laboratories]]></TERM><TERM><![CDATA[Link]]></TERM><TERM><![CDATA[macrophage]]></TERM><TERM><![CDATA[Maps]]></TERM><TERM><![CDATA[Mass Spectrum Analysis]]></TERM><TERM><![CDATA[Measurement]]></TERM><TERM><![CDATA[Metabolic]]></TERM><TERM><![CDATA[Metabolism]]></TERM><TERM><![CDATA[Methods]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[Molecular Biology]]></TERM><TERM><![CDATA[Mutation]]></TERM><TERM><![CDATA[Organelles]]></TERM><TERM><![CDATA[Peptide Hydrolases]]></TERM><TERM><![CDATA[Peptide Sequence Determination]]></TERM><TERM><![CDATA[Performance]]></TERM><TERM><![CDATA[Phase]]></TERM><TERM><![CDATA[Polyribosomes]]></TERM><TERM><![CDATA[Procedures]]></TERM><TERM><![CDATA[programs]]></TERM><TERM><![CDATA[Protein Analysis]]></TERM><TERM><![CDATA[protein protein interaction]]></TERM><TERM><![CDATA[Proteins]]></TERM><TERM><![CDATA[Publishing]]></TERM><TERM><![CDATA[Reagent]]></TERM><TERM><![CDATA[Reporting]]></TERM><TERM><![CDATA[Research Institute]]></TERM><TERM><![CDATA[research study]]></TERM><TERM><![CDATA[Resolution]]></TERM><TERM><![CDATA[Ribosomes]]></TERM><TERM><![CDATA[RNA]]></TERM><TERM><![CDATA[RNA-Protein Interaction]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Services]]></TERM><TERM><![CDATA[Signal Pathway]]></TERM><TERM><![CDATA[Site]]></TERM><TERM><![CDATA[Spectrometry]]></TERM><TERM><![CDATA[Structure]]></TERM><TERM><![CDATA[Surface Plasmon Resonance]]></TERM><TERM><![CDATA[Technical Expertise]]></TERM><TERM><![CDATA[Techniques]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Translations]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Macromolecular Interaction Core D]]></PROJECT_TITLE><SERIAL_NUMBER>029582</SERIAL_NUMBER><STUDY_SECTION>ZHL1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID>7864</SUBPROJECT_ID><SUPPORT_YEAR>32</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>75115</DIRECT_COST_AMT><INDIRECT_COST_AMT>43944</INDIRECT_COST_AMT><TOTAL_COST /><TOTAL_COST_SUB_PROJECT>119059</TOTAL_COST_SUB_PROJECT></row>
<row><APPLICATION_ID>8960943</APPLICATION_ID><ACTIVITY>P01</ACTIVITY><ADMINISTERING_IC>HL</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/26/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>P01HL029582</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>PAR-13-316</FOA_NUMBER><FULL_PROJECT_NUM>5P01HL029582-32</FULL_PROJECT_NUM><FUNDING_ICs>NHLBI:424425\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL HEART, LUNG, AND BLOOD INSTITUTE</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>CLEVELAND</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>11</ORG_DISTRICT><ORG_DUNS>135781701</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[CLEVELAND CLINIC LERNER COM-CWRU]]></ORG_NAME><ORG_STATE>OH</ORG_STATE><ORG_ZIPCODE>441950001</ORG_ZIPCODE><PHR><![CDATA[Project 3 (P3). Project Narrative
The United States is facing an accelerating epidemic of diet-induced obesity, and its associated pathological
consequences, including diabetes and atherosclerosis. We have discovered a new connection between an
agent previously known to drive dietary obesity, namely mTOR, with a protein not previously associated with
this process, i.e., EPRS. We will study the mechanisms by which EPRS exacerbates diet-induced obesity in
cells and in mice. These studies can provide novel approaches and therapeutic targets for future treatments.]]></PHR><PIS><PI><PI_NAME>FOX, PAUL L</PI_NAME><PI_ID>1891116</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START></PROJECT_START><PROJECT_END></PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[A Mouse]]></TERM><TERM><![CDATA[abstracting]]></TERM><TERM><![CDATA[Adipocytes]]></TERM><TERM><![CDATA[Adipose tissue]]></TERM><TERM><![CDATA[Adult]]></TERM><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[age related]]></TERM><TERM><![CDATA[Agonist]]></TERM><TERM><![CDATA[Amino Acyl-tRNA Synthetases]]></TERM><TERM><![CDATA[angiogenesis]]></TERM><TERM><![CDATA[Apolipoprotein E]]></TERM><TERM><![CDATA[Atherosclerosis]]></TERM><TERM><![CDATA[Bacteriophages]]></TERM><TERM><![CDATA[Binding (Molecular Function)]]></TERM><TERM><![CDATA[Blood Vessels]]></TERM><TERM><![CDATA[Carbohydrates]]></TERM><TERM><![CDATA[Cardiovascular Diseases]]></TERM><TERM><![CDATA[Cell membrane]]></TERM><TERM><![CDATA[cell type]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Complex]]></TERM><TERM><![CDATA[Coupling]]></TERM><TERM><![CDATA[Cyclin-Dependent Kinase 5]]></TERM><TERM><![CDATA[Diabetes Mellitus]]></TERM><TERM><![CDATA[Diet]]></TERM><TERM><![CDATA[dietary restriction]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Doctor of Philosophy]]></TERM><TERM><![CDATA[Drosophila genus]]></TERM><TERM><![CDATA[Economic Burden]]></TERM><TERM><![CDATA[Endothelial Cells]]></TERM><TERM><![CDATA[Energy Metabolism]]></TERM><TERM><![CDATA[Epidemic]]></TERM><TERM><![CDATA[epidoxorubicin glucuronide]]></TERM><TERM><![CDATA[Event]]></TERM><TERM><![CDATA[Exhibits]]></TERM><TERM><![CDATA[Fat Body]]></TERM><TERM><![CDATA[Fatty acid glycerol esters]]></TERM><TERM><![CDATA[fatty acid transport]]></TERM><TERM><![CDATA[fatty acid-transport protein]]></TERM><TERM><![CDATA[Food]]></TERM><TERM><![CDATA[Food Supply]]></TERM><TERM><![CDATA[Foxes]]></TERM><TERM><![CDATA[Future]]></TERM><TERM><![CDATA[gain of function]]></TERM><TERM><![CDATA[Genes]]></TERM><TERM><![CDATA[Genetic]]></TERM><TERM><![CDATA[glucose metabolism]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[human FRAP1 protein]]></TERM><TERM><![CDATA[In Vitro]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[Inflammation]]></TERM><TERM><![CDATA[Inflammatory]]></TERM><TERM><![CDATA[inhibitor/antagonist]]></TERM><TERM><![CDATA[Insulin]]></TERM><TERM><![CDATA[Insulin Resistance]]></TERM><TERM><![CDATA[Interferon Type II]]></TERM><TERM><![CDATA[Interferons]]></TERM><TERM><![CDATA[Investigation]]></TERM><TERM><![CDATA[Knock-in Mouse]]></TERM><TERM><![CDATA[Knockout Mice]]></TERM><TERM><![CDATA[Laboratories]]></TERM><TERM><![CDATA[Link]]></TERM><TERM><![CDATA[lipid metabolism]]></TERM><TERM><![CDATA[Lipids]]></TERM><TERM><![CDATA[Lipoproteins]]></TERM><TERM><![CDATA[long chain fatty acid]]></TERM><TERM><![CDATA[loss of function]]></TERM><TERM><![CDATA[macrophage]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[Messenger RNA]]></TERM><TERM><![CDATA[Metabolic]]></TERM><TERM><![CDATA[Metabolic Pathway]]></TERM><TERM><![CDATA[Metabolism]]></TERM><TERM><![CDATA[mimetics]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[mTOR protein]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[new therapeutic target]]></TERM><TERM><![CDATA[novel strategies]]></TERM><TERM><![CDATA[Obesity]]></TERM><TERM><![CDATA[Obesity associated cardiovascular disease]]></TERM><TERM><![CDATA[paracrine]]></TERM><TERM><![CDATA[Pathology]]></TERM><TERM><![CDATA[Pathway interactions]]></TERM><TERM><![CDATA[Phenocopy]]></TERM><TERM><![CDATA[Phenotype]]></TERM><TERM><![CDATA[Phosphorylation]]></TERM><TERM><![CDATA[Phosphotransferases]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[programs]]></TERM><TERM><![CDATA[proline-tRNA]]></TERM><TERM><![CDATA[Proteins]]></TERM><TERM><![CDATA[Reducing diet]]></TERM><TERM><![CDATA[Regulation]]></TERM><TERM><![CDATA[Ribosomal Protein S6 Kinase]]></TERM><TERM><![CDATA[Risk Factors]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Sclerosis]]></TERM><TERM><![CDATA[Selection (Genetics)]]></TERM><TERM><![CDATA[Signal Pathway]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[Site]]></TERM><TERM><![CDATA[System]]></TERM><TERM><![CDATA[Tertiary Protein Structure]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[therapeutic target]]></TERM><TERM><![CDATA[Transcript]]></TERM><TERM><![CDATA[Translations]]></TERM><TERM><![CDATA[Triad Acrylic Resin]]></TERM><TERM><![CDATA[uncoupling protein 1]]></TERM><TERM><![CDATA[United States]]></TERM><TERM><![CDATA[upstream kinase]]></TERM><TERM><![CDATA[uptake]]></TERM><TERM><![CDATA[Vascular Diseases]]></TERM><TERM><![CDATA[Vascular Endothelial Growth Factors]]></TERM><TERM><![CDATA[Western World]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Noncanonical activities of a tRNA synthetase in metabolism and atherosclerosis-Pr]]></PROJECT_TITLE><SERIAL_NUMBER>029582</SERIAL_NUMBER><STUDY_SECTION>ZHL1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID>7867</SUBPROJECT_ID><SUPPORT_YEAR>32</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>267776</DIRECT_COST_AMT><INDIRECT_COST_AMT>156649</INDIRECT_COST_AMT><TOTAL_COST /><TOTAL_COST_SUB_PROJECT>424425</TOTAL_COST_SUB_PROJECT></row>
<row><APPLICATION_ID>8962092</APPLICATION_ID><ACTIVITY>P60</ACTIVITY><ADMINISTERING_IC>MD</ADMINISTERING_IC><APPLICATION_TYPE>4</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/30/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>P60MD000538</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-MD-11-003</FOA_NUMBER><FULL_PROJECT_NUM>4P60MD000538-13</FULL_PROJECT_NUM><FUNDING_ICs>NIMHD:231947\</FUNDING_ICs><FUNDING_MECHANISM>RESEARCH CENTERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE ON MINORITY HEALTH AND HEALTH DISPARITIES</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>NEW YORK</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>12</ORG_DISTRICT><ORG_DUNS>121911077</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[NEW YORK UNIVERSITY SCHOOL OF MEDICINE]]></ORG_NAME><ORG_STATE>NY</ORG_STATE><ORG_ZIPCODE>100165802</ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>REY, MARIANO J (contact)</PI_NAME><PI_ID>7704072 (contact)</PI_ID></PI><PI><PI_NAME>REY, MARIANO J</PI_NAME><PI_ID>7704072</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START></PROJECT_START><PROJECT_END></PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[Agreement]]></TERM><TERM><![CDATA[Asian Americans]]></TERM><TERM><![CDATA[Communication]]></TERM><TERM><![CDATA[Communities]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Ensure]]></TERM><TERM><![CDATA[Evaluation Research]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[health disparity]]></TERM><TERM><![CDATA[Minority]]></TERM><TERM><![CDATA[Monitor]]></TERM><TERM><![CDATA[outreach]]></TERM><TERM><![CDATA[outreach program]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Research Infrastructure]]></TERM><TERM><![CDATA[Research Training]]></TERM><TERM><![CDATA[Resources]]></TERM><TERM><![CDATA[Training and Education]]></TERM><TERM><![CDATA[Training Programs]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Administrative Core]]></PROJECT_TITLE><SERIAL_NUMBER>000538</SERIAL_NUMBER><STUDY_SECTION>ZMD1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID>6306</SUBPROJECT_ID><SUPPORT_YEAR>13</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>141791</DIRECT_COST_AMT><INDIRECT_COST_AMT>90156</INDIRECT_COST_AMT><TOTAL_COST /><TOTAL_COST_SUB_PROJECT>231947</TOTAL_COST_SUB_PROJECT></row>
<row><APPLICATION_ID>8962093</APPLICATION_ID><ACTIVITY>P60</ACTIVITY><ADMINISTERING_IC>MD</ADMINISTERING_IC><APPLICATION_TYPE>4</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/30/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>P60MD000538</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-MD-11-003</FOA_NUMBER><FULL_PROJECT_NUM>4P60MD000538-13</FULL_PROJECT_NUM><FUNDING_ICs>NIMHD:131810\</FUNDING_ICs><FUNDING_MECHANISM>RESEARCH CENTERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE ON MINORITY HEALTH AND HEALTH DISPARITIES</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>NEW YORK</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>12</ORG_DISTRICT><ORG_DUNS>121911077</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[NEW YORK UNIVERSITY SCHOOL OF MEDICINE]]></ORG_NAME><ORG_STATE>NY</ORG_STATE><ORG_ZIPCODE>100165802</ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>REY, MARIANO J</PI_NAME><PI_ID>7704072</PI_ID></PI><PI><PI_NAME>TRINH-SHEVRIN, CHAU  (contact)</PI_NAME><PI_ID>7860791 (contact)</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START></PROJECT_START><PROJECT_END></PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Area]]></TERM><TERM><![CDATA[ARHGEF5 gene]]></TERM><TERM><![CDATA[Asian Americans]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Behavioral]]></TERM><TERM><![CDATA[Biological]]></TERM><TERM><![CDATA[cancer prevention]]></TERM><TERM><![CDATA[Cancer Survivor]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[clinical care]]></TERM><TERM><![CDATA[Collaborations]]></TERM><TERM><![CDATA[Communities]]></TERM><TERM><![CDATA[Community Health Centers]]></TERM><TERM><![CDATA[community living]]></TERM><TERM><![CDATA[Community Outreach]]></TERM><TERM><![CDATA[compare effectiveness]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[diabetes management]]></TERM><TERM><![CDATA[Diabetes prevention]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Ensure]]></TERM><TERM><![CDATA[Epidemiology]]></TERM><TERM><![CDATA[Fostering]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[health disparity]]></TERM><TERM><![CDATA[Health Personnel]]></TERM><TERM><![CDATA[Health Professional]]></TERM><TERM><![CDATA[Health Promotion]]></TERM><TERM><![CDATA[Health Services]]></TERM><TERM><![CDATA[Health Services Accessibility]]></TERM><TERM><![CDATA[Health Status]]></TERM><TERM><![CDATA[Healthcare]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[Information Dissemination]]></TERM><TERM><![CDATA[Link]]></TERM><TERM><![CDATA[Mental Health]]></TERM><TERM><![CDATA[Obesity]]></TERM><TERM><![CDATA[Obesity associated disease]]></TERM><TERM><![CDATA[obesity risk]]></TERM><TERM><![CDATA[Oral health]]></TERM><TERM><![CDATA[Outcome]]></TERM><TERM><![CDATA[outreach program]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Prevention]]></TERM><TERM><![CDATA[public health research]]></TERM><TERM><![CDATA[Quality of life]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Research Personnel]]></TERM><TERM><![CDATA[research study]]></TERM><TERM><![CDATA[Risk]]></TERM><TERM><![CDATA[Services]]></TERM><TERM><![CDATA[social]]></TERM><TERM><![CDATA[South Asian]]></TERM><TERM><![CDATA[Stress]]></TERM><TERM><![CDATA[Training]]></TERM><TERM><![CDATA[Underserved Population]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Research Core]]></PROJECT_TITLE><SERIAL_NUMBER>000538</SERIAL_NUMBER><STUDY_SECTION>ZMD1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID>6307</SUBPROJECT_ID><SUPPORT_YEAR>13</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>80576</DIRECT_COST_AMT><INDIRECT_COST_AMT>51234</INDIRECT_COST_AMT><TOTAL_COST /><TOTAL_COST_SUB_PROJECT>131810</TOTAL_COST_SUB_PROJECT></row>
<row><APPLICATION_ID>8962146</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>AI</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/27/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>855</CFDA_CODE><CORE_PROJECT_NUM>R01AI110297</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-11-260</FOA_NUMBER><FULL_PROJECT_NUM>5R01AI110297-03</FULL_PROJECT_NUM><FUNDING_ICs>NIAID:385000\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>LOS ANGELES</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[MICROBIOLOGY/IMMUN/VIROLOGY]]></ORG_DEPT><ORG_DISTRICT>33</ORG_DISTRICT><ORG_DUNS>092530369</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIVERSITY OF CALIFORNIA LOS ANGELES]]></ORG_NAME><ORG_STATE>CA</ORG_STATE><ORG_ZIPCODE>900952000</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: HIV not only infects T-cells and macrophages, but also has recently been reported to infect hematopoietic stem/progenitor cells. The consequences of HIV infection of stem cells will provide insight into various unexplained blood abnormalities seen in HIV patients. Page 1 of 1]]></PHR><PIS><PI><PI_NAME>CHEN, IRVIN S.Y.</PI_NAME><PI_ID>1858800</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>LAWRENCE, DIANE M</PROGRAM_OFFICER_NAME><PROJECT_START>11/20/2013</PROJECT_START><PROJECT_END>10/31/2018</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Behavior]]></TERM><TERM><![CDATA[Biological Models]]></TERM><TERM><![CDATA[Biology]]></TERM><TERM><![CDATA[Blood]]></TERM><TERM><![CDATA[Bone Marrow]]></TERM><TERM><![CDATA[Cell Fraction]]></TERM><TERM><![CDATA[Cell physiology]]></TERM><TERM><![CDATA[Cell Transplants]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Consequences of HIV]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Disputes]]></TERM><TERM><![CDATA[experience]]></TERM><TERM><![CDATA[Functional disorder]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Hematopoietic]]></TERM><TERM><![CDATA[Hematopoietic stem cells]]></TERM><TERM><![CDATA[Hematopoietic System]]></TERM><TERM><![CDATA[HIV]]></TERM><TERM><![CDATA[HIV Infections]]></TERM><TERM><![CDATA[HIV-1]]></TERM><TERM><![CDATA[In Vitro]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[Infection]]></TERM><TERM><![CDATA[insight]]></TERM><TERM><![CDATA[Investigation]]></TERM><TERM><![CDATA[latent infection]]></TERM><TERM><![CDATA[Lentivirus Vector]]></TERM><TERM><![CDATA[Life]]></TERM><TERM><![CDATA[Lymphoid]]></TERM><TERM><![CDATA[macrophage]]></TERM><TERM><![CDATA[Methodology]]></TERM><TERM><![CDATA[Methods]]></TERM><TERM><![CDATA[mouse model]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[Myelogenous]]></TERM><TERM><![CDATA[Natural regeneration]]></TERM><TERM><![CDATA[nonhuman primate]]></TERM><TERM><![CDATA[Output]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Pharmaceutical Preparations]]></TERM><TERM><![CDATA[Population]]></TERM><TERM><![CDATA[Population Heterogeneity]]></TERM><TERM><![CDATA[precursor cell]]></TERM><TERM><![CDATA[public health relevance]]></TERM><TERM><![CDATA[receptor]]></TERM><TERM><![CDATA[Relative (related person)]]></TERM><TERM><![CDATA[Reporting]]></TERM><TERM><![CDATA[self-renewal]]></TERM><TERM><![CDATA[stem]]></TERM><TERM><![CDATA[Stem cells]]></TERM><TERM><![CDATA[T-Lymphocyte]]></TERM><TERM><![CDATA[Transplantation]]></TERM><TERM><![CDATA[vector]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Hematopoietic stem/progenitor cell reservoirs]]></PROJECT_TITLE><SERIAL_NUMBER>110297</SERIAL_NUMBER><STUDY_SECTION>AMCB</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[AIDS Molecular and Cellular Biology Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>03</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>250000</DIRECT_COST_AMT><INDIRECT_COST_AMT>135000</INDIRECT_COST_AMT><TOTAL_COST>385000</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8962156</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>HL</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/29/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>837</CFDA_CODE><CORE_PROJECT_NUM>R01HL078610</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-13-302</FOA_NUMBER><FULL_PROJECT_NUM>5R01HL078610-11</FULL_PROJECT_NUM><FUNDING_ICs>NHLBI:358560\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL HEART, LUNG, AND BLOOD INSTITUTE</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>PORTLAND</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[INTERNAL MEDICINE/MEDICINE]]></ORG_DEPT><ORG_DISTRICT>03</ORG_DISTRICT><ORG_DUNS>096997515</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[OREGON HEALTH & SCIENCE UNIVERSITY]]></ORG_NAME><ORG_STATE>OR</ORG_STATE><ORG_ZIPCODE>972393098</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Platelets may not only be involved in the formation of blood clots that culminate in heart attack and stroke in patients with atherosclerotic lesions, but may also play a role much earlier In the development of atherosclerotic disease by interacting with the vessel wall. Oxidative stress may play an important role in promoting platelet attachment to the vessel wall. We propose to use ultrasound molecular imaging mouse and monkey models of atherosclerosis to determine the degree and mechanisms of platelet adhesion to the vessel wall, and to determine whether treatment with potent anti-oxidants reduces these events.]]></PHR><PIS><PI><PI_NAME>LINDNER, JONATHAN R</PI_NAME><PI_ID>1866927</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>DANTHI, NARASIMHAN </PROGRAM_OFFICER_NAME><PROJECT_START>09/22/2004</PROJECT_START><PROJECT_END>10/31/2018</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[acetovanillone]]></TERM><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[Adhesions]]></TERM><TERM><![CDATA[Aftercare]]></TERM><TERM><![CDATA[Age]]></TERM><TERM><![CDATA[age related]]></TERM><TERM><![CDATA[Animal Disease Models]]></TERM><TERM><![CDATA[Animals]]></TERM><TERM><![CDATA[Antibodies]]></TERM><TERM><![CDATA[antioxidant therapy]]></TERM><TERM><![CDATA[Antioxidants]]></TERM><TERM><![CDATA[Arterial Fatty Streak]]></TERM><TERM><![CDATA[Atherosclerosis]]></TERM><TERM><![CDATA[Blood]]></TERM><TERM><![CDATA[Blood coagulation]]></TERM><TERM><![CDATA[Blood Platelets]]></TERM><TERM><![CDATA[Blood Vessels]]></TERM><TERM><![CDATA[Cardiovascular Diseases]]></TERM><TERM><![CDATA[Cardiovascular system]]></TERM><TERM><![CDATA[Caring]]></TERM><TERM><![CDATA[Carotid Arteries]]></TERM><TERM><![CDATA[catalase]]></TERM><TERM><![CDATA[CD31 Antigens]]></TERM><TERM><![CDATA[Cell Adhesion]]></TERM><TERM><![CDATA[Cell Adhesion Molecules]]></TERM><TERM><![CDATA[Complex]]></TERM><TERM><![CDATA[Contrast Media]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[Detection]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Diet]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[disease diagnosis]]></TERM><TERM><![CDATA[Disease Progression]]></TERM><TERM><![CDATA[drug development]]></TERM><TERM><![CDATA[Endothelial Cells]]></TERM><TERM><![CDATA[Epitopes]]></TERM><TERM><![CDATA[Event]]></TERM><TERM><![CDATA[Fatty acid glycerol esters]]></TERM><TERM><![CDATA[Focal Adhesions]]></TERM><TERM><![CDATA[Functional disorder]]></TERM><TERM><![CDATA[Funding]]></TERM><TERM><![CDATA[Future]]></TERM><TERM><![CDATA[Growth]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[high risk]]></TERM><TERM><![CDATA[Histology]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[Image]]></TERM><TERM><![CDATA[imaging modality]]></TERM><TERM><![CDATA[imaging probe]]></TERM><TERM><![CDATA[Imaging Techniques]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[Inflammation]]></TERM><TERM><![CDATA[Inflammatory]]></TERM><TERM><![CDATA[Inflammatory Response]]></TERM><TERM><![CDATA[inhibitor/antagonist]]></TERM><TERM><![CDATA[insight]]></TERM><TERM><![CDATA[Insulin Resistance]]></TERM><TERM><![CDATA[Knowledge]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[Lipids]]></TERM><TERM><![CDATA[Lipoproteins]]></TERM><TERM><![CDATA[Macaca mulatta]]></TERM><TERM><![CDATA[Manganese Compounds]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[Mediator of activation protein]]></TERM><TERM><![CDATA[Methods]]></TERM><TERM><![CDATA[Microscopy]]></TERM><TERM><![CDATA[mimetics]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[molecular imaging]]></TERM><TERM><![CDATA[Monkeys]]></TERM><TERM><![CDATA[monocyte]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[Myocardial Infarction]]></TERM><TERM><![CDATA[NADPH Oxidase]]></TERM><TERM><![CDATA[nonhuman primate]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[novel therapeutics]]></TERM><TERM><![CDATA[Obesity]]></TERM><TERM><![CDATA[oxidation]]></TERM><TERM><![CDATA[Oxidative Stress]]></TERM><TERM><![CDATA[Pathologic]]></TERM><TERM><![CDATA[Pathway interactions]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Pharmacotherapy]]></TERM><TERM><![CDATA[Phenotype]]></TERM><TERM><![CDATA[Phospholipids]]></TERM><TERM><![CDATA[Placebos]]></TERM><TERM><![CDATA[Platelet Activation]]></TERM><TERM><![CDATA[Play]]></TERM><TERM><![CDATA[pre-clinical research]]></TERM><TERM><![CDATA[Preclinical Drug Development]]></TERM><TERM><![CDATA[prevent]]></TERM><TERM><![CDATA[Primates]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[Radioisotopes]]></TERM><TERM><![CDATA[Radionuclide Imaging]]></TERM><TERM><![CDATA[Reactive Oxygen Species]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[salen]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[Site]]></TERM><TERM><![CDATA[Staging]]></TERM><TERM><![CDATA[stroke]]></TERM><TERM><![CDATA[Superoxide Dismutase]]></TERM><TERM><![CDATA[Surface]]></TERM><TERM><![CDATA[Techniques]]></TERM><TERM><![CDATA[Technology]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[Tomography, Emission-Computed, Single-Photon]]></TERM><TERM><![CDATA[tool]]></TERM><TERM><![CDATA[Transfection]]></TERM><TERM><![CDATA[Transgenic Organisms]]></TERM><TERM><![CDATA[treatment effect]]></TERM><TERM><![CDATA[two-photon]]></TERM><TERM><![CDATA[Ultrasonography]]></TERM><TERM><![CDATA[Vascular Diseases]]></TERM><TERM><![CDATA[vascular inflammation]]></TERM><TERM><![CDATA[von Willebrand Factor]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Molecular Imaging of Platelets and Oxidative Stress in Atherosclerosis]]></PROJECT_TITLE><SERIAL_NUMBER>078610</SERIAL_NUMBER><STUDY_SECTION>MEDI</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Medical Imaging Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>11</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>267214</DIRECT_COST_AMT><INDIRECT_COST_AMT>91346</INDIRECT_COST_AMT><TOTAL_COST>358560</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9146943</APPLICATION_ID><ACTIVITY>U51</ACTIVITY><ADMINISTERING_IC>PS</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/22/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>U51PS004079</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-PS-13-303</FOA_NUMBER><FULL_PROJECT_NUM>5U51PS004079-04</FULL_PROJECT_NUM><FUNDING_ICs>NCHHSTP:20857\</FUNDING_ICs><FUNDING_MECHANISM>OTHERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP)</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>WASHINGTON</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>98</ORG_DISTRICT><ORG_DUNS>106731248</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[DC DEPARTMENT OF HEALTH]]></ORG_NAME><ORG_STATE>DC</ORG_STATE><ORG_ZIPCODE>200024263</ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>ROCHA, NESTOR </PI_NAME><PI_ID>12048815</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>11/01/2012</PROJECT_START><PROJECT_END>10/31/2016</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[ADULT VIRAL HEPATITIS PREVENTION COORDINATOR ENHANCED VIRAL HEPATITIS SURVEILLANC]]></PROJECT_TITLE><SERIAL_NUMBER>004079</SERIAL_NUMBER><STUDY_SECTION>ZPS1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>04</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>20857</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9149052</APPLICATION_ID><ACTIVITY>U51</ACTIVITY><ADMINISTERING_IC>PS</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/26/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>U51PS004065</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-PS-13-303</FOA_NUMBER><FULL_PROJECT_NUM>5U51PS004065-04</FULL_PROJECT_NUM><FUNDING_ICs>NCHHSTP:45716\</FUNDING_ICs><FUNDING_MECHANISM>OTHERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP)</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>TRENTON</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>12</ORG_DISTRICT><ORG_DUNS>806418075</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[NEW JERSEY STATE DEPT/HEALTH/SENIOR SRVS]]></ORG_NAME><ORG_STATE>NJ</ORG_STATE><ORG_ZIPCODE>086082308</ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>TAYLOR, LAURA </PI_NAME><PI_ID>14306876</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>11/01/2012</PROJECT_START><PROJECT_END>10/31/2016</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[Viral Hepatitis and Prevention]]></PROJECT_TITLE><SERIAL_NUMBER>004065</SERIAL_NUMBER><STUDY_SECTION>ZPS1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>04</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>45716</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9172434</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>HL</ADMINISTERING_IC><APPLICATION_TYPE>6</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/05/2015</AWARD_NOTICE_DATE><BUDGET_START>11/05/2015</BUDGET_START><BUDGET_END>03/31/2016</BUDGET_END><CFDA_CODE>837</CFDA_CODE><CORE_PROJECT_NUM>R01HL095856</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>PA-07-070</FOA_NUMBER><FULL_PROJECT_NUM>6R01HL095856-05</FULL_PROJECT_NUM><FUNDING_ICs>NHLBI:205498\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2013</FY><IC_NAME>NATIONAL HEART, LUNG, AND BLOOD INSTITUTE</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>BRONX</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>14</ORG_DISTRICT><ORG_DUNS>079783367</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[ALBERT EINSTEIN COLLEGE OF MEDICINE]]></ORG_NAME><ORG_STATE>NY</ORG_STATE><ORG_ZIPCODE>104611975</ORG_ZIPCODE><PHR><![CDATA[Project Narrative
Under-reporting of energy intake and expenditure by self-report obscures the
relationship between diet, physical activity and health outcomes. Studies using
biomarkers have had a small number of Hispanics limiting ability to assess the extent of
measurement error and its correlates in the diverse US Hispanic population. This
proposed study will be conducted in the Hispanic Community Health Study-Study of
Latinos (HCHS-SOL), an NIH-NHLBI funded study of Hispanics/Latinos in the Bronx,
Miami, Chicago and San Diego. Disparate rates of disease in the Hispanic population
will be addressed in the parent study and the biomarker data derived from the proposed
study can improve the precision of dietary and physical activity assessments related to
differences found in disease rates among Hispanic/Latino sub-groups. The biomarker
data from the proposed study will have the potential to calibrate nutrient and physical
activity self-report data to increase reliability of disease association analyses.]]></PHR><PIS><PI><PI_NAME>MOSSAVAR-RAHMANI, YASMIN </PI_NAME><PI_ID>9285254</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>LORIA, CATHERINE </PROGRAM_OFFICER_NAME><PROJECT_START>04/25/2010</PROJECT_START><PROJECT_END>03/31/2016</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[Study of Latinos: Nutrition & Physical Activity Assessment Study (SOLNAS)]]></PROJECT_TITLE><SERIAL_NUMBER>095856</SERIAL_NUMBER><STUDY_SECTION>KNOD</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Kidney, Nutrition, Obesity and Diabetes ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>05</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>169435</DIRECT_COST_AMT><INDIRECT_COST_AMT>36063</INDIRECT_COST_AMT><TOTAL_COST>205498</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9172494</APPLICATION_ID><ACTIVITY>K01</ACTIVITY><ADMINISTERING_IC>HL</ADMINISTERING_IC><APPLICATION_TYPE>6</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/06/2015</AWARD_NOTICE_DATE><BUDGET_START>11/06/2015</BUDGET_START><BUDGET_END>05/31/2016</BUDGET_END><CFDA_CODE>837</CFDA_CODE><CORE_PROJECT_NUM>K01HL129892</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>PA-14-044</FOA_NUMBER><FULL_PROJECT_NUM>6K01HL129892-02</FULL_PROJECT_NUM><FUNDING_ICs>NHLBI:103578\</FUNDING_ICs><FUNDING_MECHANISM>OTHER RESEARCH-RELATED</FUNDING_MECHANISM><FY>2015</FY><IC_NAME>NATIONAL HEART, LUNG, AND BLOOD INSTITUTE</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>BRONX</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>14</ORG_DISTRICT><ORG_DUNS>079783367</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[ALBERT EINSTEIN COLLEGE OF MEDICINE]]></ORG_NAME><ORG_STATE>NY</ORG_STATE><ORG_ZIPCODE>104611975</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE:  With long-term survival of HIV-infected patients (even reaching normal life expectancy) on highly active antiretroviral therapy, CVD has become a leading source of morbidity and mortality. The proposed research project will identify potential biomarkers and targets for individual risk prediction and prevention and holds promise for personalizing antiretroviral therapy medication choice and other interventions to avert CVD among HIV-infected patients.   
      

]]></PHR><PIS><PI><PI_NAME>QI, QIBIN </PI_NAME><PI_ID>10792184</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>REIS, JARED P</PROGRAM_OFFICER_NAME><PROJECT_START>08/15/2015</PROJECT_START><PROJECT_END>05/31/2019</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Acquired Immunodeficiency Syndrome]]></TERM><TERM><![CDATA[Advisory Committees]]></TERM><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[aged]]></TERM><TERM><![CDATA[Amino Acids]]></TERM><TERM><![CDATA[antiretroviral therapy]]></TERM><TERM><![CDATA[Archives]]></TERM><TERM><![CDATA[Area]]></TERM><TERM><![CDATA[Aromatic Amino Acids]]></TERM><TERM><![CDATA[Atherosclerosis]]></TERM><TERM><![CDATA[Biochemical]]></TERM><TERM><![CDATA[Biological Markers]]></TERM><TERM><![CDATA[Biology of HIV Infection]]></TERM><TERM><![CDATA[Biometry]]></TERM><TERM><![CDATA[blood lipid]]></TERM><TERM><![CDATA[Blood Pressure]]></TERM><TERM><![CDATA[Blood specimen]]></TERM><TERM><![CDATA[Branched-Chain Amino Acids]]></TERM><TERM><![CDATA[Cardiovascular Diseases]]></TERM><TERM><![CDATA[cardiovascular disorder risk]]></TERM><TERM><![CDATA[career]]></TERM><TERM><![CDATA[Carotid Arteries]]></TERM><TERM><![CDATA[Carotid Artery Plaques]]></TERM><TERM><![CDATA[Carotid Atherosclerotic Disease]]></TERM><TERM><![CDATA[CD4 Positive T Lymphocytes]]></TERM><TERM><![CDATA[Cell Count]]></TERM><TERM><![CDATA[Chronic]]></TERM><TERM><![CDATA[Coagulation Process]]></TERM><TERM><![CDATA[cohort]]></TERM><TERM><![CDATA[Cohort Studies]]></TERM><TERM><![CDATA[Collaborations]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[Diabetes Mellitus]]></TERM><TERM><![CDATA[diabetes risk]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Epidemiology]]></TERM><TERM><![CDATA[experience]]></TERM><TERM><![CDATA[Fatty acid glycerol esters]]></TERM><TERM><![CDATA[follow-up]]></TERM><TERM><![CDATA[Functional disorder]]></TERM><TERM><![CDATA[Future]]></TERM><TERM><![CDATA[General Population]]></TERM><TERM><![CDATA[Genes]]></TERM><TERM><![CDATA[Genetic]]></TERM><TERM><![CDATA[Genomics]]></TERM><TERM><![CDATA[Glutamine]]></TERM><TERM><![CDATA[gut microbiota]]></TERM><TERM><![CDATA[Hepatitis C virus]]></TERM><TERM><![CDATA[Highly Active Antiretroviral Therapy]]></TERM><TERM><![CDATA[HIV]]></TERM><TERM><![CDATA[HIV Infections]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[Immune]]></TERM><TERM><![CDATA[immune activation]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[Inflammation]]></TERM><TERM><![CDATA[Inflammatory]]></TERM><TERM><![CDATA[insight]]></TERM><TERM><![CDATA[Insulin Resistance]]></TERM><TERM><![CDATA[interest]]></TERM><TERM><![CDATA[Intervention]]></TERM><TERM><![CDATA[intimal medial thickening]]></TERM><TERM><![CDATA[K-Series Research Career Programs]]></TERM><TERM><![CDATA[Learning]]></TERM><TERM><![CDATA[Life Expectancy]]></TERM><TERM><![CDATA[Lipids]]></TERM><TERM><![CDATA[Measurement]]></TERM><TERM><![CDATA[Measures]]></TERM><TERM><![CDATA[men]]></TERM><TERM><![CDATA[Mentored Research Scientist Development Award]]></TERM><TERM><![CDATA[Mentors]]></TERM><TERM><![CDATA[Mentorship]]></TERM><TERM><![CDATA[Metabolic]]></TERM><TERM><![CDATA[metabolomics]]></TERM><TERM><![CDATA[Molecular Weight]]></TERM><TERM><![CDATA[Morbidity - disease rate]]></TERM><TERM><![CDATA[Mortality Vital Statistics]]></TERM><TERM><![CDATA[Multicenter Studies]]></TERM><TERM><![CDATA[multidisciplinary]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[Pathogenesis]]></TERM><TERM><![CDATA[Pathway Analysis]]></TERM><TERM><![CDATA[Pathway interactions]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Pharmaceutical Preparations]]></TERM><TERM><![CDATA[Plasma]]></TERM><TERM><![CDATA[Population]]></TERM><TERM><![CDATA[Population Study]]></TERM><TERM><![CDATA[Prevention]]></TERM><TERM><![CDATA[prospective]]></TERM><TERM><![CDATA[public health relevance]]></TERM><TERM><![CDATA[Qi]]></TERM><TERM><![CDATA[Recording of previous events]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Research Personnel]]></TERM><TERM><![CDATA[Research Project Grants]]></TERM><TERM><![CDATA[Resources]]></TERM><TERM><![CDATA[Risk]]></TERM><TERM><![CDATA[Risk Factors]]></TERM><TERM><![CDATA[RNA]]></TERM><TERM><![CDATA[Source]]></TERM><TERM><![CDATA[statistics]]></TERM><TERM><![CDATA[Techniques]]></TERM><TERM><![CDATA[Training]]></TERM><TERM><![CDATA[Training Programs]]></TERM><TERM><![CDATA[treatment duration]]></TERM><TERM><![CDATA[Ultrasonography]]></TERM><TERM><![CDATA[urea cycle]]></TERM><TERM><![CDATA[Viral]]></TERM><TERM><![CDATA[Woman]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[HIV Infection, Metabolites and Subclinical Atherosclerosis]]></PROJECT_TITLE><SERIAL_NUMBER>129892</SERIAL_NUMBER><STUDY_SECTION>MCBS</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>95906</DIRECT_COST_AMT><INDIRECT_COST_AMT>7672</INDIRECT_COST_AMT><TOTAL_COST>103578</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8905213</APPLICATION_ID><ACTIVITY>F31</ACTIVITY><ADMINISTERING_IC>MH</ADMINISTERING_IC><APPLICATION_TYPE>1</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>05/05/2015</AWARD_NOTICE_DATE><BUDGET_START>09/01/2015</BUDGET_START><BUDGET_END>08/31/2016</BUDGET_END><CFDA_CODE>242</CFDA_CODE><CORE_PROJECT_NUM>F31MH107111</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-14-147</FOA_NUMBER><FULL_PROJECT_NUM>1F31MH107111-01</FULL_PROJECT_NUM><FUNDING_ICs>NIMH:29696\</FUNDING_ICs><FUNDING_MECHANISM>TRAINING, INDIVIDUAL</FUNDING_MECHANISM><FY>2015</FY><IC_NAME>NATIONAL INSTITUTE OF MENTAL HEALTH</IC_NAME><NIH_SPENDING_CATS><CATEGORY><![CDATA[Basic Behavioral and Social Science]]></CATEGORY><CATEGORY><![CDATA[Behavioral and Social Science]]></CATEGORY><CATEGORY><![CDATA[Brain Disorders]]></CATEGORY><CATEGORY><![CDATA[Mental Health]]></CATEGORY><CATEGORY><![CDATA[Neurosciences]]></CATEGORY></NIH_SPENDING_CATS><ORG_CITY>SAINT LOUIS</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[NEUROSCIENCES]]></ORG_DEPT><ORG_DISTRICT>01</ORG_DISTRICT><ORG_DUNS>068552207</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[WASHINGTON UNIVERSITY]]></ORG_NAME><ORG_STATE>MO</ORG_STATE><ORG_ZIPCODE>631304862</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Deficits in economic decision-making are present in a wide range of psychiatric and neurological disorders, and can severely reduce patients' quality of life.
Examining the mechanisms that mediate economic decision-making under normal conditions will inform the development of more effective treatments for these impairments. In the proposed project, I will investigate the parameters and timing of contextual adaptation in value encoding neurons. By investigating how the brain appraises and compares values in a wide range of conditions, this project will provide insight into the flexibility of decision-making circuitry andthe potential consequences if this flexibility is impaired.   
   
      

]]></PHR><PIS><PI><PI_NAME>CONEN, KATHERINE E</PI_NAME><PI_ID>11547190</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>DESMOND, NANCY L</PROGRAM_OFFICER_NAME><PROJECT_START>09/01/2015</PROJECT_START><PROJECT_END>08/31/2017</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[abstracting]]></TERM><TERM><![CDATA[addiction]]></TERM><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[Animals]]></TERM><TERM><![CDATA[Area]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Behavioral]]></TERM><TERM><![CDATA[Brain]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Choice Behavior]]></TERM><TERM><![CDATA[Climacteric]]></TERM><TERM><![CDATA[Cognitive]]></TERM><TERM><![CDATA[Cues]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Decision Making]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Driving While Intoxicated]]></TERM><TERM><![CDATA[Economics]]></TERM><TERM><![CDATA[effective therapy]]></TERM><TERM><![CDATA[Environment]]></TERM><TERM><![CDATA[experience]]></TERM><TERM><![CDATA[Face]]></TERM><TERM><![CDATA[flexibility]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[Impairment]]></TERM><TERM><![CDATA[insight]]></TERM><TERM><![CDATA[Juice]]></TERM><TERM><![CDATA[Knowledge]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[Light]]></TERM><TERM><![CDATA[Macaca]]></TERM><TERM><![CDATA[Maps]]></TERM><TERM><![CDATA[Measures]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[Mental disorders]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Monkeys]]></TERM><TERM><![CDATA[nervous system disorder]]></TERM><TERM><![CDATA[neuromechanism]]></TERM><TERM><![CDATA[Neurons]]></TERM><TERM><![CDATA[nonhuman primate]]></TERM><TERM><![CDATA[Obsessive-Compulsive Disorder]]></TERM><TERM><![CDATA[Occupations]]></TERM><TERM><![CDATA[Outcome]]></TERM><TERM><![CDATA[patient population]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Persons]]></TERM><TERM><![CDATA[Play]]></TERM><TERM><![CDATA[Primates]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[psychologic]]></TERM><TERM><![CDATA[public health relevance]]></TERM><TERM><![CDATA[Quality of life]]></TERM><TERM><![CDATA[relating to nervous system]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[research study]]></TERM><TERM><![CDATA[Resolution]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[Rewards]]></TERM><TERM><![CDATA[Risk]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Semantic memory]]></TERM><TERM><![CDATA[sensorimotor system]]></TERM><TERM><![CDATA[Societies]]></TERM><TERM><![CDATA[Source]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[Unsafe Sex]]></TERM><TERM><![CDATA[Visual]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Analyzing contextual adaptation in value-encoding neurons during economic choice.]]></PROJECT_TITLE><SERIAL_NUMBER>107111</SERIAL_NUMBER><STUDY_SECTION>ZRG1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>01</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>29696</DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>29696</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8957905</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>AI</ADMINISTERING_IC><APPLICATION_TYPE>4</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/26/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>855</CFDA_CODE><CORE_PROJECT_NUM>R01AI096869</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-10-067</FOA_NUMBER><FULL_PROJECT_NUM>4R01AI096869-05</FULL_PROJECT_NUM><FUNDING_ICs>NIAID:386250\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>SAN FRANCISCO</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[BIOCHEMISTRY]]></ORG_DEPT><ORG_DISTRICT>12</ORG_DISTRICT><ORG_DUNS>094878337</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIVERSITY OF CALIFORNIA, SAN FRANCISCO]]></ORG_NAME><ORG_STATE>CA</ORG_STATE><ORG_ZIPCODE>941186215</ORG_ZIPCODE><PHR><![CDATA[The diagnosis and treatment of serious fungal infections in humans is a major unmet clinical challenge. Cryptococcus neoformans is among the most important fugal pathogens, accounting for approximately one-third of worldwide deaths from HIV/AIDS. This study, if successful, will define novel mechanisms by which this pathogen causes disease and thereby providing new targets for the development of therapeutics.]]></PHR><PIS><PI><PI_NAME>MADHANI, HITEN D</PI_NAME><PI_ID>1900165</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>DUNCAN, RORY A.</PROGRAM_OFFICER_NAME><PROJECT_START>11/04/2011</PROJECT_START><PROJECT_END>10/31/2016</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Accounting]]></TERM><TERM><![CDATA[AIDS/HIV problem]]></TERM><TERM><![CDATA[Antifungal Agents]]></TERM><TERM><![CDATA[Architecture]]></TERM><TERM><![CDATA[Bar Codes]]></TERM><TERM><![CDATA[Binding (Molecular Function)]]></TERM><TERM><![CDATA[capsule (pharmacologic)]]></TERM><TERM><![CDATA[Cell Wall]]></TERM><TERM><![CDATA[Cessation of life]]></TERM><TERM><![CDATA[ChIP-on-chip]]></TERM><TERM><![CDATA[Chitin]]></TERM><TERM><![CDATA[chromatin immunoprecipitation]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[Code]]></TERM><TERM><![CDATA[Cryptococcus neoformans]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Diagnosis]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[DNA-Binding Proteins]]></TERM><TERM><![CDATA[Encapsulated]]></TERM><TERM><![CDATA[Environment]]></TERM><TERM><![CDATA[Enzymes]]></TERM><TERM><![CDATA[fitness]]></TERM><TERM><![CDATA[Foundations]]></TERM><TERM><![CDATA[Gene Expression]]></TERM><TERM><![CDATA[gene function]]></TERM><TERM><![CDATA[Gene Targeting]]></TERM><TERM><![CDATA[Genes]]></TERM><TERM><![CDATA[Genome]]></TERM><TERM><![CDATA[genome-wide]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[Immunocompromised Host]]></TERM><TERM><![CDATA[In Vitro]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[Infection]]></TERM><TERM><![CDATA[Knock-out]]></TERM><TERM><![CDATA[Knowledge]]></TERM><TERM><![CDATA[Laboratories]]></TERM><TERM><![CDATA[macrophage]]></TERM><TERM><![CDATA[Methods]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Molecular Profiling]]></TERM><TERM><![CDATA[mouse model]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[mutant]]></TERM><TERM><![CDATA[Mycoses]]></TERM><TERM><![CDATA[network architecture]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[Output]]></TERM><TERM><![CDATA[pathogen]]></TERM><TERM><![CDATA[Pathogenicity]]></TERM><TERM><![CDATA[patient population]]></TERM><TERM><![CDATA[Phagocytosis]]></TERM><TERM><![CDATA[Phagocytosis Inhibition]]></TERM><TERM><![CDATA[Plants]]></TERM><TERM><![CDATA[Polysaccharides]]></TERM><TERM><![CDATA[Production]]></TERM><TERM><![CDATA[Property]]></TERM><TERM><![CDATA[Protein Family]]></TERM><TERM><![CDATA[Proteins]]></TERM><TERM><![CDATA[Publishing]]></TERM><TERM><![CDATA[Regulation]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[small molecule]]></TERM><TERM><![CDATA[Structure]]></TERM><TERM><![CDATA[success]]></TERM><TERM><![CDATA[System]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[therapeutic development]]></TERM><TERM><![CDATA[therapeutic target]]></TERM><TERM><![CDATA[Tissues]]></TERM><TERM><![CDATA[tool]]></TERM><TERM><![CDATA[trait]]></TERM><TERM><![CDATA[Transcript]]></TERM><TERM><![CDATA[transcription factor]]></TERM><TERM><![CDATA[Viral]]></TERM><TERM><![CDATA[Virulence]]></TERM><TERM><![CDATA[Yeasts]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Regulation of Virulence of Cryptococcus neoformans]]></PROJECT_TITLE><SERIAL_NUMBER>096869</SERIAL_NUMBER><STUDY_SECTION>ZRG1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>05</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>250000</DIRECT_COST_AMT><INDIRECT_COST_AMT>136250</INDIRECT_COST_AMT><TOTAL_COST>386250</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8958779</APPLICATION_ID><ACTIVITY>I01</ACTIVITY><ADMINISTERING_IC>VA</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/03/2015</AWARD_NOTICE_DATE><BUDGET_START>10/01/2015</BUDGET_START><BUDGET_END>09/30/2016</BUDGET_END><CFDA_CODE>999</CFDA_CODE><CORE_PROJECT_NUM>I01CX000570</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-CX-11-014</FOA_NUMBER><FULL_PROJECT_NUM>5I01CX000570-04</FULL_PROJECT_NUM><FUNDING_ICs>VA:149614\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>Veterans Affairs</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>NASHVILLE</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>05</ORG_DISTRICT><ORG_DUNS>156385783</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[VETERANS HEALTH ADMINISTRATION]]></ORG_NAME><ORG_STATE>TN</ORG_STATE><ORG_ZIPCODE>372122637</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE:    
   
A recent review concluded that most oral diabetes medications had a similar effect on reducing hemoglobin A1C (HgbA1c) however there were too few studies to determine the differential effects of the diabetes medications or medication combinations on mortality, cardiovascular disease, and microvascular complications such as kidney disease. This proposal will focus on the common treatment question facing clinicians and patients: Which medication regimen should be used after failure of metformin monotherapy? We will perform a retrospective cohort study of new users of 2nd line therapy for treatment of diabetes, to determine whether certain regimens confer an advantage on reaching goal HbA1c, along with the time to development of complications such as low blood sugar and weight gain. We will also examine if there are differences in the development of diabetes-related complications including acute myocardial infarction, stroke, kidney disease and cardiovascular death among patients.]]></PHR><PIS><PI><PI_NAME>ROUMIE, CHRISTIANNE L.</PI_NAME><PI_ID>9851566</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>10/01/2012</PROJECT_START><PROJECT_END>09/30/2016</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[18 year old]]></TERM><TERM><![CDATA[Acute myocardial infarction]]></TERM><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[Adverse effects]]></TERM><TERM><![CDATA[Antidiabetic Drugs]]></TERM><TERM><![CDATA[Area]]></TERM><TERM><![CDATA[Blood Glucose]]></TERM><TERM><![CDATA[Blood Vessels]]></TERM><TERM><![CDATA[Cardiovascular Diseases]]></TERM><TERM><![CDATA[cardiovascular disorder risk]]></TERM><TERM><![CDATA[cardiovascular risk factor]]></TERM><TERM><![CDATA[Cardiovascular system]]></TERM><TERM><![CDATA[Caring]]></TERM><TERM><![CDATA[Cause of Death]]></TERM><TERM><![CDATA[Cessation of life]]></TERM><TERM><![CDATA[Characteristics]]></TERM><TERM><![CDATA[Chronic Disease]]></TERM><TERM><![CDATA[Chronic Kidney Failure]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[Clinical effectiveness]]></TERM><TERM><![CDATA[cohort]]></TERM><TERM><![CDATA[Cohort Studies]]></TERM><TERM><![CDATA[Combination Medication]]></TERM><TERM><![CDATA[common treatment]]></TERM><TERM><![CDATA[Comorbidity]]></TERM><TERM><![CDATA[Compliance behavior]]></TERM><TERM><![CDATA[Complications of Diabetes Mellitus]]></TERM><TERM><![CDATA[Cox Proportional Hazards Models]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Data Set]]></TERM><TERM><![CDATA[Databases]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Diabetes Mellitus]]></TERM><TERM><![CDATA[diabetes mellitus therapy]]></TERM><TERM><![CDATA[Diagnosis]]></TERM><TERM><![CDATA[diet and exercise]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Distal]]></TERM><TERM><![CDATA[Drug usage]]></TERM><TERM><![CDATA[Effectiveness]]></TERM><TERM><![CDATA[Elements]]></TERM><TERM><![CDATA[Epidemiologic Studies]]></TERM><TERM><![CDATA[evidence base]]></TERM><TERM><![CDATA[experience]]></TERM><TERM><![CDATA[Exposure to]]></TERM><TERM><![CDATA[Failure (biologic function)]]></TERM><TERM><![CDATA[frailty]]></TERM><TERM><![CDATA[glycemic control]]></TERM><TERM><![CDATA[Glycosylated Hemoglobin]]></TERM><TERM><![CDATA[Glycosylated hemoglobin A]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Guidelines]]></TERM><TERM><![CDATA[health administration]]></TERM><TERM><![CDATA[Healthcare Systems]]></TERM><TERM><![CDATA[Heart Diseases]]></TERM><TERM><![CDATA[Hemoglobin]]></TERM><TERM><![CDATA[Hypoglycemia]]></TERM><TERM><![CDATA[indexing]]></TERM><TERM><![CDATA[Insulin]]></TERM><TERM><![CDATA[Interview]]></TERM><TERM><![CDATA[Judgment]]></TERM><TERM><![CDATA[Kidney]]></TERM><TERM><![CDATA[Kidney Diseases]]></TERM><TERM><![CDATA[Knowledge]]></TERM><TERM><![CDATA[Logistic Regressions]]></TERM><TERM><![CDATA[macrovascular disease]]></TERM><TERM><![CDATA[Measures]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[Medical]]></TERM><TERM><![CDATA[Medicare]]></TERM><TERM><![CDATA[men who have sex with men]]></TERM><TERM><![CDATA[Metformin]]></TERM><TERM><![CDATA[Microvascular Dysfunction]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Mortality Vital Statistics]]></TERM><TERM><![CDATA[Observational Study]]></TERM><TERM><![CDATA[older patient]]></TERM><TERM><![CDATA[Oral]]></TERM><TERM><![CDATA[Outcome]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Pattern]]></TERM><TERM><![CDATA[Persons]]></TERM><TERM><![CDATA[Pharmaceutical Preparations]]></TERM><TERM><![CDATA[Pharmacy facility]]></TERM><TERM><![CDATA[Pioglitazone]]></TERM><TERM><![CDATA[Population Heterogeneity]]></TERM><TERM><![CDATA[preference]]></TERM><TERM><![CDATA[Probability]]></TERM><TERM><![CDATA[Provider]]></TERM><TERM><![CDATA[public health relevance]]></TERM><TERM><![CDATA[randomized trial]]></TERM><TERM><![CDATA[Recording of previous events]]></TERM><TERM><![CDATA[Regimen]]></TERM><TERM><![CDATA[Relapse]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Research Methodology]]></TERM><TERM><![CDATA[Research Proposals]]></TERM><TERM><![CDATA[Risk]]></TERM><TERM><![CDATA[rosiglitazone]]></TERM><TERM><![CDATA[Safety]]></TERM><TERM><![CDATA[Social support]]></TERM><TERM><![CDATA[Specific qualifier value]]></TERM><TERM><![CDATA[stroke]]></TERM><TERM><![CDATA[Subgroup]]></TERM><TERM><![CDATA[Sulfonylurea Compounds]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[Treatment Failure]]></TERM><TERM><![CDATA[Veterans]]></TERM><TERM><![CDATA[Vital Status]]></TERM><TERM><![CDATA[Weight]]></TERM><TERM><![CDATA[Weight Gain]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Effectiveness of Second Line Hypoglycemic Medications Among Veterans]]></PROJECT_TITLE><SERIAL_NUMBER>000570</SERIAL_NUMBER><STUDY_SECTION>EPID</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Epidemiology ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>04</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST></TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8960336</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>AI</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/27/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>855</CFDA_CODE><CORE_PROJECT_NUM>R01AI107123</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>PA-14-078</FOA_NUMBER><FULL_PROJECT_NUM>5R01AI107123-03</FULL_PROJECT_NUM><FUNDING_ICs>NIAID:373750\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>CHARLESTON</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>06</ORG_DISTRICT><ORG_DUNS>183710748</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[MEDICAL UNIVERSITY OF SOUTH CAROLINA]]></ORG_NAME><ORG_STATE>SC</ORG_STATE><ORG_ZIPCODE>294035120</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: The fear that smallpox might be used as a bioterrorist weapon, the recognition that monkeypox virus is a cause of human morbidity and mortality, and the promise of using poxviruses as therapeutic vaccines reinforce the need to study the poxviral life cycle in depth. Our investigations of virion morphogenesis will define new targets for the development of rational antiviral therapies and provide fundamental insights into the membrane dynamics that are integral to many vital biological processes.   
      

]]></PHR><PIS><PI><PI_NAME>TRAKTMAN, PAULA </PI_NAME><PI_ID>1888968</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>CHALLBERG, MARK D.</PROGRAM_OFFICER_NAME><PROJECT_START>07/25/2015</PROJECT_START><PROJECT_END>10/31/2019</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Africa]]></TERM><TERM><![CDATA[Antiviral Agents]]></TERM><TERM><![CDATA[Antiviral Therapy]]></TERM><TERM><![CDATA[Biochemical]]></TERM><TERM><![CDATA[Biogenesis]]></TERM><TERM><![CDATA[Biological]]></TERM><TERM><![CDATA[Biological Process]]></TERM><TERM><![CDATA[Cell Nucleus]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Cytoplasm]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[DNA Viruses]]></TERM><TERM><![CDATA[Dominant-Negative Mutation]]></TERM><TERM><![CDATA[Engineering]]></TERM><TERM><![CDATA[Figs - dietary]]></TERM><TERM><![CDATA[Fright]]></TERM><TERM><![CDATA[Genetic]]></TERM><TERM><![CDATA[genetic analysis]]></TERM><TERM><![CDATA[genetic regulatory protein]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[human morbidity]]></TERM><TERM><![CDATA[human mortality]]></TERM><TERM><![CDATA[In Vitro]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[innovation]]></TERM><TERM><![CDATA[insight]]></TERM><TERM><![CDATA[Investigation]]></TERM><TERM><![CDATA[Life Cycle Stages]]></TERM><TERM><![CDATA[Lipid Bilayers]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[Mediator of activation protein]]></TERM><TERM><![CDATA[Membrane]]></TERM><TERM><![CDATA[membrane biogenesis]]></TERM><TERM><![CDATA[Membrane Protein Traffic]]></TERM><TERM><![CDATA[Membrane Proteins]]></TERM><TERM><![CDATA[Monkeypox]]></TERM><TERM><![CDATA[Monkeypox virus]]></TERM><TERM><![CDATA[Morphogenesis]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[Oncolytic]]></TERM><TERM><![CDATA[pathogen]]></TERM><TERM><![CDATA[Pathway interactions]]></TERM><TERM><![CDATA[pet animal]]></TERM><TERM><![CDATA[Plague]]></TERM><TERM><![CDATA[Poxviridae]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[Property]]></TERM><TERM><![CDATA[Protein Kinase]]></TERM><TERM><![CDATA[Proteins]]></TERM><TERM><![CDATA[public health relevance]]></TERM><TERM><![CDATA[Recombinant Vaccines]]></TERM><TERM><![CDATA[Renaissance]]></TERM><TERM><![CDATA[Research Infrastructure]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Secretory Component]]></TERM><TERM><![CDATA[Shapes]]></TERM><TERM><![CDATA[Site]]></TERM><TERM><![CDATA[Smallpox]]></TERM><TERM><![CDATA[System]]></TERM><TERM><![CDATA[Techniques]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Therapeutic]]></TERM><TERM><![CDATA[therapeutic vaccine]]></TERM><TERM><![CDATA[Vaccines]]></TERM><TERM><![CDATA[Vesicle]]></TERM><TERM><![CDATA[Viral]]></TERM><TERM><![CDATA[Viral Proteins]]></TERM><TERM><![CDATA[Viral Regulatory Proteins]]></TERM><TERM><![CDATA[Virion]]></TERM><TERM><![CDATA[weapons]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Biogenesis of the Poxvirus Membrane]]></PROJECT_TITLE><SERIAL_NUMBER>107123</SERIAL_NUMBER><STUDY_SECTION>VIRA</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Virology - A Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>03</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>250000</DIRECT_COST_AMT><INDIRECT_COST_AMT>123750</INDIRECT_COST_AMT><TOTAL_COST>373750</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8960924</APPLICATION_ID><ACTIVITY>R21</ACTIVITY><ADMINISTERING_IC>AI</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/28/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>855</CFDA_CODE><CORE_PROJECT_NUM>R21AI115230</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-13-303</FOA_NUMBER><FULL_PROJECT_NUM>5R21AI115230-02</FULL_PROJECT_NUM><FUNDING_ICs>NIAID:238073\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>HERSHEY</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[MICROBIOLOGY/IMMUN/VIROLOGY]]></ORG_DEPT><ORG_DISTRICT>15</ORG_DISTRICT><ORG_DUNS>129348186</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[PENNSYLVANIA STATE UNIV HERSHEY MED CTR]]></ORG_NAME><ORG_STATE>PA</ORG_STATE><ORG_ZIPCODE>170332360</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: The study of poxvirus biology, the immune response to poxviruses, and the modulation of that immune response by the virus is relevant for emerging poxvirus infections, such as monkeypox, and as a model of molluscum contagiosum infection which infects the skin of over 130 million people worldwide. This study focuses on the novel area of changes in the production of pro-resolving lipids that are induced by virus infection. Pro-resolving lipids reduce immune activation and promote tissue function and are vital for survival following challenge with ectromelia, the virus used for these studies.]]></PHR><PIS><PI><PI_NAME>NORBURY, CHRISTOPHER C</PI_NAME><PI_ID>8112587</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>CHALLBERG, MARK D.</PROGRAM_OFFICER_NAME><PROJECT_START>11/10/2014</PROJECT_START><PROJECT_END>10/31/2016</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Acute]]></TERM><TERM><![CDATA[adaptive immunity]]></TERM><TERM><![CDATA[Anti-inflammatory]]></TERM><TERM><![CDATA[Anti-Inflammatory Agents]]></TERM><TERM><![CDATA[Antiviral Agents]]></TERM><TERM><![CDATA[Arachidonate 15-Lipoxygenase]]></TERM><TERM><![CDATA[Arachidonic Acids]]></TERM><TERM><![CDATA[Area]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Biology]]></TERM><TERM><![CDATA[CD4 Positive T Lymphocytes]]></TERM><TERM><![CDATA[CD59 Antigen]]></TERM><TERM><![CDATA[CD8B1 gene]]></TERM><TERM><![CDATA[cell type]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Cessation of life]]></TERM><TERM><![CDATA[Chronic]]></TERM><TERM><![CDATA[Collaborations]]></TERM><TERM><![CDATA[Complex]]></TERM><TERM><![CDATA[cytokine]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Dendritic Cells]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[Diet]]></TERM><TERM><![CDATA[Ectromelia]]></TERM><TERM><![CDATA[Enzymes]]></TERM><TERM><![CDATA[experience]]></TERM><TERM><![CDATA[Family]]></TERM><TERM><![CDATA[Fatty Acids]]></TERM><TERM><![CDATA[Future]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Healed]]></TERM><TERM><![CDATA[healing]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Homeostasis]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[Immune]]></TERM><TERM><![CDATA[immune activation]]></TERM><TERM><![CDATA[immune function]]></TERM><TERM><![CDATA[Immune response]]></TERM><TERM><![CDATA[Immune system]]></TERM><TERM><![CDATA[Immunity]]></TERM><TERM><![CDATA[Immunocompromised Host]]></TERM><TERM><![CDATA[immunopathology]]></TERM><TERM><![CDATA[In Vitro]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[Infection]]></TERM><TERM><![CDATA[Infectious Ectromelia]]></TERM><TERM><![CDATA[Inflammation]]></TERM><TERM><![CDATA[Inflammatory]]></TERM><TERM><![CDATA[Interferon Type I]]></TERM><TERM><![CDATA[Interleukin-6]]></TERM><TERM><![CDATA[Knowledge]]></TERM><TERM><![CDATA[Laboratories]]></TERM><TERM><![CDATA[lipid mediator]]></TERM><TERM><![CDATA[Lipids]]></TERM><TERM><![CDATA[Lipoxins]]></TERM><TERM><![CDATA[Liver]]></TERM><TERM><![CDATA[Lymph Node Tissue]]></TERM><TERM><![CDATA[macrophage]]></TERM><TERM><![CDATA[medical schools]]></TERM><TERM><![CDATA[Membrane]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Molluscum Contagiosum]]></TERM><TERM><![CDATA[Molluscum contagiosum virus]]></TERM><TERM><![CDATA[Monkeypox]]></TERM><TERM><![CDATA[Monkeypox virus]]></TERM><TERM><![CDATA[Mouse Pox Virus]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[Natural Killer Cells]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[Omega-3 Fatty Acids]]></TERM><TERM><![CDATA[pathogen]]></TERM><TERM><![CDATA[Phenotype]]></TERM><TERM><![CDATA[Poxviridae]]></TERM><TERM><![CDATA[Poxviridae Infections]]></TERM><TERM><![CDATA[Predisposition]]></TERM><TERM><![CDATA[prevent]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[Production]]></TERM><TERM><![CDATA[programs]]></TERM><TERM><![CDATA[Proteins]]></TERM><TERM><![CDATA[Resolution]]></TERM><TERM><![CDATA[Risk]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Serpins]]></TERM><TERM><![CDATA[Skin]]></TERM><TERM><![CDATA[Smallpox]]></TERM><TERM><![CDATA[Somatic Cell]]></TERM><TERM><![CDATA[Spleen]]></TERM><TERM><![CDATA[Sterility]]></TERM><TERM><![CDATA[System]]></TERM><TERM><![CDATA[Systemic infection]]></TERM><TERM><![CDATA[tissue regeneration]]></TERM><TERM><![CDATA[Tissues]]></TERM><TERM><![CDATA[transmission process]]></TERM><TERM><![CDATA[Vaccinia virus]]></TERM><TERM><![CDATA[vector]]></TERM><TERM><![CDATA[Vertebral column]]></TERM><TERM><![CDATA[Viral]]></TERM><TERM><![CDATA[Viral Vaccines]]></TERM><TERM><![CDATA[Virus]]></TERM><TERM><![CDATA[Virus Activation]]></TERM><TERM><![CDATA[Virus Diseases]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Poxviruses and Pro-Resolving Lipids]]></PROJECT_TITLE><SERIAL_NUMBER>115230</SERIAL_NUMBER><STUDY_SECTION>VIRB</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Virology - B Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>150000</DIRECT_COST_AMT><INDIRECT_COST_AMT>88073</INDIRECT_COST_AMT><TOTAL_COST>238073</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8962089</APPLICATION_ID><ACTIVITY>P60</ACTIVITY><ADMINISTERING_IC>MD</ADMINISTERING_IC><APPLICATION_TYPE>4</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/30/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>375</CFDA_CODE><CORE_PROJECT_NUM>P60MD000538</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>RFA-MD-11-003</FOA_NUMBER><FULL_PROJECT_NUM>4P60MD000538-13</FULL_PROJECT_NUM><FUNDING_ICs>NIMHD:1234872\</FUNDING_ICs><FUNDING_MECHANISM>RESEARCH CENTERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE ON MINORITY HEALTH AND HEALTH DISPARITIES</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>NEW YORK</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[INTERNAL MEDICINE/MEDICINE]]></ORG_DEPT><ORG_DISTRICT>12</ORG_DISTRICT><ORG_DUNS>121911077</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[NEW YORK UNIVERSITY SCHOOL OF MEDICINE]]></ORG_NAME><ORG_STATE>NY</ORG_STATE><ORG_ZIPCODE>100165802</ORG_ZIPCODE><PHR><![CDATA[There are significant and pervasive disparities in health status and access to care for Asian Americans in the U.S. The goal of this project is to implement a community-engaged and multi-level approach to conducting research, dissemination, research training and educational strategies to reduce health disparities in Asian American populations.]]></PHR><PIS><PI><PI_NAME>TRINH-SHEVRIN, CHAU </PI_NAME><PI_ID>7860791</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>CASTILLE, DOROTHY M</PROGRAM_OFFICER_NAME><PROJECT_START>09/30/2003</PROJECT_START><PROJECT_END>10/31/2017</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[Advocacy]]></TERM><TERM><![CDATA[Asian Americans]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Behavioral]]></TERM><TERM><![CDATA[Biological]]></TERM><TERM><![CDATA[Cardiovascular Diseases]]></TERM><TERM><![CDATA[Chinese People]]></TERM><TERM><![CDATA[Communities]]></TERM><TERM><![CDATA[Community Health]]></TERM><TERM><![CDATA[Diabetes Mellitus]]></TERM><TERM><![CDATA[dissemination research]]></TERM><TERM><![CDATA[Education and Outreach]]></TERM><TERM><![CDATA[efficacy testing]]></TERM><TERM><![CDATA[Evaluation]]></TERM><TERM><![CDATA[faith-based intervention]]></TERM><TERM><![CDATA[Fostering]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Government]]></TERM><TERM><![CDATA[Grant]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[health disparity]]></TERM><TERM><![CDATA[Health Professional]]></TERM><TERM><![CDATA[Health Resources]]></TERM><TERM><![CDATA[Health Services]]></TERM><TERM><![CDATA[Health Services Accessibility]]></TERM><TERM><![CDATA[Health Status]]></TERM><TERM><![CDATA[Healthcare]]></TERM><TERM><![CDATA[hospital organization]]></TERM><TERM><![CDATA[Improve Access]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[Intervention]]></TERM><TERM><![CDATA[Lymphedema]]></TERM><TERM><![CDATA[Medical Research]]></TERM><TERM><![CDATA[Mental Health]]></TERM><TERM><![CDATA[Mission]]></TERM><TERM><![CDATA[Needs Assessment]]></TERM><TERM><![CDATA[New York]]></TERM><TERM><![CDATA[Obesity]]></TERM><TERM><![CDATA[Outcome]]></TERM><TERM><![CDATA[outreach]]></TERM><TERM><![CDATA[Outreach Research]]></TERM><TERM><![CDATA[Ownership]]></TERM><TERM><![CDATA[Pilot Projects]]></TERM><TERM><![CDATA[Population]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[programs]]></TERM><TERM><![CDATA[public health medicine (field)]]></TERM><TERM><![CDATA[Public Hospitals]]></TERM><TERM><![CDATA[public-private partnership]]></TERM><TERM><![CDATA[Quality of life]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Research Project Grants]]></TERM><TERM><![CDATA[Research Training]]></TERM><TERM><![CDATA[Risk]]></TERM><TERM><![CDATA[service intervention]]></TERM><TERM><![CDATA[Services]]></TERM><TERM><![CDATA[social]]></TERM><TERM><![CDATA[social inequality]]></TERM><TERM><![CDATA[South Asian]]></TERM><TERM><![CDATA[stressor]]></TERM><TERM><![CDATA[Training]]></TERM><TERM><![CDATA[Training and Education]]></TERM><TERM><![CDATA[tumorigenesis]]></TERM><TERM><![CDATA[Universities]]></TERM><TERM><![CDATA[Woman]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[NYU Center for the Study of Asian American Health]]></PROJECT_TITLE><SERIAL_NUMBER>000538</SERIAL_NUMBER><STUDY_SECTION>ZMD1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>13</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>754889</DIRECT_COST_AMT><INDIRECT_COST_AMT>479983</INDIRECT_COST_AMT><TOTAL_COST>1234872</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8962153</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>HL</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/02/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>837</CFDA_CODE><CORE_PROJECT_NUM>R01HL072166</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-13-302</FOA_NUMBER><FULL_PROJECT_NUM>5R01HL072166-12</FULL_PROJECT_NUM><FUNDING_ICs>NHLBI:326250\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL HEART, LUNG, AND BLOOD INSTITUTE</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>VERMILLION</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[OTHER BASIC SCIENCES]]></ORG_DEPT><ORG_DISTRICT>00</ORG_DISTRICT><ORG_DUNS>929930808</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIVERSITY OF SOUTH DAKOTA]]></ORG_NAME><ORG_STATE>SD</ORG_STATE><ORG_ZIPCODE>570692307</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Congestive heart failure is the final common pathway of virtually all heart disease and is the most expensive single diagnosis in US health care. It is a highly lethal and disabling syndrome. Despite recent advances in its clinical management, it remains the leading cause of death in the US. This research project will help deepen our understanding on the molecular mechanisms underlying the progression from various primary heart diseases to congestive heart failure, which will ultimately facilitate the search for new measures to prevent or more effectively treat this common and yet life-threatening disorder.]]></PHR><PIS><PI><PI_NAME>WANG, XUEJUN </PI_NAME><PI_ID>7051696</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>WANG, LAN-HSIANG </PROGRAM_OFFICER_NAME><PROJECT_START>12/01/2002</PROJECT_START><PROJECT_END>10/31/2018</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Adverse effects]]></TERM><TERM><![CDATA[American]]></TERM><TERM><![CDATA[Animals]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Binding (Molecular Function)]]></TERM><TERM><![CDATA[C-terminal]]></TERM><TERM><![CDATA[Cardiac]]></TERM><TERM><![CDATA[Cardiac Myocytes]]></TERM><TERM><![CDATA[Cardiomyopathies]]></TERM><TERM><![CDATA[Cause of Death]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Clinical Management]]></TERM><TERM><![CDATA[Congestive Heart Failure]]></TERM><TERM><![CDATA[Coupled]]></TERM><TERM><![CDATA[Coupling]]></TERM><TERM><![CDATA[Crystallins]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Defect]]></TERM><TERM><![CDATA[Desmin]]></TERM><TERM><![CDATA[Diagnosis]]></TERM><TERM><![CDATA[Dilated Cardiomyopathy]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Excision]]></TERM><TERM><![CDATA[Family]]></TERM><TERM><![CDATA[fighting]]></TERM><TERM><![CDATA[Figs - dietary]]></TERM><TERM><![CDATA[fly]]></TERM><TERM><![CDATA[Functional disorder]]></TERM><TERM><![CDATA[Genetic Models]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Healthcare]]></TERM><TERM><![CDATA[Heart]]></TERM><TERM><![CDATA[Heart Diseases]]></TERM><TERM><![CDATA[heart function]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[induced pluripotent stem cell]]></TERM><TERM><![CDATA[Infarction]]></TERM><TERM><![CDATA[innovation]]></TERM><TERM><![CDATA[Invertebrates]]></TERM><TERM><![CDATA[Ischemia]]></TERM><TERM><![CDATA[knockout gene]]></TERM><TERM><![CDATA[Knowledge]]></TERM><TERM><![CDATA[Life]]></TERM><TERM><![CDATA[Measures]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[Molecular Target]]></TERM><TERM><![CDATA[mouse model]]></TERM><TERM><![CDATA[multicatalytic endopeptidase complex]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[mutant]]></TERM><TERM><![CDATA[Myocardial]]></TERM><TERM><![CDATA[Myocardial Ischemia]]></TERM><TERM><![CDATA[Myocardium]]></TERM><TERM><![CDATA[N-terminal]]></TERM><TERM><![CDATA[Nodal]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[overexpression]]></TERM><TERM><![CDATA[Pathway interactions]]></TERM><TERM><![CDATA[Peptide Hydrolases]]></TERM><TERM><![CDATA[Physiological]]></TERM><TERM><![CDATA[Pilot Projects]]></TERM><TERM><![CDATA[Play]]></TERM><TERM><![CDATA[prevent]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[Production]]></TERM><TERM><![CDATA[Protein Family]]></TERM><TERM><![CDATA[protein misfolding]]></TERM><TERM><![CDATA[Proteins]]></TERM><TERM><![CDATA[Proteolysis]]></TERM><TERM><![CDATA[Quality Control]]></TERM><TERM><![CDATA[receptor]]></TERM><TERM><![CDATA[Recruitment Activity]]></TERM><TERM><![CDATA[Reperfusion Injury]]></TERM><TERM><![CDATA[Reperfusion Therapy]]></TERM><TERM><![CDATA[Research Project Grants]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Staging]]></TERM><TERM><![CDATA[Stress]]></TERM><TERM><![CDATA[Syndrome]]></TERM><TERM><![CDATA[System]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[Tissues]]></TERM><TERM><![CDATA[Transgenic Organisms]]></TERM><TERM><![CDATA[UBA Domain]]></TERM><TERM><![CDATA[Ubiquitin]]></TERM><TERM><![CDATA[Ubiquitin family]]></TERM><TERM><![CDATA[Ubiquitinated Protein Degradation]]></TERM><TERM><![CDATA[Ubiquitination]]></TERM><TERM><![CDATA[Up-Regulation (Physiology)]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Ubiquitin receptors and cardiac proteotoxicity]]></PROJECT_TITLE><SERIAL_NUMBER>072166</SERIAL_NUMBER><STUDY_SECTION>CCHF</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Cardiac Contractility, Hypertrophy, and Failure Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>12</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>225000</DIRECT_COST_AMT><INDIRECT_COST_AMT>101250</INDIRECT_COST_AMT><TOTAL_COST>326250</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8963474</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>HL</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/05/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>837</CFDA_CODE><CORE_PROJECT_NUM>R01HL094326</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-13-302</FOA_NUMBER><FULL_PROJECT_NUM>5R01HL094326-07</FULL_PROJECT_NUM><FUNDING_ICs>NHLBI:360000\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL HEART, LUNG, AND BLOOD INSTITUTE</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>PHILADELPHIA</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[INTERNAL MEDICINE/MEDICINE]]></ORG_DEPT><ORG_DISTRICT>02</ORG_DISTRICT><ORG_DUNS>042250712</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIVERSITY OF PENNSYLVANIA]]></ORG_NAME><ORG_STATE>PA</ORG_STATE><ORG_ZIPCODE>191046205</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: This proposal investigates a newly discovered role for the Cerebral Cavernous Malformation pathway in heart development. This pathway is known to cause human vascular malformations, but the mechanism by which it does so is not understood. Our studies reveal a new role for the pathway in the developing heart, and new molecular information regarding how the pathway works in endothelial cells. These findings are therefore relevant to both cardiac development and the pathogenesis of vascular malformations.]]></PHR><PIS><PI><PI_NAME>KAHN, MARK L</PI_NAME><PI_ID>2081461</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>GAO, YUNLING </PROGRAM_OFFICER_NAME><PROJECT_START>01/01/2009</PROJECT_START><PROJECT_END>10/31/2018</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Adaptor Signaling Protein]]></TERM><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[Alleles]]></TERM><TERM><![CDATA[Animals]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Binding (Molecular Function)]]></TERM><TERM><![CDATA[Blood Vessels]]></TERM><TERM><![CDATA[Bypass]]></TERM><TERM><![CDATA[cadherin 5]]></TERM><TERM><![CDATA[Cardiac]]></TERM><TERM><![CDATA[Cardiac Jelly]]></TERM><TERM><![CDATA[cardiogenesis]]></TERM><TERM><![CDATA[Cardiovascular system]]></TERM><TERM><![CDATA[Cavernous Malformation]]></TERM><TERM><![CDATA[CCM1 gene]]></TERM><TERM><![CDATA[Cell physiology]]></TERM><TERM><![CDATA[Cell Surface Receptors]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Cerebrum]]></TERM><TERM><![CDATA[ChIP-seq]]></TERM><TERM><![CDATA[Cleaved cell]]></TERM><TERM><![CDATA[Congenital Heart Defects]]></TERM><TERM><![CDATA[Defect]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Disease model]]></TERM><TERM><![CDATA[Embryo]]></TERM><TERM><![CDATA[Embryonic Heart]]></TERM><TERM><![CDATA[Endocardium]]></TERM><TERM><![CDATA[Endothelial Cells]]></TERM><TERM><![CDATA[Fishes]]></TERM><TERM><![CDATA[Gene Expression]]></TERM><TERM><![CDATA[Gene Targeting]]></TERM><TERM><![CDATA[Genes]]></TERM><TERM><![CDATA[Glass]]></TERM><TERM><![CDATA[Growth]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Heart]]></TERM><TERM><![CDATA[Heart failure]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[insight]]></TERM><TERM><![CDATA[Link]]></TERM><TERM><![CDATA[loss of function mutation]]></TERM><TERM><![CDATA[malformation]]></TERM><TERM><![CDATA[MAP Kinase Gene]]></TERM><TERM><![CDATA[mature animal]]></TERM><TERM><![CDATA[Metalloproteases]]></TERM><TERM><![CDATA[mitogen-activated protein kinase 7]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[Molecular Genetics]]></TERM><TERM><![CDATA[molecular modeling]]></TERM><TERM><![CDATA[Molecular Models]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[Mutation]]></TERM><TERM><![CDATA[Myocardial]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[Pathogenesis]]></TERM><TERM><![CDATA[Pathway interactions]]></TERM><TERM><![CDATA[Peptide Hydrolases]]></TERM><TERM><![CDATA[Phenotype]]></TERM><TERM><![CDATA[Phosphotransferases]]></TERM><TERM><![CDATA[postnatal]]></TERM><TERM><![CDATA[Proteolysis]]></TERM><TERM><![CDATA[rapid growth]]></TERM><TERM><![CDATA[Regulation]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Signal Pathway]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[transcription factor]]></TERM><TERM><![CDATA[Vascular Diseases]]></TERM><TERM><![CDATA[versican]]></TERM><TERM><![CDATA[Work]]></TERM><TERM><![CDATA[Zebrafish]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Heg-CCM Signaling in Cardiovascular Development and Disease]]></PROJECT_TITLE><SERIAL_NUMBER>094326</SERIAL_NUMBER><STUDY_SECTION>CDD</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Cardiovascular Differentiation and Development Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>07</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>225000</DIRECT_COST_AMT><INDIRECT_COST_AMT>135000</INDIRECT_COST_AMT><TOTAL_COST>360000</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8963478</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>HL</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/27/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>837</CFDA_CODE><CORE_PROJECT_NUM>R01HL125436</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-13-302</FOA_NUMBER><FULL_PROJECT_NUM>5R01HL125436-02</FULL_PROJECT_NUM><FUNDING_ICs>NHLBI:341156\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL HEART, LUNG, AND BLOOD INSTITUTE</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>IOWA CITY</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[INTERNAL MEDICINE/MEDICINE]]></ORG_DEPT><ORG_DISTRICT>02</ORG_DISTRICT><ORG_DUNS>062761671</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIVERSITY OF IOWA]]></ORG_NAME><ORG_STATE>IA</ORG_STATE><ORG_ZIPCODE>522463111</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Obesity, hypothyroidism and heart disease are major health concerns in today's society with significant health and economic consequences. The studies in this proposal provide mechanistic insight into a complex regulatory network that controls cardiac transcriptional reprograming and mitochondrial energetics. The current treatments for these diseases are often ineffective providing a need to develop new therapeutic targets.]]></PHR><PIS><PI><PI_NAME>GRUETER, CHAD E</PI_NAME><PI_ID>7159947</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>ADHIKARI, BISHOW B.</PROGRAM_OFFICER_NAME><PROJECT_START>11/15/2014</PROJECT_START><PROJECT_END>10/31/2019</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Agonist]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Biogenesis]]></TERM><TERM><![CDATA[Cardiac]]></TERM><TERM><![CDATA[Chronic]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[cofactor]]></TERM><TERM><![CDATA[Complex]]></TERM><TERM><![CDATA[Cues]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Defect]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[Diet]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Energy Metabolism]]></TERM><TERM><![CDATA[Epidemic]]></TERM><TERM><![CDATA[Event]]></TERM><TERM><![CDATA[Exhibits]]></TERM><TERM><![CDATA[Fatty acid glycerol esters]]></TERM><TERM><![CDATA[Foundations]]></TERM><TERM><![CDATA[Gene Expression]]></TERM><TERM><![CDATA[Gene Expression Profile]]></TERM><TERM><![CDATA[Gene Expression Profiling]]></TERM><TERM><![CDATA[Genes]]></TERM><TERM><![CDATA[Genetic Transcription]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[health economics]]></TERM><TERM><![CDATA[Heart]]></TERM><TERM><![CDATA[Heart Diseases]]></TERM><TERM><![CDATA[heart function]]></TERM><TERM><![CDATA[heart metabolism]]></TERM><TERM><![CDATA[Homeostasis]]></TERM><TERM><![CDATA[Hypothyroidism]]></TERM><TERM><![CDATA[In Vitro]]></TERM><TERM><![CDATA[in vitro Model]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[insight]]></TERM><TERM><![CDATA[Invertebrates]]></TERM><TERM><![CDATA[Link]]></TERM><TERM><![CDATA[loss of function]]></TERM><TERM><![CDATA[Mammals]]></TERM><TERM><![CDATA[Mediator of activation protein]]></TERM><TERM><![CDATA[member]]></TERM><TERM><![CDATA[Metabolic]]></TERM><TERM><![CDATA[Metabolism]]></TERM><TERM><![CDATA[metabolomics]]></TERM><TERM><![CDATA[Mitochondria]]></TERM><TERM><![CDATA[mitochondrial dysfunction]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[Myocardial dysfunction]]></TERM><TERM><![CDATA[new therapeutic target]]></TERM><TERM><![CDATA[Nodal]]></TERM><TERM><![CDATA[Nuclear Receptors]]></TERM><TERM><![CDATA[Obesity]]></TERM><TERM><![CDATA[Outcome]]></TERM><TERM><![CDATA[Pathology]]></TERM><TERM><![CDATA[Pathway interactions]]></TERM><TERM><![CDATA[Pharmacological Treatment]]></TERM><TERM><![CDATA[Phosphotransferases]]></TERM><TERM><![CDATA[Physiological]]></TERM><TERM><![CDATA[Play]]></TERM><TERM><![CDATA[Predisposition]]></TERM><TERM><![CDATA[Production]]></TERM><TERM><![CDATA[programs]]></TERM><TERM><![CDATA[Publishing]]></TERM><TERM><![CDATA[Pump]]></TERM><TERM><![CDATA[Regulation]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[research study]]></TERM><TERM><![CDATA[Resistance]]></TERM><TERM><![CDATA[Respiratory physiology]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[Risk Factors]]></TERM><TERM><![CDATA[RNA Polymerase II]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Signal Pathway]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[Societies]]></TERM><TERM><![CDATA[Solid]]></TERM><TERM><![CDATA[Stress]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Therapeutic]]></TERM><TERM><![CDATA[therapeutic target]]></TERM><TERM><![CDATA[Thyroid Hormone Receptor]]></TERM><TERM><![CDATA[Thyroid Hormones]]></TERM><TERM><![CDATA[tool]]></TERM><TERM><![CDATA[Transcriptional Regulation]]></TERM><TERM><![CDATA[Translating]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[MED13 regulation of cardiac transcription in obesity and hypothyroidism]]></PROJECT_TITLE><SERIAL_NUMBER>125436</SERIAL_NUMBER><STUDY_SECTION>CCHF</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Cardiac Contractility, Hypertrophy, and Failure Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>225000</DIRECT_COST_AMT><INDIRECT_COST_AMT>116156</INDIRECT_COST_AMT><TOTAL_COST>341156</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8966615</APPLICATION_ID><ACTIVITY>I01</ACTIVITY><ADMINISTERING_IC>VA</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/03/2015</AWARD_NOTICE_DATE><BUDGET_START>10/01/2015</BUDGET_START><BUDGET_END>09/30/2016</BUDGET_END><CFDA_CODE>999</CFDA_CODE><CORE_PROJECT_NUM>I01BX000556</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-BX-12-001</FOA_NUMBER><FULL_PROJECT_NUM>5I01BX000556-07</FULL_PROJECT_NUM><FUNDING_ICs>VA:150000\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>Veterans Affairs</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>SALT LAKE CITY</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>02</ORG_DISTRICT><ORG_DUNS>009094756</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[VA SALT LAKE CITY HEALTHCARE SYSTEM]]></ORG_NAME><ORG_STATE>UT</ORG_STATE><ORG_ZIPCODE>841480001</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE:    
   
Project Narrative Corneal neovascularization is a sight-threatening complication of ocular injury, and can occur from shrapnel, improvised explosive devices, or blowing sand injuries. Macular degeneration is the leading cause of blindness among the elderly, including in veterans. Preventing or regressing neovascularization in these conditions may prevent loss of or restore vision. Corneal transplantation is frequently required to restore vision after trauma to the eye (70% of battlefield eye injuries involve the cornea), but has a significantly higher risk of rejecton in younger patients and patients with eye trauma. Over a million veterans have eye conditions which would benefit from this proposal, (corneal disease, macular degeneration, diabetic retinopathy, and solid tumors) which depend on angiogenesis. Combining morpholinos with long-term targeted nanoparticles (for topical or intravenous use) is particularly promising for both corneal transplant rejection and macular degeneration. This study will enable new treatments which avoid the risks of current standard of care while preserving efficacy.]]></PHR><PIS><PI><PI_NAME>AMBATI, BALAMURALI K</PI_NAME><PI_ID>7936184</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>10/01/2009</PROJECT_START><PROJECT_END>09/30/2017</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Age related macular degeneration]]></TERM><TERM><![CDATA[Albumins]]></TERM><TERM><![CDATA[Alternative Splicing]]></TERM><TERM><![CDATA[angiogenesis]]></TERM><TERM><![CDATA[Arginine]]></TERM><TERM><![CDATA[Aspartic Acid]]></TERM><TERM><![CDATA[Atrophic]]></TERM><TERM><![CDATA[Avastin]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Binding (Molecular Function)]]></TERM><TERM><![CDATA[Blindness]]></TERM><TERM><![CDATA[Caring]]></TERM><TERM><![CDATA[Choroidal Neovascularization]]></TERM><TERM><![CDATA[Chronic]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[Code]]></TERM><TERM><![CDATA[Complication]]></TERM><TERM><![CDATA[Cornea]]></TERM><TERM><![CDATA[Corneal Diseases]]></TERM><TERM><![CDATA[corneal epithelium]]></TERM><TERM><![CDATA[Corneal Neovascularization]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[Devices]]></TERM><TERM><![CDATA[Diabetic Retinopathy]]></TERM><TERM><![CDATA[Elderly]]></TERM><TERM><![CDATA[Event]]></TERM><TERM><![CDATA[Eye]]></TERM><TERM><![CDATA[Eye Injuries]]></TERM><TERM><![CDATA[Eyedrops]]></TERM><TERM><![CDATA[Fab Immunoglobulins]]></TERM><TERM><![CDATA[Fibrosis]]></TERM><TERM><![CDATA[Funding]]></TERM><TERM><![CDATA[geographic atrophy]]></TERM><TERM><![CDATA[Glycine]]></TERM><TERM><![CDATA[Graft Rejection]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Hemorrhage]]></TERM><TERM><![CDATA[high risk]]></TERM><TERM><![CDATA[Home environment]]></TERM><TERM><![CDATA[Infection]]></TERM><TERM><![CDATA[Injection of therapeutic agent]]></TERM><TERM><![CDATA[Injury]]></TERM><TERM><![CDATA[Intravenous]]></TERM><TERM><![CDATA[intravenous injection]]></TERM><TERM><![CDATA[Introns]]></TERM><TERM><![CDATA[Keratoplasty]]></TERM><TERM><![CDATA[Lasers]]></TERM><TERM><![CDATA[Length]]></TERM><TERM><![CDATA[Lucentis]]></TERM><TERM><![CDATA[Macular degeneration]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[Medical]]></TERM><TERM><![CDATA[Membrane]]></TERM><TERM><![CDATA[Messenger RNA]]></TERM><TERM><![CDATA[Modality]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[nanoparticle]]></TERM><TERM><![CDATA[neovascular]]></TERM><TERM><![CDATA[neovascularization]]></TERM><TERM><![CDATA[ocular angiogenesis]]></TERM><TERM><![CDATA[Ocular Vascular Disorder]]></TERM><TERM><![CDATA[Oligopeptides]]></TERM><TERM><![CDATA[Pathway interactions]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Plasmids]]></TERM><TERM><![CDATA[prevent]]></TERM><TERM><![CDATA[Protein Isoforms]]></TERM><TERM><![CDATA[ranibizumab]]></TERM><TERM><![CDATA[receptor]]></TERM><TERM><![CDATA[receptor expression]]></TERM><TERM><![CDATA[retinal angiogenesis]]></TERM><TERM><![CDATA[Risk]]></TERM><TERM><![CDATA[Route]]></TERM><TERM><![CDATA[serum sodium transport inhibitor]]></TERM><TERM><![CDATA[Silicon Dioxide]]></TERM><TERM><![CDATA[Solid Neoplasm]]></TERM><TERM><![CDATA[standard of care]]></TERM><TERM><![CDATA[targeted delivery]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Tissues]]></TERM><TERM><![CDATA[Transferrin]]></TERM><TERM><![CDATA[Transgenic Model]]></TERM><TERM><![CDATA[Trauma]]></TERM><TERM><![CDATA[Vascular Endothelial Growth Factor Receptor]]></TERM><TERM><![CDATA[Vascular Endothelial Growth Factor Receptor-1]]></TERM><TERM><![CDATA[Vascular Endothelial Growth Factors]]></TERM><TERM><![CDATA[Veterans]]></TERM><TERM><![CDATA[Vision]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Targeted Morpholino Interference of VEGF Pathways in Ocular Angiogenesis]]></PROJECT_TITLE><SERIAL_NUMBER>000556</SERIAL_NUMBER><STUDY_SECTION>NURC</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Neurobiology C ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>07</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST></TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8966626</APPLICATION_ID><ACTIVITY>I01</ACTIVITY><ADMINISTERING_IC>VA</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/03/2015</AWARD_NOTICE_DATE><BUDGET_START>10/01/2015</BUDGET_START><BUDGET_END>09/30/2016</BUDGET_END><CFDA_CODE>999</CFDA_CODE><CORE_PROJECT_NUM>I01BX001659</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-BX-12-003</FOA_NUMBER><FULL_PROJECT_NUM>5I01BX001659-03</FULL_PROJECT_NUM><FUNDING_ICs>VA:149886\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>Veterans Affairs</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>PORTLAND</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>03</ORG_DISTRICT><ORG_DUNS>089461255</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[PORTLAND VA MEDICAL CENTER]]></ORG_NAME><ORG_STATE>OR</ORG_STATE><ORG_ZIPCODE>972392964</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE:    
   
The objective of the proposed study is to explore a novel hypothesis, namely that the brainstem is an important mediator of cerebral blood flow during traumatic subarachnoid hemorrhage (SAH). More specifically, the medulla oblongata modulates cerebral blood flow (CBF) as part of a coordinated response to SAH aimed at preventing critical declines in CBF, and that failure of brainstem compensatory mechanisms contributes to the poor outcomes of traumatic subarachnoid hemorrhage.]]></PHR><PIS><PI><PI_NAME>CETAS, JUSTIN S.</PI_NAME><PI_ID>2107230</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>10/01/2013</PROJECT_START><PROJECT_END>09/30/2017</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Acute]]></TERM><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[Arteries]]></TERM><TERM><![CDATA[Attention]]></TERM><TERM><![CDATA[Autologous]]></TERM><TERM><![CDATA[Blast Injuries]]></TERM><TERM><![CDATA[Blood]]></TERM><TERM><![CDATA[Brain Stem]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Cerebral Ischemia]]></TERM><TERM><![CDATA[Cerebrovascular Circulation]]></TERM><TERM><![CDATA[Cerebrum]]></TERM><TERM><![CDATA[Chronic]]></TERM><TERM><![CDATA[cognitive change]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Defect]]></TERM><TERM><![CDATA[Endothelium]]></TERM><TERM><![CDATA[Event]]></TERM><TERM><![CDATA[extracellular]]></TERM><TERM><![CDATA[Failure (biologic function)]]></TERM><TERM><![CDATA[Functional disorder]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Image]]></TERM><TERM><![CDATA[Impaired cognition]]></TERM><TERM><![CDATA[Inflammation]]></TERM><TERM><![CDATA[Injury]]></TERM><TERM><![CDATA[Ischemia]]></TERM><TERM><![CDATA[Lasers]]></TERM><TERM><![CDATA[Learning]]></TERM><TERM><![CDATA[Magnetic Resonance Imaging]]></TERM><TERM><![CDATA[Maintenance]]></TERM><TERM><![CDATA[Measures]]></TERM><TERM><![CDATA[Medial]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[Mediator of activation protein]]></TERM><TERM><![CDATA[Medulla Oblongata]]></TERM><TERM><![CDATA[microangiography]]></TERM><TERM><![CDATA[Morbidity - disease rate]]></TERM><TERM><![CDATA[morris water maze]]></TERM><TERM><![CDATA[Mortality Vital Statistics]]></TERM><TERM><![CDATA[Nerve]]></TERM><TERM><![CDATA[nerve supply]]></TERM><TERM><![CDATA[neural circuit]]></TERM><TERM><![CDATA[Neural Pathways]]></TERM><TERM><![CDATA[Neuraxis]]></TERM><TERM><![CDATA[neurochemistry]]></TERM><TERM><![CDATA[Neurocognitive]]></TERM><TERM><![CDATA[Neuronal Injury]]></TERM><TERM><![CDATA[Neurons]]></TERM><TERM><![CDATA[neurophysiology]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[Optics]]></TERM><TERM><![CDATA[Outcome]]></TERM><TERM><![CDATA[Pathogenesis]]></TERM><TERM><![CDATA[Pathway interactions]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Perfusion]]></TERM><TERM><![CDATA[Pharmacology]]></TERM><TERM><![CDATA[Physiology]]></TERM><TERM><![CDATA[Play]]></TERM><TERM><![CDATA[Population]]></TERM><TERM><![CDATA[prevent]]></TERM><TERM><![CDATA[Regulation]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[Rest]]></TERM><TERM><![CDATA[restoration]]></TERM><TERM><![CDATA[Rodent Model]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Rotarod Performance Test]]></TERM><TERM><![CDATA[Sensory]]></TERM><TERM><![CDATA[Smooth muscle (tissue)]]></TERM><TERM><![CDATA[Subarachnoid Hemorrhage]]></TERM><TERM><![CDATA[Techniques]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[tool]]></TERM><TERM><![CDATA[Traumatic Brain Injury]]></TERM><TERM><![CDATA[Traumatic Subarachnoid Hemorrhage]]></TERM><TERM><![CDATA[Trigeminal System]]></TERM><TERM><![CDATA[Vasospasm]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Brainstem Control of Cerebral Blood Flow in Traumatic Subarachnoid Hemorrhage]]></PROJECT_TITLE><SERIAL_NUMBER>001659</SERIAL_NUMBER><STUDY_SECTION>NURC</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Neurobiology C ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>03</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST></TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8966690</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>HL</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/05/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>837</CFDA_CODE><CORE_PROJECT_NUM>R01HL061610</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-13-302</FOA_NUMBER><FULL_PROJECT_NUM>5R01HL061610-11</FULL_PROJECT_NUM><FUNDING_ICs>NHLBI:462919\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL HEART, LUNG, AND BLOOD INSTITUTE</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>BUFFALO</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[INTERNAL MEDICINE/MEDICINE]]></ORG_DEPT><ORG_DISTRICT>26</ORG_DISTRICT><ORG_DUNS>038633251</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[STATE UNIVERSITY OF NEW YORK AT BUFFALO]]></ORG_NAME><ORG_STATE>NY</ORG_STATE><ORG_ZIPCODE>142600001</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: This project will advance our understanding of cardiac stem cell therapy for heart failure which remains a major cause of death and disability in patients with
coronary artery disease and survivors of myocardial infarction. The research will determine whether random donor cardiac stem cells can be used successfully with standard immunosuppressive therapy and, using a randomized blinded design similar to clinical trials, identify the best stem cells source for therapy. Using cardiac stem cells that don't need to be harvested from the recipient along with administering the stem cells through a standard coronary infusion catheter would make the therapies more widely available to the increasing number of patients in need of treatments for heart failure. The research is translational, clinicaly relevant and conducted in a fashion that will provide information that could form the basis of a subsequent Phase I/II clinical trial of allogeneic intracoronary cKit+ cardiac stem cells in patients.]]></PHR><PIS><PI><PI_NAME>CANTY, JOHN M</PI_NAME><PI_ID>1882750</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>LATHROP, DAVID A.</PROGRAM_OFFICER_NAME><PROJECT_START>01/10/2000</PROJECT_START><PROJECT_END>10/31/2018</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[Adult]]></TERM><TERM><![CDATA[Allogenic]]></TERM><TERM><![CDATA[Animal Model]]></TERM><TERM><![CDATA[Animals]]></TERM><TERM><![CDATA[Arteries]]></TERM><TERM><![CDATA[auricular appendage]]></TERM><TERM><![CDATA[Autologous]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Bioluminescence]]></TERM><TERM><![CDATA[Biopsy]]></TERM><TERM><![CDATA[Blinded]]></TERM><TERM><![CDATA[Bone Marrow]]></TERM><TERM><![CDATA[Cardiac]]></TERM><TERM><![CDATA[Cardiac Catheterization Procedures]]></TERM><TERM><![CDATA[Cardiac Myocytes]]></TERM><TERM><![CDATA[cardiac regeneration]]></TERM><TERM><![CDATA[cardiac repair]]></TERM><TERM><![CDATA[Cardiac Surgery procedures]]></TERM><TERM><![CDATA[Cardiomyopathies]]></TERM><TERM><![CDATA[Catheters]]></TERM><TERM><![CDATA[Cause of Death]]></TERM><TERM><![CDATA[cell preparation]]></TERM><TERM><![CDATA[Cell Therapy]]></TERM><TERM><![CDATA[Cell Transplants]]></TERM><TERM><![CDATA[cell type]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Characteristics]]></TERM><TERM><![CDATA[Chronic]]></TERM><TERM><![CDATA[Cicatrix]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[clinical efficacy]]></TERM><TERM><![CDATA[Clinical Trials]]></TERM><TERM><![CDATA[comparative effectiveness]]></TERM><TERM><![CDATA[Coronary]]></TERM><TERM><![CDATA[Coronary Arteriosclerosis]]></TERM><TERM><![CDATA[Coronary artery]]></TERM><TERM><![CDATA[Coronary Occlusions]]></TERM><TERM><![CDATA[Cyclosporine]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[disability]]></TERM><TERM><![CDATA[Effectiveness]]></TERM><TERM><![CDATA[EFRAC]]></TERM><TERM><![CDATA[Family suidae]]></TERM><TERM><![CDATA[Fluorescence]]></TERM><TERM><![CDATA[Functional disorder]]></TERM><TERM><![CDATA[functional improvement]]></TERM><TERM><![CDATA[Harvest]]></TERM><TERM><![CDATA[Healed]]></TERM><TERM><![CDATA[healing]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Heart]]></TERM><TERM><![CDATA[Heart Atrium]]></TERM><TERM><![CDATA[heart dimension/size]]></TERM><TERM><![CDATA[Heart failure]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[Immunohistochemistry]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[improved functioning]]></TERM><TERM><![CDATA[Infarction]]></TERM><TERM><![CDATA[Infusion procedures]]></TERM><TERM><![CDATA[insight]]></TERM><TERM><![CDATA[Investigation]]></TERM><TERM><![CDATA[Laboratories]]></TERM><TERM><![CDATA[Left Ventricular Mass]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[Miniature Swine]]></TERM><TERM><![CDATA[morphometry]]></TERM><TERM><![CDATA[Muscle Cells]]></TERM><TERM><![CDATA[Myocardial]]></TERM><TERM><![CDATA[Myocardial Infarction]]></TERM><TERM><![CDATA[Myocardial Ischemia]]></TERM><TERM><![CDATA[Myocardium]]></TERM><TERM><![CDATA[Natural immunosuppression]]></TERM><TERM><![CDATA[Natural regeneration]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Phase]]></TERM><TERM><![CDATA[Population]]></TERM><TERM><![CDATA[Positron-Emission Tomography]]></TERM><TERM><![CDATA[pre-clinical]]></TERM><TERM><![CDATA[preclinical study]]></TERM><TERM><![CDATA[progenitor]]></TERM><TERM><![CDATA[Randomized]]></TERM><TERM><![CDATA[repaired]]></TERM><TERM><![CDATA[Reporter Genes]]></TERM><TERM><![CDATA[Reporting]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Research Personnel]]></TERM><TERM><![CDATA[Rodent]]></TERM><TERM><![CDATA[Rodent Model]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Safety]]></TERM><TERM><![CDATA[sex]]></TERM><TERM><![CDATA[Source]]></TERM><TERM><![CDATA[stem cell therapy]]></TERM><TERM><![CDATA[Stem cells]]></TERM><TERM><![CDATA[success]]></TERM><TERM><![CDATA[Survivors]]></TERM><TERM><![CDATA[Techniques]]></TERM><TERM><![CDATA[Therapeutic]]></TERM><TERM><![CDATA[Therapeutic immunosuppression]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[Transplantation]]></TERM><TERM><![CDATA[Ventricular]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Mechanisms of cKit+ Cardiac Stem Cell-Mediated Repair in Ischemic Cardiomyopathy]]></PROJECT_TITLE><SERIAL_NUMBER>061610</SERIAL_NUMBER><STUDY_SECTION>MIM</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Myocardial Ischemia and Metabolism Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>11</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>290232</DIRECT_COST_AMT><INDIRECT_COST_AMT>172687</INDIRECT_COST_AMT><TOTAL_COST>462919</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8967098</APPLICATION_ID><ACTIVITY>I01</ACTIVITY><ADMINISTERING_IC>VA</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/03/2015</AWARD_NOTICE_DATE><BUDGET_START>10/01/2015</BUDGET_START><BUDGET_END>09/30/2016</BUDGET_END><CFDA_CODE>999</CFDA_CODE><CORE_PROJECT_NUM>I01BX002495</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-BX-13-001</FOA_NUMBER><FULL_PROJECT_NUM>5I01BX002495-02</FULL_PROJECT_NUM><FUNDING_ICs>VA:150000\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>Veterans Affairs</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>PITTSBURGH</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>12</ORG_DISTRICT><ORG_DUNS>033127569</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[VETERANS HEALTH ADMINISTRATION]]></ORG_NAME><ORG_STATE>PA</ORG_STATE><ORG_ZIPCODE>152401003</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE:    
   
Stroke is a devastating clinical condition for which an effective neuroprotective treatment is currently unavailable. We have identified HSP27 as a promising therapeutic agent for the treatment of ischemic stroke. The objective of this proposal is to investigate whether and how HSP27 protects against the loss of blood brain barrier integrity after ischemic/reperfusion brain injury in both young and aged rodents. This information will be valuable for future development of new therapeutic strategies for the treatment of stroke and, possibly, other neurological disorders.   
   
      

]]></PHR><PIS><PI><PI_NAME>CHEN, JUN </PI_NAME><PI_ID>2084976</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>10/01/2014</PROJECT_START><PROJECT_END>09/30/2019</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[abstracting]]></TERM><TERM><![CDATA[Actins]]></TERM><TERM><![CDATA[Adult]]></TERM><TERM><![CDATA[aged]]></TERM><TERM><![CDATA[Apoptotic]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Blood - brain barrier anatomy]]></TERM><TERM><![CDATA[Brain]]></TERM><TERM><![CDATA[Brain Injuries]]></TERM><TERM><![CDATA[cell type]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Cellular Structures]]></TERM><TERM><![CDATA[Central Nervous System Diseases]]></TERM><TERM><![CDATA[Cerebral Ischemia]]></TERM><TERM><![CDATA[Cerebrum]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[Cytoskeletal Modeling]]></TERM><TERM><![CDATA[Cytoskeleton]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[depolymerization]]></TERM><TERM><![CDATA[deprivation]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[disability]]></TERM><TERM><![CDATA[Disabled Persons]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Edema]]></TERM><TERM><![CDATA[Endothelial Cells]]></TERM><TERM><![CDATA[Endothelium]]></TERM><TERM><![CDATA[Event]]></TERM><TERM><![CDATA[Exhibits]]></TERM><TERM><![CDATA[Extravasation]]></TERM><TERM><![CDATA[Future]]></TERM><TERM><![CDATA[Gelatinase A]]></TERM><TERM><![CDATA[Gene Targeting]]></TERM><TERM><![CDATA[Genes]]></TERM><TERM><![CDATA[Glucose]]></TERM><TERM><![CDATA[Heat Shock Protein 27]]></TERM><TERM><![CDATA[Heat shock proteins]]></TERM><TERM><![CDATA[Immune]]></TERM><TERM><![CDATA[Impairment]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[In Vitro]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[Infarction]]></TERM><TERM><![CDATA[Infiltration]]></TERM><TERM><![CDATA[Inflammation]]></TERM><TERM><![CDATA[Inflammation Mediators]]></TERM><TERM><![CDATA[Inflammatory]]></TERM><TERM><![CDATA[innovation]]></TERM><TERM><![CDATA[intravenous administration]]></TERM><TERM><![CDATA[intravenous injection]]></TERM><TERM><![CDATA[Ischemia]]></TERM><TERM><![CDATA[Ischemic Stroke]]></TERM><TERM><![CDATA[Lentivirus Vector]]></TERM><TERM><![CDATA[Life]]></TERM><TERM><![CDATA[Liquid substance]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[Medical]]></TERM><TERM><![CDATA[member]]></TERM><TERM><![CDATA[Middle Cerebral Artery Occlusion]]></TERM><TERM><![CDATA[Military Personnel]]></TERM><TERM><![CDATA[MMP2 gene]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Molecular Chaperones]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[nervous system disorder]]></TERM><TERM><![CDATA[Nervous System Physiology]]></TERM><TERM><![CDATA[Neurologic]]></TERM><TERM><![CDATA[Neurological outcome]]></TERM><TERM><![CDATA[neuroprotection]]></TERM><TERM><![CDATA[NF-kappa B]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[novel therapeutics]]></TERM><TERM><![CDATA[Outcome]]></TERM><TERM><![CDATA[overexpression]]></TERM><TERM><![CDATA[Oxygen]]></TERM><TERM><![CDATA[Pathogenesis]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Permeability]]></TERM><TERM><![CDATA[Plasma Proteins]]></TERM><TERM><![CDATA[polymerization]]></TERM><TERM><![CDATA[post stroke]]></TERM><TERM><![CDATA[prevent]]></TERM><TERM><![CDATA[Production]]></TERM><TERM><![CDATA[Protective Agents]]></TERM><TERM><![CDATA[protective effect]]></TERM><TERM><![CDATA[Protein Family]]></TERM><TERM><![CDATA[Proteins]]></TERM><TERM><![CDATA[public health relevance]]></TERM><TERM><![CDATA[Quality of life]]></TERM><TERM><![CDATA[Reperfusion Injury]]></TERM><TERM><![CDATA[Reperfusion Therapy]]></TERM><TERM><![CDATA[Rodent]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Signaling Molecule]]></TERM><TERM><![CDATA[small molecule]]></TERM><TERM><![CDATA[stroke]]></TERM><TERM><![CDATA[stroke therapy]]></TERM><TERM><![CDATA[Survivors]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Therapeutic]]></TERM><TERM><![CDATA[Therapeutic Agents]]></TERM><TERM><![CDATA[Thrombolytic Therapy]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[Transfection]]></TERM><TERM><![CDATA[Transgenic Mice]]></TERM><TERM><![CDATA[Transgenic Organisms]]></TERM><TERM><![CDATA[treatment strategy]]></TERM><TERM><![CDATA[United States]]></TERM><TERM><![CDATA[Veterans]]></TERM><TERM><![CDATA[vpr Genes]]></TERM><TERM><![CDATA[white matter injury]]></TERM><TERM><![CDATA[young adult]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Heat shock proteins and neuroprotection in cerebral ischemia]]></PROJECT_TITLE><SERIAL_NUMBER>002495</SERIAL_NUMBER><STUDY_SECTION>NURC</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Neurobiology C ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST></TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8968267</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>HL</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/29/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>837</CFDA_CODE><CORE_PROJECT_NUM>R01HL126141</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-13-302</FOA_NUMBER><FULL_PROJECT_NUM>5R01HL126141-02</FULL_PROJECT_NUM><FUNDING_ICs>NHLBI:430617\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL HEART, LUNG, AND BLOOD INSTITUTE</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>BOSTON</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[INTERNAL MEDICINE/MEDICINE]]></ORG_DEPT><ORG_DISTRICT>07</ORG_DISTRICT><ORG_DUNS>604483045</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[BOSTON UNIVERSITY MEDICAL CAMPUS]]></ORG_NAME><ORG_STATE>MA</ORG_STATE><ORG_ZIPCODE>021182841</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: The number of obese Americans persists at record levels as 69% of the US population is currently overweight or obese. Cardiovascular disease is the main cause of death in this population and this project seeks to investigate clinically important mechanisms of obesity-related vascular and metabolic disease as an area of high priority research.]]></PHR><PIS><PI><PI_NAME>GOKCE, NOYAN  (contact)</PI_NAME><PI_ID>2094774 (contact)</PI_ID></PI><PI><PI_NAME>WALSH, KENNETH </PI_NAME><PI_ID>1876551</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>MCDONALD, CHERYL </PROGRAM_OFFICER_NAME><PROJECT_START>11/14/2014</PROJECT_START><PROJECT_END>10/31/2019</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Adipose tissue]]></TERM><TERM><![CDATA[American]]></TERM><TERM><![CDATA[angiogenesis]]></TERM><TERM><![CDATA[Angiogenesis Modulating Agents]]></TERM><TERM><![CDATA[Area]]></TERM><TERM><![CDATA[bariatric surgery]]></TERM><TERM><![CDATA[Bariatrics]]></TERM><TERM><![CDATA[Biological]]></TERM><TERM><![CDATA[Biology]]></TERM><TERM><![CDATA[Biopsy]]></TERM><TERM><![CDATA[Blood Vessels]]></TERM><TERM><![CDATA[Body mass index]]></TERM><TERM><![CDATA[Body Weight decreased]]></TERM><TERM><![CDATA[burden of illness]]></TERM><TERM><![CDATA[Cancer Biology]]></TERM><TERM><![CDATA[Cardiovascular Diseases]]></TERM><TERM><![CDATA[Cardiovascular system]]></TERM><TERM><![CDATA[Categories]]></TERM><TERM><![CDATA[Cause of Death]]></TERM><TERM><![CDATA[Cessation of life]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[effective therapy]]></TERM><TERM><![CDATA[Fatty acid glycerol esters]]></TERM><TERM><![CDATA[Functional disorder]]></TERM><TERM><![CDATA[Future]]></TERM><TERM><![CDATA[Generations]]></TERM><TERM><![CDATA[Guidelines]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Health Care Costs]]></TERM><TERM><![CDATA[Healthcare]]></TERM><TERM><![CDATA[Homeostasis]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[Human Cell Line]]></TERM><TERM><![CDATA[human VEGF protein]]></TERM><TERM><![CDATA[Hypoxia]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[Inflammation]]></TERM><TERM><![CDATA[inhibitor/antagonist]]></TERM><TERM><![CDATA[Intervention]]></TERM><TERM><![CDATA[Knowledge]]></TERM><TERM><![CDATA[Laboratories]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[Link]]></TERM><TERM><![CDATA[macrophage]]></TERM><TERM><![CDATA[Metabolic]]></TERM><TERM><![CDATA[Metabolic Diseases]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[Morbid Obesity]]></TERM><TERM><![CDATA[Mortality Vital Statistics]]></TERM><TERM><![CDATA[multidisciplinary]]></TERM><TERM><![CDATA[Myocardial Ischemia]]></TERM><TERM><![CDATA[new therapeutic target]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[Obesity]]></TERM><TERM><![CDATA[Obesity associated cardiovascular disease]]></TERM><TERM><![CDATA[Operative Surgical Procedures]]></TERM><TERM><![CDATA[Overweight]]></TERM><TERM><![CDATA[Pathogenesis]]></TERM><TERM><![CDATA[Pathway interactions]]></TERM><TERM><![CDATA[Phenotype]]></TERM><TERM><![CDATA[Population]]></TERM><TERM><![CDATA[premature]]></TERM><TERM><![CDATA[Prevalence]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[Property]]></TERM><TERM><![CDATA[Protein Isoforms]]></TERM><TERM><![CDATA[Regulation]]></TERM><TERM><![CDATA[Research Priority]]></TERM><TERM><![CDATA[research study]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[RNA Splicing]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Sampling]]></TERM><TERM><![CDATA[Scientist]]></TERM><TERM><![CDATA[Secure]]></TERM><TERM><![CDATA[Shapes]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[stroke]]></TERM><TERM><![CDATA[System]]></TERM><TERM><![CDATA[Systemic disease]]></TERM><TERM><![CDATA[Techniques]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Tissue Expansion]]></TERM><TERM><![CDATA[Tissue Sample]]></TERM><TERM><![CDATA[Variant]]></TERM><TERM><![CDATA[Vascular Diseases]]></TERM><TERM><![CDATA[Vascular Endothelial Growth Factor A]]></TERM><TERM><![CDATA[Vascular Endothelial Growth Factors]]></TERM><TERM><![CDATA[Vascularization]]></TERM><TERM><![CDATA[Visceral]]></TERM><TERM><![CDATA[weight loss intervention]]></TERM><TERM><![CDATA[Western Blotting]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Anti-Angiogenic Mechanisms in Human Obesity]]></PROJECT_TITLE><SERIAL_NUMBER>126141</SERIAL_NUMBER><STUDY_SECTION>CICS</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Clinical and Integrative Cardiovascular Sciences Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>263053</DIRECT_COST_AMT><INDIRECT_COST_AMT>167564</INDIRECT_COST_AMT><TOTAL_COST>430617</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8974787</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>HL</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/02/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>837</CFDA_CODE><CORE_PROJECT_NUM>R01HL122599</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-13-302</FOA_NUMBER><FULL_PROJECT_NUM>5R01HL122599-02</FULL_PROJECT_NUM><FUNDING_ICs>NHLBI:376875\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL HEART, LUNG, AND BLOOD INSTITUTE</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>WORCESTER</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[GENETICS]]></ORG_DEPT><ORG_DISTRICT>02</ORG_DISTRICT><ORG_DUNS>603847393</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIV OF MASSACHUSETTS MED SCH WORCESTER]]></ORG_NAME><ORG_STATE>MA</ORG_STATE><ORG_ZIPCODE>016550002</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: The studies in this project will focus on signaling by the FLT4 receptor, which is mutated in forms of congenital lymphedema in humans. A better understanding of how FLT4 functions will provide insights into pathological mechanisms and possible treatments in these cases.]]></PHR><PIS><PI><PI_NAME>LAWSON, NATHAN D</PI_NAME><PI_ID>1892275</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>TOLUNAY, ESER </PROGRAM_OFFICER_NAME><PROJECT_START>11/24/2014</PROJECT_START><PROJECT_END>10/31/2018</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[absorption]]></TERM><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[angiogenesis]]></TERM><TERM><![CDATA[Automobile Driving]]></TERM><TERM><![CDATA[Biological Models]]></TERM><TERM><![CDATA[blind]]></TERM><TERM><![CDATA[Blood]]></TERM><TERM><![CDATA[Blood Vessels]]></TERM><TERM><![CDATA[Cardiovascular system]]></TERM><TERM><![CDATA[Cell Line]]></TERM><TERM><![CDATA[cell type]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Chromatin]]></TERM><TERM><![CDATA[Collaborations]]></TERM><TERM><![CDATA[Cytoplasmic Tail]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Defect]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Embryo]]></TERM><TERM><![CDATA[Embryonic Development]]></TERM><TERM><![CDATA[Endocrine system]]></TERM><TERM><![CDATA[Endothelial Cells]]></TERM><TERM><![CDATA[Enhancers]]></TERM><TERM><![CDATA[Erythrocytes]]></TERM><TERM><![CDATA[Exhibits]]></TERM><TERM><![CDATA[Fibroblast Growth Factor Receptors]]></TERM><TERM><![CDATA[FLT4 gene]]></TERM><TERM><![CDATA[gastrointestinal system]]></TERM><TERM><![CDATA[Genes]]></TERM><TERM><![CDATA[Genetic]]></TERM><TERM><![CDATA[Genome]]></TERM><TERM><![CDATA[Growth]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Hormones]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[Human Development]]></TERM><TERM><![CDATA[Immune]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[Indium]]></TERM><TERM><![CDATA[insight]]></TERM><TERM><![CDATA[Intercellular Fluid]]></TERM><TERM><![CDATA[Investigation]]></TERM><TERM><![CDATA[Knock-out]]></TERM><TERM><![CDATA[Knowledge]]></TERM><TERM><![CDATA[Ligand Binding]]></TERM><TERM><![CDATA[Lipids]]></TERM><TERM><![CDATA[Lymphatic]]></TERM><TERM><![CDATA[Lymphatic Endothelial Cells]]></TERM><TERM><![CDATA[Lymphatic System]]></TERM><TERM><![CDATA[Lymphatic vessel]]></TERM><TERM><![CDATA[Lymphedema]]></TERM><TERM><![CDATA[Lymphoid Cell]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[mutant]]></TERM><TERM><![CDATA[Mutate]]></TERM><TERM><![CDATA[Mutation]]></TERM><TERM><![CDATA[notch protein]]></TERM><TERM><![CDATA[nuclease]]></TERM><TERM><![CDATA[Output]]></TERM><TERM><![CDATA[Oxygen]]></TERM><TERM><![CDATA[Pathway interactions]]></TERM><TERM><![CDATA[Pattern]]></TERM><TERM><![CDATA[Phenotype]]></TERM><TERM><![CDATA[Platelet-Derived Growth Factor Receptor]]></TERM><TERM><![CDATA[Play]]></TERM><TERM><![CDATA[progenitor]]></TERM><TERM><![CDATA[receptor]]></TERM><TERM><![CDATA[Receptor Protein-Tyrosine Kinases]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[Signaling Molecule]]></TERM><TERM><![CDATA[Site]]></TERM><TERM><![CDATA[System]]></TERM><TERM><![CDATA[Techniques]]></TERM><TERM><![CDATA[Transcript]]></TERM><TERM><![CDATA[transcription factor]]></TERM><TERM><![CDATA[Transgenic Organisms]]></TERM><TERM><![CDATA[Tyrosine]]></TERM><TERM><![CDATA[Vascular Endothelial Growth Factor Receptor-3]]></TERM><TERM><![CDATA[Vascular Endothelial Growth Factors]]></TERM><TERM><![CDATA[Vascular System]]></TERM><TERM><![CDATA[Veins]]></TERM><TERM><![CDATA[Venous]]></TERM><TERM><![CDATA[Zebrafish]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Flt4 signaling in vascular and lymphatic development]]></PROJECT_TITLE><SERIAL_NUMBER>122599</SERIAL_NUMBER><STUDY_SECTION>CDD</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Cardiovascular Differentiation and Development Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>225000</DIRECT_COST_AMT><INDIRECT_COST_AMT>151875</INDIRECT_COST_AMT><TOTAL_COST>376875</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8977261</APPLICATION_ID><ACTIVITY>F32</ACTIVITY><ADMINISTERING_IC>NS</ADMINISTERING_IC><APPLICATION_TYPE>1</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>09/23/2015</AWARD_NOTICE_DATE><BUDGET_START>09/30/2015</BUDGET_START><BUDGET_END>09/29/2016</BUDGET_END><CFDA_CODE>853</CFDA_CODE><CORE_PROJECT_NUM>F32NS090748</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-14-149</FOA_NUMBER><FULL_PROJECT_NUM>1F32NS090748-01A1</FULL_PROJECT_NUM><FUNDING_ICs>NINDS:54194\</FUNDING_ICs><FUNDING_MECHANISM>TRAINING, INDIVIDUAL</FUNDING_MECHANISM><FY>2015</FY><IC_NAME>NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE</IC_NAME><NIH_SPENDING_CATS><CATEGORY><![CDATA[Brain Disorders]]></CATEGORY><CATEGORY><![CDATA[Injury (total) Accidents/Adverse Effects]]></CATEGORY><CATEGORY><![CDATA[Injury - Trauma - (Head and Spine)]]></CATEGORY><CATEGORY><![CDATA[Injury - Traumatic brain injury]]></CATEGORY><CATEGORY><![CDATA[Neurosciences]]></CATEGORY></NIH_SPENDING_CATS><ORG_CITY>PITTSBURGH</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[NEUROSURGERY]]></ORG_DEPT><ORG_DISTRICT>14</ORG_DISTRICT><ORG_DUNS>004514360</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIVERSITY OF PITTSBURGH AT PITTSBURGH]]></ORG_NAME><ORG_STATE>PA</ORG_STATE><ORG_ZIPCODE>152132303</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Annually, there are an estimated 1.7 million cases of traumatic brain injury. Traumatic brain injury is a complex condition that can leave patients with a lifetime of debilitating cognitive impairments. This research project will focus on evaluating th ability of lithium to improve synaptic function and promote functional recovery after traumatic brain injury.   
   
      

]]></PHR><PIS><PI><PI_NAME>CARLSON, SHAUN </PI_NAME><PI_ID>10394281</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>BELLGOWAN, PATRICK S. F.</PROGRAM_OFFICER_NAME><PROJECT_START>09/30/2015</PROJECT_START><PROJECT_END>09/29/2017</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Acetylcholine]]></TERM><TERM><![CDATA[Acute]]></TERM><TERM><![CDATA[alpha synuclein]]></TERM><TERM><![CDATA[Aminobutyric Acids]]></TERM><TERM><![CDATA[Attenuated]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Behavioral]]></TERM><TERM><![CDATA[Biological Assay]]></TERM><TERM><![CDATA[Brain]]></TERM><TERM><![CDATA[Brain region]]></TERM><TERM><![CDATA[Calcium]]></TERM><TERM><![CDATA[Cell Survival]]></TERM><TERM><![CDATA[Cessation of life]]></TERM><TERM><![CDATA[Clinical Trials]]></TERM><TERM><![CDATA[Complex]]></TERM><TERM><![CDATA[cysteine string protein]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Dendritic Spines]]></TERM><TERM><![CDATA[density]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Docking]]></TERM><TERM><![CDATA[efficacy testing]]></TERM><TERM><![CDATA[Evaluation]]></TERM><TERM><![CDATA[Functional disorder]]></TERM><TERM><![CDATA[Glutamates]]></TERM><TERM><![CDATA[High Pressure Liquid Chromatography]]></TERM><TERM><![CDATA[Hippocampus (Brain)]]></TERM><TERM><![CDATA[Histology]]></TERM><TERM><![CDATA[Hour]]></TERM><TERM><![CDATA[Immunoblotting]]></TERM><TERM><![CDATA[Impaired cognition]]></TERM><TERM><![CDATA[Impairment]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[injured]]></TERM><TERM><![CDATA[Injury]]></TERM><TERM><![CDATA[insight]]></TERM><TERM><![CDATA[Knockout Mice]]></TERM><TERM><![CDATA[Learning]]></TERM><TERM><![CDATA[Left]]></TERM><TERM><![CDATA[Lithium]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[Membrane]]></TERM><TERM><![CDATA[Memory]]></TERM><TERM><![CDATA[Microdialysis]]></TERM><TERM><![CDATA[Molecular Chaperones]]></TERM><TERM><![CDATA[Morphology]]></TERM><TERM><![CDATA[Motor]]></TERM><TERM><![CDATA[motor disorder]]></TERM><TERM><![CDATA[mouse model]]></TERM><TERM><![CDATA[N-ethylmaleimide-sensitive protein]]></TERM><TERM><![CDATA[Names]]></TERM><TERM><![CDATA[neurobehavioral]]></TERM><TERM><![CDATA[Neurobehavioral Manifestations]]></TERM><TERM><![CDATA[Neurons]]></TERM><TERM><![CDATA[neurotransmission]]></TERM><TERM><![CDATA[neurotransmitter release]]></TERM><TERM><![CDATA[Neurotransmitters]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[Pathology]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Phase]]></TERM><TERM><![CDATA[Physiologic Monitoring]]></TERM><TERM><![CDATA[Polymerase Chain Reaction]]></TERM><TERM><![CDATA[presynaptic]]></TERM><TERM><![CDATA[Property]]></TERM><TERM><![CDATA[Proteins]]></TERM><TERM><![CDATA[public health relevance]]></TERM><TERM><![CDATA[Quality of life]]></TERM><TERM><![CDATA[Rattus]]></TERM><TERM><![CDATA[receptor]]></TERM><TERM><![CDATA[reconstruction]]></TERM><TERM><![CDATA[Recovery]]></TERM><TERM><![CDATA[Recovery of Function]]></TERM><TERM><![CDATA[Research Project Grants]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[S-nitro-N-acetylpenicillamine]]></TERM><TERM><![CDATA[SNAP receptor]]></TERM><TERM><![CDATA[Specificity]]></TERM><TERM><![CDATA[Survivors]]></TERM><TERM><![CDATA[Synapses]]></TERM><TERM><![CDATA[Synaptic Cleft]]></TERM><TERM><![CDATA[synaptic function]]></TERM><TERM><![CDATA[Synaptic Membranes]]></TERM><TERM><![CDATA[Synaptic plasticity]]></TERM><TERM><![CDATA[Synaptic Vesicles]]></TERM><TERM><![CDATA[syntaxin]]></TERM><TERM><![CDATA[Therapeutic]]></TERM><TERM><![CDATA[Therapeutic Effect]]></TERM><TERM><![CDATA[Therapeutic Intervention]]></TERM><TERM><![CDATA[Three-dimensional analysis]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[Transmission Electron Microscopy]]></TERM><TERM><![CDATA[Traumatic Brain Injury]]></TERM><TERM><![CDATA[VAMP-2]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Lithium as a Therapeutic Approach to Attenuate Synaptic Deficits after TBI]]></PROJECT_TITLE><SERIAL_NUMBER>090748</SERIAL_NUMBER><STUDY_SECTION>ZRG1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>01</SUPPORT_YEAR><SUFFIX>A1</SUFFIX><DIRECT_COST_AMT>54194</DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>54194</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8979720</APPLICATION_ID><ACTIVITY>K23</ACTIVITY><ADMINISTERING_IC>MH</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/31/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>242</CFDA_CODE><CORE_PROJECT_NUM>K23MH103396</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-14-049</FOA_NUMBER><FULL_PROJECT_NUM>5K23MH103396-02</FULL_PROJECT_NUM><FUNDING_ICs>NIMH:177540\</FUNDING_ICs><FUNDING_MECHANISM>OTHER RESEARCH-RELATED</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF MENTAL HEALTH</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>BOSTON</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[PSYCHIATRY]]></ORG_DEPT><ORG_DISTRICT>07</ORG_DISTRICT><ORG_DUNS>604483045</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[BOSTON UNIVERSITY MEDICAL CAMPUS]]></ORG_NAME><ORG_STATE>MA</ORG_STATE><ORG_ZIPCODE>021182841</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: The Unified Protocol is a treatment that targets common underlying symptoms of emotional disorders. By studying the feasibility of this treatment in routine clinical settings, we will better understand its potential for widespread implementation. I effective, this treatment has the potential to decrease the amount of treatment necessary for individuals with multiple disorders.]]></PHR><PIS><PI><PI_NAME>GUTNER, CASSIDY AUBIN</PI_NAME><PI_ID>11550599</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>HILL, LAUREN D.</PROGRAM_OFFICER_NAME><PROJECT_START>12/15/2014</PROJECT_START><PROJECT_END>10/31/2019</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[Adult]]></TERM><TERM><![CDATA[Aftercare]]></TERM><TERM><![CDATA[Anxiety]]></TERM><TERM><![CDATA[Anxiety Disorders]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[career]]></TERM><TERM><![CDATA[Chronic]]></TERM><TERM><![CDATA[Classification]]></TERM><TERM><![CDATA[Clinic]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[clinical care]]></TERM><TERM><![CDATA[clinical Diagnosis]]></TERM><TERM><![CDATA[clinical practice]]></TERM><TERM><![CDATA[Clinical Research]]></TERM><TERM><![CDATA[common treatment]]></TERM><TERM><![CDATA[Comorbidity]]></TERM><TERM><![CDATA[Complement]]></TERM><TERM><![CDATA[Complex]]></TERM><TERM><![CDATA[Consultations]]></TERM><TERM><![CDATA[Controlled Study]]></TERM><TERM><![CDATA[cost]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Depressive disorder]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Diagnosis]]></TERM><TERM><![CDATA[Direct Costs]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Dual diagnosis (psychiatry)]]></TERM><TERM><![CDATA[effective therapy]]></TERM><TERM><![CDATA[Effectiveness]]></TERM><TERM><![CDATA[effectiveness clinical trial]]></TERM><TERM><![CDATA[effectiveness research]]></TERM><TERM><![CDATA[efficacy research]]></TERM><TERM><![CDATA[efficacy trial]]></TERM><TERM><![CDATA[Emotional disorder]]></TERM><TERM><![CDATA[evidence base]]></TERM><TERM><![CDATA[Evidence based treatment]]></TERM><TERM><![CDATA[experience]]></TERM><TERM><![CDATA[Exposure to]]></TERM><TERM><![CDATA[Feasibility Studies]]></TERM><TERM><![CDATA[Fostering]]></TERM><TERM><![CDATA[General Practitioners]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Health system]]></TERM><TERM><![CDATA[Healthcare Systems]]></TERM><TERM><![CDATA[Hospitals]]></TERM><TERM><![CDATA[Hybrids]]></TERM><TERM><![CDATA[implementation science]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[innovation]]></TERM><TERM><![CDATA[Intervention Studies]]></TERM><TERM><![CDATA[Interview]]></TERM><TERM><![CDATA[Laboratory Study]]></TERM><TERM><![CDATA[Literature]]></TERM><TERM><![CDATA[Measurement]]></TERM><TERM><![CDATA[Measures]]></TERM><TERM><![CDATA[Medical]]></TERM><TERM><![CDATA[Mental Depression]]></TERM><TERM><![CDATA[Mental disorders]]></TERM><TERM><![CDATA[Mental Health]]></TERM><TERM><![CDATA[Mentors]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Moods]]></TERM><TERM><![CDATA[Outcome]]></TERM><TERM><![CDATA[Participant]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Population]]></TERM><TERM><![CDATA[programs]]></TERM><TERM><![CDATA[Protocols documentation]]></TERM><TERM><![CDATA[psychosocial]]></TERM><TERM><![CDATA[Psychotherapy]]></TERM><TERM><![CDATA[public health medicine (field)]]></TERM><TERM><![CDATA[Qualitative Research]]></TERM><TERM><![CDATA[Relative (related person)]]></TERM><TERM><![CDATA[Reporting]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Research Design]]></TERM><TERM><![CDATA[Research Personnel]]></TERM><TERM><![CDATA[research study]]></TERM><TERM><![CDATA[Research Training]]></TERM><TERM><![CDATA[Resources]]></TERM><TERM><![CDATA[routine care]]></TERM><TERM><![CDATA[Sampling]]></TERM><TERM><![CDATA[satisfaction]]></TERM><TERM><![CDATA[Science]]></TERM><TERM><![CDATA[scientific organization]]></TERM><TERM><![CDATA[Sequential Treatment]]></TERM><TERM><![CDATA[Severities]]></TERM><TERM><![CDATA[Specific qualifier value]]></TERM><TERM><![CDATA[standard of care]]></TERM><TERM><![CDATA[Suicide]]></TERM><TERM><![CDATA[Supportive care]]></TERM><TERM><![CDATA[Surveys]]></TERM><TERM><![CDATA[Symptoms]]></TERM><TERM><![CDATA[System]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[Training]]></TERM><TERM><![CDATA[Traumatic Stress Disorders]]></TERM><TERM><![CDATA[Treatment Protocols]]></TERM><TERM><![CDATA[treatment strategy]]></TERM><TERM><![CDATA[Unipolar Depression]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Effectiveness of a unified transdiagnostic treatment in routine clinical care]]></PROJECT_TITLE><SERIAL_NUMBER>103396</SERIAL_NUMBER><STUDY_SECTION>SERV</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>165198</DIRECT_COST_AMT><INDIRECT_COST_AMT>12342</INDIRECT_COST_AMT><TOTAL_COST>177540</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8982512</APPLICATION_ID><ACTIVITY>F31</ACTIVITY><ADMINISTERING_IC>HL</ADMINISTERING_IC><APPLICATION_TYPE>1</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>07/27/2015</AWARD_NOTICE_DATE><BUDGET_START>08/17/2015</BUDGET_START><BUDGET_END>08/16/2016</BUDGET_END><CFDA_CODE>837</CFDA_CODE><CORE_PROJECT_NUM>F31HL129766</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[BIOMED ENGR/COL ENGR/ENGR STA]]></ED_INST_TYPE><FOA_NUMBER>PA-14-147</FOA_NUMBER><FULL_PROJECT_NUM>1F31HL129766-01</FULL_PROJECT_NUM><FUNDING_ICs>NHLBI:37714\</FUNDING_ICs><FUNDING_MECHANISM>TRAINING, INDIVIDUAL</FUNDING_MECHANISM><FY>2015</FY><IC_NAME>NATIONAL HEART, LUNG, AND BLOOD INSTITUTE</IC_NAME><NIH_SPENDING_CATS><CATEGORY><![CDATA[Cardiovascular]]></CATEGORY><CATEGORY><![CDATA[Heart Disease]]></CATEGORY></NIH_SPENDING_CATS><ORG_CITY>COLUMBUS</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[ENGINEERING (ALL TYPES)]]></ORG_DEPT><ORG_DISTRICT>03</ORG_DISTRICT><ORG_DUNS>832127323</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[OHIO STATE UNIVERSITY]]></ORG_NAME><ORG_STATE>OH</ORG_STATE><ORG_ZIPCODE>432101016</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: The normal heartbeat (sinus rhythm) begins with an electrical impulse generated by the sinoatrial node, a specialized collection of cells located in the right atrium. Sinoatrial node dysfunction, results in irregular pacemaking and is a high indicator for permanent cardiac pacemaker implantation. This research seeks to discover the role of beta-IV spectrin, an actin-associated polypeptide, in control of normal cardiac pacemaking through membrane targeting of a recently discovered mechanosensitive background K+ channel, TREK-1. These studies will combine original experiments with novel quantitative analyses to determine the contribution of the spectrin/TREK-1 complex to sinoatrial node dysfunction. We anticipate that results from this study will uncover a novel molecular pathway for control of pacemaking and cell membrane excitability in the sinoatrial node, and will potentially identify new therapeuti targets for human heart disease patients with sinoatrial node dysfunction.   
      

]]></PHR><PIS><PI><PI_NAME>ONAL, BIRCE </PI_NAME><PI_ID>12509703</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>MEADOWS, TAWANNA </PROGRAM_OFFICER_NAME><PROJECT_START>08/17/2015</PROJECT_START><PROJECT_END>08/16/2017</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Abnormal Cell]]></TERM><TERM><![CDATA[Actins]]></TERM><TERM><![CDATA[aging population]]></TERM><TERM><![CDATA[analytical method]]></TERM><TERM><![CDATA[Artificial cardiac pacemaker]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[betaIV spectrin]]></TERM><TERM><![CDATA[Binding (Molecular Function)]]></TERM><TERM><![CDATA[Cardiac]]></TERM><TERM><![CDATA[Cardiovascular Diseases]]></TERM><TERM><![CDATA[cell behavior]]></TERM><TERM><![CDATA[Cell membrane]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Collection]]></TERM><TERM><![CDATA[Complex]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Defect]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Experimental Models]]></TERM><TERM><![CDATA[Functional disorder]]></TERM><TERM><![CDATA[Heart]]></TERM><TERM><![CDATA[Heart Diseases]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[implantation]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[innovation]]></TERM><TERM><![CDATA[insight]]></TERM><TERM><![CDATA[Ion Channel]]></TERM><TERM><![CDATA[Knowledge]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[Length]]></TERM><TERM><![CDATA[Link]]></TERM><TERM><![CDATA[mathematical model]]></TERM><TERM><![CDATA[Membrane]]></TERM><TERM><![CDATA[membrane activity]]></TERM><TERM><![CDATA[Methods]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[Muscle Cells]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[Pacemakers]]></TERM><TERM><![CDATA[Pathway interactions]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Phase]]></TERM><TERM><![CDATA[polypeptide]]></TERM><TERM><![CDATA[Potassium Channel]]></TERM><TERM><![CDATA[potassium channel protein TREK-1]]></TERM><TERM><![CDATA[Predisposition]]></TERM><TERM><![CDATA[public health relevance]]></TERM><TERM><![CDATA[Regulation]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[research study]]></TERM><TERM><![CDATA[Right atrial structure]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Safety]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[Sinoatrial Node]]></TERM><TERM><![CDATA[Sinus]]></TERM><TERM><![CDATA[Spectrin]]></TERM><TERM><![CDATA[Structural Protein]]></TERM><TERM><![CDATA[Techniques]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Tissues]]></TERM><TERM><![CDATA[tool]]></TERM><TERM><![CDATA[Ventricular]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Spectrin-based pathway for regulation of cardiac pacemaking]]></PROJECT_TITLE><SERIAL_NUMBER>129766</SERIAL_NUMBER><STUDY_SECTION>ZRG1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>01</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>37714</DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>37714</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9042707</APPLICATION_ID><ACTIVITY>F31</ACTIVITY><ADMINISTERING_IC>DK</ADMINISTERING_IC><APPLICATION_TYPE>1</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>09/16/2015</AWARD_NOTICE_DATE><BUDGET_START>09/30/2015</BUDGET_START><BUDGET_END>09/29/2016</BUDGET_END><CFDA_CODE>847</CFDA_CODE><CORE_PROJECT_NUM>F31DK107049</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-14-147</FOA_NUMBER><FULL_PROJECT_NUM>1F31DK107049-01A1</FULL_PROJECT_NUM><FUNDING_ICs>NIDDK:30589\</FUNDING_ICs><FUNDING_MECHANISM>TRAINING, INDIVIDUAL</FUNDING_MECHANISM><FY>2015</FY><IC_NAME>NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES</IC_NAME><NIH_SPENDING_CATS><CATEGORY><![CDATA[Biotechnology]]></CATEGORY><CATEGORY><![CDATA[Digestive Diseases]]></CATEGORY><CATEGORY><![CDATA[Injury (total) Accidents/Adverse Effects]]></CATEGORY><CATEGORY><![CDATA[Liver Disease]]></CATEGORY><CATEGORY><![CDATA[Regenerative Medicine]]></CATEGORY><CATEGORY><![CDATA[Stem Cell Research]]></CATEGORY><CATEGORY><![CDATA[Stem Cell Research - Nonembryonic - Human]]></CATEGORY></NIH_SPENDING_CATS><ORG_CITY>BOSTON</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[BIOLOGY]]></ORG_DEPT><ORG_DISTRICT>07</ORG_DISTRICT><ORG_DUNS>047006379</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[HARVARD MEDICAL SCHOOL]]></ORG_NAME><ORG_STATE>MA</ORG_STATE><ORG_ZIPCODE>021156027</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE The adult liver has a remarkable ability to regenerate and under certain injury conditions, it has been shown that the liver activates ductal progenitor cells
to respond. Since, the Hippo Signaling pathway is vital for maintaining stem cells in adult organs and has been shown to regulate liver cancer, it is imperative to understand the role of this pathway in controlling the regeneration and preservation of the adult liver. In this proposal, I wil utilize mouse models, genetic tools, and cell culture techniques to address the role of Hippo Signaling in the regulation of adult ductal progenitors in the liver.      

]]></PHR><PIS><PI><PI_NAME>PEPE-MOONEY, BRIAN JOSEPH</PI_NAME><PI_ID>12479975</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>DENSMORE, CHRISTINE L</PROGRAM_OFFICER_NAME><PROJECT_START>09/30/2015</PROJECT_START><PROJECT_END>09/29/2017</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[Adult]]></TERM><TERM><![CDATA[adult stem cell]]></TERM><TERM><![CDATA[Area]]></TERM><TERM><![CDATA[Attenuated]]></TERM><TERM><![CDATA[Basic Science]]></TERM><TERM><![CDATA[Biliary]]></TERM><TERM><![CDATA[Biological]]></TERM><TERM><![CDATA[Biological Preservation]]></TERM><TERM><![CDATA[body system]]></TERM><TERM><![CDATA[Boston]]></TERM><TERM><![CDATA[Breeding]]></TERM><TERM><![CDATA[career]]></TERM><TERM><![CDATA[Cell Culture Techniques]]></TERM><TERM><![CDATA[Cell physiology]]></TERM><TERM><![CDATA[Cell Proliferation]]></TERM><TERM><![CDATA[Cell Therapy]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Chemical Injury]]></TERM><TERM><![CDATA[connective tissue growth factor]]></TERM><TERM><![CDATA[Ductal]]></TERM><TERM><![CDATA[Ductal Epithelial Cell]]></TERM><TERM><![CDATA[Fibrinogen]]></TERM><TERM><![CDATA[Genetic]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Growth]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Hepatocyte]]></TERM><TERM><![CDATA[Heterogeneity]]></TERM><TERM><![CDATA[Homeostasis]]></TERM><TERM><![CDATA[Homologous Gene]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[In Vitro]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[Injury]]></TERM><TERM><![CDATA[Knowledge]]></TERM><TERM><![CDATA[Laboratories]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[Liver]]></TERM><TERM><![CDATA[Liver diseases]]></TERM><TERM><![CDATA[liver injury]]></TERM><TERM><![CDATA[liver transplantation]]></TERM><TERM><![CDATA[Maintenance]]></TERM><TERM><![CDATA[Malignant neoplasm of liver]]></TERM><TERM><![CDATA[Methods]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Modification]]></TERM><TERM><![CDATA[mouse model]]></TERM><TERM><![CDATA[Natural regeneration]]></TERM><TERM><![CDATA[Nature]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[Organ]]></TERM><TERM><![CDATA[Organoids]]></TERM><TERM><![CDATA[Pathway interactions]]></TERM><TERM><![CDATA[Pediatric Hospitals]]></TERM><TERM><![CDATA[Phenotype]]></TERM><TERM><![CDATA[Physiological]]></TERM><TERM><![CDATA[Population]]></TERM><TERM><![CDATA[progenitor]]></TERM><TERM><![CDATA[public health relevance]]></TERM><TERM><![CDATA[Publishing]]></TERM><TERM><![CDATA[Recovery]]></TERM><TERM><![CDATA[Regulation]]></TERM><TERM><![CDATA[Reporter]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[research study]]></TERM><TERM><![CDATA[Resources]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[response to injury]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Scientist]]></TERM><TERM><![CDATA[Signal Pathway]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[Source]]></TERM><TERM><![CDATA[stem cell biology]]></TERM><TERM><![CDATA[Stem cells]]></TERM><TERM><![CDATA[Surgical Injuries]]></TERM><TERM><![CDATA[Techniques]]></TERM><TERM><![CDATA[Technology]]></TERM><TERM><![CDATA[tissue regeneration]]></TERM><TERM><![CDATA[tool]]></TERM><TERM><![CDATA[Transgenic Mice]]></TERM><TERM><![CDATA[Universities]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Dissecting Yap Activity in the Regulation of Adult Liver Ductal Progenitors]]></PROJECT_TITLE><SERIAL_NUMBER>107049</SERIAL_NUMBER><STUDY_SECTION>ZDK1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>01</SUPPORT_YEAR><SUFFIX>A1</SUFFIX><DIRECT_COST_AMT>30589</DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>30589</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9051177</APPLICATION_ID><ACTIVITY>F31</ACTIVITY><ADMINISTERING_IC>NS</ADMINISTERING_IC><APPLICATION_TYPE>1</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>09/11/2015</AWARD_NOTICE_DATE><BUDGET_START>09/25/2015</BUDGET_START><BUDGET_END>09/24/2016</BUDGET_END><CFDA_CODE>853</CFDA_CODE><CORE_PROJECT_NUM>F31NS093947</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-14-147</FOA_NUMBER><FULL_PROJECT_NUM>1F31NS093947-01A1</FULL_PROJECT_NUM><FUNDING_ICs>NINDS:34350\</FUNDING_ICs><FUNDING_MECHANISM>TRAINING, INDIVIDUAL</FUNDING_MECHANISM><FY>2015</FY><IC_NAME>NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE</IC_NAME><NIH_SPENDING_CATS><CATEGORY><![CDATA[Estrogen]]></CATEGORY><CATEGORY><![CDATA[Neurosciences]]></CATEGORY><CATEGORY><![CDATA[Prevention]]></CATEGORY></NIH_SPENDING_CATS><ORG_CITY>BALTIMORE</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[PHARMACOLOGY]]></ORG_DEPT><ORG_DISTRICT>07</ORG_DISTRICT><ORG_DUNS>188435911</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIVERSITY OF MARYLAND BALTIMORE]]></ORG_NAME><ORG_STATE>MD</ORG_STATE><ORG_ZIPCODE>212011508</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: The goal of this proposal is to determine the role of early life hormones and inflammation in normal brain development as a model to understand mechanisms underlying naturally occurring cell death and neuroprotection. Elucidating natural mechanisms for induction or prevention of cell death will provide a framework for the development of novel therapies for prevention of pathological cytotoxicity in the brain as well as insights into potential nodes of vulnerability.   
   
      

]]></PHR><PIS><PI><PI_NAME>PICKETT, LINDSAY ANN</PI_NAME><PI_ID>12013186</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>GNADT, JAMES W</PROGRAM_OFFICER_NAME><PROJECT_START>09/25/2015</PROJECT_START><PROJECT_END>09/24/2018</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Androgens]]></TERM><TERM><![CDATA[Apoptosis]]></TERM><TERM><![CDATA[Apoptotic]]></TERM><TERM><![CDATA[Architecture]]></TERM><TERM><![CDATA[Behavior]]></TERM><TERM><![CDATA[Biological Models]]></TERM><TERM><![CDATA[Brain]]></TERM><TERM><![CDATA[Brain Injuries]]></TERM><TERM><![CDATA[Brain region]]></TERM><TERM><![CDATA[calbindin]]></TERM><TERM><![CDATA[Case Study]]></TERM><TERM><![CDATA[Cell Count]]></TERM><TERM><![CDATA[Cell Death]]></TERM><TERM><![CDATA[Cell Nucleus]]></TERM><TERM><![CDATA[Cell physiology]]></TERM><TERM><![CDATA[Cell surface]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[cellular targeting]]></TERM><TERM><![CDATA[Collection]]></TERM><TERM><![CDATA[Coupled]]></TERM><TERM><![CDATA[critical period]]></TERM><TERM><![CDATA[cytotoxicity]]></TERM><TERM><![CDATA[Dendrites]]></TERM><TERM><![CDATA[Dendritic Spines]]></TERM><TERM><![CDATA[density]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Dinoprostone]]></TERM><TERM><![CDATA[Eating]]></TERM><TERM><![CDATA[Estradiol]]></TERM><TERM><![CDATA[Event]]></TERM><TERM><![CDATA[Female]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Hormones]]></TERM><TERM><![CDATA[Hypoxia]]></TERM><TERM><![CDATA[Immune]]></TERM><TERM><![CDATA[immune activation]]></TERM><TERM><![CDATA[Inflammation]]></TERM><TERM><![CDATA[inhibitor/antagonist]]></TERM><TERM><![CDATA[insight]]></TERM><TERM><![CDATA[interest]]></TERM><TERM><![CDATA[Investigation]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[Life]]></TERM><TERM><![CDATA[Light]]></TERM><TERM><![CDATA[male]]></TERM><TERM><![CDATA[Mammals]]></TERM><TERM><![CDATA[Maternal Behavior]]></TERM><TERM><![CDATA[medial preoptic nucleus]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[Microglia]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Names]]></TERM><TERM><![CDATA[Neonatal]]></TERM><TERM><![CDATA[Neuroglia]]></TERM><TERM><![CDATA[Neuroimmunomodulation]]></TERM><TERM><![CDATA[neuron apoptosis]]></TERM><TERM><![CDATA[Neurons]]></TERM><TERM><![CDATA[neuroprotection]]></TERM><TERM><![CDATA[Neuroprotective Agents]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[novel therapeutics]]></TERM><TERM><![CDATA[Perinatal]]></TERM><TERM><![CDATA[Phagocytosis]]></TERM><TERM><![CDATA[Physiological]]></TERM><TERM><![CDATA[Play]]></TERM><TERM><![CDATA[Population]]></TERM><TERM><![CDATA[preference]]></TERM><TERM><![CDATA[Pregnancy]]></TERM><TERM><![CDATA[Preoptic Areas]]></TERM><TERM><![CDATA[prevent]]></TERM><TERM><![CDATA[Prevention]]></TERM><TERM><![CDATA[Prevention therapy]]></TERM><TERM><![CDATA[Production]]></TERM><TERM><![CDATA[progenitor]]></TERM><TERM><![CDATA[programs]]></TERM><TERM><![CDATA[public health relevance]]></TERM><TERM><![CDATA[Rattus]]></TERM><TERM><![CDATA[Reporting]]></TERM><TERM><![CDATA[research study]]></TERM><TERM><![CDATA[Risk]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Serine]]></TERM><TERM><![CDATA[Sex Characteristics]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[Source]]></TERM><TERM><![CDATA[Stress]]></TERM><TERM><![CDATA[Surveys]]></TERM><TERM><![CDATA[System]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Thick]]></TERM><TERM><![CDATA[Up-Regulation (Physiology)]]></TERM><TERM><![CDATA[Vertebral column]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Microglia mediate cell death in a model system for sex differences in the brain]]></PROJECT_TITLE><SERIAL_NUMBER>093947</SERIAL_NUMBER><STUDY_SECTION>ZRG1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>01</SUPPORT_YEAR><SUFFIX>A1</SUFFIX><DIRECT_COST_AMT>34350</DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>34350</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9054631</APPLICATION_ID><ACTIVITY>U54</ACTIVITY><ADMINISTERING_IC>HD</ADMINISTERING_IC><APPLICATION_TYPE>1</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/30/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>U54HD086984</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-HD-15-033</FOA_NUMBER><FULL_PROJECT_NUM>1U54HD086984-01</FULL_PROJECT_NUM><FUNDING_ICs>NICHD:124000\</FUNDING_ICs><FUNDING_MECHANISM>RESEARCH CENTERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &amp; HUMAN DEVELOPMENT</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>PHILADELPHIA</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>02</ORG_DISTRICT><ORG_DUNS>073757627</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[CHILDREN'S HOSP OF PHILADELPHIA]]></ORG_NAME><ORG_STATE>PA</ORG_STATE><ORG_ZIPCODE>191044318</ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>YUDKOFF, MARC </PI_NAME><PI_ID>1876167</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>11/01/2015</PROJECT_START><PROJECT_END>05/31/2020</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Admission activity]]></TERM><TERM><![CDATA[Advertising]]></TERM><TERM><![CDATA[Advisory Committees]]></TERM><TERM><![CDATA[Advocacy]]></TERM><TERM><![CDATA[Advocate]]></TERM><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[Award]]></TERM><TERM><![CDATA[Behavior]]></TERM><TERM><![CDATA[Blood Circulation]]></TERM><TERM><![CDATA[brain behavior]]></TERM><TERM><![CDATA[Budgets]]></TERM><TERM><![CDATA[Chalk]]></TERM><TERM><![CDATA[Clinical Trials]]></TERM><TERM><![CDATA[Cognition]]></TERM><TERM><![CDATA[cohort]]></TERM><TERM><![CDATA[Collaborations]]></TERM><TERM><![CDATA[Communication]]></TERM><TERM><![CDATA[Communities]]></TERM><TERM><![CDATA[cost effective]]></TERM><TERM><![CDATA[data mining]]></TERM><TERM><![CDATA[Developmental Disabilities]]></TERM><TERM><![CDATA[Diagnostic]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Educational aspects]]></TERM><TERM><![CDATA[Educational workshop]]></TERM><TERM><![CDATA[effectiveness research]]></TERM><TERM><![CDATA[Ensure]]></TERM><TERM><![CDATA[Equipment]]></TERM><TERM><![CDATA[Family]]></TERM><TERM><![CDATA[Fellowship]]></TERM><TERM><![CDATA[Fostering]]></TERM><TERM><![CDATA[Friends]]></TERM><TERM><![CDATA[Genes]]></TERM><TERM><![CDATA[Genetic]]></TERM><TERM><![CDATA[Genomics]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Government]]></TERM><TERM><![CDATA[Grant]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Human Resources]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[Inherited]]></TERM><TERM><![CDATA[innovation]]></TERM><TERM><![CDATA[instrument]]></TERM><TERM><![CDATA[Intellectual functioning disability]]></TERM><TERM><![CDATA[interest]]></TERM><TERM><![CDATA[Journals]]></TERM><TERM><![CDATA[Laboratories]]></TERM><TERM><![CDATA[Leadership]]></TERM><TERM><![CDATA[Learning]]></TERM><TERM><![CDATA[lectures]]></TERM><TERM><![CDATA[Lobbying]]></TERM><TERM><![CDATA[meetings]]></TERM><TERM><![CDATA[Mental Retardation and Developmental Disabilities Research Centers]]></TERM><TERM><![CDATA[Mission]]></TERM><TERM><![CDATA[Monitor]]></TERM><TERM><![CDATA[Mutation]]></TERM><TERM><![CDATA[National Institute of Child Health and Human Development]]></TERM><TERM><![CDATA[Neonatal Screening]]></TERM><TERM><![CDATA[neurochemistry]]></TERM><TERM><![CDATA[Neurodevelopmental Disability]]></TERM><TERM><![CDATA[Newborn Infant]]></TERM><TERM><![CDATA[Outcome]]></TERM><TERM><![CDATA[patient population]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Phenotype]]></TERM><TERM><![CDATA[Procedures]]></TERM><TERM><![CDATA[Program Development]]></TERM><TERM><![CDATA[programs]]></TERM><TERM><![CDATA[Progress Reports]]></TERM><TERM><![CDATA[Quality Control]]></TERM><TERM><![CDATA[Recruitment Activity]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Research Personnel]]></TERM><TERM><![CDATA[Research Support]]></TERM><TERM><![CDATA[Resource Allocation]]></TERM><TERM><![CDATA[Resources]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[satisfaction]]></TERM><TERM><![CDATA[Scientific Advances and Accomplishments]]></TERM><TERM><![CDATA[Secure]]></TERM><TERM><![CDATA[Series]]></TERM><TERM><![CDATA[Services]]></TERM><TERM><![CDATA[solidarity]]></TERM><TERM><![CDATA[success]]></TERM><TERM><![CDATA[Support Groups]]></TERM><TERM><![CDATA[Surveys]]></TERM><TERM><![CDATA[symposium]]></TERM><TERM><![CDATA[Therapeutic]]></TERM><TERM><![CDATA[Training]]></TERM><TERM><![CDATA[Training Programs]]></TERM><TERM><![CDATA[Translational Research]]></TERM><TERM><![CDATA[Visit]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Administrative: Core A]]></PROJECT_TITLE><SERIAL_NUMBER>086984</SERIAL_NUMBER><STUDY_SECTION>ZHD1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID>8059</SUBPROJECT_ID><SUPPORT_YEAR>01</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>83017</DIRECT_COST_AMT><INDIRECT_COST_AMT>56451</INDIRECT_COST_AMT><TOTAL_COST /><TOTAL_COST_SUB_PROJECT>124000</TOTAL_COST_SUB_PROJECT></row>
<row><APPLICATION_ID>9054634</APPLICATION_ID><ACTIVITY>U54</ACTIVITY><ADMINISTERING_IC>HD</ADMINISTERING_IC><APPLICATION_TYPE>1</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/30/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>U54HD086984</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-HD-15-033</FOA_NUMBER><FULL_PROJECT_NUM>1U54HD086984-01</FULL_PROJECT_NUM><FUNDING_ICs>NICHD:174288\</FUNDING_ICs><FUNDING_MECHANISM>RESEARCH CENTERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &amp; HUMAN DEVELOPMENT</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>PHILADELPHIA</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>02</ORG_DISTRICT><ORG_DUNS>073757627</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[CHILDREN'S HOSP OF PHILADELPHIA]]></ORG_NAME><ORG_STATE>PA</ORG_STATE><ORG_ZIPCODE>191044318</ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>ROBERTS, TIMOTHY P</PI_NAME><PI_ID>6282327</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>11/01/2015</PROJECT_START><PROJECT_END>05/31/2020</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Achievement]]></TERM><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[Animal Model]]></TERM><TERM><![CDATA[Area]]></TERM><TERM><![CDATA[autism spectrum disorder]]></TERM><TERM><![CDATA[Autistic Disorder]]></TERM><TERM><![CDATA[Basal Ganglia]]></TERM><TERM><![CDATA[Behavior]]></TERM><TERM><![CDATA[Behavioral]]></TERM><TERM><![CDATA[Bioinformatics]]></TERM><TERM><![CDATA[Biometry]]></TERM><TERM><![CDATA[Blinded]]></TERM><TERM><![CDATA[Brain]]></TERM><TERM><![CDATA[brain behavior]]></TERM><TERM><![CDATA[Brain Pathology]]></TERM><TERM><![CDATA[calcium indicator]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Central Nervous System Diseases]]></TERM><TERM><![CDATA[Cerebral Palsy]]></TERM><TERM><![CDATA[cognitive function]]></TERM><TERM><![CDATA[Collaborations]]></TERM><TERM><![CDATA[Complex]]></TERM><TERM><![CDATA[Consult]]></TERM><TERM><![CDATA[Consultations]]></TERM><TERM><![CDATA[Coupled]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Developmental Disabilities]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[DNA Sequence Alteration]]></TERM><TERM><![CDATA[Dyes]]></TERM><TERM><![CDATA[Eligibility Determination]]></TERM><TERM><![CDATA[Epilepsy]]></TERM><TERM><![CDATA[experimental analysis]]></TERM><TERM><![CDATA[Experimental Designs]]></TERM><TERM><![CDATA[Functional disorder]]></TERM><TERM><![CDATA[Functional Imaging]]></TERM><TERM><![CDATA[Generations]]></TERM><TERM><![CDATA[Genes]]></TERM><TERM><![CDATA[Genetic]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[Image]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[In Vitro]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[Intellectual functioning disability]]></TERM><TERM><![CDATA[Investigation]]></TERM><TERM><![CDATA[Limbic System]]></TERM><TERM><![CDATA[Magnetic Resonance Imaging]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[member]]></TERM><TERM><![CDATA[Mental Retardation and Developmental Disabilities Research Centers]]></TERM><TERM><![CDATA[Meta-Analysis]]></TERM><TERM><![CDATA[Methodology]]></TERM><TERM><![CDATA[Methods]]></TERM><TERM><![CDATA[Microscopic]]></TERM><TERM><![CDATA[Microscopy]]></TERM><TERM><![CDATA[Mission]]></TERM><TERM><![CDATA[Modality]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Monitor]]></TERM><TERM><![CDATA[Mutation]]></TERM><TERM><![CDATA[Neocortex]]></TERM><TERM><![CDATA[Neuraxis]]></TERM><TERM><![CDATA[neurochemistry]]></TERM><TERM><![CDATA[neuroimaging]]></TERM><TERM><![CDATA[neuronal circuitry]]></TERM><TERM><![CDATA[Neurons]]></TERM><TERM><![CDATA[neurophysiology]]></TERM><TERM><![CDATA[Neurosciences Research]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[novel strategies]]></TERM><TERM><![CDATA[operation]]></TERM><TERM><![CDATA[patch clamp]]></TERM><TERM><![CDATA[Pathologic]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Phenotype]]></TERM><TERM><![CDATA[Population]]></TERM><TERM><![CDATA[pre-clinical]]></TERM><TERM><![CDATA[Pre-Clinical Model]]></TERM><TERM><![CDATA[Procedures]]></TERM><TERM><![CDATA[programs]]></TERM><TERM><![CDATA[protein expression]]></TERM><TERM><![CDATA[Protocols documentation]]></TERM><TERM><![CDATA[Quality Control]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Research Design]]></TERM><TERM><![CDATA[Research Personnel]]></TERM><TERM><![CDATA[Research Support]]></TERM><TERM><![CDATA[Resolution]]></TERM><TERM><![CDATA[Series]]></TERM><TERM><![CDATA[Services]]></TERM><TERM><![CDATA[spectroscopic imaging]]></TERM><TERM><![CDATA[Stem cells]]></TERM><TERM><![CDATA[Structure]]></TERM><TERM><![CDATA[Symptoms]]></TERM><TERM><![CDATA[Techniques]]></TERM><TERM><![CDATA[Technology]]></TERM><TERM><![CDATA[tissue culture]]></TERM><TERM><![CDATA[Tissues]]></TERM><TERM><![CDATA[Training]]></TERM><TERM><![CDATA[translational approach]]></TERM><TERM><![CDATA[Variation (Genetics)]]></TERM><TERM><![CDATA[voltage]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Neuroimaging and Neurocircuitry: Core E]]></PROJECT_TITLE><SERIAL_NUMBER>086984</SERIAL_NUMBER><STUDY_SECTION>ZHD1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID>8062</SUBPROJECT_ID><SUPPORT_YEAR>01</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>116683</DIRECT_COST_AMT><INDIRECT_COST_AMT>79344</INDIRECT_COST_AMT><TOTAL_COST /><TOTAL_COST_SUB_PROJECT>174288</TOTAL_COST_SUB_PROJECT></row>
<row><APPLICATION_ID>9136277</APPLICATION_ID><ACTIVITY>P30</ACTIVITY><ADMINISTERING_IC>DK</ADMINISTERING_IC><APPLICATION_TYPE>6</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/03/2015</AWARD_NOTICE_DATE><BUDGET_START>09/01/2015</BUDGET_START><BUDGET_END>03/31/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>P30DK020541</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-DK-13-004</FOA_NUMBER><FULL_PROJECT_NUM>6P30DK020541-39</FULL_PROJECT_NUM><FUNDING_ICs>NIDDK:175413\</FUNDING_ICs><FUNDING_MECHANISM>RESEARCH CENTERS</FUNDING_MECHANISM><FY>2015</FY><IC_NAME>NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES</IC_NAME><NIH_SPENDING_CATS><CATEGORY><![CDATA[Clinical Research]]></CATEGORY><CATEGORY><![CDATA[Diabetes]]></CATEGORY><CATEGORY><![CDATA[Nutrition]]></CATEGORY></NIH_SPENDING_CATS><ORG_CITY>BRONX</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>14</ORG_DISTRICT><ORG_DUNS>079783367</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[ALBERT EINSTEIN COLLEGE OF MEDICINE]]></ORG_NAME><ORG_STATE>NY</ORG_STATE><ORG_ZIPCODE>104611975</ORG_ZIPCODE><PHR><![CDATA[The Stable Isotope & Metabolomics Core of the Einstein-Mount Sinai Diabetes Research Center provides cost 
effective, high quality resources that facilitate the scientific progress made by a large group of scientists 
committed to improve our understanding of the integrative physiology of diabetes in order to improve the 
treatment of patients with diabetes.]]></PHR><PIS><PI><PI_NAME>KURLAND, IRWIN JACK</PI_NAME><PI_ID>8259869</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START></PROJECT_START><PROJECT_END></PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Acyl Coenzyme A]]></TERM><TERM><![CDATA[Adipocytes]]></TERM><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[Aging]]></TERM><TERM><![CDATA[Amino Acids]]></TERM><TERM><![CDATA[Anabolism]]></TERM><TERM><![CDATA[Animal Model]]></TERM><TERM><![CDATA[Animals]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Beta Cell]]></TERM><TERM><![CDATA[Biochemical]]></TERM><TERM><![CDATA[Biochemical Pathway]]></TERM><TERM><![CDATA[Biological Assay]]></TERM><TERM><![CDATA[Biological Markers]]></TERM><TERM><![CDATA[Biological Models]]></TERM><TERM><![CDATA[blood glucose regulation]]></TERM><TERM><![CDATA[Caloric Restriction]]></TERM><TERM><![CDATA[Carnitine]]></TERM><TERM><![CDATA[Cell Line]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Citric Acid Cycle]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[Complement]]></TERM><TERM><![CDATA[complement C2b]]></TERM><TERM><![CDATA[Complex]]></TERM><TERM><![CDATA[Core Facility]]></TERM><TERM><![CDATA[cost effective]]></TERM><TERM><![CDATA[cost effectiveness]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[detection of nutrient]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Diabetes Mellitus]]></TERM><TERM><![CDATA[Diagnosis]]></TERM><TERM><![CDATA[Diet]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Evaluation]]></TERM><TERM><![CDATA[Exercise]]></TERM><TERM><![CDATA[extracellular]]></TERM><TERM><![CDATA[Fatty Acids]]></TERM><TERM><![CDATA[fly]]></TERM><TERM><![CDATA[Gene Targeting]]></TERM><TERM><![CDATA[Genus Hippocampus]]></TERM><TERM><![CDATA[Glucose]]></TERM><TERM><![CDATA[glucose disposal]]></TERM><TERM><![CDATA[glucose metabolism]]></TERM><TERM><![CDATA[Glycerol]]></TERM><TERM><![CDATA[Glycolysis]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Hepatic]]></TERM><TERM><![CDATA[Hepatocyte]]></TERM><TERM><![CDATA[high throughput screening]]></TERM><TERM><![CDATA[Homeostasis]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[Hypothalamic structure]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[In Vitro]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[Insulin]]></TERM><TERM><![CDATA[Insulin Resistance]]></TERM><TERM><![CDATA[insulin sensitivity]]></TERM><TERM><![CDATA[interest]]></TERM><TERM><![CDATA[Investigation]]></TERM><TERM><![CDATA[lipid biosynthesis]]></TERM><TERM><![CDATA[lipid metabolism]]></TERM><TERM><![CDATA[Lipids]]></TERM><TERM><![CDATA[mass spectrometer]]></TERM><TERM><![CDATA[Measurement]]></TERM><TERM><![CDATA[meetings]]></TERM><TERM><![CDATA[member]]></TERM><TERM><![CDATA[Mentorship]]></TERM><TERM><![CDATA[Metabolic]]></TERM><TERM><![CDATA[Metabolic Diseases]]></TERM><TERM><![CDATA[Metabolic Pathway]]></TERM><TERM><![CDATA[Metabolism]]></TERM><TERM><![CDATA[metabolomics]]></TERM><TERM><![CDATA[Methodology]]></TERM><TERM><![CDATA[Methods]]></TERM><TERM><![CDATA[microbiome]]></TERM><TERM><![CDATA[Mission]]></TERM><TERM><![CDATA[Mitochondria]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[Mutation]]></TERM><TERM><![CDATA[Neurons]]></TERM><TERM><![CDATA[Obesity]]></TERM><TERM><![CDATA[Organ]]></TERM><TERM><![CDATA[Organelles]]></TERM><TERM><![CDATA[Oxygen Consumption]]></TERM><TERM><![CDATA[Pathway interactions]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Pentosephosphates]]></TERM><TERM><![CDATA[Pentoses]]></TERM><TERM><![CDATA[Peripheral]]></TERM><TERM><![CDATA[Phospholipids]]></TERM><TERM><![CDATA[Physiological]]></TERM><TERM><![CDATA[Physiology]]></TERM><TERM><![CDATA[Plasma]]></TERM><TERM><![CDATA[Postdoctoral Fellow]]></TERM><TERM><![CDATA[Protein Biosynthesis]]></TERM><TERM><![CDATA[protein metabolism]]></TERM><TERM><![CDATA[protocol development]]></TERM><TERM><![CDATA[Recording of previous events]]></TERM><TERM><![CDATA[Recycling]]></TERM><TERM><![CDATA[Regulation]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Research Personnel]]></TERM><TERM><![CDATA[Resources]]></TERM><TERM><![CDATA[Respiration]]></TERM><TERM><![CDATA[Rodent]]></TERM><TERM><![CDATA[Rodent Model]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Scientist]]></TERM><TERM><![CDATA[Sense Organs]]></TERM><TERM><![CDATA[Services]]></TERM><TERM><![CDATA[Skeletal muscle structure]]></TERM><TERM><![CDATA[stable isotope]]></TERM><TERM><![CDATA[Students]]></TERM><TERM><![CDATA[System]]></TERM><TERM><![CDATA[Systems Biology]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[tissue culture]]></TERM><TERM><![CDATA[tissue/cell culture]]></TERM><TERM><![CDATA[Tissues]]></TERM><TERM><![CDATA[translational study]]></TERM><TERM><![CDATA[Urine]]></TERM><TERM><![CDATA[Work]]></TERM><TERM><![CDATA[Yeasts]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Stable Isotope & Metabolomics Core]]></PROJECT_TITLE><SERIAL_NUMBER>020541</SERIAL_NUMBER><STUDY_SECTION>ZDK1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID>7653</SUBPROJECT_ID><SUPPORT_YEAR>39</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>105038</DIRECT_COST_AMT><INDIRECT_COST_AMT>70375</INDIRECT_COST_AMT><TOTAL_COST /><TOTAL_COST_SUB_PROJECT>175413</TOTAL_COST_SUB_PROJECT></row>
<row><APPLICATION_ID>9136281</APPLICATION_ID><ACTIVITY>P30</ACTIVITY><ADMINISTERING_IC>DK</ADMINISTERING_IC><APPLICATION_TYPE>6</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/03/2015</AWARD_NOTICE_DATE><BUDGET_START>09/01/2015</BUDGET_START><BUDGET_END>03/31/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>P30DK020541</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-DK-13-004</FOA_NUMBER><FULL_PROJECT_NUM>6P30DK020541-39</FULL_PROJECT_NUM><FUNDING_ICs>NIDDK:188226\</FUNDING_ICs><FUNDING_MECHANISM>RESEARCH CENTERS</FUNDING_MECHANISM><FY>2015</FY><IC_NAME>NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES</IC_NAME><NIH_SPENDING_CATS><CATEGORY><![CDATA[Clinical Research]]></CATEGORY><CATEGORY><![CDATA[Diabetes]]></CATEGORY></NIH_SPENDING_CATS><ORG_CITY>BRONX</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>14</ORG_DISTRICT><ORG_DUNS>079783367</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[ALBERT EINSTEIN COLLEGE OF MEDICINE]]></ORG_NAME><ORG_STATE>NY</ORG_STATE><ORG_ZIPCODE>104611975</ORG_ZIPCODE><PHR><![CDATA[The Pilot & Feasibility Study Program provides cost effective funding to support and attract new diabetes 
investigators and/or for established diabetes research investigators to explore new and promising directions for 
the improved treatment and delivery of care for patients with diabetes.]]></PHR><PIS><PI><PI_NAME>CHUA, STREAMSON C</PI_NAME><PI_ID>1877213</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START></PROJECT_START><PROJECT_END></PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Advertising]]></TERM><TERM><![CDATA[Area]]></TERM><TERM><![CDATA[Award]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Budgets]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[Clinical Sciences]]></TERM><TERM><![CDATA[Collaborations]]></TERM><TERM><![CDATA[Communities]]></TERM><TERM><![CDATA[Complications of Diabetes Mellitus]]></TERM><TERM><![CDATA[Core Facility]]></TERM><TERM><![CDATA[cost effective]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[Diabetes Mellitus]]></TERM><TERM><![CDATA[Discipline]]></TERM><TERM><![CDATA[Eligibility Determination]]></TERM><TERM><![CDATA[Ensure]]></TERM><TERM><![CDATA[experience]]></TERM><TERM><![CDATA[Extramural Activities]]></TERM><TERM><![CDATA[Faculty]]></TERM><TERM><![CDATA[Feasibility Studies]]></TERM><TERM><![CDATA[Fostering]]></TERM><TERM><![CDATA[Funding]]></TERM><TERM><![CDATA[Funding Agency]]></TERM><TERM><![CDATA[Future]]></TERM><TERM><![CDATA[Generations]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Grant]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[Institutes]]></TERM><TERM><![CDATA[interest]]></TERM><TERM><![CDATA[Laboratories]]></TERM><TERM><![CDATA[member]]></TERM><TERM><![CDATA[Mentors]]></TERM><TERM><![CDATA[Metabolic Diseases]]></TERM><TERM><![CDATA[Metabolism]]></TERM><TERM><![CDATA[Mission]]></TERM><TERM><![CDATA[Modality]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Monitor]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[novel strategies]]></TERM><TERM><![CDATA[Obesity]]></TERM><TERM><![CDATA[Patient Care]]></TERM><TERM><![CDATA[Pilot Projects]]></TERM><TERM><![CDATA[programs]]></TERM><TERM><![CDATA[Publications]]></TERM><TERM><![CDATA[Recording of previous events]]></TERM><TERM><![CDATA[Request for Applications]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Research Personnel]]></TERM><TERM><![CDATA[Scientist]]></TERM><TERM><![CDATA[Seeds]]></TERM><TERM><![CDATA[Services]]></TERM><TERM><![CDATA[success]]></TERM><TERM><![CDATA[Textiles]]></TERM><TERM><![CDATA[Translational Research]]></TERM><TERM><![CDATA[United States National Institutes of Health]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Einstein-Mount Sinai Diabetes Research Center]]></PROJECT_TITLE><SERIAL_NUMBER>020541</SERIAL_NUMBER><STUDY_SECTION>ZDK1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID>7658</SUBPROJECT_ID><SUPPORT_YEAR>39</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>112710</DIRECT_COST_AMT><INDIRECT_COST_AMT>75516</INDIRECT_COST_AMT><TOTAL_COST /><TOTAL_COST_SUB_PROJECT>188226</TOTAL_COST_SUB_PROJECT></row>
<row><APPLICATION_ID>9146920</APPLICATION_ID><ACTIVITY>U51</ACTIVITY><ADMINISTERING_IC>PS</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/22/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>U51PS004049</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-PS-13-303</FOA_NUMBER><FULL_PROJECT_NUM>5U51PS004049-04</FULL_PROJECT_NUM><FUNDING_ICs>NCHHSTP:51165\</FUNDING_ICs><FUNDING_MECHANISM>OTHERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP)</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>BATON ROUGE</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>06</ORG_DISTRICT><ORG_DUNS>014740455</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[LOUISIANA STATE OFFICE OF PUBLIC HEALTH]]></ORG_NAME><ORG_STATE>LA</ORG_STATE><ORG_ZIPCODE>708025342</ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>RATARD, RAOULT </PI_NAME><PI_ID>9004147</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>11/01/2012</PROJECT_START><PROJECT_END>10/31/2016</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[Adult Viral Hepatitis Prevention and Surveillance for Louisianians]]></PROJECT_TITLE><SERIAL_NUMBER>004049</SERIAL_NUMBER><STUDY_SECTION>ZPS1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>04</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>51165</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9149042</APPLICATION_ID><ACTIVITY>U51</ACTIVITY><ADMINISTERING_IC>PS</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/23/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>U51PS004021</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-PS-13-303</FOA_NUMBER><FULL_PROJECT_NUM>5U51PS004021-04</FULL_PROJECT_NUM><FUNDING_ICs>NCHHSTP:62347\</FUNDING_ICs><FUNDING_MECHANISM>OTHERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP)</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>PROVIDENCE</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>02</ORG_DISTRICT><ORG_DUNS>929922664</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[RHODE ISLAND STATE DEPT OF HEALTH]]></ORG_NAME><ORG_STATE>RI</ORG_STATE><ORG_ZIPCODE>029085034</ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>COMELLA, JAMIE </PI_NAME><PI_ID>14304863</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>11/01/2012</PROJECT_START><PROJECT_END>10/31/2016</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[RI Viral Hepatitis Prevention Coordinator]]></PROJECT_TITLE><SERIAL_NUMBER>004021</SERIAL_NUMBER><STUDY_SECTION>ZPS1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>04</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>62347</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9149046</APPLICATION_ID><ACTIVITY>U51</ACTIVITY><ADMINISTERING_IC>PS</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/23/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>U51PS004047</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-PS-13-303</FOA_NUMBER><FULL_PROJECT_NUM>5U51PS004047-04</FULL_PROJECT_NUM><FUNDING_ICs>NCHHSTP:87480\</FUNDING_ICs><FUNDING_MECHANISM>OTHERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP)</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>MENANDS</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>20</ORG_DISTRICT><ORG_DUNS>157119657</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[NYS DEPARTMENT OF HEALTH--AIDS INSTITUTE]]></ORG_NAME><ORG_STATE>NY</ORG_STATE><ORG_ZIPCODE>122042726</ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>STEVENS, LYN C</PI_NAME><PI_ID>9542334</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>11/01/2012</PROJECT_START><PROJECT_END>10/31/2016</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[Viral Hepatitis Prevention and Surveillance]]></PROJECT_TITLE><SERIAL_NUMBER>004047</SERIAL_NUMBER><STUDY_SECTION>ZPS1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>04</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>87480</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9149047</APPLICATION_ID><ACTIVITY>U51</ACTIVITY><ADMINISTERING_IC>PS</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/23/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>U51PS004053</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-PS-13-303</FOA_NUMBER><FULL_PROJECT_NUM>5U51PS004053-04</FULL_PROJECT_NUM><FUNDING_ICs>NCHHSTP:57204\</FUNDING_ICs><FUNDING_MECHANISM>OTHERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP)</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>COLUMBUS</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>03</ORG_DISTRICT><ORG_DUNS>808847933</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[OHIO STATE DEPARTMENT OF HEALTH]]></ORG_NAME><ORG_STATE>OH</ORG_STATE><ORG_ZIPCODE>432152406</ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>CROSS, ELIZABETH </PI_NAME><PI_ID>10572377</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>11/01/2012</PROJECT_START><PROJECT_END>10/31/2016</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[VIRAL HEPATITIS - PREVENTION AND SURVEILLANCE]]></PROJECT_TITLE><SERIAL_NUMBER>004053</SERIAL_NUMBER><STUDY_SECTION>ZPS1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>04</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>57204</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9170883</APPLICATION_ID><ACTIVITY>K23</ACTIVITY><ADMINISTERING_IC>DK</ADMINISTERING_IC><APPLICATION_TYPE>7</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/03/2015</AWARD_NOTICE_DATE><BUDGET_START>09/01/2015</BUDGET_START><BUDGET_END>07/31/2016</BUDGET_END><CFDA_CODE>847</CFDA_CODE><CORE_PROJECT_NUM>K23DK091558</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-11-194</FOA_NUMBER><FULL_PROJECT_NUM>7K23DK091558-05</FULL_PROJECT_NUM><FUNDING_ICs>NIDDK:167218\</FUNDING_ICs><FUNDING_MECHANISM>OTHER RESEARCH-RELATED</FUNDING_MECHANISM><FY>2015</FY><IC_NAME>NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>AURORA</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[PEDIATRICS]]></ORG_DEPT><ORG_DISTRICT>06</ORG_DISTRICT><ORG_DUNS>041096314</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIVERSITY OF COLORADO DENVER]]></ORG_NAME><ORG_STATE>CO</ORG_STATE><ORG_ZIPCODE>800452570</ORG_ZIPCODE><PHR><![CDATA[The overall goal of this project is to address the critical need for improving insulin pump adherence where non- adherence has severe and potentially life threatening consequences by providing intervention to adolescents with type 1 diabetes (T1D) who use insulin pumps. This study is relevant to public health because continued misuse of insulin pumps compromises the health of patients with T1D and the ability of physicians to provide effective treatment. If the aims of this project are achieved, this study will change insuln pump practices by providing a comprehensive assessment approach relevant to insulin pump use.]]></PHR><PIS><PI><PI_NAME>DRISCOLL, KIMBERLY </PI_NAME><PI_ID>8493139</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>HYDE, JAMES F</PROGRAM_OFFICER_NAME><PROJECT_START>09/01/2012</PROJECT_START><PROJECT_END>07/31/2016</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[Adherence (attribute)]]></TERM><TERM><![CDATA[Adolescent]]></TERM><TERM><![CDATA[Adult]]></TERM><TERM><![CDATA[American]]></TERM><TERM><![CDATA[Award]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Behavior]]></TERM><TERM><![CDATA[Behavioral]]></TERM><TERM><![CDATA[Behavioral Research]]></TERM><TERM><![CDATA[Blood Glucose]]></TERM><TERM><![CDATA[Bolus Infusion]]></TERM><TERM><![CDATA[career]]></TERM><TERM><![CDATA[career development]]></TERM><TERM><![CDATA[Caring]]></TERM><TERM><![CDATA[Child]]></TERM><TERM><![CDATA[Childhood]]></TERM><TERM><![CDATA[Clinic]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[Clinical Research]]></TERM><TERM><![CDATA[Clinical Trials]]></TERM><TERM><![CDATA[college]]></TERM><TERM><![CDATA[Communities]]></TERM><TERM><![CDATA[Comorbidity]]></TERM><TERM><![CDATA[Consult]]></TERM><TERM><![CDATA[cost effective]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Data Analyses]]></TERM><TERM><![CDATA[Decision Making]]></TERM><TERM><![CDATA[depressive symptoms]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[diabetes management]]></TERM><TERM><![CDATA[Diabetes Mellitus]]></TERM><TERM><![CDATA[effective intervention]]></TERM><TERM><![CDATA[effective therapy]]></TERM><TERM><![CDATA[Endocrinologist]]></TERM><TERM><![CDATA[Environment]]></TERM><TERM><![CDATA[Evaluation]]></TERM><TERM><![CDATA[Evidence based intervention]]></TERM><TERM><![CDATA[Evidence based treatment]]></TERM><TERM><![CDATA[Experimental Designs]]></TERM><TERM><![CDATA[Extramural Activities]]></TERM><TERM><![CDATA[Faculty]]></TERM><TERM><![CDATA[Family]]></TERM><TERM><![CDATA[Feedback]]></TERM><TERM><![CDATA[flexibility]]></TERM><TERM><![CDATA[Florida]]></TERM><TERM><![CDATA[Foundations]]></TERM><TERM><![CDATA[Frequencies (time pattern)]]></TERM><TERM><![CDATA[Fright]]></TERM><TERM><![CDATA[Functional disorder]]></TERM><TERM><![CDATA[Funding]]></TERM><TERM><![CDATA[Future]]></TERM><TERM><![CDATA[glucose monitor]]></TERM><TERM><![CDATA[glycemic control]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Gold]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Housing]]></TERM><TERM><![CDATA[Hypoglycemia]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[Information Technology]]></TERM><TERM><![CDATA[innovation]]></TERM><TERM><![CDATA[Insulin]]></TERM><TERM><![CDATA[Insulin Infusion Systems]]></TERM><TERM><![CDATA[Insulin-Dependent Diabetes Mellitus]]></TERM><TERM><![CDATA[Intervention]]></TERM><TERM><![CDATA[Knowledge]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[Libraries]]></TERM><TERM><![CDATA[Licensing]]></TERM><TERM><![CDATA[Life]]></TERM><TERM><![CDATA[Literature]]></TERM><TERM><![CDATA[Measurement]]></TERM><TERM><![CDATA[Measures]]></TERM><TERM><![CDATA[Medical]]></TERM><TERM><![CDATA[Medicine]]></TERM><TERM><![CDATA[meetings]]></TERM><TERM><![CDATA[Mental Depression]]></TERM><TERM><![CDATA[Mentored Patient-Oriented Research Career Development Award]]></TERM><TERM><![CDATA[Mentors]]></TERM><TERM><![CDATA[Mentorship]]></TERM><TERM><![CDATA[Metabolic Control]]></TERM><TERM><![CDATA[Methodology]]></TERM><TERM><![CDATA[National Institute of Diabetes and Digestive and Kidney Diseases]]></TERM><TERM><![CDATA[National Research Service Awards]]></TERM><TERM><![CDATA[new technology]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[patient oriented]]></TERM><TERM><![CDATA[Patient Self-Report]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Performance]]></TERM><TERM><![CDATA[Physicians]]></TERM><TERM><![CDATA[point of care]]></TERM><TERM><![CDATA[Population]]></TERM><TERM><![CDATA[Positioning Attribute]]></TERM><TERM><![CDATA[Problem Solving]]></TERM><TERM><![CDATA[programs]]></TERM><TERM><![CDATA[Protocols documentation]]></TERM><TERM><![CDATA[Psychologist]]></TERM><TERM><![CDATA[psychosocial]]></TERM><TERM><![CDATA[Psychosocial Factor]]></TERM><TERM><![CDATA[public health medicine (field)]]></TERM><TERM><![CDATA[Publications]]></TERM><TERM><![CDATA[Publishing]]></TERM><TERM><![CDATA[Pump]]></TERM><TERM><![CDATA[Quality of life]]></TERM><TERM><![CDATA[Reading]]></TERM><TERM><![CDATA[Recording of previous events]]></TERM><TERM><![CDATA[Reporting]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Research Personnel]]></TERM><TERM><![CDATA[Research Training]]></TERM><TERM><![CDATA[Resources]]></TERM><TERM><![CDATA[routine care]]></TERM><TERM><![CDATA[Secure]]></TERM><TERM><![CDATA[skills]]></TERM><TERM><![CDATA[Statistical Models]]></TERM><TERM><![CDATA[statistics]]></TERM><TERM><![CDATA[Strategic Planning]]></TERM><TERM><![CDATA[Summary Reports]]></TERM><TERM><![CDATA[Techniques]]></TERM><TERM><![CDATA[Technology]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[Training]]></TERM><TERM><![CDATA[Translating]]></TERM><TERM><![CDATA[Translational Research]]></TERM><TERM><![CDATA[Treatment Protocols]]></TERM><TERM><![CDATA[United States National Institutes of Health]]></TERM><TERM><![CDATA[Universities]]></TERM><TERM><![CDATA[user-friendly]]></TERM><TERM><![CDATA[Wit]]></TERM><TERM><![CDATA[Writing]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Adherence intervention to promote optimal use of insulin pumps in adolescents wit]]></PROJECT_TITLE><SERIAL_NUMBER>091558</SERIAL_NUMBER><STUDY_SECTION>DDK</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Diabetes, Endocrinology and Metabolic Diseases B Subcommittee ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>05</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>155325</DIRECT_COST_AMT><INDIRECT_COST_AMT>11893</INDIRECT_COST_AMT><TOTAL_COST>167218</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9174501</APPLICATION_ID><ACTIVITY>Y01</ACTIVITY><ADMINISTERING_IC>EY</ADMINISTERING_IC><APPLICATION_TYPE></APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE></AWARD_NOTICE_DATE><BUDGET_START></BUDGET_START><BUDGET_END></BUDGET_END><CFDA_CODE>867</CFDA_CODE><CORE_PROJECT_NUM>Y01EY150060</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER></FOA_NUMBER><FULL_PROJECT_NUM>AEY15006001-1-0-1</FULL_PROJECT_NUM><FUNDING_ICs>NEI:375000\</FUNDING_ICs><FUNDING_MECHANISM>INTERAGENCY AGREEMENTS</FUNDING_MECHANISM><FY>2015</FY><IC_NAME>NATIONAL EYE INSTITUTE</IC_NAME><NIH_SPENDING_CATS><CATEGORY><![CDATA[Burden of Illness]]></CATEGORY><CATEGORY><![CDATA[Eye Disease and Disorders of Vision]]></CATEGORY><CATEGORY><![CDATA[Neurosciences]]></CATEGORY><CATEGORY><![CDATA[Prevention]]></CATEGORY></NIH_SPENDING_CATS><ORG_CITY></ORG_CITY><ORG_COUNTRY></ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT></ORG_DISTRICT><ORG_DUNS></ORG_DUNS><ORG_FIPS></ORG_FIPS><ORG_NAME><![CDATA[NATIONAL EYE INSTITUTE]]></ORG_NAME><ORG_STATE></ORG_STATE><ORG_ZIPCODE></ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>,  </PI_NAME><PI_ID></PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START></PROJECT_START><PROJECT_END></PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[American]]></TERM><TERM><![CDATA[burden of illness]]></TERM><TERM><![CDATA[Centers for Disease Control and Prevention (U.S.)]]></TERM><TERM><![CDATA[Collection]]></TERM><TERM><![CDATA[Consultations]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Data Collection]]></TERM><TERM><![CDATA[Data Files]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[disorder prevention]]></TERM><TERM><![CDATA[Early Diagnosis]]></TERM><TERM><![CDATA[Eye diseases]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Healthy People 2020]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[Information Dissemination]]></TERM><TERM><![CDATA[Institutional Review Boards]]></TERM><TERM><![CDATA[instrument]]></TERM><TERM><![CDATA[Interviewer]]></TERM><TERM><![CDATA[Maintenance]]></TERM><TERM><![CDATA[Mission]]></TERM><TERM><![CDATA[Monitor]]></TERM><TERM><![CDATA[National Center for Health Statistics (U.S.)]]></TERM><TERM><![CDATA[National Eye Institute]]></TERM><TERM><![CDATA[National Health Interview Survey]]></TERM><TERM><![CDATA[operation]]></TERM><TERM><![CDATA[Policies]]></TERM><TERM><![CDATA[Preparation]]></TERM><TERM><![CDATA[Prevention]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[programs]]></TERM><TERM><![CDATA[Publications]]></TERM><TERM><![CDATA[Questionnaire Designs]]></TERM><TERM><![CDATA[Rehabilitation therapy]]></TERM><TERM><![CDATA[Sampling]]></TERM><TERM><![CDATA[statistics]]></TERM><TERM><![CDATA[Surveys]]></TERM><TERM><![CDATA[System]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Training]]></TERM><TERM><![CDATA[Travel]]></TERM><TERM><![CDATA[Vision]]></TERM><TERM><![CDATA[Visit]]></TERM><TERM><![CDATA[Visual]]></TERM><TERM><![CDATA[Weight]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Vision questions on the 2016 National Health Interview Survey]]></PROJECT_TITLE><SERIAL_NUMBER></SERIAL_NUMBER><STUDY_SECTION></STUDY_SECTION><STUDY_SECTION_NAME xsi:nil='true' /><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR></SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>375000</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8926243</APPLICATION_ID><ACTIVITY>IK2</ACTIVITY><ADMINISTERING_IC>VA</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/05/2015</AWARD_NOTICE_DATE><BUDGET_START>10/01/2015</BUDGET_START><BUDGET_END>09/30/2016</BUDGET_END><CFDA_CODE>999</CFDA_CODE><CORE_PROJECT_NUM>IK2RX000902</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-RX-13-009</FOA_NUMBER><FULL_PROJECT_NUM>5IK2RX000902-02</FULL_PROJECT_NUM><FUNDING_ICs>VA:163019\</FUNDING_ICs><FUNDING_MECHANISM>OTHERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>Veterans Affairs</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>GAINESVILLE</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>03</ORG_DISTRICT><ORG_DUNS>097378632</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[VETERANS HEALTH ADMINISTRATION]]></ORG_NAME><ORG_STATE>FL</ORG_STATE><ORG_ZIPCODE>326081135</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE:    
The purpose of this career development award (2) is to provide Dr. J. Kay Waid-Ebbs with a strong mentored- based training program designed to advance her progress towards becoming an independent VA research scientist. Dr. Waid-Ebbs' interests are in cognition and brain injury. Her proposal involves a cognitive intervention enhanced with innovative technology to improve executive functioning following blast-related mild traumatic brain injury. The relevance of her proposed research to Veterans' health is of the utmost importance. Traumatic brain injury has been called the signature wound of the current wars and has affected over 287,861 Veterans to date. Effective treatments to restore these men and women to their greatest possible functional capacity are needed. This award would potentially lead to efficacious treatment and develop Dr. Waid-Ebbs into an independent researcher that will continue to address the needs of current and future Veterans.   
   
      

]]></PHR><PIS><PI><PI_NAME>WAID-EBBS, JULIA KAY</PI_NAME><PI_ID>10905885</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>10/01/2014</PROJECT_START><PROJECT_END>09/30/2018</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Activities of Daily Living]]></TERM><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[Adult]]></TERM><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[Award]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Beck depression inventory]]></TERM><TERM><![CDATA[Behavior]]></TERM><TERM><![CDATA[Blast Cell]]></TERM><TERM><![CDATA[Brain]]></TERM><TERM><![CDATA[Brain Concussion]]></TERM><TERM><![CDATA[Brain Injuries]]></TERM><TERM><![CDATA[Case Series]]></TERM><TERM><![CDATA[Cellular Phone]]></TERM><TERM><![CDATA[Clinical Trials]]></TERM><TERM><![CDATA[Cognition]]></TERM><TERM><![CDATA[Cognitive]]></TERM><TERM><![CDATA[Color]]></TERM><TERM><![CDATA[combat]]></TERM><TERM><![CDATA[Communities]]></TERM><TERM><![CDATA[Community Participation]]></TERM><TERM><![CDATA[community reintegration]]></TERM><TERM><![CDATA[Comorbidity]]></TERM><TERM><![CDATA[computerized]]></TERM><TERM><![CDATA[Control Groups]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Decision Making]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[Diagnosis]]></TERM><TERM><![CDATA[disability]]></TERM><TERM><![CDATA[Educational workshop]]></TERM><TERM><![CDATA[effective therapy]]></TERM><TERM><![CDATA[Effectiveness]]></TERM><TERM><![CDATA[Emotional]]></TERM><TERM><![CDATA[Environment]]></TERM><TERM><![CDATA[Equipment and supply inventories]]></TERM><TERM><![CDATA[Executive Dysfunction]]></TERM><TERM><![CDATA[executive function]]></TERM><TERM><![CDATA[Florida]]></TERM><TERM><![CDATA[Freedom]]></TERM><TERM><![CDATA[Frequencies (time pattern)]]></TERM><TERM><![CDATA[Future]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[group intervention]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Home environment]]></TERM><TERM><![CDATA[Impairment]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[indexing]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[Informal Social Control]]></TERM><TERM><![CDATA[Injury]]></TERM><TERM><![CDATA[innovation]]></TERM><TERM><![CDATA[innovative technologies]]></TERM><TERM><![CDATA[Intention]]></TERM><TERM><![CDATA[interest]]></TERM><TERM><![CDATA[Intervention]]></TERM><TERM><![CDATA[Investigation]]></TERM><TERM><![CDATA[K-Series Research Career Programs]]></TERM><TERM><![CDATA[Laboratories]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[Learning]]></TERM><TERM><![CDATA[Life]]></TERM><TERM><![CDATA[Linear Regressions]]></TERM><TERM><![CDATA[London]]></TERM><TERM><![CDATA[Measures]]></TERM><TERM><![CDATA[member]]></TERM><TERM><![CDATA[men]]></TERM><TERM><![CDATA[Mental Depression]]></TERM><TERM><![CDATA[Mentors]]></TERM><TERM><![CDATA[Methods]]></TERM><TERM><![CDATA[Monitor]]></TERM><TERM><![CDATA[neuromechanism]]></TERM><TERM><![CDATA[operation]]></TERM><TERM><![CDATA[Outcome]]></TERM><TERM><![CDATA[Participant]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Performance]]></TERM><TERM><![CDATA[Pilot Projects]]></TERM><TERM><![CDATA[Post-Traumatic Stress Disorders]]></TERM><TERM><![CDATA[preference]]></TERM><TERM><![CDATA[Probability]]></TERM><TERM><![CDATA[Problem Solving]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[public health relevance]]></TERM><TERM><![CDATA[Randomized]]></TERM><TERM><![CDATA[Recovery]]></TERM><TERM><![CDATA[Recruitment Activity]]></TERM><TERM><![CDATA[Regression Analysis]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Research Personnel]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Sample Size]]></TERM><TERM><![CDATA[Sampling]]></TERM><TERM><![CDATA[Schedule]]></TERM><TERM><![CDATA[Scientist]]></TERM><TERM><![CDATA[Services]]></TERM><TERM><![CDATA[Severities]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[Site]]></TERM><TERM><![CDATA[skills]]></TERM><TERM><![CDATA[skills training]]></TERM><TERM><![CDATA[Sleep]]></TERM><TERM><![CDATA[Sleep Disorders]]></TERM><TERM><![CDATA[social skills]]></TERM><TERM><![CDATA[Soldier]]></TERM><TERM><![CDATA[Speech]]></TERM><TERM><![CDATA[Sports]]></TERM><TERM><![CDATA[success]]></TERM><TERM><![CDATA[Symptoms]]></TERM><TERM><![CDATA[Technology]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[Training]]></TERM><TERM><![CDATA[Training Programs]]></TERM><TERM><![CDATA[Translating]]></TERM><TERM><![CDATA[Translations]]></TERM><TERM><![CDATA[Traumatic Brain Injury]]></TERM><TERM><![CDATA[treatment effect]]></TERM><TERM><![CDATA[treatment response]]></TERM><TERM><![CDATA[Veterans]]></TERM><TERM><![CDATA[War]]></TERM><TERM><![CDATA[Woman]]></TERM><TERM><![CDATA[Work]]></TERM><TERM><![CDATA[wound]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Metacognitive Training to Enhance Strategy Use In Blast Related TBI]]></PROJECT_TITLE><SERIAL_NUMBER>000902</SERIAL_NUMBER><STUDY_SECTION>RRD8</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Blank ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST></TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8957907</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>AI</ADMINISTERING_IC><APPLICATION_TYPE>4</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/26/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>855</CFDA_CODE><CORE_PROJECT_NUM>R01AI099300</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-11-260</FOA_NUMBER><FULL_PROJECT_NUM>4R01AI099300-04</FULL_PROJECT_NUM><FUNDING_ICs>NIAID:405000\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>BALTIMORE</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[INTERNAL MEDICINE/MEDICINE]]></ORG_DEPT><ORG_DISTRICT>07</ORG_DISTRICT><ORG_DUNS>001910777</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[JOHNS HOPKINS UNIVERSITY]]></ORG_NAME><ORG_STATE>MD</ORG_STATE><ORG_ZIPCODE>212051832</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: The proposed research will explore how HIF-1, an integrator of metabolic signals, controls the balance between T cell subsets both in vitro and in vivo. Importantly, this study will determine the therapeutic potential of HIF-1 targeting as a therapeuti strategy for altering cancer immunity. While we focus specifically on models of colitis and colitis
associated colon cancer as well as implantable melanoma, numerous immune mediated pathologies stand to benefit from novel and potent agents capable of reversing the nature of harmful immune responses. Therefore, if our hypotheses are supported by the proposed studies the strategy of HIF-1 targeting will likely be advanced to clinical trials with enthusiasm.   
   
PUBLIC HEALTH RELEVANCE:  The proposed research will expand our understanding of the mechanisms through which T cell fate decisions are affected by metabolic cues via HIF-1 and determine the translational relevance of targeting this molecule as means of promoting cancer immunity. The results of these studies may provide the basis for future clinical testing of this immune modulating strategy and will further define several aspects of T cell differentiation and the interface between immune cells and the unique cancer microenvironment.]]></PHR><PIS><PI><PI_NAME>PAN, FAN </PI_NAME><PI_ID>9349638</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>LAPHAM, CHERYL K.</PROGRAM_OFFICER_NAME><PROJECT_START>11/15/2012</PROJECT_START><PROJECT_END>10/31/2017</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[Anti-inflammatory]]></TERM><TERM><![CDATA[Anti-Inflammatory Agents]]></TERM><TERM><![CDATA[Antibodies]]></TERM><TERM><![CDATA[Autoantigens]]></TERM><TERM><![CDATA[Autoimmune Diseases]]></TERM><TERM><![CDATA[Autoimmunity]]></TERM><TERM><![CDATA[Automobile Driving]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[cancer immunotherapy]]></TERM><TERM><![CDATA[Cancer Model]]></TERM><TERM><![CDATA[cancer type]]></TERM><TERM><![CDATA[carcinogenesis]]></TERM><TERM><![CDATA[Cell Lineage]]></TERM><TERM><![CDATA[Cell Maintenance]]></TERM><TERM><![CDATA[Cell physiology]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[ChIP-seq]]></TERM><TERM><![CDATA[Chronic]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[Clinical Trials]]></TERM><TERM><![CDATA[Colitis]]></TERM><TERM><![CDATA[Colon Carcinoma]]></TERM><TERM><![CDATA[commensal microbes]]></TERM><TERM><![CDATA[Coupled]]></TERM><TERM><![CDATA[Cues]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Digoxin]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Ectopic Expression]]></TERM><TERM><![CDATA[efficacy testing]]></TERM><TERM><![CDATA[Elements]]></TERM><TERM><![CDATA[Environment]]></TERM><TERM><![CDATA[Equilibrium]]></TERM><TERM><![CDATA[flexibility]]></TERM><TERM><![CDATA[Future]]></TERM><TERM><![CDATA[Genes]]></TERM><TERM><![CDATA[Growth]]></TERM><TERM><![CDATA[Growth and Development function]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[hypoxia inducible factor 1]]></TERM><TERM><![CDATA[IL2RA gene]]></TERM><TERM><![CDATA[Immune]]></TERM><TERM><![CDATA[Immune response]]></TERM><TERM><![CDATA[Immunity]]></TERM><TERM><![CDATA[Immunotherapy]]></TERM><TERM><![CDATA[In Vitro]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[Indium]]></TERM><TERM><![CDATA[Inflammation]]></TERM><TERM><![CDATA[Inflammatory disease of the intestine]]></TERM><TERM><![CDATA[inhibiting antibody]]></TERM><TERM><![CDATA[inhibitor/antagonist]]></TERM><TERM><![CDATA[Interleukin-17]]></TERM><TERM><![CDATA[Intestines]]></TERM><TERM><![CDATA[Maintenance]]></TERM><TERM><![CDATA[Malignant Neoplasms]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[melanoma]]></TERM><TERM><![CDATA[Metabolic]]></TERM><TERM><![CDATA[metabolic abnormality assessment]]></TERM><TERM><![CDATA[Metabolism]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[Nature]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[Organism]]></TERM><TERM><![CDATA[pathogen]]></TERM><TERM><![CDATA[Pathology]]></TERM><TERM><![CDATA[Pathway interactions]]></TERM><TERM><![CDATA[Phenotype]]></TERM><TERM><![CDATA[Play]]></TERM><TERM><![CDATA[Population]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[Production]]></TERM><TERM><![CDATA[public health relevance]]></TERM><TERM><![CDATA[Regulation]]></TERM><TERM><![CDATA[Reporter]]></TERM><TERM><![CDATA[Reporting]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[research clinical testing]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[small molecule]]></TERM><TERM><![CDATA[subcutaneous]]></TERM><TERM><![CDATA[success]]></TERM><TERM><![CDATA[Supporting Cell]]></TERM><TERM><![CDATA[System]]></TERM><TERM><![CDATA[T cell differentiation]]></TERM><TERM><![CDATA[T cell regulation]]></TERM><TERM><![CDATA[T cell response]]></TERM><TERM><![CDATA[T-Lymphocyte]]></TERM><TERM><![CDATA[T-Lymphocyte Subsets]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Therapeutic]]></TERM><TERM><![CDATA[therapeutic target]]></TERM><TERM><![CDATA[Touch sensation]]></TERM><TERM><![CDATA[transcription factor]]></TERM><TERM><![CDATA[Transgenic Mice]]></TERM><TERM><![CDATA[treatment strategy]]></TERM><TERM><![CDATA[tumor]]></TERM><TERM><![CDATA[Tumor Antigens]]></TERM><TERM><![CDATA[tumor growth]]></TERM><TERM><![CDATA[Tumor Immunity]]></TERM><TERM><![CDATA[tumor initiation]]></TERM><TERM><![CDATA[tumor microenvironment]]></TERM><TERM><![CDATA[tumor progression]]></TERM><TERM><![CDATA[tumorigenesis]]></TERM><TERM><![CDATA[Up-Regulation (Physiology)]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Metabolic regulation of T cell fate and tumor immunity]]></PROJECT_TITLE><SERIAL_NUMBER>099300</SERIAL_NUMBER><STUDY_SECTION>TME</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Tumor Microenvironment Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>04</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>250000</DIRECT_COST_AMT><INDIRECT_COST_AMT>155000</INDIRECT_COST_AMT><TOTAL_COST>405000</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8958766</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>AI</ADMINISTERING_IC><APPLICATION_TYPE>4</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/27/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>855</CFDA_CODE><CORE_PROJECT_NUM>R01AI041236</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-11-260</FOA_NUMBER><FULL_PROJECT_NUM>4R01AI041236-22</FULL_PROJECT_NUM><FUNDING_ICs>NIAID:395000\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>CHARLOTTESVILLE</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[PATHOLOGY]]></ORG_DEPT><ORG_DISTRICT>05</ORG_DISTRICT><ORG_DUNS>065391526</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIVERSITY OF VIRGINIA]]></ORG_NAME><ORG_STATE>VA</ORG_STATE><ORG_ZIPCODE>229044195</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Autoimmune diseases are a major cause of human suffering and premature human death. They are chronic diseases and require costly management. There is no cure and palliative treatment has serious side effects. Therefore, top priorities are the discovery of new mechanisms of autoimmune disease and the identification of effective therapeutic measures. We have developed a model of human Type I Autoimmune Polyendocrine Syndrome (APS1): A human disease of extreme immunological significance. Our focus will be on autoimmune disease of the gonads. These diseases are cause of idiopathic human infertility affecting 1 of 7 married couples desiring children. Infertility is not fatal but t prevents life. Autoimmune orchitis and epididymitis occur in vasectomized animals and humans. Over half a million men per year are vasectomized in the US. Despite the great need, gonadal immunology is a major under-represented area of research. We will accrue new knowledge applicable to other human diseases such as glomerulonephritis, pemphigus vulgaris and systemic lupus erythematosus.]]></PHR><PIS><PI><PI_NAME>TUNG, KENNETH S.K.</PI_NAME><PI_ID>1963931</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>ESCH, THOMAS R.</PROGRAM_OFFICER_NAME><PROJECT_START>09/01/1993</PROJECT_START><PROJECT_END>10/31/2017</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Adverse effects]]></TERM><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[Animals]]></TERM><TERM><![CDATA[Antigen-Antibody Complex]]></TERM><TERM><![CDATA[Applications Grants]]></TERM><TERM><![CDATA[Area]]></TERM><TERM><![CDATA[Artificial Chromosomes]]></TERM><TERM><![CDATA[ATP phosphohydrolase]]></TERM><TERM><![CDATA[Autoantibodies]]></TERM><TERM><![CDATA[Autoimmune Diseases]]></TERM><TERM><![CDATA[Autoimmune orchitis]]></TERM><TERM><![CDATA[Autoimmune Process]]></TERM><TERM><![CDATA[Autoimmune Responses]]></TERM><TERM><![CDATA[Autoimmunity]]></TERM><TERM><![CDATA[autoreactive T cell]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Blood-Testis Barrier]]></TERM><TERM><![CDATA[cell injury]]></TERM><TERM><![CDATA[Cell physiology]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[central tolerance]]></TERM><TERM><![CDATA[Cessation of life]]></TERM><TERM><![CDATA[Child]]></TERM><TERM><![CDATA[Chronic Disease]]></TERM><TERM><![CDATA[Couples]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Diphtheria Toxin]]></TERM><TERM><![CDATA[diphtheria toxin receptor]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Disease model]]></TERM><TERM><![CDATA[Disease Outcome]]></TERM><TERM><![CDATA[Effector Cell]]></TERM><TERM><![CDATA[Elements]]></TERM><TERM><![CDATA[eosinophil]]></TERM><TERM><![CDATA[Eosinophilia]]></TERM><TERM><![CDATA[Epididymitis]]></TERM><TERM><![CDATA[Epitopes]]></TERM><TERM><![CDATA[Eragrostis]]></TERM><TERM><![CDATA[Event]]></TERM><TERM><![CDATA[Extramedullary]]></TERM><TERM><![CDATA[Failure (biologic function)]]></TERM><TERM><![CDATA[Fc Receptor]]></TERM><TERM><![CDATA[Female]]></TERM><TERM><![CDATA[Gastritis]]></TERM><TERM><![CDATA[Genes]]></TERM><TERM><![CDATA[Germ Cells]]></TERM><TERM><![CDATA[Glomerulonephritis]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Gonadal structure]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Hemorrhage]]></TERM><TERM><![CDATA[Homeostasis]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[human disease]]></TERM><TERM><![CDATA[IgG1]]></TERM><TERM><![CDATA[IL2RA gene]]></TERM><TERM><![CDATA[Immune]]></TERM><TERM><![CDATA[Immune Complex Diseases]]></TERM><TERM><![CDATA[Immunoglobulins]]></TERM><TERM><![CDATA[Immunology]]></TERM><TERM><![CDATA[Infertility]]></TERM><TERM><![CDATA[Infiltration]]></TERM><TERM><![CDATA[Inflammation]]></TERM><TERM><![CDATA[Injury]]></TERM><TERM><![CDATA[Intercellular Junctions]]></TERM><TERM><![CDATA[Investigation]]></TERM><TERM><![CDATA[Knowledge]]></TERM><TERM><![CDATA[Lacrimal gland structure]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[leydig interstitial cell]]></TERM><TERM><![CDATA[Life]]></TERM><TERM><![CDATA[lymph nodes]]></TERM><TERM><![CDATA[Lymphatic vessel]]></TERM><TERM><![CDATA[macrophage]]></TERM><TERM><![CDATA[male]]></TERM><TERM><![CDATA[Measures]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[men]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[monocyte]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[Mutation]]></TERM><TERM><![CDATA[Myelopoiesis]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[Organ]]></TERM><TERM><![CDATA[Outcome]]></TERM><TERM><![CDATA[Ovarian]]></TERM><TERM><![CDATA[Ovary]]></TERM><TERM><![CDATA[Palliative Care]]></TERM><TERM><![CDATA[Participant]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Pemphigus Vulgaris]]></TERM><TERM><![CDATA[Population]]></TERM><TERM><![CDATA[Positioning Attribute]]></TERM><TERM><![CDATA[premature]]></TERM><TERM><![CDATA[prevent]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[Production]]></TERM><TERM><![CDATA[receptor]]></TERM><TERM><![CDATA[Recovery]]></TERM><TERM><![CDATA[Regulation]]></TERM><TERM><![CDATA[Regulatory T-Lymphocyte]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Resistance]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[Self Tolerance]]></TERM><TERM><![CDATA[sertoli cell]]></TERM><TERM><![CDATA[Sjogren's Syndrome]]></TERM><TERM><![CDATA[sperm cell]]></TERM><TERM><![CDATA[Stomach]]></TERM><TERM><![CDATA[Syndrome]]></TERM><TERM><![CDATA[Systemic Lupus Erythematosus]]></TERM><TERM><![CDATA[T cell response]]></TERM><TERM><![CDATA[T-Cell Receptor]]></TERM><TERM><![CDATA[T-Lymphocyte]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Testis]]></TERM><TERM><![CDATA[Testosterone]]></TERM><TERM><![CDATA[theca cell]]></TERM><TERM><![CDATA[Therapeutic]]></TERM><TERM><![CDATA[Tissues]]></TERM><TERM><![CDATA[Toxin]]></TERM><TERM><![CDATA[Transgenes]]></TERM><TERM><![CDATA[ubiquitin-protein ligase]]></TERM><TERM><![CDATA[Weight Gain]]></TERM><TERM><![CDATA[Zona Pellucida]]></TERM><TERM><![CDATA[zona pellucida glycoprotein]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Zona Pellucida: Immunopathologic Study]]></PROJECT_TITLE><SERIAL_NUMBER>041236</SERIAL_NUMBER><STUDY_SECTION>HAI</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Hypersensitivity, Autoimmune, and Immune-mediated Diseases Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>22</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>250000</DIRECT_COST_AMT><INDIRECT_COST_AMT>145000</INDIRECT_COST_AMT><TOTAL_COST>395000</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8959615</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>AI</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/22/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>855</CFDA_CODE><CORE_PROJECT_NUM>R01AI095753</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-11-260</FOA_NUMBER><FULL_PROJECT_NUM>5R01AI095753-03</FULL_PROJECT_NUM><FUNDING_ICs>NIAID:387500\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>GALVESTON</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[PATHOLOGY]]></ORG_DEPT><ORG_DISTRICT>14</ORG_DISTRICT><ORG_DUNS>800771149</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIVERSITY OF TEXAS MEDICAL BR GALVESTON]]></ORG_NAME><ORG_STATE>TX</ORG_STATE><ORG_ZIPCODE>775555302</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: This project investigates the under-researched area of viral diversity and how it influences the evolution and ecology of arboviruses. Specifically I intend to study the level of diversity and the factors that influence this diversity during experimental infections of Venezuelan equine encephalitis virus in the mosquito vectors and the vertebrate host, and also during a transmission cycle. This will enable better models of the emergence, evolution and persistence in the environment of other important public health arboviruses such as West Nile virus and Chikungunya virus.]]></PHR><PIS><PI><PI_NAME>FORRESTER, NAOMI LYNNE</PI_NAME><PI_ID>9770353</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>REPIK, PATRICIA M.</PROGRAM_OFFICER_NAME><PROJECT_START>11/18/2013</PROJECT_START><PROJECT_END>10/31/2018</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Aedes (genus)]]></TERM><TERM><![CDATA[Arboviruses]]></TERM><TERM><![CDATA[Area]]></TERM><TERM><![CDATA[Arthropod Vectors]]></TERM><TERM><![CDATA[Attenuated]]></TERM><TERM><![CDATA[Bacteria]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[chikungunya]]></TERM><TERM><![CDATA[Chikungunya virus]]></TERM><TERM><![CDATA[Communicable Diseases]]></TERM><TERM><![CDATA[Complex]]></TERM><TERM><![CDATA[Culex (Genus)]]></TERM><TERM><![CDATA[Culicidae]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Dengue]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Disease Outbreaks]]></TERM><TERM><![CDATA[Ecology]]></TERM><TERM><![CDATA[Engineering]]></TERM><TERM><![CDATA[Environment]]></TERM><TERM><![CDATA[enzootic]]></TERM><TERM><![CDATA[Epidemic]]></TERM><TERM><![CDATA[Event]]></TERM><TERM><![CDATA[Evolution]]></TERM><TERM><![CDATA[Exhibits]]></TERM><TERM><![CDATA[experience]]></TERM><TERM><![CDATA[Extinction (Psychology)]]></TERM><TERM><![CDATA[fitness]]></TERM><TERM><![CDATA[Frequencies (time pattern)]]></TERM><TERM><![CDATA[Genetic Drift]]></TERM><TERM><![CDATA[genetic manipulation]]></TERM><TERM><![CDATA[Genome]]></TERM><TERM><![CDATA[Geographic Locations]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[human morbidity]]></TERM><TERM><![CDATA[human mortality]]></TERM><TERM><![CDATA[Incidence]]></TERM><TERM><![CDATA[Infection]]></TERM><TERM><![CDATA[Insect Viruses]]></TERM><TERM><![CDATA[interest]]></TERM><TERM><![CDATA[Laboratories]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[Licensing]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[Mexico]]></TERM><TERM><![CDATA[Midgut]]></TERM><TERM><![CDATA[Minority]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Mutate]]></TERM><TERM><![CDATA[Mutation]]></TERM><TERM><![CDATA[Natural regeneration]]></TERM><TERM><![CDATA[Natural Selections]]></TERM><TERM><![CDATA[next generation sequencing]]></TERM><TERM><![CDATA[particle]]></TERM><TERM><![CDATA[pathogen]]></TERM><TERM><![CDATA[Polymerase]]></TERM><TERM><![CDATA[Population]]></TERM><TERM><![CDATA[Population Genetics]]></TERM><TERM><![CDATA[Protocols documentation]]></TERM><TERM><![CDATA[public health medicine (field)]]></TERM><TERM><![CDATA[Recording of previous events]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Research Proposals]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[RNA Viruses]]></TERM><TERM><![CDATA[Rodent]]></TERM><TERM><![CDATA[Salivary Glands]]></TERM><TERM><![CDATA[Sampling]]></TERM><TERM><![CDATA[Selection (Genetics)]]></TERM><TERM><![CDATA[Severities]]></TERM><TERM><![CDATA[Technology]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Ticks]]></TERM><TERM><![CDATA[Translating]]></TERM><TERM><![CDATA[transmission process]]></TERM><TERM><![CDATA[Vaccines]]></TERM><TERM><![CDATA[Variant]]></TERM><TERM><![CDATA[Variation (Genetics)]]></TERM><TERM><![CDATA[vector]]></TERM><TERM><![CDATA[vector mosquito]]></TERM><TERM><![CDATA[Venezuelan Equine Encephalitis Virus]]></TERM><TERM><![CDATA[Viral]]></TERM><TERM><![CDATA[viral RNA]]></TERM><TERM><![CDATA[Virus]]></TERM><TERM><![CDATA[West Nile virus]]></TERM><TERM><![CDATA[Wolbachia]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Effects of Arboviral Population Diversity on Transmission]]></PROJECT_TITLE><SERIAL_NUMBER>095753</SERIAL_NUMBER><STUDY_SECTION>VB</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Vector Biology Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>03</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>250000</DIRECT_COST_AMT><INDIRECT_COST_AMT>137500</INDIRECT_COST_AMT><TOTAL_COST>387500</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8959616</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>AI</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/27/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>855</CFDA_CODE><CORE_PROJECT_NUM>R01AI109008</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF PHARMACY]]></ED_INST_TYPE><FOA_NUMBER>PA-11-260</FOA_NUMBER><FULL_PROJECT_NUM>5R01AI109008-04</FULL_PROJECT_NUM><FUNDING_ICs>NIAID:308078\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>ATHENS</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[PHARMACOLOGY]]></ORG_DEPT><ORG_DISTRICT>10</ORG_DISTRICT><ORG_DUNS>004315578</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIVERSITY OF GEORGIA]]></ORG_NAME><ORG_STATE>GA</ORG_STATE><ORG_ZIPCODE>306021589</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Crimean-Congo hemorrhagic fever (CCHF), Thunderclap headaches, Hazara hemorrhagic fever, and Nairobi sheep disease, are dangerous emerging human and animal diseases that can potentially cause widespread health and economic devastation. The causative agents for these diseases are different forms of nairoviruses. Recently, nairoviruses have been suggested to share a conserved evasion mechanism that hinders the human innate immune response. This proposal serves to evaluate that mechanism's influence on virulence amongst diverse nairoviruses with an emphasis on the CCHF virus through synergetic in vitro, in cellulo and in vivo means. In doing so, this proposal will provide information on the practicality of developing selective and broad-based anti-viral treatments.]]></PHR><PIS><PI><PI_NAME>PEGAN, SCOTT DUSAN</PI_NAME><PI_ID>7796285</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>REPIK, PATRICIA M.</PROGRAM_OFFICER_NAME><PROJECT_START>11/20/2013</PROJECT_START><PROJECT_END>10/31/2018</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Affinity]]></TERM><TERM><![CDATA[Africa]]></TERM><TERM><![CDATA[Animal Diseases]]></TERM><TERM><![CDATA[Animals]]></TERM><TERM><![CDATA[Antiviral Agents]]></TERM><TERM><![CDATA[Antiviral Response]]></TERM><TERM><![CDATA[Asia]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Binding (Molecular Function)]]></TERM><TERM><![CDATA[Biochemical]]></TERM><TERM><![CDATA[Bunyaviridae]]></TERM><TERM><![CDATA[Central Asia]]></TERM><TERM><![CDATA[Cleaved cell]]></TERM><TERM><![CDATA[Congo]]></TERM><TERM><![CDATA[Crimean Hemorrhagic Fever]]></TERM><TERM><![CDATA[Crimean-Congo Hemorrhagic Fever Virus]]></TERM><TERM><![CDATA[cytokine]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Disease Outcome]]></TERM><TERM><![CDATA[Distress]]></TERM><TERM><![CDATA[Down-Regulation]]></TERM><TERM><![CDATA[Economics]]></TERM><TERM><![CDATA[Elements]]></TERM><TERM><![CDATA[Endogenous Retroviruses]]></TERM><TERM><![CDATA[Engineering]]></TERM><TERM><![CDATA[Europe]]></TERM><TERM><![CDATA[Family]]></TERM><TERM><![CDATA[Far East]]></TERM><TERM><![CDATA[FDA approved]]></TERM><TERM><![CDATA[Fever]]></TERM><TERM><![CDATA[Genes]]></TERM><TERM><![CDATA[Genome]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[health economics]]></TERM><TERM><![CDATA[Hemorrhage]]></TERM><TERM><![CDATA[Homologous Gene]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[human disease]]></TERM><TERM><![CDATA[Human Ubiquitin]]></TERM><TERM><![CDATA[Immune response]]></TERM><TERM><![CDATA[Immune system]]></TERM><TERM><![CDATA[In Vitro]]></TERM><TERM><![CDATA[in vitro activity]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[Inflammatory]]></TERM><TERM><![CDATA[insight]]></TERM><TERM><![CDATA[Interferon Suppression]]></TERM><TERM><![CDATA[Interferons]]></TERM><TERM><![CDATA[Measures]]></TERM><TERM><![CDATA[Middle East]]></TERM><TERM><![CDATA[Mono-S]]></TERM><TERM><![CDATA[Mortality Vital Statistics]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[Nairobi Sheep Disease]]></TERM><TERM><![CDATA[Nairobi sheep disease virus]]></TERM><TERM><![CDATA[Nairovirus]]></TERM><TERM><![CDATA[Natural Immunity]]></TERM><TERM><![CDATA[ovarian neoplasm]]></TERM><TERM><![CDATA[particle]]></TERM><TERM><![CDATA[Peptide Hydrolases]]></TERM><TERM><![CDATA[Phylogenetic Analysis]]></TERM><TERM><![CDATA[Play]]></TERM><TERM><![CDATA[Polyubiquitin]]></TERM><TERM><![CDATA[Post-Translational Protein Processing]]></TERM><TERM><![CDATA[prophylactic]]></TERM><TERM><![CDATA[prostration]]></TERM><TERM><![CDATA[Protease Domain]]></TERM><TERM><![CDATA[Proteins]]></TERM><TERM><![CDATA[Recombinants]]></TERM><TERM><![CDATA[Relative (related person)]]></TERM><TERM><![CDATA[Reporting]]></TERM><TERM><![CDATA[research study]]></TERM><TERM><![CDATA[Risk]]></TERM><TERM><![CDATA[RNA]]></TERM><TERM><![CDATA[RNA-Directed RNA Polymerase]]></TERM><TERM><![CDATA[Roentgen Rays]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Route]]></TERM><TERM><![CDATA[Russia]]></TERM><TERM><![CDATA[Severities]]></TERM><TERM><![CDATA[Specificity]]></TERM><TERM><![CDATA[Structure]]></TERM><TERM><![CDATA[Substrate Specificity]]></TERM><TERM><![CDATA[System]]></TERM><TERM><![CDATA[Therapeutic]]></TERM><TERM><![CDATA[Thunderclap Headaches]]></TERM><TERM><![CDATA[Ticks]]></TERM><TERM><![CDATA[trafficking]]></TERM><TERM><![CDATA[transmission process]]></TERM><TERM><![CDATA[Ubiquitin]]></TERM><TERM><![CDATA[Ubiquitination]]></TERM><TERM><![CDATA[United States]]></TERM><TERM><![CDATA[Vaccines]]></TERM><TERM><![CDATA[Variant]]></TERM><TERM><![CDATA[vector]]></TERM><TERM><![CDATA[Viral]]></TERM><TERM><![CDATA[Viral Hemorrhagic Fevers]]></TERM><TERM><![CDATA[Virulence]]></TERM><TERM><![CDATA[Virulence Factors]]></TERM><TERM><![CDATA[Virus]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Origin of the innate immunity suppression caused by nairovirus' protease activity]]></PROJECT_TITLE><SERIAL_NUMBER>109008</SERIAL_NUMBER><STUDY_SECTION>VIRB</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Virology - B Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>04</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>243149</DIRECT_COST_AMT><INDIRECT_COST_AMT>64929</INDIRECT_COST_AMT><TOTAL_COST>308078</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8960332</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>AI</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/28/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>855</CFDA_CODE><CORE_PROJECT_NUM>R01AI105114</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-11-260</FOA_NUMBER><FULL_PROJECT_NUM>5R01AI105114-03</FULL_PROJECT_NUM><FUNDING_ICs>NIAID:463541\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>STONY BROOK</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[GENETICS]]></ORG_DEPT><ORG_DISTRICT>01</ORG_DISTRICT><ORG_DUNS>804878247</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[STATE UNIVERSITY NEW YORK STONY BROOK]]></ORG_NAME><ORG_STATE>NY</ORG_STATE><ORG_ZIPCODE>117940001</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Infectious disease remains a leading cause of morbidity and mortality worldwide. The proposed research is relevant to the mission of NIH, notably NIAID, NHLBI, and NIGMS, because it will provide fundamental knowledge of a critical component of innate immunity to combat pathogenic effects of disease, particularly chronic herpesvirus infection, and will open a new avenue of research by potentially providing new targets of intervention.]]></PHR><PIS><PI><PI_NAME>REICH, NANCY C.</PI_NAME><PI_ID>1901937</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>SINGLETON, KENTNER L</PROGRAM_OFFICER_NAME><PROJECT_START>11/15/2013</PROJECT_START><PROJECT_END>10/31/2018</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Achievement]]></TERM><TERM><![CDATA[Animal Model]]></TERM><TERM><![CDATA[Antiviral Agents]]></TERM><TERM><![CDATA[Apoptosis]]></TERM><TERM><![CDATA[Apoptotic]]></TERM><TERM><![CDATA[Autoimmunity]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[BCL2 gene]]></TERM><TERM><![CDATA[Binding (Molecular Function)]]></TERM><TERM><![CDATA[Biological]]></TERM><TERM><![CDATA[Biological Models]]></TERM><TERM><![CDATA[Bone Marrow]]></TERM><TERM><![CDATA[cancer cell]]></TERM><TERM><![CDATA[Carcinoma]]></TERM><TERM><![CDATA[Cell Nucleus]]></TERM><TERM><![CDATA[Cell Surface Receptors]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Chimera organism]]></TERM><TERM><![CDATA[Chronic]]></TERM><TERM><![CDATA[combat]]></TERM><TERM><![CDATA[Communicable Diseases]]></TERM><TERM><![CDATA[Complex]]></TERM><TERM><![CDATA[cytokine]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Disease model]]></TERM><TERM><![CDATA[Evaluation]]></TERM><TERM><![CDATA[Family]]></TERM><TERM><![CDATA[gene function]]></TERM><TERM><![CDATA[Genes]]></TERM><TERM><![CDATA[Genetic]]></TERM><TERM><![CDATA[Genetic Transcription]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Hematopoietic]]></TERM><TERM><![CDATA[Herpesviridae]]></TERM><TERM><![CDATA[Herpesviridae Infections]]></TERM><TERM><![CDATA[Homologous Gene]]></TERM><TERM><![CDATA[Host Defense]]></TERM><TERM><![CDATA[Host Defense Mechanism]]></TERM><TERM><![CDATA[Human Herpesvirus 4]]></TERM><TERM><![CDATA[human herpesvirus 8]]></TERM><TERM><![CDATA[Immune]]></TERM><TERM><![CDATA[Immune response]]></TERM><TERM><![CDATA[Immune system]]></TERM><TERM><![CDATA[immunosuppressed]]></TERM><TERM><![CDATA[In Vitro]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[in vivo Model]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[Infection]]></TERM><TERM><![CDATA[insight]]></TERM><TERM><![CDATA[Interferons]]></TERM><TERM><![CDATA[Intervention]]></TERM><TERM><![CDATA[Knock-out]]></TERM><TERM><![CDATA[Knockout Mice]]></TERM><TERM><![CDATA[Knowledge]]></TERM><TERM><![CDATA[latent infection]]></TERM><TERM><![CDATA[Life]]></TERM><TERM><![CDATA[Lymphoma]]></TERM><TERM><![CDATA[Lymphoproliferative Disorders]]></TERM><TERM><![CDATA[Mediator of activation protein]]></TERM><TERM><![CDATA[Methods]]></TERM><TERM><![CDATA[microbial]]></TERM><TERM><![CDATA[Mission]]></TERM><TERM><![CDATA[Mitochondria]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[Morbidity - disease rate]]></TERM><TERM><![CDATA[Mortality Vital Statistics]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[National Heart, Lung, and Blood Institute]]></TERM><TERM><![CDATA[National Institute of Allergy and Infectious Disease]]></TERM><TERM><![CDATA[National Institute of General Medical Sciences]]></TERM><TERM><![CDATA[Natural Immunity]]></TERM><TERM><![CDATA[novel therapeutics]]></TERM><TERM><![CDATA[Outcome]]></TERM><TERM><![CDATA[pathogen]]></TERM><TERM><![CDATA[Pathogenesis]]></TERM><TERM><![CDATA[Phenotype]]></TERM><TERM><![CDATA[Predisposition]]></TERM><TERM><![CDATA[Production]]></TERM><TERM><![CDATA[protective effect]]></TERM><TERM><![CDATA[Protein Binding]]></TERM><TERM><![CDATA[Proteins]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Research Design]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[sarcoma]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[System]]></TERM><TERM><![CDATA[Therapeutic]]></TERM><TERM><![CDATA[therapeutic development]]></TERM><TERM><![CDATA[Therapeutic Intervention]]></TERM><TERM><![CDATA[tissue culture]]></TERM><TERM><![CDATA[Transgenes]]></TERM><TERM><![CDATA[Tropism]]></TERM><TERM><![CDATA[tumorigenesis]]></TERM><TERM><![CDATA[United States National Institutes of Health]]></TERM><TERM><![CDATA[Viral]]></TERM><TERM><![CDATA[Viral Genome]]></TERM><TERM><![CDATA[Virus]]></TERM><TERM><![CDATA[Virus Diseases]]></TERM><TERM><![CDATA[virus host interaction]]></TERM><TERM><![CDATA[Virus Latency]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Viral Interface with an Interferon-Induced Gene]]></PROJECT_TITLE><SERIAL_NUMBER>105114</SERIAL_NUMBER><STUDY_SECTION>VIRB</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Virology - B Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>03</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>294918</DIRECT_COST_AMT><INDIRECT_COST_AMT>168623</INDIRECT_COST_AMT><TOTAL_COST>463541</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8960338</APPLICATION_ID><ACTIVITY>R21</ACTIVITY><ADMINISTERING_IC>AI</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/27/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>855</CFDA_CODE><CORE_PROJECT_NUM>R21AI110895</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF ARTS AND SCIENCES]]></ED_INST_TYPE><FOA_NUMBER>PA-13-303</FOA_NUMBER><FULL_PROJECT_NUM>5R21AI110895-02</FULL_PROJECT_NUM><FUNDING_ICs>NIAID:227241\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>BOULDER</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[BIOCHEMISTRY]]></ORG_DEPT><ORG_DISTRICT>02</ORG_DISTRICT><ORG_DUNS>007431505</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIVERSITY OF COLORADO]]></ORG_NAME><ORG_STATE>CO</ORG_STATE><ORG_ZIPCODE>803031058</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE:  As a first step in infection polyomaviruses bind specific cell surface gangliosides, which signal the activation of genes important for virus replication. These signals represent potentially important anti-viral targets, which could be significant for the treatment of human BKV and JCV infections in immunocompromised individuals. Targets also may be identified whose therapeutic potential extends beyond the polyomaviruses to the many other viruses that use gangliosides and glycoproteins as attachment proteins.]]></PHR><PIS><PI><PI_NAME>GARCEA, ROBERT L</PI_NAME><PI_ID>1881471</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>PARK, EUN-CHUNG </PROGRAM_OFFICER_NAME><PROJECT_START>11/01/2014</PROJECT_START><PROJECT_END>10/31/2016</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[Antibodies]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Binding (Molecular Function)]]></TERM><TERM><![CDATA[Binding Sites]]></TERM><TERM><![CDATA[Biological Assay]]></TERM><TERM><![CDATA[c-myc Genes]]></TERM><TERM><![CDATA[Capsid]]></TERM><TERM><![CDATA[Capsid Proteins]]></TERM><TERM><![CDATA[Cell membrane]]></TERM><TERM><![CDATA[Cell Nucleus]]></TERM><TERM><![CDATA[Cell surface]]></TERM><TERM><![CDATA[Cell Surface Receptors]]></TERM><TERM><![CDATA[Cell-Matrix Junction]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Coupled]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Dimerization]]></TERM><TERM><![CDATA[DNA Viruses]]></TERM><TERM><![CDATA[Dose]]></TERM><TERM><![CDATA[Embryo]]></TERM><TERM><![CDATA[Endocytosis]]></TERM><TERM><![CDATA[Epidermal Growth Factor Receptor]]></TERM><TERM><![CDATA[ERG gene]]></TERM><TERM><![CDATA[Event]]></TERM><TERM><![CDATA[Fibroblasts]]></TERM><TERM><![CDATA[FOS gene]]></TERM><TERM><![CDATA[ganglioside receptor]]></TERM><TERM><![CDATA[Gangliosides]]></TERM><TERM><![CDATA[Gene Activation]]></TERM><TERM><![CDATA[gene induction]]></TERM><TERM><![CDATA[Generations]]></TERM><TERM><![CDATA[Genes]]></TERM><TERM><![CDATA[Genetic Transcription]]></TERM><TERM><![CDATA[Genistein]]></TERM><TERM><![CDATA[genome-wide analysis]]></TERM><TERM><![CDATA[Glycolipids]]></TERM><TERM><![CDATA[Glycoproteins]]></TERM><TERM><![CDATA[Glycosphingolipids]]></TERM><TERM><![CDATA[Growth Factor Receptors]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[Immunocompromised Host]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[Infection]]></TERM><TERM><![CDATA[inhibitor/antagonist]]></TERM><TERM><![CDATA[Insulin Receptor]]></TERM><TERM><![CDATA[Integrin Binding]]></TERM><TERM><![CDATA[Integrins]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[Life Cycle Stages]]></TERM><TERM><![CDATA[Ligands]]></TERM><TERM><![CDATA[Lipids]]></TERM><TERM><![CDATA[Measures]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[Membrane Microdomains]]></TERM><TERM><![CDATA[Messenger RNA]]></TERM><TERM><![CDATA[Modification]]></TERM><TERM><![CDATA[mouse polyomavirus]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[Mutate]]></TERM><TERM><![CDATA[Mutation]]></TERM><TERM><![CDATA[PDGFRB gene]]></TERM><TERM><![CDATA[Phosphotransferases]]></TERM><TERM><![CDATA[Play]]></TERM><TERM><![CDATA[Polyomavirus]]></TERM><TERM><![CDATA[Polyomavirus Infections]]></TERM><TERM><![CDATA[Polysaccharides]]></TERM><TERM><![CDATA[Protein Binding]]></TERM><TERM><![CDATA[Proteins]]></TERM><TERM><![CDATA[Reagent]]></TERM><TERM><![CDATA[receptor]]></TERM><TERM><![CDATA[Receptor Inhibition]]></TERM><TERM><![CDATA[Receptor Signaling]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[screening]]></TERM><TERM><![CDATA[Serum]]></TERM><TERM><![CDATA[Sialic Acids]]></TERM><TERM><![CDATA[Signal Pathway]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[Signal Transduction Pathway]]></TERM><TERM><![CDATA[Simian virus 40]]></TERM><TERM><![CDATA[small molecule]]></TERM><TERM><![CDATA[Specificity]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Therapeutic]]></TERM><TERM><![CDATA[transcriptome sequencing]]></TERM><TERM><![CDATA[Tyrosine Kinase Inhibitor]]></TERM><TERM><![CDATA[Viral]]></TERM><TERM><![CDATA[Viral Genome]]></TERM><TERM><![CDATA[Viral Pathogenesis]]></TERM><TERM><![CDATA[Virus]]></TERM><TERM><![CDATA[Virus Replication]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Transcriptional Responses Induced by Polyomavirus Attachment and Entry]]></PROJECT_TITLE><SERIAL_NUMBER>110895</SERIAL_NUMBER><STUDY_SECTION>VIRA</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Virology - A Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>150000</DIRECT_COST_AMT><INDIRECT_COST_AMT>77241</INDIRECT_COST_AMT><TOTAL_COST>227241</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8960923</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>AI</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/04/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>855</CFDA_CODE><CORE_PROJECT_NUM>R01AI108441</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF PUBLIC HEALTH]]></ED_INST_TYPE><FOA_NUMBER>PA-13-302</FOA_NUMBER><FULL_PROJECT_NUM>5R01AI108441-02</FULL_PROJECT_NUM><FUNDING_ICs>NIAID:708750\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>PROVIDENCE</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[BIOSTATISTICS & OTHER MATH SCI]]></ORG_DEPT><ORG_DISTRICT>01</ORG_DISTRICT><ORG_DUNS>001785542</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[BROWN UNIVERSITY]]></ORG_NAME><ORG_STATE>RI</ORG_STATE><ORG_ZIPCODE>029129002</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Effective use of antiretroviral therapy is critical for managing and preventing the spread of HIV in the developing world. This proposal develops methods that make optimal use of diagnostic tests having limited availability to monitor the effectiveness of therapy and to prompt a change in regimen when it is warranted. Successful implementation will improve patient outcomes and help to prevent the spread of treatment-resistant strains of HIV.]]></PHR><PIS><PI><PI_NAME>HOGAN, JOSEPH W (contact)</PI_NAME><PI_ID>1881384 (contact)</PI_ID></PI><PI><PI_NAME>KANTOR, RAMI </PI_NAME><PI_ID>8826783</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>GEZMU, MISRAK </PROGRAM_OFFICER_NAME><PROJECT_START>11/15/2014</PROJECT_START><PROJECT_END>10/31/2019</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Algorithms]]></TERM><TERM><![CDATA[Anti-Retroviral Agents]]></TERM><TERM><![CDATA[antiretroviral therapy]]></TERM><TERM><![CDATA[Archives]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Biological Assay]]></TERM><TERM><![CDATA[Calibration]]></TERM><TERM><![CDATA[Canada]]></TERM><TERM><![CDATA[Caring]]></TERM><TERM><![CDATA[Cations]]></TERM><TERM><![CDATA[Characteristics]]></TERM><TERM><![CDATA[Cities]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[Clinical Markers]]></TERM><TERM><![CDATA[clinically relevant]]></TERM><TERM><![CDATA[cohort]]></TERM><TERM><![CDATA[Computer software]]></TERM><TERM><![CDATA[cost]]></TERM><TERM><![CDATA[Cost Savings]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[Diagnosis]]></TERM><TERM><![CDATA[Diagnostic]]></TERM><TERM><![CDATA[Diagnostic tests]]></TERM><TERM><![CDATA[Drug resistance]]></TERM><TERM><![CDATA[Early Diagnosis]]></TERM><TERM><![CDATA[effective therapy]]></TERM><TERM><![CDATA[Effectiveness]]></TERM><TERM><![CDATA[Europe]]></TERM><TERM><![CDATA[Failure (biologic function)]]></TERM><TERM><![CDATA[Funding]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Gold]]></TERM><TERM><![CDATA[Guidelines]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Health Services Accessibility]]></TERM><TERM><![CDATA[HIV]]></TERM><TERM><![CDATA[HIV therapy]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[Kenya]]></TERM><TERM><![CDATA[Laboratories]]></TERM><TERM><![CDATA[Machine Learning]]></TERM><TERM><![CDATA[Methods]]></TERM><TERM><![CDATA[Modality]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Monitor]]></TERM><TERM><![CDATA[Morbidity - disease rate]]></TERM><TERM><![CDATA[Mortality Vital Statistics]]></TERM><TERM><![CDATA[Motivation]]></TERM><TERM><![CDATA[novel diagnostics]]></TERM><TERM><![CDATA[Outcome]]></TERM><TERM><![CDATA[Patient Care]]></TERM><TERM><![CDATA[patient population]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Plasma]]></TERM><TERM><![CDATA[Population]]></TERM><TERM><![CDATA[prevent]]></TERM><TERM><![CDATA[Prevention therapy]]></TERM><TERM><![CDATA[Primary Health Care]]></TERM><TERM><![CDATA[programs]]></TERM><TERM><![CDATA[Property]]></TERM><TERM><![CDATA[Protocols documentation]]></TERM><TERM><![CDATA[Provider]]></TERM><TERM><![CDATA[Regimen]]></TERM><TERM><![CDATA[Research Infrastructure]]></TERM><TERM><![CDATA[resistant strain]]></TERM><TERM><![CDATA[Resources]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[Risk]]></TERM><TERM><![CDATA[Sampling]]></TERM><TERM><![CDATA[Schedule]]></TERM><TERM><![CDATA[Side]]></TERM><TERM><![CDATA[simulation]]></TERM><TERM><![CDATA[software development]]></TERM><TERM><![CDATA[standard care]]></TERM><TERM><![CDATA[Statistical Methods]]></TERM><TERM><![CDATA[Techniques]]></TERM><TERM><![CDATA[Technology]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[theories]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[Treatment Failure]]></TERM><TERM><![CDATA[treatment program]]></TERM><TERM><![CDATA[Viral]]></TERM><TERM><![CDATA[Viral Load result]]></TERM><TERM><![CDATA[World Health Organization]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Optimizing HIV Treatment Monitoring under Resource Constraints]]></PROJECT_TITLE><SERIAL_NUMBER>108441</SERIAL_NUMBER><STUDY_SECTION>ZRG1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>581467</DIRECT_COST_AMT><INDIRECT_COST_AMT>127283</INDIRECT_COST_AMT><TOTAL_COST>708750</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8960938</APPLICATION_ID><ACTIVITY>P01</ACTIVITY><ADMINISTERING_IC>HL</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/26/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>P01HL029582</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>PAR-13-316</FOA_NUMBER><FULL_PROJECT_NUM>5P01HL029582-32</FULL_PROJECT_NUM><FUNDING_ICs>NHLBI:124972\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL HEART, LUNG, AND BLOOD INSTITUTE</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>CLEVELAND</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>11</ORG_DISTRICT><ORG_DUNS>135781701</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[CLEVELAND CLINIC LERNER COM-CWRU]]></ORG_NAME><ORG_STATE>OH</ORG_STATE><ORG_ZIPCODE>441950001</ORG_ZIPCODE><PHR><![CDATA[Primary Cell and Mouse Metabolism Core (Core B). Project Narrative
The Core will facilitate primary cell-based experiments, including isolation and culturing of primary cells; co-
culture model to enable ex vivo study of crosstalk between cell types, and evaluate cell metabolism. Another
purpose of the Core is to provide technical assistance to in vivo studies of the obesity-associated inflammatory
disease model. The Core will offer consultation for setting up the high-fat diet (HFD) induced obesity model;
perform glucose and insulin tolerance tests; provide technical assistance in sample preparation and analyses
from experimental mice.]]></PHR><PIS><PI><PI_NAME>LI, XIAOXIA </PI_NAME><PI_ID>7919432</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START></PROJECT_START><PROJECT_END></PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[abstracting]]></TERM><TERM><![CDATA[Atherosclerosis]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Cell Culture System]]></TERM><TERM><![CDATA[cell type]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Coculture Techniques]]></TERM><TERM><![CDATA[Collaborations]]></TERM><TERM><![CDATA[Consultations]]></TERM><TERM><![CDATA[cost]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[data acquisition]]></TERM><TERM><![CDATA[Diet]]></TERM><TERM><![CDATA[Disease model]]></TERM><TERM><![CDATA[Doctor of Philosophy]]></TERM><TERM><![CDATA[experience]]></TERM><TERM><![CDATA[Fatty acid glycerol esters]]></TERM><TERM><![CDATA[Genus Hippocampus]]></TERM><TERM><![CDATA[glucose tolerance]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[Inflammation]]></TERM><TERM><![CDATA[Inflammatory]]></TERM><TERM><![CDATA[insulin tolerance]]></TERM><TERM><![CDATA[Laboratories]]></TERM><TERM><![CDATA[Link]]></TERM><TERM><![CDATA[Metabolic]]></TERM><TERM><![CDATA[Metabolism]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[Obesity]]></TERM><TERM><![CDATA[Phenotype]]></TERM><TERM><![CDATA[Preparation]]></TERM><TERM><![CDATA[Primary Cell Cultures]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[research study]]></TERM><TERM><![CDATA[Sampling]]></TERM><TERM><![CDATA[Services]]></TERM><TERM><![CDATA[Standardization]]></TERM><TERM><![CDATA[Techniques]]></TERM><TERM><![CDATA[Testing]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Primary Cell and Mouse Metabolism Core B]]></PROJECT_TITLE><SERIAL_NUMBER>029582</SERIAL_NUMBER><STUDY_SECTION>ZHL1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID>7862</SUBPROJECT_ID><SUPPORT_YEAR>32</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>78847</DIRECT_COST_AMT><INDIRECT_COST_AMT>46125</INDIRECT_COST_AMT><TOTAL_COST /><TOTAL_COST_SUB_PROJECT>124972</TOTAL_COST_SUB_PROJECT></row>
<row><APPLICATION_ID>8962169</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>HL</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/26/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>837</CFDA_CODE><CORE_PROJECT_NUM>R01HL125838</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-13-302</FOA_NUMBER><FULL_PROJECT_NUM>5R01HL125838-02</FULL_PROJECT_NUM><FUNDING_ICs>NHLBI:375531\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL HEART, LUNG, AND BLOOD INSTITUTE</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>SAINT LOUIS</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[INTERNAL MEDICINE/MEDICINE]]></ORG_DEPT><ORG_DISTRICT>01</ORG_DISTRICT><ORG_DUNS>068552207</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[WASHINGTON UNIVERSITY]]></ORG_NAME><ORG_STATE>MO</ORG_STATE><ORG_ZIPCODE>631304862</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE:  Progressive plaque formation, or atherosclerosis, is the pathogenic mediator of the vast majority of cardiovascular diseases and is primarily caused by an inability of the vascular system to handle increased circulating lipid. Macrophages are cells that specialize in removing the excess lipids and other debris present in the plaque. We have found that macrophages have the ability to augment their degradation machinery and propose to study the underlying mechanisms with the goal of learning how to reduce the accumulation of toxic materials that cause atherosclerosis.]]></PHR><PIS><PI><PI_NAME>RAZANI, BABAK </PI_NAME><PI_ID>9758106</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>CHEN, JUE </PROGRAM_OFFICER_NAME><PROJECT_START>11/04/2014</PROJECT_START><PROJECT_END>10/31/2019</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[Area]]></TERM><TERM><![CDATA[Arterial Fatty Streak]]></TERM><TERM><![CDATA[atherogenesis]]></TERM><TERM><![CDATA[atheroprotective]]></TERM><TERM><![CDATA[Atherosclerosis]]></TERM><TERM><![CDATA[Autophagocytosis]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Biogenesis]]></TERM><TERM><![CDATA[Cardiovascular Diseases]]></TERM><TERM><![CDATA[Cause of Death]]></TERM><TERM><![CDATA[Cell physiology]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Cholesterol]]></TERM><TERM><![CDATA[Complex]]></TERM><TERM><![CDATA[Coronary Arteriosclerosis]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Deposition]]></TERM><TERM><![CDATA[detection of nutrient]]></TERM><TERM><![CDATA[Digestion]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Environment]]></TERM><TERM><![CDATA[Event]]></TERM><TERM><![CDATA[Exposure to]]></TERM><TERM><![CDATA[Foam Cells]]></TERM><TERM><![CDATA[Functional disorder]]></TERM><TERM><![CDATA[Future]]></TERM><TERM><![CDATA[Genes]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[human FRAP1 protein]]></TERM><TERM><![CDATA[Hyperlipidemia]]></TERM><TERM><![CDATA[Impairment]]></TERM><TERM><![CDATA[In Vitro]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[Infiltration]]></TERM><TERM><![CDATA[Inflammatory]]></TERM><TERM><![CDATA[insight]]></TERM><TERM><![CDATA[interest]]></TERM><TERM><![CDATA[Investigation]]></TERM><TERM><![CDATA[Learning]]></TERM><TERM><![CDATA[Link]]></TERM><TERM><![CDATA[lipid metabolism]]></TERM><TERM><![CDATA[Lipids]]></TERM><TERM><![CDATA[Lipoprotein Receptor]]></TERM><TERM><![CDATA[Lysosomes]]></TERM><TERM><![CDATA[macrophage]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[Mediator of activation protein]]></TERM><TERM><![CDATA[member]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Modification]]></TERM><TERM><![CDATA[Morbidity - disease rate]]></TERM><TERM><![CDATA[Mortality Vital Statistics]]></TERM><TERM><![CDATA[mouse model]]></TERM><TERM><![CDATA[mTOR Inhibitor]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[Myocardial Infarction]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[Nuclear Translocation]]></TERM><TERM><![CDATA[Organelles]]></TERM><TERM><![CDATA[overexpression]]></TERM><TERM><![CDATA[oxidized low density lipoprotein]]></TERM><TERM><![CDATA[Pathogenesis]]></TERM><TERM><![CDATA[Pathway interactions]]></TERM><TERM><![CDATA[Phagocytosis]]></TERM><TERM><![CDATA[Phenotype]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[programs]]></TERM><TERM><![CDATA[Proteins]]></TERM><TERM><![CDATA[receptor mediated endocytosis]]></TERM><TERM><![CDATA[Regulation]]></TERM><TERM><![CDATA[Reporting]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[Risk Factors]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Signal Pathway]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[Sirolimus]]></TERM><TERM><![CDATA[Stress]]></TERM><TERM><![CDATA[stroke]]></TERM><TERM><![CDATA[System]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Therapeutic]]></TERM><TERM><![CDATA[tool]]></TERM><TERM><![CDATA[transcription factor]]></TERM><TERM><![CDATA[treatment strategy]]></TERM><TERM><![CDATA[United States]]></TERM><TERM><![CDATA[uptake]]></TERM><TERM><![CDATA[Vascular System]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[THE ROLE OF MACROPHAGE LYSOSOMAL BIOGENESIS IN ATHEROSCLEROSIS]]></PROJECT_TITLE><SERIAL_NUMBER>125838</SERIAL_NUMBER><STUDY_SECTION>AICS</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Atherosclerosis and Inflammation of the Cardiovascular System Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>246250</DIRECT_COST_AMT><INDIRECT_COST_AMT>129281</INDIRECT_COST_AMT><TOTAL_COST>375531</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8966027</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>HL</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/29/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>837</CFDA_CODE><CORE_PROJECT_NUM>R01HL094414</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>PA-13-302</FOA_NUMBER><FULL_PROJECT_NUM>5R01HL094414-08</FULL_PROJECT_NUM><FUNDING_ICs>NHLBI:382500\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL HEART, LUNG, AND BLOOD INSTITUTE</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>LOS ANGELES</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>28</ORG_DISTRICT><ORG_DUNS>075307785</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[CEDARS-SINAI MEDICAL CENTER]]></ORG_NAME><ORG_STATE>CA</ORG_STATE><ORG_ZIPCODE>900481804</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: The proposed research is relevant to NIH because it will introduce new targets for therapeutic interventions capable of limiting malignant arrhythmias and progression of heart failure in millions of Americans. Sudden cardiac death and heart failure are major syndromes in the United States. A better molecular understanding of how cardiomyocyte are regulated and how, in failing hearts, they progressively lose their electrical and mechanical function is a critical step to developing new medical solutions.]]></PHR><PIS><PI><PI_NAME>SHAW, ROBIN MARK</PI_NAME><PI_ID>1929147</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>LATHROP, DAVID A.</PROGRAM_OFFICER_NAME><PROJECT_START>12/01/2008</PROJECT_START><PROJECT_END>10/31/2018</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Actins]]></TERM><TERM><![CDATA[Action Potentials]]></TERM><TERM><![CDATA[Adult]]></TERM><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[American]]></TERM><TERM><![CDATA[Arrhythmia]]></TERM><TERM><![CDATA[Award]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Biochemical]]></TERM><TERM><![CDATA[Biological Markers]]></TERM><TERM><![CDATA[Biological Phenomena]]></TERM><TERM><![CDATA[Biology]]></TERM><TERM><![CDATA[Calcium]]></TERM><TERM><![CDATA[Cardiac]]></TERM><TERM><![CDATA[Cardiac Myocytes]]></TERM><TERM><![CDATA[Cardiovascular Diseases]]></TERM><TERM><![CDATA[Cause of Death]]></TERM><TERM><![CDATA[Cell Communication]]></TERM><TERM><![CDATA[Cell membrane]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[cellular targeting]]></TERM><TERM><![CDATA[Cessation of life]]></TERM><TERM><![CDATA[Code]]></TERM><TERM><![CDATA[Connexin 43]]></TERM><TERM><![CDATA[Critical Pathways]]></TERM><TERM><![CDATA[Cytoskeleton]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Death, Sudden, Cardiac]]></TERM><TERM><![CDATA[disability]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Endoplasmic Reticulum]]></TERM><TERM><![CDATA[Exons]]></TERM><TERM><![CDATA[experience]]></TERM><TERM><![CDATA[gap junction channel]]></TERM><TERM><![CDATA[Genes]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Golgi Apparatus]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Heart]]></TERM><TERM><![CDATA[Heart Contractilities]]></TERM><TERM><![CDATA[Heart Diseases]]></TERM><TERM><![CDATA[Heart failure]]></TERM><TERM><![CDATA[Hour]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[insight]]></TERM><TERM><![CDATA[Intercalated disc]]></TERM><TERM><![CDATA[interest]]></TERM><TERM><![CDATA[Ion Channel]]></TERM><TERM><![CDATA[Knowledge]]></TERM><TERM><![CDATA[L-Type Calcium Channels]]></TERM><TERM><![CDATA[Laboratories]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[Life Cycle Stages]]></TERM><TERM><![CDATA[Location]]></TERM><TERM><![CDATA[Malignant - descriptor]]></TERM><TERM><![CDATA[Mechanics]]></TERM><TERM><![CDATA[Medical]]></TERM><TERM><![CDATA[Membrane]]></TERM><TERM><![CDATA[Membrane Protein Traffic]]></TERM><TERM><![CDATA[Methods]]></TERM><TERM><![CDATA[Microfluidics]]></TERM><TERM><![CDATA[Microscopy]]></TERM><TERM><![CDATA[Microtubules]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[Morbidity - disease rate]]></TERM><TERM><![CDATA[Mortality Vital Statistics]]></TERM><TERM><![CDATA[Movement]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[Muscle Cells]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[novel diagnostics]]></TERM><TERM><![CDATA[novel therapeutic intervention]]></TERM><TERM><![CDATA[novel therapeutics]]></TERM><TERM><![CDATA[Outcome]]></TERM><TERM><![CDATA[Pathologic]]></TERM><TERM><![CDATA[Pathway interactions]]></TERM><TERM><![CDATA[Pattern]]></TERM><TERM><![CDATA[Phosphorylation]]></TERM><TERM><![CDATA[Phosphorylation Site]]></TERM><TERM><![CDATA[Post-Translational Protein Processing]]></TERM><TERM><![CDATA[Protein Dephosphorylation]]></TERM><TERM><![CDATA[Protein Isoforms]]></TERM><TERM><![CDATA[protein kinase C epsilon]]></TERM><TERM><![CDATA[Proteins]]></TERM><TERM><![CDATA[Proto-Oncogene Proteins c-akt]]></TERM><TERM><![CDATA[Recruitment Activity]]></TERM><TERM><![CDATA[Regulation]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[research study]]></TERM><TERM><![CDATA[Rest]]></TERM><TERM><![CDATA[Scaffolding Protein]]></TERM><TERM><![CDATA[Serine]]></TERM><TERM><![CDATA[Site]]></TERM><TERM><![CDATA[Solutions]]></TERM><TERM><![CDATA[Sorting - Cell Movement]]></TERM><TERM><![CDATA[Specificity]]></TERM><TERM><![CDATA[Stress]]></TERM><TERM><![CDATA[Structure]]></TERM><TERM><![CDATA[Syndrome]]></TERM><TERM><![CDATA[System]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[therapeutic development]]></TERM><TERM><![CDATA[Therapeutic Intervention]]></TERM><TERM><![CDATA[tool]]></TERM><TERM><![CDATA[trafficking]]></TERM><TERM><![CDATA[Translation Initiation]]></TERM><TERM><![CDATA[Translations]]></TERM><TERM><![CDATA[United States]]></TERM><TERM><![CDATA[United States National Institutes of Health]]></TERM><TERM><![CDATA[Ventricular Arrhythmia]]></TERM><TERM><![CDATA[Vesicle]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Novel Mechanisms of Cardiac Ion Channel Regulation]]></PROJECT_TITLE><SERIAL_NUMBER>094414</SERIAL_NUMBER><STUDY_SECTION>ESTA</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Electrical Signaling, Ion Transport, and Arrhythmias Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>08</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>225000</DIRECT_COST_AMT><INDIRECT_COST_AMT>157500</INDIRECT_COST_AMT><TOTAL_COST>382500</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8966692</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>HL</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/30/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>837</CFDA_CODE><CORE_PROJECT_NUM>R01HL093056</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-13-302</FOA_NUMBER><FULL_PROJECT_NUM>5R01HL093056-07</FULL_PROJECT_NUM><FUNDING_ICs>NHLBI:362035\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL HEART, LUNG, AND BLOOD INSTITUTE</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>PORTLAND</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[PHYSIOLOGY]]></ORG_DEPT><ORG_DISTRICT>03</ORG_DISTRICT><ORG_DUNS>096997515</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[OREGON HEALTH & SCIENCE UNIVERSITY]]></ORG_NAME><ORG_STATE>OR</ORG_STATE><ORG_ZIPCODE>972393098</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Coronary heart disease is the leading cause of death in the U.S, and patients have a high risk for cardiac arrhythmias after surviving a myocardial infarction (heart attack). Spatial heterogeneity of sympathetic nerves, including denervation, is a major contributor to post-infarct cardiac arrhythmias. These studies will determine if preventing denervation or restoring nerve regeneration decreases arrhythmia susceptibility. This will have important implications for the treatment of patients after myocardial infarction.]]></PHR><PIS><PI><PI_NAME>HABECKER, BETH A</PI_NAME><PI_ID>1915288</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>LATHROP, DAVID A.</PROGRAM_OFFICER_NAME><PROJECT_START>07/01/2008</PROJECT_START><PROJECT_END>10/31/2018</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Adrenergic Fibers]]></TERM><TERM><![CDATA[American]]></TERM><TERM><![CDATA[Animal Model]]></TERM><TERM><![CDATA[Arrhythmia]]></TERM><TERM><![CDATA[Axon]]></TERM><TERM><![CDATA[axon growth]]></TERM><TERM><![CDATA[axon regeneration]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Brain-Derived Neurotrophic Factor]]></TERM><TERM><![CDATA[Cardiac]]></TERM><TERM><![CDATA[Cardiac Myocytes]]></TERM><TERM><![CDATA[Cause of Death]]></TERM><TERM><![CDATA[Chondroitin Sulfate Proteoglycan]]></TERM><TERM><![CDATA[Cicatrix]]></TERM><TERM><![CDATA[Clinical Trials]]></TERM><TERM><![CDATA[Coronary heart disease]]></TERM><TERM><![CDATA[Coupling]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Death, Sudden, Cardiac]]></TERM><TERM><![CDATA[Denervation]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[electrical property]]></TERM><TERM><![CDATA[Electrocardiogram]]></TERM><TERM><![CDATA[Frequencies (time pattern)]]></TERM><TERM><![CDATA[Genetic]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Heart]]></TERM><TERM><![CDATA[Heterogeneity]]></TERM><TERM><![CDATA[high risk]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[human PTPRT protein]]></TERM><TERM><![CDATA[Infarction]]></TERM><TERM><![CDATA[Intervention]]></TERM><TERM><![CDATA[Left]]></TERM><TERM><![CDATA[Left ventricular structure]]></TERM><TERM><![CDATA[Ligands]]></TERM><TERM><![CDATA[Location]]></TERM><TERM><![CDATA[Maps]]></TERM><TERM><![CDATA[Methods]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[Muscle Cells]]></TERM><TERM><![CDATA[Myocardial Infarction]]></TERM><TERM><![CDATA[Myocardium]]></TERM><TERM><![CDATA[Natural regeneration]]></TERM><TERM><![CDATA[Nerve]]></TERM><TERM><![CDATA[Nerve Growth Factors]]></TERM><TERM><![CDATA[Nerve Regeneration]]></TERM><TERM><![CDATA[nerve supply]]></TERM><TERM><![CDATA[Neurons]]></TERM><TERM><![CDATA[neurotrophic factor]]></TERM><TERM><![CDATA[NGFR Protein]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[Optics]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Phosphoric Monoester Hydrolases]]></TERM><TERM><![CDATA[Predisposition]]></TERM><TERM><![CDATA[prevent]]></TERM><TERM><![CDATA[receptor]]></TERM><TERM><![CDATA[reinnervation]]></TERM><TERM><![CDATA[Resistance]]></TERM><TERM><![CDATA[reuptake]]></TERM><TERM><![CDATA[Risk]]></TERM><TERM><![CDATA[Sympathectomy]]></TERM><TERM><![CDATA[Sympathetic Nerve Block]]></TERM><TERM><![CDATA[Telemetry]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Therapeutic]]></TERM><TERM><![CDATA[therapeutic development]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[tool]]></TERM><TERM><![CDATA[transcriptional coactivator p75]]></TERM><TERM><![CDATA[transmission process]]></TERM><TERM><![CDATA[Ventricular Arrhythmia]]></TERM><TERM><![CDATA[Wild Type Mouse]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Neurotrophins and post-infarct plasticity in cardiac sympathetic neurons]]></PROJECT_TITLE><SERIAL_NUMBER>093056</SERIAL_NUMBER><STUDY_SECTION>CNNT</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Clinical Neuroplasticity and Neurotransmitters Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>07</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>255597</DIRECT_COST_AMT><INDIRECT_COST_AMT>106438</INDIRECT_COST_AMT><TOTAL_COST>362035</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8967222</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>HL</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/30/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>837</CFDA_CODE><CORE_PROJECT_NUM>R01HL121877</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-13-302</FOA_NUMBER><FULL_PROJECT_NUM>5R01HL121877-02</FULL_PROJECT_NUM><FUNDING_ICs>NHLBI:492172\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL HEART, LUNG, AND BLOOD INSTITUTE</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>AURORA</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[INTERNAL MEDICINE/MEDICINE]]></ORG_DEPT><ORG_DISTRICT>06</ORG_DISTRICT><ORG_DUNS>041096314</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIVERSITY OF COLORADO DENVER]]></ORG_NAME><ORG_STATE>CO</ORG_STATE><ORG_ZIPCODE>800452570</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: We demonstrated that a subpopulation of resident vascular progenitor cells (VPCs) that reside in the outer wall of postnatal vessels derive from mature vascular smooth muscle cells that underwent reprogramming to a stem-like phenotype. We will characterize and define the function of these cells and determine the mechanism underlying reprogramming. Our data could have a profound impact on defining the endogenous molecular mechanisms underlying the formation and maintenance of VPCs, which could lead to the potential to activate or repress these cells in situ to improve therapeutic applications.]]></PHR><PIS><PI><PI_NAME>WEISER-EVANS, MARY CM</PI_NAME><PI_ID>1916726</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>OLIVE, MICHELLE </PROGRAM_OFFICER_NAME><PROJECT_START>11/15/2014</PROJECT_START><PROJECT_END>10/31/2018</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Aneurysm]]></TERM><TERM><![CDATA[Animal Genetics]]></TERM><TERM><![CDATA[Arterial Injury]]></TERM><TERM><![CDATA[Atherosclerosis]]></TERM><TERM><![CDATA[Biological]]></TERM><TERM><![CDATA[Biological Assay]]></TERM><TERM><![CDATA[Blood Vessels]]></TERM><TERM><![CDATA[CD34 gene]]></TERM><TERM><![CDATA[cell dedifferentiation]]></TERM><TERM><![CDATA[Cell physiology]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Contractile Proteins]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[deep sequencing]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Exhibits]]></TERM><TERM><![CDATA[Gene Expression Profile]]></TERM><TERM><![CDATA[Genetic]]></TERM><TERM><![CDATA[Genetic Models]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Hematopoietic stem cells]]></TERM><TERM><![CDATA[Heterogeneity]]></TERM><TERM><![CDATA[Homeostasis]]></TERM><TERM><![CDATA[human MYH11 protein]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[In Situ]]></TERM><TERM><![CDATA[In Vitro]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[Inflammatory]]></TERM><TERM><![CDATA[Injury]]></TERM><TERM><![CDATA[innovation]]></TERM><TERM><![CDATA[Label]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[Lesion]]></TERM><TERM><![CDATA[loss of function]]></TERM><TERM><![CDATA[Maintenance]]></TERM><TERM><![CDATA[Maps]]></TERM><TERM><![CDATA[matrigel]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[monocyte]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[Myosin Heavy Chains]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[osteogenic]]></TERM><TERM><![CDATA[overexpression]]></TERM><TERM><![CDATA[Pathway interactions]]></TERM><TERM><![CDATA[Phenotype]]></TERM><TERM><![CDATA[Play]]></TERM><TERM><![CDATA[pluripotency]]></TERM><TERM><![CDATA[Population]]></TERM><TERM><![CDATA[postnatal]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[progenitor]]></TERM><TERM><![CDATA[Property]]></TERM><TERM><![CDATA[Proteins]]></TERM><TERM><![CDATA[PTEN gene]]></TERM><TERM><![CDATA[repaired]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[response to injury]]></TERM><TERM><![CDATA[restenosis]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[Smooth muscle (tissue)]]></TERM><TERM><![CDATA[Smooth Muscle Actin Staining Method]]></TERM><TERM><![CDATA[Smooth Muscle Myocytes]]></TERM><TERM><![CDATA[Smooth Muscle Myosins]]></TERM><TERM><![CDATA[smoothened signaling pathway]]></TERM><TERM><![CDATA[Source]]></TERM><TERM><![CDATA[Staging]]></TERM><TERM><![CDATA[stem]]></TERM><TERM><![CDATA[Stem cells]]></TERM><TERM><![CDATA[subcutaneous]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Therapeutic]]></TERM><TERM><![CDATA[Tissues]]></TERM><TERM><![CDATA[transcription factor]]></TERM><TERM><![CDATA[Tumor Angiogenesis]]></TERM><TERM><![CDATA[Tumor Suppressor Proteins]]></TERM><TERM><![CDATA[Tunica Adventitia]]></TERM><TERM><![CDATA[Wild Type Mouse]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Reprogramming of mature smooth muscle cells to vascular progenitor cells]]></PROJECT_TITLE><SERIAL_NUMBER>121877</SERIAL_NUMBER><STUDY_SECTION>AICS</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Atherosclerosis and Inflammation of the Cardiovascular System Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>357100</DIRECT_COST_AMT><INDIRECT_COST_AMT>135072</INDIRECT_COST_AMT><TOTAL_COST>492172</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8969701</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>HL</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/02/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>837</CFDA_CODE><CORE_PROJECT_NUM>R01HL125736</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-13-302</FOA_NUMBER><FULL_PROJECT_NUM>5R01HL125736-02</FULL_PROJECT_NUM><FUNDING_ICs>NHLBI:673101\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL HEART, LUNG, AND BLOOD INSTITUTE</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>OMAHA</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[SURGERY]]></ORG_DEPT><ORG_DISTRICT>02</ORG_DISTRICT><ORG_DUNS>168559177</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIVERSITY OF NEBRASKA MEDICAL CENTER]]></ORG_NAME><ORG_STATE>NE</ORG_STATE><ORG_ZIPCODE>681987835</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Balloon angioplasty and stenting for peripheral artery disease has the highest rate of failure. We propose to use real human arteries, stents, and computational modeling to help determine the optimal patient and disease-specific stents that produce the best clinical outcomes. This will result in more durable reconstructions for patients with peripheral artery disease and help conserve vital healthcare resources.]]></PHR><PIS><PI><PI_NAME>KAMENSKIY, ALEXEY  (contact)</PI_NAME><PI_ID>11699316 (contact)</PI_ID></PI><PI><PI_NAME>MACTAGGART, JASON </PI_NAME><PI_ID>2104427</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>REID, DIANE M.</PROGRAM_OFFICER_NAME><PROJECT_START>12/01/2014</PROJECT_START><PROJECT_END>10/31/2019</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Age]]></TERM><TERM><![CDATA[age effect]]></TERM><TERM><![CDATA[Anatomy]]></TERM><TERM><![CDATA[Angiography]]></TERM><TERM><![CDATA[Angioplasty]]></TERM><TERM><![CDATA[Area]]></TERM><TERM><![CDATA[Arteries]]></TERM><TERM><![CDATA[Balloon Angioplasty]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Blood flow]]></TERM><TERM><![CDATA[Cadaver]]></TERM><TERM><![CDATA[calcification]]></TERM><TERM><![CDATA[Cardiovascular system]]></TERM><TERM><![CDATA[Carotid Arteries]]></TERM><TERM><![CDATA[Characteristics]]></TERM><TERM><![CDATA[claudication]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[comparative effectiveness]]></TERM><TERM><![CDATA[Computer Simulation]]></TERM><TERM><![CDATA[cost effective]]></TERM><TERM><![CDATA[Custom]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Devices]]></TERM><TERM><![CDATA[Diabetes Mellitus]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Environment]]></TERM><TERM><![CDATA[Failure (biologic function)]]></TERM><TERM><![CDATA[Foundations]]></TERM><TERM><![CDATA[Fracture]]></TERM><TERM><![CDATA[Functional disorder]]></TERM><TERM><![CDATA[Future]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Healthcare]]></TERM><TERM><![CDATA[Heart]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[human tissue]]></TERM><TERM><![CDATA[iliac artery]]></TERM><TERM><![CDATA[Image Analysis]]></TERM><TERM><![CDATA[Incidence]]></TERM><TERM><![CDATA[Injury]]></TERM><TERM><![CDATA[Ischemia]]></TERM><TERM><![CDATA[Knowledge]]></TERM><TERM><![CDATA[Leg]]></TERM><TERM><![CDATA[Length]]></TERM><TERM><![CDATA[Lesion]]></TERM><TERM><![CDATA[Limb structure]]></TERM><TERM><![CDATA[mathematical model]]></TERM><TERM><![CDATA[Measurement]]></TERM><TERM><![CDATA[Mechanical Stress]]></TERM><TERM><![CDATA[Mechanics]]></TERM><TERM><![CDATA[Medicine]]></TERM><TERM><![CDATA[Methods]]></TERM><TERM><![CDATA[Microtomy]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[nanoindentation]]></TERM><TERM><![CDATA[nitinol]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[Outcome]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Peripheral]]></TERM><TERM><![CDATA[Peripheral arterial disease]]></TERM><TERM><![CDATA[personalized medicine]]></TERM><TERM><![CDATA[Positioning Attribute]]></TERM><TERM><![CDATA[Procedures]]></TERM><TERM><![CDATA[Property]]></TERM><TERM><![CDATA[Publishing]]></TERM><TERM><![CDATA[reconstruction]]></TERM><TERM><![CDATA[Recruitment Activity]]></TERM><TERM><![CDATA[renal artery]]></TERM><TERM><![CDATA[repaired]]></TERM><TERM><![CDATA[Resources]]></TERM><TERM><![CDATA[restenosis]]></TERM><TERM><![CDATA[segmentation Image analysis]]></TERM><TERM><![CDATA[Stents]]></TERM><TERM><![CDATA[Stress]]></TERM><TERM><![CDATA[Structure of popliteal artery]]></TERM><TERM><![CDATA[Superficial Femoral Artery]]></TERM><TERM><![CDATA[Techniques]]></TERM><TERM><![CDATA[Temperature]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[Tissue Donors]]></TERM><TERM><![CDATA[Torsion (malposition)]]></TERM><TERM><![CDATA[Translating]]></TERM><TERM><![CDATA[Treatment Failure]]></TERM><TERM><![CDATA[Validation]]></TERM><TERM><![CDATA[X-Ray Computed Tomography]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Optimal Stent Selection for the Femoropopliteal Artery]]></PROJECT_TITLE><SERIAL_NUMBER>125736</SERIAL_NUMBER><STUDY_SECTION>BTSS</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Bioengineering, Technology and Surgical Sciences Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>509298</DIRECT_COST_AMT><INDIRECT_COST_AMT>163803</INDIRECT_COST_AMT><TOTAL_COST>673101</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8970724</APPLICATION_ID><ACTIVITY>R34</ACTIVITY><ADMINISTERING_IC>MH</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/26/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>242</CFDA_CODE><CORE_PROJECT_NUM>R34MH103570</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PAR-12-279</FOA_NUMBER><FULL_PROJECT_NUM>5R34MH103570-02</FULL_PROJECT_NUM><FUNDING_ICs>NIMH:215724\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF MENTAL HEALTH</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>PROVIDENCE</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[PSYCHIATRY]]></ORG_DEPT><ORG_DISTRICT>01</ORG_DISTRICT><ORG_DUNS>001785542</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[BROWN UNIVERSITY]]></ORG_NAME><ORG_STATE>RI</ORG_STATE><ORG_ZIPCODE>029129002</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Pregnant and postpartum women with bipolar disorder are at risk for numerous adverse consequences, both for themselves and their developing infants. Treatment is critical during this time, however many perinatal women with BD discontinue treatment during pregnancy. This study will examine the reasons why some pregnant women with BD discontinue their treatment, and others do not. Results of this study will lay the groundwork for developing interventions to help women with BD actively engage in BD treatment during the perinatal period.]]></PHR><PIS><PI><PI_NAME>BATTLE, CYNTHIA L.</PI_NAME><PI_ID>6700492</PI_ID></PI><PI><PI_NAME>WEINSTOCK, LAUREN M (contact)</PI_NAME><PI_ID>6772971 (contact)</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>AZRIN, SUSAN </PROGRAM_OFFICER_NAME><PROJECT_START>11/21/2014</PROJECT_START><PROJECT_END>10/31/2017</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Accounting]]></TERM><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[adverse outcome]]></TERM><TERM><![CDATA[Attitude]]></TERM><TERM><![CDATA[Belief]]></TERM><TERM><![CDATA[Bipolar Disorder]]></TERM><TERM><![CDATA[Birth]]></TERM><TERM><![CDATA[Caring]]></TERM><TERM><![CDATA[Characteristics]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[Cognition]]></TERM><TERM><![CDATA[Complex]]></TERM><TERM><![CDATA[Counseling]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Decision Making]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[disorder risk]]></TERM><TERM><![CDATA[disturbance in affect]]></TERM><TERM><![CDATA[Dose]]></TERM><TERM><![CDATA[effective therapy]]></TERM><TERM><![CDATA[Empirical Research]]></TERM><TERM><![CDATA[Equilibrium]]></TERM><TERM><![CDATA[Evaluation]]></TERM><TERM><![CDATA[experience]]></TERM><TERM><![CDATA[Eye]]></TERM><TERM><![CDATA[Fetus]]></TERM><TERM><![CDATA[Future]]></TERM><TERM><![CDATA[General Population]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Impairment]]></TERM><TERM><![CDATA[Infant]]></TERM><TERM><![CDATA[innovation]]></TERM><TERM><![CDATA[Intervention]]></TERM><TERM><![CDATA[Interview]]></TERM><TERM><![CDATA[Investigation]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[Learning]]></TERM><TERM><![CDATA[Light]]></TERM><TERM><![CDATA[Literature]]></TERM><TERM><![CDATA[Manic]]></TERM><TERM><![CDATA[Measures]]></TERM><TERM><![CDATA[Methods]]></TERM><TERM><![CDATA[Microcephaly]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Moods]]></TERM><TERM><![CDATA[Morbidity - disease rate]]></TERM><TERM><![CDATA[Mothers]]></TERM><TERM><![CDATA[Outcome]]></TERM><TERM><![CDATA[Perinatal]]></TERM><TERM><![CDATA[Pharmaceutical Preparations]]></TERM><TERM><![CDATA[Pharmacotherapy]]></TERM><TERM><![CDATA[Phase]]></TERM><TERM><![CDATA[Postpartum Period]]></TERM><TERM><![CDATA[Postpartum Women]]></TERM><TERM><![CDATA[Predisposition]]></TERM><TERM><![CDATA[Pregnancy]]></TERM><TERM><![CDATA[Pregnancy Outcome]]></TERM><TERM><![CDATA[pregnant]]></TERM><TERM><![CDATA[Pregnant Women]]></TERM><TERM><![CDATA[Premature Birth]]></TERM><TERM><![CDATA[prenatal]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[prophylactic]]></TERM><TERM><![CDATA[Prospective Studies]]></TERM><TERM><![CDATA[Provider]]></TERM><TERM><![CDATA[Psychiatric Diagnosis]]></TERM><TERM><![CDATA[psychosocial]]></TERM><TERM><![CDATA[Psychotic Disorders]]></TERM><TERM><![CDATA[public health medicine (field)]]></TERM><TERM><![CDATA[Publications]]></TERM><TERM><![CDATA[Publishing]]></TERM><TERM><![CDATA[Qualitative Methods]]></TERM><TERM><![CDATA[Recommendation]]></TERM><TERM><![CDATA[Recording of previous events]]></TERM><TERM><![CDATA[Recruitment Activity]]></TERM><TERM><![CDATA[Recurrence]]></TERM><TERM><![CDATA[Relative (related person)]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Research Personnel]]></TERM><TERM><![CDATA[Risk]]></TERM><TERM><![CDATA[Safety]]></TERM><TERM><![CDATA[Sampling]]></TERM><TERM><![CDATA[service intervention]]></TERM><TERM><![CDATA[severe mental illness]]></TERM><TERM><![CDATA[Severities]]></TERM><TERM><![CDATA[Shapes]]></TERM><TERM><![CDATA[Small for Gestational Age Infant]]></TERM><TERM><![CDATA[social stigma]]></TERM><TERM><![CDATA[suicidal risk]]></TERM><TERM><![CDATA[Symptoms]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[Woman]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Treatment Decisions for Perinatal Bipolar Disorder]]></PROJECT_TITLE><SERIAL_NUMBER>103570</SERIAL_NUMBER><STUDY_SECTION>ZMH1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>158112</DIRECT_COST_AMT><INDIRECT_COST_AMT>57612</INDIRECT_COST_AMT><TOTAL_COST>215724</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8982844</APPLICATION_ID><ACTIVITY>F32</ACTIVITY><ADMINISTERING_IC>DA</ADMINISTERING_IC><APPLICATION_TYPE>1</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>08/01/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>279</CFDA_CODE><CORE_PROJECT_NUM>F32DA038927</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[GRADUATE SCHOOLS]]></ED_INST_TYPE><FOA_NUMBER>PA-14-149</FOA_NUMBER><FULL_PROJECT_NUM>1F32DA038927-01A1</FULL_PROJECT_NUM><FUNDING_ICs>NIDA:52406\</FUNDING_ICs><FUNDING_MECHANISM>TRAINING, INDIVIDUAL</FUNDING_MECHANISM><FY>2015</FY><IC_NAME>NATIONAL INSTITUTE ON DRUG ABUSE</IC_NAME><NIH_SPENDING_CATS><CATEGORY><![CDATA[Basic Behavioral and Social Science]]></CATEGORY><CATEGORY><![CDATA[Behavioral and Social Science]]></CATEGORY><CATEGORY><![CDATA[Brain Disorders]]></CATEGORY><CATEGORY><![CDATA[Clinical Research]]></CATEGORY><CATEGORY><![CDATA[Drug Abuse (NIDA only)]]></CATEGORY><CATEGORY><![CDATA[Mental Health]]></CATEGORY><CATEGORY><![CDATA[Neurosciences]]></CATEGORY><CATEGORY><![CDATA[Substance Abuse]]></CATEGORY></NIH_SPENDING_CATS><ORG_CITY>BERKELEY</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[PSYCHOLOGY]]></ORG_DEPT><ORG_DISTRICT>13</ORG_DISTRICT><ORG_DUNS>124726725</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIVERSITY OF CALIFORNIA BERKELEY]]></ORG_NAME><ORG_STATE>CA</ORG_STATE><ORG_ZIPCODE>947045940</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Dopamine plays a critical role in our ability to flexibly adapt cognition and behavior in the face of a changing or threatening environment. Indeed, a range of neurobehavioral disorders, including Parkinson's disease, drug addiction, and ADHD, are characterized not only by dopamine system dysfunction, but also by abnormalities in cognitive flexibility, even in situations involving potential negative consequences. Elucidating the role of dopamine in regulating cognitive flexibility under conditions of potential harm will enhance our basic knowledge of dopamine system function and variation, and provide insights into the impact of disease state and both therapeutic and illicit drug use on aspects of cognitive control.  
   
      

]]></PHR><PIS><PI><PI_NAME>FURMAN, DANIELLA JULIA</PI_NAME><PI_ID>12199779</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>GRANT, STEVEN J</PROGRAM_OFFICER_NAME><PROJECT_START>11/01/2015</PROJECT_START><PROJECT_END>10/31/2018</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Architecture]]></TERM><TERM><![CDATA[Attention deficit hyperactivity disorder]]></TERM><TERM><![CDATA[Attentional deficit]]></TERM><TERM><![CDATA[Behavior]]></TERM><TERM><![CDATA[Behavioral]]></TERM><TERM><![CDATA[Brain]]></TERM><TERM><![CDATA[Brain region]]></TERM><TERM><![CDATA[Cognition]]></TERM><TERM><![CDATA[Cognitive]]></TERM><TERM><![CDATA[cognitive control]]></TERM><TERM><![CDATA[cognitive performance]]></TERM><TERM><![CDATA[Corpus striatum structure]]></TERM><TERM><![CDATA[Cues]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Dopamine]]></TERM><TERM><![CDATA[dopamine system]]></TERM><TERM><![CDATA[dopaminergic neuron]]></TERM><TERM><![CDATA[Drug Addiction]]></TERM><TERM><![CDATA[Drug usage]]></TERM><TERM><![CDATA[Environment]]></TERM><TERM><![CDATA[environmental change]]></TERM><TERM><![CDATA[Epithalamic structure]]></TERM><TERM><![CDATA[Event]]></TERM><TERM><![CDATA[Exhibits]]></TERM><TERM><![CDATA[flexibility]]></TERM><TERM><![CDATA[Functional disorder]]></TERM><TERM><![CDATA[Functional Magnetic Resonance Imaging]]></TERM><TERM><![CDATA[Future]]></TERM><TERM><![CDATA[Genetic]]></TERM><TERM><![CDATA[Genetic Polymorphism]]></TERM><TERM><![CDATA[genetic variant]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Habenula]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[Illicit Drugs]]></TERM><TERM><![CDATA[Impulsivity]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[Individual Differences]]></TERM><TERM><![CDATA[insight]]></TERM><TERM><![CDATA[interest]]></TERM><TERM><![CDATA[Intervention]]></TERM><TERM><![CDATA[Knowledge]]></TERM><TERM><![CDATA[Link]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[meetings]]></TERM><TERM><![CDATA[Methods]]></TERM><TERM><![CDATA[Motivation]]></TERM><TERM><![CDATA[neurobehavioral disorder]]></TERM><TERM><![CDATA[neurobiological mechanism]]></TERM><TERM><![CDATA[neuroimaging]]></TERM><TERM><![CDATA[Neuromodulator]]></TERM><TERM><![CDATA[neuropsychiatry]]></TERM><TERM><![CDATA[neurotransmission]]></TERM><TERM><![CDATA[Outcome]]></TERM><TERM><![CDATA[Parkinson Disease]]></TERM><TERM><![CDATA[Participant]]></TERM><TERM><![CDATA[Pattern]]></TERM><TERM><![CDATA[Play]]></TERM><TERM><![CDATA[Prefrontal Cortex]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[psychopharmacologic]]></TERM><TERM><![CDATA[public health relevance]]></TERM><TERM><![CDATA[Punishment]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Research Personnel]]></TERM><TERM><![CDATA[research study]]></TERM><TERM><![CDATA[Resources]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[Rewards]]></TERM><TERM><![CDATA[Risk]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Schizophrenia]]></TERM><TERM><![CDATA[Short-Term Memory]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[Structure]]></TERM><TERM><![CDATA[Therapeutic]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[Update]]></TERM><TERM><![CDATA[Variant]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Aversive motivation and cognitive control]]></PROJECT_TITLE><SERIAL_NUMBER>038927</SERIAL_NUMBER><STUDY_SECTION>ZRG1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>01</SUPPORT_YEAR><SUFFIX>A1</SUFFIX><DIRECT_COST_AMT>52406</DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>52406</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8983263</APPLICATION_ID><ACTIVITY>I01</ACTIVITY><ADMINISTERING_IC>VA</ADMINISTERING_IC><APPLICATION_TYPE>1</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/03/2015</AWARD_NOTICE_DATE><BUDGET_START>10/01/2015</BUDGET_START><BUDGET_END>09/30/2016</BUDGET_END><CFDA_CODE>999</CFDA_CODE><CORE_PROJECT_NUM>I01RX001539</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-RX-15-005</FOA_NUMBER><FULL_PROJECT_NUM>1I01RX001539-01A2</FULL_PROJECT_NUM><FUNDING_ICs>VA:278463\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>Veterans Affairs</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>SAN FRANCISCO</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>12</ORG_DISTRICT><ORG_DUNS>078763885</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[VETERANS AFFAIRS MED CTR SAN FRANCISCO]]></ORG_NAME><ORG_STATE>CA</ORG_STATE><ORG_ZIPCODE>941211545</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE:    
The proposed study addresses insomnia, an issue of critical importance that is related to Iraq and Afghanistan Veterans' social and occupational functioning and overall health. Insomnia is associated with a host of poor functional outcomes, and has long-term ramifications for Veterans' health and wellbeing as they mature. Given that poor sleep is one of the most common concerns in this newly retuning cohort of Veterans, a behavioral treatment that directly addresses insomnia in this group is of utmost importance to the VA. We also know that Iraq and Afghanistan Veterans report serious barriers to seeking care in mental health clinics, where behavioral insomnia treatment is most commonly provided, and that those most in need are least likely to seek services. Consequently, this treatment is designed to respond to all of these issues by examining the rehabilitative efficacy of a brief, telephone-facilitated treatment for insomnia in primary care.   
      

]]></PHR><PIS><PI><PI_NAME>MAGUEN, SHIRA </PI_NAME><PI_ID>10229435</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>10/01/2015</PROJECT_START><PROJECT_END>09/30/2018</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[active method]]></TERM><TERM><![CDATA[Activities of Daily Living]]></TERM><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[Afghanistan]]></TERM><TERM><![CDATA[Aftercare]]></TERM><TERM><![CDATA[Alcohol consumption]]></TERM><TERM><![CDATA[Area]]></TERM><TERM><![CDATA[Arousal]]></TERM><TERM><![CDATA[Attention Concentration]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Behavior Therapy]]></TERM><TERM><![CDATA[Behavioral]]></TERM><TERM><![CDATA[care seeking]]></TERM><TERM><![CDATA[Caring]]></TERM><TERM><![CDATA[Categories]]></TERM><TERM><![CDATA[Clinic]]></TERM><TERM><![CDATA[Code]]></TERM><TERM><![CDATA[cognitive function]]></TERM><TERM><![CDATA[Cognitive Therapy]]></TERM><TERM><![CDATA[cohort]]></TERM><TERM><![CDATA[combat]]></TERM><TERM><![CDATA[comparison group]]></TERM><TERM><![CDATA[Control Groups]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[Diagnosis]]></TERM><TERM><![CDATA[Diagnostic]]></TERM><TERM><![CDATA[Diagnostic and Statistical Manual of Mental Disorders]]></TERM><TERM><![CDATA[diaries]]></TERM><TERM><![CDATA[efficacy testing]]></TERM><TERM><![CDATA[emotion regulation]]></TERM><TERM><![CDATA[Ensure]]></TERM><TERM><![CDATA[Evaluation]]></TERM><TERM><![CDATA[evidence base]]></TERM><TERM><![CDATA[Evidence based treatment]]></TERM><TERM><![CDATA[executive function]]></TERM><TERM><![CDATA[Feedback]]></TERM><TERM><![CDATA[follow-up]]></TERM><TERM><![CDATA[frontal lobe]]></TERM><TERM><![CDATA[functional outcomes]]></TERM><TERM><![CDATA[Generations]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Health behavior]]></TERM><TERM><![CDATA[high risk]]></TERM><TERM><![CDATA[Hour]]></TERM><TERM><![CDATA[Hygiene]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[improved functioning]]></TERM><TERM><![CDATA[indexing]]></TERM><TERM><![CDATA[Intervention]]></TERM><TERM><![CDATA[Interview]]></TERM><TERM><![CDATA[Iraq]]></TERM><TERM><![CDATA[Measurement]]></TERM><TERM><![CDATA[Measures]]></TERM><TERM><![CDATA[meetings]]></TERM><TERM><![CDATA[Mental Health]]></TERM><TERM><![CDATA[Methods]]></TERM><TERM><![CDATA[Military Personnel]]></TERM><TERM><![CDATA[mobile application]]></TERM><TERM><![CDATA[Movement]]></TERM><TERM><![CDATA[Muscle relaxation phase]]></TERM><TERM><![CDATA[Occupational]]></TERM><TERM><![CDATA[Outcome]]></TERM><TERM><![CDATA[Paper]]></TERM><TERM><![CDATA[Participant]]></TERM><TERM><![CDATA[Patient Self-Report]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Persons]]></TERM><TERM><![CDATA[Pharmaceutical Preparations]]></TERM><TERM><![CDATA[Play]]></TERM><TERM><![CDATA[preference]]></TERM><TERM><![CDATA[primary care setting]]></TERM><TERM><![CDATA[Primary Health Care]]></TERM><TERM><![CDATA[primary outcome]]></TERM><TERM><![CDATA[Productivity]]></TERM><TERM><![CDATA[Psyche structure]]></TERM><TERM><![CDATA[psychosocial]]></TERM><TERM><![CDATA[public health relevance]]></TERM><TERM><![CDATA[Quality of life]]></TERM><TERM><![CDATA[Questionnaires]]></TERM><TERM><![CDATA[Randomized]]></TERM><TERM><![CDATA[Randomized Controlled Trials]]></TERM><TERM><![CDATA[Rehabilitation therapy]]></TERM><TERM><![CDATA[Relaxation Therapy]]></TERM><TERM><![CDATA[Reporting]]></TERM><TERM><![CDATA[Research Personnel]]></TERM><TERM><![CDATA[Rest]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[San Francisco]]></TERM><TERM><![CDATA[Science]]></TERM><TERM><![CDATA[secondary outcome]]></TERM><TERM><![CDATA[Services]]></TERM><TERM><![CDATA[Severities]]></TERM><TERM><![CDATA[Short-Term Memory]]></TERM><TERM><![CDATA[Sleep]]></TERM><TERM><![CDATA[Sleep disturbances]]></TERM><TERM><![CDATA[sleep onset]]></TERM><TERM><![CDATA[sleep regulation]]></TERM><TERM><![CDATA[Sleep Wake Cycle]]></TERM><TERM><![CDATA[Sleeplessness]]></TERM><TERM><![CDATA[Smoking]]></TERM><TERM><![CDATA[social]]></TERM><TERM><![CDATA[Stimulus]]></TERM><TERM><![CDATA[Suggestion]]></TERM><TERM><![CDATA[Target Populations]]></TERM><TERM><![CDATA[Telephone]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[Training]]></TERM><TERM><![CDATA[Universities]]></TERM><TERM><![CDATA[Veterans]]></TERM><TERM><![CDATA[Visit]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Telephone-Facilitated Insomnia Treatment in Primary Care for OEF/OIF/OND Veterans]]></PROJECT_TITLE><SERIAL_NUMBER>001539</SERIAL_NUMBER><STUDY_SECTION>RRD4</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Psychological Health & Social Reintegration  ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>01</SUPPORT_YEAR><SUFFIX>A2</SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST></TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8983841</APPLICATION_ID><ACTIVITY>F30</ACTIVITY><ADMINISTERING_IC>GM</ADMINISTERING_IC><APPLICATION_TYPE>1</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>07/01/2015</AWARD_NOTICE_DATE><BUDGET_START>08/01/2015</BUDGET_START><BUDGET_END>07/31/2016</BUDGET_END><CFDA_CODE>859</CFDA_CODE><CORE_PROJECT_NUM>F30GM116810</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-14-150</FOA_NUMBER><FULL_PROJECT_NUM>1F30GM116810-01</FULL_PROJECT_NUM><FUNDING_ICs>NIGMS:37404\</FUNDING_ICs><FUNDING_MECHANISM>TRAINING, INDIVIDUAL</FUNDING_MECHANISM><FY>2015</FY><IC_NAME>NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES</IC_NAME><NIH_SPENDING_CATS><CATEGORY><![CDATA[Basic Behavioral and Social Science]]></CATEGORY><CATEGORY><![CDATA[Behavioral and Social Science]]></CATEGORY><CATEGORY><![CDATA[Brain Disorders]]></CATEGORY><CATEGORY><![CDATA[Mental Health]]></CATEGORY><CATEGORY><![CDATA[Neurosciences]]></CATEGORY></NIH_SPENDING_CATS><ORG_CITY>LOS ANGELES</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[MICROBIOLOGY/IMMUN/VIROLOGY]]></ORG_DEPT><ORG_DISTRICT>33</ORG_DISTRICT><ORG_DUNS>092530369</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIVERSITY OF CALIFORNIA LOS ANGELES]]></ORG_NAME><ORG_STATE>CA</ORG_STATE><ORG_ZIPCODE>900952000</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: In an environment that is constantly changing, our brains must appropriately respond to external conditions while still addressing our bodies' internal needs like hunger and thirst. In people suffering from psychiatric diseases like depression and schizophrenia, the brain's ability to properly interpret sensory information is impaired. This research will uncover how context affects sensory processing in the round worm C. elegans and will provide insight into mechanisms of how sensory processing might be perturbed in psychiatric disease.   
   
      

]]></PHR><PIS><PI><PI_NAME>RENGARAJAN, SOPHIE </PI_NAME><PI_ID>11013356</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>DOUTHARD, REGINE </PROGRAM_OFFICER_NAME><PROJECT_START>08/01/2015</PROJECT_START><PROJECT_END>07/31/2018</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[Adult]]></TERM><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[Animals]]></TERM><TERM><![CDATA[Attenuated]]></TERM><TERM><![CDATA[Automobile Driving]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Behavior]]></TERM><TERM><![CDATA[Behavioral]]></TERM><TERM><![CDATA[Biogenic Amines]]></TERM><TERM><![CDATA[Biological Models]]></TERM><TERM><![CDATA[Brain]]></TERM><TERM><![CDATA[Caenorhabditis elegans]]></TERM><TERM><![CDATA[Carbon Dioxide]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Cues]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Dopamine]]></TERM><TERM><![CDATA[Dopamine Receptor]]></TERM><TERM><![CDATA[dopaminergic neuron]]></TERM><TERM><![CDATA[driving behavior]]></TERM><TERM><![CDATA[Environment]]></TERM><TERM><![CDATA[feeding]]></TERM><TERM><![CDATA[Food]]></TERM><TERM><![CDATA[Food deprivation (experimental)]]></TERM><TERM><![CDATA[functional mimics]]></TERM><TERM><![CDATA[Genes]]></TERM><TERM><![CDATA[Genetic]]></TERM><TERM><![CDATA[genetic manipulation]]></TERM><TERM><![CDATA[Global Change]]></TERM><TERM><![CDATA[Heating]]></TERM><TERM><![CDATA[Hour]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[Hunger]]></TERM><TERM><![CDATA[Image]]></TERM><TERM><![CDATA[insight]]></TERM><TERM><![CDATA[Link]]></TERM><TERM><![CDATA[loss of function]]></TERM><TERM><![CDATA[Maps]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[Mental Depression]]></TERM><TERM><![CDATA[Mental disorders]]></TERM><TERM><![CDATA[Motion]]></TERM><TERM><![CDATA[Motivation]]></TERM><TERM><![CDATA[Motor]]></TERM><TERM><![CDATA[mutant]]></TERM><TERM><![CDATA[Nematoda]]></TERM><TERM><![CDATA[Nervous system structure]]></TERM><TERM><![CDATA[neural circuit]]></TERM><TERM><![CDATA[Neuromodulator]]></TERM><TERM><![CDATA[neuronal circuitry]]></TERM><TERM><![CDATA[Neurons]]></TERM><TERM><![CDATA[neuropsychiatry]]></TERM><TERM><![CDATA[optogenetics]]></TERM><TERM><![CDATA[Organism]]></TERM><TERM><![CDATA[Parkinson Disease]]></TERM><TERM><![CDATA[Pharmacogenetics]]></TERM><TERM><![CDATA[Physiology]]></TERM><TERM><![CDATA[public health relevance]]></TERM><TERM><![CDATA[Regulation]]></TERM><TERM><![CDATA[relating to nervous system]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[research study]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[Rewards]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Schizophrenia]]></TERM><TERM><![CDATA[Sensory]]></TERM><TERM><![CDATA[Sensory Process]]></TERM><TERM><![CDATA[sensory stimulus]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[small molecule]]></TERM><TERM><![CDATA[Source]]></TERM><TERM><![CDATA[Staging]]></TERM><TERM><![CDATA[Starvation]]></TERM><TERM><![CDATA[stimulus processing]]></TERM><TERM><![CDATA[System]]></TERM><TERM><![CDATA[Thirst]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[Translating]]></TERM><TERM><![CDATA[Update]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Dopaminergic modulation of CO2 response during starvation in C. elegans]]></PROJECT_TITLE><SERIAL_NUMBER>116810</SERIAL_NUMBER><STUDY_SECTION>ZRG1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>01</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>37404</DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>37404</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8986039</APPLICATION_ID><ACTIVITY>I01</ACTIVITY><ADMINISTERING_IC>VA</ADMINISTERING_IC><APPLICATION_TYPE>1</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/03/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>999</CFDA_CODE><CORE_PROJECT_NUM>I01RX001613</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-RX-15-004</FOA_NUMBER><FULL_PROJECT_NUM>1I01RX001613-01A2</FULL_PROJECT_NUM><FUNDING_ICs>VA:261428\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>Veterans Affairs</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>AUGUSTA</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>12</ORG_DISTRICT><ORG_DUNS>010116408</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[CHARLIE NORWOOD VA MEDICAL CENTER]]></ORG_NAME><ORG_STATE>GA</ORG_STATE><ORG_ZIPCODE>309046285</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE:    
Parkinson's disease (PD) is a devastating progressive neurological condition. The cost of management of VA population suffering from PD is phenomenal. Neuroinflammation is central in PD pathology. GPR109A is an anti-inflammatory receptor which is present everywhere in the body especially in the immune cells. We have observed up-regulation of this receptor in the substantia nigra and white blood cells (WBCs) of the PD patients. Niacin (Vitamin B3) acts as an agonist to this receptor and our preliminary findings in PD patients demonstrates its regulatory effects on GPR109A levels in WBCs. We propose to use niacin to facilitate rehabilitation of VA PD patients. Also we will study the mechanisms involved in the anti-inflammatory role of niacin via GPR109A in in-vitro models. Our goal is to ameliorate motor, coordination and cognitive symptoms of PD patients and find new avenues in treating our Veteran suffering from PD.   
      

]]></PHR><PIS><PI><PI_NAME>WAKADE, CHANDRAMOHAN </PI_NAME><PI_ID>7919704</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>11/01/2015</PROJECT_START><PROJECT_END>10/31/2019</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[abstracting]]></TERM><TERM><![CDATA[Age]]></TERM><TERM><![CDATA[Agonist]]></TERM><TERM><![CDATA[Anti-inflammatory]]></TERM><TERM><![CDATA[Anti-Inflammatory Agents]]></TERM><TERM><![CDATA[Blood]]></TERM><TERM><![CDATA[Carbidopa]]></TERM><TERM><![CDATA[Case Study]]></TERM><TERM><![CDATA[Cell Line]]></TERM><TERM><![CDATA[Cell Nucleus]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Cerebrospinal Fluid]]></TERM><TERM><![CDATA[Cognition]]></TERM><TERM><![CDATA[cognitive function]]></TERM><TERM><![CDATA[Complement Factor B]]></TERM><TERM><![CDATA[cost]]></TERM><TERM><![CDATA[Coupled]]></TERM><TERM><![CDATA[cytokine]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Dopamine]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[GTP-Binding Proteins]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[Immune]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[In Vitro]]></TERM><TERM><![CDATA[in vitro Model]]></TERM><TERM><![CDATA[indexing]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[Inflammation]]></TERM><TERM><![CDATA[Inflammatory]]></TERM><TERM><![CDATA[inflammatory marker]]></TERM><TERM><![CDATA[Interleukin-6]]></TERM><TERM><![CDATA[Leukocytes]]></TERM><TERM><![CDATA[macrophage]]></TERM><TERM><![CDATA[Measures]]></TERM><TERM><![CDATA[Microglia]]></TERM><TERM><![CDATA[Mitochondria]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[Motor]]></TERM><TERM><![CDATA[motor function improvement]]></TERM><TERM><![CDATA[NADP]]></TERM><TERM><![CDATA[Neurobehavioral Manifestations]]></TERM><TERM><![CDATA[neuroinflammation]]></TERM><TERM><![CDATA[Neurologic]]></TERM><TERM><![CDATA[Neurons]]></TERM><TERM><![CDATA[NF-kappa B]]></TERM><TERM><![CDATA[Niacinamide]]></TERM><TERM><![CDATA[Nicotinic Acids]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[Nuclear]]></TERM><TERM><![CDATA[Outcome Measure]]></TERM><TERM><![CDATA[Oxidative Stress]]></TERM><TERM><![CDATA[Parkinson Disease]]></TERM><TERM><![CDATA[Pathology]]></TERM><TERM><![CDATA[Pathway interactions]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Performance]]></TERM><TERM><![CDATA[Pharmaceutical Preparations]]></TERM><TERM><![CDATA[Population]]></TERM><TERM><![CDATA[Production]]></TERM><TERM><![CDATA[public health relevance]]></TERM><TERM><![CDATA[receptor]]></TERM><TERM><![CDATA[receptor expression]]></TERM><TERM><![CDATA[Receptor Up-Regulation]]></TERM><TERM><![CDATA[Rehabilitation therapy]]></TERM><TERM><![CDATA[Reporting]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Signal Pathway]]></TERM><TERM><![CDATA[skills]]></TERM><TERM><![CDATA[Staging]]></TERM><TERM><![CDATA[Substantia nigra structure]]></TERM><TERM><![CDATA[Supplementation]]></TERM><TERM><![CDATA[Symptoms]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Therapeutic]]></TERM><TERM><![CDATA[therapeutic target]]></TERM><TERM><![CDATA[Tumor Necrosis Factor-alpha]]></TERM><TERM><![CDATA[Up-Regulation (Physiology)]]></TERM><TERM><![CDATA[Veterans]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[GPR109A and Parkinson's Disease: Role of Niacin in Outcome Measures]]></PROJECT_TITLE><SERIAL_NUMBER>001613</SERIAL_NUMBER><STUDY_SECTION>RRD6</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Blank ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>01</SUPPORT_YEAR><SUFFIX>A2</SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST></TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8987437</APPLICATION_ID><ACTIVITY>U10</ACTIVITY><ADMINISTERING_IC>HL</ADMINISTERING_IC><APPLICATION_TYPE>4</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/29/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>837</CFDA_CODE><CORE_PROJECT_NUM>U10HL084904</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>RFA-HL-12-002</FOA_NUMBER><FULL_PROJECT_NUM>4U10HL084904-10</FULL_PROJECT_NUM><FUNDING_ICs>NHLBI:4860645\</FUNDING_ICs><FUNDING_MECHANISM>OTHER RESEARCH-RELATED</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL HEART, LUNG, AND BLOOD INSTITUTE</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>DURHAM</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[BIOSTATISTICS & OTHER MATH SCI]]></ORG_DEPT><ORG_DISTRICT>01</ORG_DISTRICT><ORG_DUNS>044387793</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[DUKE UNIVERSITY]]></ORG_NAME><ORG_STATE>NC</ORG_STATE><ORG_ZIPCODE>277054673</ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>ANSTROM, KEVIN J (contact)</PI_NAME><PI_ID>1934824 (contact)</PI_ID></PI><PI><PI_NAME>HERNANDEZ, ADRIAN </PI_NAME><PI_ID>8603009</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>SHAH, MONICA R</PROGRAM_OFFICER_NAME><PROJECT_START>09/30/2006</PROJECT_START><PROJECT_END>10/31/2018</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Ancillary Study]]></TERM><TERM><![CDATA[Attention]]></TERM><TERM><![CDATA[Certification]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[clinical care]]></TERM><TERM><![CDATA[Clinical Research]]></TERM><TERM><![CDATA[clinical research site]]></TERM><TERM><![CDATA[Clinical Trials]]></TERM><TERM><![CDATA[Clinical Trials Data Monitoring Committees]]></TERM><TERM><![CDATA[Communication]]></TERM><TERM><![CDATA[Complex]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Data Analyses]]></TERM><TERM><![CDATA[Data Collection]]></TERM><TERM><![CDATA[Data Coordinating Center]]></TERM><TERM><![CDATA[Data Element]]></TERM><TERM><![CDATA[data management]]></TERM><TERM><![CDATA[Data Storage and Retrieval]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[Diagnosis]]></TERM><TERM><![CDATA[Economic Development]]></TERM><TERM><![CDATA[editorial]]></TERM><TERM><![CDATA[electronic data]]></TERM><TERM><![CDATA[Enrollment]]></TERM><TERM><![CDATA[Ensure]]></TERM><TERM><![CDATA[experience]]></TERM><TERM><![CDATA[Functional disorder]]></TERM><TERM><![CDATA[Funding]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Grant]]></TERM><TERM><![CDATA[Guidelines]]></TERM><TERM><![CDATA[Heart failure]]></TERM><TERM><![CDATA[Human Resources]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[Informed Consent]]></TERM><TERM><![CDATA[innovation]]></TERM><TERM><![CDATA[Institutes]]></TERM><TERM><![CDATA[Instruction]]></TERM><TERM><![CDATA[interest]]></TERM><TERM><![CDATA[International]]></TERM><TERM><![CDATA[Journals]]></TERM><TERM><![CDATA[Leadership]]></TERM><TERM><![CDATA[lectures]]></TERM><TERM><![CDATA[Legal]]></TERM><TERM><![CDATA[Manuals]]></TERM><TERM><![CDATA[Measures]]></TERM><TERM><![CDATA[Medical Economics]]></TERM><TERM><![CDATA[meetings]]></TERM><TERM><![CDATA[Methodology]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Monitor]]></TERM><TERM><![CDATA[National Heart, Lung, and Blood Institute]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[Occupational activity of managing finances]]></TERM><TERM><![CDATA[operation]]></TERM><TERM><![CDATA[Outcome]]></TERM><TERM><![CDATA[Patient Monitoring]]></TERM><TERM><![CDATA[Patient Outcomes Assessments]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Performance]]></TERM><TERM><![CDATA[Pharmaceutical Preparations]]></TERM><TERM><![CDATA[Phase]]></TERM><TERM><![CDATA[Procedures]]></TERM><TERM><![CDATA[protocol development]]></TERM><TERM><![CDATA[Protocols documentation]]></TERM><TERM><![CDATA[Publications]]></TERM><TERM><![CDATA[Quality Control]]></TERM><TERM><![CDATA[Quality of life]]></TERM><TERM><![CDATA[Randomized]]></TERM><TERM><![CDATA[Reporting]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Research Design]]></TERM><TERM><![CDATA[Research Infrastructure]]></TERM><TERM><![CDATA[Research Institute]]></TERM><TERM><![CDATA[Research Personnel]]></TERM><TERM><![CDATA[Resources]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[Review Committee]]></TERM><TERM><![CDATA[Sample Size]]></TERM><TERM><![CDATA[Site]]></TERM><TERM><![CDATA[Standardization]]></TERM><TERM><![CDATA[Statistical Methods]]></TERM><TERM><![CDATA[Structure]]></TERM><TERM><![CDATA[Subgroup]]></TERM><TERM><![CDATA[System]]></TERM><TERM><![CDATA[Technology]]></TERM><TERM><![CDATA[Therapy Evaluation]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[Training]]></TERM><TERM><![CDATA[translational medicine]]></TERM><TERM><![CDATA[Vendor]]></TERM><TERM><![CDATA[web site]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Heart Failure Clinical Research Network Coordinating Center]]></PROJECT_TITLE><SERIAL_NUMBER>084904</SERIAL_NUMBER><STUDY_SECTION>ZHL1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>10</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>4161841</DIRECT_COST_AMT><INDIRECT_COST_AMT>698804</INDIRECT_COST_AMT><TOTAL_COST>4860645</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9002766</APPLICATION_ID><ACTIVITY>F32</ACTIVITY><ADMINISTERING_IC>AI</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/28/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>855</CFDA_CODE><CORE_PROJECT_NUM>F32AI109855</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>PA-11-113</FOA_NUMBER><FULL_PROJECT_NUM>5F32AI109855-02</FULL_PROJECT_NUM><FUNDING_ICs>NIAID:53282\</FUNDING_ICs><FUNDING_MECHANISM>TRAINING, INDIVIDUAL</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>BOSTON</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>08</ORG_DISTRICT><ORG_DUNS>073825945</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[MASSACHUSETTS EYE AND EAR INFIRMARY]]></ORG_NAME><ORG_STATE>MA</ORG_STATE><ORG_ZIPCODE>021143002</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Enterococcus faecalis are normally found as a commensal member of the intestinal microbiota in a wide range of hosts, but recently these bacteria have arisen as hyper-virulent, multi-drug resistant, hospital-acquired superbugs. Studies such as this one, which is aimed at understanding some of the basic biological mechanisms of E. faecalis, will undoubtedly aid in the development of treatment and control efforts that target this
important human pathogen.]]></PHR><PIS><PI><PI_NAME>VAN TYNE, DARIA N</PI_NAME><PI_ID>9468673</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>HUNTLEY, CLAYTON C.</PROGRAM_OFFICER_NAME><PROJECT_START>11/01/2014</PROJECT_START><PROJECT_END>10/31/2016</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Active Sites]]></TERM><TERM><![CDATA[Antibiotic Therapy]]></TERM><TERM><![CDATA[Bacteria]]></TERM><TERM><![CDATA[bacteriocin]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Biological]]></TERM><TERM><![CDATA[Biological Assay]]></TERM><TERM><![CDATA[career development]]></TERM><TERM><![CDATA[Cell membrane]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Characteristics]]></TERM><TERM><![CDATA[Cleaved cell]]></TERM><TERM><![CDATA[Cytolysins]]></TERM><TERM><![CDATA[Cytolysis]]></TERM><TERM><![CDATA[Ear structure]]></TERM><TERM><![CDATA[Elements]]></TERM><TERM><![CDATA[Enterococcus faecalis]]></TERM><TERM><![CDATA[Eukaryotic Cell]]></TERM><TERM><![CDATA[Exotoxins]]></TERM><TERM><![CDATA[experience]]></TERM><TERM><![CDATA[Eye]]></TERM><TERM><![CDATA[Gene Expression]]></TERM><TERM><![CDATA[Genes]]></TERM><TERM><![CDATA[Genetic Transcription]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Gram-Positive Bacteria]]></TERM><TERM><![CDATA[gut microbiota]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Hospitals]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[Immunity]]></TERM><TERM><![CDATA[In Vitro]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[Infection]]></TERM><TERM><![CDATA[insight]]></TERM><TERM><![CDATA[Killings]]></TERM><TERM><![CDATA[Laboratories]]></TERM><TERM><![CDATA[lanthionine]]></TERM><TERM><![CDATA[lipid biosynthesis]]></TERM><TERM><![CDATA[Maps]]></TERM><TERM><![CDATA[Massachusetts]]></TERM><TERM><![CDATA[member]]></TERM><TERM><![CDATA[Membrane]]></TERM><TERM><![CDATA[Messenger RNA]]></TERM><TERM><![CDATA[Metalloproteases]]></TERM><TERM><![CDATA[Molecular Biology]]></TERM><TERM><![CDATA[Multi-Drug Resistance]]></TERM><TERM><![CDATA[Operon]]></TERM><TERM><![CDATA[pathogen]]></TERM><TERM><![CDATA[Pathway interactions]]></TERM><TERM><![CDATA[Pattern]]></TERM><TERM><![CDATA[Peptide Hydrolases]]></TERM><TERM><![CDATA[perforin]]></TERM><TERM><![CDATA[Plasmids]]></TERM><TERM><![CDATA[Point Mutation]]></TERM><TERM><![CDATA[Postdoctoral Fellow]]></TERM><TERM><![CDATA[preference]]></TERM><TERM><![CDATA[Principal Investigator]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[Production]]></TERM><TERM><![CDATA[professor]]></TERM><TERM><![CDATA[Promotor (Genetics)]]></TERM><TERM><![CDATA[Proteins]]></TERM><TERM><![CDATA[Proteolysis]]></TERM><TERM><![CDATA[Regulation]]></TERM><TERM><![CDATA[Research Project Grants]]></TERM><TERM><![CDATA[research study]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[RNA Sequences]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[Stress]]></TERM><TERM><![CDATA[Tertiary Protein Structure]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[therapy development]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[Toxin]]></TERM><TERM><![CDATA[Training]]></TERM><TERM><![CDATA[Transcript]]></TERM><TERM><![CDATA[Transcription Initiation Site]]></TERM><TERM><![CDATA[transcriptome sequencing]]></TERM><TERM><![CDATA[Virulent]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Regulation of Expression and Immunity in the Enterococcus Faecalis Cytolysin]]></PROJECT_TITLE><SERIAL_NUMBER>109855</SERIAL_NUMBER><STUDY_SECTION>ZRG1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>53282</DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>53282</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9010465</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>AI</ADMINISTERING_IC><APPLICATION_TYPE>1</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/04/2015</AWARD_NOTICE_DATE><BUDGET_START>11/05/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>855</CFDA_CODE><CORE_PROJECT_NUM>R01AI121216</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF VETERINARY MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-13-302</FOA_NUMBER><FULL_PROJECT_NUM>1R01AI121216-01</FULL_PROJECT_NUM><FUNDING_ICs>NIAID:364025\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>ITHACA</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[VETERINARY SCIENCES]]></ORG_DEPT><ORG_DISTRICT>23</ORG_DISTRICT><ORG_DUNS>872612445</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[CORNELL UNIVERSITY]]></ORG_NAME><ORG_STATE>NY</ORG_STATE><ORG_ZIPCODE>148502820</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Basic knowledge about the mechanisms by which human viruses overcome innate cellular restrictions to viral replication provide fundamental knowledge of virus biology and often provide critical insights into how viral infection can be controlled by identification of novel therapeutic targets. This project will investigate a novel mechanism by which a human virus, mammalian orthoreovirus, co-opts the cellular biosynthetic protein synthesis machinery to promote synthesis of viral proteins.   
      

]]></PHR><PIS><PI><PI_NAME>PARKER, JOHN S</PI_NAME><PI_ID>2238023</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>CASSETTI, CRISTINA </PROGRAM_OFFICER_NAME><PROJECT_START>11/05/2015</PROJECT_START><PROJECT_END>10/31/2020</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Anabolism]]></TERM><TERM><![CDATA[Animal Viruses]]></TERM><TERM><![CDATA[Animals]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[biological adaptation to stress]]></TERM><TERM><![CDATA[Biology]]></TERM><TERM><![CDATA[cell growth regulation]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Cellular Stress]]></TERM><TERM><![CDATA[Complex]]></TERM><TERM><![CDATA[Cytoplasm]]></TERM><TERM><![CDATA[Cytosol]]></TERM><TERM><![CDATA[Defense Mechanisms]]></TERM><TERM><![CDATA[Environment]]></TERM><TERM><![CDATA[Eukaryotic Cell]]></TERM><TERM><![CDATA[GADD34 protein]]></TERM><TERM><![CDATA[Genetic Translation]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Host Defense]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[Human Virus]]></TERM><TERM><![CDATA[Infection]]></TERM><TERM><![CDATA[insight]]></TERM><TERM><![CDATA[Knowledge]]></TERM><TERM><![CDATA[Mammalian Orthoreovirus]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[Messenger RNA]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[new therapeutic target]]></TERM><TERM><![CDATA[Nonstructural Protein]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[Outcome]]></TERM><TERM><![CDATA[pathogen]]></TERM><TERM><![CDATA[Peptide Initiation Factors]]></TERM><TERM><![CDATA[Phosphorylation]]></TERM><TERM><![CDATA[prevent]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[Protein Biosynthesis]]></TERM><TERM><![CDATA[Protein phosphatase]]></TERM><TERM><![CDATA[Protein Synthesis Inhibition]]></TERM><TERM><![CDATA[Proteins]]></TERM><TERM><![CDATA[public health relevance]]></TERM><TERM><![CDATA[Recombinant Proteins]]></TERM><TERM><![CDATA[Recruitment Activity]]></TERM><TERM><![CDATA[Reoviridae Infections]]></TERM><TERM><![CDATA[Reovirus sp.]]></TERM><TERM><![CDATA[Resources]]></TERM><TERM><![CDATA[Ribosomes]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Site]]></TERM><TERM><![CDATA[Stress]]></TERM><TERM><![CDATA[Stress Response Signaling]]></TERM><TERM><![CDATA[stressor]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[translation factor]]></TERM><TERM><![CDATA[Translations]]></TERM><TERM><![CDATA[Viral]]></TERM><TERM><![CDATA[Viral Nonstructural Proteins]]></TERM><TERM><![CDATA[Viral Pathogenesis]]></TERM><TERM><![CDATA[Viral Proteins]]></TERM><TERM><![CDATA[Virus]]></TERM><TERM><![CDATA[Virus Diseases]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Mechanisms of virus-mediated compartmentalization of the host translational machinery]]></PROJECT_TITLE><SERIAL_NUMBER>121216</SERIAL_NUMBER><STUDY_SECTION>VIRA</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Virology - A Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>01</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>250000</DIRECT_COST_AMT><INDIRECT_COST_AMT>114025</INDIRECT_COST_AMT><TOTAL_COST>364025</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9026515</APPLICATION_ID><ACTIVITY>I21</ACTIVITY><ADMINISTERING_IC>VA</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/03/2015</AWARD_NOTICE_DATE><BUDGET_START>10/01/2015</BUDGET_START><BUDGET_END>09/30/2016</BUDGET_END><CFDA_CODE>999</CFDA_CODE><CORE_PROJECT_NUM>I21RX001572</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-RX-13-011</FOA_NUMBER><FULL_PROJECT_NUM>5I21RX001572-02</FULL_PROJECT_NUM><FUNDING_ICs>VA:100000\</FUNDING_ICs><FUNDING_MECHANISM>RESEARCH CENTERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>Veterans Affairs</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>SALT LAKE CITY</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>02</ORG_DISTRICT><ORG_DUNS>009094756</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[VA SALT LAKE CITY HEALTHCARE SYSTEM]]></ORG_NAME><ORG_STATE>UT</ORG_STATE><ORG_ZIPCODE>841480001</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE:    
   
 Heart failure (HF) affects almost 6 million Americans and remains the number one reason for discharge from VA hospitals nationwide. Even with optimized pharmacological therapy, prognosis for HF remains very poor suggesting that innovative approaches are needed to improve care for this growing patient population. Veterans with HF are characterized by substantial functional disability primarily caused by excessive premature fatigue upon exertion. Although various factors could contribute to this impairment, the disease-related increase in group III/IV muscle afferent feedback might depict a substantial determinant of the patients' attenuated fatigue resistance and exercise intolerance. The overall purpose of this proposal is to explore the role of group III/IV sensory neurons in the development of central and peripheral fatigue and examine whether the attenuation of this heightened feedback in HF could improve fatigue resistance, and thus exercise tolerance and overall functionality, in Veterans with HF. 1  

      

]]></PHR><PIS><PI><PI_NAME>AMANN, MARKUS </PI_NAME><PI_ID>11723176</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>10/01/2014</PROJECT_START><PROJECT_END>09/30/2016</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[afferent nerve]]></TERM><TERM><![CDATA[Afferent Neurons]]></TERM><TERM><![CDATA[Age]]></TERM><TERM><![CDATA[American]]></TERM><TERM><![CDATA[Attenuated]]></TERM><TERM><![CDATA[attenuation]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Bicycling]]></TERM><TERM><![CDATA[Blood Circulation]]></TERM><TERM><![CDATA[Brain]]></TERM><TERM><![CDATA[Cardiac rehabilitation]]></TERM><TERM><![CDATA[Caring]]></TERM><TERM><![CDATA[Characteristics]]></TERM><TERM><![CDATA[Congestive Heart Failure]]></TERM><TERM><![CDATA[Corticospinal Tracts]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[disability]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[EFRAC]]></TERM><TERM><![CDATA[Electric Stimulation]]></TERM><TERM><![CDATA[Environmental air flow]]></TERM><TERM><![CDATA[excessive exercise]]></TERM><TERM><![CDATA[Exercise]]></TERM><TERM><![CDATA[Exercise Tolerance]]></TERM><TERM><![CDATA[Exertion]]></TERM><TERM><![CDATA[Failure (biologic function)]]></TERM><TERM><![CDATA[Fatigue]]></TERM><TERM><![CDATA[Feedback]]></TERM><TERM><![CDATA[femoral nerve]]></TERM><TERM><![CDATA[Fentanyl]]></TERM><TERM><![CDATA[Fiber]]></TERM><TERM><![CDATA[Foundations]]></TERM><TERM><![CDATA[functional disability]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Heart failure]]></TERM><TERM><![CDATA[Hospitals]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[Impairment]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[innovation]]></TERM><TERM><![CDATA[Isometric Contraction]]></TERM><TERM><![CDATA[Knee]]></TERM><TERM><![CDATA[Knowledge]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[Leg]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[Morbidity - disease rate]]></TERM><TERM><![CDATA[Mortality Vital Statistics]]></TERM><TERM><![CDATA[Motor]]></TERM><TERM><![CDATA[Muscle]]></TERM><TERM><![CDATA[muscle form]]></TERM><TERM><![CDATA[Neuraxis]]></TERM><TERM><![CDATA[Neurons]]></TERM><TERM><![CDATA[outcome forecast]]></TERM><TERM><![CDATA[patient population]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Peripheral]]></TERM><TERM><![CDATA[Pharmacologic Substance]]></TERM><TERM><![CDATA[Physical activity]]></TERM><TERM><![CDATA[Play]]></TERM><TERM><![CDATA[Population]]></TERM><TERM><![CDATA[premature]]></TERM><TERM><![CDATA[public health relevance]]></TERM><TERM><![CDATA[Quadriceps Muscle of the Thigh]]></TERM><TERM><![CDATA[Quality of life]]></TERM><TERM><![CDATA[Regulation]]></TERM><TERM><![CDATA[Rehabilitation therapy]]></TERM><TERM><![CDATA[relating to nervous system]]></TERM><TERM><![CDATA[Relative (related person)]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Resistance]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Site]]></TERM><TERM><![CDATA[Source]]></TERM><TERM><![CDATA[Spinal Cord]]></TERM><TERM><![CDATA[success]]></TERM><TERM><![CDATA[Synapses]]></TERM><TERM><![CDATA[Techniques]]></TERM><TERM><![CDATA[Transcranial magnetic stimulation]]></TERM><TERM><![CDATA[treatment strategy]]></TERM><TERM><![CDATA[Veterans]]></TERM><TERM><![CDATA[Walking]]></TERM><TERM><![CDATA[Work]]></TERM><TERM><![CDATA[Workload]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Premature fatigue in veterans with heart failure: neuronal influences]]></PROJECT_TITLE><SERIAL_NUMBER>001572</SERIAL_NUMBER><STUDY_SECTION>RRDS</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST></TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9027974</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>AI</ADMINISTERING_IC><APPLICATION_TYPE>1</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/05/2015</AWARD_NOTICE_DATE><BUDGET_START>11/05/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>855</CFDA_CODE><CORE_PROJECT_NUM>R01AI117911</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-13-302</FOA_NUMBER><FULL_PROJECT_NUM>1R01AI117911-01A1</FULL_PROJECT_NUM><FUNDING_ICs>NIAID:394588\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>DURHAM</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[GENETICS]]></ORG_DEPT><ORG_DISTRICT>01</ORG_DISTRICT><ORG_DUNS>044387793</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[DUKE UNIVERSITY]]></ORG_NAME><ORG_STATE>NC</ORG_STATE><ORG_ZIPCODE>277054673</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE Infections by bacterial pathogens generate substantial tissue damage and alteration in metabolism that have detrimental consequences even after infections have been cleared. Failure to reverse the alterations in host physiology that take place in response to infections may result in recurrent infections, inappropriate wound healing, autoimmune diseases, and chronic inflammatory disorders. We plan to dissect mechanisms of control of recovery from infections that operate at the whole animal level. A better understanding of organismal responses that take place after an infection has been cleared could lead to new therapeutic targets for inflammatory diseases.   
      

]]></PHR><PIS><PI><PI_NAME>ABALLAY, ALEJANDRO </PI_NAME><PI_ID>7604113</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>SINGLETON, KENTNER L</PROGRAM_OFFICER_NAME><PROJECT_START>11/05/2015</PROJECT_START><PROJECT_END>10/31/2020</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Ablation]]></TERM><TERM><![CDATA[Acute]]></TERM><TERM><![CDATA[American Society of Hematology]]></TERM><TERM><![CDATA[Animals]]></TERM><TERM><![CDATA[Antibiotic Therapy]]></TERM><TERM><![CDATA[Antibiotics]]></TERM><TERM><![CDATA[Bacterial Infections]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Biological]]></TERM><TERM><![CDATA[C. elegans genome]]></TERM><TERM><![CDATA[Caenorhabditis elegans]]></TERM><TERM><![CDATA[cell growth regulation]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[chronic autoimmune disease]]></TERM><TERM><![CDATA[Collaborations]]></TERM><TERM><![CDATA[Computer Simulation]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Dissection]]></TERM><TERM><![CDATA[dopaminergic neuron]]></TERM><TERM><![CDATA[Drug Metabolic Detoxication]]></TERM><TERM><![CDATA[Endocrine]]></TERM><TERM><![CDATA[Exhibits]]></TERM><TERM><![CDATA[Failure (biologic function)]]></TERM><TERM><![CDATA[G Protein-Coupled Receptor Signaling]]></TERM><TERM><![CDATA[G-Protein-Coupled Receptors]]></TERM><TERM><![CDATA[Gene Expression Profiling]]></TERM><TERM><![CDATA[Genes]]></TERM><TERM><![CDATA[Genetic]]></TERM><TERM><![CDATA[Homeostasis]]></TERM><TERM><![CDATA[immune activation]]></TERM><TERM><![CDATA[Immune response]]></TERM><TERM><![CDATA[Immune system]]></TERM><TERM><![CDATA[Immunity]]></TERM><TERM><![CDATA[Infection]]></TERM><TERM><![CDATA[Inflammation]]></TERM><TERM><![CDATA[Inflammatory]]></TERM><TERM><![CDATA[insight]]></TERM><TERM><![CDATA[Killings]]></TERM><TERM><![CDATA[Laboratories]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[Ligands]]></TERM><TERM><![CDATA[Link]]></TERM><TERM><![CDATA[Mediator of activation protein]]></TERM><TERM><![CDATA[Metabolism]]></TERM><TERM><![CDATA[microbial]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[mutant]]></TERM><TERM><![CDATA[Natural Immunity]]></TERM><TERM><![CDATA[Nature]]></TERM><TERM><![CDATA[Nematoda]]></TERM><TERM><![CDATA[Nervous system structure]]></TERM><TERM><![CDATA[neural circuit]]></TERM><TERM><![CDATA[Neurons]]></TERM><TERM><![CDATA[Neuropeptides]]></TERM><TERM><![CDATA[neuroregulation]]></TERM><TERM><![CDATA[Neurosecretory Systems]]></TERM><TERM><![CDATA[Neurotransmitters]]></TERM><TERM><![CDATA[new therapeutic target]]></TERM><TERM><![CDATA[optogenetics]]></TERM><TERM><![CDATA[Organism]]></TERM><TERM><![CDATA[Oxidation-Reduction]]></TERM><TERM><![CDATA[pathogen]]></TERM><TERM><![CDATA[Pathway interactions]]></TERM><TERM><![CDATA[Pharmaceutical Preparations]]></TERM><TERM><![CDATA[Phase]]></TERM><TERM><![CDATA[Physiological]]></TERM><TERM><![CDATA[Physiological Processes]]></TERM><TERM><![CDATA[Physiology]]></TERM><TERM><![CDATA[Promotor (Genetics)]]></TERM><TERM><![CDATA[protein folding]]></TERM><TERM><![CDATA[Proteins]]></TERM><TERM><![CDATA[public health relevance]]></TERM><TERM><![CDATA[Publishing]]></TERM><TERM><![CDATA[receptor-mediated signaling]]></TERM><TERM><![CDATA[Recovery]]></TERM><TERM><![CDATA[Recurrence]]></TERM><TERM><![CDATA[Regulation]]></TERM><TERM><![CDATA[relating to nervous system]]></TERM><TERM><![CDATA[research study]]></TERM><TERM><![CDATA[Resolution]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[Signaling Molecule]]></TERM><TERM><![CDATA[Surface]]></TERM><TERM><![CDATA[Synapses]]></TERM><TERM><![CDATA[System]]></TERM><TERM><![CDATA[Technology]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Tissues]]></TERM><TERM><![CDATA[transcription factor]]></TERM><TERM><![CDATA[Universities]]></TERM><TERM><![CDATA[Virulence Factors]]></TERM><TERM><![CDATA[Wound Healing]]></TERM><TERM><![CDATA[Xenobiotics]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[C. elegans to study organismal control of recovery from bacterial infections]]></PROJECT_TITLE><SERIAL_NUMBER>117911</SERIAL_NUMBER><STUDY_SECTION>III</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Innate Immunity and Inflammation Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>01</SUPPORT_YEAR><SUFFIX>A1</SUFFIX><DIRECT_COST_AMT>250000</DIRECT_COST_AMT><INDIRECT_COST_AMT>144588</INDIRECT_COST_AMT><TOTAL_COST>394588</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9031468</APPLICATION_ID><ACTIVITY>I21</ACTIVITY><ADMINISTERING_IC>VA</ADMINISTERING_IC><APPLICATION_TYPE>1</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/27/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>999</CFDA_CODE><CORE_PROJECT_NUM>I21RX002034</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-RX-14-009</FOA_NUMBER><FULL_PROJECT_NUM>1I21RX002034-01</FULL_PROJECT_NUM><FUNDING_ICs>VA:99968\</FUNDING_ICs><FUNDING_MECHANISM>RESEARCH CENTERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>Veterans Affairs</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>MINNEAPOLIS</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>05</ORG_DISTRICT><ORG_DUNS>071774624</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[MINNEAPOLIS VA  MEDICAL CENTER]]></ORG_NAME><ORG_STATE>MN</ORG_STATE><ORG_ZIPCODE>554172309</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE   
Veterans with amputations are a growing and important group within the Department of Veteran Affairs with special needs and challenges. Veterans suffer from amputations from traumatic causes, such as combat, but even more so from vascular disease such as diabetes. This project is designed to evaluate how well Veterans who suffer from amputation are reintegrating into their roles with family, friends, communities, and the workplace. It will use surveys and interviews to learn from Veterans who have lower limb amputations. The information from the study will help investigators to design new medical devices (such as wheel chairs and prosthetic limbs), mHealth programs (such as smart phone apps), and psychological treatments (such as group or individual psychotherapies) to aid Veterans who have amputations in maximizing their quality of life and participation in their families and communities.   
   
      

]]></PHR><PIS><PI><PI_NAME>ERBES, CHRISTOPHER R</PI_NAME><PI_ID>9048334</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>11/01/2015</PROJECT_START><PROJECT_END>10/31/2017</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[Advanced Development]]></TERM><TERM><![CDATA[Afghanistan]]></TERM><TERM><![CDATA[Amputation]]></TERM><TERM><![CDATA[Amputees]]></TERM><TERM><![CDATA[Anxiety]]></TERM><TERM><![CDATA[Area]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Biomedical Engineering]]></TERM><TERM><![CDATA[Body Image]]></TERM><TERM><![CDATA[care systems]]></TERM><TERM><![CDATA[Caring]]></TERM><TERM><![CDATA[Cellular Phone]]></TERM><TERM><![CDATA[Child Rearing]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[Cognitive Therapy]]></TERM><TERM><![CDATA[Collaborations]]></TERM><TERM><![CDATA[combat]]></TERM><TERM><![CDATA[Communities]]></TERM><TERM><![CDATA[community living]]></TERM><TERM><![CDATA[Community Participation]]></TERM><TERM><![CDATA[community reintegration]]></TERM><TERM><![CDATA[Comorbidity]]></TERM><TERM><![CDATA[contextual factors]]></TERM><TERM><![CDATA[Country]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Databases]]></TERM><TERM><![CDATA[Demographic Factors]]></TERM><TERM><![CDATA[Department of Defense]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Devices]]></TERM><TERM><![CDATA[Diabetes Mellitus]]></TERM><TERM><![CDATA[disability]]></TERM><TERM><![CDATA[Economics]]></TERM><TERM><![CDATA[Educational aspects]]></TERM><TERM><![CDATA[Emotional]]></TERM><TERM><![CDATA[Environmental Risk Factor]]></TERM><TERM><![CDATA[Equilibrium]]></TERM><TERM><![CDATA[Evaluation]]></TERM><TERM><![CDATA[Event]]></TERM><TERM><![CDATA[Exhibits]]></TERM><TERM><![CDATA[experience]]></TERM><TERM><![CDATA[Family]]></TERM><TERM><![CDATA[Friends]]></TERM><TERM><![CDATA[Future]]></TERM><TERM><![CDATA[General Population]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Guidelines]]></TERM><TERM><![CDATA[Health Services]]></TERM><TERM><![CDATA[Healthcare Systems]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[indexing]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[Injury]]></TERM><TERM><![CDATA[interest]]></TERM><TERM><![CDATA[Intervention]]></TERM><TERM><![CDATA[Interview]]></TERM><TERM><![CDATA[Investigation]]></TERM><TERM><![CDATA[Iraq]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[Learning]]></TERM><TERM><![CDATA[Life]]></TERM><TERM><![CDATA[limb amputation]]></TERM><TERM><![CDATA[Limb Prosthesis]]></TERM><TERM><![CDATA[Linear Regressions]]></TERM><TERM><![CDATA[Lower Extremity]]></TERM><TERM><![CDATA[Measures]]></TERM><TERM><![CDATA[Medical]]></TERM><TERM><![CDATA[Medical Device]]></TERM><TERM><![CDATA[Medical Technology]]></TERM><TERM><![CDATA[Mental Depression]]></TERM><TERM><![CDATA[Methodology]]></TERM><TERM><![CDATA[Methods]]></TERM><TERM><![CDATA[mHealth]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[Occupational]]></TERM><TERM><![CDATA[Outcome]]></TERM><TERM><![CDATA[Pain]]></TERM><TERM><![CDATA[Persian Gulf]]></TERM><TERM><![CDATA[Population]]></TERM><TERM><![CDATA[programs]]></TERM><TERM><![CDATA[Prosthesis]]></TERM><TERM><![CDATA[Prosthesis Design]]></TERM><TERM><![CDATA[Protocols documentation]]></TERM><TERM><![CDATA[Psychiatric Social Work]]></TERM><TERM><![CDATA[psychologic]]></TERM><TERM><![CDATA[psychological distress]]></TERM><TERM><![CDATA[Psychological Factors]]></TERM><TERM><![CDATA[Psychologist]]></TERM><TERM><![CDATA[psychosocial]]></TERM><TERM><![CDATA[Psychotherapy]]></TERM><TERM><![CDATA[public health relevance]]></TERM><TERM><![CDATA[Quality of life]]></TERM><TERM><![CDATA[Regression Analysis]]></TERM><TERM><![CDATA[Rehabilitation therapy]]></TERM><TERM><![CDATA[Religion and Spirituality]]></TERM><TERM><![CDATA[Research Personnel]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Sampling]]></TERM><TERM><![CDATA[Schools]]></TERM><TERM><![CDATA[Self Care]]></TERM><TERM><![CDATA[Services]]></TERM><TERM><![CDATA[social]]></TERM><TERM><![CDATA[Social support]]></TERM><TERM><![CDATA[Specific qualifier value]]></TERM><TERM><![CDATA[Spouses]]></TERM><TERM><![CDATA[statistics]]></TERM><TERM><![CDATA[Structure]]></TERM><TERM><![CDATA[Subgroup]]></TERM><TERM><![CDATA[Survey Methodology]]></TERM><TERM><![CDATA[Surveys]]></TERM><TERM><![CDATA[technological innovation]]></TERM><TERM><![CDATA[Technology]]></TERM><TERM><![CDATA[Transcript]]></TERM><TERM><![CDATA[Traumatic Amputation]]></TERM><TERM><![CDATA[Vascular Diseases]]></TERM><TERM><![CDATA[Veterans]]></TERM><TERM><![CDATA[Vietnam]]></TERM><TERM><![CDATA[Visit]]></TERM><TERM><![CDATA[Vocational rehabilitation]]></TERM><TERM><![CDATA[Wheelchairs]]></TERM><TERM><![CDATA[Work]]></TERM><TERM><![CDATA[Workplace]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Understanding Participation in Veterans with Amputations]]></PROJECT_TITLE><SERIAL_NUMBER>002034</SERIAL_NUMBER><STUDY_SECTION>RRDS</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>01</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST></TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9032599</APPLICATION_ID><ACTIVITY>I21</ACTIVITY><ADMINISTERING_IC>VA</ADMINISTERING_IC><APPLICATION_TYPE>1</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/03/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>999</CFDA_CODE><CORE_PROJECT_NUM>I21RX001896</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-RX-14-009</FOA_NUMBER><FULL_PROJECT_NUM>1I21RX001896-01A1</FULL_PROJECT_NUM><FUNDING_ICs>VA:100000\</FUNDING_ICs><FUNDING_MECHANISM>RESEARCH CENTERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>Veterans Affairs</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>PHILADELPHIA</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>02</ORG_DISTRICT><ORG_DUNS>071609291</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[PHILADELPHIA VA MEDICAL CENTER]]></ORG_NAME><ORG_STATE>PA</ORG_STATE><ORG_ZIPCODE>191044551</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE   
More than 130,000 active service members received diagnoses of intervertebral disc (IVD) degeneration between 2001 and 2010, with annual incidence rates more than doubling over this period. Among Veterans, chronic back pain accounts for over 70 percent of chiropractic visits and in many cases is directly connected to their period of service. We expect that IVDs repaired with chondrocytes seeded in hydrogel will show improved biomechanical properties, decreased inflammation, and improved structure. These studies in the rabbit will lay the groundwork for clinical studies that will test if transplanted chondrocytes are effective in reducing disc degeneration and back pain, thus benefiting patients.   
   
      

]]></PHR><PIS><PI><PI_NAME>ZHANG, YEJIA </PI_NAME><PI_ID>6089157</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>11/01/2015</PROJECT_START><PROJECT_END>10/31/2017</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Accounting]]></TERM><TERM><![CDATA[Acute]]></TERM><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[Adenoviruses]]></TERM><TERM><![CDATA[Allogenic]]></TERM><TERM><![CDATA[Animal Model]]></TERM><TERM><![CDATA[Area]]></TERM><TERM><![CDATA[Back Pain]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Biocompatible]]></TERM><TERM><![CDATA[Biological Preservation]]></TERM><TERM><![CDATA[Biomechanics]]></TERM><TERM><![CDATA[Body Temperature]]></TERM><TERM><![CDATA[bone morphogenetic protein 7]]></TERM><TERM><![CDATA[Bone Morphogenetic Proteins]]></TERM><TERM><![CDATA[cartilage repair]]></TERM><TERM><![CDATA[Cell Survival]]></TERM><TERM><![CDATA[Cell Therapy]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Cellular biology]]></TERM><TERM><![CDATA[Chiropractic (field)]]></TERM><TERM><![CDATA[Chondrocytes]]></TERM><TERM><![CDATA[chronic back pain]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[Clinical Research]]></TERM><TERM><![CDATA[cost]]></TERM><TERM><![CDATA[crosslink]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Deposition]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Diagnosis]]></TERM><TERM><![CDATA[Drug Formulations]]></TERM><TERM><![CDATA[Dyes]]></TERM><TERM><![CDATA[enhancing factor]]></TERM><TERM><![CDATA[Evaluation]]></TERM><TERM><![CDATA[Extracellular Matrix]]></TERM><TERM><![CDATA[Extravasation]]></TERM><TERM><![CDATA[Fluorescence]]></TERM><TERM><![CDATA[functional restoration]]></TERM><TERM><![CDATA[Gel]]></TERM><TERM><![CDATA[Gene Expression]]></TERM><TERM><![CDATA[General Population]]></TERM><TERM><![CDATA[Growth]]></TERM><TERM><![CDATA[Growth Factor]]></TERM><TERM><![CDATA[Histology]]></TERM><TERM><![CDATA[Homologous Transplantation]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[Hyaluronic Acid]]></TERM><TERM><![CDATA[Hydrogels]]></TERM><TERM><![CDATA[IL1B gene]]></TERM><TERM><![CDATA[Image]]></TERM><TERM><![CDATA[Implant]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[In Situ]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[Incidence]]></TERM><TERM><![CDATA[Inflammation]]></TERM><TERM><![CDATA[Inflammatory Response]]></TERM><TERM><![CDATA[Injectable]]></TERM><TERM><![CDATA[Injection of therapeutic agent]]></TERM><TERM><![CDATA[injured]]></TERM><TERM><![CDATA[Injury]]></TERM><TERM><![CDATA[Interleukin-8]]></TERM><TERM><![CDATA[Intervertebral disc structure]]></TERM><TERM><![CDATA[intervertebral disk degeneration]]></TERM><TERM><![CDATA[Label]]></TERM><TERM><![CDATA[Literature]]></TERM><TERM><![CDATA[macrophage]]></TERM><TERM><![CDATA[Magnetic Resonance Imaging]]></TERM><TERM><![CDATA[Mechanics]]></TERM><TERM><![CDATA[member]]></TERM><TERM><![CDATA[Military Personnel]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Modification]]></TERM><TERM><![CDATA[Morphology]]></TERM><TERM><![CDATA[Motion]]></TERM><TERM><![CDATA[Neck Pain]]></TERM><TERM><![CDATA[Needles]]></TERM><TERM><![CDATA[novel strategies]]></TERM><TERM><![CDATA[nucleus pulposus]]></TERM><TERM><![CDATA[operation]]></TERM><TERM><![CDATA[Operative Surgical Procedures]]></TERM><TERM><![CDATA[Oryctolagus cuniculus]]></TERM><TERM><![CDATA[overexpression]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Phenotype]]></TERM><TERM><![CDATA[Physiological]]></TERM><TERM><![CDATA[Pilot Projects]]></TERM><TERM><![CDATA[preclinical study]]></TERM><TERM><![CDATA[Prevalence]]></TERM><TERM><![CDATA[prevent]]></TERM><TERM><![CDATA[Progressive Disease]]></TERM><TERM><![CDATA[Property]]></TERM><TERM><![CDATA[public health relevance]]></TERM><TERM><![CDATA[regenerative]]></TERM><TERM><![CDATA[repaired]]></TERM><TERM><![CDATA[Risk]]></TERM><TERM><![CDATA[scaffold]]></TERM><TERM><![CDATA[Services]]></TERM><TERM><![CDATA[Site]]></TERM><TERM><![CDATA[Source]]></TERM><TERM><![CDATA[spinal disk injury]]></TERM><TERM><![CDATA[stem cell differentiation]]></TERM><TERM><![CDATA[Structure]]></TERM><TERM><![CDATA[Supporting Cell]]></TERM><TERM><![CDATA[Symptoms]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Therapeutic]]></TERM><TERM><![CDATA[Therapeutic Effect]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[Tissue Engineering]]></TERM><TERM><![CDATA[Tissues]]></TERM><TERM><![CDATA[Training]]></TERM><TERM><![CDATA[Translations]]></TERM><TERM><![CDATA[Transplantation]]></TERM><TERM><![CDATA[Tumor Necrosis Factors]]></TERM><TERM><![CDATA[Veterans]]></TERM><TERM><![CDATA[Visit]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Cell Therapy for the Degenerating Intervertebral Disc]]></PROJECT_TITLE><SERIAL_NUMBER>001896</SERIAL_NUMBER><STUDY_SECTION>RRDS</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>01</SUPPORT_YEAR><SUFFIX>A1</SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST></TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9034937</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>AI</ADMINISTERING_IC><APPLICATION_TYPE>1</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/04/2015</AWARD_NOTICE_DATE><BUDGET_START>11/05/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>855</CFDA_CODE><CORE_PROJECT_NUM>R01AI120202</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>PA-13-302</FOA_NUMBER><FULL_PROJECT_NUM>1R01AI120202-01A1</FULL_PROJECT_NUM><FUNDING_ICs>NIAID:390000\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>CINCINNATI</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>01</ORG_DISTRICT><ORG_DUNS>071284913</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[CINCINNATI CHILDRENS HOSP MED CTR]]></ORG_NAME><ORG_STATE>OH</ORG_STATE><ORG_ZIPCODE>452293039</ORG_ZIPCODE><PHR><![CDATA[Public Health Relevance. Immune tolerance expands during pregnancy to accommodate discordant paternal
antigens expressed by the developing fetus. By characterizing the antigen-specific memory features for
immune cells that drive expanded fetal tolerance during pregnancy and after parturition, the long-term goals of
this research is to develop new strategies aimed at reinforcing fetal tolerance and protecting against pregnancy
complications such as stillbirth and preeclampsia.]]></PHR><PIS><PI><PI_NAME>WAY, SING SING </PI_NAME><PI_ID>8232500</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>PRABHUDAS, MERCY R.</PROGRAM_OFFICER_NAME><PROJECT_START>11/05/2015</PROJECT_START><PROJECT_END>10/31/2020</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[abstracting]]></TERM><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[Agreement]]></TERM><TERM><![CDATA[Allogenic]]></TERM><TERM><![CDATA[Animals]]></TERM><TERM><![CDATA[Antigens]]></TERM><TERM><![CDATA[Autoantigens]]></TERM><TERM><![CDATA[Autoimmune Diseases]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Biology]]></TERM><TERM><![CDATA[Birth]]></TERM><TERM><![CDATA[CD4 Positive T Lymphocytes]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[cellular engineering]]></TERM><TERM><![CDATA[Disease remission]]></TERM><TERM><![CDATA[embryo/fetus antigen]]></TERM><TERM><![CDATA[Engineering]]></TERM><TERM><![CDATA[Epidemiology]]></TERM><TERM><![CDATA[experience]]></TERM><TERM><![CDATA[Experimental Autoimmune Encephalomyelitis]]></TERM><TERM><![CDATA[Female]]></TERM><TERM><![CDATA[fetal]]></TERM><TERM><![CDATA[Fetus]]></TERM><TERM><![CDATA[fetus cell]]></TERM><TERM><![CDATA[Flow Cytometry]]></TERM><TERM><![CDATA[Fracture]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[Immune]]></TERM><TERM><![CDATA[Immune Tolerance]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[in vivo Model]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[innovation]]></TERM><TERM><![CDATA[Knowledge]]></TERM><TERM><![CDATA[Link]]></TERM><TERM><![CDATA[magnetic beads]]></TERM><TERM><![CDATA[Maintenance]]></TERM><TERM><![CDATA[Memory]]></TERM><TERM><![CDATA[memory CD4 T lymphocyte]]></TERM><TERM><![CDATA[Microchimerism]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[molecular phenotype]]></TERM><TERM><![CDATA[Mothers]]></TERM><TERM><![CDATA[Multiple Sclerosis]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[Organ]]></TERM><TERM><![CDATA[Peptides]]></TERM><TERM><![CDATA[Physiological]]></TERM><TERM><![CDATA[Postpartum Period]]></TERM><TERM><![CDATA[Pre-Eclampsia]]></TERM><TERM><![CDATA[Pregnancy]]></TERM><TERM><![CDATA[Pregnancy Complications]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[Property]]></TERM><TERM><![CDATA[public health relevance]]></TERM><TERM><![CDATA[Recurrence]]></TERM><TERM><![CDATA[Regulatory T-Lymphocyte]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Severity of illness]]></TERM><TERM><![CDATA[Specificity]]></TERM><TERM><![CDATA[Spontaneous abortion]]></TERM><TERM><![CDATA[Staining method]]></TERM><TERM><![CDATA[Stains]]></TERM><TERM><![CDATA[Stillbirth]]></TERM><TERM><![CDATA[T-Cell Antigen Receptor Specificity]]></TERM><TERM><![CDATA[T-Cell Receptor]]></TERM><TERM><![CDATA[T-Lymphocyte]]></TERM><TERM><![CDATA[T-Lymphocyte Subsets]]></TERM><TERM><![CDATA[Tissues]]></TERM><TERM><![CDATA[tool]]></TERM><TERM><![CDATA[Transgenic Mice]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Maternal Regulatory T cell antigen-specificity]]></PROJECT_TITLE><SERIAL_NUMBER>120202</SERIAL_NUMBER><STUDY_SECTION>CMIB</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Cellular and Molecular Immunology - B Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>01</SUPPORT_YEAR><SUFFIX>A1</SUFFIX><DIRECT_COST_AMT>250000</DIRECT_COST_AMT><INDIRECT_COST_AMT>140000</INDIRECT_COST_AMT><TOTAL_COST>390000</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9051320</APPLICATION_ID><ACTIVITY>F30</ACTIVITY><ADMINISTERING_IC>HD</ADMINISTERING_IC><APPLICATION_TYPE>1</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>09/24/2015</AWARD_NOTICE_DATE><BUDGET_START>09/24/2015</BUDGET_START><BUDGET_END>09/23/2016</BUDGET_END><CFDA_CODE>865</CFDA_CODE><CORE_PROJECT_NUM>F30HD084144</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-14-150</FOA_NUMBER><FULL_PROJECT_NUM>1F30HD084144-01A1</FULL_PROJECT_NUM><FUNDING_ICs>NICHD:39306\</FUNDING_ICs><FUNDING_MECHANISM>TRAINING, INDIVIDUAL</FUNDING_MECHANISM><FY>2015</FY><IC_NAME>EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &amp; HUMAN DEVELOPMENT</IC_NAME><NIH_SPENDING_CATS><CATEGORY><![CDATA[Bioengineering]]></CATEGORY><CATEGORY><![CDATA[Brain Disorders]]></CATEGORY><CATEGORY><![CDATA[Clinical Research]]></CATEGORY><CATEGORY><![CDATA[Diagnostic Radiology]]></CATEGORY><CATEGORY><![CDATA[Injury (total) Accidents/Adverse Effects]]></CATEGORY><CATEGORY><![CDATA[Injury - Trauma - (Head and Spine)]]></CATEGORY><CATEGORY><![CDATA[Injury - Traumatic brain injury]]></CATEGORY><CATEGORY><![CDATA[Neurosciences]]></CATEGORY></NIH_SPENDING_CATS><ORG_CITY>DETROIT</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[PSYCHIATRY]]></ORG_DEPT><ORG_DISTRICT>13</ORG_DISTRICT><ORG_DUNS>001962224</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[WAYNE STATE UNIVERSITY]]></ORG_NAME><ORG_STATE>MI</ORG_STATE><ORG_ZIPCODE>482024050</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: This research will benefit public health by helping to improve our understanding of blood supply and metabolic changes in the brain following concussion. We propose to determine the relationship between cerebral blood flow and metabolism and concussion symptoms, leading to a better understanding of the physiological underpinnings of these symptoms and allowing physicians to order patient-specific treatments.   
   
      

]]></PHR><PIS><PI><PI_NAME>WISEMAN, NATALIE </PI_NAME><PI_ID>11579941</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>MICHEL, MARY E</PROGRAM_OFFICER_NAME><PROJECT_START>09/24/2015</PROJECT_START><PROJECT_END>09/23/2019</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Accounting]]></TERM><TERM><![CDATA[Acute]]></TERM><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[American]]></TERM><TERM><![CDATA[arm]]></TERM><TERM><![CDATA[Blood]]></TERM><TERM><![CDATA[blood flow measurement]]></TERM><TERM><![CDATA[Blood gas]]></TERM><TERM><![CDATA[Brain]]></TERM><TERM><![CDATA[Brain Concussion]]></TERM><TERM><![CDATA[Brain imaging]]></TERM><TERM><![CDATA[Brain Injuries]]></TERM><TERM><![CDATA[brain metabolism]]></TERM><TERM><![CDATA[Brain region]]></TERM><TERM><![CDATA[brain tissue]]></TERM><TERM><![CDATA[Calibration]]></TERM><TERM><![CDATA[Catheters]]></TERM><TERM><![CDATA[Cerebrovascular Circulation]]></TERM><TERM><![CDATA[Cerebrum]]></TERM><TERM><![CDATA[Chronic]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[clinical practice]]></TERM><TERM><![CDATA[cohort]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Devices]]></TERM><TERM><![CDATA[Diagnostic]]></TERM><TERM><![CDATA[Emotional]]></TERM><TERM><![CDATA[Evaluation]]></TERM><TERM><![CDATA[Family member]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Health Care Costs]]></TERM><TERM><![CDATA[Hematocrit procedure]]></TERM><TERM><![CDATA[hemodynamics]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[Hypoxia]]></TERM><TERM><![CDATA[Image]]></TERM><TERM><![CDATA[Image Analysis]]></TERM><TERM><![CDATA[Imaging Techniques]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[injured]]></TERM><TERM><![CDATA[Injury]]></TERM><TERM><![CDATA[insight]]></TERM><TERM><![CDATA[internal cerebral vein]]></TERM><TERM><![CDATA[Investigation]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[Left]]></TERM><TERM><![CDATA[Living Costs]]></TERM><TERM><![CDATA[Location]]></TERM><TERM><![CDATA[Magnetic Resonance]]></TERM><TERM><![CDATA[Magnetic Resonance Imaging]]></TERM><TERM><![CDATA[Maps]]></TERM><TERM><![CDATA[Measurement]]></TERM><TERM><![CDATA[Measures]]></TERM><TERM><![CDATA[Metabolic]]></TERM><TERM><![CDATA[Metabolism]]></TERM><TERM><![CDATA[Methods]]></TERM><TERM><![CDATA[molecular imaging]]></TERM><TERM><![CDATA[Negative Finding]]></TERM><TERM><![CDATA[Neurobehavioral Manifestations]]></TERM><TERM><![CDATA[Neurocognitive]]></TERM><TERM><![CDATA[Neurocognitive Deficit]]></TERM><TERM><![CDATA[neuroimaging]]></TERM><TERM><![CDATA[Neuronal Injury]]></TERM><TERM><![CDATA[neuropsychological]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[Outcome]]></TERM><TERM><![CDATA[Oxygen]]></TERM><TERM><![CDATA[Oxygen Consumption]]></TERM><TERM><![CDATA[Paint]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Perfusion]]></TERM><TERM><![CDATA[Physicians]]></TERM><TERM><![CDATA[Physiological]]></TERM><TERM><![CDATA[point of care]]></TERM><TERM><![CDATA[Post-Concussion Syndrome]]></TERM><TERM><![CDATA[Predictive Value]]></TERM><TERM><![CDATA[Predisposition]]></TERM><TERM><![CDATA[prevent]]></TERM><TERM><![CDATA[Protocols documentation]]></TERM><TERM><![CDATA[public health medicine (field)]]></TERM><TERM><![CDATA[public health relevance]]></TERM><TERM><![CDATA[Quality of life]]></TERM><TERM><![CDATA[Radioactive]]></TERM><TERM><![CDATA[Recruitment Activity]]></TERM><TERM><![CDATA[Relative (related person)]]></TERM><TERM><![CDATA[Reporting]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Resolution]]></TERM><TERM><![CDATA[response to injury]]></TERM><TERM><![CDATA[Risk]]></TERM><TERM><![CDATA[Scanning]]></TERM><TERM><![CDATA[Staging]]></TERM><TERM><![CDATA[stroke]]></TERM><TERM><![CDATA[Symptoms]]></TERM><TERM><![CDATA[System]]></TERM><TERM><![CDATA[TBI Patients]]></TERM><TERM><![CDATA[Techniques]]></TERM><TERM><![CDATA[time use]]></TERM><TERM><![CDATA[tissue oxygenation]]></TERM><TERM><![CDATA[Tissue Viability]]></TERM><TERM><![CDATA[Tissues]]></TERM><TERM><![CDATA[Tracer]]></TERM><TERM><![CDATA[Translating]]></TERM><TERM><![CDATA[Traumatic Brain Injury]]></TERM><TERM><![CDATA[Vascular blood supply]]></TERM><TERM><![CDATA[Veins]]></TERM><TERM><![CDATA[Venous]]></TERM><TERM><![CDATA[Weight]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Susceptibility Mapping of Cerebral Metabolism in Traumatic Brain Injury]]></PROJECT_TITLE><SERIAL_NUMBER>084144</SERIAL_NUMBER><STUDY_SECTION>ZRG1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>01</SUPPORT_YEAR><SUFFIX>A1</SUFFIX><DIRECT_COST_AMT>39306</DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>39306</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9053925</APPLICATION_ID><ACTIVITY>R13</ACTIVITY><ADMINISTERING_IC>TR</ADMINISTERING_IC><APPLICATION_TYPE>1</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/06/2015</AWARD_NOTICE_DATE><BUDGET_START>11/06/2015</BUDGET_START><BUDGET_END>11/05/2016</BUDGET_END><CFDA_CODE>350</CFDA_CODE><CORE_PROJECT_NUM>R13TR001399</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>PA-13-347</FOA_NUMBER><FULL_PROJECT_NUM>1R13TR001399-01</FULL_PROJECT_NUM><FUNDING_ICs>NCATS:10000\</FUNDING_ICs><FUNDING_MECHANISM>OTHER RESEARCH-RELATED</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>ALEXANDRIA</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>08</ORG_DISTRICT><ORG_DUNS>879826506</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[ASSOCIATION OF SUBSPECIALTY PROFESSORS]]></ORG_NAME><ORG_STATE>VA</ORG_STATE><ORG_ZIPCODE>223145946</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE (provided by applicant): The Alliance for Academic Internal Medicine and Association of Subspecialty Professors' project, Third Consensus Conference on the PI Workforce: Re-examining the Physician Investigator Workforce: New and Evolving Areas of Research and Pathways to Success in Academic Institutions is focused on assessing current environment in which academic medical centers develop the careers of physician-investigators, and to seek innovative solutions (beyond federal funding) to overcome existing challenges to maintain and expand a vigorous workforce. The conference will bring together key thought-leaders and content experts in the academic biomedical research community to develop recommendations leading to a set of best practices by which academic institutions optimally identify scientific talent and foster biomedical research careers of physicians.      

]]></PHR><PIS><PI><PI_NAME>SALATA, ROBERT A</PI_NAME><PI_ID>2057791</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>WILDE, DAVID B.</PROGRAM_OFFICER_NAME><PROJECT_START>11/06/2015</PROJECT_START><PROJECT_END>11/05/2016</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Academic Medical Centers]]></TERM><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[Adopted]]></TERM><TERM><![CDATA[Agreement]]></TERM><TERM><![CDATA[Area]]></TERM><TERM><![CDATA[Award]]></TERM><TERM><![CDATA[Biomedical Research]]></TERM><TERM><![CDATA[Budgets]]></TERM><TERM><![CDATA[career]]></TERM><TERM><![CDATA[career development]]></TERM><TERM><![CDATA[Charge]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[Communities]]></TERM><TERM><![CDATA[Consensus]]></TERM><TERM><![CDATA[Coupled]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Discipline]]></TERM><TERM><![CDATA[District of Columbia]]></TERM><TERM><![CDATA[Educational workshop]]></TERM><TERM><![CDATA[Ensure]]></TERM><TERM><![CDATA[Environment]]></TERM><TERM><![CDATA[Equilibrium]]></TERM><TERM><![CDATA[Fostering]]></TERM><TERM><![CDATA[Funding]]></TERM><TERM><![CDATA[Funding Mechanisms]]></TERM><TERM><![CDATA[Future]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Government Agencies]]></TERM><TERM><![CDATA[Grant]]></TERM><TERM><![CDATA[Growth]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[health care delivery]]></TERM><TERM><![CDATA[Healthcare]]></TERM><TERM><![CDATA[implementation science]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[Industry]]></TERM><TERM><![CDATA[innovation]]></TERM><TERM><![CDATA[Institution]]></TERM><TERM><![CDATA[interest]]></TERM><TERM><![CDATA[Internal Medicine]]></TERM><TERM><![CDATA[Investigation]]></TERM><TERM><![CDATA[Laboratories]]></TERM><TERM><![CDATA[Medical]]></TERM><TERM><![CDATA[medical schools]]></TERM><TERM><![CDATA[medical specialties]]></TERM><TERM><![CDATA[Medicine]]></TERM><TERM><![CDATA[meetings]]></TERM><TERM><![CDATA[Mentorship]]></TERM><TERM><![CDATA[Mission]]></TERM><TERM><![CDATA[Nursing Faculty]]></TERM><TERM><![CDATA[Outcome]]></TERM><TERM><![CDATA[Outcome Measure]]></TERM><TERM><![CDATA[Paper]]></TERM><TERM><![CDATA[Participant]]></TERM><TERM><![CDATA[Pathway interactions]]></TERM><TERM><![CDATA[patient oriented]]></TERM><TERM><![CDATA[Physician's Role]]></TERM><TERM><![CDATA[Physicians]]></TERM><TERM><![CDATA[post-doctoral training]]></TERM><TERM><![CDATA[professor]]></TERM><TERM><![CDATA[public health relevance]]></TERM><TERM><![CDATA[Publishing]]></TERM><TERM><![CDATA[Recommendation]]></TERM><TERM><![CDATA[Reporting]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Research Personnel]]></TERM><TERM><![CDATA[Research Support]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[Scientist]]></TERM><TERM><![CDATA[Self Assessment (Psychology)]]></TERM><TERM><![CDATA[Series]]></TERM><TERM><![CDATA[Solutions]]></TERM><TERM><![CDATA[success]]></TERM><TERM><![CDATA[symposium]]></TERM><TERM><![CDATA[Talents]]></TERM><TERM><![CDATA[tool]]></TERM><TERM><![CDATA[Training]]></TERM><TERM><![CDATA[United States National Institutes of Health]]></TERM><TERM><![CDATA[university student]]></TERM><TERM><![CDATA[Woman]]></TERM><TERM><![CDATA[Work]]></TERM><TERM><![CDATA[working group]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Third Consensus Conference on the PI Workforce: Re-examining the Physician Investigator Workforce: New and Evolving Areas of Research and Pathways to Success in Academic Institutions]]></PROJECT_TITLE><SERIAL_NUMBER>001399</SERIAL_NUMBER><STUDY_SECTION>ZTR1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>01</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>10000</DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>10000</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8965500</APPLICATION_ID><ACTIVITY>R03</ACTIVITY><ADMINISTERING_IC>AI</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/27/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>855</CFDA_CODE><CORE_PROJECT_NUM>R03AI110990</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-13-304</FOA_NUMBER><FULL_PROJECT_NUM>5R03AI110990-02</FULL_PROJECT_NUM><FUNDING_ICs>NIAID:78000\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>INDIANAPOLIS</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[MICROBIOLOGY/IMMUN/VIROLOGY]]></ORG_DEPT><ORG_DISTRICT>07</ORG_DISTRICT><ORG_DUNS>603007902</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS]]></ORG_NAME><ORG_STATE>IN</ORG_STATE><ORG_ZIPCODE>462022915</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Methicillin-resistant S. aureus is a major public health threat worldwide, and both treatment protocols and vaccine development is an area of major interest. Virulent MSRA clones have emerged as a cause of severe skin and soft tissue infection. In this proposal, we are planning on employing a successful protocol on both treatment and prevention of MSRA infection by employing a potent bioactive lipid, LTB4, to enhance host defense in murine models.]]></PHR><PIS><PI><PI_NAME>SEREZANI, CARLOS </PI_NAME><PI_ID>10188661</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>HUNTLEY, CLAYTON C.</PROGRAM_OFFICER_NAME><PROJECT_START>11/07/2014</PROJECT_START><PROJECT_END>10/31/2016</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[Antibiotic Resistance]]></TERM><TERM><![CDATA[Antibody Formation]]></TERM><TERM><![CDATA[Antigens]]></TERM><TERM><![CDATA[Area]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Biological]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Chemotactic Factors]]></TERM><TERM><![CDATA[Child]]></TERM><TERM><![CDATA[Clinical Trials]]></TERM><TERM><![CDATA[Communities]]></TERM><TERM><![CDATA[Cutaneous]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Dendritic Cells]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[effective therapy]]></TERM><TERM><![CDATA[Employment]]></TERM><TERM><![CDATA[Exhibits]]></TERM><TERM><![CDATA[Folliculitis]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Gram-Positive Bacteria]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Host Defense]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[Immune]]></TERM><TERM><![CDATA[Immune response]]></TERM><TERM><![CDATA[Immunologics]]></TERM><TERM><![CDATA[Immunomodulators]]></TERM><TERM><![CDATA[Immunotherapeutic agent]]></TERM><TERM><![CDATA[Impetigo]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[In Vitro]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[Infection]]></TERM><TERM><![CDATA[Infectious Skin Diseases]]></TERM><TERM><![CDATA[Inflammation]]></TERM><TERM><![CDATA[innovation]]></TERM><TERM><![CDATA[interest]]></TERM><TERM><![CDATA[Killings]]></TERM><TERM><![CDATA[Leishmania (genus)]]></TERM><TERM><![CDATA[Leukocytes]]></TERM><TERM><![CDATA[Leukotriene B4]]></TERM><TERM><![CDATA[Life]]></TERM><TERM><![CDATA[Ligation]]></TERM><TERM><![CDATA[lipid mediator]]></TERM><TERM><![CDATA[Lipids]]></TERM><TERM><![CDATA[Lung]]></TERM><TERM><![CDATA[Lymphocyte]]></TERM><TERM><![CDATA[macrophage]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[Methicillin Resistance]]></TERM><TERM><![CDATA[methicillin resistant Staphylococcus aureus (organism)]]></TERM><TERM><![CDATA[microbial]]></TERM><TERM><![CDATA[microorganism interaction]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[Myelogenous]]></TERM><TERM><![CDATA[National Institute of Allergy and Infectious Disease]]></TERM><TERM><![CDATA[neutrophil]]></TERM><TERM><![CDATA[Neutrophil Activation]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[Organ]]></TERM><TERM><![CDATA[pathogen]]></TERM><TERM><![CDATA[Pathogenesis]]></TERM><TERM><![CDATA[Pattern]]></TERM><TERM><![CDATA[Phagocytes]]></TERM><TERM><![CDATA[Phagocytosis]]></TERM><TERM><![CDATA[prevent]]></TERM><TERM><![CDATA[Prevention]]></TERM><TERM><![CDATA[Prevention strategy]]></TERM><TERM><![CDATA[Preventive]]></TERM><TERM><![CDATA[Production]]></TERM><TERM><![CDATA[programs]]></TERM><TERM><![CDATA[Property]]></TERM><TERM><![CDATA[Protocols documentation]]></TERM><TERM><![CDATA[public health medicine (field)]]></TERM><TERM><![CDATA[receptor]]></TERM><TERM><![CDATA[Receptor Activation]]></TERM><TERM><![CDATA[research study]]></TERM><TERM><![CDATA[Resistance]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[Site]]></TERM><TERM><![CDATA[Skin]]></TERM><TERM><![CDATA[Skin Tissue]]></TERM><TERM><![CDATA[Soft Tissue Infections]]></TERM><TERM><![CDATA[Staphylococcus aureus]]></TERM><TERM><![CDATA[Streptococcus pneumoniae]]></TERM><TERM><![CDATA[T-Cell Activation]]></TERM><TERM><![CDATA[T-Lymphocyte]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Therapeutic]]></TERM><TERM><![CDATA[Therapeutic Effect]]></TERM><TERM><![CDATA[Toll-like receptors]]></TERM><TERM><![CDATA[Toxin]]></TERM><TERM><![CDATA[Treatment Protocols]]></TERM><TERM><![CDATA[Ulcer]]></TERM><TERM><![CDATA[United States National Institutes of Health]]></TERM><TERM><![CDATA[Vaccination]]></TERM><TERM><![CDATA[vaccine candidate]]></TERM><TERM><![CDATA[vaccine development]]></TERM><TERM><![CDATA[Vaccines]]></TERM><TERM><![CDATA[Virulence Factors]]></TERM><TERM><![CDATA[Virulent]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[LTB4 and the control of methicilin resistant Staphylococcus aureus infection]]></PROJECT_TITLE><SERIAL_NUMBER>110990</SERIAL_NUMBER><STUDY_SECTION>III</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Innate Immunity and Inflammation Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>50000</DIRECT_COST_AMT><INDIRECT_COST_AMT>28000</INDIRECT_COST_AMT><TOTAL_COST>78000</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8965503</APPLICATION_ID><ACTIVITY>R03</ACTIVITY><ADMINISTERING_IC>AI</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/28/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>855</CFDA_CODE><CORE_PROJECT_NUM>R03AI115339</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[ORGANIZED RESEARCH UNITS]]></ED_INST_TYPE><FOA_NUMBER>PA-13-304</FOA_NUMBER><FULL_PROJECT_NUM>5R03AI115339-02</FULL_PROJECT_NUM><FUNDING_ICs>NIAID:75000\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>ATHENS</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[PUBLIC HEALTH & PREV MEDICINE]]></ORG_DEPT><ORG_DISTRICT>10</ORG_DISTRICT><ORG_DUNS>004315578</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIVERSITY OF GEORGIA]]></ORG_NAME><ORG_STATE>GA</ORG_STATE><ORG_ZIPCODE>306021589</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Toxoplasma gondii is a parasite of global significance that primarily causes disease in pregnant women and immunocompromised individuals. In this proposal we seek to correct errors in the reference genome sequence and define the extent and potential significance of recently duplicated, nearly identical regions of the parasite genome. We anticipate that the results of these studies will ultimately lead to a better understanding of genetic differences that may be linked to pathogenicity.]]></PHR><PIS><PI><PI_NAME>KISSINGER, JESSICA C</PI_NAME><PI_ID>1924970</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>JOY, DEIRDRE A.</PROGRAM_OFFICER_NAME><PROJECT_START>11/10/2014</PROJECT_START><PROJECT_END>10/31/2016</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[Algorithms]]></TERM><TERM><![CDATA[Archives]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Bioinformatics]]></TERM><TERM><![CDATA[Cataloging]]></TERM><TERM><![CDATA[Catalogs]]></TERM><TERM><![CDATA[Communities]]></TERM><TERM><![CDATA[Copy Number Polymorphism]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Deposition]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Elements]]></TERM><TERM><![CDATA[Event]]></TERM><TERM><![CDATA[Evolution]]></TERM><TERM><![CDATA[Family member]]></TERM><TERM><![CDATA[Gene Duplication]]></TERM><TERM><![CDATA[Gene Family]]></TERM><TERM><![CDATA[Genes]]></TERM><TERM><![CDATA[Genetic]]></TERM><TERM><![CDATA[Genome]]></TERM><TERM><![CDATA[genome sequencing]]></TERM><TERM><![CDATA[Genomic Segment]]></TERM><TERM><![CDATA[Genomics]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[Immunocompromised Host]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[insertion/deletion mutation]]></TERM><TERM><![CDATA[insight]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[Link]]></TERM><TERM><![CDATA[Location]]></TERM><TERM><![CDATA[Maps]]></TERM><TERM><![CDATA[Morphologic artifacts]]></TERM><TERM><![CDATA[next generation sequencing]]></TERM><TERM><![CDATA[Outcome]]></TERM><TERM><![CDATA[parasite genome]]></TERM><TERM><![CDATA[Parasites]]></TERM><TERM><![CDATA[pathogen]]></TERM><TERM><![CDATA[Pathogenicity]]></TERM><TERM><![CDATA[Pattern]]></TERM><TERM><![CDATA[Phenotype]]></TERM><TERM><![CDATA[Phylogeny]]></TERM><TERM><![CDATA[Pregnant Women]]></TERM><TERM><![CDATA[Procedures]]></TERM><TERM><![CDATA[Reading]]></TERM><TERM><![CDATA[Repetitive Sequence]]></TERM><TERM><![CDATA[repository]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Research Personnel]]></TERM><TERM><![CDATA[Resolution]]></TERM><TERM><![CDATA[Resources]]></TERM><TERM><![CDATA[Sequence Analysis]]></TERM><TERM><![CDATA[single molecule]]></TERM><TERM><![CDATA[Single Nucleotide Polymorphism]]></TERM><TERM><![CDATA[Technology]]></TERM><TERM><![CDATA[Toxoplasma gondii]]></TERM><TERM><![CDATA[Virulence]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[R03 - Resolution of genome duplications in Toxoplasma gondii]]></PROJECT_TITLE><SERIAL_NUMBER>115339</SERIAL_NUMBER><STUDY_SECTION>PTHE</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Pathogenic Eukaryotes Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>50000</DIRECT_COST_AMT><INDIRECT_COST_AMT>25000</INDIRECT_COST_AMT><TOTAL_COST>75000</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8965516</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>HL</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/29/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>837</CFDA_CODE><CORE_PROJECT_NUM>R01HL122967</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-13-302</FOA_NUMBER><FULL_PROJECT_NUM>5R01HL122967-02</FULL_PROJECT_NUM><FUNDING_ICs>NHLBI:462907\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL HEART, LUNG, AND BLOOD INSTITUTE</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>DURHAM</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[INTERNAL MEDICINE/MEDICINE]]></ORG_DEPT><ORG_DISTRICT>01</ORG_DISTRICT><ORG_DUNS>044387793</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[DUKE UNIVERSITY]]></ORG_NAME><ORG_STATE>NC</ORG_STATE><ORG_ZIPCODE>277054673</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: This grant explores the role of Ca2+/calmodulin-dependent regulation of voltage-gated Na+ channels in physiology and disease, such as in autism, epilepsy, and cardiac arrhythmias, through analysis of the channels' structure and function.]]></PHR><PIS><PI><PI_NAME>MARX, STEVEN O</PI_NAME><PI_ID>8052876</PI_ID></PI><PI><PI_NAME>PITT, GEOFFREY S (contact)</PI_NAME><PI_ID>1901054 (contact)</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>WANG, LAN-HSIANG </PROGRAM_OFFICER_NAME><PROJECT_START>11/15/2014</PROJECT_START><PROJECT_END>10/31/2018</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Action Potentials]]></TERM><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[Affinity]]></TERM><TERM><![CDATA[Arrhythmia]]></TERM><TERM><![CDATA[Ataxia]]></TERM><TERM><![CDATA[Autistic Disorder]]></TERM><TERM><![CDATA[Binding (Molecular Function)]]></TERM><TERM><![CDATA[Biochemical]]></TERM><TERM><![CDATA[C-terminal]]></TERM><TERM><![CDATA[Calmodulin]]></TERM><TERM><![CDATA[Cardiac]]></TERM><TERM><![CDATA[Cardiac Myocytes]]></TERM><TERM><![CDATA[Cardiomyopathies]]></TERM><TERM><![CDATA[cell type]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Conflict (Psychology)]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[disease-causing mutation]]></TERM><TERM><![CDATA[Epilepsy]]></TERM><TERM><![CDATA[Feedback]]></TERM><TERM><![CDATA[Functional disorder]]></TERM><TERM><![CDATA[Gap Junctions]]></TERM><TERM><![CDATA[Genes]]></TERM><TERM><![CDATA[Grant]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Inherited]]></TERM><TERM><![CDATA[innovation]]></TERM><TERM><![CDATA[Intellectual functioning disability]]></TERM><TERM><![CDATA[Knowledge]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[Ligand Binding Domain]]></TERM><TERM><![CDATA[Link]]></TERM><TERM><![CDATA[Mediator of activation protein]]></TERM><TERM><![CDATA[Membrane]]></TERM><TERM><![CDATA[Methods]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[mutant]]></TERM><TERM><![CDATA[Mutate]]></TERM><TERM><![CDATA[Mutation]]></TERM><TERM><![CDATA[Neurons]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[novel strategies]]></TERM><TERM><![CDATA[Pathologic]]></TERM><TERM><![CDATA[Physiological]]></TERM><TERM><![CDATA[Physiology]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[Regulation]]></TERM><TERM><![CDATA[Resolution]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Schizophrenia]]></TERM><TERM><![CDATA[SCN1A protein]]></TERM><TERM><![CDATA[SCN2A protein]]></TERM><TERM><![CDATA[sensor]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[Site]]></TERM><TERM><![CDATA[Structure]]></TERM><TERM><![CDATA[Sudden infant death syndrome]]></TERM><TERM><![CDATA[Syndrome]]></TERM><TERM><![CDATA[System]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[voltage]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Calmodulin regulation of Na+ channels in neurons and cardiomyocytes]]></PROJECT_TITLE><SERIAL_NUMBER>122967</SERIAL_NUMBER><STUDY_SECTION>NTRC</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Neurotransporters, Receptors, and Calcium Signaling Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>378502</DIRECT_COST_AMT><INDIRECT_COST_AMT>84405</INDIRECT_COST_AMT><TOTAL_COST>462907</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8966558</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>HL</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/30/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>837</CFDA_CODE><CORE_PROJECT_NUM>R01HL124096</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-13-302</FOA_NUMBER><FULL_PROJECT_NUM>5R01HL124096-02</FULL_PROJECT_NUM><FUNDING_ICs>NHLBI:549315\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL HEART, LUNG, AND BLOOD INSTITUTE</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>COLUMBUS</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[RADIATION-DIAGNOSTIC/ONCOLOGY]]></ORG_DEPT><ORG_DISTRICT>03</ORG_DISTRICT><ORG_DUNS>832127323</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[OHIO STATE UNIVERSITY]]></ORG_NAME><ORG_STATE>OH</ORG_STATE><ORG_ZIPCODE>432101016</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Abdominal aortic aneurysms (AAA) enlarge over time and lead to sudden rupture and death in up to 90% of patients. Currently, AAA diameter > 5.5 cm is the criteria for surgical or endovascular aneurysm repair. However, it is a poor predictor of AAA rupture. Aortic wall stiffness (WS) is a fundamental biomechanical parameter that reflects the structural integrity of normal and aneurysmal aortic tissue. Aortic magnetic resonance elastography (AMRE) is a novel non-invasive technique to spatially estimate the stiffness of the aorta. The overall goal of this project is to validate AMRE-derived stiffness against both mechanical testing and histopathology; and that AMRE-derived stiffness will improve our understanding of AAA pathogenesis and provide superior prognostic information compared to aortic diameter.]]></PHR><PIS><PI><PI_NAME>KOLIPAKA, ARUNARK </PI_NAME><PI_ID>11125418</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>DANTHI, NARASIMHAN </PROGRAM_OFFICER_NAME><PROJECT_START>11/14/2014</PROJECT_START><PROJECT_END>10/31/2019</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[abdominal aorta]]></TERM><TERM><![CDATA[Abdominal Aortic Aneurysm]]></TERM><TERM><![CDATA[Acoustics]]></TERM><TERM><![CDATA[Adopted]]></TERM><TERM><![CDATA[Aneurysm]]></TERM><TERM><![CDATA[Animal Model]]></TERM><TERM><![CDATA[Aorta]]></TERM><TERM><![CDATA[Arteries]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Biomechanics]]></TERM><TERM><![CDATA[Caliber]]></TERM><TERM><![CDATA[Cardiac]]></TERM><TERM><![CDATA[Catheters]]></TERM><TERM><![CDATA[Cessation of life]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[Cytoskeleton]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Diagnostic]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[elastography]]></TERM><TERM><![CDATA[Functional disorder]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Growth]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Histopathology]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[human subject]]></TERM><TERM><![CDATA[Image]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[innovation]]></TERM><TERM><![CDATA[innovative technologies]]></TERM><TERM><![CDATA[insight]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[Magnetic Resonance Elastography]]></TERM><TERM><![CDATA[Magnetic Resonance Imaging]]></TERM><TERM><![CDATA[Maps]]></TERM><TERM><![CDATA[Measurement]]></TERM><TERM><![CDATA[Measures]]></TERM><TERM><![CDATA[Mechanics]]></TERM><TERM><![CDATA[Methods]]></TERM><TERM><![CDATA[Normal Range]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[Operative Surgical Procedures]]></TERM><TERM><![CDATA[Pathogenesis]]></TERM><TERM><![CDATA[Patient Schedules]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Peripheral]]></TERM><TERM><![CDATA[Physiologic pulse]]></TERM><TERM><![CDATA[pressure]]></TERM><TERM><![CDATA[prognostic]]></TERM><TERM><![CDATA[repaired]]></TERM><TERM><![CDATA[Reporting]]></TERM><TERM><![CDATA[research clinical testing]]></TERM><TERM><![CDATA[Risk]]></TERM><TERM><![CDATA[Rupture]]></TERM><TERM><![CDATA[Ruptured Abdominal Aortic Aneurysm]]></TERM><TERM><![CDATA[Techniques]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[Tissues]]></TERM><TERM><![CDATA[Translations]]></TERM><TERM><![CDATA[Ultrasonography]]></TERM><TERM><![CDATA[Validation]]></TERM><TERM><![CDATA[volunteer]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Improved Understanding of Abdominal Aortic Aneurysm Progression using MR Elastography]]></PROJECT_TITLE><SERIAL_NUMBER>124096</SERIAL_NUMBER><STUDY_SECTION>BTSS</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Bioengineering, Technology and Surgical Sciences Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>356699</DIRECT_COST_AMT><INDIRECT_COST_AMT>192616</INDIRECT_COST_AMT><TOTAL_COST>549315</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8968858</APPLICATION_ID><ACTIVITY>R21</ACTIVITY><ADMINISTERING_IC>HL</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/02/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>837</CFDA_CODE><CORE_PROJECT_NUM>R21HL122882</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-12-284</FOA_NUMBER><FULL_PROJECT_NUM>5R21HL122882-02</FULL_PROJECT_NUM><FUNDING_ICs>NHLBI:178312\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL HEART, LUNG, AND BLOOD INSTITUTE</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>WASHINGTON</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[PHARMACOLOGY]]></ORG_DEPT><ORG_DISTRICT>98</ORG_DISTRICT><ORG_DUNS>043990498</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[GEORGE WASHINGTON UNIVERSITY]]></ORG_NAME><ORG_STATE>DC</ORG_STATE><ORG_ZIPCODE>200520001</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE:   We propose to create a regularly contracting layer of cardiomyocytes around vein segments of lower extremities with the goal of aiding venous return and treating chronic deep venous insufficiency. The proposed approach opens up doors to the development of a new treatment strategy to millions of patients suffering from chronic venous disease.]]></PHR><PIS><PI><PI_NAME>SARVAZYAN, NARINE </PI_NAME><PI_ID>1867742</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>LEE, ALBERT </PROGRAM_OFFICER_NAME><PROJECT_START>11/15/2014</PROJECT_START><PROJECT_END>10/31/2016</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[abstracting]]></TERM><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[Adipose tissue]]></TERM><TERM><![CDATA[Area]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Biocompatible]]></TERM><TERM><![CDATA[Blood]]></TERM><TERM><![CDATA[Blood Circulation]]></TERM><TERM><![CDATA[Blood flow]]></TERM><TERM><![CDATA[Blood Vessels]]></TERM><TERM><![CDATA[Bone Marrow]]></TERM><TERM><![CDATA[Canis familiaris]]></TERM><TERM><![CDATA[Cardiac Myocytes]]></TERM><TERM><![CDATA[Cartoons]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Chronic]]></TERM><TERM><![CDATA[Contracts]]></TERM><TERM><![CDATA[Coupled]]></TERM><TERM><![CDATA[Critiques]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Devices]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Electric Stimulation]]></TERM><TERM><![CDATA[Embryonic Development]]></TERM><TERM><![CDATA[Engineering]]></TERM><TERM><![CDATA[Family suidae]]></TERM><TERM><![CDATA[Fibroblasts]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Heart]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[human embryonic stem cell]]></TERM><TERM><![CDATA[immunogenicity]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[induced pluripotent stem cell]]></TERM><TERM><![CDATA[Injury]]></TERM><TERM><![CDATA[interest]]></TERM><TERM><![CDATA[Invertebrates]]></TERM><TERM><![CDATA[Liquid substance]]></TERM><TERM><![CDATA[Location]]></TERM><TERM><![CDATA[Lower Extremity]]></TERM><TERM><![CDATA[Mechanical Stimulation]]></TERM><TERM><![CDATA[Methodology]]></TERM><TERM><![CDATA[Muscle]]></TERM><TERM><![CDATA[Myocardium]]></TERM><TERM><![CDATA[Neonatal]]></TERM><TERM><![CDATA[Nodal]]></TERM><TERM><![CDATA[nodal myocyte]]></TERM><TERM><![CDATA[novel strategies]]></TERM><TERM><![CDATA[Operative Surgical Procedures]]></TERM><TERM><![CDATA[Organ]]></TERM><TERM><![CDATA[Pacemakers]]></TERM><TERM><![CDATA[Paper]]></TERM><TERM><![CDATA[Paraplegia]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[peripheral blood]]></TERM><TERM><![CDATA[Phenotype]]></TERM><TERM><![CDATA[Pluripotent Stem Cells]]></TERM><TERM><![CDATA[pressure]]></TERM><TERM><![CDATA[Protocols documentation]]></TERM><TERM><![CDATA[Publishing]]></TERM><TERM><![CDATA[Pump]]></TERM><TERM><![CDATA[Rattus]]></TERM><TERM><![CDATA[Recreation]]></TERM><TERM><![CDATA[repaired]]></TERM><TERM><![CDATA[research study]]></TERM><TERM><![CDATA[Saphenous Vein]]></TERM><TERM><![CDATA[scaffold]]></TERM><TERM><![CDATA[Source]]></TERM><TERM><![CDATA[stem cell biology]]></TERM><TERM><![CDATA[Stem cells]]></TERM><TERM><![CDATA[Structure]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Tissue Engineering]]></TERM><TERM><![CDATA[Tissues]]></TERM><TERM><![CDATA[treatment strategy]]></TERM><TERM><![CDATA[Tube]]></TERM><TERM><![CDATA[Veins]]></TERM><TERM><![CDATA[Venous]]></TERM><TERM><![CDATA[Venous Insufficiency]]></TERM><TERM><![CDATA[Ventricular]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Cardiomyocyte-derived Venous Assist Device: Aiding peripheral blood flow]]></PROJECT_TITLE><SERIAL_NUMBER>122882</SERIAL_NUMBER><STUDY_SECTION>BMBI</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Biomaterials and Biointerfaces Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>112500</DIRECT_COST_AMT><INDIRECT_COST_AMT>65812</INDIRECT_COST_AMT><TOTAL_COST>178312</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8969605</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>HL</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/05/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>837</CFDA_CODE><CORE_PROJECT_NUM>R01HL123160</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>PAR-13-137</FOA_NUMBER><FULL_PROJECT_NUM>5R01HL123160-02</FULL_PROJECT_NUM><FUNDING_ICs>NHLBI:671681\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL HEART, LUNG, AND BLOOD INSTITUTE</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>ROCHESTER</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>01</ORG_DISTRICT><ORG_DUNS>006471700</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[MAYO CLINIC ROCHESTER]]></ORG_NAME><ORG_STATE>MN</ORG_STATE><ORG_ZIPCODE>559050001</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Adequate strategies to attenuate remodeling and loss of microvessels distal to an arterial obstruction are yet to be identified and remain in dire need. Non-invasive low-energy extracorporeal shock wave treatment (SWT) is a novel experimental strategy, which can promote neovascularization, suppresses inflammation, and improves function, but is yet to be attempted in microvascular disease associated with renovascular hypertension. The proposed studies may establish this novel, clinically feasible therapeutic strategy and will likely contribute significantly towards management of patients with this disease.]]></PHR><PIS><PI><PI_NAME>LERMAN, AMIR  (contact)</PI_NAME><PI_ID>1901040 (contact)</PI_ID></PI><PI><PI_NAME>LERMAN, LILACH O</PI_NAME><PI_ID>1915713</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>OH, YOUNGSUK </PROGRAM_OFFICER_NAME><PROJECT_START>11/15/2014</PROJECT_START><PROJECT_END>10/31/2018</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Adoption]]></TERM><TERM><![CDATA[aging population]]></TERM><TERM><![CDATA[Angioplasty]]></TERM><TERM><![CDATA[artery occlusion]]></TERM><TERM><![CDATA[Attenuated]]></TERM><TERM><![CDATA[Autologous]]></TERM><TERM><![CDATA[Basic Science]]></TERM><TERM><![CDATA[Biochemical]]></TERM><TERM><![CDATA[Biological]]></TERM><TERM><![CDATA[Biological Sciences]]></TERM><TERM><![CDATA[Biomedical Engineering]]></TERM><TERM><![CDATA[Blood Circulation]]></TERM><TERM><![CDATA[Bone Regeneration]]></TERM><TERM><![CDATA[cardiovascular risk factor]]></TERM><TERM><![CDATA[Cardiovascular system]]></TERM><TERM><![CDATA[Cell membrane]]></TERM><TERM><![CDATA[Chronic]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[Clinical Medicine]]></TERM><TERM><![CDATA[Clinical Sciences]]></TERM><TERM><![CDATA[Collaborations]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[density]]></TERM><TERM><![CDATA[detector]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Disease Management]]></TERM><TERM><![CDATA[Distal]]></TERM><TERM><![CDATA[Failure (biologic function)]]></TERM><TERM><![CDATA[Family suidae]]></TERM><TERM><![CDATA[Focal Adhesion Kinase 1]]></TERM><TERM><![CDATA[Functional disorder]]></TERM><TERM><![CDATA[functional restoration]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[hemodynamics]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[Hypertension]]></TERM><TERM><![CDATA[Imaging Techniques]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[improved functioning]]></TERM><TERM><![CDATA[In Situ]]></TERM><TERM><![CDATA[Inflammation]]></TERM><TERM><![CDATA[injured]]></TERM><TERM><![CDATA[Injury]]></TERM><TERM><![CDATA[Injury to Kidney]]></TERM><TERM><![CDATA[innovation]]></TERM><TERM><![CDATA[Integrins]]></TERM><TERM><![CDATA[Interdisciplinary Study]]></TERM><TERM><![CDATA[Intervention]]></TERM><TERM><![CDATA[Ischemia]]></TERM><TERM><![CDATA[Kidney]]></TERM><TERM><![CDATA[kidney vascular structure]]></TERM><TERM><![CDATA[Limb structure]]></TERM><TERM><![CDATA[Link]]></TERM><TERM><![CDATA[Magnetic Resonance Imaging]]></TERM><TERM><![CDATA[Mechanics]]></TERM><TERM><![CDATA[Mechanoreceptors]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[Medicine]]></TERM><TERM><![CDATA[Membrane]]></TERM><TERM><![CDATA[Metabolic syndrome]]></TERM><TERM><![CDATA[Microcirculation]]></TERM><TERM><![CDATA[Microvascular Dysfunction]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[multidisciplinary]]></TERM><TERM><![CDATA[Myocardial Ischemia]]></TERM><TERM><![CDATA[Natural regeneration]]></TERM><TERM><![CDATA[neovascularization]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[novel strategies]]></TERM><TERM><![CDATA[novel therapeutics]]></TERM><TERM><![CDATA[Outcome]]></TERM><TERM><![CDATA[Oxidative Stress]]></TERM><TERM><![CDATA[Pathogenesis]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Peripheral Vascular Diseases]]></TERM><TERM><![CDATA[Permeability]]></TERM><TERM><![CDATA[physical science]]></TERM><TERM><![CDATA[Physiology]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[receptor]]></TERM><TERM><![CDATA[Recovery]]></TERM><TERM><![CDATA[renal artery]]></TERM><TERM><![CDATA[Renal function]]></TERM><TERM><![CDATA[Renovascular Hypertension]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Research Project Grants]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[Rodent Model]]></TERM><TERM><![CDATA[Shock]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[Site]]></TERM><TERM><![CDATA[Stem cells]]></TERM><TERM><![CDATA[Stenosis]]></TERM><TERM><![CDATA[Stress]]></TERM><TERM><![CDATA[Structure]]></TERM><TERM><![CDATA[Techniques]]></TERM><TERM><![CDATA[Tendon structure]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Therapeutic]]></TERM><TERM><![CDATA[therapeutic target]]></TERM><TERM><![CDATA[tool]]></TERM><TERM><![CDATA[Translating]]></TERM><TERM><![CDATA[Translational Research]]></TERM><TERM><![CDATA[translational study]]></TERM><TERM><![CDATA[Tubular formation]]></TERM><TERM><![CDATA[Ultrasonography]]></TERM><TERM><![CDATA[Vascular Diseases]]></TERM><TERM><![CDATA[Western World]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Ultrasound Shockwave Therapy for Post-Stenotic Microvascular Remodeling]]></PROJECT_TITLE><SERIAL_NUMBER>123160</SERIAL_NUMBER><STUDY_SECTION>ZRG1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>422441</DIRECT_COST_AMT><INDIRECT_COST_AMT>249240</INDIRECT_COST_AMT><TOTAL_COST>671681</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8969608</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>MH</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/31/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>242</CFDA_CODE><CORE_PROJECT_NUM>R01MH105513</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF ARTS AND SCIENCES]]></ED_INST_TYPE><FOA_NUMBER>PAR-13-055</FOA_NUMBER><FULL_PROJECT_NUM>5R01MH105513-02</FULL_PROJECT_NUM><FUNDING_ICs>NIMH:612470\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF MENTAL HEALTH</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>BERKELEY</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[PSYCHOLOGY]]></ORG_DEPT><ORG_DISTRICT>13</ORG_DISTRICT><ORG_DUNS>124726725</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIVERSITY OF CALIFORNIA BERKELEY]]></ORG_NAME><ORG_STATE>CA</ORG_STATE><ORG_ZIPCODE>947045940</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Mental illness is often severe, chronic and difficult to treat. The sleep disturbance commonly experienced by individuals with a severe mental illness reduces their capacity to function and contributes to key symptoms. This study seeks to determine if an intervention to improve sleep can improve functioning and reduce symptoms and impairment. We will conduct this study in community mental health centers to ensure that the results contribute to closing the worrisome gap between research and practice and ensure that the findings are generalizable to the real world.]]></PHR><PIS><PI><PI_NAME>HARVEY, ALLISON G</PI_NAME><PI_ID>8365495</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>RUDORFER, MATTHEW V.</PROGRAM_OFFICER_NAME><PROJECT_START>11/17/2014</PROJECT_START><PROJECT_END>10/31/2018</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[Adult]]></TERM><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[Aftercare]]></TERM><TERM><![CDATA[Area]]></TERM><TERM><![CDATA[Arousal]]></TERM><TERM><![CDATA[Award]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Basic Science]]></TERM><TERM><![CDATA[behavioral health]]></TERM><TERM><![CDATA[Biological Rhythm]]></TERM><TERM><![CDATA[Centers for Disease Control and Prevention (U.S.)]]></TERM><TERM><![CDATA[Chronic]]></TERM><TERM><![CDATA[Chronotherapy]]></TERM><TERM><![CDATA[Circadian Rhythms]]></TERM><TERM><![CDATA[cognitive function]]></TERM><TERM><![CDATA[Cognitive Therapy]]></TERM><TERM><![CDATA[Communities]]></TERM><TERM><![CDATA[Community Mental Health Centers]]></TERM><TERM><![CDATA[community setting]]></TERM><TERM><![CDATA[Comorbid Insomnia]]></TERM><TERM><![CDATA[Comorbidity]]></TERM><TERM><![CDATA[County]]></TERM><TERM><![CDATA[demographics]]></TERM><TERM><![CDATA[Diagnosis]]></TERM><TERM><![CDATA[Diagnostic]]></TERM><TERM><![CDATA[Diagnostic and Statistical Manual of Mental Disorders]]></TERM><TERM><![CDATA[diaries]]></TERM><TERM><![CDATA[disability]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[efficacy testing]]></TERM><TERM><![CDATA[Elements]]></TERM><TERM><![CDATA[Ensure]]></TERM><TERM><![CDATA[evidence base]]></TERM><TERM><![CDATA[Evidence based treatment]]></TERM><TERM><![CDATA[Exhibits]]></TERM><TERM><![CDATA[experience]]></TERM><TERM><![CDATA[follow-up]]></TERM><TERM><![CDATA[Foundations]]></TERM><TERM><![CDATA[functional disability]]></TERM><TERM><![CDATA[Functional disorder]]></TERM><TERM><![CDATA[Genetic Complementation Test]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Grant]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Health Services]]></TERM><TERM><![CDATA[Impairment]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[improved functioning]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[Intervention]]></TERM><TERM><![CDATA[intervention effect]]></TERM><TERM><![CDATA[Life]]></TERM><TERM><![CDATA[Major Depressive Disorder]]></TERM><TERM><![CDATA[Measures]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[Mediation]]></TERM><TERM><![CDATA[Medical]]></TERM><TERM><![CDATA[Mental Depression]]></TERM><TERM><![CDATA[Mental disorders]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[motivational enhancement therapy]]></TERM><TERM><![CDATA[National Institute of Mental Health (U.S.)]]></TERM><TERM><![CDATA[novel strategies]]></TERM><TERM><![CDATA[Outcome]]></TERM><TERM><![CDATA[Outcome Measure]]></TERM><TERM><![CDATA[Participant]]></TERM><TERM><![CDATA[Patient Self-Report]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[performance site]]></TERM><TERM><![CDATA[personalized medicine]]></TERM><TERM><![CDATA[Pharmaceutical Preparations]]></TERM><TERM><![CDATA[Phase]]></TERM><TERM><![CDATA[physical conditioning]]></TERM><TERM><![CDATA[Prevalence]]></TERM><TERM><![CDATA[primary outcome]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[programs]]></TERM><TERM><![CDATA[prospective]]></TERM><TERM><![CDATA[Protocols documentation]]></TERM><TERM><![CDATA[Provider]]></TERM><TERM><![CDATA[Psychiatric Diagnosis]]></TERM><TERM><![CDATA[Randomized]]></TERM><TERM><![CDATA[Randomized Controlled Trials]]></TERM><TERM><![CDATA[Recruitment Activity]]></TERM><TERM><![CDATA[Regulation]]></TERM><TERM><![CDATA[Reporting]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Research Domain Criteria]]></TERM><TERM><![CDATA[Risk Factors]]></TERM><TERM><![CDATA[Schedule]]></TERM><TERM><![CDATA[Seasons]]></TERM><TERM><![CDATA[Services]]></TERM><TERM><![CDATA[severe mental illness]]></TERM><TERM><![CDATA[Severities]]></TERM><TERM><![CDATA[Site]]></TERM><TERM><![CDATA[Sleep]]></TERM><TERM><![CDATA[Sleep Disorders]]></TERM><TERM><![CDATA[Sleep disturbances]]></TERM><TERM><![CDATA[Sleeplessness]]></TERM><TERM><![CDATA[social]]></TERM><TERM><![CDATA[Staging]]></TERM><TERM><![CDATA[Symptoms]]></TERM><TERM><![CDATA[System]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[therapy development]]></TERM><TERM><![CDATA[treatment as usual]]></TERM><TERM><![CDATA[Treatment Efficacy]]></TERM><TERM><![CDATA[United States National Institutes of Health]]></TERM><TERM><![CDATA[World Health Organization Disability Assessment Schedule]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[A transdiagnostic sleep and circadian treatment to improve community SMI outcomes]]></PROJECT_TITLE><SERIAL_NUMBER>105513</SERIAL_NUMBER><STUDY_SECTION>NRCS</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Nursing and Related Clinical Sciences Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>498920</DIRECT_COST_AMT><INDIRECT_COST_AMT>113550</INDIRECT_COST_AMT><TOTAL_COST>612470</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8969702</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>HL</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/30/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>837</CFDA_CODE><CORE_PROJECT_NUM>R01HL125815</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-13-302</FOA_NUMBER><FULL_PROJECT_NUM>5R01HL125815-02</FULL_PROJECT_NUM><FUNDING_ICs>NHLBI:374625\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL HEART, LUNG, AND BLOOD INSTITUTE</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>NEW HAVEN</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[INTERNAL MEDICINE/MEDICINE]]></ORG_DEPT><ORG_DISTRICT>03</ORG_DISTRICT><ORG_DUNS>043207562</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[YALE UNIVERSITY]]></ORG_NAME><ORG_STATE>CT</ORG_STATE><ORG_ZIPCODE>065113572</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Many devastating human diseases of the arteries are characterized by excessive smooth muscle which effectively decreases the artery diameter, thereby resulting in inadequate blood flow beyond the narrowing.  Herein, we use a genetic mouse model of one such human disease (i.e., supravalvular aortic stenosis) to identify the cellular origins of the excess smooth muscle cells and novel mechanisms underlying their accumulation.  These studies promise to identify novel therapeutic strategies to combat human arterial disease.]]></PHR><PIS><PI><PI_NAME>GREIF, DANIEL </PI_NAME><PI_ID>8852846</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>OLIVE, MICHELLE </PROGRAM_OFFICER_NAME><PROJECT_START>11/17/2014</PROJECT_START><PROJECT_END>10/31/2018</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Actins]]></TERM><TERM><![CDATA[Adhesions]]></TERM><TERM><![CDATA[Aorta]]></TERM><TERM><![CDATA[Aortic Valve Stenosis]]></TERM><TERM><![CDATA[Arterial Disorder]]></TERM><TERM><![CDATA[Arterial Medias]]></TERM><TERM><![CDATA[Arteries]]></TERM><TERM><![CDATA[arteriole]]></TERM><TERM><![CDATA[Atherosclerosis]]></TERM><TERM><![CDATA[Attenuated]]></TERM><TERM><![CDATA[Blood flow]]></TERM><TERM><![CDATA[Blood Vessels]]></TERM><TERM><![CDATA[Caliber]]></TERM><TERM><![CDATA[Cardiovascular Diseases]]></TERM><TERM><![CDATA[Cell Differentiation process]]></TERM><TERM><![CDATA[cell motility]]></TERM><TERM><![CDATA[Cell Proliferation]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[combat]]></TERM><TERM><![CDATA[Cytoskeleton]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Distal]]></TERM><TERM><![CDATA[dosage]]></TERM><TERM><![CDATA[Down-Regulation]]></TERM><TERM><![CDATA[effective therapy]]></TERM><TERM><![CDATA[Elastin]]></TERM><TERM><![CDATA[Embryo]]></TERM><TERM><![CDATA[Endothelial Cells]]></TERM><TERM><![CDATA[Extracellular Matrix]]></TERM><TERM><![CDATA[Gene Dosage]]></TERM><TERM><![CDATA[Genes]]></TERM><TERM><![CDATA[Genetic]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Growth]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Homeobox]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[human disease]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[induced pluripotent stem cell]]></TERM><TERM><![CDATA[injured]]></TERM><TERM><![CDATA[Injury]]></TERM><TERM><![CDATA[Integrins]]></TERM><TERM><![CDATA[Intervention]]></TERM><TERM><![CDATA[Knockout Mice]]></TERM><TERM><![CDATA[Link]]></TERM><TERM><![CDATA[Longevity]]></TERM><TERM><![CDATA[loss of function mutation]]></TERM><TERM><![CDATA[Lung]]></TERM><TERM><![CDATA[Maps]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[migration]]></TERM><TERM><![CDATA[Mitogens]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[mouse model]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[mutant]]></TERM><TERM><![CDATA[Mutant Strains Mice]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[novel therapeutics]]></TERM><TERM><![CDATA[null mutation]]></TERM><TERM><![CDATA[Operative Surgical Procedures]]></TERM><TERM><![CDATA[overexpression]]></TERM><TERM><![CDATA[Pathogenesis]]></TERM><TERM><![CDATA[Pathology]]></TERM><TERM><![CDATA[Pericytes]]></TERM><TERM><![CDATA[Phenotype]]></TERM><TERM><![CDATA[Plague]]></TERM><TERM><![CDATA[Population]]></TERM><TERM><![CDATA[postnatal]]></TERM><TERM><![CDATA[prevent]]></TERM><TERM><![CDATA[Pulmonary Hypertension]]></TERM><TERM><![CDATA[pup]]></TERM><TERM><![CDATA[receptor]]></TERM><TERM><![CDATA[Regulation]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[restenosis]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Series]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[Smooth muscle (tissue)]]></TERM><TERM><![CDATA[Smooth Muscle Myocytes]]></TERM><TERM><![CDATA[Source]]></TERM><TERM><![CDATA[Stenosis]]></TERM><TERM><![CDATA[Stimulus]]></TERM><TERM><![CDATA[Sum]]></TERM><TERM><![CDATA[Supravalvular aortic stenosis]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Tissues]]></TERM><TERM><![CDATA[transcription factor]]></TERM><TERM><![CDATA[Transgenic Organisms]]></TERM><TERM><![CDATA[Tunica Media]]></TERM><TERM><![CDATA[Up-Regulation (Physiology)]]></TERM><TERM><![CDATA[Vascular Diseases]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Pathological arterial muscularization and the role of integrins]]></PROJECT_TITLE><SERIAL_NUMBER>125815</SERIAL_NUMBER><STUDY_SECTION>VCMB</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Vascular Cell and Molecular Biology Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>225000</DIRECT_COST_AMT><INDIRECT_COST_AMT>149625</INDIRECT_COST_AMT><TOTAL_COST>374625</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8974439</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>HL</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/05/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>837</CFDA_CODE><CORE_PROJECT_NUM>R01HL125649</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-13-302</FOA_NUMBER><FULL_PROJECT_NUM>5R01HL125649-02</FULL_PROJECT_NUM><FUNDING_ICs>NHLBI:360000\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL HEART, LUNG, AND BLOOD INSTITUTE</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>NEW YORK</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[PATHOLOGY]]></ORG_DEPT><ORG_DISTRICT>13</ORG_DISTRICT><ORG_DUNS>621889815</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[COLUMBIA UNIVERSITY HEALTH SCIENCES]]></ORG_NAME><ORG_STATE>NY</ORG_STATE><ORG_ZIPCODE>100320049</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Diabetes and the metabolic syndrome are major risk factors for cardiovascular disease, which is the leading cause of death in the United States. Impairments in HDL functions such as reverse cholesterol transport or vasoprotection may link these disorders, but the mechanisms remain unclear. Identifying the key players in the relationships between insulin resistance, reverse cholesterol transport, and HDL function will improve our ability to treat patients more effectively.]]></PHR><PIS><PI><PI_NAME>HAEUSLER, REBECCA ANNE</PI_NAME><PI_ID>10098932</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>LIU, LIJUAN </PROGRAM_OFFICER_NAME><PROJECT_START>11/21/2014</PROJECT_START><PROJECT_END>10/31/2019</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[Apolipoproteins]]></TERM><TERM><![CDATA[Arteries]]></TERM><TERM><![CDATA[atheroprotective]]></TERM><TERM><![CDATA[Atherosclerosis]]></TERM><TERM><![CDATA[Cardiovascular Diseases]]></TERM><TERM><![CDATA[cardiovascular disorder risk]]></TERM><TERM><![CDATA[Cardiovascular system]]></TERM><TERM><![CDATA[Catabolism]]></TERM><TERM><![CDATA[Cause of Death]]></TERM><TERM><![CDATA[Cholesterol]]></TERM><TERM><![CDATA[Cholesterol Esters]]></TERM><TERM><![CDATA[Clinical Trials]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Defect]]></TERM><TERM><![CDATA[Diabetes Mellitus]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Dyes]]></TERM><TERM><![CDATA[endothelial dysfunction]]></TERM><TERM><![CDATA[Enzymes]]></TERM><TERM><![CDATA[Evans blue stain]]></TERM><TERM><![CDATA[Excretory function]]></TERM><TERM><![CDATA[Expenditure]]></TERM><TERM><![CDATA[Feces]]></TERM><TERM><![CDATA[feeding]]></TERM><TERM><![CDATA[Functional disorder]]></TERM><TERM><![CDATA[Gene Expression]]></TERM><TERM><![CDATA[Genes]]></TERM><TERM><![CDATA[Glucose]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Healthcare]]></TERM><TERM><![CDATA[Hepatic]]></TERM><TERM><![CDATA[hepatic lipase]]></TERM><TERM><![CDATA[High Density Lipoprotein Cholesterol]]></TERM><TERM><![CDATA[High Density Lipoproteins]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[human NOS3 protein]]></TERM><TERM><![CDATA[Impairment]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[insight]]></TERM><TERM><![CDATA[Insulin]]></TERM><TERM><![CDATA[Insulin Resistance]]></TERM><TERM><![CDATA[insulin signaling]]></TERM><TERM><![CDATA[Intervention]]></TERM><TERM><![CDATA[Investigation]]></TERM><TERM><![CDATA[Knock-out]]></TERM><TERM><![CDATA[Knockout Mice]]></TERM><TERM><![CDATA[Light]]></TERM><TERM><![CDATA[Link]]></TERM><TERM><![CDATA[Lipids]]></TERM><TERM><![CDATA[Lipoproteins]]></TERM><TERM><![CDATA[Liver]]></TERM><TERM><![CDATA[macrophage]]></TERM><TERM><![CDATA[Measures]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[Mediator of activation protein]]></TERM><TERM><![CDATA[Metabolic syndrome]]></TERM><TERM><![CDATA[Metabolism]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[mouse model]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[Non-Insulin-Dependent Diabetes Mellitus]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[Obesity]]></TERM><TERM><![CDATA[particle]]></TERM><TERM><![CDATA[Pathway interactions]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Phenotype]]></TERM><TERM><![CDATA[Physiology]]></TERM><TERM><![CDATA[Population]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[Proteins]]></TERM><TERM><![CDATA[Radiolabeled]]></TERM><TERM><![CDATA[radiotracer]]></TERM><TERM><![CDATA[Regulation]]></TERM><TERM><![CDATA[reverse cholesterol transport]]></TERM><TERM><![CDATA[Risk Factors]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Serum]]></TERM><TERM><![CDATA[sphingosine 1-phosphate]]></TERM><TERM><![CDATA[SR-BI receptor]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Therapeutic Intervention]]></TERM><TERM><![CDATA[tool]]></TERM><TERM><![CDATA[Tracer]]></TERM><TERM><![CDATA[transcription factor]]></TERM><TERM><![CDATA[Transgenic Mice]]></TERM><TERM><![CDATA[Triglycerides]]></TERM><TERM><![CDATA[United States]]></TERM><TERM><![CDATA[uptake]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Insulin action, reverse cholesterol transport, and HDL function]]></PROJECT_TITLE><SERIAL_NUMBER>125649</SERIAL_NUMBER><STUDY_SECTION>INMP</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Integrative Nutrition and Metabolic Processes Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>225000</DIRECT_COST_AMT><INDIRECT_COST_AMT>135000</INDIRECT_COST_AMT><TOTAL_COST>360000</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9046372</APPLICATION_ID><ACTIVITY>I01</ACTIVITY><ADMINISTERING_IC>VA</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/03/2015</AWARD_NOTICE_DATE><BUDGET_START>10/01/2015</BUDGET_START><BUDGET_END>09/30/2016</BUDGET_END><CFDA_CODE>999</CFDA_CODE><CORE_PROJECT_NUM>I01CX000954</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-CX-13-007</FOA_NUMBER><FULL_PROJECT_NUM>5I01CX000954-02</FULL_PROJECT_NUM><FUNDING_ICs>VA:659688\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>Veterans Affairs</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>SALT LAKE CITY</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>02</ORG_DISTRICT><ORG_DUNS>009094756</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[VA SALT LAKE CITY HEALTHCARE SYSTEM]]></ORG_NAME><ORG_STATE>UT</ORG_STATE><ORG_ZIPCODE>841480001</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE:    
   
Osteoarthritis (OA) is the most common form of arthritis and affects almost 27 million Americans. It is seen more commonly in individuals who have served in the military, and thus is of particular interest to the Department of Veterans Affairs. The prevalence of OA is increasing rapidly; it is projected that by 2030, over 60 million Americans will be affected. Current treatments for OA are only marginally effective in treating pain, and none have been shown to alter the progression of OA. Degenerative joint cartilage is a central feature of OA, yet joint cartilage has a limited capacity for repair. Results from animal research demonstrate that pulsed low intensity ultrasound (PLIUS) mechanically stimulates, and may promote, cartilage repair. This exploratory trial will investigate whether PLIUS is potentially effective as a disease and symptom modifying intervention in 160 patients with early knee OA. If sufficient evidence of efficacy is observed, it would strongly support further clinic research in humans. If efficacy is subsequently confirmed after more definitive clinical trials, the standard of care for this highly prevalent and debilitating disease could radically change.]]></PHR><PIS><PI><PI_NAME>CLEGG, DANIEL O (contact)</PI_NAME><PI_ID>1999244 (contact)</PI_ID></PI><PI><PI_NAME>KWOH, C KENT</PI_NAME><PI_ID>1895478</PI_ID></PI><PI><PI_NAME>LEE, SUSAN JUNG-AH</PI_NAME><PI_ID>6084963</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>10/01/2014</PROJECT_START><PROJECT_END>09/30/2019</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[Age]]></TERM><TERM><![CDATA[American]]></TERM><TERM><![CDATA[Animal Experimentation]]></TERM><TERM><![CDATA[arm]]></TERM><TERM><![CDATA[Arthritis]]></TERM><TERM><![CDATA[Arthroplasty, Replacement, Knee]]></TERM><TERM><![CDATA[articular cartilage]]></TERM><TERM><![CDATA[attenuation]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Basic Science]]></TERM><TERM><![CDATA[bench to bedside]]></TERM><TERM><![CDATA[Biological Markers]]></TERM><TERM><![CDATA[Bone Marrow]]></TERM><TERM><![CDATA[Cartilage]]></TERM><TERM><![CDATA[cartilage regeneration]]></TERM><TERM><![CDATA[cartilage repair]]></TERM><TERM><![CDATA[Cavia]]></TERM><TERM><![CDATA[Chondrocytes]]></TERM><TERM><![CDATA[Cities]]></TERM><TERM><![CDATA[Clinic]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[Clinical Data]]></TERM><TERM><![CDATA[Clinical Trials]]></TERM><TERM><![CDATA[Controlled Clinical Trials]]></TERM><TERM><![CDATA[cost]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Degenerative polyarthritis]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Devices]]></TERM><TERM><![CDATA[disability]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Disease Marker]]></TERM><TERM><![CDATA[effective therapy]]></TERM><TERM><![CDATA[Engineering]]></TERM><TERM><![CDATA[Enrollment]]></TERM><TERM><![CDATA[experience]]></TERM><TERM><![CDATA[FDA approved]]></TERM><TERM><![CDATA[Fracture]]></TERM><TERM><![CDATA[Fracture Healing]]></TERM><TERM><![CDATA[Gold]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[Image]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[indexing]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[innovation]]></TERM><TERM><![CDATA[interest]]></TERM><TERM><![CDATA[Intervention]]></TERM><TERM><![CDATA[Joints]]></TERM><TERM><![CDATA[Knee]]></TERM><TERM><![CDATA[Knee Osteoarthritis]]></TERM><TERM><![CDATA[knee pain]]></TERM><TERM><![CDATA[Lesion]]></TERM><TERM><![CDATA[Light]]></TERM><TERM><![CDATA[Literature]]></TERM><TERM><![CDATA[Lower Extremity]]></TERM><TERM><![CDATA[Magnetic Resonance Imaging]]></TERM><TERM><![CDATA[Measures]]></TERM><TERM><![CDATA[Mechanical Stimulation]]></TERM><TERM><![CDATA[Medial]]></TERM><TERM><![CDATA[Medical]]></TERM><TERM><![CDATA[Medical center]]></TERM><TERM><![CDATA[meetings]]></TERM><TERM><![CDATA[member]]></TERM><TERM><![CDATA[Metabolism]]></TERM><TERM><![CDATA[Military Personnel]]></TERM><TERM><![CDATA[Modality]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Modification]]></TERM><TERM><![CDATA[Nature]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[Orthopedics]]></TERM><TERM><![CDATA[Outcome]]></TERM><TERM><![CDATA[Pain]]></TERM><TERM><![CDATA[Pain management]]></TERM><TERM><![CDATA[Pathogenesis]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Phase]]></TERM><TERM><![CDATA[Physiologic pulse]]></TERM><TERM><![CDATA[pilot trial]]></TERM><TERM><![CDATA[Placebos]]></TERM><TERM><![CDATA[pre-clinical]]></TERM><TERM><![CDATA[preclinical study]]></TERM><TERM><![CDATA[Prevalence]]></TERM><TERM><![CDATA[primary outcome]]></TERM><TERM><![CDATA[Procedures]]></TERM><TERM><![CDATA[Production]]></TERM><TERM><![CDATA[Publishing]]></TERM><TERM><![CDATA[Quality of life]]></TERM><TERM><![CDATA[Randomized]]></TERM><TERM><![CDATA[Recruitment Activity]]></TERM><TERM><![CDATA[repaired]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[Running]]></TERM><TERM><![CDATA[Scientist]]></TERM><TERM><![CDATA[screening]]></TERM><TERM><![CDATA[Serum]]></TERM><TERM><![CDATA[Services]]></TERM><TERM><![CDATA[Severities]]></TERM><TERM><![CDATA[Sodium Chloride]]></TERM><TERM><![CDATA[Staging]]></TERM><TERM><![CDATA[standard of care]]></TERM><TERM><![CDATA[Structure]]></TERM><TERM><![CDATA[symptomatic improvement]]></TERM><TERM><![CDATA[Symptoms]]></TERM><TERM><![CDATA[System]]></TERM><TERM><![CDATA[Therapeutic]]></TERM><TERM><![CDATA[Thick]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[treatment duration]]></TERM><TERM><![CDATA[Ultrasonography]]></TERM><TERM><![CDATA[Urine]]></TERM><TERM><![CDATA[Veterans]]></TERM><TERM><![CDATA[Weight-Bearing state]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[A Pilot Trial to Assess Low-Intensity Ultrasound in Osteoarthritis]]></PROJECT_TITLE><SERIAL_NUMBER>000954</SERIAL_NUMBER><STUDY_SECTION>CLIN</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Clinical Trials ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST></TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9054635</APPLICATION_ID><ACTIVITY>U54</ACTIVITY><ADMINISTERING_IC>HD</ADMINISTERING_IC><APPLICATION_TYPE>1</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/30/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>U54HD086984</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-HD-15-033</FOA_NUMBER><FULL_PROJECT_NUM>1U54HD086984-01</FULL_PROJECT_NUM><FUNDING_ICs>NICHD:131957\</FUNDING_ICs><FUNDING_MECHANISM>RESEARCH CENTERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &amp; HUMAN DEVELOPMENT</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>PHILADELPHIA</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>02</ORG_DISTRICT><ORG_DUNS>073757627</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[CHILDREN'S HOSP OF PHILADELPHIA]]></ORG_NAME><ORG_STATE>PA</ORG_STATE><ORG_ZIPCODE>191044318</ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>ABEL, EDWIN (TED) </PI_NAME><PI_ID>1925867</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>11/01/2015</PROJECT_START><PROJECT_END>05/31/2020</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[Anxiety]]></TERM><TERM><![CDATA[Astrocytes]]></TERM><TERM><![CDATA[Behavior]]></TERM><TERM><![CDATA[behavior test]]></TERM><TERM><![CDATA[Behavioral]]></TERM><TERM><![CDATA[Bioinformatics]]></TERM><TERM><![CDATA[Biological Assay]]></TERM><TERM><![CDATA[Biometry]]></TERM><TERM><![CDATA[Brain]]></TERM><TERM><![CDATA[brain behavior]]></TERM><TERM><![CDATA[brain cell]]></TERM><TERM><![CDATA[Cell Line]]></TERM><TERM><![CDATA[Cell model]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Cellular biology]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[Clustered Regularly Interspaced Short Palindromic Repeats]]></TERM><TERM><![CDATA[Consultations]]></TERM><TERM><![CDATA[cost]]></TERM><TERM><![CDATA[Data Analyses]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[disability]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Disease model]]></TERM><TERM><![CDATA[Educational aspects]]></TERM><TERM><![CDATA[effective therapy]]></TERM><TERM><![CDATA[Electroencephalography]]></TERM><TERM><![CDATA[Eligibility Determination]]></TERM><TERM><![CDATA[Endothelium]]></TERM><TERM><![CDATA[Ensure]]></TERM><TERM><![CDATA[Equipment]]></TERM><TERM><![CDATA[Experimental Designs]]></TERM><TERM><![CDATA[Genes]]></TERM><TERM><![CDATA[Genetic]]></TERM><TERM><![CDATA[Genetically Modified Animals]]></TERM><TERM><![CDATA[Hand]]></TERM><TERM><![CDATA[Hematopoietic]]></TERM><TERM><![CDATA[Hereditary Disease]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[implantation]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[In Vitro]]></TERM><TERM><![CDATA[in vitro Model]]></TERM><TERM><![CDATA[induced pluripotent stem cell]]></TERM><TERM><![CDATA[Intellectual functioning disability]]></TERM><TERM><![CDATA[Joints]]></TERM><TERM><![CDATA[Laboratories]]></TERM><TERM><![CDATA[Learning]]></TERM><TERM><![CDATA[Maintenance]]></TERM><TERM><![CDATA[Measures]]></TERM><TERM><![CDATA[member]]></TERM><TERM><![CDATA[Memory]]></TERM><TERM><![CDATA[Mental Retardation and Developmental Disabilities Research Centers]]></TERM><TERM><![CDATA[Methodology]]></TERM><TERM><![CDATA[Methods]]></TERM><TERM><![CDATA[Microdissection]]></TERM><TERM><![CDATA[Microglia]]></TERM><TERM><![CDATA[Mission]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Monitor]]></TERM><TERM><![CDATA[Motor]]></TERM><TERM><![CDATA[mouse model]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[Mutation]]></TERM><TERM><![CDATA[neurochemistry]]></TERM><TERM><![CDATA[neuroimaging]]></TERM><TERM><![CDATA[neuromuscular]]></TERM><TERM><![CDATA[Neurons]]></TERM><TERM><![CDATA[Normal Cell]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[Oligodendroglia]]></TERM><TERM><![CDATA[Patient Recruitments]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Performance]]></TERM><TERM><![CDATA[Peripheral]]></TERM><TERM><![CDATA[Pharmaceutical Preparations]]></TERM><TERM><![CDATA[Phenotype]]></TERM><TERM><![CDATA[Population]]></TERM><TERM><![CDATA[Pre-Clinical Model]]></TERM><TERM><![CDATA[preference]]></TERM><TERM><![CDATA[Procedures]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[Production]]></TERM><TERM><![CDATA[Protocols documentation]]></TERM><TERM><![CDATA[Publications]]></TERM><TERM><![CDATA[Reflex action]]></TERM><TERM><![CDATA[Research Personnel]]></TERM><TERM><![CDATA[research study]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[Rodent]]></TERM><TERM><![CDATA[Rodent Model]]></TERM><TERM><![CDATA[Services]]></TERM><TERM><![CDATA[Skin]]></TERM><TERM><![CDATA[Sleep]]></TERM><TERM><![CDATA[social]]></TERM><TERM><![CDATA[Social Interaction]]></TERM><TERM><![CDATA[Somatic Cell]]></TERM><TERM><![CDATA[stem cell technology]]></TERM><TERM><![CDATA[Stem cells]]></TERM><TERM><![CDATA[Stimulus]]></TERM><TERM><![CDATA[Structure]]></TERM><TERM><![CDATA[Surveys]]></TERM><TERM><![CDATA[System]]></TERM><TERM><![CDATA[Techniques]]></TERM><TERM><![CDATA[Technology]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[tissue culture]]></TERM><TERM><![CDATA[Tissue Harvesting]]></TERM><TERM><![CDATA[Toxin]]></TERM><TERM><![CDATA[Training]]></TERM><TERM><![CDATA[Treatment Efficacy]]></TERM><TERM><![CDATA[Ultrasonics]]></TERM><TERM><![CDATA[Virus]]></TERM><TERM><![CDATA[vocalization]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Preclinical Models: Core F]]></PROJECT_TITLE><SERIAL_NUMBER>086984</SERIAL_NUMBER><STUDY_SECTION>ZHD1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID>8063</SUBPROJECT_ID><SUPPORT_YEAR>01</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>121688</DIRECT_COST_AMT><INDIRECT_COST_AMT>32941</INDIRECT_COST_AMT><TOTAL_COST /><TOTAL_COST_SUB_PROJECT>131957</TOTAL_COST_SUB_PROJECT></row>
<row><APPLICATION_ID>9056014</APPLICATION_ID><ACTIVITY>U54</ACTIVITY><ADMINISTERING_IC>HD</ADMINISTERING_IC><APPLICATION_TYPE>1</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/30/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>865</CFDA_CODE><CORE_PROJECT_NUM>U54HD087101</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>RFA-HD-15-033</FOA_NUMBER><FULL_PROJECT_NUM>1U54HD087101-01</FULL_PROJECT_NUM><FUNDING_ICs>NICHD:1298372\</FUNDING_ICs><FUNDING_MECHANISM>RESEARCH CENTERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &amp; HUMAN DEVELOPMENT</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>LOS ANGELES</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[NONE]]></ORG_DEPT><ORG_DISTRICT>33</ORG_DISTRICT><ORG_DUNS>092530369</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIVERSITY OF CALIFORNIA LOS ANGELES]]></ORG_NAME><ORG_STATE>CA</ORG_STATE><ORG_ZIPCODE>900952000</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: This is a new application for the UCLA IDDRC, the UCLA Center for Translational Research in Neurodevelopment (UC-TRaN). The Center is dedicated to improving the lives of individuals with intellectual and developmental disabilities by creating a research environment optimized for studying the basic cases and mechanisms leading to IDDs, and designing effective treatments and prevention strategies. Our center is strongly focused on building collaborations among researchers studying the same problems with different techniques, and partnering with the community to ensure scientific discoveries will benefit individuals. Our application builds on over 50 years of dedicated research into intellectual and developmental disorders.      

]]></PHR><PIS><PI><PI_NAME>BOOKHEIMER, SUSAN Y (contact)</PI_NAME><PI_ID>6250126 (contact)</PI_ID></PI><PI><PI_NAME>DE VELLIS, JEAN </PI_NAME><PI_ID>1863163</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>PARISI, MELISSA </PROGRAM_OFFICER_NAME><PROJECT_START>11/01/2015</PROJECT_START><PROJECT_END>05/31/2020</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Agonist]]></TERM><TERM><![CDATA[Animal Model]]></TERM><TERM><![CDATA[Animals]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Basic Science]]></TERM><TERM><![CDATA[Behavior]]></TERM><TERM><![CDATA[Behavioral]]></TERM><TERM><![CDATA[Big Data]]></TERM><TERM><![CDATA[Bioinformatics]]></TERM><TERM><![CDATA[Biological Markers]]></TERM><TERM><![CDATA[Biological Models]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Center for Translational Science Activities]]></TERM><TERM><![CDATA[Cerebrum]]></TERM><TERM><![CDATA[Child]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[clinical practice]]></TERM><TERM><![CDATA[Clinical Trials]]></TERM><TERM><![CDATA[Cognition]]></TERM><TERM><![CDATA[cohort]]></TERM><TERM><![CDATA[Collaborations]]></TERM><TERM><![CDATA[Collection]]></TERM><TERM><![CDATA[Communication]]></TERM><TERM><![CDATA[Communities]]></TERM><TERM><![CDATA[Core Facility]]></TERM><TERM><![CDATA[cost effective]]></TERM><TERM><![CDATA[Databases]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Developmental Delay Disorders]]></TERM><TERM><![CDATA[developmental disease/disorder]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Education and Outreach]]></TERM><TERM><![CDATA[Educational Activities]]></TERM><TERM><![CDATA[Educational aspects]]></TERM><TERM><![CDATA[Educational workshop]]></TERM><TERM><![CDATA[effective therapy]]></TERM><TERM><![CDATA[Electroencephalography]]></TERM><TERM><![CDATA[Electrophysiology (science)]]></TERM><TERM><![CDATA[Elements]]></TERM><TERM><![CDATA[Ensure]]></TERM><TERM><![CDATA[Environment]]></TERM><TERM><![CDATA[Epigenetic Process]]></TERM><TERM><![CDATA[financial incentive]]></TERM><TERM><![CDATA[Fostering]]></TERM><TERM><![CDATA[Functional Imaging]]></TERM><TERM><![CDATA[gamma-Aminobutyric Acid]]></TERM><TERM><![CDATA[Gene Expression]]></TERM><TERM><![CDATA[Genes]]></TERM><TERM><![CDATA[Genetic]]></TERM><TERM><![CDATA[genetic analysis]]></TERM><TERM><![CDATA[Genomics]]></TERM><TERM><![CDATA[Genotype]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[Human Resources]]></TERM><TERM><![CDATA[Image]]></TERM><TERM><![CDATA[Imagery]]></TERM><TERM><![CDATA[Imaging Device]]></TERM><TERM><![CDATA[Impaired cognition]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[induced pluripotent stem cell]]></TERM><TERM><![CDATA[innovation]]></TERM><TERM><![CDATA[Intellectual functioning disability]]></TERM><TERM><![CDATA[Interdisciplinary Study]]></TERM><TERM><![CDATA[Leadership]]></TERM><TERM><![CDATA[Life]]></TERM><TERM><![CDATA[Magnetic Resonance Imaging]]></TERM><TERM><![CDATA[Mental Retardation and Developmental Disabilities Research Centers]]></TERM><TERM><![CDATA[Microscope]]></TERM><TERM><![CDATA[Microscopy]]></TERM><TERM><![CDATA[miniaturize]]></TERM><TERM><![CDATA[Mission]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[mouse model]]></TERM><TERM><![CDATA[neurodevelopment]]></TERM><TERM><![CDATA[neurophysiology]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[optogenetics]]></TERM><TERM><![CDATA[Organelles]]></TERM><TERM><![CDATA[Organoids]]></TERM><TERM><![CDATA[Outcome]]></TERM><TERM><![CDATA[outreach]]></TERM><TERM><![CDATA[overexpression]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Pattern]]></TERM><TERM><![CDATA[Phenotype]]></TERM><TERM><![CDATA[Positioning Attribute]]></TERM><TERM><![CDATA[Prevention strategy]]></TERM><TERM><![CDATA[public health relevance]]></TERM><TERM><![CDATA[receptor]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Research Infrastructure]]></TERM><TERM><![CDATA[Research Personnel]]></TERM><TERM><![CDATA[Research Project Grants]]></TERM><TERM><![CDATA[Research Proposals]]></TERM><TERM><![CDATA[research study]]></TERM><TERM><![CDATA[Research Support]]></TERM><TERM><![CDATA[Resources]]></TERM><TERM><![CDATA[Science]]></TERM><TERM><![CDATA[Scientist]]></TERM><TERM><![CDATA[Series]]></TERM><TERM><![CDATA[Serine]]></TERM><TERM><![CDATA[Services]]></TERM><TERM><![CDATA[sharing data]]></TERM><TERM><![CDATA[Sirolimus]]></TERM><TERM><![CDATA[Structure]]></TERM><TERM><![CDATA[Symptoms]]></TERM><TERM><![CDATA[Syndrome]]></TERM><TERM><![CDATA[System]]></TERM><TERM><![CDATA[Systems Analysis]]></TERM><TERM><![CDATA[Techniques]]></TERM><TERM><![CDATA[Technology]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[tool]]></TERM><TERM><![CDATA[Training]]></TERM><TERM><![CDATA[Translational Research]]></TERM><TERM><![CDATA[Translations]]></TERM><TERM><![CDATA[Universities]]></TERM><TERM><![CDATA[Visit]]></TERM><TERM><![CDATA[voucher]]></TERM><TERM><![CDATA[Washington]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[UCLA Center for Translational Research in Neurodevelopment: UC-TRaN]]></PROJECT_TITLE><SERIAL_NUMBER>087101</SERIAL_NUMBER><STUDY_SECTION>ZHD1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>01</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>843099</DIRECT_COST_AMT><INDIRECT_COST_AMT>455273</INDIRECT_COST_AMT><TOTAL_COST>1298372</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9064960</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>AI</ADMINISTERING_IC><APPLICATION_TYPE>2</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/30/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>855</CFDA_CODE><CORE_PROJECT_NUM>R01AI033325</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-13-302</FOA_NUMBER><FULL_PROJECT_NUM>2R01AI033325-21A1</FULL_PROJECT_NUM><FUNDING_ICs>NIAID:396250\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>WASHINGTON</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[MICROBIOLOGY/IMMUN/VIROLOGY]]></ORG_DEPT><ORG_DISTRICT>98</ORG_DISTRICT><ORG_DUNS>043990498</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[GEORGE WASHINGTON UNIVERSITY]]></ORG_NAME><ORG_STATE>DC</ORG_STATE><ORG_ZIPCODE>200520001</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Toxoplasma encephalitis, due to reactivation of latent infection during advanced HIV infection poses a problem for these patients. The goal of this proposal is to determine the strategy, which will reinvigorate the CD8 T cell response, needed to maintain the chronicity of infection.      

]]></PHR><PIS><PI><PI_NAME>KHAN, IMTIAZ AHMED</PI_NAME><PI_ID>1870644</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>WALI, TONU M.</PROGRAM_OFFICER_NAME><PROJECT_START>07/01/1992</PROJECT_START><PROJECT_END>10/31/2020</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Acquired Immunodeficiency Syndrome]]></TERM><TERM><![CDATA[Agonist]]></TERM><TERM><![CDATA[Animals]]></TERM><TERM><![CDATA[Antibodies]]></TERM><TERM><![CDATA[Antigens]]></TERM><TERM><![CDATA[antiretroviral therapy]]></TERM><TERM><![CDATA[Apoptosis]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Blocking Antibodies]]></TERM><TERM><![CDATA[Brain]]></TERM><TERM><![CDATA[brain tissue]]></TERM><TERM><![CDATA[CD4 Positive T Lymphocytes]]></TERM><TERM><![CDATA[CD8B1 gene]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Central Nervous System Infections]]></TERM><TERM><![CDATA[Chronic]]></TERM><TERM><![CDATA[Chronic Phase]]></TERM><TERM><![CDATA[combinatorial]]></TERM><TERM><![CDATA[Communicable Diseases]]></TERM><TERM><![CDATA[Complex]]></TERM><TERM><![CDATA[Country]]></TERM><TERM><![CDATA[Cyst]]></TERM><TERM><![CDATA[cytokine]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Defect]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[effective therapy]]></TERM><TERM><![CDATA[Encephalitis]]></TERM><TERM><![CDATA[exhaust]]></TERM><TERM><![CDATA[exhaustion]]></TERM><TERM><![CDATA[Exhibits]]></TERM><TERM><![CDATA[Functional disorder]]></TERM><TERM><![CDATA[functional restoration]]></TERM><TERM><![CDATA[Funding]]></TERM><TERM><![CDATA[Generations]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[High Prevalence]]></TERM><TERM><![CDATA[HIV]]></TERM><TERM><![CDATA[HIV Infections]]></TERM><TERM><![CDATA[Immune]]></TERM><TERM><![CDATA[Immune System Diseases]]></TERM><TERM><![CDATA[Immunity]]></TERM><TERM><![CDATA[Immunocompromised Host]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[Incidence]]></TERM><TERM><![CDATA[Infection]]></TERM><TERM><![CDATA[inhibitor/antagonist]]></TERM><TERM><![CDATA[insight]]></TERM><TERM><![CDATA[Kinetics]]></TERM><TERM><![CDATA[Laboratories]]></TERM><TERM><![CDATA[latent infection]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[Life]]></TERM><TERM><![CDATA[Maintenance]]></TERM><TERM><![CDATA[Measures]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[Memory]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[mouse model]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[Muscle]]></TERM><TERM><![CDATA[Organism]]></TERM><TERM><![CDATA[Parasites]]></TERM><TERM><![CDATA[Parasitic infection]]></TERM><TERM><![CDATA[pathogen]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Pattern]]></TERM><TERM><![CDATA[Play]]></TERM><TERM><![CDATA[Population]]></TERM><TERM><![CDATA[prevent]]></TERM><TERM><![CDATA[Prevention]]></TERM><TERM><![CDATA[Production]]></TERM><TERM><![CDATA[public health relevance]]></TERM><TERM><![CDATA[Publications]]></TERM><TERM><![CDATA[receptor]]></TERM><TERM><![CDATA[Regimen]]></TERM><TERM><![CDATA[Reporting]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Shapes]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[Source]]></TERM><TERM><![CDATA[Staging]]></TERM><TERM><![CDATA[T cell response]]></TERM><TERM><![CDATA[T memory cell]]></TERM><TERM><![CDATA[T-Lymphocyte]]></TERM><TERM><![CDATA[Therapeutic]]></TERM><TERM><![CDATA[therapy design]]></TERM><TERM><![CDATA[TNFRSF5 gene]]></TERM><TERM><![CDATA[TNFSF5 gene]]></TERM><TERM><![CDATA[Toxoplasma]]></TERM><TERM><![CDATA[Toxoplasma gondii]]></TERM><TERM><![CDATA[Toxoplasmosis]]></TERM><TERM><![CDATA[Up-Regulation (Physiology)]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Long Term Immunity against Toxoplasmosis]]></PROJECT_TITLE><SERIAL_NUMBER>033325</SERIAL_NUMBER><STUDY_SECTION>AOIC</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[AIDS-associated Opportunistic Infections and Cancer Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>21</SUPPORT_YEAR><SUFFIX>A1</SUFFIX><DIRECT_COST_AMT>250000</DIRECT_COST_AMT><INDIRECT_COST_AMT>146250</INDIRECT_COST_AMT><TOTAL_COST>396250</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9072464</APPLICATION_ID><ACTIVITY>Y01</ACTIVITY><ADMINISTERING_IC>HL</ADMINISTERING_IC><APPLICATION_TYPE></APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE></AWARD_NOTICE_DATE><BUDGET_START></BUDGET_START><BUDGET_END></BUDGET_END><CFDA_CODE>837</CFDA_CODE><CORE_PROJECT_NUM>Y01HL130010</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER></FOA_NUMBER><FULL_PROJECT_NUM>AHL13001001-1-0-1</FULL_PROJECT_NUM><FUNDING_ICs>NHLBI:1042313\</FUNDING_ICs><FUNDING_MECHANISM>INTERAGENCY AGREEMENTS</FUNDING_MECHANISM><FY>2015</FY><IC_NAME>NATIONAL HEART, LUNG, AND BLOOD INSTITUTE</IC_NAME><NIH_SPENDING_CATS><CATEGORY><![CDATA[Infant Mortality]]></CATEGORY><CATEGORY><![CDATA[Infant Mortality/ (LBW)]]></CATEGORY><CATEGORY><![CDATA[Pediatric]]></CATEGORY><CATEGORY><![CDATA[Perinatal Period - Conditions Originating in Perinatal Period]]></CATEGORY><CATEGORY><![CDATA[Rare Diseases]]></CATEGORY><CATEGORY><![CDATA[Sudden Infant Death Syndrome]]></CATEGORY></NIH_SPENDING_CATS><ORG_CITY></ORG_CITY><ORG_COUNTRY></ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT></ORG_DISTRICT><ORG_DUNS></ORG_DUNS><ORG_FIPS></ORG_FIPS><ORG_NAME><![CDATA[NATIONAL HEART, LUNG, AND BLOOD INSTITUTE]]></ORG_NAME><ORG_STATE></ORG_STATE><ORG_ZIPCODE></ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>,  </PI_NAME><PI_ID></PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START></PROJECT_START><PROJECT_END></PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Age-Years]]></TERM><TERM><![CDATA[authority]]></TERM><TERM><![CDATA[Award]]></TERM><TERM><![CDATA[Centers for Disease Control and Prevention (U.S.)]]></TERM><TERM><![CDATA[Cessation of life]]></TERM><TERM><![CDATA[Child]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[data registry]]></TERM><TERM><![CDATA[Data Set]]></TERM><TERM><![CDATA[Death Certificates]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[DNA]]></TERM><TERM><![CDATA[Evaluation]]></TERM><TERM><![CDATA[Funding]]></TERM><TERM><![CDATA[Future]]></TERM><TERM><![CDATA[Grant]]></TERM><TERM><![CDATA[Incidence]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[Investigation]]></TERM><TERM><![CDATA[Medical Records]]></TERM><TERM><![CDATA[National Heart, Lung, and Blood Institute]]></TERM><TERM><![CDATA[Pathology Report]]></TERM><TERM><![CDATA[Phase]]></TERM><TERM><![CDATA[population based]]></TERM><TERM><![CDATA[programs]]></TERM><TERM><![CDATA[prospective]]></TERM><TERM><![CDATA[public health medicine (field)]]></TERM><TERM><![CDATA[Registries]]></TERM><TERM><![CDATA[Research Infrastructure]]></TERM><TERM><![CDATA[Research Personnel]]></TERM><TERM><![CDATA[Resources]]></TERM><TERM><![CDATA[Sampling]]></TERM><TERM><![CDATA[Serum]]></TERM><TERM><![CDATA[Services]]></TERM><TERM><![CDATA[Specimen]]></TERM><TERM><![CDATA[Sudden Death]]></TERM><TERM><![CDATA[Sudden infant death syndrome]]></TERM><TERM><![CDATA[System]]></TERM><TERM><![CDATA[United States]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Sudden Death in the Young (SDY) Initiative]]></PROJECT_TITLE><SERIAL_NUMBER></SERIAL_NUMBER><STUDY_SECTION></STUDY_SECTION><STUDY_SECTION_NAME xsi:nil='true' /><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR></SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>1042313</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9136275</APPLICATION_ID><ACTIVITY>P30</ACTIVITY><ADMINISTERING_IC>DK</ADMINISTERING_IC><APPLICATION_TYPE>6</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/03/2015</AWARD_NOTICE_DATE><BUDGET_START>09/01/2015</BUDGET_START><BUDGET_END>03/31/2016</BUDGET_END><CFDA_CODE>847</CFDA_CODE><CORE_PROJECT_NUM>P30DK020541</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-DK-13-004</FOA_NUMBER><FULL_PROJECT_NUM>6P30DK020541-39</FULL_PROJECT_NUM><FUNDING_ICs>NIDDK:1234065\</FUNDING_ICs><FUNDING_MECHANISM>RESEARCH CENTERS</FUNDING_MECHANISM><FY>2015</FY><IC_NAME>NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>BRONX</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>14</ORG_DISTRICT><ORG_DUNS>079783367</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[ALBERT EINSTEIN COLLEGE OF MEDICINE]]></ORG_NAME><ORG_STATE>NY</ORG_STATE><ORG_ZIPCODE>104611975</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Diabetes and related metabolic disorders are rapidly increasing and have major impacts on both the quality of life and the lifespan of the US population, and are therefore responsible for a large portion of our health care cost burden. The goals of this project are to provide resources for molecular, cellular, tissue, organismal, pre- clinical, clinical and translation research to improve and diabetes treatment and reduce its cost.  
      

]]></PHR><PIS><PI><PI_NAME>PESSIN, JEFFREY E</PI_NAME><PI_ID>6199091</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>HYDE, JAMES F</PROGRAM_OFFICER_NAME><PROJECT_START>12/01/1996</PROJECT_START><PROJECT_END>03/31/2020</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Adenoviruses]]></TERM><TERM><![CDATA[American]]></TERM><TERM><![CDATA[Animal Model]]></TERM><TERM><![CDATA[animal tissue]]></TERM><TERM><![CDATA[Animals]]></TERM><TERM><![CDATA[Area]]></TERM><TERM><![CDATA[Award]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Basic Science]]></TERM><TERM><![CDATA[Behavioral Research]]></TERM><TERM><![CDATA[Behavioral Sciences]]></TERM><TERM><![CDATA[bench to bedside]]></TERM><TERM><![CDATA[Biological Markers]]></TERM><TERM><![CDATA[Biomedical Research]]></TERM><TERM><![CDATA[Cities]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[Clinical and Translational Science Awards]]></TERM><TERM><![CDATA[clinical care]]></TERM><TERM><![CDATA[Clinical Research]]></TERM><TERM><![CDATA[Clinical Sciences]]></TERM><TERM><![CDATA[Cohort Studies]]></TERM><TERM><![CDATA[Collaborations]]></TERM><TERM><![CDATA[college]]></TERM><TERM><![CDATA[Communities]]></TERM><TERM><![CDATA[Core Facility]]></TERM><TERM><![CDATA[cost]]></TERM><TERM><![CDATA[Coupled]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[data acquisition]]></TERM><TERM><![CDATA[Data Analyses]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Diabetes Mellitus]]></TERM><TERM><![CDATA[Educational workshop]]></TERM><TERM><![CDATA[Epidemiology]]></TERM><TERM><![CDATA[Equipment]]></TERM><TERM><![CDATA[Etiology]]></TERM><TERM><![CDATA[Evolution]]></TERM><TERM><![CDATA[Faculty]]></TERM><TERM><![CDATA[Faculty Workshop]]></TERM><TERM><![CDATA[Feasibility Studies]]></TERM><TERM><![CDATA[Fees]]></TERM><TERM><![CDATA[Fostering]]></TERM><TERM><![CDATA[Foundations]]></TERM><TERM><![CDATA[Funding]]></TERM><TERM><![CDATA[Funding Agency]]></TERM><TERM><![CDATA[Gap Junctions]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Grant]]></TERM><TERM><![CDATA[Growth]]></TERM><TERM><![CDATA[Growth and Development function]]></TERM><TERM><![CDATA[Health Care Costs]]></TERM><TERM><![CDATA[HIV]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[Human Resources]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[innovation]]></TERM><TERM><![CDATA[Institutes]]></TERM><TERM><![CDATA[Institution]]></TERM><TERM><![CDATA[Insulin-Dependent Diabetes Mellitus]]></TERM><TERM><![CDATA[interdisciplinary collaboration]]></TERM><TERM><![CDATA[International]]></TERM><TERM><![CDATA[Investigation]]></TERM><TERM><![CDATA[islet]]></TERM><TERM><![CDATA[Knowledge]]></TERM><TERM><![CDATA[Laboratories]]></TERM><TERM><![CDATA[Longevity]]></TERM><TERM><![CDATA[Management Information Systems]]></TERM><TERM><![CDATA[medical schools]]></TERM><TERM><![CDATA[Medicine]]></TERM><TERM><![CDATA[meetings]]></TERM><TERM><![CDATA[member]]></TERM><TERM><![CDATA[Mentors]]></TERM><TERM><![CDATA[Metabolic Diseases]]></TERM><TERM><![CDATA[Metabolism]]></TERM><TERM><![CDATA[metabolomics]]></TERM><TERM><![CDATA[Methodology]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[Monitor]]></TERM><TERM><![CDATA[Nature]]></TERM><TERM><![CDATA[New York]]></TERM><TERM><![CDATA[New York City]]></TERM><TERM><![CDATA[Obesity]]></TERM><TERM><![CDATA[outreach]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Physiology]]></TERM><TERM><![CDATA[Pilot Projects]]></TERM><TERM><![CDATA[Population]]></TERM><TERM><![CDATA[population based]]></TERM><TERM><![CDATA[Positioning Attribute]]></TERM><TERM><![CDATA[pre-clinical]]></TERM><TERM><![CDATA[Productivity]]></TERM><TERM><![CDATA[programs]]></TERM><TERM><![CDATA[public health relevance]]></TERM><TERM><![CDATA[Quality of life]]></TERM><TERM><![CDATA[Recording of previous events]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[research and development]]></TERM><TERM><![CDATA[Research Infrastructure]]></TERM><TERM><![CDATA[Research Personnel]]></TERM><TERM><![CDATA[Research Project Grants]]></TERM><TERM><![CDATA[Research Training]]></TERM><TERM><![CDATA[Resources]]></TERM><TERM><![CDATA[Services]]></TERM><TERM><![CDATA[stable isotope]]></TERM><TERM><![CDATA[Structure]]></TERM><TERM><![CDATA[success]]></TERM><TERM><![CDATA[symposium]]></TERM><TERM><![CDATA[Technology]]></TERM><TERM><![CDATA[Tissues]]></TERM><TERM><![CDATA[Training and Education]]></TERM><TERM><![CDATA[Translating]]></TERM><TERM><![CDATA[Translational Research]]></TERM><TERM><![CDATA[Translations]]></TERM><TERM><![CDATA[type I and type II diabetes]]></TERM><TERM><![CDATA[Underrepresented Minority]]></TERM><TERM><![CDATA[Universities]]></TERM><TERM><![CDATA[University Hospitals]]></TERM><TERM><![CDATA[Vision]]></TERM><TERM><![CDATA[Woman]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Einstein-Mount Sinai Diabetes Research Center]]></PROJECT_TITLE><SERIAL_NUMBER>020541</SERIAL_NUMBER><STUDY_SECTION>ZDK1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>39</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>830878</DIRECT_COST_AMT><INDIRECT_COST_AMT>403187</INDIRECT_COST_AMT><TOTAL_COST>1234065</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9136280</APPLICATION_ID><ACTIVITY>P30</ACTIVITY><ADMINISTERING_IC>DK</ADMINISTERING_IC><APPLICATION_TYPE>6</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/03/2015</AWARD_NOTICE_DATE><BUDGET_START>09/01/2015</BUDGET_START><BUDGET_END>03/31/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>P30DK020541</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-DK-13-004</FOA_NUMBER><FULL_PROJECT_NUM>6P30DK020541-39</FULL_PROJECT_NUM><FUNDING_ICs>NIDDK:3460\</FUNDING_ICs><FUNDING_MECHANISM>RESEARCH CENTERS</FUNDING_MECHANISM><FY>2015</FY><IC_NAME>NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES</IC_NAME><NIH_SPENDING_CATS><CATEGORY><![CDATA[Diabetes]]></CATEGORY></NIH_SPENDING_CATS><ORG_CITY>BRONX</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>14</ORG_DISTRICT><ORG_DUNS>079783367</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[ALBERT EINSTEIN COLLEGE OF MEDICINE]]></ORG_NAME><ORG_STATE>NY</ORG_STATE><ORG_ZIPCODE>104611975</ORG_ZIPCODE><PHR><![CDATA[The Enrichment Program provides essential education and facilitates interaction between scientists. Through 
conferences and lectures from experts in diabetes research and related fields, we facilitate increased 
collaboration and scientific interaction designed to promote interchange of ideas and hasten scientific progress 
in the field of diabetes research and related areas of study.]]></PHR><PIS><PI><PI_NAME>HAWKINS, MEREDITH A</PI_NAME><PI_ID>6488817</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START></PROJECT_START><PROJECT_END></PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Area]]></TERM><TERM><![CDATA[Award]]></TERM><TERM><![CDATA[Basic Science]]></TERM><TERM><![CDATA[Behavioral]]></TERM><TERM><![CDATA[Behavioral Research]]></TERM><TERM><![CDATA[bench to bedside]]></TERM><TERM><![CDATA[Caliber]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[Clinical Research]]></TERM><TERM><![CDATA[Clinical Sciences]]></TERM><TERM><![CDATA[Collaborations]]></TERM><TERM><![CDATA[Communities]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[Diabetes Mellitus]]></TERM><TERM><![CDATA[Educational aspects]]></TERM><TERM><![CDATA[Educational workshop]]></TERM><TERM><![CDATA[Ensure]]></TERM><TERM><![CDATA[Environment]]></TERM><TERM><![CDATA[Event]]></TERM><TERM><![CDATA[experience]]></TERM><TERM><![CDATA[Exposure to]]></TERM><TERM><![CDATA[Faculty]]></TERM><TERM><![CDATA[Faculty Workshop]]></TERM><TERM><![CDATA[Feedback]]></TERM><TERM><![CDATA[Fostering]]></TERM><TERM><![CDATA[Future]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[Information Dissemination]]></TERM><TERM><![CDATA[Institution]]></TERM><TERM><![CDATA[interest]]></TERM><TERM><![CDATA[International]]></TERM><TERM><![CDATA[Investigation]]></TERM><TERM><![CDATA[Joints]]></TERM><TERM><![CDATA[journal article]]></TERM><TERM><![CDATA[Journals]]></TERM><TERM><![CDATA[Language]]></TERM><TERM><![CDATA[Leadership]]></TERM><TERM><![CDATA[lectures]]></TERM><TERM><![CDATA[meetings]]></TERM><TERM><![CDATA[member]]></TERM><TERM><![CDATA[Mentors]]></TERM><TERM><![CDATA[Metabolic Diseases]]></TERM><TERM><![CDATA[Metabolism]]></TERM><TERM><![CDATA[Mission]]></TERM><TERM><![CDATA[New York]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[Nursing Faculty]]></TERM><TERM><![CDATA[Play]]></TERM><TERM><![CDATA[Postdoctoral Fellow]]></TERM><TERM><![CDATA[pre-doctoral]]></TERM><TERM><![CDATA[professor]]></TERM><TERM><![CDATA[programs]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Research Methodology]]></TERM><TERM><![CDATA[Research Personnel]]></TERM><TERM><![CDATA[Research Training]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Scientist]]></TERM><TERM><![CDATA[Series]]></TERM><TERM><![CDATA[Services]]></TERM><TERM><![CDATA[Students]]></TERM><TERM><![CDATA[symposium]]></TERM><TERM><![CDATA[Targeted Research]]></TERM><TERM><![CDATA[Training]]></TERM><TERM><![CDATA[Training and Infrastructure]]></TERM><TERM><![CDATA[Translational Research]]></TERM><TERM><![CDATA[Videoconferences]]></TERM><TERM><![CDATA[Videoconferencing]]></TERM><TERM><![CDATA[Visit]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Enrichment Program]]></PROJECT_TITLE><SERIAL_NUMBER>020541</SERIAL_NUMBER><STUDY_SECTION>ZDK1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID>7657</SUBPROJECT_ID><SUPPORT_YEAR>39</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>2072</DIRECT_COST_AMT><INDIRECT_COST_AMT>1388</INDIRECT_COST_AMT><TOTAL_COST /><TOTAL_COST_SUB_PROJECT>3460</TOTAL_COST_SUB_PROJECT></row>
<row><APPLICATION_ID>9136282</APPLICATION_ID><ACTIVITY>P30</ACTIVITY><ADMINISTERING_IC>DK</ADMINISTERING_IC><APPLICATION_TYPE>6</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/03/2015</AWARD_NOTICE_DATE><BUDGET_START>09/01/2015</BUDGET_START><BUDGET_END>03/31/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>P30DK020541</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-DK-13-004</FOA_NUMBER><FULL_PROJECT_NUM>6P30DK020541-39</FULL_PROJECT_NUM><FUNDING_ICs>NIDDK:422185\</FUNDING_ICs><FUNDING_MECHANISM>RESEARCH CENTERS</FUNDING_MECHANISM><FY>2015</FY><IC_NAME>NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES</IC_NAME><NIH_SPENDING_CATS><CATEGORY><![CDATA[Diabetes]]></CATEGORY></NIH_SPENDING_CATS><ORG_CITY>BRONX</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>14</ORG_DISTRICT><ORG_DUNS>079783367</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[ALBERT EINSTEIN COLLEGE OF MEDICINE]]></ORG_NAME><ORG_STATE>NY</ORG_STATE><ORG_ZIPCODE>104611975</ORG_ZIPCODE><PHR><![CDATA[The Administrative Core of the Einstein-Mount Sinai Diabetes Research Center provides cost effective 
administrative support to facilitate diabetes and related research and to attract new diabetes 
investigators and/or for established diabetes research investigators to explore new and promising 
directions for the treatment and delivery of improved methods for patients with diabetes.&#160;]]></PHR><PIS><PI><PI_NAME>PESSIN, JEFFREY E</PI_NAME><PI_ID>6199091</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START></PROJECT_START><PROJECT_END></PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Adenoviruses]]></TERM><TERM><![CDATA[Advisory Committees]]></TERM><TERM><![CDATA[Advocacy]]></TERM><TERM><![CDATA[Animals]]></TERM><TERM><![CDATA[Area]]></TERM><TERM><![CDATA[Award]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Biology]]></TERM><TERM><![CDATA[Biomedical Research]]></TERM><TERM><![CDATA[Climate]]></TERM><TERM><![CDATA[Clinical Trials]]></TERM><TERM><![CDATA[Collaborations]]></TERM><TERM><![CDATA[college]]></TERM><TERM><![CDATA[Communities]]></TERM><TERM><![CDATA[Complications of Diabetes Mellitus]]></TERM><TERM><![CDATA[cost effective]]></TERM><TERM><![CDATA[cost effectiveness]]></TERM><TERM><![CDATA[cost efficient]]></TERM><TERM><![CDATA[density]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Diabetes Mellitus]]></TERM><TERM><![CDATA[Doctor of Philosophy]]></TERM><TERM><![CDATA[Educational workshop]]></TERM><TERM><![CDATA[Endocrine System Diseases]]></TERM><TERM><![CDATA[Ensure]]></TERM><TERM><![CDATA[Environment]]></TERM><TERM><![CDATA[Ethics]]></TERM><TERM><![CDATA[Evaluation]]></TERM><TERM><![CDATA[Evolution]]></TERM><TERM><![CDATA[expectation]]></TERM><TERM><![CDATA[experience]]></TERM><TERM><![CDATA[Faculty]]></TERM><TERM><![CDATA[Feasibility Studies]]></TERM><TERM><![CDATA[Fertilization]]></TERM><TERM><![CDATA[Financial Support]]></TERM><TERM><![CDATA[flexibility]]></TERM><TERM><![CDATA[Fostering]]></TERM><TERM><![CDATA[Funding]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Health system]]></TERM><TERM><![CDATA[Heart]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[Human Resources]]></TERM><TERM><![CDATA[Immunology]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[innovation]]></TERM><TERM><![CDATA[Institutes]]></TERM><TERM><![CDATA[Institution]]></TERM><TERM><![CDATA[islet]]></TERM><TERM><![CDATA[Leadership]]></TERM><TERM><![CDATA[Maintenance]]></TERM><TERM><![CDATA[Medical center]]></TERM><TERM><![CDATA[medical schools]]></TERM><TERM><![CDATA[Medicine]]></TERM><TERM><![CDATA[meetings]]></TERM><TERM><![CDATA[member]]></TERM><TERM><![CDATA[Mentors]]></TERM><TERM><![CDATA[Mentorship]]></TERM><TERM><![CDATA[Metabolic]]></TERM><TERM><![CDATA[Metabolic Diseases]]></TERM><TERM><![CDATA[Metabolism]]></TERM><TERM><![CDATA[metabolomics]]></TERM><TERM><![CDATA[Methods]]></TERM><TERM><![CDATA[metropolitan]]></TERM><TERM><![CDATA[Mission]]></TERM><TERM><![CDATA[multidisciplinary]]></TERM><TERM><![CDATA[New York]]></TERM><TERM><![CDATA[Obesity]]></TERM><TERM><![CDATA[patient oriented research]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Peripheral]]></TERM><TERM><![CDATA[Physiology]]></TERM><TERM><![CDATA[Pilot Projects]]></TERM><TERM><![CDATA[Policies]]></TERM><TERM><![CDATA[Principal Investigator]]></TERM><TERM><![CDATA[Procedures]]></TERM><TERM><![CDATA[Productivity]]></TERM><TERM><![CDATA[programs]]></TERM><TERM><![CDATA[public health medicine (field)]]></TERM><TERM><![CDATA[Quality Control]]></TERM><TERM><![CDATA[Regulation]]></TERM><TERM><![CDATA[Reporting]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Research Activity]]></TERM><TERM><![CDATA[Research Infrastructure]]></TERM><TERM><![CDATA[Research Personnel]]></TERM><TERM><![CDATA[Research Project Grants]]></TERM><TERM><![CDATA[Research Support]]></TERM><TERM><![CDATA[Resources]]></TERM><TERM><![CDATA[Services]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[social]]></TERM><TERM><![CDATA[stable isotope]]></TERM><TERM><![CDATA[Structure]]></TERM><TERM><![CDATA[success]]></TERM><TERM><![CDATA[Supervision]]></TERM><TERM><![CDATA[symposium]]></TERM><TERM><![CDATA[System]]></TERM><TERM><![CDATA[Technology]]></TERM><TERM><![CDATA[tool]]></TERM><TERM><![CDATA[Translational Research]]></TERM><TERM><![CDATA[Translations]]></TERM><TERM><![CDATA[United States National Institutes of Health]]></TERM><TERM><![CDATA[Universities]]></TERM><TERM><![CDATA[Vision]]></TERM><TERM><![CDATA[web site]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[The Administrative Core]]></PROJECT_TITLE><SERIAL_NUMBER>020541</SERIAL_NUMBER><STUDY_SECTION>ZDK1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID>7659</SUBPROJECT_ID><SUPPORT_YEAR>39</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>340271</DIRECT_COST_AMT><INDIRECT_COST_AMT>81914</INDIRECT_COST_AMT><TOTAL_COST /><TOTAL_COST_SUB_PROJECT>422185</TOTAL_COST_SUB_PROJECT></row>
<row><APPLICATION_ID>9146929</APPLICATION_ID><ACTIVITY>U51</ACTIVITY><ADMINISTERING_IC>PS</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/23/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>U51PS004056</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-PS-13-303</FOA_NUMBER><FULL_PROJECT_NUM>5U51PS004056-04</FULL_PROJECT_NUM><FUNDING_ICs>NCHHSTP:269548\</FUNDING_ICs><FUNDING_MECHANISM>OTHERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP)</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>BOSTON</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>08</ORG_DISTRICT><ORG_DUNS>878298900</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[MASSACHUSETTS STATE DEPT OF PUB HEALTH]]></ORG_NAME><ORG_STATE>MA</ORG_STATE><ORG_ZIPCODE>021084619</ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>DEMARIA, ALFRED </PI_NAME><PI_ID>9100941</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>11/01/2012</PROJECT_START><PROJECT_END>10/31/2016</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[VIRAL HEPATITIS-PREVENTION & SURVEILLANCE]]></PROJECT_TITLE><SERIAL_NUMBER>004056</SERIAL_NUMBER><STUDY_SECTION>ZPS1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>04</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>269548</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9146937</APPLICATION_ID><ACTIVITY>U51</ACTIVITY><ADMINISTERING_IC>PS</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/23/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>U51PS004071</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-PS-13-303</FOA_NUMBER><FULL_PROJECT_NUM>5U51PS004071-04</FULL_PROJECT_NUM><FUNDING_ICs>NCHHSTP:43936\</FUNDING_ICs><FUNDING_MECHANISM>OTHERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP)</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>BALTIMORE</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>07</ORG_DISTRICT><ORG_DUNS>042426812; 144280372</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[MARYLAND STATE DEPT OF HLTH/MTL HYGIENE]]></ORG_NAME><ORG_STATE>MD</ORG_STATE><ORG_ZIPCODE>212012301</ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>HITT, JEFFREY </PI_NAME><PI_ID>14115902</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>11/01/2012</PROJECT_START><PROJECT_END>10/31/2016</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[MARYLAND VIRAL HEPATITIS PREVENTION PROGRAM]]></PROJECT_TITLE><SERIAL_NUMBER>004071</SERIAL_NUMBER><STUDY_SECTION>ZPS1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>04</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>43936</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9149041</APPLICATION_ID><ACTIVITY>U51</ACTIVITY><ADMINISTERING_IC>PS</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/23/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>U51PS004020</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-PS-13-303</FOA_NUMBER><FULL_PROJECT_NUM>5U51PS004020-04</FULL_PROJECT_NUM><FUNDING_ICs>NCHHSTP:36095\</FUNDING_ICs><FUNDING_MECHANISM>OTHERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP)</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>SANTA FE</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>03</ORG_DISTRICT><ORG_DUNS>808389274</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[NEW MEXICO STATE DEPARTMENT OF HEALTH]]></ORG_NAME><ORG_STATE>NM</ORG_STATE><ORG_ZIPCODE>875054173</ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>ZURLO, DOMINICK </PI_NAME><PI_ID>14304745</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>11/01/2012</PROJECT_START><PROJECT_END>10/31/2016</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[Viral Hepatitis-Prevention and Surveillance]]></PROJECT_TITLE><SERIAL_NUMBER>004020</SERIAL_NUMBER><STUDY_SECTION>ZPS1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>04</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>36095</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9149049</APPLICATION_ID><ACTIVITY>U51</ACTIVITY><ADMINISTERING_IC>PS</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/26/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>U51PS004062</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-PS-13-303</FOA_NUMBER><FULL_PROJECT_NUM>5U51PS004062-04</FULL_PROJECT_NUM><FUNDING_ICs>NCHHSTP:36901\</FUNDING_ICs><FUNDING_MECHANISM>OTHERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP)</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>CONCORD</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>02</ORG_DISTRICT><ORG_DUNS>011040545</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[NH STATE DEPT/HLTH STATISTICS/DATA MGMT]]></ORG_NAME><ORG_STATE>NH</ORG_STATE><ORG_ZIPCODE>033016503</ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>BOBINSKY, MARCELLA J</PI_NAME><PI_ID>12681270</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>11/01/2012</PROJECT_START><PROJECT_END>10/31/2016</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[VIRAL HEPATITIS - PREVENTION AND SURVEILLANCE]]></PROJECT_TITLE><SERIAL_NUMBER>004062</SERIAL_NUMBER><STUDY_SECTION>ZPS1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>04</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>36901</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9149057</APPLICATION_ID><ACTIVITY>U51</ACTIVITY><ADMINISTERING_IC>PS</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/26/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>U51PS004075</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-PS-13-303</FOA_NUMBER><FULL_PROJECT_NUM>5U51PS004075-04</FULL_PROJECT_NUM><FUNDING_ICs>NCHHSTP:43644\</FUNDING_ICs><FUNDING_MECHANISM>OTHERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP)</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>NASHVILLE</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>05</ORG_DISTRICT><ORG_DUNS>172636268</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[TENNESSEE STATE DEPARTMENT OF HEALTH]]></ORG_NAME><ORG_STATE>TN</ORG_STATE><ORG_ZIPCODE>372431219</ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>WESTER, CAROLYN </PI_NAME><PI_ID>8004409</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>11/01/2012</PROJECT_START><PROJECT_END>10/31/2016</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[VIRAL HEPATITIS-PREVENTION AND SURVEILLANCE]]></PROJECT_TITLE><SERIAL_NUMBER>004075</SERIAL_NUMBER><STUDY_SECTION>ZPS1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>04</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>43644</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9149066</APPLICATION_ID><ACTIVITY>U51</ACTIVITY><ADMINISTERING_IC>PS</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/26/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>U51PS004092</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-PS-13-303</FOA_NUMBER><FULL_PROJECT_NUM>5U51PS004092-04</FULL_PROJECT_NUM><FUNDING_ICs>NCHHSTP:34232\</FUNDING_ICs><FUNDING_MECHANISM>OTHERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP)</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>CARSON CITY</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>02</ORG_DISTRICT><ORG_DUNS>625364849</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[STATE OF NEVADA HEALTH DIVISION]]></ORG_NAME><ORG_STATE>NV</ORG_STATE><ORG_ZIPCODE>897062029</ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>WHITLEY, RICHARD </PI_NAME><PI_ID>10869364</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>11/01/2012</PROJECT_START><PROJECT_END>10/31/2016</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[Viral Hepatitis - Prevention and Surveillance]]></PROJECT_TITLE><SERIAL_NUMBER>004092</SERIAL_NUMBER><STUDY_SECTION>ZPS1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>04</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>34232</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9149067</APPLICATION_ID><ACTIVITY>U51</ACTIVITY><ADMINISTERING_IC>PS</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/26/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>U51PS004093</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-PS-13-303</FOA_NUMBER><FULL_PROJECT_NUM>5U51PS004093-04</FULL_PROJECT_NUM><FUNDING_ICs>NCHHSTP:332820\</FUNDING_ICs><FUNDING_MECHANISM>OTHERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP)</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>MENANDS</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>20</ORG_DISTRICT><ORG_DUNS>002436061</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[NYSDOH/HEALTH RESEARCH, INC.]]></ORG_NAME><ORG_STATE>NY</ORG_STATE><ORG_ZIPCODE>122042719</ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>BLOG, DEBRA S.</PI_NAME><PI_ID>8368230</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>11/01/2012</PROJECT_START><PROJECT_END>10/31/2016</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[Viral Hepatitis Prevention and Surveillance]]></PROJECT_TITLE><SERIAL_NUMBER>004093</SERIAL_NUMBER><STUDY_SECTION>ZPS1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>04</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>332820</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9167638</APPLICATION_ID><ACTIVITY>U19</ACTIVITY><ADMINISTERING_IC>GH</ADMINISTERING_IC><APPLICATION_TYPE>7</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/05/2015</AWARD_NOTICE_DATE><BUDGET_START>10/01/2015</BUDGET_START><BUDGET_END>08/14/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>U19GH000041</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-GH-10-001</FOA_NUMBER><FULL_PROJECT_NUM>7U19GH000041-06</FULL_PROJECT_NUM><FUNDING_ICs>COGH:903000\NCHHSTP:66500\NCIRD:199882\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2015</FY><IC_NAME>Center for Global Health</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>BETHESDA</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>08</ORG_DISTRICT><ORG_DUNS>144676566</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[HENRY M. JACKSON FDN FOR THE ADV MIL/MED]]></ORG_NAME><ORG_STATE>MD</ORG_STATE><ORG_ZIPCODE>208171888</ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>HAPNER, ARTHUR W</PI_NAME><PI_ID>14312308</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>10/01/2015</PROJECT_START><PROJECT_END>08/14/2016</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[GH10-1001:COOPERATIVE AGREEMENT WITH THE KENYA MEDICAL RESEARCH INSTITUTE (KEMRI)]]></PROJECT_TITLE><SERIAL_NUMBER>000041</SERIAL_NUMBER><STUDY_SECTION>ZGH1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>06</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>1169382</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9167640</APPLICATION_ID><ACTIVITY>U01</ACTIVITY><ADMINISTERING_IC>GH</ADMINISTERING_IC><APPLICATION_TYPE>7</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/05/2015</AWARD_NOTICE_DATE><BUDGET_START>10/01/2015</BUDGET_START><BUDGET_END>08/14/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>U01GH000048</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-GH-10-003</FOA_NUMBER><FULL_PROJECT_NUM>7U01GH000048-06</FULL_PROJECT_NUM><FUNDING_ICs>COGH:651838\NCHHSTP:701131\NCIRD:988452\ODCDC:129532\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2015</FY><IC_NAME>Center for Global Health</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>BETHESDA</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>08</ORG_DISTRICT><ORG_DUNS>144676566</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[HENRY M. JACKSON FDN FOR THE ADV MIL/MED]]></ORG_NAME><ORG_STATE>MD</ORG_STATE><ORG_ZIPCODE>208171888</ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>HAPNER, ARTHUR W</PI_NAME><PI_ID>14312308</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>10/01/2015</PROJECT_START><PROJECT_END>08/14/2016</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[GH10-003:  Conducting Public Health Research in Kenya (U01)]]></PROJECT_TITLE><SERIAL_NUMBER>000048</SERIAL_NUMBER><STUDY_SECTION>ZGH1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>06</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>2470953</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9172430</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>HL</ADMINISTERING_IC><APPLICATION_TYPE>6</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/05/2015</AWARD_NOTICE_DATE><BUDGET_START>11/05/2015</BUDGET_START><BUDGET_END>01/31/2016</BUDGET_END><CFDA_CODE>837</CFDA_CODE><CORE_PROJECT_NUM>R01HL076246</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>PA-13-302</FOA_NUMBER><FULL_PROJECT_NUM>6R01HL076246-12</FULL_PROJECT_NUM><FUNDING_ICs>NHLBI:173959\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2015</FY><IC_NAME>NATIONAL HEART, LUNG, AND BLOOD INSTITUTE</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>BRONX</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>14</ORG_DISTRICT><ORG_DUNS>079783367</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[ALBERT EINSTEIN COLLEGE OF MEDICINE]]></ORG_NAME><ORG_STATE>NY</ORG_STATE><ORG_ZIPCODE>104611975</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: The proposed project explores the role of monocyte subsets and regulatory T cells in preventing uncontrolled inflammation and excessive injury in myocardial infarction. Chemokine-mediated interactions responsible for recruitment of suppressive mononuclear cell subpopulations may play an essential protective role in the pathogenesis of adverse cardiac remodeling. The findings may identify novel therapeutic targets for pharmacologic interventions and cell therapy in patients with acute myocardial infarction.]]></PHR><PIS><PI><PI_NAME>FRANGOGIANNIS, NIKOLAOS G</PI_NAME><PI_ID>7729979</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>SCHWARTZ, LISA </PROGRAM_OFFICER_NAME><PROJECT_START>04/01/2004</PROJECT_START><PROJECT_END>01/31/2019</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[3' Untranslated Regions]]></TERM><TERM><![CDATA[Ablation]]></TERM><TERM><![CDATA[Acute]]></TERM><TERM><![CDATA[Acute myocardial infarction]]></TERM><TERM><![CDATA[Adoptive Transfer]]></TERM><TERM><![CDATA[Animals]]></TERM><TERM><![CDATA[Anti-inflammatory]]></TERM><TERM><![CDATA[Anti-Inflammatory Agents]]></TERM><TERM><![CDATA[Antibodies]]></TERM><TERM><![CDATA[Area]]></TERM><TERM><![CDATA[beta-Chemokines]]></TERM><TERM><![CDATA[Binding (Molecular Function)]]></TERM><TERM><![CDATA[Cardiac]]></TERM><TERM><![CDATA[cardiac repair]]></TERM><TERM><![CDATA[CCR1 gene]]></TERM><TERM><![CDATA[CD4 Positive T Lymphocytes]]></TERM><TERM><![CDATA[Cell surface]]></TERM><TERM><![CDATA[Cell Therapy]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Characteristics]]></TERM><TERM><![CDATA[chemokine]]></TERM><TERM><![CDATA[Chemokine (C-C Motif) Receptor 5]]></TERM><TERM><![CDATA[chemokine receptor]]></TERM><TERM><![CDATA[Code]]></TERM><TERM><![CDATA[Coupled]]></TERM><TERM><![CDATA[cytokine]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[diphtheria toxin receptor]]></TERM><TERM><![CDATA[Endothelial Cells]]></TERM><TERM><![CDATA[Exhibits]]></TERM><TERM><![CDATA[Experimental Models]]></TERM><TERM><![CDATA[Extracellular Matrix]]></TERM><TERM><![CDATA[Extracellular Matrix Degradation]]></TERM><TERM><![CDATA[Flow Cytometry]]></TERM><TERM><![CDATA[Genetic]]></TERM><TERM><![CDATA[GTP-Binding Proteins]]></TERM><TERM><![CDATA[Healed]]></TERM><TERM><![CDATA[healing]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Heart failure]]></TERM><TERM><![CDATA[Homing]]></TERM><TERM><![CDATA[IL2RA gene]]></TERM><TERM><![CDATA[Immune response]]></TERM><TERM><![CDATA[In Vitro]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[Infarction]]></TERM><TERM><![CDATA[Infiltration]]></TERM><TERM><![CDATA[Inflammation]]></TERM><TERM><![CDATA[Inflammatory]]></TERM><TERM><![CDATA[Inflammatory Response]]></TERM><TERM><![CDATA[Injury]]></TERM><TERM><![CDATA[Interleukin-10]]></TERM><TERM><![CDATA[Intervention]]></TERM><TERM><![CDATA[Knock-in Mouse]]></TERM><TERM><![CDATA[Knockout Mice]]></TERM><TERM><![CDATA[Leukocytes]]></TERM><TERM><![CDATA[Ligands]]></TERM><TERM><![CDATA[Ligation]]></TERM><TERM><![CDATA[Lymphocyte Subset]]></TERM><TERM><![CDATA[Matrix Metalloproteinases]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[Mediator of activation protein]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[Molecular Profiling]]></TERM><TERM><![CDATA[monocyte]]></TERM><TERM><![CDATA[Mononuclear]]></TERM><TERM><![CDATA[Mortality Vital Statistics]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[Myocardial Infarction]]></TERM><TERM><![CDATA[Myocardial Ischemia]]></TERM><TERM><![CDATA[Myocardium]]></TERM><TERM><![CDATA[new therapeutic target]]></TERM><TERM><![CDATA[Pathogenesis]]></TERM><TERM><![CDATA[Pathway interactions]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Peptide Hydrolases]]></TERM><TERM><![CDATA[Phenotype]]></TERM><TERM><![CDATA[Play]]></TERM><TERM><![CDATA[prevent]]></TERM><TERM><![CDATA[Prevention]]></TERM><TERM><![CDATA[Prognostic Marker]]></TERM><TERM><![CDATA[Property]]></TERM><TERM><![CDATA[protective effect]]></TERM><TERM><![CDATA[Protocols documentation]]></TERM><TERM><![CDATA[Reaction]]></TERM><TERM><![CDATA[receptor expression]]></TERM><TERM><![CDATA[Recruitment Activity]]></TERM><TERM><![CDATA[Regulation]]></TERM><TERM><![CDATA[Regulatory T-Lymphocyte]]></TERM><TERM><![CDATA[research study]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Serum]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[T-Lymphocyte]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[Tissues]]></TERM><TERM><![CDATA[trafficking]]></TERM><TERM><![CDATA[Transforming Growth Factors]]></TERM><TERM><![CDATA[Transgenic Mice]]></TERM><TERM><![CDATA[Ventricular Arrhythmia]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Chemokines in Healing Myocardial Infarction]]></PROJECT_TITLE><SERIAL_NUMBER>076246</SERIAL_NUMBER><STUDY_SECTION>MIM</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Myocardial Ischemia and Metabolism Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>12</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>104167</DIRECT_COST_AMT><INDIRECT_COST_AMT>69792</INDIRECT_COST_AMT><TOTAL_COST>173959</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9172471</APPLICATION_ID><ACTIVITY>K23</ACTIVITY><ADMINISTERING_IC>HL</ADMINISTERING_IC><APPLICATION_TYPE>6</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/05/2015</AWARD_NOTICE_DATE><BUDGET_START>11/05/2015</BUDGET_START><BUDGET_END>04/30/2016</BUDGET_END><CFDA_CODE>837</CFDA_CODE><CORE_PROJECT_NUM>K23HL118733</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>PA-11-194</FOA_NUMBER><FULL_PROJECT_NUM>6K23HL118733-03</FULL_PROJECT_NUM><FUNDING_ICs>NHLBI:103680\</FUNDING_ICs><FUNDING_MECHANISM>OTHER RESEARCH-RELATED</FUNDING_MECHANISM><FY>2015</FY><IC_NAME>NATIONAL HEART, LUNG, AND BLOOD INSTITUTE</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>BRONX</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>14</ORG_DISTRICT><ORG_DUNS>079783367</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[ALBERT EINSTEIN COLLEGE OF MEDICINE]]></ORG_NAME><ORG_STATE>NY</ORG_STATE><ORG_ZIPCODE>104611975</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Obese asthmatics have increased asthma severity and suboptimal response to conventional asthma management, likely due to a non-allergic pattern of T cell inflammation that differs from allergic inflammation found in normal-weight asthmatics. However, the molecular mechanisms associated with non-allergic inflammation are not known. Our proposed studies will investigate T cell gene expression and its genetic, including ethnicity, and epigenetic determinants to identify key molecules and associated molecular pathways specific to inflammation observed in obesity-associated asthma. While key molecules and pathways will identify novel targets for therapeutic interventions and improve our understanding of mechanisms linked to obesity-associated asthma, the genetic variants may be used to screen high-risk individuals.]]></PHR><PIS><PI><PI_NAME>RASTOGI, DEEPA </PI_NAME><PI_ID>9772813</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>TIGNO, XENIA </PROGRAM_OFFICER_NAME><PROJECT_START>05/01/2014</PROJECT_START><PROJECT_END>04/30/2019</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[African American]]></TERM><TERM><![CDATA[Age]]></TERM><TERM><![CDATA[Airway Obstruction]]></TERM><TERM><![CDATA[Allergic inflammation]]></TERM><TERM><![CDATA[Asthma]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Biological Assay]]></TERM><TERM><![CDATA[career development]]></TERM><TERM><![CDATA[CD4 Positive T Lymphocytes]]></TERM><TERM><![CDATA[Cell Culture System]]></TERM><TERM><![CDATA[Cell Differentiation process]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Cellular biology]]></TERM><TERM><![CDATA[Child]]></TERM><TERM><![CDATA[Childhood]]></TERM><TERM><![CDATA[Childhood Asthma]]></TERM><TERM><![CDATA[clinical phenotype]]></TERM><TERM><![CDATA[cohort]]></TERM><TERM><![CDATA[college]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Development Plans]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[disorder control]]></TERM><TERM><![CDATA[DNA Methylation]]></TERM><TERM><![CDATA[Environment]]></TERM><TERM><![CDATA[Environmental Exposure]]></TERM><TERM><![CDATA[Environmental Risk Factor]]></TERM><TERM><![CDATA[Epigenetic Process]]></TERM><TERM><![CDATA[epigenome]]></TERM><TERM><![CDATA[epigenomics]]></TERM><TERM><![CDATA[Equipment]]></TERM><TERM><![CDATA[Ethnicity aspects]]></TERM><TERM><![CDATA[Figs - dietary]]></TERM><TERM><![CDATA[Foundations]]></TERM><TERM><![CDATA[Gender]]></TERM><TERM><![CDATA[Gene Expression]]></TERM><TERM><![CDATA[Genes]]></TERM><TERM><![CDATA[Genetic]]></TERM><TERM><![CDATA[Genetic Polymorphism]]></TERM><TERM><![CDATA[Genetic Predisposition to Disease]]></TERM><TERM><![CDATA[genetic variant]]></TERM><TERM><![CDATA[Genome]]></TERM><TERM><![CDATA[genome-wide]]></TERM><TERM><![CDATA[Genotype]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Hand]]></TERM><TERM><![CDATA[Haplotypes]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Health Personnel]]></TERM><TERM><![CDATA[Helper-Inducer T-Lymphocyte]]></TERM><TERM><![CDATA[high risk]]></TERM><TERM><![CDATA[Hispanic Americans]]></TERM><TERM><![CDATA[Hispanics]]></TERM><TERM><![CDATA[Home environment]]></TERM><TERM><![CDATA[Hospitals]]></TERM><TERM><![CDATA[Housing]]></TERM><TERM><![CDATA[Human Resources]]></TERM><TERM><![CDATA[Immunity]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[In Vitro]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[Inflammation]]></TERM><TERM><![CDATA[inhibitor/antagonist]]></TERM><TERM><![CDATA[insight]]></TERM><TERM><![CDATA[Investigation]]></TERM><TERM><![CDATA[Link]]></TERM><TERM><![CDATA[Lung]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[Medical center]]></TERM><TERM><![CDATA[Medicine]]></TERM><TERM><![CDATA[meetings]]></TERM><TERM><![CDATA[Mentored Patient-Oriented Research Career Development Award]]></TERM><TERM><![CDATA[Mentors]]></TERM><TERM><![CDATA[Mentorship]]></TERM><TERM><![CDATA[Methods]]></TERM><TERM><![CDATA[Methylation]]></TERM><TERM><![CDATA[Minority]]></TERM><TERM><![CDATA[Modification]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[New York]]></TERM><TERM><![CDATA[non-genetic]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[Obesity]]></TERM><TERM><![CDATA[Obesity associated disease]]></TERM><TERM><![CDATA[obesity in children]]></TERM><TERM><![CDATA[Pathogenesis]]></TERM><TERM><![CDATA[Pathway interactions]]></TERM><TERM><![CDATA[patient population]]></TERM><TERM><![CDATA[Pattern]]></TERM><TERM><![CDATA[Pediatric Hospitals]]></TERM><TERM><![CDATA[Phenotype]]></TERM><TERM><![CDATA[Positioning Attribute]]></TERM><TERM><![CDATA[Predisposition]]></TERM><TERM><![CDATA[Prevalence]]></TERM><TERM><![CDATA[Promotor (Genetics)]]></TERM><TERM><![CDATA[prospective]]></TERM><TERM><![CDATA[Quantitative Trait Loci]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Research Personnel]]></TERM><TERM><![CDATA[research study]]></TERM><TERM><![CDATA[Resources]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[Risk]]></TERM><TERM><![CDATA[Risk Factors]]></TERM><TERM><![CDATA[RNA Sequences]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Severities]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[Single Nucleotide Polymorphism]]></TERM><TERM><![CDATA[T-Lymphocyte]]></TERM><TERM><![CDATA[Teaching Hospitals]]></TERM><TERM><![CDATA[tertiary care]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Therapeutic Intervention]]></TERM><TERM><![CDATA[Tissue-Specific Gene Expression]]></TERM><TERM><![CDATA[Training]]></TERM><TERM><![CDATA[transcriptome sequencing]]></TERM><TERM><![CDATA[Validation]]></TERM><TERM><![CDATA[Variant]]></TERM><TERM><![CDATA[Weight]]></TERM><TERM><![CDATA[Weight Gain]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Genetic and Epigenetic Determinants of Pediatric Obesity-Associated Asthma]]></PROJECT_TITLE><SERIAL_NUMBER>118733</SERIAL_NUMBER><STUDY_SECTION>ZHL1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>03</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>96000</DIRECT_COST_AMT><INDIRECT_COST_AMT>7680</INDIRECT_COST_AMT><TOTAL_COST>103680</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9172486</APPLICATION_ID><ACTIVITY>F30</ACTIVITY><ADMINISTERING_IC>HL</ADMINISTERING_IC><APPLICATION_TYPE>6</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/06/2015</AWARD_NOTICE_DATE><BUDGET_START>11/06/2015</BUDGET_START><BUDGET_END>08/04/2016</BUDGET_END><CFDA_CODE>837</CFDA_CODE><CORE_PROJECT_NUM>F30HL126283</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>PA-14-150</FOA_NUMBER><FULL_PROJECT_NUM>6F30HL126283-02</FULL_PROJECT_NUM><FUNDING_ICs>NHLBI:44110\</FUNDING_ICs><FUNDING_MECHANISM>TRAINING, INDIVIDUAL</FUNDING_MECHANISM><FY>2015</FY><IC_NAME>NATIONAL HEART, LUNG, AND BLOOD INSTITUTE</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>BRONX</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>14</ORG_DISTRICT><ORG_DUNS>079783367</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[ALBERT EINSTEIN COLLEGE OF MEDICINE]]></ORG_NAME><ORG_STATE>NY</ORG_STATE><ORG_ZIPCODE>104611975</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Malfunction of hERG ion channel through mutation is a common cause of heart rhythm disturbances with risk for sudden cardiac death. The hERG channel has unique properties that make it susceptible to malfunction that are not completely understood. We hypothesize that some of these properties come from information hidden within the coding region of the RNA. We propose to explore and understand this information and test whether it contributes to malfunction of the channel and risk for heart rhythm disturbance.   
      

]]></PHR><PIS><PI><PI_NAME>OSTERBUR, MARIKA LEE</PI_NAME><PI_ID>11018461</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>MEADOWS, TAWANNA </PROGRAM_OFFICER_NAME><PROJECT_START>08/05/2015</PROJECT_START><PROJECT_END>08/04/2019</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[Amino Acid Sequence]]></TERM><TERM><![CDATA[Area]]></TERM><TERM><![CDATA[Arrhythmia]]></TERM><TERM><![CDATA[Attention]]></TERM><TERM><![CDATA[Capillary Electrophoresis]]></TERM><TERM><![CDATA[Cardiac]]></TERM><TERM><![CDATA[Cardiac Myocytes]]></TERM><TERM><![CDATA[Cell surface]]></TERM><TERM><![CDATA[Characteristics]]></TERM><TERM><![CDATA[Code]]></TERM><TERM><![CDATA[Codon Nucleotides]]></TERM><TERM><![CDATA[Death, Sudden, Cardiac]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Electrophysiology (science)]]></TERM><TERM><![CDATA[Ethers]]></TERM><TERM><![CDATA[Evaluation]]></TERM><TERM><![CDATA[GC Rich Sequence]]></TERM><TERM><![CDATA[Genes]]></TERM><TERM><![CDATA[Guanine + Cytosine Composition]]></TERM><TERM><![CDATA[heart rhythm]]></TERM><TERM><![CDATA[Hereditary Disease]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[Human Characteristics]]></TERM><TERM><![CDATA[Inherited]]></TERM><TERM><![CDATA[Investigation]]></TERM><TERM><![CDATA[Ion Channel]]></TERM><TERM><![CDATA[Ions]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[Length]]></TERM><TERM><![CDATA[Link]]></TERM><TERM><![CDATA[Location]]></TERM><TERM><![CDATA[Long QT Syndrome]]></TERM><TERM><![CDATA[Messenger RNA]]></TERM><TERM><![CDATA[Missense Mutation]]></TERM><TERM><![CDATA[Modification]]></TERM><TERM><![CDATA[Movement]]></TERM><TERM><![CDATA[Mutation]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[Patch-Clamp Techniques]]></TERM><TERM><![CDATA[Pathogenesis]]></TERM><TERM><![CDATA[patient population]]></TERM><TERM><![CDATA[Pharmaceutical Preparations]]></TERM><TERM><![CDATA[Physiologic pulse]]></TERM><TERM><![CDATA[Play]]></TERM><TERM><![CDATA[Potassium Channel]]></TERM><TERM><![CDATA[Property]]></TERM><TERM><![CDATA[Protein Biosynthesis]]></TERM><TERM><![CDATA[protein folding]]></TERM><TERM><![CDATA[protein function]]></TERM><TERM><![CDATA[protein transport]]></TERM><TERM><![CDATA[Proteins]]></TERM><TERM><![CDATA[Proteolysis]]></TERM><TERM><![CDATA[Proteus]]></TERM><TERM><![CDATA[public health relevance]]></TERM><TERM><![CDATA[Risk]]></TERM><TERM><![CDATA[RNA]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Secondary to]]></TERM><TERM><![CDATA[Site]]></TERM><TERM><![CDATA[Structure]]></TERM><TERM><![CDATA[Sudden Death]]></TERM><TERM><![CDATA[Syncope]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[trafficking]]></TERM><TERM><![CDATA[Translating]]></TERM><TERM><![CDATA[Translations]]></TERM><TERM><![CDATA[Ventricular Arrhythmia]]></TERM><TERM><![CDATA[Ventricular Tachycardia]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Extra-coding features of mRNA are essential for hERG channel function]]></PROJECT_TITLE><SERIAL_NUMBER>126283</SERIAL_NUMBER><STUDY_SECTION>ZRG1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>44110</DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>44110</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9173498</APPLICATION_ID><ACTIVITY>Y01</ACTIVITY><ADMINISTERING_IC>HL</ADMINISTERING_IC><APPLICATION_TYPE></APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE></AWARD_NOTICE_DATE><BUDGET_START></BUDGET_START><BUDGET_END></BUDGET_END><CFDA_CODE>837</CFDA_CODE><CORE_PROJECT_NUM>Y01HL120290</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER></FOA_NUMBER><FULL_PROJECT_NUM>AHL12029001-1-0-1</FULL_PROJECT_NUM><FUNDING_ICs>NHLBI:21945\</FUNDING_ICs><FUNDING_MECHANISM>INTERAGENCY AGREEMENTS</FUNDING_MECHANISM><FY>2015</FY><IC_NAME>NATIONAL HEART, LUNG, AND BLOOD INSTITUTE</IC_NAME><NIH_SPENDING_CATS><CATEGORY><![CDATA[Chronic Obstructive Pulmonary Disease]]></CATEGORY><CATEGORY><![CDATA[Clinical Research]]></CATEGORY><CATEGORY><![CDATA[Clinical Trials and Supportive Activities]]></CATEGORY><CATEGORY><![CDATA[Lung]]></CATEGORY></NIH_SPENDING_CATS><ORG_CITY></ORG_CITY><ORG_COUNTRY></ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT></ORG_DISTRICT><ORG_DUNS></ORG_DUNS><ORG_FIPS></ORG_FIPS><ORG_NAME><![CDATA[NATIONAL HEART, LUNG, AND BLOOD INSTITUTE]]></ORG_NAME><ORG_STATE></ORG_STATE><ORG_ZIPCODE></ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>,  </PI_NAME><PI_ID></PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START></PROJECT_START><PROJECT_END></PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Adverse event]]></TERM><TERM><![CDATA[Agreement]]></TERM><TERM><![CDATA[Chronic Obstructive Airway Disease]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[Contractor]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Data Coordinating Center]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[Enrollment]]></TERM><TERM><![CDATA[follow-up]]></TERM><TERM><![CDATA[Funding]]></TERM><TERM><![CDATA[Healthcare Systems]]></TERM><TERM><![CDATA[Hypoxemia]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[Journals]]></TERM><TERM><![CDATA[Life]]></TERM><TERM><![CDATA[Monitoring Clinical Trials]]></TERM><TERM><![CDATA[Oxygen]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Peer Review]]></TERM><TERM><![CDATA[programs]]></TERM><TERM><![CDATA[Publications]]></TERM><TERM><![CDATA[Reporting]]></TERM><TERM><![CDATA[Rest]]></TERM><TERM><![CDATA[Site]]></TERM><TERM><![CDATA[sound]]></TERM><TERM><![CDATA[treatment trial]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Long-term Oxygen Treatment Trial (LOTT)]]></PROJECT_TITLE><SERIAL_NUMBER></SERIAL_NUMBER><STUDY_SECTION></STUDY_SECTION><STUDY_SECTION_NAME xsi:nil='true' /><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR></SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>21945</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9177923</APPLICATION_ID><ACTIVITY>U2G</ACTIVITY><ADMINISTERING_IC>GH</ADMINISTERING_IC><APPLICATION_TYPE>3</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/06/2015</AWARD_NOTICE_DATE><BUDGET_START>04/01/2015</BUDGET_START><BUDGET_END>03/31/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>U2GGH000840</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-GH-12-228</FOA_NUMBER><FULL_PROJECT_NUM>3U2GGH000840-03S1</FULL_PROJECT_NUM><FUNDING_ICs>COGH:350000\</FUNDING_ICs><FUNDING_MECHANISM>OTHERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>Center for Global Health</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>KIEV</ORG_CITY><ORG_COUNTRY>UKRAINE</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT></ORG_DISTRICT><ORG_DUNS>683518092</ORG_DUNS><ORG_FIPS>UP</ORG_FIPS><ORG_NAME><![CDATA[INTERNATIONAL HIV/AIDS ALLIANCE/ UKRAINE]]></ORG_NAME><ORG_STATE></ORG_STATE><ORG_ZIPCODE>03680</ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>VARETSKA, OLGA </PI_NAME><PI_ID>11678489</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>09/30/2012</PROJECT_START><PROJECT_END>03/31/2018</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[GH12-1228: Engaging Local Indigenous Organizations in Developing HIV/AIDS Monitoring and Eva]]></PROJECT_TITLE><SERIAL_NUMBER>000840</SERIAL_NUMBER><STUDY_SECTION>ZGH1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>03</SUPPORT_YEAR><SUFFIX>S1</SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>350000</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8856297</APPLICATION_ID><ACTIVITY>K01</ACTIVITY><ADMINISTERING_IC>HD</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/05/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>865</CFDA_CODE><CORE_PROJECT_NUM>K01HD079554</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[ORGANIZED RESEARCH UNITS]]></ED_INST_TYPE><FOA_NUMBER>PA-11-190</FOA_NUMBER><FULL_PROJECT_NUM>5K01HD079554-02</FULL_PROJECT_NUM><FUNDING_ICs>NICHD:130680\</FUNDING_ICs><FUNDING_MECHANISM>OTHER RESEARCH-RELATED</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &amp; HUMAN DEVELOPMENT</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>ANN ARBOR</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[MISCELLANEOUS]]></ORG_DEPT><ORG_DISTRICT>12</ORG_DISTRICT><ORG_DUNS>073133571</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIVERSITY OF MICHIGAN]]></ORG_NAME><ORG_STATE>MI</ORG_STATE><ORG_ZIPCODE>481091276</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: In this K award, I propose to learn and repurpose methods of choice modeling currently used in marketing for applications in population and health research. Marketing researchers have highly sophisticated statistical models of decision-making that allow for the estimation of heuristic rules individuals use to reduce the cognitive complexity of the decision problem. I will apply these methods in two substantive areas: residential choice and mate choice.]]></PHR><PIS><PI><PI_NAME>BRUCH, ELIZABETH EVE</PI_NAME><PI_ID>8775340</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>KING, ROSALIND B</PROGRAM_OFFICER_NAME><PROJECT_START>06/01/2014</PROJECT_START><PROJECT_END>10/31/2019</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Alcohol consumption]]></TERM><TERM><![CDATA[Architecture]]></TERM><TERM><![CDATA[Area]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Bayesian Analysis]]></TERM><TERM><![CDATA[Behavior]]></TERM><TERM><![CDATA[behavior change]]></TERM><TERM><![CDATA[Behavioral]]></TERM><TERM><![CDATA[Behavioral Model]]></TERM><TERM><![CDATA[Businesses]]></TERM><TERM><![CDATA[California]]></TERM><TERM><![CDATA[Cause of Death]]></TERM><TERM><![CDATA[Choice Behavior]]></TERM><TERM><![CDATA[Cognitive]]></TERM><TERM><![CDATA[Cognitive Science]]></TERM><TERM><![CDATA[Complex]]></TERM><TERM><![CDATA[Computer software]]></TERM><TERM><![CDATA[Conceptions]]></TERM><TERM><![CDATA[cost]]></TERM><TERM><![CDATA[Coupled]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[data management]]></TERM><TERM><![CDATA[Data Set]]></TERM><TERM><![CDATA[Decision Making]]></TERM><TERM><![CDATA[Decision Theory]]></TERM><TERM><![CDATA[Demography]]></TERM><TERM><![CDATA[Diet]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Disease Management]]></TERM><TERM><![CDATA[Doctor of Philosophy]]></TERM><TERM><![CDATA[Eating]]></TERM><TERM><![CDATA[Educational aspects]]></TERM><TERM><![CDATA[Educational process of instructing]]></TERM><TERM><![CDATA[Environment]]></TERM><TERM><![CDATA[Estimation Techniques]]></TERM><TERM><![CDATA[Evolution]]></TERM><TERM><![CDATA[Exercise]]></TERM><TERM><![CDATA[Family]]></TERM><TERM><![CDATA[Feedback]]></TERM><TERM><![CDATA[Food]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Grant]]></TERM><TERM><![CDATA[Habits]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Health Care Costs]]></TERM><TERM><![CDATA[Healthcare]]></TERM><TERM><![CDATA[heuristics]]></TERM><TERM><![CDATA[high risk sexual behavior]]></TERM><TERM><![CDATA[Household]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[Injury]]></TERM><TERM><![CDATA[insight]]></TERM><TERM><![CDATA[Intervention]]></TERM><TERM><![CDATA[Investigation]]></TERM><TERM><![CDATA[K-Series Research Career Programs]]></TERM><TERM><![CDATA[learned behavior]]></TERM><TERM><![CDATA[Learning]]></TERM><TERM><![CDATA[Link]]></TERM><TERM><![CDATA[Literature]]></TERM><TERM><![CDATA[Los Angeles]]></TERM><TERM><![CDATA[Market Research]]></TERM><TERM><![CDATA[Marketing]]></TERM><TERM><![CDATA[Mentors]]></TERM><TERM><![CDATA[Methods]]></TERM><TERM><![CDATA[Michigan]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Neighborhoods]]></TERM><TERM><![CDATA[Occupations]]></TERM><TERM><![CDATA[Outcome]]></TERM><TERM><![CDATA[Partner in relationship]]></TERM><TERM><![CDATA[Pattern]]></TERM><TERM><![CDATA[Persons]]></TERM><TERM><![CDATA[Policies]]></TERM><TERM><![CDATA[Population Dynamics]]></TERM><TERM><![CDATA[population health]]></TERM><TERM><![CDATA[Population Research]]></TERM><TERM><![CDATA[Population Study]]></TERM><TERM><![CDATA[preference]]></TERM><TERM><![CDATA[Prevention]]></TERM><TERM><![CDATA[Price]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[programs]]></TERM><TERM><![CDATA[prototype]]></TERM><TERM><![CDATA[Psychological Techniques]]></TERM><TERM><![CDATA[Psychologist]]></TERM><TERM><![CDATA[Psychology]]></TERM><TERM><![CDATA[public health research]]></TERM><TERM><![CDATA[Recommendation]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Research Methodology]]></TERM><TERM><![CDATA[Research Personnel]]></TERM><TERM><![CDATA[Research Project Grants]]></TERM><TERM><![CDATA[Research Scientist Award]]></TERM><TERM><![CDATA[residence]]></TERM><TERM><![CDATA[Residential Mobility]]></TERM><TERM><![CDATA[Resources]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[Schools]]></TERM><TERM><![CDATA[Science]]></TERM><TERM><![CDATA[screening]]></TERM><TERM><![CDATA[segregation]]></TERM><TERM><![CDATA[Sex Behavior]]></TERM><TERM><![CDATA[Shapes]]></TERM><TERM><![CDATA[simulation]]></TERM><TERM><![CDATA[Site]]></TERM><TERM><![CDATA[skills]]></TERM><TERM><![CDATA[social]]></TERM><TERM><![CDATA[social cognition]]></TERM><TERM><![CDATA[Social Environment]]></TERM><TERM><![CDATA[social integration]]></TERM><TERM><![CDATA[Social Sciences]]></TERM><TERM><![CDATA[social separation]]></TERM><TERM><![CDATA[Sociology]]></TERM><TERM><![CDATA[Sorting - Cell Movement]]></TERM><TERM><![CDATA[Specific qualifier value]]></TERM><TERM><![CDATA[Staging]]></TERM><TERM><![CDATA[Statistical Models]]></TERM><TERM><![CDATA[statistics]]></TERM><TERM><![CDATA[Stratification]]></TERM><TERM><![CDATA[Students]]></TERM><TERM><![CDATA[Surveys]]></TERM><TERM><![CDATA[System]]></TERM><TERM><![CDATA[Techniques]]></TERM><TERM><![CDATA[theories]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[Tobacco use]]></TERM><TERM><![CDATA[Training]]></TERM><TERM><![CDATA[United States]]></TERM><TERM><![CDATA[Universities]]></TERM><TERM><![CDATA[web site]]></TERM><TERM><![CDATA[Work]]></TERM><TERM><![CDATA[Writing]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Cognitively Plausible Models of Decision Making]]></PROJECT_TITLE><SERIAL_NUMBER>079554</SERIAL_NUMBER><STUDY_SECTION>CHHD</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Pediatrics Subcommittee ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>121000</DIRECT_COST_AMT><INDIRECT_COST_AMT>9680</INDIRECT_COST_AMT><TOTAL_COST>130680</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8960820</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>AI</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/22/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>855</CFDA_CODE><CORE_PROJECT_NUM>R01AI045135</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF ARTS AND SCIENCES]]></ED_INST_TYPE><FOA_NUMBER>PA-11-260</FOA_NUMBER><FULL_PROJECT_NUM>5R01AI045135-13</FULL_PROJECT_NUM><FUNDING_ICs>NIAID:350599\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>ATLANTA</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[BIOLOGY]]></ORG_DEPT><ORG_DISTRICT>05</ORG_DISTRICT><ORG_DUNS>837322494</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[GEORGIA STATE UNIVERSITY]]></ORG_NAME><ORG_STATE>GA</ORG_STATE><ORG_ZIPCODE>303023999</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Many flaviviruses, such as West Nile virus, yellow fever virus, tick-borne encephalitis virus, and dengue virus, are human pathogens that cause significant human morbidity and mortality in ever-expanding regions of the world. Little is known about the specific interactions of viral products with cell proteins and cell pathways that are required to establish an efficient infection. A naturally-occurring, flavivirus-specific resistance phenotype controlled by the alleles of a since host gene was previously discovered in mice. Analysis of the mechanism by which the product (Oas1b) of the resistance allele specifically restricts the replication of flaviviruses provides a tool for obtaining new detailed knowledge about the intracellular flavivirus-host cell interfaces as well as about a novel flavivirus-specific host antiviral mechanism. No effective anti-flaviviral therapies currently exist. The data obtained are expected to identify new cell targets for future development of novel pan-flavivirus antiviral therapies for humans.]]></PHR><PIS><PI><PI_NAME>BRINTON, MARGO A (contact)</PI_NAME><PI_ID>6410097 (contact)</PI_ID></PI><PI><PI_NAME>KAUR, PARJIT </PI_NAME><PI_ID>1887641</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>REPIK, PATRICIA M.</PROGRAM_OFFICER_NAME><PROJECT_START>06/01/2000</PROJECT_START><PROJECT_END>10/31/2018</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[2-5A Synthetase]]></TERM><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[Alleles]]></TERM><TERM><![CDATA[Animals]]></TERM><TERM><![CDATA[Antiviral Agents]]></TERM><TERM><![CDATA[Antiviral Therapy]]></TERM><TERM><![CDATA[autosomal dominant trait]]></TERM><TERM><![CDATA[Bacteria]]></TERM><TERM><![CDATA[Binding (Molecular Function)]]></TERM><TERM><![CDATA[Brain]]></TERM><TERM><![CDATA[Breeding]]></TERM><TERM><![CDATA[C-terminal]]></TERM><TERM><![CDATA[C57BL/6 Mouse]]></TERM><TERM><![CDATA[Cell Culture Techniques]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Cleaved cell]]></TERM><TERM><![CDATA[Complex]]></TERM><TERM><![CDATA[congenic]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Dengue Virus]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Disease Resistance]]></TERM><TERM><![CDATA[Dose]]></TERM><TERM><![CDATA[Double-Stranded RNA]]></TERM><TERM><![CDATA[Endocytosis]]></TERM><TERM><![CDATA[Endoplasmic Reticulum]]></TERM><TERM><![CDATA[extracellular]]></TERM><TERM><![CDATA[Family]]></TERM><TERM><![CDATA[Flavivirus]]></TERM><TERM><![CDATA[Flavivirus Infections]]></TERM><TERM><![CDATA[Future]]></TERM><TERM><![CDATA[Genes]]></TERM><TERM><![CDATA[Geographic Locations]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[homologous recombination]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[human morbidity]]></TERM><TERM><![CDATA[human mortality]]></TERM><TERM><![CDATA[In Vitro]]></TERM><TERM><![CDATA[Infection]]></TERM><TERM><![CDATA[Inherited]]></TERM><TERM><![CDATA[Injection of therapeutic agent]]></TERM><TERM><![CDATA[insight]]></TERM><TERM><![CDATA[Japanese Encephalitis]]></TERM><TERM><![CDATA[Killings]]></TERM><TERM><![CDATA[knock-down]]></TERM><TERM><![CDATA[Knock-in Mouse]]></TERM><TERM><![CDATA[Knockout Mice]]></TERM><TERM><![CDATA[Knowledge]]></TERM><TERM><![CDATA[late endosome]]></TERM><TERM><![CDATA[Length]]></TERM><TERM><![CDATA[Libraries]]></TERM><TERM><![CDATA[Ligase]]></TERM><TERM><![CDATA[Lipids]]></TERM><TERM><![CDATA[Mammalian Cell]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[member]]></TERM><TERM><![CDATA[Membrane]]></TERM><TERM><![CDATA[Morbidity - disease rate]]></TERM><TERM><![CDATA[Mortality Vital Statistics]]></TERM><TERM><![CDATA[mouse genome]]></TERM><TERM><![CDATA[Movement]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[Nature]]></TERM><TERM><![CDATA[Neurons]]></TERM><TERM><![CDATA[Nonsense Codon]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[Oocytes]]></TERM><TERM><![CDATA[overexpression]]></TERM><TERM><![CDATA[pathogen]]></TERM><TERM><![CDATA[Pathogenesis]]></TERM><TERM><![CDATA[Pathway interactions]]></TERM><TERM><![CDATA[Peptides]]></TERM><TERM><![CDATA[Phenotype]]></TERM><TERM><![CDATA[positional cloning]]></TERM><TERM><![CDATA[Predisposition]]></TERM><TERM><![CDATA[Production]]></TERM><TERM><![CDATA[Proteins]]></TERM><TERM><![CDATA[Rana (genus)]]></TERM><TERM><![CDATA[Regulation]]></TERM><TERM><![CDATA[Reporting]]></TERM><TERM><![CDATA[Resistance]]></TERM><TERM><![CDATA[resistance allele]]></TERM><TERM><![CDATA[resistance mechanism]]></TERM><TERM><![CDATA[Ribonucleases]]></TERM><TERM><![CDATA[RNA]]></TERM><TERM><![CDATA[RNA Viruses]]></TERM><TERM><![CDATA[screening]]></TERM><TERM><![CDATA[sensor]]></TERM><TERM><![CDATA[Sterols]]></TERM><TERM><![CDATA[Symptoms]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Therapeutic]]></TERM><TERM><![CDATA[Tick-Borne Encephalitis]]></TERM><TERM><![CDATA[Tick-Borne Encephalitis Virus]]></TERM><TERM><![CDATA[Tick-Borne Encephalitis Viruses]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[tool]]></TERM><TERM><![CDATA[Transmembrane Domain]]></TERM><TERM><![CDATA[Vaccines]]></TERM><TERM><![CDATA[Viral]]></TERM><TERM><![CDATA[viral RNA]]></TERM><TERM><![CDATA[Virus]]></TERM><TERM><![CDATA[Virus Diseases]]></TERM><TERM><![CDATA[Virus Replication]]></TERM><TERM><![CDATA[West Nile virus]]></TERM><TERM><![CDATA[yeast two hybrid system]]></TERM><TERM><![CDATA[Yeasts]]></TERM><TERM><![CDATA[Yellow Fever]]></TERM><TERM><![CDATA[Yellow fever virus]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Functional analysis of flavivirus genetic resistance]]></PROJECT_TITLE><SERIAL_NUMBER>045135</SERIAL_NUMBER><STUDY_SECTION>VIRB</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Virology - B Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>13</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>236891</DIRECT_COST_AMT><INDIRECT_COST_AMT>113708</INDIRECT_COST_AMT><TOTAL_COST>350599</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8960826</APPLICATION_ID><ACTIVITY>P20</ACTIVITY><ADMINISTERING_IC>MD</ADMINISTERING_IC><APPLICATION_TYPE>4</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/05/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>375</CFDA_CODE><CORE_PROJECT_NUM>P20MD000173</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>RFA-MD-11-002</FOA_NUMBER><FULL_PROJECT_NUM>4P20MD000173-14</FULL_PROJECT_NUM><FUNDING_ICs>NIMHD:1155957\</FUNDING_ICs><FUNDING_MECHANISM>RESEARCH CENTERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE ON MINORITY HEALTH AND HEALTH DISPARITIES</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>HONOLULU</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[INTERNAL MEDICINE/MEDICINE]]></ORG_DEPT><ORG_DISTRICT>01</ORG_DISTRICT><ORG_DUNS>965088057</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIVERSITY OF HAWAII AT MANOA]]></ORG_NAME><ORG_STATE>HI</ORG_STATE><ORG_ZIPCODE>968222234</ORG_ZIPCODE><PHR><![CDATA[RELEVANCE (See instructions): 
Heart disease, obesity, and diabetes effect Native Hawaiians, Alaska Native, Pacific Peoples (Pacific Islanders, Micronesian and Filipinos), and New Zealand (NZ) Maoris more than other populations. This proposal will provide resources for research studies, training and educating scientists and community partners, and will work on reducing these diseases.]]></PHR><PIS><PI><PI_NAME>MAU, MARJORIE K. LEIMOMI MALA</PI_NAME><PI_ID>1875407</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>MCCLURE, SHELIA A.</PROGRAM_OFFICER_NAME><PROJECT_START>09/30/2002</PROJECT_START><PROJECT_END>10/31/2017</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Alaska Native]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Cerebral hemisphere hemorrhage]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[Communities]]></TERM><TERM><![CDATA[Community Participation]]></TERM><TERM><![CDATA[cost]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[Diabetes Mellitus]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[empowered]]></TERM><TERM><![CDATA[empowerment]]></TERM><TERM><![CDATA[Filipino]]></TERM><TERM><![CDATA[Funding]]></TERM><TERM><![CDATA[Future]]></TERM><TERM><![CDATA[Hawaiian population]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[health disparity]]></TERM><TERM><![CDATA[health equity]]></TERM><TERM><![CDATA[health related quality of life]]></TERM><TERM><![CDATA[Health Services]]></TERM><TERM><![CDATA[Healthcare]]></TERM><TERM><![CDATA[heart disease education]]></TERM><TERM><![CDATA[Heart Diseases]]></TERM><TERM><![CDATA[Hospitalization]]></TERM><TERM><![CDATA[Hospitals]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[innovation]]></TERM><TERM><![CDATA[Intervention]]></TERM><TERM><![CDATA[Intervention Studies]]></TERM><TERM><![CDATA[Investigation]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[meetings]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[New Zealand]]></TERM><TERM><![CDATA[Obesity]]></TERM><TERM><![CDATA[outcome forecast]]></TERM><TERM><![CDATA[Ownership]]></TERM><TERM><![CDATA[Pacific Island Americans]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Population]]></TERM><TERM><![CDATA[post stroke depression]]></TERM><TERM><![CDATA[Prevalence]]></TERM><TERM><![CDATA[prevent]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[programs]]></TERM><TERM><![CDATA[racial/ethnic difference]]></TERM><TERM><![CDATA[Randomized]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Research Design]]></TERM><TERM><![CDATA[Research Infrastructure]]></TERM><TERM><![CDATA[Research Personnel]]></TERM><TERM><![CDATA[research study]]></TERM><TERM><![CDATA[Research Training]]></TERM><TERM><![CDATA[Resources]]></TERM><TERM><![CDATA[Risk Factors]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Science]]></TERM><TERM><![CDATA[Scientist]]></TERM><TERM><![CDATA[stroke]]></TERM><TERM><![CDATA[success]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Training]]></TERM><TERM><![CDATA[Training and Education]]></TERM><TERM><![CDATA[Translational Research]]></TERM><TERM><![CDATA[Trust]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[The Center for Native and Pacific Health Disparities Research]]></PROJECT_TITLE><SERIAL_NUMBER>000173</SERIAL_NUMBER><STUDY_SECTION>ZMD1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>14</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>854287</DIRECT_COST_AMT><INDIRECT_COST_AMT>301670</INDIRECT_COST_AMT><TOTAL_COST>1155957</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8960854</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>AI</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/03/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>855</CFDA_CODE><CORE_PROJECT_NUM>R01AI105147</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-13-302</FOA_NUMBER><FULL_PROJECT_NUM>5R01AI105147-02</FULL_PROJECT_NUM><FUNDING_ICs>NIAID:376250\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>OMAHA</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[PATHOLOGY]]></ORG_DEPT><ORG_DISTRICT>02</ORG_DISTRICT><ORG_DUNS>168559177</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIVERSITY OF NEBRASKA MEDICAL CENTER]]></ORG_NAME><ORG_STATE>NE</ORG_STATE><ORG_ZIPCODE>681987835</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: The ESKAPE superbugs, including Enteroccus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumanii, Pseudomonas aeruginosa, and Enterobacter species, can escape the action of traditional antibiotics, leading to severe illness and causing 99,000 deaths annually in the United States. It is stunning that the total number of deaths due to MRSA infection alone is comparable to AIDS/HIV mortality rates. Therefore, it is urgent to develop a new generation of antimicrobials. This proposal takes an innovative strategy to develop novel antimicrobial compounds that effectively control these dangerous pathogens.]]></PHR><PIS><PI><PI_NAME>WANG, GUANGSHUN </PI_NAME><PI_ID>7838372</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>XU, ZUOYU </PROGRAM_OFFICER_NAME><PROJECT_START>11/01/2014</PROJECT_START><PROJECT_END>10/31/2019</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Acinetobacter]]></TERM><TERM><![CDATA[Action Potentials]]></TERM><TERM><![CDATA[AIDS/HIV problem]]></TERM><TERM><![CDATA[Amino Acid Sequence]]></TERM><TERM><![CDATA[Animal Model]]></TERM><TERM><![CDATA[Antibiotics]]></TERM><TERM><![CDATA[Antimalarials]]></TERM><TERM><![CDATA[antimicrobial]]></TERM><TERM><![CDATA[antimicrobial drug]]></TERM><TERM><![CDATA[antimicrobial peptide]]></TERM><TERM><![CDATA[Apoptosis]]></TERM><TERM><![CDATA[Attenuated]]></TERM><TERM><![CDATA[Bacterial DNA]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Biological]]></TERM><TERM><![CDATA[Biology]]></TERM><TERM><![CDATA[Biophysics]]></TERM><TERM><![CDATA[Catheters]]></TERM><TERM><![CDATA[Cessation of life]]></TERM><TERM><![CDATA[Classification]]></TERM><TERM><![CDATA[combat]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[database design]]></TERM><TERM><![CDATA[Databases]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[DNA Microarray Chip]]></TERM><TERM><![CDATA[Educational aspects]]></TERM><TERM><![CDATA[Engineering]]></TERM><TERM><![CDATA[Enterobacter]]></TERM><TERM><![CDATA[Enterococcus faecium]]></TERM><TERM><![CDATA[Evaluation]]></TERM><TERM><![CDATA[Frequencies (time pattern)]]></TERM><TERM><![CDATA[Future]]></TERM><TERM><![CDATA[Generations]]></TERM><TERM><![CDATA[Genes]]></TERM><TERM><![CDATA[Genetic]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Healthcare]]></TERM><TERM><![CDATA[Host Defense]]></TERM><TERM><![CDATA[Hydrophobicity]]></TERM><TERM><![CDATA[Immune response]]></TERM><TERM><![CDATA[immunoregulation]]></TERM><TERM><![CDATA[In Vitro]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[Indium]]></TERM><TERM><![CDATA[Infection]]></TERM><TERM><![CDATA[innovation]]></TERM><TERM><![CDATA[interest]]></TERM><TERM><![CDATA[Invaded]]></TERM><TERM><![CDATA[Investigation]]></TERM><TERM><![CDATA[Killings]]></TERM><TERM><![CDATA[Klebsiella pneumonia bacterium]]></TERM><TERM><![CDATA[Laboratories]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[Life]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[Medical center]]></TERM><TERM><![CDATA[Membrane]]></TERM><TERM><![CDATA[membrane model]]></TERM><TERM><![CDATA[methicillin resistant Staphylococcus aureus (organism)]]></TERM><TERM><![CDATA[microbial]]></TERM><TERM><![CDATA[Microbial Biofilms]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[Mortality Vital Statistics]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[Names]]></TERM><TERM><![CDATA[natural antimicrobial]]></TERM><TERM><![CDATA[Natural Immunity]]></TERM><TERM><![CDATA[Nebraska]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[Outcome]]></TERM><TERM><![CDATA[pathogen]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Peptides]]></TERM><TERM><![CDATA[Positioning Attribute]]></TERM><TERM><![CDATA[prevent]]></TERM><TERM><![CDATA[Prevention]]></TERM><TERM><![CDATA[Property]]></TERM><TERM><![CDATA[Pseudomonas aeruginosa]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Resistance]]></TERM><TERM><![CDATA[Resources]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[Scientist]]></TERM><TERM><![CDATA[Solid]]></TERM><TERM><![CDATA[Source]]></TERM><TERM><![CDATA[Staphylococcus aureus]]></TERM><TERM><![CDATA[structural biology]]></TERM><TERM><![CDATA[Structural Protein]]></TERM><TERM><![CDATA[Structure]]></TERM><TERM><![CDATA[Surface]]></TERM><TERM><![CDATA[System]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[three dimensional structure]]></TERM><TERM><![CDATA[tool]]></TERM><TERM><![CDATA[United States]]></TERM><TERM><![CDATA[Universities]]></TERM><TERM><![CDATA[Update]]></TERM><TERM><![CDATA[Virulence Factors]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Database designed novel anti-MRSA peptides]]></PROJECT_TITLE><SERIAL_NUMBER>105147</SERIAL_NUMBER><STUDY_SECTION>DDR</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Drug Discovery and Mechanisms of Antimicrobial Resistance Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>250000</DIRECT_COST_AMT><INDIRECT_COST_AMT>126250</INDIRECT_COST_AMT><TOTAL_COST>376250</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8960936</APPLICATION_ID><ACTIVITY>P01</ACTIVITY><ADMINISTERING_IC>HL</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/26/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>837</CFDA_CODE><CORE_PROJECT_NUM>P01HL029582</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PAR-13-316</FOA_NUMBER><FULL_PROJECT_NUM>5P01HL029582-32</FULL_PROJECT_NUM><FUNDING_ICs>NHLBI:1730372\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL HEART, LUNG, AND BLOOD INSTITUTE</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>CLEVELAND</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[OTHER BASIC SCIENCES]]></ORG_DEPT><ORG_DISTRICT>11</ORG_DISTRICT><ORG_DUNS>135781701</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[CLEVELAND CLINIC LERNER COM-CWRU]]></ORG_NAME><ORG_STATE>OH</ORG_STATE><ORG_ZIPCODE>441950001</ORG_ZIPCODE><PHR><![CDATA[Overall Program. Narrative 
Atherosclerosis is the leading cause of cardiovascular disease in the United States. An epidemic of obesity is 
driving the incidence of atherosclerosis and diabetes, and consequent morbidity and mortality. It is now clear 
that excess nutrient input generates chronic inflammation that contributes to atherogenesis. The long-term goal 
of our Program Project is to gain a deep and mechanistic understanding of the genetic events, and cellular and 
physiological processes, underlying the connections between inflammation, metabolism and atherosclerosis.]]></PHR><PIS><PI><PI_NAME>FOX, PAUL L</PI_NAME><PI_ID>1891116</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>HASAN, AHMED A.K.</PROGRAM_OFFICER_NAME><PROJECT_START>07/01/1997</PROJECT_START><PROJECT_END>10/31/2019</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[Adipocytes]]></TERM><TERM><![CDATA[Amino Acyl-tRNA Synthetases]]></TERM><TERM><![CDATA[angiogenesis]]></TERM><TERM><![CDATA[Area]]></TERM><TERM><![CDATA[Arterial Fatty Streak]]></TERM><TERM><![CDATA[atherogenesis]]></TERM><TERM><![CDATA[Atherosclerosis]]></TERM><TERM><![CDATA[Automobile Driving]]></TERM><TERM><![CDATA[Autophagocytosis]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Binding (Molecular Function)]]></TERM><TERM><![CDATA[Biochemistry]]></TERM><TERM><![CDATA[Bioinformatics]]></TERM><TERM><![CDATA[Cardiovascular Diseases]]></TERM><TERM><![CDATA[Cell physiology]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Central obesity]]></TERM><TERM><![CDATA[Cholesterol]]></TERM><TERM><![CDATA[Chronic]]></TERM><TERM><![CDATA[Coin]]></TERM><TERM><![CDATA[Coronary Arteriosclerosis]]></TERM><TERM><![CDATA[cost effective]]></TERM><TERM><![CDATA[cytokine]]></TERM><TERM><![CDATA[Diabetes Mellitus]]></TERM><TERM><![CDATA[Diet]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Endothelial Cells]]></TERM><TERM><![CDATA[Epidemic]]></TERM><TERM><![CDATA[Event]]></TERM><TERM><![CDATA[fatty acid metabolism]]></TERM><TERM><![CDATA[Foam Cells]]></TERM><TERM><![CDATA[Foxes]]></TERM><TERM><![CDATA[Gene Expression]]></TERM><TERM><![CDATA[Genes]]></TERM><TERM><![CDATA[Genetic]]></TERM><TERM><![CDATA[Genomics]]></TERM><TERM><![CDATA[glutamyl-prolyl-tRNA synthetase]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[human FRAP1 protein]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[Incidence]]></TERM><TERM><![CDATA[Inflammation]]></TERM><TERM><![CDATA[Inflammatory]]></TERM><TERM><![CDATA[Inflammatory Response]]></TERM><TERM><![CDATA[insight]]></TERM><TERM><![CDATA[Institution]]></TERM><TERM><![CDATA[Insulin Resistance]]></TERM><TERM><![CDATA[interest]]></TERM><TERM><![CDATA[Interleukin-1]]></TERM><TERM><![CDATA[Interleukin-1 Receptors]]></TERM><TERM><![CDATA[Interleukin-2]]></TERM><TERM><![CDATA[Intra-abdominal]]></TERM><TERM><![CDATA[Laboratories]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[Link]]></TERM><TERM><![CDATA[Lipids]]></TERM><TERM><![CDATA[Lipoproteins]]></TERM><TERM><![CDATA[Longevity]]></TERM><TERM><![CDATA[macrophage]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[Metabolic]]></TERM><TERM><![CDATA[Metabolic stress]]></TERM><TERM><![CDATA[Metabolism]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[Molecular and Cellular Biology]]></TERM><TERM><![CDATA[Morbidity - disease rate]]></TERM><TERM><![CDATA[Mortality Vital Statistics]]></TERM><TERM><![CDATA[mouse model]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[Nutrient]]></TERM><TERM><![CDATA[Obesity]]></TERM><TERM><![CDATA[oxidation]]></TERM><TERM><![CDATA[Oxygen]]></TERM><TERM><![CDATA[paracrine]]></TERM><TERM><![CDATA[Pathogenesis]]></TERM><TERM><![CDATA[Pathway interactions]]></TERM><TERM><![CDATA[Phosphorylation]]></TERM><TERM><![CDATA[Physiological]]></TERM><TERM><![CDATA[Physiological Processes]]></TERM><TERM><![CDATA[Play]]></TERM><TERM><![CDATA[Positioning Attribute]]></TERM><TERM><![CDATA[Post-Transcriptional Regulation]]></TERM><TERM><![CDATA[prevent]]></TERM><TERM><![CDATA[programs]]></TERM><TERM><![CDATA[proline-tRNA]]></TERM><TERM><![CDATA[Proteomics]]></TERM><TERM><![CDATA[receptor]]></TERM><TERM><![CDATA[Receptor Signaling]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Research Personnel]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[Risk Factors]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Sclerosis]]></TERM><TERM><![CDATA[sensor]]></TERM><TERM><![CDATA[Services]]></TERM><TERM><![CDATA[Signal Pathway]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[Signal Transduction Pathway]]></TERM><TERM><![CDATA[Signaling Pathway Gene]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Toll-like receptors]]></TERM><TERM><![CDATA[tool]]></TERM><TERM><![CDATA[United States]]></TERM><TERM><![CDATA[Vascular Diseases]]></TERM><TERM><![CDATA[vascular inflammation]]></TERM><TERM><![CDATA[Western World]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Mechanisms linking inflammation, metabolism, and atherosclerosis.]]></PROJECT_TITLE><SERIAL_NUMBER>029582</SERIAL_NUMBER><STUDY_SECTION>ZHL1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>32</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>1091718</DIRECT_COST_AMT><INDIRECT_COST_AMT>638654</INDIRECT_COST_AMT><TOTAL_COST>1730372</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8960937</APPLICATION_ID><ACTIVITY>P01</ACTIVITY><ADMINISTERING_IC>HL</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/26/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>P01HL029582</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>PAR-13-316</FOA_NUMBER><FULL_PROJECT_NUM>5P01HL029582-32</FULL_PROJECT_NUM><FUNDING_ICs>NHLBI:83325\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL HEART, LUNG, AND BLOOD INSTITUTE</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>CLEVELAND</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>11</ORG_DISTRICT><ORG_DUNS>135781701</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[CLEVELAND CLINIC LERNER COM-CWRU]]></ORG_NAME><ORG_STATE>OH</ORG_STATE><ORG_ZIPCODE>441950001</ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>FOX, PAUL L</PI_NAME><PI_ID>1891116</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START></PROJECT_START><PROJECT_END></PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[abstracting]]></TERM><TERM><![CDATA[Advisory Committees]]></TERM><TERM><![CDATA[Arts]]></TERM><TERM><![CDATA[Atherosclerosis]]></TERM><TERM><![CDATA[Charge]]></TERM><TERM><![CDATA[Committee Members]]></TERM><TERM><![CDATA[Communication]]></TERM><TERM><![CDATA[Contract Services]]></TERM><TERM><![CDATA[Deposition]]></TERM><TERM><![CDATA[Doctor of Philosophy]]></TERM><TERM><![CDATA[Fostering]]></TERM><TERM><![CDATA[Foxes]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Human Resources]]></TERM><TERM><![CDATA[Inflammation]]></TERM><TERM><![CDATA[Institution]]></TERM><TERM><![CDATA[instrument]]></TERM><TERM><![CDATA[Link]]></TERM><TERM><![CDATA[Manuscripts]]></TERM><TERM><![CDATA[meetings]]></TERM><TERM><![CDATA[Metabolism]]></TERM><TERM><![CDATA[Obesity]]></TERM><TERM><![CDATA[Participant]]></TERM><TERM><![CDATA[Photography]]></TERM><TERM><![CDATA[Preparation]]></TERM><TERM><![CDATA[programs]]></TERM><TERM><![CDATA[PubMed]]></TERM><TERM><![CDATA[Research Activity]]></TERM><TERM><![CDATA[Schedule]]></TERM><TERM><![CDATA[Services]]></TERM><TERM><![CDATA[Travel]]></TERM><TERM><![CDATA[United States National Institutes of Health]]></TERM><TERM><![CDATA[Visit]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Administration Core A]]></PROJECT_TITLE><SERIAL_NUMBER>029582</SERIAL_NUMBER><STUDY_SECTION>ZHL1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID>7861</SUBPROJECT_ID><SUPPORT_YEAR>32</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>52571</DIRECT_COST_AMT><INDIRECT_COST_AMT>30754</INDIRECT_COST_AMT><TOTAL_COST /><TOTAL_COST_SUB_PROJECT>83325</TOTAL_COST_SUB_PROJECT></row>
<row><APPLICATION_ID>8962090</APPLICATION_ID><ACTIVITY>P60</ACTIVITY><ADMINISTERING_IC>MD</ADMINISTERING_IC><APPLICATION_TYPE>4</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/30/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>P60MD000538</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-MD-11-003</FOA_NUMBER><FULL_PROJECT_NUM>4P60MD000538-13</FULL_PROJECT_NUM><FUNDING_ICs>NIMHD:349104\</FUNDING_ICs><FUNDING_MECHANISM>RESEARCH CENTERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE ON MINORITY HEALTH AND HEALTH DISPARITIES</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>NEW YORK</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>12</ORG_DISTRICT><ORG_DUNS>121911077</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[NEW YORK UNIVERSITY SCHOOL OF MEDICINE]]></ORG_NAME><ORG_STATE>NY</ORG_STATE><ORG_ZIPCODE>100165802</ORG_ZIPCODE><PHR><![CDATA[The project aims to adapt an evidence-based faith interventions to reduce obesity and obesity-related conditions, which has not been done in this community. By targeting two South Asian sub-groups within two different faith settings, we will be able to examine the barriers and facilitators for effective adoption of these strategies across contexts. We will be able to identify successful components that can be generalized across different Asian ethnic groups and different religious and cultural contexts.]]></PHR><PIS><PI><PI_NAME>ISLAM, NADIA S (contact)</PI_NAME><PI_ID>9251277 (contact)</PI_ID></PI><PI><PI_NAME>REY, MARIANO J</PI_NAME><PI_ID>7704072</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START></PROJECT_START><PROJECT_END></PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Acculturation]]></TERM><TERM><![CDATA[Adoption]]></TERM><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[African American]]></TERM><TERM><![CDATA[Asian Americans]]></TERM><TERM><![CDATA[Asians]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Behavior]]></TERM><TERM><![CDATA[Behavioral]]></TERM><TERM><![CDATA[Cardiovascular Diseases]]></TERM><TERM><![CDATA[caucasian American]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[Communication]]></TERM><TERM><![CDATA[Communities]]></TERM><TERM><![CDATA[community based participatory research]]></TERM><TERM><![CDATA[Community Networks]]></TERM><TERM><![CDATA[Consumption]]></TERM><TERM><![CDATA[contextual factors]]></TERM><TERM><![CDATA[Control Groups]]></TERM><TERM><![CDATA[Discrimination (Psychology)]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[disorder prevention]]></TERM><TERM><![CDATA[Doctor of Philosophy]]></TERM><TERM><![CDATA[Educational Background]]></TERM><TERM><![CDATA[Effectiveness]]></TERM><TERM><![CDATA[Environmental Policy]]></TERM><TERM><![CDATA[Ethnic group]]></TERM><TERM><![CDATA[evidence base]]></TERM><TERM><![CDATA[Face]]></TERM><TERM><![CDATA[faith-based intervention]]></TERM><TERM><![CDATA[Fatty acid glycerol esters]]></TERM><TERM><![CDATA[Food]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Health behavior]]></TERM><TERM><![CDATA[Health Benefit]]></TERM><TERM><![CDATA[health disparity]]></TERM><TERM><![CDATA[Health Promotion]]></TERM><TERM><![CDATA[Immigrant]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[Income]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[Institution]]></TERM><TERM><![CDATA[Intervention]]></TERM><TERM><![CDATA[Intervention Trial]]></TERM><TERM><![CDATA[Leadership]]></TERM><TERM><![CDATA[Life]]></TERM><TERM><![CDATA[Life Stress]]></TERM><TERM><![CDATA[Link]]></TERM><TERM><![CDATA[Low income]]></TERM><TERM><![CDATA[Minority Groups]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Muslim religion]]></TERM><TERM><![CDATA[New York City]]></TERM><TERM><![CDATA[Non-Insulin-Dependent Diabetes Mellitus]]></TERM><TERM><![CDATA[Obesity]]></TERM><TERM><![CDATA[Obesity associated disease]]></TERM><TERM><![CDATA[obesity risk]]></TERM><TERM><![CDATA[Outcome]]></TERM><TERM><![CDATA[Overweight]]></TERM><TERM><![CDATA[Patient Self-Report]]></TERM><TERM><![CDATA[Physical activity]]></TERM><TERM><![CDATA[Play]]></TERM><TERM><![CDATA[Population]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[Qualitative Methods]]></TERM><TERM><![CDATA[Randomized]]></TERM><TERM><![CDATA[Readiness]]></TERM><TERM><![CDATA[Religion and Spirituality]]></TERM><TERM><![CDATA[religious group]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Research Infrastructure]]></TERM><TERM><![CDATA[Risk]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Secure]]></TERM><TERM><![CDATA[social]]></TERM><TERM><![CDATA[Social Network]]></TERM><TERM><![CDATA[Social support]]></TERM><TERM><![CDATA[Socioeconomic Status]]></TERM><TERM><![CDATA[South Asian]]></TERM><TERM><![CDATA[southeast Asian]]></TERM><TERM><![CDATA[Stress]]></TERM><TERM><![CDATA[stressor]]></TERM><TERM><![CDATA[therapy design]]></TERM><TERM><![CDATA[Translating]]></TERM><TERM><![CDATA[Translations]]></TERM><TERM><![CDATA[Weight]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Obesity and Stress in South and Southeast Asians (OASIS)]]></PROJECT_TITLE><SERIAL_NUMBER>000538</SERIAL_NUMBER><STUDY_SECTION>ZMD1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID>6304</SUBPROJECT_ID><SUPPORT_YEAR>13</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>213411</DIRECT_COST_AMT><INDIRECT_COST_AMT>135693</INDIRECT_COST_AMT><TOTAL_COST /><TOTAL_COST_SUB_PROJECT>349104</TOTAL_COST_SUB_PROJECT></row>
<row><APPLICATION_ID>8962167</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>HL</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/04/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>837</CFDA_CODE><CORE_PROJECT_NUM>R01HL122416</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-13-302</FOA_NUMBER><FULL_PROJECT_NUM>5R01HL122416-02</FULL_PROJECT_NUM><FUNDING_ICs>NHLBI:435066\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL HEART, LUNG, AND BLOOD INSTITUTE</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>ANN ARBOR</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[PHARMACOLOGY]]></ORG_DEPT><ORG_DISTRICT>12</ORG_DISTRICT><ORG_DUNS>073133571</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIVERSITY OF MICHIGAN]]></ORG_NAME><ORG_STATE>MI</ORG_STATE><ORG_ZIPCODE>481091276</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Lysosomal phospholipase A2 (LPLA2) is a recently discovered enzyme that catabolizes glycerophospholipids and breaks down lung surfactants. Inhibition of LPLA2 correlates with phospholipidosis during long-term administration of the antiarrhythmic drug amiodarone. LPLA2 is closely related to lecithin-cholesterol acyltransferase (LCAT), a plasma protein that plays a critical role in reverse cholesterol transport via HDLs to the liver. Mutations in LCAT are responsible for a devastating disease known as familial LCAT deficiency. Both enzymes are believed to be important for amelioration of atherosclerosis. This proposal seeks to determine the molecular basis for substrate selectivity, catalysis, small molecule activation, and disease in this structurally uncharacterized family of lipid metabolizing enzymes.]]></PHR><PIS><PI><PI_NAME>TESMER, JOHN J G</PI_NAME><PI_ID>7038414</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>LIU, LIJUAN </PROGRAM_OFFICER_NAME><PROJECT_START>11/04/2014</PROJECT_START><PROJECT_END>10/31/2018</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Active Sites]]></TERM><TERM><![CDATA[acute coronary syndrome]]></TERM><TERM><![CDATA[Acyltransferase]]></TERM><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[Adverse effects]]></TERM><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[Alveolar Macrophages]]></TERM><TERM><![CDATA[Amiodarone]]></TERM><TERM><![CDATA[analog]]></TERM><TERM><![CDATA[Anti-Arrhythmia Agents]]></TERM><TERM><![CDATA[Apolipoprotein A-I]]></TERM><TERM><![CDATA[Atherosclerosis]]></TERM><TERM><![CDATA[Autoimmune Diseases]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Binding (Molecular Function)]]></TERM><TERM><![CDATA[Biological Assay]]></TERM><TERM><![CDATA[Biological Response Modifier Therapy]]></TERM><TERM><![CDATA[Catabolism]]></TERM><TERM><![CDATA[Catalysis]]></TERM><TERM><![CDATA[Cholesterol]]></TERM><TERM><![CDATA[Cholesterol Esters]]></TERM><TERM><![CDATA[Complex]]></TERM><TERM><![CDATA[Cryoelectron Microscopy]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[disease phenotype]]></TERM><TERM><![CDATA[DNA Sequence Alteration]]></TERM><TERM><![CDATA[Electron Microscopy]]></TERM><TERM><![CDATA[Engineering]]></TERM><TERM><![CDATA[enzyme replacement therapy]]></TERM><TERM><![CDATA[Enzymes]]></TERM><TERM><![CDATA[esterase]]></TERM><TERM><![CDATA[Eye diseases]]></TERM><TERM><![CDATA[familial cholesteryl ester deficiency]]></TERM><TERM><![CDATA[Family]]></TERM><TERM><![CDATA[Fishes]]></TERM><TERM><![CDATA[flexibility]]></TERM><TERM><![CDATA[Future]]></TERM><TERM><![CDATA[Glycerophospholipids]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Hereditary Disease]]></TERM><TERM><![CDATA[High Density Lipoproteins]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[Image]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[Infusion procedures]]></TERM><TERM><![CDATA[insight]]></TERM><TERM><![CDATA[Kidney Failure]]></TERM><TERM><![CDATA[Knowledge]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[Learning]]></TERM><TERM><![CDATA[lecithin cholesterol acyltransferase deficiency]]></TERM><TERM><![CDATA[Ligands]]></TERM><TERM><![CDATA[Lipase]]></TERM><TERM><![CDATA[lipid metabolism]]></TERM><TERM><![CDATA[Lipids]]></TERM><TERM><![CDATA[Lipoprotein Binding]]></TERM><TERM><![CDATA[Liposomes]]></TERM><TERM><![CDATA[Liver]]></TERM><TERM><![CDATA[macrophage]]></TERM><TERM><![CDATA[Maps]]></TERM><TERM><![CDATA[meetings]]></TERM><TERM><![CDATA[Membrane]]></TERM><TERM><![CDATA[mimetics]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[Mutate]]></TERM><TERM><![CDATA[Mutation]]></TERM><TERM><![CDATA[Negative Staining]]></TERM><TERM><![CDATA[Outcome Study]]></TERM><TERM><![CDATA[particle]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Peptides]]></TERM><TERM><![CDATA[Pharmaceutical Preparations]]></TERM><TERM><![CDATA[Phosphatidylcholine-Sterol O-Acyltransferase]]></TERM><TERM><![CDATA[Phospholipase A2]]></TERM><TERM><![CDATA[Plasma Proteins]]></TERM><TERM><![CDATA[Play]]></TERM><TERM><![CDATA[Positioning Attribute]]></TERM><TERM><![CDATA[Proteins]]></TERM><TERM><![CDATA[Pulmonary Surfactants]]></TERM><TERM><![CDATA[Reaction]]></TERM><TERM><![CDATA[Recombinants]]></TERM><TERM><![CDATA[reconstruction]]></TERM><TERM><![CDATA[Regulation]]></TERM><TERM><![CDATA[Reporting]]></TERM><TERM><![CDATA[Resolution]]></TERM><TERM><![CDATA[reverse cholesterol transport]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Series]]></TERM><TERM><![CDATA[Serum]]></TERM><TERM><![CDATA[Site-Directed Mutagenesis]]></TERM><TERM><![CDATA[small molecule]]></TERM><TERM><![CDATA[Somatic Mutation]]></TERM><TERM><![CDATA[Structure]]></TERM><TERM><![CDATA[Surface]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[theories]]></TERM><TERM><![CDATA[therapy design]]></TERM><TERM><![CDATA[Transacylase]]></TERM><TERM><![CDATA[Variant]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Structure and Function of the LPLA2/LCAT Acyltransferase Family]]></PROJECT_TITLE><SERIAL_NUMBER>122416</SERIAL_NUMBER><STUDY_SECTION>BBM</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Biochemistry and Biophysics of Membranes Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>280688</DIRECT_COST_AMT><INDIRECT_COST_AMT>154378</INDIRECT_COST_AMT><TOTAL_COST>435066</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8962170</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>MH</ADMINISTERING_IC><APPLICATION_TYPE>4</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/27/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>242</CFDA_CODE><CORE_PROJECT_NUM>R01MH082017</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-11-260</FOA_NUMBER><FULL_PROJECT_NUM>4R01MH082017-09</FULL_PROJECT_NUM><FUNDING_ICs>NIMH:451857\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF MENTAL HEALTH</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>NEW YORK</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[NEUROSCIENCES]]></ORG_DEPT><ORG_DISTRICT>13</ORG_DISTRICT><ORG_DUNS>621889815</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[COLUMBIA UNIVERSITY HEALTH SCIENCES]]></ORG_NAME><ORG_STATE>NY</ORG_STATE><ORG_ZIPCODE>100320049</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: The aim of this proposal is to understand how neural representations of value are updated in the brain. Since many psychiatric disorders, like anxiety and mood disorders, involve dysfunction in the neural circuits that update representations of value, this project promises to lay the groundwork for developing new treatments.]]></PHR><PIS><PI><PI_NAME>SALZMAN, C DANIEL</PI_NAME><PI_ID>1897398</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>SIMMONS, JANINE M</PROGRAM_OFFICER_NAME><PROJECT_START>12/01/2007</PROJECT_START><PROJECT_END>10/31/2017</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Accounting]]></TERM><TERM><![CDATA[Adaptive Behaviors]]></TERM><TERM><![CDATA[Affective]]></TERM><TERM><![CDATA[Air]]></TERM><TERM><![CDATA[Amygdaloid structure]]></TERM><TERM><![CDATA[Anterior]]></TERM><TERM><![CDATA[Anxiety Disorders]]></TERM><TERM><![CDATA[Area]]></TERM><TERM><![CDATA[Association Learning]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Behavior]]></TERM><TERM><![CDATA[Behavioral]]></TERM><TERM><![CDATA[Biological Assay]]></TERM><TERM><![CDATA[Brain]]></TERM><TERM><![CDATA[cingulate cortex]]></TERM><TERM><![CDATA[Cognitive]]></TERM><TERM><![CDATA[Coupling]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Dorsal]]></TERM><TERM><![CDATA[emotion regulation]]></TERM><TERM><![CDATA[Emotional]]></TERM><TERM><![CDATA[emotional adjustment]]></TERM><TERM><![CDATA[Etiology]]></TERM><TERM><![CDATA[Event]]></TERM><TERM><![CDATA[Exhibits]]></TERM><TERM><![CDATA[expectation]]></TERM><TERM><![CDATA[experience]]></TERM><TERM><![CDATA[Extinction (Psychology)]]></TERM><TERM><![CDATA[flexibility]]></TERM><TERM><![CDATA[Functional disorder]]></TERM><TERM><![CDATA[Grant]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Learning]]></TERM><TERM><![CDATA[Link]]></TERM><TERM><![CDATA[Liquid substance]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[Mental disorders]]></TERM><TERM><![CDATA[Mental Health]]></TERM><TERM><![CDATA[Monitor]]></TERM><TERM><![CDATA[Monkeys]]></TERM><TERM><![CDATA[Mood Disorders]]></TERM><TERM><![CDATA[neural circuit]]></TERM><TERM><![CDATA[Neurons]]></TERM><TERM><![CDATA[neurophysiology]]></TERM><TERM><![CDATA[neurotransmission]]></TERM><TERM><![CDATA[Physiological Processes]]></TERM><TERM><![CDATA[Play]]></TERM><TERM><![CDATA[Prefrontal Cortex]]></TERM><TERM><![CDATA[Procedures]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[Property]]></TERM><TERM><![CDATA[Psychological reinforcement]]></TERM><TERM><![CDATA[Regulation]]></TERM><TERM><![CDATA[relating to nervous system]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[Reversal Learning]]></TERM><TERM><![CDATA[Rewards]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Schizophrenia]]></TERM><TERM><![CDATA[Scientist]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[Sorting - Cell Movement]]></TERM><TERM><![CDATA[Stimulus]]></TERM><TERM><![CDATA[Structure]]></TERM><TERM><![CDATA[Study Subject]]></TERM><TERM><![CDATA[Task Performances]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Update]]></TERM><TERM><![CDATA[Visual]]></TERM><TERM><![CDATA[Wit]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Neurophysiology underlying neural representations of value]]></PROJECT_TITLE><SERIAL_NUMBER>082017</SERIAL_NUMBER><STUDY_SECTION>SPC</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>09</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>282411</DIRECT_COST_AMT><INDIRECT_COST_AMT>169446</INDIRECT_COST_AMT><TOTAL_COST>451857</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8963433</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>AI</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/26/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>855</CFDA_CODE><CORE_PROJECT_NUM>R01AI115703</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-13-302</FOA_NUMBER><FULL_PROJECT_NUM>5R01AI115703-02</FULL_PROJECT_NUM><FUNDING_ICs>NIAID:405000\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>BALTIMORE</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[INTERNAL MEDICINE/MEDICINE]]></ORG_DEPT><ORG_DISTRICT>07</ORG_DISTRICT><ORG_DUNS>001910777</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[JOHNS HOPKINS UNIVERSITY]]></ORG_NAME><ORG_STATE>MD</ORG_STATE><ORG_ZIPCODE>212051832</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Dendritic cells and basophils are types of white blood cells that instruct other white blood cells, such as T cells, to respond to substances that cause allergies. By identifying the parameters and mechanisms underlying how dendritic cells and basophils regulate these interactions, we might better understand why allergy persists and, more importantly, develop new strategies to treat allergic diseases in general.]]></PHR><PIS><PI><PI_NAME>SCHROEDER, JOHN T</PI_NAME><PI_ID>1885538</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>DAVIDSON, WENDY F.</PROGRAM_OFFICER_NAME><PROJECT_START>11/05/2014</PROJECT_START><PROJECT_END>10/31/2019</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Accounting]]></TERM><TERM><![CDATA[adaptive immunity]]></TERM><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[Agonist]]></TERM><TERM><![CDATA[Allergens]]></TERM><TERM><![CDATA[Allergic]]></TERM><TERM><![CDATA[Allergic Disease]]></TERM><TERM><![CDATA[Allergic inflammation]]></TERM><TERM><![CDATA[American]]></TERM><TERM><![CDATA[Ancillary Study]]></TERM><TERM><![CDATA[Antigen-Presenting Cells]]></TERM><TERM><![CDATA[Antigens]]></TERM><TERM><![CDATA[Asthma]]></TERM><TERM><![CDATA[atopy]]></TERM><TERM><![CDATA[Attention]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Basophils]]></TERM><TERM><![CDATA[Biological Markers]]></TERM><TERM><![CDATA[Blocking Antibodies]]></TERM><TERM><![CDATA[Blood]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Child]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[clinically relevant]]></TERM><TERM><![CDATA[cytokine]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Dendritic Cells]]></TERM><TERM><![CDATA[Developed Countries]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Food]]></TERM><TERM><![CDATA[Genetic]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[Hypersensitivity]]></TERM><TERM><![CDATA[IgE]]></TERM><TERM><![CDATA[IgG4]]></TERM><TERM><![CDATA[IL2RA gene]]></TERM><TERM><![CDATA[IL7R gene]]></TERM><TERM><![CDATA[Immune]]></TERM><TERM><![CDATA[Immune response]]></TERM><TERM><![CDATA[Immunoglobulin G]]></TERM><TERM><![CDATA[Immunotherapy]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[innate immune function]]></TERM><TERM><![CDATA[innovation]]></TERM><TERM><![CDATA[insight]]></TERM><TERM><![CDATA[Interferons]]></TERM><TERM><![CDATA[Interleukin-10]]></TERM><TERM><![CDATA[Interleukin-13]]></TERM><TERM><![CDATA[Interleukin-3]]></TERM><TERM><![CDATA[Interleukin-4]]></TERM><TERM><![CDATA[Interleukin-5]]></TERM><TERM><![CDATA[Intervention]]></TERM><TERM><![CDATA[Leukocytes]]></TERM><TERM><![CDATA[Ligands]]></TERM><TERM><![CDATA[Lymphocyte]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[Memory]]></TERM><TERM><![CDATA[Monitor]]></TERM><TERM><![CDATA[Morbidity - disease rate]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[Myelogenous]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[Pathogenesis]]></TERM><TERM><![CDATA[peripheral tolerance]]></TERM><TERM><![CDATA[Phenotype]]></TERM><TERM><![CDATA[Play]]></TERM><TERM><![CDATA[Probability]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[pyroglyphid]]></TERM><TERM><![CDATA[Regulation]]></TERM><TERM><![CDATA[Regulatory T-Lymphocyte]]></TERM><TERM><![CDATA[research study]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[Risk Factors]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Stimulus]]></TERM><TERM><![CDATA[T cell response]]></TERM><TERM><![CDATA[T-Lymphocyte]]></TERM><TERM><![CDATA[Th1 Cells]]></TERM><TERM><![CDATA[Th2 Cells]]></TERM><TERM><![CDATA[Therapeutic Intervention]]></TERM><TERM><![CDATA[TLR2 gene]]></TERM><TERM><![CDATA[TLR7 gene]]></TERM><TERM><![CDATA[TSLP gene]]></TERM><TERM><![CDATA[United States]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Human DC Subtypes in Regulating T-Helper-2 Responses]]></PROJECT_TITLE><SERIAL_NUMBER>115703</SERIAL_NUMBER><STUDY_SECTION>HAI</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Hypersensitivity, Autoimmune, and Immune-mediated Diseases Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>250000</DIRECT_COST_AMT><INDIRECT_COST_AMT>155000</INDIRECT_COST_AMT><TOTAL_COST>405000</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8965502</APPLICATION_ID><ACTIVITY>R21</ACTIVITY><ADMINISTERING_IC>AI</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/28/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>855</CFDA_CODE><CORE_PROJECT_NUM>R21AI115092</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-13-303</FOA_NUMBER><FULL_PROJECT_NUM>5R21AI115092-02</FULL_PROJECT_NUM><FUNDING_ICs>NIAID:239750\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>CHICAGO</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[MICROBIOLOGY/IMMUN/VIROLOGY]]></ORG_DEPT><ORG_DISTRICT>07</ORG_DISTRICT><ORG_DUNS>098987217</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIVERSITY OF ILLINOIS AT CHICAGO]]></ORG_NAME><ORG_STATE>IL</ORG_STATE><ORG_ZIPCODE>606127224</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Listeria monocytogenes continues to be an increasingly significant health threat as it has been associated with numerous multi-state food-borne outbreaks that have resulted in thousands of illnesses and several hundred deaths within the past few years. In the US, the three most deadly bacterial food-borne outbreaks occurred as a result of L. monocytogenes contamination, and the bacterium generally ranks as the third or fourth most common cause of bacterial meningitis in North America. This proposal is focused on deciphering how a novel peptide pheromone signaling system contributes L. monocytogenes survival within mammalian host cells; the ultimate goal is to identify critical pathways that can b targeted to reduce the severity of Lm infections.]]></PHR><PIS><PI><PI_NAME>FREITAG, NANCY ELIZABETH</PI_NAME><PI_ID>1892579</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>MILLS, MELODY </PROGRAM_OFFICER_NAME><PROJECT_START>11/06/2014</PROJECT_START><PROJECT_END>10/31/2016</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[abortion]]></TERM><TERM><![CDATA[Animals]]></TERM><TERM><![CDATA[Antibiotic Resistance]]></TERM><TERM><![CDATA[Antibiotic Therapy]]></TERM><TERM><![CDATA[Antibiotics]]></TERM><TERM><![CDATA[Bacteria]]></TERM><TERM><![CDATA[Bacterial Meningitis]]></TERM><TERM><![CDATA[bacteriocin]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Biochemical]]></TERM><TERM><![CDATA[Brain Abscess]]></TERM><TERM><![CDATA[Cardiac]]></TERM><TERM><![CDATA[cell transformation]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Cessation of life]]></TERM><TERM><![CDATA[Competence]]></TERM><TERM><![CDATA[Critical Pathways]]></TERM><TERM><![CDATA[Cytolysis]]></TERM><TERM><![CDATA[Cytosol]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Disease Outbreaks]]></TERM><TERM><![CDATA[Disease Reservoirs]]></TERM><TERM><![CDATA[DNA]]></TERM><TERM><![CDATA[Elderly]]></TERM><TERM><![CDATA[Enterococcus faecalis]]></TERM><TERM><![CDATA[Environment]]></TERM><TERM><![CDATA[Exhibits]]></TERM><TERM><![CDATA[Food]]></TERM><TERM><![CDATA[foodborne]]></TERM><TERM><![CDATA[foodborne outbreak]]></TERM><TERM><![CDATA[Gastroenteritis]]></TERM><TERM><![CDATA[Gene Expression]]></TERM><TERM><![CDATA[Genetic]]></TERM><TERM><![CDATA[Gentamicins]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Gram-Positive Bacteria]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[human disease]]></TERM><TERM><![CDATA[Immunocompromised Host]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[Infection]]></TERM><TERM><![CDATA[interest]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[Life]]></TERM><TERM><![CDATA[Lipoproteins]]></TERM><TERM><![CDATA[Listeria]]></TERM><TERM><![CDATA[Listeria monocytogenes]]></TERM><TERM><![CDATA[Location]]></TERM><TERM><![CDATA[Mammalian Cell]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[Membrane]]></TERM><TERM><![CDATA[Meningitis]]></TERM><TERM><![CDATA[Meningoencephalitis]]></TERM><TERM><![CDATA[Microbe]]></TERM><TERM><![CDATA[Microbial Biofilms]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[Mortality Vital Statistics]]></TERM><TERM><![CDATA[neonate]]></TERM><TERM><![CDATA[Neurologic]]></TERM><TERM><![CDATA[North America]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[novel strategies]]></TERM><TERM><![CDATA[older patient]]></TERM><TERM><![CDATA[Organism]]></TERM><TERM><![CDATA[pathogen]]></TERM><TERM><![CDATA[Pathogenesis]]></TERM><TERM><![CDATA[Pathway interactions]]></TERM><TERM><![CDATA[Pattern]]></TERM><TERM><![CDATA[Peptide Signal Sequences]]></TERM><TERM><![CDATA[Peptides]]></TERM><TERM><![CDATA[Perforation]]></TERM><TERM><![CDATA[Pharmaceutical Preparations]]></TERM><TERM><![CDATA[Pheromone]]></TERM><TERM><![CDATA[Physiological Processes]]></TERM><TERM><![CDATA[Placenta]]></TERM><TERM><![CDATA[Population]]></TERM><TERM><![CDATA[Pregnant Women]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[Production]]></TERM><TERM><![CDATA[Proteins]]></TERM><TERM><![CDATA[Recording of previous events]]></TERM><TERM><![CDATA[Regulon]]></TERM><TERM><![CDATA[Relapse]]></TERM><TERM><![CDATA[Reporting]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Risk]]></TERM><TERM><![CDATA[Septicemia]]></TERM><TERM><![CDATA[Severities]]></TERM><TERM><![CDATA[Severity of illness]]></TERM><TERM><![CDATA[Signal Pathway]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[Soil]]></TERM><TERM><![CDATA[Stillbirth]]></TERM><TERM><![CDATA[System]]></TERM><TERM><![CDATA[tool]]></TERM><TERM><![CDATA[Treatment Protocols]]></TERM><TERM><![CDATA[uptake]]></TERM><TERM><![CDATA[Vacuole]]></TERM><TERM><![CDATA[Virulence]]></TERM><TERM><![CDATA[Virulence Factors]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Deciphering how bacterial pheromone signaling enhances Listeria virulence]]></PROJECT_TITLE><SERIAL_NUMBER>115092</SERIAL_NUMBER><STUDY_SECTION>ZRG1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>150000</DIRECT_COST_AMT><INDIRECT_COST_AMT>89750</INDIRECT_COST_AMT><TOTAL_COST>239750</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8966634</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>AI</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/27/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>855</CFDA_CODE><CORE_PROJECT_NUM>R01AI114585</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-13-302</FOA_NUMBER><FULL_PROJECT_NUM>5R01AI114585-02</FULL_PROJECT_NUM><FUNDING_ICs>NIAID:461600\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>LA JOLLA</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[INTERNAL MEDICINE/MEDICINE]]></ORG_DEPT><ORG_DISTRICT>52</ORG_DISTRICT><ORG_DUNS>804355790</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIVERSITY OF CALIFORNIA SAN DIEGO]]></ORG_NAME><ORG_STATE>CA</ORG_STATE><ORG_ZIPCODE>920930934</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Asthma currently afflicts 7% of the US population and identification of novel targets is critical in order to develop future treatments for those who do ot respond to available therapy. A new white blood cell termed the type 2 innate lymphoid cell or ILC2 has recently been discovered in human lungs and contributes to asthma features in animal models. We propose to identify a new pathway used by the ILC2 to induce lung inflammation that may represent a therapeutic target for asthma.]]></PHR><PIS><PI><PI_NAME>DOHERTY, TAYLOR A</PI_NAME><PI_ID>8817993</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>DAVIDSON, WENDY F.</PROGRAM_OFFICER_NAME><PROJECT_START>11/10/2014</PROJECT_START><PROJECT_END>10/31/2019</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Adoptive Transfer]]></TERM><TERM><![CDATA[airway hyperresponsiveness]]></TERM><TERM><![CDATA[airway inflammation]]></TERM><TERM><![CDATA[Allergens]]></TERM><TERM><![CDATA[Allergic]]></TERM><TERM><![CDATA[Allergic Disease]]></TERM><TERM><![CDATA[Allergic inflammation]]></TERM><TERM><![CDATA[Amino Acid Motifs]]></TERM><TERM><![CDATA[Animal Model]]></TERM><TERM><![CDATA[antigen challenge]]></TERM><TERM><![CDATA[Asthma]]></TERM><TERM><![CDATA[B-Lymphocytes]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Biological Assay]]></TERM><TERM><![CDATA[Biology]]></TERM><TERM><![CDATA[Blood]]></TERM><TERM><![CDATA[cell type]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[cytokine]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Elements]]></TERM><TERM><![CDATA[eosinophil]]></TERM><TERM><![CDATA[Epithelial]]></TERM><TERM><![CDATA[Exclusion]]></TERM><TERM><![CDATA[Extrinsic asthma]]></TERM><TERM><![CDATA[Future]]></TERM><TERM><![CDATA[Genetic]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[Immune]]></TERM><TERM><![CDATA[In Vitro]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[Infiltration]]></TERM><TERM><![CDATA[Interleukin-13]]></TERM><TERM><![CDATA[Interleukin-5]]></TERM><TERM><![CDATA[knock-down]]></TERM><TERM><![CDATA[Knockout Mice]]></TERM><TERM><![CDATA[Leukocytes]]></TERM><TERM><![CDATA[Lung]]></TERM><TERM><![CDATA[Lung Inflammation]]></TERM><TERM><![CDATA[Lymphocyte]]></TERM><TERM><![CDATA[Lymphoid Cell]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[Messenger RNA]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[Monitor]]></TERM><TERM><![CDATA[mRNA Stability]]></TERM><TERM><![CDATA[Mucous body substance]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[Nasal Polyps]]></TERM><TERM><![CDATA[new therapeutic target]]></TERM><TERM><![CDATA[Northern Blotting]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[Pathogenesis]]></TERM><TERM><![CDATA[Pathway interactions]]></TERM><TERM><![CDATA[Phenotype]]></TERM><TERM><![CDATA[Population]]></TERM><TERM><![CDATA[Production]]></TERM><TERM><![CDATA[Reagent]]></TERM><TERM><![CDATA[Regulation]]></TERM><TERM><![CDATA[Reporter]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[RNA Binding]]></TERM><TERM><![CDATA[RNA-Binding Proteins]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Small Interfering RNA]]></TERM><TERM><![CDATA[T-Lymphocyte]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[therapeutic target]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[Transcript]]></TERM><TERM><![CDATA[TSLP gene]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[RBM3 regulation of type 2 innate lymphoid cells in allergic inflammation]]></PROJECT_TITLE><SERIAL_NUMBER>114585</SERIAL_NUMBER><STUDY_SECTION>HAI</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Hypersensitivity, Autoimmune, and Immune-mediated Diseases Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>351600</DIRECT_COST_AMT><INDIRECT_COST_AMT>110000</INDIRECT_COST_AMT><TOTAL_COST>461600</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8967582</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>HL</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/26/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>837</CFDA_CODE><CORE_PROJECT_NUM>R01HL125753</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF PUBLIC HEALTH]]></ED_INST_TYPE><FOA_NUMBER>PA-13-302</FOA_NUMBER><FULL_PROJECT_NUM>5R01HL125753-02</FULL_PROJECT_NUM><FUNDING_ICs>NHLBI:397693\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL HEART, LUNG, AND BLOOD INSTITUTE</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>BOSTON</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[GENETICS]]></ORG_DEPT><ORG_DISTRICT>07</ORG_DISTRICT><ORG_DUNS>149617367</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[HARVARD SCHOOL OF PUBLIC HEALTH]]></ORG_NAME><ORG_STATE>MA</ORG_STATE><ORG_ZIPCODE>021156028</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: The work proposed in these aims will determine the role for PKR in the development of atherosclerosis, specifically investigating the importance of PKR function in driving macrophage function in response to lipotoxicity. This work will provide novel insight into the molecular mechanisms that underlie the connection between metabolism, inflammation, and cardiometabolic disease, and thus may suggest new therapeutic strategies or targets. Cardiovascular disease is a leading cause of death and poses a major threat to human health. Hence, the development of novel, mechanism-based therapeutic approaches against atherosclerosis is highly relevant to public health and to the NIH mission.]]></PHR><PIS><PI><PI_NAME>HOTAMISLIGIL, GOKHAN S</PI_NAME><PI_ID>1857755</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>CHEN, JUE </PROGRAM_OFFICER_NAME><PROJECT_START>11/15/2014</PROJECT_START><PROJECT_END>10/31/2018</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Arterial Fatty Streak]]></TERM><TERM><![CDATA[Arteries]]></TERM><TERM><![CDATA[atherogenesis]]></TERM><TERM><![CDATA[Atherosclerosis]]></TERM><TERM><![CDATA[Automobile Driving]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[biological adaptation to stress]]></TERM><TERM><![CDATA[blood glucose regulation]]></TERM><TERM><![CDATA[Blood Vessels]]></TERM><TERM><![CDATA[Bone Marrow]]></TERM><TERM><![CDATA[Bone Marrow Transplantation]]></TERM><TERM><![CDATA[Cardiovascular Diseases]]></TERM><TERM><![CDATA[Cause of Death]]></TERM><TERM><![CDATA[Cell physiology]]></TERM><TERM><![CDATA[cell type]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Cellular Stress]]></TERM><TERM><![CDATA[Cessation of life]]></TERM><TERM><![CDATA[Chronic]]></TERM><TERM><![CDATA[Coronary]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Deterioration]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Diabetes Mellitus]]></TERM><TERM><![CDATA[diabetic]]></TERM><TERM><![CDATA[Diet]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Double-Stranded RNA]]></TERM><TERM><![CDATA[Dyslipidemias]]></TERM><TERM><![CDATA[eIF-2 Kinase]]></TERM><TERM><![CDATA[Exposure to]]></TERM><TERM><![CDATA[Fatty acid glycerol esters]]></TERM><TERM><![CDATA[Glucose]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Histology]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[Immune]]></TERM><TERM><![CDATA[Immune Cell Activation]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[Inflammation]]></TERM><TERM><![CDATA[Inflammatory]]></TERM><TERM><![CDATA[innovation]]></TERM><TERM><![CDATA[insight]]></TERM><TERM><![CDATA[Insulin]]></TERM><TERM><![CDATA[Insulin Resistance]]></TERM><TERM><![CDATA[Link]]></TERM><TERM><![CDATA[lipid metabolism]]></TERM><TERM><![CDATA[Lipids]]></TERM><TERM><![CDATA[Lipoproteins]]></TERM><TERM><![CDATA[liver function]]></TERM><TERM><![CDATA[loss of function]]></TERM><TERM><![CDATA[macrophage]]></TERM><TERM><![CDATA[Macrophage Activation]]></TERM><TERM><![CDATA[MAPK8 gene]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[Metabolic]]></TERM><TERM><![CDATA[Metabolic Diseases]]></TERM><TERM><![CDATA[Metabolism]]></TERM><TERM><![CDATA[Mission]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[Morbidity - disease rate]]></TERM><TERM><![CDATA[Mortality Vital Statistics]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[novel strategies]]></TERM><TERM><![CDATA[novel therapeutics]]></TERM><TERM><![CDATA[Nutrient]]></TERM><TERM><![CDATA[Obesity]]></TERM><TERM><![CDATA[pathogen]]></TERM><TERM><![CDATA[Pathogenesis]]></TERM><TERM><![CDATA[Pathway interactions]]></TERM><TERM><![CDATA[Peripheral arterial disease]]></TERM><TERM><![CDATA[Phenotype]]></TERM><TERM><![CDATA[Plaque (lesion)]]></TERM><TERM><![CDATA[Play]]></TERM><TERM><![CDATA[Protein Biosynthesis]]></TERM><TERM><![CDATA[public health medicine (field)]]></TERM><TERM><![CDATA[Publishing]]></TERM><TERM><![CDATA[Reporting]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[research study]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[Risk]]></TERM><TERM><![CDATA[Risk Factors]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Saturated Fatty Acids]]></TERM><TERM><![CDATA[Signal Pathway]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[Stimulus]]></TERM><TERM><![CDATA[Stress]]></TERM><TERM><![CDATA[System]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Therapeutic]]></TERM><TERM><![CDATA[therapeutic target]]></TERM><TERM><![CDATA[Tissues]]></TERM><TERM><![CDATA[United States National Institutes of Health]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[The role of immunometabolic pathways in atherosclerosis]]></PROJECT_TITLE><SERIAL_NUMBER>125753</SERIAL_NUMBER><STUDY_SECTION>AICS</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Atherosclerosis and Inflammation of the Cardiovascular System Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>246250</DIRECT_COST_AMT><INDIRECT_COST_AMT>151443</INDIRECT_COST_AMT><TOTAL_COST>397693</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8970725</APPLICATION_ID><ACTIVITY>R21</ACTIVITY><ADMINISTERING_IC>MH</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/31/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>242</CFDA_CODE><CORE_PROJECT_NUM>R21MH105734</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-13-303</FOA_NUMBER><FULL_PROJECT_NUM>5R21MH105734-02</FULL_PROJECT_NUM><FUNDING_ICs>NIMH:176155\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF MENTAL HEALTH</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>DAVIS</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[PSYCHIATRY]]></ORG_DEPT><ORG_DISTRICT>03</ORG_DISTRICT><ORG_DUNS>047120084</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIVERSITY OF CALIFORNIA AT DAVIS]]></ORG_NAME><ORG_STATE>CA</ORG_STATE><ORG_ZIPCODE>956186153</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Antibodies directed at one's own body cause a variety of autoimmune diseases such as rheumatoid arthritis, multiple sclerosis and systemic lupus erythematosus. During pregnancy, autoimmune disease can affect the fetus in syndromes such as Graves disease and myasthenia gravis. This application is for funding to study if, and when, antibodies in pregnant rhesus monkeys cross the placenta and ultimately enter the fetal brain. The outcome of this research will have important implications for our proposal that anti-brain antibodies may be one cause of psychiatric illnesses such as autism spectrum disorder.]]></PHR><PIS><PI><PI_NAME>AMARAL, DAVID G</PI_NAME><PI_ID>1857963</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>DESMOND, NANCY L</PROGRAM_OFFICER_NAME><PROJECT_START>11/18/2014</PROJECT_START><PROJECT_END>10/31/2016</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Acute]]></TERM><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[Age]]></TERM><TERM><![CDATA[Animal Model]]></TERM><TERM><![CDATA[Animals]]></TERM><TERM><![CDATA[Antibodies]]></TERM><TERM><![CDATA[autism spectrum disorder]]></TERM><TERM><![CDATA[Autoimmune Diseases]]></TERM><TERM><![CDATA[Behavior]]></TERM><TERM><![CDATA[Behavioral]]></TERM><TERM><![CDATA[Binding (Molecular Function)]]></TERM><TERM><![CDATA[Birth]]></TERM><TERM><![CDATA[Blood]]></TERM><TERM><![CDATA[Blood Circulation]]></TERM><TERM><![CDATA[Brain]]></TERM><TERM><![CDATA[Brain Pathology]]></TERM><TERM><![CDATA[brain tissue]]></TERM><TERM><![CDATA[Child]]></TERM><TERM><![CDATA[Collection]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Diamond]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Dissection]]></TERM><TERM><![CDATA[Dose]]></TERM><TERM><![CDATA[Drug Kinetics]]></TERM><TERM><![CDATA[Evaluation]]></TERM><TERM><![CDATA[Exposure to]]></TERM><TERM><![CDATA[fetal]]></TERM><TERM><![CDATA[fetal blood]]></TERM><TERM><![CDATA[Fetal development of the mammalian embryo or fetus]]></TERM><TERM><![CDATA[Fetal Tissues]]></TERM><TERM><![CDATA[Fetus]]></TERM><TERM><![CDATA[Funding]]></TERM><TERM><![CDATA[Gamma counter]]></TERM><TERM><![CDATA[Gene Proteins]]></TERM><TERM><![CDATA[Glycoproteins]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Growth]]></TERM><TERM><![CDATA[Growth and Development function]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[human subject]]></TERM><TERM><![CDATA[Image]]></TERM><TERM><![CDATA[Immune response]]></TERM><TERM><![CDATA[Immunoglobulin G]]></TERM><TERM><![CDATA[Immunology]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[Injection of therapeutic agent]]></TERM><TERM><![CDATA[interest]]></TERM><TERM><![CDATA[intravenous injection]]></TERM><TERM><![CDATA[Label]]></TERM><TERM><![CDATA[Life]]></TERM><TERM><![CDATA[longitudinal positron emission tomography]]></TERM><TERM><![CDATA[Macaca mulatta]]></TERM><TERM><![CDATA[Maternal antibody]]></TERM><TERM><![CDATA[meetings]]></TERM><TERM><![CDATA[Membrane]]></TERM><TERM><![CDATA[Membrane Proteins]]></TERM><TERM><![CDATA[Memory impairment]]></TERM><TERM><![CDATA[Mental disorders]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Monitor]]></TERM><TERM><![CDATA[Monkeys]]></TERM><TERM><![CDATA[Monoclonal Antibodies]]></TERM><TERM><![CDATA[Mothers]]></TERM><TERM><![CDATA[Multiple Sclerosis]]></TERM><TERM><![CDATA[Myasthenia Gravis]]></TERM><TERM><![CDATA[nervous system disorder]]></TERM><TERM><![CDATA[Neuraxis]]></TERM><TERM><![CDATA[Neurons]]></TERM><TERM><![CDATA[Neurosciences]]></TERM><TERM><![CDATA[nonhuman primate]]></TERM><TERM><![CDATA[offspring]]></TERM><TERM><![CDATA[Outcomes Research]]></TERM><TERM><![CDATA[Paper]]></TERM><TERM><![CDATA[Patient currently pregnant]]></TERM><TERM><![CDATA[Phase]]></TERM><TERM><![CDATA[Placenta]]></TERM><TERM><![CDATA[Positron-Emission Tomography]]></TERM><TERM><![CDATA[Pregnancy]]></TERM><TERM><![CDATA[pregnant]]></TERM><TERM><![CDATA[Protein Databases]]></TERM><TERM><![CDATA[Proteins]]></TERM><TERM><![CDATA[Protocols documentation]]></TERM><TERM><![CDATA[Publications]]></TERM><TERM><![CDATA[Radioactivity]]></TERM><TERM><![CDATA[Recruitment Activity]]></TERM><TERM><![CDATA[Research Personnel]]></TERM><TERM><![CDATA[research study]]></TERM><TERM><![CDATA[Rheumatoid Arthritis]]></TERM><TERM><![CDATA[Second Pregnancy Trimester]]></TERM><TERM><![CDATA[Staging]]></TERM><TERM><![CDATA[Surface]]></TERM><TERM><![CDATA[Syndrome]]></TERM><TERM><![CDATA[Systemic Lupus Erythematosus]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Third Pregnancy Trimester]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[Tissue Harvesting]]></TERM><TERM><![CDATA[Tissues]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[DETECTING THE TRANSFER OF MATERNAL ANTIBODIES INTO THE FETAL RHESUS MONKEY BRAIN]]></PROJECT_TITLE><SERIAL_NUMBER>105734</SERIAL_NUMBER><STUDY_SECTION>DBD</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Developmental Brain Disorders Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>112500</DIRECT_COST_AMT><INDIRECT_COST_AMT>63655</INDIRECT_COST_AMT><TOTAL_COST>176155</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8972032</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>HL</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/04/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>837</CFDA_CODE><CORE_PROJECT_NUM>R01HL122822</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-13-302</FOA_NUMBER><FULL_PROJECT_NUM>5R01HL122822-02</FULL_PROJECT_NUM><FUNDING_ICs>NHLBI:469576\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL HEART, LUNG, AND BLOOD INSTITUTE</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>NEW HAVEN</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[INTERNAL MEDICINE/MEDICINE]]></ORG_DEPT><ORG_DISTRICT>03</ORG_DISTRICT><ORG_DUNS>043207562</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[YALE UNIVERSITY]]></ORG_NAME><ORG_STATE>CT</ORG_STATE><ORG_ZIPCODE>065113572</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Hyperlipidemia is a major risk factor for coronary artery disease. We recently identified a mutation in a gene called LRP6, which causes early blockages of heart arteries, and hyperlipidemia. The current proposal studies the mechanism of hyperlipidemia in a mouse model of this mutation in order to identify novel drug targets.]]></PHR><PIS><PI><PI_NAME>MANI, ARYA </PI_NAME><PI_ID>6798779</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>LIU, LIJUAN </PROGRAM_OFFICER_NAME><PROJECT_START>11/19/2014</PROJECT_START><PROJECT_END>10/31/2018</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Accounting]]></TERM><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[Animal Model]]></TERM><TERM><![CDATA[Apolipoproteins B]]></TERM><TERM><![CDATA[Atherosclerosis]]></TERM><TERM><![CDATA[biological systems]]></TERM><TERM><![CDATA[Cardiovascular Diseases]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Cholesterol]]></TERM><TERM><![CDATA[Clinical Research]]></TERM><TERM><![CDATA[Combined Modality Therapy]]></TERM><TERM><![CDATA[Coronary Arteriosclerosis]]></TERM><TERM><![CDATA[Coronary artery]]></TERM><TERM><![CDATA[Crossbreeding]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Diabetes Mellitus]]></TERM><TERM><![CDATA[Diet]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Disease Pathway]]></TERM><TERM><![CDATA[Drug Targeting]]></TERM><TERM><![CDATA[early onset]]></TERM><TERM><![CDATA[Exhibits]]></TERM><TERM><![CDATA[Familial Combined Hyperlipidemia]]></TERM><TERM><![CDATA[Fatty Liver]]></TERM><TERM><![CDATA[Functional disorder]]></TERM><TERM><![CDATA[General Population]]></TERM><TERM><![CDATA[Genes]]></TERM><TERM><![CDATA[Genetic Predisposition to Disease]]></TERM><TERM><![CDATA[genetic variant]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Hepatic]]></TERM><TERM><![CDATA[Hepatocyte]]></TERM><TERM><![CDATA[Heterozygote]]></TERM><TERM><![CDATA[Homeostasis]]></TERM><TERM><![CDATA[Homozygote]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[human disease]]></TERM><TERM><![CDATA[human FRAP1 protein]]></TERM><TERM><![CDATA[Hyperlipidemia]]></TERM><TERM><![CDATA[IGF1 gene]]></TERM><TERM><![CDATA[IGF1R gene]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[Insulin]]></TERM><TERM><![CDATA[insulin signaling]]></TERM><TERM><![CDATA[Investigation]]></TERM><TERM><![CDATA[Knock-out]]></TERM><TERM><![CDATA[Knockout Mice]]></TERM><TERM><![CDATA[LDL Cholesterol Lipoproteins]]></TERM><TERM><![CDATA[Link]]></TERM><TERM><![CDATA[lipid biosynthesis]]></TERM><TERM><![CDATA[lipid disorder]]></TERM><TERM><![CDATA[Lipids]]></TERM><TERM><![CDATA[Lipoproteins]]></TERM><TERM><![CDATA[Liver]]></TERM><TERM><![CDATA[Liver diseases]]></TERM><TERM><![CDATA[loss of function mutation]]></TERM><TERM><![CDATA[low density lipoprotein triglyceride]]></TERM><TERM><![CDATA[Low-Density Lipoproteins]]></TERM><TERM><![CDATA[Mediator of activation protein]]></TERM><TERM><![CDATA[Metabolic]]></TERM><TERM><![CDATA[Metabolic syndrome]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[mouse model]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[Mutation]]></TERM><TERM><![CDATA[Non-Insulin-Dependent Diabetes Mellitus]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[novel therapeutics]]></TERM><TERM><![CDATA[Online Mendelian Inheritance In Man]]></TERM><TERM><![CDATA[overexpression]]></TERM><TERM><![CDATA[Pathway interactions]]></TERM><TERM><![CDATA[Phenotype]]></TERM><TERM><![CDATA[Phosphorylation]]></TERM><TERM><![CDATA[Plasma]]></TERM><TERM><![CDATA[Point Mutation]]></TERM><TERM><![CDATA[prevent]]></TERM><TERM><![CDATA[Proteins]]></TERM><TERM><![CDATA[Proto-Oncogene Proteins c-akt]]></TERM><TERM><![CDATA[Regulation]]></TERM><TERM><![CDATA[Risk]]></TERM><TERM><![CDATA[Risk Factors]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Science]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[TCF7L2 gene]]></TERM><TERM><![CDATA[Therapeutic Agents]]></TERM><TERM><![CDATA[therapeutic development]]></TERM><TERM><![CDATA[transcription factor]]></TERM><TERM><![CDATA[Triglycerides]]></TERM><TERM><![CDATA[Variant]]></TERM><TERM><![CDATA[Very low density lipoprotein]]></TERM><TERM><![CDATA[Wnt proteins]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Hepatic Wnt/LRP6 Regulation of Plasma Lipids]]></PROJECT_TITLE><SERIAL_NUMBER>122822</SERIAL_NUMBER><STUDY_SECTION>CADO</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Cellular Aspects of Diabetes and Obesity Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>289488</DIRECT_COST_AMT><INDIRECT_COST_AMT>180088</INDIRECT_COST_AMT><TOTAL_COST>469576</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8973566</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>HL</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/27/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>837</CFDA_CODE><CORE_PROJECT_NUM>R01HL063030</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-13-302</FOA_NUMBER><FULL_PROJECT_NUM>5R01HL063030-11</FULL_PROJECT_NUM><FUNDING_ICs>NHLBI:364500\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL HEART, LUNG, AND BLOOD INSTITUTE</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>BALTIMORE</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[INTERNAL MEDICINE/MEDICINE]]></ORG_DEPT><ORG_DISTRICT>07</ORG_DISTRICT><ORG_DUNS>001910777</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[JOHNS HOPKINS UNIVERSITY]]></ORG_NAME><ORG_STATE>MD</ORG_STATE><ORG_ZIPCODE>212051832</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: The heart uses chemical energy to fuel muscle contraction and support the body's functions at rest and during stress/exercise. This proposal will study the role of creatine kinase, a major energy reserve reaction, under conditions of stress and heart failure. These studies will evaluate the mechanisms by which creatine kinase could improve energy metabolism and heart function in the failing heart and, as such are timely, practical questions that could significantly impact heart failure morbidity and mortality.]]></PHR><PIS><PI><PI_NAME>WEISS, ROBERT G</PI_NAME><PI_ID>1916091</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>ADHIKARI, BISHOW B.</PROGRAM_OFFICER_NAME><PROJECT_START>04/01/2000</PROJECT_START><PROJECT_END>10/31/2018</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[adrenergic]]></TERM><TERM><![CDATA[Adrenergic Agents]]></TERM><TERM><![CDATA[Adriamycin PFS]]></TERM><TERM><![CDATA[Adverse effects]]></TERM><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[American]]></TERM><TERM><![CDATA[ATP Synthesis Pathway]]></TERM><TERM><![CDATA[Calcium]]></TERM><TERM><![CDATA[Cardiac]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Cessation of life]]></TERM><TERM><![CDATA[Chemicals]]></TERM><TERM><![CDATA[Chest]]></TERM><TERM><![CDATA[Chronic]]></TERM><TERM><![CDATA[Cicatrix]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[clinically relevant]]></TERM><TERM><![CDATA[Conflict (Psychology)]]></TERM><TERM><![CDATA[constriction]]></TERM><TERM><![CDATA[cost]]></TERM><TERM><![CDATA[Creatine]]></TERM><TERM><![CDATA[Creatine Kinase]]></TERM><TERM><![CDATA[Creatine Kinase MB Isoenzyme]]></TERM><TERM><![CDATA[Depressed mood]]></TERM><TERM><![CDATA[Diagnosis]]></TERM><TERM><![CDATA[Energy Metabolism]]></TERM><TERM><![CDATA[Event]]></TERM><TERM><![CDATA[Exercise]]></TERM><TERM><![CDATA[Exercise Tolerance]]></TERM><TERM><![CDATA[Exhibits]]></TERM><TERM><![CDATA[Functional disorder]]></TERM><TERM><![CDATA[Funding]]></TERM><TERM><![CDATA[Genes]]></TERM><TERM><![CDATA[genetic manipulation]]></TERM><TERM><![CDATA[Guanidinoacetate N-Methyltransferase]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Heart]]></TERM><TERM><![CDATA[Heart Diseases]]></TERM><TERM><![CDATA[Heart failure]]></TERM><TERM><![CDATA[heart function]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[Image]]></TERM><TERM><![CDATA[Imaging technology]]></TERM><TERM><![CDATA[Impairment]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[inorganic phosphate]]></TERM><TERM><![CDATA[insight]]></TERM><TERM><![CDATA[Knock-out]]></TERM><TERM><![CDATA[Left]]></TERM><TERM><![CDATA[Left Ventricular Function]]></TERM><TERM><![CDATA[Link]]></TERM><TERM><![CDATA[Magnetic Resonance Imaging]]></TERM><TERM><![CDATA[Magnetic Resonance Spectroscopy]]></TERM><TERM><![CDATA[Medicare]]></TERM><TERM><![CDATA[Metabolic]]></TERM><TERM><![CDATA[Metabolism]]></TERM><TERM><![CDATA[Mitochondria]]></TERM><TERM><![CDATA[MM form creatine kinase]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Morbidity - disease rate]]></TERM><TERM><![CDATA[Mortality Vital Statistics]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[Muscle Cells]]></TERM><TERM><![CDATA[Muscle Contraction]]></TERM><TERM><![CDATA[Myocardial]]></TERM><TERM><![CDATA[Myocardial dysfunction]]></TERM><TERM><![CDATA[Myocardial Infarction]]></TERM><TERM><![CDATA[Myocardium]]></TERM><TERM><![CDATA[Necrosis]]></TERM><TERM><![CDATA[overexpression]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Phosphocreatine]]></TERM><TERM><![CDATA[Play]]></TERM><TERM><![CDATA[Production]]></TERM><TERM><![CDATA[Protein Isoforms]]></TERM><TERM><![CDATA[public health medicine (field)]]></TERM><TERM><![CDATA[Reaction]]></TERM><TERM><![CDATA[Reactive Oxygen Species]]></TERM><TERM><![CDATA[Reporting]]></TERM><TERM><![CDATA[Residual state]]></TERM><TERM><![CDATA[Rest]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Signal Pathway]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[Site]]></TERM><TERM><![CDATA[Stress]]></TERM><TERM><![CDATA[Techniques]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Therapeutic]]></TERM><TERM><![CDATA[Transgenic Mice]]></TERM><TERM><![CDATA[Transgenic Organisms]]></TERM><TERM><![CDATA[treatment strategy]]></TERM><TERM><![CDATA[Ventricular]]></TERM><TERM><![CDATA[Ventricular Function]]></TERM><TERM><![CDATA[Ventricular Remodeling]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Creatine Kinase Metabolism in Failing Murine Hearts]]></PROJECT_TITLE><SERIAL_NUMBER>063030</SERIAL_NUMBER><STUDY_SECTION>ZRG1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>11</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>225000</DIRECT_COST_AMT><INDIRECT_COST_AMT>139500</INDIRECT_COST_AMT><TOTAL_COST>364500</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9003823</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>MH</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/03/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>242</CFDA_CODE><CORE_PROJECT_NUM>R01MH062349</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF ARTS AND SCIENCES]]></ED_INST_TYPE><FOA_NUMBER>PA-11-260</FOA_NUMBER><FULL_PROJECT_NUM>5R01MH062349-14</FULL_PROJECT_NUM><FUNDING_ICs>NIMH:334893\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF MENTAL HEALTH</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>NEW YORK</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[NEUROLOGY]]></ORG_DEPT><ORG_DISTRICT>12</ORG_DISTRICT><ORG_DUNS>041968306</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[NEW YORK UNIVERSITY]]></ORG_NAME><ORG_STATE>NY</ORG_STATE><ORG_ZIPCODE>100122300</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Impaired behavioral flexibility and executive control are robust characteristics of schizophrenic and ADHD patients. The parieto-frontal circuitry has been demonstrated to be critical for decision-making and inhibitory control of action, both in human imaging studies and animal physiological experiments. However, we still do not understand core computations and their underlying mechanisms. Brain circuit modeling proposed in this application, with a focus on the parieto-frontal system, will elucidate gating mechanisms that underlie flexible visuo-motor behavior. It will be capable of accounting for single-neuron data and performance data from behaving animals, and provide a platform to elucidate the brain circuit mechanisms of different types of behavioral errors observed in humans. By uncovering the required biological mechanisms for flexible behavior, our work has a high potential for understanding molecular and circuit abnormalities that cause these cognitive deficits associated with mental illness like Schizophrenia and ADHD.]]></PHR><PIS><PI><PI_NAME>WANG, XIAO-JING </PI_NAME><PI_ID>1891037</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>ROSSI, ANDREW </PROGRAM_OFFICER_NAME><PROJECT_START>12/01/2000</PROJECT_START><PROJECT_END>10/31/2017</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Accounting]]></TERM><TERM><![CDATA[Animals]]></TERM><TERM><![CDATA[Attention deficit hyperactivity disorder]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Base of the Brain]]></TERM><TERM><![CDATA[Behavior]]></TERM><TERM><![CDATA[Behavioral]]></TERM><TERM><![CDATA[Biological]]></TERM><TERM><![CDATA[Brain]]></TERM><TERM><![CDATA[Characteristics]]></TERM><TERM><![CDATA[Code]]></TERM><TERM><![CDATA[Cognition]]></TERM><TERM><![CDATA[Cognitive deficits]]></TERM><TERM><![CDATA[Collaborations]]></TERM><TERM><![CDATA[Color]]></TERM><TERM><![CDATA[Complex]]></TERM><TERM><![CDATA[Cues]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Decision Making]]></TERM><TERM><![CDATA[Discrimination (Psychology)]]></TERM><TERM><![CDATA[Equilibrium]]></TERM><TERM><![CDATA[executive function]]></TERM><TERM><![CDATA[flexibility]]></TERM><TERM><![CDATA[Functional disorder]]></TERM><TERM><![CDATA[Future]]></TERM><TERM><![CDATA[gaze]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[Image]]></TERM><TERM><![CDATA[information processing]]></TERM><TERM><![CDATA[insight]]></TERM><TERM><![CDATA[Laboratories]]></TERM><TERM><![CDATA[Maps]]></TERM><TERM><![CDATA[Mental disorders]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[Monkeys]]></TERM><TERM><![CDATA[Motion]]></TERM><TERM><![CDATA[Motor]]></TERM><TERM><![CDATA[Nature]]></TERM><TERM><![CDATA[network models]]></TERM><TERM><![CDATA[Network-based]]></TERM><TERM><![CDATA[neural circuit]]></TERM><TERM><![CDATA[Neurons]]></TERM><TERM><![CDATA[operation]]></TERM><TERM><![CDATA[Output]]></TERM><TERM><![CDATA[Pathway interactions]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Performance]]></TERM><TERM><![CDATA[Physiological]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[programs]]></TERM><TERM><![CDATA[Property]]></TERM><TERM><![CDATA[Recurrence]]></TERM><TERM><![CDATA[regenerative]]></TERM><TERM><![CDATA[relating to nervous system]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[research study]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[Rewards]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Saccades]]></TERM><TERM><![CDATA[Schizophrenia]]></TERM><TERM><![CDATA[Sensory]]></TERM><TERM><![CDATA[sensory stimulus]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[Staging]]></TERM><TERM><![CDATA[Stimulus]]></TERM><TERM><![CDATA[Synaptic plasticity]]></TERM><TERM><![CDATA[System]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[Weather]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Gated sensori-motor mapping and cortical circuit reconfiguration in flexible deci]]></PROJECT_TITLE><SERIAL_NUMBER>062349</SERIAL_NUMBER><STUDY_SECTION>SMI</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Sensorimotor Integration Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>14</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>225000</DIRECT_COST_AMT><INDIRECT_COST_AMT>109893</INDIRECT_COST_AMT><TOTAL_COST>334893</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9050845</APPLICATION_ID><ACTIVITY>F31</ACTIVITY><ADMINISTERING_IC>NR</ADMINISTERING_IC><APPLICATION_TYPE>1</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>09/18/2015</AWARD_NOTICE_DATE><BUDGET_START>09/30/2015</BUDGET_START><BUDGET_END>09/29/2016</BUDGET_END><CFDA_CODE>361</CFDA_CODE><CORE_PROJECT_NUM>F31NR015686</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF NURSING]]></ED_INST_TYPE><FOA_NUMBER>PA-14-147</FOA_NUMBER><FULL_PROJECT_NUM>1F31NR015686-01A1</FULL_PROJECT_NUM><FUNDING_ICs>NINR:43120\</FUNDING_ICs><FUNDING_MECHANISM>TRAINING, INDIVIDUAL</FUNDING_MECHANISM><FY>2015</FY><IC_NAME>NATIONAL INSTITUTE OF NURSING RESEARCH</IC_NAME><NIH_SPENDING_CATS><CATEGORY><![CDATA[Behavioral and Social Science]]></CATEGORY><CATEGORY><![CDATA[Cancer]]></CATEGORY><CATEGORY><![CDATA[Clinical Research]]></CATEGORY><CATEGORY><![CDATA[Mental Health]]></CATEGORY><CATEGORY><![CDATA[Sleep Research]]></CATEGORY></NIH_SPENDING_CATS><ORG_CITY>DURHAM</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[NONE]]></ORG_DEPT><ORG_DISTRICT>01</ORG_DISTRICT><ORG_DUNS>044387793</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[DUKE UNIVERSITY]]></ORG_NAME><ORG_STATE>NC</ORG_STATE><ORG_ZIPCODE>277054673</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: When melanoma and renal cancer patients receive treatment for their disease with an immunotherapy drug, high-dose Interleukin-2 (IL-2), they might experience severe changes in behavior, memory, communication or sleep. The cause of these changes is unclear and needs further study; therefore, in order to prevent or lessen the symptoms from IL-2 treatment, a deeper understanding of what the symptoms are and the degree to which they are experienced is needed. This study will describe these symptoms from patients', their care partners' and their nurses' points of view, and results from this study will contribute to the knowledge needed to minimize the symptoms related to IL-2 therapy to improve the patient's quality of life, treatment adherence, and safety while potentially allowing the patient to receive adequate treatment for their cancer.   
      

]]></PHR><PIS><PI><PI_NAME>MANN, TARA KAUR</PI_NAME><PI_ID>12239122</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>BANKS, DAVID </PROGRAM_OFFICER_NAME><PROJECT_START>09/30/2015</PROJECT_START><PROJECT_END>09/29/2018</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Admission activity]]></TERM><TERM><![CDATA[Adverse effects]]></TERM><TERM><![CDATA[Affective]]></TERM><TERM><![CDATA[Aftercare]]></TERM><TERM><![CDATA[Aggressive behavior]]></TERM><TERM><![CDATA[Anxiety]]></TERM><TERM><![CDATA[Arithmetic]]></TERM><TERM><![CDATA[Attention]]></TERM><TERM><![CDATA[Attention Concentration]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Behavior]]></TERM><TERM><![CDATA[Bolus Infusion]]></TERM><TERM><![CDATA[Cancer Patient]]></TERM><TERM><![CDATA[Cancerous]]></TERM><TERM><![CDATA[Caring]]></TERM><TERM><![CDATA[Case Study]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Cessation of life]]></TERM><TERM><![CDATA[Characteristics]]></TERM><TERM><![CDATA[chemotherapy]]></TERM><TERM><![CDATA[Cognitive]]></TERM><TERM><![CDATA[Coma]]></TERM><TERM><![CDATA[Communication]]></TERM><TERM><![CDATA[Confusion]]></TERM><TERM><![CDATA[cytokine]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[Diagnosis]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Disease remission]]></TERM><TERM><![CDATA[disturbance in affect]]></TERM><TERM><![CDATA[Dose]]></TERM><TERM><![CDATA[Early treatment]]></TERM><TERM><![CDATA[executive function]]></TERM><TERM><![CDATA[experience]]></TERM><TERM><![CDATA[Feeling suicidal]]></TERM><TERM><![CDATA[fighting]]></TERM><TERM><![CDATA[Future]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Hallucinations]]></TERM><TERM><![CDATA[Hospitalization]]></TERM><TERM><![CDATA[Hospitals]]></TERM><TERM><![CDATA[Immune system]]></TERM><TERM><![CDATA[Immunotherapy]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[Initial Insomnia]]></TERM><TERM><![CDATA[Interleukin-2]]></TERM><TERM><![CDATA[Intervention]]></TERM><TERM><![CDATA[Interview]]></TERM><TERM><![CDATA[Kidney]]></TERM><TERM><![CDATA[Knowledge]]></TERM><TERM><![CDATA[Language]]></TERM><TERM><![CDATA[Length]]></TERM><TERM><![CDATA[Life]]></TERM><TERM><![CDATA[Malignant Neoplasms]]></TERM><TERM><![CDATA[Measures]]></TERM><TERM><![CDATA[Medical]]></TERM><TERM><![CDATA[melanoma]]></TERM><TERM><![CDATA[Memory]]></TERM><TERM><![CDATA[Mental Depression]]></TERM><TERM><![CDATA[Mental Fatigue]]></TERM><TERM><![CDATA[Metastatic Melanoma]]></TERM><TERM><![CDATA[Metastatic Renal Cell Cancer]]></TERM><TERM><![CDATA[Methods]]></TERM><TERM><![CDATA[National Cancer Institute]]></TERM><TERM><![CDATA[Neoplasm Metastasis]]></TERM><TERM><![CDATA[Nurses]]></TERM><TERM><![CDATA[Operative Surgical Procedures]]></TERM><TERM><![CDATA[Patient Care]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Pattern]]></TERM><TERM><![CDATA[Pharmaceutical Preparations]]></TERM><TERM><![CDATA[prevent]]></TERM><TERM><![CDATA[Psychotic Disorders]]></TERM><TERM><![CDATA[public health relevance]]></TERM><TERM><![CDATA[Quality of life]]></TERM><TERM><![CDATA[Radiation therapy]]></TERM><TERM><![CDATA[Renal carcinoma]]></TERM><TERM><![CDATA[Reporting]]></TERM><TERM><![CDATA[Research Design]]></TERM><TERM><![CDATA[Residual state]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[Safety]]></TERM><TERM><![CDATA[Science]]></TERM><TERM><![CDATA[Secondary to]]></TERM><TERM><![CDATA[Severities]]></TERM><TERM><![CDATA[Short-Term Memory]]></TERM><TERM><![CDATA[Side]]></TERM><TERM><![CDATA[Sleep]]></TERM><TERM><![CDATA[Sleep disturbances]]></TERM><TERM><![CDATA[Sleeplessness]]></TERM><TERM><![CDATA[Staging]]></TERM><TERM><![CDATA[Symptoms]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[treatment adherence]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Investigating Cognitive/Affective/Sleep Symptoms during High-Dose Interleukin-2 Therapy]]></PROJECT_TITLE><SERIAL_NUMBER>015686</SERIAL_NUMBER><STUDY_SECTION>NRRC</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[National Institute of Nursing Research Initial Review Group ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>01</SUPPORT_YEAR><SUFFIX>A1</SUFFIX><DIRECT_COST_AMT>43120</DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>43120</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9051763</APPLICATION_ID><ACTIVITY>F32</ACTIVITY><ADMINISTERING_IC>NS</ADMINISTERING_IC><APPLICATION_TYPE>1</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>09/18/2015</AWARD_NOTICE_DATE><BUDGET_START>09/01/2015</BUDGET_START><BUDGET_END>08/31/2016</BUDGET_END><CFDA_CODE>853</CFDA_CODE><CORE_PROJECT_NUM>F32NS095690</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF ARTS AND SCIENCES]]></ED_INST_TYPE><FOA_NUMBER>PA-14-149</FOA_NUMBER><FULL_PROJECT_NUM>1F32NS095690-01</FULL_PROJECT_NUM><FUNDING_ICs>NINDS:52406\</FUNDING_ICs><FUNDING_MECHANISM>TRAINING, INDIVIDUAL</FUNDING_MECHANISM><FY>2015</FY><IC_NAME>NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE</IC_NAME><NIH_SPENDING_CATS><CATEGORY><![CDATA[Neurosciences]]></CATEGORY></NIH_SPENDING_CATS><ORG_CITY>BERKELEY</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[BIOCHEMISTRY]]></ORG_DEPT><ORG_DISTRICT>13</ORG_DISTRICT><ORG_DUNS>124726725</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIVERSITY OF CALIFORNIA BERKELEY]]></ORG_NAME><ORG_STATE>CA</ORG_STATE><ORG_ZIPCODE>947045940</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Our brains are a computational machine that take input from our sensory organs and encode information to generate sensation, allowing us to experience the natural world. Fundamental gaps remain in our basic understanding of these neural codes that, if filled, could open the door to new generations of therapies for people who suffer from neurological disorders. In this proposal we will develop and use cutting edge optical technology to investigate the basic nature of neural codes underlying sensation.   
   
      

]]></PHR><PIS><PI><PI_NAME>MARDINLY, ALAN ROBERT</PI_NAME><PI_ID>12181260</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>GNADT, JAMES W</PROGRAM_OFFICER_NAME><PROJECT_START>09/01/2015</PROJECT_START><PROJECT_END>08/31/2018</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Action Potentials]]></TERM><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[Animals]]></TERM><TERM><![CDATA[awake]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Behavior]]></TERM><TERM><![CDATA[Brain]]></TERM><TERM><![CDATA[Calcium]]></TERM><TERM><![CDATA[Code]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Detection]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Dimensions]]></TERM><TERM><![CDATA[Esthesia]]></TERM><TERM><![CDATA[experience]]></TERM><TERM><![CDATA[Generations]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Image]]></TERM><TERM><![CDATA[Investigation]]></TERM><TERM><![CDATA[Measures]]></TERM><TERM><![CDATA[Microscopy]]></TERM><TERM><![CDATA[millisecond]]></TERM><TERM><![CDATA[Monitor]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[Nature]]></TERM><TERM><![CDATA[nervous system disorder]]></TERM><TERM><![CDATA[neural patterning]]></TERM><TERM><![CDATA[Neurobiology]]></TERM><TERM><![CDATA[neuronal patterning]]></TERM><TERM><![CDATA[Neurons]]></TERM><TERM><![CDATA[neuroregulation]]></TERM><TERM><![CDATA[Optics]]></TERM><TERM><![CDATA[optogenetics]]></TERM><TERM><![CDATA[Organ]]></TERM><TERM><![CDATA[Pattern]]></TERM><TERM><![CDATA[Perception]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[public health relevance]]></TERM><TERM><![CDATA[relating to nervous system]]></TERM><TERM><![CDATA[Relative (related person)]]></TERM><TERM><![CDATA[Resolution]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Sensory]]></TERM><TERM><![CDATA[sensory cortex]]></TERM><TERM><![CDATA[sensory discrimination]]></TERM><TERM><![CDATA[Slice]]></TERM><TERM><![CDATA[spatiotemporal]]></TERM><TERM><![CDATA[Stimulus]]></TERM><TERM><![CDATA[System]]></TERM><TERM><![CDATA[Technology]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[Training]]></TERM><TERM><![CDATA[two-photon]]></TERM><TERM><![CDATA[Vibrissae]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Holographic control of neural ensembles during sensation]]></PROJECT_TITLE><SERIAL_NUMBER>095690</SERIAL_NUMBER><STUDY_SECTION>ZRG1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>01</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>52406</DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>52406</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9054630</APPLICATION_ID><ACTIVITY>U54</ACTIVITY><ADMINISTERING_IC>HD</ADMINISTERING_IC><APPLICATION_TYPE>1</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/30/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>865</CFDA_CODE><CORE_PROJECT_NUM>U54HD086984</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-HD-15-033</FOA_NUMBER><FULL_PROJECT_NUM>1U54HD086984-01</FULL_PROJECT_NUM><FUNDING_ICs>NICHD:1145899\</FUNDING_ICs><FUNDING_MECHANISM>RESEARCH CENTERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &amp; HUMAN DEVELOPMENT</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>PHILADELPHIA</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>02</ORG_DISTRICT><ORG_DUNS>073757627</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[CHILDREN'S HOSP OF PHILADELPHIA]]></ORG_NAME><ORG_STATE>PA</ORG_STATE><ORG_ZIPCODE>191044318</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Funding for the IDDRC at CHOP/Penn will advance research into the causes and treatment of the developmental disabilities. The Center advances this agenda with these initiatives: (a) A research project to develop a novel biomarker for language disability in autism; (b) Providing research support to the faculty at CHOP/Penn; (c) Creating and nurturing a true IDD Research Community; (d) Mentoring and supporting promising young investigators who want to enter the field of IDD research; (e) Creating research Centers of Excellence to favor inter-disciplinary investigations into IDD; and (f) Constructively partnering with the IDDRC Network to realize the goals of the IDD branch of NICHD.      

]]></PHR><PIS><PI><PI_NAME>YUDKOFF, MARC </PI_NAME><PI_ID>1876167</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>PARISI, MELISSA </PROGRAM_OFFICER_NAME><PROJECT_START>11/01/2015</PROJECT_START><PROJECT_END>05/31/2020</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Advocacy]]></TERM><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[Attenuated]]></TERM><TERM><![CDATA[authority]]></TERM><TERM><![CDATA[autism spectrum disorder]]></TERM><TERM><![CDATA[Autistic Disorder]]></TERM><TERM><![CDATA[Award]]></TERM><TERM><![CDATA[Biochemistry]]></TERM><TERM><![CDATA[Bioinformatics]]></TERM><TERM><![CDATA[Biological Markers]]></TERM><TERM><![CDATA[Brain]]></TERM><TERM><![CDATA[brain behavior]]></TERM><TERM><![CDATA[career]]></TERM><TERM><![CDATA[career development]]></TERM><TERM><![CDATA[Centers of Research Excellence]]></TERM><TERM><![CDATA[Chalk]]></TERM><TERM><![CDATA[Child]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[Clinical Oncology Supplement (K12)]]></TERM><TERM><![CDATA[Collaborations]]></TERM><TERM><![CDATA[Communities]]></TERM><TERM><![CDATA[Complement]]></TERM><TERM><![CDATA[Core Facility]]></TERM><TERM><![CDATA[cost effective]]></TERM><TERM><![CDATA[cost effectiveness]]></TERM><TERM><![CDATA[Cultural Diversity]]></TERM><TERM><![CDATA[Developmental Disabilities]]></TERM><TERM><![CDATA[disability]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Dissection]]></TERM><TERM><![CDATA[Educational aspects]]></TERM><TERM><![CDATA[Electronic Mail]]></TERM><TERM><![CDATA[Electronics]]></TERM><TERM><![CDATA[Evolution]]></TERM><TERM><![CDATA[experience]]></TERM><TERM><![CDATA[Faculty]]></TERM><TERM><![CDATA[Family]]></TERM><TERM><![CDATA[Feeling]]></TERM><TERM><![CDATA[Fellowship]]></TERM><TERM><![CDATA[Fostering]]></TERM><TERM><![CDATA[Foundations]]></TERM><TERM><![CDATA[Funding]]></TERM><TERM><![CDATA[Future]]></TERM><TERM><![CDATA[gene therapy]]></TERM><TERM><![CDATA[Genes]]></TERM><TERM><![CDATA[Genetic]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Grant]]></TERM><TERM><![CDATA[Head]]></TERM><TERM><![CDATA[Health Policy]]></TERM><TERM><![CDATA[Health Services]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[innovation]]></TERM><TERM><![CDATA[Intellectual functioning disability]]></TERM><TERM><![CDATA[Interdisciplinary Study]]></TERM><TERM><![CDATA[Investigation]]></TERM><TERM><![CDATA[Knowledge]]></TERM><TERM><![CDATA[knowledge translation]]></TERM><TERM><![CDATA[Language Disorders]]></TERM><TERM><![CDATA[Leadership]]></TERM><TERM><![CDATA[lectures]]></TERM><TERM><![CDATA[Magnetoencephalography]]></TERM><TERM><![CDATA[Medical center]]></TERM><TERM><![CDATA[Medical Research]]></TERM><TERM><![CDATA[meetings]]></TERM><TERM><![CDATA[member]]></TERM><TERM><![CDATA[Mental Retardation and Developmental Disabilities Research Centers]]></TERM><TERM><![CDATA[Mentors]]></TERM><TERM><![CDATA[Mission]]></TERM><TERM><![CDATA[Mitochondrial Diseases]]></TERM><TERM><![CDATA[Modification]]></TERM><TERM><![CDATA[Mutation]]></TERM><TERM><![CDATA[National Institute of Child Health and Human Development]]></TERM><TERM><![CDATA[National Institute of Neurological Disorders and Stroke]]></TERM><TERM><![CDATA[Neonatal Screening]]></TERM><TERM><![CDATA[Neurodevelopmental Disability]]></TERM><TERM><![CDATA[neurophysiology]]></TERM><TERM><![CDATA[Neurosciences Research]]></TERM><TERM><![CDATA[new technology]]></TERM><TERM><![CDATA[Newsletter]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[Organizational Objectives]]></TERM><TERM><![CDATA[organizational structure]]></TERM><TERM><![CDATA[Outcome]]></TERM><TERM><![CDATA[Parents]]></TERM><TERM><![CDATA[patient advocacy group]]></TERM><TERM><![CDATA[Philadelphia]]></TERM><TERM><![CDATA[Pre-Clinical Model]]></TERM><TERM><![CDATA[prevent]]></TERM><TERM><![CDATA[Private Sector]]></TERM><TERM><![CDATA[Program Development]]></TERM><TERM><![CDATA[programs]]></TERM><TERM><![CDATA[Psyche structure]]></TERM><TERM><![CDATA[public health relevance]]></TERM><TERM><![CDATA[Publications]]></TERM><TERM><![CDATA[Quality Control]]></TERM><TERM><![CDATA[Rare Diseases]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[research facility]]></TERM><TERM><![CDATA[Research Personnel]]></TERM><TERM><![CDATA[Research Project Grants]]></TERM><TERM><![CDATA[Research Support]]></TERM><TERM><![CDATA[Resources]]></TERM><TERM><![CDATA[Science]]></TERM><TERM><![CDATA[Scientist]]></TERM><TERM><![CDATA[Series]]></TERM><TERM><![CDATA[Services]]></TERM><TERM><![CDATA[Severity of illness]]></TERM><TERM><![CDATA[Shapes]]></TERM><TERM><![CDATA[Source]]></TERM><TERM><![CDATA[Stem cells]]></TERM><TERM><![CDATA[Technology]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[therapy development]]></TERM><TERM><![CDATA[tool]]></TERM><TERM><![CDATA[Training]]></TERM><TERM><![CDATA[Training Programs]]></TERM><TERM><![CDATA[Translational Research]]></TERM><TERM><![CDATA[trend]]></TERM><TERM><![CDATA[Underrepresented Minority]]></TERM><TERM><![CDATA[urea cycle]]></TERM><TERM><![CDATA[Vocabulary]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[The Intellectual and Developmental Disabilities Research Center at CHOP/Penn]]></PROJECT_TITLE><SERIAL_NUMBER>086984</SERIAL_NUMBER><STUDY_SECTION>ZHD1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>01</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>827109</DIRECT_COST_AMT><INDIRECT_COST_AMT>472891</INDIRECT_COST_AMT><TOTAL_COST>1145899</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9056015</APPLICATION_ID><ACTIVITY>U54</ACTIVITY><ADMINISTERING_IC>HD</ADMINISTERING_IC><APPLICATION_TYPE>1</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/30/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>U54HD087101</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-HD-15-033</FOA_NUMBER><FULL_PROJECT_NUM>1U54HD087101-01</FULL_PROJECT_NUM><FUNDING_ICs>NICHD:320513\</FUNDING_ICs><FUNDING_MECHANISM>RESEARCH CENTERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &amp; HUMAN DEVELOPMENT</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>LOS ANGELES</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>33</ORG_DISTRICT><ORG_DUNS>092530369</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIVERSITY OF CALIFORNIA LOS ANGELES]]></ORG_NAME><ORG_STATE>CA</ORG_STATE><ORG_ZIPCODE>900952000</ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>BOOKHEIMER, SUSAN Y</PI_NAME><PI_ID>6250126</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>11/01/2015</PROJECT_START><PROJECT_END>05/31/2020</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[abstracting]]></TERM><TERM><![CDATA[Administrator]]></TERM><TERM><![CDATA[Advisory Committees]]></TERM><TERM><![CDATA[Advocacy]]></TERM><TERM><![CDATA[Animals]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Bioinformatics]]></TERM><TERM><![CDATA[Center for Translational Science Activities]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[Collaborations]]></TERM><TERM><![CDATA[Communities]]></TERM><TERM><![CDATA[cost efficient]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Databases]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Developmental Disabilities]]></TERM><TERM><![CDATA[digital]]></TERM><TERM><![CDATA[Discipline]]></TERM><TERM><![CDATA[dissemination research]]></TERM><TERM><![CDATA[Education and Outreach]]></TERM><TERM><![CDATA[Ensure]]></TERM><TERM><![CDATA[Environment]]></TERM><TERM><![CDATA[Evaluation]]></TERM><TERM><![CDATA[Faculty]]></TERM><TERM><![CDATA[Fostering]]></TERM><TERM><![CDATA[Funding]]></TERM><TERM><![CDATA[Funding Agency]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Grant]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[innovation]]></TERM><TERM><![CDATA[Institution]]></TERM><TERM><![CDATA[Intellectual functioning disability]]></TERM><TERM><![CDATA[Investigation]]></TERM><TERM><![CDATA[Leadership]]></TERM><TERM><![CDATA[meetings]]></TERM><TERM><![CDATA[Mental Retardation and Developmental Disabilities Research Centers]]></TERM><TERM><![CDATA[Mission]]></TERM><TERM><![CDATA[Monitor]]></TERM><TERM><![CDATA[multidisciplinary]]></TERM><TERM><![CDATA[NCI Scholars Program]]></TERM><TERM><![CDATA[neurodevelopment]]></TERM><TERM><![CDATA[Neurosciences Research]]></TERM><TERM><![CDATA[Occupational activity of managing finances]]></TERM><TERM><![CDATA[patient registry]]></TERM><TERM><![CDATA[programs]]></TERM><TERM><![CDATA[quality assurance]]></TERM><TERM><![CDATA[Reporting]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Research Activity]]></TERM><TERM><![CDATA[Research Infrastructure]]></TERM><TERM><![CDATA[Research Personnel]]></TERM><TERM><![CDATA[Resource Sharing]]></TERM><TERM><![CDATA[Resources]]></TERM><TERM><![CDATA[Scientist]]></TERM><TERM><![CDATA[Secure]]></TERM><TERM><![CDATA[Services]]></TERM><TERM><![CDATA[symposium]]></TERM><TERM><![CDATA[System]]></TERM><TERM><![CDATA[Training]]></TERM><TERM><![CDATA[Training and Education]]></TERM><TERM><![CDATA[Translational Research]]></TERM><TERM><![CDATA[Translations]]></TERM><TERM><![CDATA[Universities]]></TERM><TERM><![CDATA[Visit]]></TERM><TERM><![CDATA[Washington]]></TERM><TERM><![CDATA[web site]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[UCLA Center for Translational Research in Neurodevelopment (UC-TRaN): Administrative Core (Core A)]]></PROJECT_TITLE><SERIAL_NUMBER>087101</SERIAL_NUMBER><STUDY_SECTION>ZHD1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID>8265</SUBPROJECT_ID><SUPPORT_YEAR>01</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>208125</DIRECT_COST_AMT><INDIRECT_COST_AMT>112388</INDIRECT_COST_AMT><TOTAL_COST /><TOTAL_COST_SUB_PROJECT>320513</TOTAL_COST_SUB_PROJECT></row>
<row><APPLICATION_ID>9056016</APPLICATION_ID><ACTIVITY>U54</ACTIVITY><ADMINISTERING_IC>HD</ADMINISTERING_IC><APPLICATION_TYPE>1</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/30/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>U54HD087101</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-HD-15-033</FOA_NUMBER><FULL_PROJECT_NUM>1U54HD087101-01</FULL_PROJECT_NUM><FUNDING_ICs>NICHD:119442\</FUNDING_ICs><FUNDING_MECHANISM>RESEARCH CENTERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &amp; HUMAN DEVELOPMENT</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>LOS ANGELES</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>33</ORG_DISTRICT><ORG_DUNS>092530369</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIVERSITY OF CALIFORNIA LOS ANGELES]]></ORG_NAME><ORG_STATE>CA</ORG_STATE><ORG_ZIPCODE>900952000</ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>COPPOLA, GIOVANNI </PI_NAME><PI_ID>8844263</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>11/01/2015</PROJECT_START><PROJECT_END>05/31/2020</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[abstracting]]></TERM><TERM><![CDATA[analytical method]]></TERM><TERM><![CDATA[Animal Model]]></TERM><TERM><![CDATA[autism spectrum disorder]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Base Sequence]]></TERM><TERM><![CDATA[Basic Science]]></TERM><TERM><![CDATA[Bioinformatics]]></TERM><TERM><![CDATA[Biological Assay]]></TERM><TERM><![CDATA[Cell Line]]></TERM><TERM><![CDATA[Cell model]]></TERM><TERM><![CDATA[Center for Translational Science Activities]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[cohort]]></TERM><TERM><![CDATA[Collaborations]]></TERM><TERM><![CDATA[Computerized Medical Record]]></TERM><TERM><![CDATA[computing resources]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Data Analyses]]></TERM><TERM><![CDATA[Data Set]]></TERM><TERM><![CDATA[Data Storage and Retrieval]]></TERM><TERM><![CDATA[Databases]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[DNA]]></TERM><TERM><![CDATA[Environment]]></TERM><TERM><![CDATA[Epigenetic Process]]></TERM><TERM><![CDATA[exome sequencing]]></TERM><TERM><![CDATA[experimental analysis]]></TERM><TERM><![CDATA[Experimental Designs]]></TERM><TERM><![CDATA[Experimental Models]]></TERM><TERM><![CDATA[Explosion]]></TERM><TERM><![CDATA[Foundations]]></TERM><TERM><![CDATA[Funding]]></TERM><TERM><![CDATA[Gene Expression]]></TERM><TERM><![CDATA[Gene Expression Profiling]]></TERM><TERM><![CDATA[Genes]]></TERM><TERM><![CDATA[Genetic]]></TERM><TERM><![CDATA[Genome]]></TERM><TERM><![CDATA[genome-wide]]></TERM><TERM><![CDATA[Genomics]]></TERM><TERM><![CDATA[Genotype]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[High Performance Computing]]></TERM><TERM><![CDATA[Informatics]]></TERM><TERM><![CDATA[innovation]]></TERM><TERM><![CDATA[Institution]]></TERM><TERM><![CDATA[Intellectual functioning disability]]></TERM><TERM><![CDATA[Investigation]]></TERM><TERM><![CDATA[Laboratories]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[meetings]]></TERM><TERM><![CDATA[Mental Retardation and Developmental Disabilities Research Centers]]></TERM><TERM><![CDATA[Methods]]></TERM><TERM><![CDATA[Methylation]]></TERM><TERM><![CDATA[National Institute of Mental Health (U.S.)]]></TERM><TERM><![CDATA[National Institute of Neurological Disorders and Stroke]]></TERM><TERM><![CDATA[Network-based]]></TERM><TERM><![CDATA[Neurodegenerative Disorders]]></TERM><TERM><![CDATA[neurodevelopment]]></TERM><TERM><![CDATA[neurogenetics]]></TERM><TERM><![CDATA[neuroimaging]]></TERM><TERM><![CDATA[Neurosciences]]></TERM><TERM><![CDATA[next generation sequencing]]></TERM><TERM><![CDATA[Online Systems]]></TERM><TERM><![CDATA[Pathway Analysis]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Postdoctoral Fellow]]></TERM><TERM><![CDATA[Protocols documentation]]></TERM><TERM><![CDATA[Recording of previous events]]></TERM><TERM><![CDATA[repository]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Research Design]]></TERM><TERM><![CDATA[Research Infrastructure]]></TERM><TERM><![CDATA[Research Personnel]]></TERM><TERM><![CDATA[research study]]></TERM><TERM><![CDATA[Resource Informatics]]></TERM><TERM><![CDATA[Resources]]></TERM><TERM><![CDATA[RNA]]></TERM><TERM><![CDATA[sharing data]]></TERM><TERM><![CDATA[single cell analysis]]></TERM><TERM><![CDATA[Solid]]></TERM><TERM><![CDATA[Students]]></TERM><TERM><![CDATA[Study models]]></TERM><TERM><![CDATA[Technology]]></TERM><TERM><![CDATA[Tissues]]></TERM><TERM><![CDATA[tool]]></TERM><TERM><![CDATA[Training]]></TERM><TERM><![CDATA[translational study]]></TERM><TERM><![CDATA[Validation]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[UCLA Center for Translational Research in Neurodevelopment (UC-TRaN): Genetics,ics and Informatics (Core C)]]></PROJECT_TITLE><SERIAL_NUMBER>087101</SERIAL_NUMBER><STUDY_SECTION>ZHD1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID>8266</SUBPROJECT_ID><SUPPORT_YEAR>01</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>77560</DIRECT_COST_AMT><INDIRECT_COST_AMT>41882</INDIRECT_COST_AMT><TOTAL_COST /><TOTAL_COST_SUB_PROJECT>119442</TOTAL_COST_SUB_PROJECT></row>
<row><APPLICATION_ID>9056017</APPLICATION_ID><ACTIVITY>U54</ACTIVITY><ADMINISTERING_IC>HD</ADMINISTERING_IC><APPLICATION_TYPE>1</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/30/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>U54HD087101</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-HD-15-033</FOA_NUMBER><FULL_PROJECT_NUM>1U54HD087101-01</FULL_PROJECT_NUM><FUNDING_ICs>NICHD:159170\</FUNDING_ICs><FUNDING_MECHANISM>RESEARCH CENTERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &amp; HUMAN DEVELOPMENT</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>LOS ANGELES</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>33</ORG_DISTRICT><ORG_DUNS>092530369</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIVERSITY OF CALIFORNIA LOS ANGELES]]></ORG_NAME><ORG_STATE>CA</ORG_STATE><ORG_ZIPCODE>900952000</ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>LEVINE, MICHAEL S.</PI_NAME><PI_ID>6225001</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>11/01/2015</PROJECT_START><PROJECT_END>05/31/2020</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[abstracting]]></TERM><TERM><![CDATA[Animal Model]]></TERM><TERM><![CDATA[Area]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Bioinformatics]]></TERM><TERM><![CDATA[Biological Models]]></TERM><TERM><![CDATA[Brain]]></TERM><TERM><![CDATA[Cell Culture Techniques]]></TERM><TERM><![CDATA[Cell model]]></TERM><TERM><![CDATA[cell type]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Center for Translational Science Activities]]></TERM><TERM><![CDATA[Cerebrum]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[Collaborations]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[disability]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Disease model]]></TERM><TERM><![CDATA[DNA Sequence Alteration]]></TERM><TERM><![CDATA[drug development]]></TERM><TERM><![CDATA[drug discovery]]></TERM><TERM><![CDATA[effective therapy]]></TERM><TERM><![CDATA[Electroencephalography]]></TERM><TERM><![CDATA[Electrophysiology (science)]]></TERM><TERM><![CDATA[Faculty]]></TERM><TERM><![CDATA[fetal]]></TERM><TERM><![CDATA[Functional Imaging]]></TERM><TERM><![CDATA[Gene Expression]]></TERM><TERM><![CDATA[Genetic]]></TERM><TERM><![CDATA[Genomics]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[human embryonic stem cell]]></TERM><TERM><![CDATA[Imagery]]></TERM><TERM><![CDATA[In Vitro]]></TERM><TERM><![CDATA[in vitro Model]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[induced pluripotent stem cell]]></TERM><TERM><![CDATA[innovation]]></TERM><TERM><![CDATA[insight]]></TERM><TERM><![CDATA[interest]]></TERM><TERM><![CDATA[Knowledge]]></TERM><TERM><![CDATA[Mental Retardation and Developmental Disabilities Research Centers]]></TERM><TERM><![CDATA[Methods]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[Molecular Profiling]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[Mutation]]></TERM><TERM><![CDATA[nerve stem cell]]></TERM><TERM><![CDATA[Nervous System Physiology]]></TERM><TERM><![CDATA[Nervous system structure]]></TERM><TERM><![CDATA[neural circuit]]></TERM><TERM><![CDATA[neurodevelopment]]></TERM><TERM><![CDATA[Neuroglia]]></TERM><TERM><![CDATA[Neurologic]]></TERM><TERM><![CDATA[Neurons]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[novel strategies]]></TERM><TERM><![CDATA[optogenetics]]></TERM><TERM><![CDATA[Organoids]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Physiological]]></TERM><TERM><![CDATA[Physiology]]></TERM><TERM><![CDATA[Pluripotent Stem Cells]]></TERM><TERM><![CDATA[Preparation]]></TERM><TERM><![CDATA[Prevention]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[Rattus]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Research Personnel]]></TERM><TERM><![CDATA[research study]]></TERM><TERM><![CDATA[Resource Sharing]]></TERM><TERM><![CDATA[Resources]]></TERM><TERM><![CDATA[screening]]></TERM><TERM><![CDATA[Services]]></TERM><TERM><![CDATA[Slice]]></TERM><TERM><![CDATA[Specimen]]></TERM><TERM><![CDATA[Stem Cell Research]]></TERM><TERM><![CDATA[stem cell technology]]></TERM><TERM><![CDATA[Stem cells]]></TERM><TERM><![CDATA[Structure of thyroid parafollicular cell]]></TERM><TERM><![CDATA[Syndrome]]></TERM><TERM><![CDATA[System]]></TERM><TERM><![CDATA[Systems Analysis]]></TERM><TERM><![CDATA[Techniques]]></TERM><TERM><![CDATA[Tissues]]></TERM><TERM><![CDATA[Translating]]></TERM><TERM><![CDATA[translational study]]></TERM><TERM><![CDATA[Translations]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[UCLA Center for Translational Research in Neurodevelopment (UC-TRaN): Cells, Circuits, Systems (Core D)]]></PROJECT_TITLE><SERIAL_NUMBER>087101</SERIAL_NUMBER><STUDY_SECTION>ZHD1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID>8267</SUBPROJECT_ID><SUPPORT_YEAR>01</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>103357</DIRECT_COST_AMT><INDIRECT_COST_AMT>55813</INDIRECT_COST_AMT><TOTAL_COST /><TOTAL_COST_SUB_PROJECT>159170</TOTAL_COST_SUB_PROJECT></row>
<row><APPLICATION_ID>9077091</APPLICATION_ID><ACTIVITY>IK2</ACTIVITY><ADMINISTERING_IC>VA</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/03/2015</AWARD_NOTICE_DATE><BUDGET_START>10/01/2015</BUDGET_START><BUDGET_END>09/30/2016</BUDGET_END><CFDA_CODE>999</CFDA_CODE><CORE_PROJECT_NUM>IK2RX000750</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-RX-11-020</FOA_NUMBER><FULL_PROJECT_NUM>5IK2RX000750-04</FULL_PROJECT_NUM><FUNDING_ICs>VA:163600\</FUNDING_ICs><FUNDING_MECHANISM>OTHERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>Veterans Affairs</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>CHARLESTON</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>01</ORG_DISTRICT><ORG_DUNS>039807318</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[RALPH H JOHNSON VA MEDICAL CENTER]]></ORG_NAME><ORG_STATE>SC</ORG_STATE><ORG_ZIPCODE>294015703</ORG_ZIPCODE><PHR><![CDATA[Every year, approximately 15,000 American veterans experience a stroke, with an estimated cost of acute and follow-up care in the hundreds of millions of dollars. Following a stroke, the restoration or improvement of walking is a high-ranking goal among patients, but only about half of the population is able to return to typical levels of community ambulation. The resultant decrease in independent mobility is strongly associated with a decline in quality of life. The proposed project will investigate how post-stroke changes in neural control accuracy contribute to decreases in gait stability and increases in the energetic cost of walking, both factors that ca reduce mobility. These results will serve as the basis for the development of novel gait rehabilitation techniques, which has the potential to increase the quality of life of thousands of veterans and save millions of dollars.]]></PHR><PIS><PI><PI_NAME>DEAN, JESSE C.</PI_NAME><PI_ID>9947238</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>10/01/2012</PROJECT_START><PROJECT_END>09/30/2016</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[achilles tendon]]></TERM><TERM><![CDATA[active control]]></TERM><TERM><![CDATA[Acute]]></TERM><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[American]]></TERM><TERM><![CDATA[Award]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Cardiovascular system]]></TERM><TERM><![CDATA[career development]]></TERM><TERM><![CDATA[Caring]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[Clinical Research]]></TERM><TERM><![CDATA[Communities]]></TERM><TERM><![CDATA[cost]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Development Plans]]></TERM><TERM><![CDATA[direct application]]></TERM><TERM><![CDATA[disability]]></TERM><TERM><![CDATA[Elasticity]]></TERM><TERM><![CDATA[Engineering]]></TERM><TERM><![CDATA[Esthesia]]></TERM><TERM><![CDATA[experience]]></TERM><TERM><![CDATA[fall risk]]></TERM><TERM><![CDATA[Fatigue]]></TERM><TERM><![CDATA[Feedback]]></TERM><TERM><![CDATA[follow-up]]></TERM><TERM><![CDATA[foot]]></TERM><TERM><![CDATA[Foundations]]></TERM><TERM><![CDATA[Freedom]]></TERM><TERM><![CDATA[Gait]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Hip region structure]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[improved functioning]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[Intervention]]></TERM><TERM><![CDATA[Investigation]]></TERM><TERM><![CDATA[kinematics]]></TERM><TERM><![CDATA[Lateral]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[Leg]]></TERM><TERM><![CDATA[limb movement]]></TERM><TERM><![CDATA[Literature]]></TERM><TERM><![CDATA[mathematical model]]></TERM><TERM><![CDATA[Measures]]></TERM><TERM><![CDATA[Mechanics]]></TERM><TERM><![CDATA[Metabolic]]></TERM><TERM><![CDATA[Methods]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Motion]]></TERM><TERM><![CDATA[motor control]]></TERM><TERM><![CDATA[Movement]]></TERM><TERM><![CDATA[Muscle]]></TERM><TERM><![CDATA[muscle strength]]></TERM><TERM><![CDATA[Nervous System Trauma]]></TERM><TERM><![CDATA[neuroregulation]]></TERM><TERM><![CDATA[Neurorehabilitation]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[Paresis]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Pattern]]></TERM><TERM><![CDATA[Persons]]></TERM><TERM><![CDATA[Physiology]]></TERM><TERM><![CDATA[Play]]></TERM><TERM><![CDATA[Population]]></TERM><TERM><![CDATA[post stroke]]></TERM><TERM><![CDATA[Production]]></TERM><TERM><![CDATA[programs]]></TERM><TERM><![CDATA[Property]]></TERM><TERM><![CDATA[Quality of life]]></TERM><TERM><![CDATA[Recovery]]></TERM><TERM><![CDATA[Rehabilitation therapy]]></TERM><TERM><![CDATA[Relative (related person)]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[research study]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[restoration]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[sensory feedback]]></TERM><TERM><![CDATA[Series]]></TERM><TERM><![CDATA[skills]]></TERM><TERM><![CDATA[stroke]]></TERM><TERM><![CDATA[stroke rehabilitation]]></TERM><TERM><![CDATA[System]]></TERM><TERM><![CDATA[Techniques]]></TERM><TERM><![CDATA[Tendon structure]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Tissues]]></TERM><TERM><![CDATA[Translating]]></TERM><TERM><![CDATA[Veterans]]></TERM><TERM><![CDATA[Walking]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Post-Stroke Contributors to Increased Energetic Cost and Decreased Gait Stability]]></PROJECT_TITLE><SERIAL_NUMBER>000750</SERIAL_NUMBER><STUDY_SECTION>RRD9</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Blank ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>04</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST></TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9096615</APPLICATION_ID><ACTIVITY>K23</ACTIVITY><ADMINISTERING_IC>AI</ADMINISTERING_IC><APPLICATION_TYPE>7</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/06/2015</AWARD_NOTICE_DATE><BUDGET_START>07/01/2015</BUDGET_START><BUDGET_END>02/29/2016</BUDGET_END><CFDA_CODE>855</CFDA_CODE><CORE_PROJECT_NUM>K23AI108293</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-14-078</FOA_NUMBER><FULL_PROJECT_NUM>7K23AI108293-03</FULL_PROJECT_NUM><FUNDING_ICs>NIAID:149202\</FUNDING_ICs><FUNDING_MECHANISM>OTHER RESEARCH-RELATED</FUNDING_MECHANISM><FY>2015</FY><IC_NAME>NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>SEATTLE</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[PUBLIC HEALTH & PREV MEDICINE]]></ORG_DEPT><ORG_DISTRICT>07</ORG_DISTRICT><ORG_DUNS>605799469</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIVERSITY OF WASHINGTON]]></ORG_NAME><ORG_STATE>WA</ORG_STATE><ORG_ZIPCODE>981959472</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Cryptococcal meningitis is a leading cause of AIDS-related mortality worldwide, due mostly to delays in diagnosing the infection and promptly initiating anti-fungal therapy in resource-limited settings. I will evaluate whether rapid, point-of-care, clinic-based screening for cryptococcal disease will prevent cryptococcal-related mortality and be cost-effective among HIV-infected adults in an urban township of Durban, South Africa. This project will produce strategies for clinicians in HIV-endemic areas to promptly diagnose life-threatening cryptococcal infections to prevent cryptococcal meningitis, and for policy makers to implement a cost-effective screening program among people living with HIV/AIDS.]]></PHR><PIS><PI><PI_NAME>DRAIN, PAUL </PI_NAME><PI_ID>10917183</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>LAMBROS, CHRIS </PROGRAM_OFFICER_NAME><PROJECT_START>03/01/2014</PROJECT_START><PROJECT_END>02/28/2019</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Acquired Immunodeficiency Syndrome]]></TERM><TERM><![CDATA[Adult]]></TERM><TERM><![CDATA[Africa South of the Sahara]]></TERM><TERM><![CDATA[AIDS/HIV problem]]></TERM><TERM><![CDATA[Antifungal Agents]]></TERM><TERM><![CDATA[Antigens]]></TERM><TERM><![CDATA[antiretroviral therapy]]></TERM><TERM><![CDATA[Applications Grants]]></TERM><TERM><![CDATA[Area]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Bedside Testings]]></TERM><TERM><![CDATA[Biological Assay]]></TERM><TERM><![CDATA[Blood specimen]]></TERM><TERM><![CDATA[Boston]]></TERM><TERM><![CDATA[career]]></TERM><TERM><![CDATA[Caring]]></TERM><TERM><![CDATA[CD4 Lymphocyte Count]]></TERM><TERM><![CDATA[Cessation of life]]></TERM><TERM><![CDATA[Characteristics]]></TERM><TERM><![CDATA[Clinic]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[clinical Diagnosis]]></TERM><TERM><![CDATA[Clinical Research]]></TERM><TERM><![CDATA[Clinical Treatment]]></TERM><TERM><![CDATA[cost]]></TERM><TERM><![CDATA[cost effective]]></TERM><TERM><![CDATA[cost effectiveness]]></TERM><TERM><![CDATA[Cost Effectiveness Analysis]]></TERM><TERM><![CDATA[Coupled]]></TERM><TERM><![CDATA[Cryptococcal Meningitis]]></TERM><TERM><![CDATA[Cryptococcus]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Diagnosis]]></TERM><TERM><![CDATA[Diagnostic tests]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Dose]]></TERM><TERM><![CDATA[Early Diagnosis]]></TERM><TERM><![CDATA[education planning]]></TERM><TERM><![CDATA[Evaluation]]></TERM><TERM><![CDATA[experience]]></TERM><TERM><![CDATA[Fingers]]></TERM><TERM><![CDATA[Fluconazole]]></TERM><TERM><![CDATA[Foundations]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Gold]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[HIV]]></TERM><TERM><![CDATA[HIV diagnosis]]></TERM><TERM><![CDATA[HIV Seropositivity]]></TERM><TERM><![CDATA[Immune]]></TERM><TERM><![CDATA[implementation science]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[Incidence]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[Infection]]></TERM><TERM><![CDATA[Infection prevention]]></TERM><TERM><![CDATA[innovation]]></TERM><TERM><![CDATA[Intervention Trial]]></TERM><TERM><![CDATA[Knowledge]]></TERM><TERM><![CDATA[Laboratories]]></TERM><TERM><![CDATA[Lateral]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[Life]]></TERM><TERM><![CDATA[Measures]]></TERM><TERM><![CDATA[Mentored Patient-Oriented Research Career Development Award]]></TERM><TERM><![CDATA[Mentors]]></TERM><TERM><![CDATA[Mentorship]]></TERM><TERM><![CDATA[Mortality Vital Statistics]]></TERM><TERM><![CDATA[Natural immunosuppression]]></TERM><TERM><![CDATA[Neurologic]]></TERM><TERM><![CDATA[Newly Diagnosed]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[Nurses]]></TERM><TERM><![CDATA[Oral]]></TERM><TERM><![CDATA[Outcome]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[point of care]]></TERM><TERM><![CDATA[point-of-care diagnostics]]></TERM><TERM><![CDATA[Policy Maker]]></TERM><TERM><![CDATA[Positioning Attribute]]></TERM><TERM><![CDATA[Prevalence]]></TERM><TERM><![CDATA[prevent]]></TERM><TERM><![CDATA[programs]]></TERM><TERM><![CDATA[prophylactic]]></TERM><TERM><![CDATA[prospective]]></TERM><TERM><![CDATA[reconstitution]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Research Infrastructure]]></TERM><TERM><![CDATA[Research Personnel]]></TERM><TERM><![CDATA[Resources]]></TERM><TERM><![CDATA[Risk]]></TERM><TERM><![CDATA[Sampling]]></TERM><TERM><![CDATA[screening]]></TERM><TERM><![CDATA[Serum]]></TERM><TERM><![CDATA[skills]]></TERM><TERM><![CDATA[South Africa]]></TERM><TERM><![CDATA[Specimen]]></TERM><TERM><![CDATA[Symptoms]]></TERM><TERM><![CDATA[Test Result]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[tool]]></TERM><TERM><![CDATA[Training]]></TERM><TERM><![CDATA[Tuberculosis]]></TERM><TERM><![CDATA[Urine]]></TERM><TERM><![CDATA[Whole Blood]]></TERM><TERM><![CDATA[Work]]></TERM><TERM><![CDATA[World Health Organization]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Clinic-based Screening to Prevent HIV-associated Cryptococcal Mortality]]></PROJECT_TITLE><SERIAL_NUMBER>108293</SERIAL_NUMBER><STUDY_SECTION>AIDS</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Acquired Immunodeficiency Syndrome Research Review Committee ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>03</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>138812</DIRECT_COST_AMT><INDIRECT_COST_AMT>10390</INDIRECT_COST_AMT><TOTAL_COST>149202</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9130602</APPLICATION_ID><ACTIVITY>I01</ACTIVITY><ADMINISTERING_IC>VA</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/04/2015</AWARD_NOTICE_DATE><BUDGET_START>10/01/2015</BUDGET_START><BUDGET_END>09/30/2016</BUDGET_END><CFDA_CODE>999</CFDA_CODE><CORE_PROJECT_NUM>I01RX000998</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-RX-11-013</FOA_NUMBER><FULL_PROJECT_NUM>5I01RX000998-03</FULL_PROJECT_NUM><FUNDING_ICs>VA:1\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>Veterans Affairs</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>WEST HAVEN</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>03</ORG_DISTRICT><ORG_DUNS>039624291</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[VA CONNECTICUT HEALTHCARE SYSTEM]]></ORG_NAME><ORG_STATE>CT</ORG_STATE><ORG_ZIPCODE>065162770</ORG_ZIPCODE><PHR><![CDATA[    
Chronic low back pain (CLBP) is among the most prevalent and costly disorders among Veterans receiving care in VHA facilities. Behavioral interventions such as exercise and cognitive behavior therapy are known to be effective for CLBP but are often not readily available or easily accessed. The overall objective of the proposed project is to develop and test the preliminary efficacy and usability of and satisfaction with an integrative, Internet-based, behavioral pain self-management program, the Veterans Pain Management Resource Center (VPMRC), in Veterans with CLBP. The VPMRC will be designed and built to be compatible with MyHealtheVet (MHV). If successful, the long term objective is to migrate the VPMRC to the MHV platform to provide widespread and easy access for Veterans across VHA, regardless of geography or other access barriers.   
      

]]></PHR><PIS><PI><PI_NAME>HIGGINS, DIANA M. (contact)</PI_NAME><PI_ID>9439212 (contact)</PI_ID></PI><PI><PI_NAME>KERNS, ROBERT D</PI_NAME><PI_ID>9359110</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>10/01/2013</PROJECT_START><PROJECT_END>03/31/2017</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Behavior Therapy]]></TERM><TERM><![CDATA[Behavioral]]></TERM><TERM><![CDATA[Caring]]></TERM><TERM><![CDATA[Cellular Phone]]></TERM><TERM><![CDATA[Chronic]]></TERM><TERM><![CDATA[Chronic low back pain]]></TERM><TERM><![CDATA[chronic pain]]></TERM><TERM><![CDATA[Clinic]]></TERM><TERM><![CDATA[Clinic Visits]]></TERM><TERM><![CDATA[Cognitive]]></TERM><TERM><![CDATA[Cognitive Therapy]]></TERM><TERM><![CDATA[Commuting]]></TERM><TERM><![CDATA[Coping Skills]]></TERM><TERM><![CDATA[cost]]></TERM><TERM><![CDATA[cost effective]]></TERM><TERM><![CDATA[Cues]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[depressive symptoms]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Dimensions]]></TERM><TERM><![CDATA[disability]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Educational aspects]]></TERM><TERM><![CDATA[Effectiveness]]></TERM><TERM><![CDATA[efficacy evaluation]]></TERM><TERM><![CDATA[Equipment and supply inventories]]></TERM><TERM><![CDATA[evidence base]]></TERM><TERM><![CDATA[Evidence based program]]></TERM><TERM><![CDATA[Exercise]]></TERM><TERM><![CDATA[experience]]></TERM><TERM><![CDATA[Exposure to]]></TERM><TERM><![CDATA[Failure (biologic function)]]></TERM><TERM><![CDATA[Family]]></TERM><TERM><![CDATA[Fatigue]]></TERM><TERM><![CDATA[Feedback]]></TERM><TERM><![CDATA[follow-up]]></TERM><TERM><![CDATA[Geography]]></TERM><TERM><![CDATA[Hand]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[improved functioning]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[Institute of Medicine (U.S.)]]></TERM><TERM><![CDATA[interdisciplinary approach]]></TERM><TERM><![CDATA[interest]]></TERM><TERM><![CDATA[Internet]]></TERM><TERM><![CDATA[Intervention]]></TERM><TERM><![CDATA[Learning]]></TERM><TERM><![CDATA[Letters]]></TERM><TERM><![CDATA[Life]]></TERM><TERM><![CDATA[Literature]]></TERM><TERM><![CDATA[Measures]]></TERM><TERM><![CDATA[Medical]]></TERM><TERM><![CDATA[Medicine]]></TERM><TERM><![CDATA[Mental Health]]></TERM><TERM><![CDATA[Methods]]></TERM><TERM><![CDATA[mobile application]]></TERM><TERM><![CDATA[Modification]]></TERM><TERM><![CDATA[Monitor]]></TERM><TERM><![CDATA[Moods]]></TERM><TERM><![CDATA[negative mood]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[Numeric Rating Scale]]></TERM><TERM><![CDATA[Opioid]]></TERM><TERM><![CDATA[Outcome]]></TERM><TERM><![CDATA[Pain]]></TERM><TERM><![CDATA[Pain Clinics]]></TERM><TERM><![CDATA[Pain intensity]]></TERM><TERM><![CDATA[Pain management]]></TERM><TERM><![CDATA[Participant]]></TERM><TERM><![CDATA[patient expectation]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Persons]]></TERM><TERM><![CDATA[Phase]]></TERM><TERM><![CDATA[Physical activity]]></TERM><TERM><![CDATA[Pilot Projects]]></TERM><TERM><![CDATA[prevent]]></TERM><TERM><![CDATA[Private Sector]]></TERM><TERM><![CDATA[programs]]></TERM><TERM><![CDATA[Provider]]></TERM><TERM><![CDATA[psychologic]]></TERM><TERM><![CDATA[Public Health Informatics]]></TERM><TERM><![CDATA[public health relevance]]></TERM><TERM><![CDATA[Qualifying]]></TERM><TERM><![CDATA[Randomized Controlled Trials]]></TERM><TERM><![CDATA[Recommendation]]></TERM><TERM><![CDATA[Recruitment Activity]]></TERM><TERM><![CDATA[Relative (related person)]]></TERM><TERM><![CDATA[Relaxation]]></TERM><TERM><![CDATA[Reporting]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Research Institute]]></TERM><TERM><![CDATA[Resources]]></TERM><TERM><![CDATA[Risk]]></TERM><TERM><![CDATA[Rural]]></TERM><TERM><![CDATA[Safety]]></TERM><TERM><![CDATA[Sampling]]></TERM><TERM><![CDATA[satisfaction]]></TERM><TERM><![CDATA[Self Management]]></TERM><TERM><![CDATA[Services]]></TERM><TERM><![CDATA[Site]]></TERM><TERM><![CDATA[skills]]></TERM><TERM><![CDATA[Sleep]]></TERM><TERM><![CDATA[Sleep Disorders]]></TERM><TERM><![CDATA[social stigma]]></TERM><TERM><![CDATA[Solutions]]></TERM><TERM><![CDATA[Stress]]></TERM><TERM><![CDATA[Structure]]></TERM><TERM><![CDATA[Symptoms]]></TERM><TERM><![CDATA[Telephone]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Therapeutic]]></TERM><TERM><![CDATA[tool]]></TERM><TERM><![CDATA[Training and Education]]></TERM><TERM><![CDATA[Travel]]></TERM><TERM><![CDATA[treatment as usual]]></TERM><TERM><![CDATA[usability]]></TERM><TERM><![CDATA[Veterans]]></TERM><TERM><![CDATA[West Haven-Yale Multidimensional Pain Inventory]]></TERM><TERM><![CDATA[Woman]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Development of an Internet-based Behavioral Pain Management Intervention]]></PROJECT_TITLE><SERIAL_NUMBER>000998</SERIAL_NUMBER><STUDY_SECTION>RRDC</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>03</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST></TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9136278</APPLICATION_ID><ACTIVITY>P30</ACTIVITY><ADMINISTERING_IC>DK</ADMINISTERING_IC><APPLICATION_TYPE>6</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/03/2015</AWARD_NOTICE_DATE><BUDGET_START>09/01/2015</BUDGET_START><BUDGET_END>03/31/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>P30DK020541</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-DK-13-004</FOA_NUMBER><FULL_PROJECT_NUM>6P30DK020541-39</FULL_PROJECT_NUM><FUNDING_ICs>NIDDK:163106\</FUNDING_ICs><FUNDING_MECHANISM>RESEARCH CENTERS</FUNDING_MECHANISM><FY>2015</FY><IC_NAME>NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES</IC_NAME><NIH_SPENDING_CATS><CATEGORY><![CDATA[Bioengineering]]></CATEGORY><CATEGORY><![CDATA[Clinical Research]]></CATEGORY><CATEGORY><![CDATA[Diabetes]]></CATEGORY></NIH_SPENDING_CATS><ORG_CITY>BRONX</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>14</ORG_DISTRICT><ORG_DUNS>079783367</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[ALBERT EINSTEIN COLLEGE OF MEDICINE]]></ORG_NAME><ORG_STATE>NY</ORG_STATE><ORG_ZIPCODE>104611975</ORG_ZIPCODE><PHR><![CDATA[The Biomarker Analytical Research Core provides cost effective, high quality assays that facilitate the scientific 
progress made by a large group of scientists committed to improving our understanding and treatment of 
patients with diabetes.]]></PHR><PIS><PI><PI_NAME>STEIN, DANIEL T</PI_NAME><PI_ID>1885632</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START></PROJECT_START><PROJECT_END></PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Affinity]]></TERM><TERM><![CDATA[American]]></TERM><TERM><![CDATA[Amino Acids]]></TERM><TERM><![CDATA[Anabolism]]></TERM><TERM><![CDATA[Animals]]></TERM><TERM><![CDATA[Area]]></TERM><TERM><![CDATA[Automation]]></TERM><TERM><![CDATA[Award]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Biological Assay]]></TERM><TERM><![CDATA[Biological Markers]]></TERM><TERM><![CDATA[Biological Preservation]]></TERM><TERM><![CDATA[Blood flow]]></TERM><TERM><![CDATA[C-Peptide]]></TERM><TERM><![CDATA[Carbohydrates]]></TERM><TERM><![CDATA[Chemistry]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[Clinical Research]]></TERM><TERM><![CDATA[Clinical Sciences]]></TERM><TERM><![CDATA[Collaborations]]></TERM><TERM><![CDATA[computerized]]></TERM><TERM><![CDATA[Core Facility]]></TERM><TERM><![CDATA[cost effective]]></TERM><TERM><![CDATA[cost efficient]]></TERM><TERM><![CDATA[Coupled]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Databases]]></TERM><TERM><![CDATA[Diabetes Mellitus]]></TERM><TERM><![CDATA[DNA]]></TERM><TERM><![CDATA[Enzymes]]></TERM><TERM><![CDATA[Equipment]]></TERM><TERM><![CDATA[Fatty Acids]]></TERM><TERM><![CDATA[Financial Support]]></TERM><TERM><![CDATA[flexibility]]></TERM><TERM><![CDATA[Fostering]]></TERM><TERM><![CDATA[Funding]]></TERM><TERM><![CDATA[Glucose]]></TERM><TERM><![CDATA[glucose disposal]]></TERM><TERM><![CDATA[glucose production]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Gold]]></TERM><TERM><![CDATA[Heart]]></TERM><TERM><![CDATA[Hepatic]]></TERM><TERM><![CDATA[Hormones]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[Human Resources]]></TERM><TERM><![CDATA[human study]]></TERM><TERM><![CDATA[human subject]]></TERM><TERM><![CDATA[Immunoassay]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[innovation]]></TERM><TERM><![CDATA[Institutes]]></TERM><TERM><![CDATA[Insulin]]></TERM><TERM><![CDATA[insulin secretion]]></TERM><TERM><![CDATA[Kinetics]]></TERM><TERM><![CDATA[Label]]></TERM><TERM><![CDATA[Laboratories]]></TERM><TERM><![CDATA[liquid chromatography mass spectrometry]]></TERM><TERM><![CDATA[Management Information Systems]]></TERM><TERM><![CDATA[Mass Fragmentography]]></TERM><TERM><![CDATA[Measurement]]></TERM><TERM><![CDATA[Measures]]></TERM><TERM><![CDATA[Medical center]]></TERM><TERM><![CDATA[member]]></TERM><TERM><![CDATA[Metabolism]]></TERM><TERM><![CDATA[metabolomics]]></TERM><TERM><![CDATA[Methodology]]></TERM><TERM><![CDATA[Methods]]></TERM><TERM><![CDATA[Molecular Biology]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[Obesity]]></TERM><TERM><![CDATA[Output]]></TERM><TERM><![CDATA[Pathology]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Physiological]]></TERM><TERM><![CDATA[Plasma]]></TERM><TERM><![CDATA[polypeptide C]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[Proteins]]></TERM><TERM><![CDATA[Proteomics]]></TERM><TERM><![CDATA[Radioactive]]></TERM><TERM><![CDATA[Radioimmunoassay]]></TERM><TERM><![CDATA[Recording of previous events]]></TERM><TERM><![CDATA[Recovery]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Research Design]]></TERM><TERM><![CDATA[Research Personnel]]></TERM><TERM><![CDATA[Research Training]]></TERM><TERM><![CDATA[Resources]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[RNA]]></TERM><TERM><![CDATA[Robot]]></TERM><TERM><![CDATA[Robotics]]></TERM><TERM><![CDATA[Rodent]]></TERM><TERM><![CDATA[Running]]></TERM><TERM><![CDATA[Sampling]]></TERM><TERM><![CDATA[Scientist]]></TERM><TERM><![CDATA[Secure]]></TERM><TERM><![CDATA[Services]]></TERM><TERM><![CDATA[Source]]></TERM><TERM><![CDATA[stable isotope]]></TERM><TERM><![CDATA[Staging]]></TERM><TERM><![CDATA[steroid hormone]]></TERM><TERM><![CDATA[Steroids]]></TERM><TERM><![CDATA[System]]></TERM><TERM><![CDATA[Techniques]]></TERM><TERM><![CDATA[Technology]]></TERM><TERM><![CDATA[technology development]]></TERM><TERM><![CDATA[Translational Research]]></TERM><TERM><![CDATA[Triglycerides]]></TERM><TERM><![CDATA[United States National Institutes of Health]]></TERM><TERM><![CDATA[University Hospitals]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[The Biomarker & Analytical Research Core]]></PROJECT_TITLE><SERIAL_NUMBER>020541</SERIAL_NUMBER><STUDY_SECTION>ZDK1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID>7655</SUBPROJECT_ID><SUPPORT_YEAR>39</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>97668</DIRECT_COST_AMT><INDIRECT_COST_AMT>65438</INDIRECT_COST_AMT><TOTAL_COST /><TOTAL_COST_SUB_PROJECT>163106</TOTAL_COST_SUB_PROJECT></row>
<row><APPLICATION_ID>9146702</APPLICATION_ID><ACTIVITY>U51</ACTIVITY><ADMINISTERING_IC>PS</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/22/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>U51PS004032</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-PS-13-303</FOA_NUMBER><FULL_PROJECT_NUM>5U51PS004032-04</FULL_PROJECT_NUM><FUNDING_ICs>NCHHSTP:48834\</FUNDING_ICs><FUNDING_MECHANISM>OTHERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP)</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>JUNEAU</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>00</ORG_DISTRICT><ORG_DUNS>809386543</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[ALASKA STATE DEPARTMENT OF HLTH-SOC SVCS]]></ORG_NAME><ORG_STATE>AK</ORG_STATE><ORG_ZIPCODE>998110650</ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>PROVO, GINGER </PI_NAME><PI_ID>9211208</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>11/01/2012</PROJECT_START><PROJECT_END>10/31/2016</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[COORDINATING VIRAL HEPATITIS PREVENTION IN ALASKA]]></PROJECT_TITLE><SERIAL_NUMBER>004032</SERIAL_NUMBER><STUDY_SECTION>ZPS1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>04</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>48834</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9146905</APPLICATION_ID><ACTIVITY>U51</ACTIVITY><ADMINISTERING_IC>PS</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/26/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>U51PS004029</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-PS-13-303</FOA_NUMBER><FULL_PROJECT_NUM>5U51PS004029-04</FULL_PROJECT_NUM><FUNDING_ICs>NCHHSTP:44629\</FUNDING_ICs><FUNDING_MECHANISM>OTHERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP)</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>SPRINGFIELD</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>18</ORG_DISTRICT><ORG_DUNS>806660296</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[ILLINOIS STATE DEPT OF PUBLIC HEALTH]]></ORG_NAME><ORG_STATE>IL</ORG_STATE><ORG_ZIPCODE>627610002</ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>CHOAT, LESLI </PI_NAME><PI_ID>14216872</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>11/01/2012</PROJECT_START><PROJECT_END>10/31/2016</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[VIRAL HEPATITIS-PREVENTION & SURVEILLANCE ]]></PROJECT_TITLE><SERIAL_NUMBER>004029</SERIAL_NUMBER><STUDY_SECTION>ZPS1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>04</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>44629</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9146908</APPLICATION_ID><ACTIVITY>U51</ACTIVITY><ADMINISTERING_IC>PS</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/23/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>U51PS004033</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-PS-13-303</FOA_NUMBER><FULL_PROJECT_NUM>5U51PS004033-04</FULL_PROJECT_NUM><FUNDING_ICs>NCHHSTP:47707\</FUNDING_ICs><FUNDING_MECHANISM>OTHERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP)</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>DENVER</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>01</ORG_DISTRICT><ORG_DUNS>878208826</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[COLORADO STATE DEPT/PUB HLTH & ENVIRONMT]]></ORG_NAME><ORG_STATE>CO</ORG_STATE><ORG_ZIPCODE>802461530</ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>WARNER, AMY ELAINE</PI_NAME><PI_ID>9841940</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>11/01/2012</PROJECT_START><PROJECT_END>10/31/2016</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[VIRAL HEPATITIS-PREVENTION AND SURVEILLANCE]]></PROJECT_TITLE><SERIAL_NUMBER>004033</SERIAL_NUMBER><STUDY_SECTION>ZPS1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>04</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>47707</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9146910</APPLICATION_ID><ACTIVITY>U51</ACTIVITY><ADMINISTERING_IC>PS</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/26/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>U51PS004036</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-PS-13-303</FOA_NUMBER><FULL_PROJECT_NUM>5U51PS004036-04</FULL_PROJECT_NUM><FUNDING_ICs>NCHHSTP:53948\</FUNDING_ICs><FUNDING_MECHANISM>OTHERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP)</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>ST. PAUL</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>04</ORG_DISTRICT><ORG_DUNS>804887321</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[MINNESOTA STATE DEPT OF HEALTH]]></ORG_NAME><ORG_STATE>MN</ORG_STATE><ORG_ZIPCODE>551552538</ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>MILLER, CLAUDIA ANN</PI_NAME><PI_ID>12241565</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>11/01/2012</PROJECT_START><PROJECT_END>10/31/2016</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[Viral Hepatitis - Prevention and Surveillance;Category A, Part 1 (Prevention);Cat]]></PROJECT_TITLE><SERIAL_NUMBER>004036</SERIAL_NUMBER><STUDY_SECTION>ZPS1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>04</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>53948</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9146930</APPLICATION_ID><ACTIVITY>U51</ACTIVITY><ADMINISTERING_IC>PS</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/23/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>U51PS004057</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-PS-13-303</FOA_NUMBER><FULL_PROJECT_NUM>5U51PS004057-04</FULL_PROJECT_NUM><FUNDING_ICs>NCHHSTP:42823\</FUNDING_ICs><FUNDING_MECHANISM>OTHERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP)</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>JEFFERSON CITY</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>03</ORG_DISTRICT><ORG_DUNS>878092600</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[MISSOURI STATE DEPT/ HEALTH & SENIOR SRV]]></ORG_NAME><ORG_STATE>MO</ORG_STATE><ORG_ZIPCODE>651095796</ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>PALERMO, KEN </PI_NAME><PI_ID>11380458</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>11/01/2012</PROJECT_START><PROJECT_END>10/31/2016</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[STATE OF MISSOURI VIRAL HEPATITIS PREVENTION & SURVEILLANCE]]></PROJECT_TITLE><SERIAL_NUMBER>004057</SERIAL_NUMBER><STUDY_SECTION>ZPS1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>04</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>42823</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9054633</APPLICATION_ID><ACTIVITY>U54</ACTIVITY><ADMINISTERING_IC>HD</ADMINISTERING_IC><APPLICATION_TYPE>1</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/30/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>U54HD086984</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-HD-15-033</FOA_NUMBER><FULL_PROJECT_NUM>1U54HD086984-01</FULL_PROJECT_NUM><FUNDING_ICs>NICHD:191169\</FUNDING_ICs><FUNDING_MECHANISM>RESEARCH CENTERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &amp; HUMAN DEVELOPMENT</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>PHILADELPHIA</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>02</ORG_DISTRICT><ORG_DUNS>073757627</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[CHILDREN'S HOSP OF PHILADELPHIA]]></ORG_NAME><ORG_STATE>PA</ORG_STATE><ORG_ZIPCODE>191044318</ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>ROBINSON, MICHAEL BYRNE</PI_NAME><PI_ID>1893215</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>11/01/2015</PROJECT_START><PROJECT_END>05/31/2020</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[Amino Acids]]></TERM><TERM><![CDATA[Animal Model]]></TERM><TERM><![CDATA[Behavior]]></TERM><TERM><![CDATA[Behavioral]]></TERM><TERM><![CDATA[Biochemistry]]></TERM><TERM><![CDATA[Bioenergetics]]></TERM><TERM><![CDATA[Biogenic Amines]]></TERM><TERM><![CDATA[Bioinformatics]]></TERM><TERM><![CDATA[Biological Assay]]></TERM><TERM><![CDATA[Biological Markers]]></TERM><TERM><![CDATA[Biometry]]></TERM><TERM><![CDATA[Blinded]]></TERM><TERM><![CDATA[Brain]]></TERM><TERM><![CDATA[brain behavior]]></TERM><TERM><![CDATA[Calcium]]></TERM><TERM><![CDATA[Cataloging]]></TERM><TERM><![CDATA[Catalogs]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Cerebral Palsy]]></TERM><TERM><![CDATA[Charge]]></TERM><TERM><![CDATA[Chemicals]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Data Analyses]]></TERM><TERM><![CDATA[Defect]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Developmental Disabilities]]></TERM><TERM><![CDATA[disability]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Electrophysiology (science)]]></TERM><TERM><![CDATA[Eligibility Determination]]></TERM><TERM><![CDATA[Epilepsy]]></TERM><TERM><![CDATA[Experimental Designs]]></TERM><TERM><![CDATA[Free Radicals]]></TERM><TERM><![CDATA[Gene Mutation]]></TERM><TERM><![CDATA[Genes]]></TERM><TERM><![CDATA[Genetic]]></TERM><TERM><![CDATA[glucose metabolism]]></TERM><TERM><![CDATA[Glutamates]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[High Pressure Liquid Chromatography]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[Hypoxia]]></TERM><TERM><![CDATA[Impaired cognition]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[In Vitro]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[Inherited]]></TERM><TERM><![CDATA[Intellectual functioning disability]]></TERM><TERM><![CDATA[Investigation]]></TERM><TERM><![CDATA[Kinetics]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[leukodystrophy]]></TERM><TERM><![CDATA[Mass Spectrum Analysis]]></TERM><TERM><![CDATA[Measurement]]></TERM><TERM><![CDATA[Measures]]></TERM><TERM><![CDATA[Membrane Potentials]]></TERM><TERM><![CDATA[Mental Retardation and Developmental Disabilities Research Centers]]></TERM><TERM><![CDATA[Metabolic]]></TERM><TERM><![CDATA[Metabolic Diseases]]></TERM><TERM><![CDATA[Metabolic Pathway]]></TERM><TERM><![CDATA[Mission]]></TERM><TERM><![CDATA[Mitochondria]]></TERM><TERM><![CDATA[Mitochondrial DNA]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Modification]]></TERM><TERM><![CDATA[Motion]]></TERM><TERM><![CDATA[Myelin]]></TERM><TERM><![CDATA[neurochemistry]]></TERM><TERM><![CDATA[neuroimaging]]></TERM><TERM><![CDATA[Neurotransmitters]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[Outcome]]></TERM><TERM><![CDATA[Oxidative Phosphorylation]]></TERM><TERM><![CDATA[Pathologic]]></TERM><TERM><![CDATA[Pathology]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Pattern]]></TERM><TERM><![CDATA[Peptides]]></TERM><TERM><![CDATA[Physiology]]></TERM><TERM><![CDATA[pre-clinical]]></TERM><TERM><![CDATA[Pre-Clinical Model]]></TERM><TERM><![CDATA[preference]]></TERM><TERM><![CDATA[protein expression]]></TERM><TERM><![CDATA[Proteins]]></TERM><TERM><![CDATA[Quality Control]]></TERM><TERM><![CDATA[Reaction]]></TERM><TERM><![CDATA[Regulation]]></TERM><TERM><![CDATA[Reporting]]></TERM><TERM><![CDATA[Reproducibility]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[research study]]></TERM><TERM><![CDATA[Residual state]]></TERM><TERM><![CDATA[Sample Size]]></TERM><TERM><![CDATA[Services]]></TERM><TERM><![CDATA[small molecule]]></TERM><TERM><![CDATA[stable isotope]]></TERM><TERM><![CDATA[System]]></TERM><TERM><![CDATA[Technology]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Therapeutic Intervention]]></TERM><TERM><![CDATA[therapy development]]></TERM><TERM><![CDATA[Tissues]]></TERM><TERM><![CDATA[Tracer]]></TERM><TERM><![CDATA[urea cycle]]></TERM><TERM><![CDATA[Variant]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Analytical Neurochemistry: Core D]]></PROJECT_TITLE><SERIAL_NUMBER>086984</SERIAL_NUMBER><STUDY_SECTION>ZHD1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID>8061</SUBPROJECT_ID><SUPPORT_YEAR>01</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>127985</DIRECT_COST_AMT><INDIRECT_COST_AMT>87030</INDIRECT_COST_AMT><TOTAL_COST /><TOTAL_COST_SUB_PROJECT>191169</TOTAL_COST_SUB_PROJECT></row>
<row><APPLICATION_ID>9054636</APPLICATION_ID><ACTIVITY>U54</ACTIVITY><ADMINISTERING_IC>HD</ADMINISTERING_IC><APPLICATION_TYPE>1</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/30/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>U54HD086984</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-HD-15-033</FOA_NUMBER><FULL_PROJECT_NUM>1U54HD086984-01</FULL_PROJECT_NUM><FUNDING_ICs>NICHD:245548\</FUNDING_ICs><FUNDING_MECHANISM>RESEARCH CENTERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &amp; HUMAN DEVELOPMENT</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>PHILADELPHIA</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>02</ORG_DISTRICT><ORG_DUNS>073757627</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[CHILDREN'S HOSP OF PHILADELPHIA]]></ORG_NAME><ORG_STATE>PA</ORG_STATE><ORG_ZIPCODE>191044318</ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>ROBERTS, TIMOTHY P</PI_NAME><PI_ID>6282327</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>11/01/2015</PROJECT_START><PROJECT_END>05/31/2020</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[Age]]></TERM><TERM><![CDATA[aged]]></TERM><TERM><![CDATA[Animal Behavior]]></TERM><TERM><![CDATA[Animal Model]]></TERM><TERM><![CDATA[Area]]></TERM><TERM><![CDATA[Auditory]]></TERM><TERM><![CDATA[autism spectrum disorder]]></TERM><TERM><![CDATA[Autistic Disorder]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Behavioral]]></TERM><TERM><![CDATA[Biological Markers]]></TERM><TERM><![CDATA[Brain]]></TERM><TERM><![CDATA[Cerebral Dominance]]></TERM><TERM><![CDATA[Child]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[Cognitive]]></TERM><TERM><![CDATA[cognitive function]]></TERM><TERM><![CDATA[Control Groups]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Data Collection]]></TERM><TERM><![CDATA[Detection]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Developmental Disabilities]]></TERM><TERM><![CDATA[Diagnosis]]></TERM><TERM><![CDATA[disability]]></TERM><TERM><![CDATA[Elements]]></TERM><TERM><![CDATA[Feedback]]></TERM><TERM><![CDATA[Financial compensation]]></TERM><TERM><![CDATA[Foundations]]></TERM><TERM><![CDATA[Frequencies (time pattern)]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Head]]></TERM><TERM><![CDATA[Image]]></TERM><TERM><![CDATA[Impaired cognition]]></TERM><TERM><![CDATA[Impairment]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[insight]]></TERM><TERM><![CDATA[Intellectual functioning disability]]></TERM><TERM><![CDATA[Intervention]]></TERM><TERM><![CDATA[Language]]></TERM><TERM><![CDATA[Language Delays]]></TERM><TERM><![CDATA[Left]]></TERM><TERM><![CDATA[lexical]]></TERM><TERM><![CDATA[Linguistics]]></TERM><TERM><![CDATA[Literature]]></TERM><TERM><![CDATA[Magnetic Resonance Imaging]]></TERM><TERM><![CDATA[Magnetoencephalography]]></TERM><TERM><![CDATA[Measures]]></TERM><TERM><![CDATA[Mental Retardation and Developmental Disabilities Research Centers]]></TERM><TERM><![CDATA[Motion]]></TERM><TERM><![CDATA[National Institute of Mental Health (U.S.)]]></TERM><TERM><![CDATA[neuroimaging]]></TERM><TERM><![CDATA[Outcome]]></TERM><TERM><![CDATA[Outcome Measure]]></TERM><TERM><![CDATA[Parents]]></TERM><TERM><![CDATA[Participant]]></TERM><TERM><![CDATA[Pathogenesis]]></TERM><TERM><![CDATA[Pharmaceutical Preparations]]></TERM><TERM><![CDATA[Pharmacologic Substance]]></TERM><TERM><![CDATA[Phenotype]]></TERM><TERM><![CDATA[Population]]></TERM><TERM><![CDATA[Population Study]]></TERM><TERM><![CDATA[pre-clinical]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[Protocols documentation]]></TERM><TERM><![CDATA[Provider]]></TERM><TERM><![CDATA[relating to nervous system]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Research Project Grants]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[Scanning]]></TERM><TERM><![CDATA[Severities]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[Source]]></TERM><TERM><![CDATA[Stimulus]]></TERM><TERM><![CDATA[success]]></TERM><TERM><![CDATA[Therapeutic Intervention]]></TERM><TERM><![CDATA[Time]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[MEG Studies of Auditory Processing in Minimally/Non-Verbal Children with ASD and Intellectual Disability]]></PROJECT_TITLE><SERIAL_NUMBER>086984</SERIAL_NUMBER><STUDY_SECTION>ZHD1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID>8064</SUBPROJECT_ID><SUPPORT_YEAR>01</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>177303</DIRECT_COST_AMT><INDIRECT_COST_AMT>101278</INDIRECT_COST_AMT><TOTAL_COST /><TOTAL_COST_SUB_PROJECT>245548</TOTAL_COST_SUB_PROJECT></row>
<row><APPLICATION_ID>9130943</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>AI</ADMINISTERING_IC><APPLICATION_TYPE>7</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/31/2015</AWARD_NOTICE_DATE><BUDGET_START>09/01/2015</BUDGET_START><BUDGET_END>12/31/2015</BUDGET_END><CFDA_CODE>855</CFDA_CODE><CORE_PROJECT_NUM>R01AI110542</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>PA-13-302</FOA_NUMBER><FULL_PROJECT_NUM>7R01AI110542-02</FULL_PROJECT_NUM><FUNDING_ICs>NIAID:324056\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2015</FY><IC_NAME>NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>PHILADELPHIA</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>02</ORG_DISTRICT><ORG_DUNS>073757627</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[CHILDREN'S HOSP OF PHILADELPHIA]]></ORG_NAME><ORG_STATE>PA</ORG_STATE><ORG_ZIPCODE>191044318</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: CD4+ T cells are a critical component of the immune response that establishes protection against poxviruses, which remain a threat to mankind. Decades of work with purified proteins have produced a picture of CD4+ T cell activation that, according to our experiments, does not reflect actual responses to viruses. The work proposed here, using a natural poxvirus of mice, will determine the extent of these differences and may guide new strategies for development of more effective treatments and vaccines.]]></PHR><PIS><PI><PI_NAME>EISENLOHR, LAURENCE CRANE (contact)</PI_NAME><PI_ID>1866616 (contact)</PI_ID></PI><PI><PI_NAME>HERSPERGER, ADAM </PI_NAME><PI_ID>12497193</PI_ID></PI><PI><PI_NAME>ROPER, RACHEL L</PI_NAME><PI_ID>1945586</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>GONDRE-LEWIS, TIMOTHY A.</PROGRAM_OFFICER_NAME><PROJECT_START>07/15/2015</PROJECT_START><PROJECT_END>12/31/2019</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[adaptive immunity]]></TERM><TERM><![CDATA[Algorithms]]></TERM><TERM><![CDATA[antigen processing]]></TERM><TERM><![CDATA[Antigen-Presenting Cells]]></TERM><TERM><![CDATA[Antigens]]></TERM><TERM><![CDATA[arm]]></TERM><TERM><![CDATA[B-Lymphocytes]]></TERM><TERM><![CDATA[CD4 Positive T Lymphocytes]]></TERM><TERM><![CDATA[CD8B1 gene]]></TERM><TERM><![CDATA[cell type]]></TERM><TERM><![CDATA[Complex]]></TERM><TERM><![CDATA[Cross Presentation]]></TERM><TERM><![CDATA[cytokine]]></TERM><TERM><![CDATA[Cytoplasmic Granules]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[effective therapy]]></TERM><TERM><![CDATA[Epitopes]]></TERM><TERM><![CDATA[Generations]]></TERM><TERM><![CDATA[Genetic Engineering]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Histocompatibility Antigens Class II]]></TERM><TERM><![CDATA[Host Defense]]></TERM><TERM><![CDATA[Hybridomas]]></TERM><TERM><![CDATA[Image]]></TERM><TERM><![CDATA[Immune response]]></TERM><TERM><![CDATA[Immune system]]></TERM><TERM><![CDATA[in vitro Assay]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[Infectious Ectromelia]]></TERM><TERM><![CDATA[Influenza]]></TERM><TERM><![CDATA[innovation]]></TERM><TERM><![CDATA[Invaded]]></TERM><TERM><![CDATA[Kinetics]]></TERM><TERM><![CDATA[Knock-out]]></TERM><TERM><![CDATA[Maps]]></TERM><TERM><![CDATA[member]]></TERM><TERM><![CDATA[Memory]]></TERM><TERM><![CDATA[Mouse Pox Virus]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[pathogen]]></TERM><TERM><![CDATA[Pathway interactions]]></TERM><TERM><![CDATA[Peptide Library]]></TERM><TERM><![CDATA[Peptides]]></TERM><TERM><![CDATA[Play]]></TERM><TERM><![CDATA[Population]]></TERM><TERM><![CDATA[Poxviridae]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[Production]]></TERM><TERM><![CDATA[protein aminoacid sequence]]></TERM><TERM><![CDATA[Proteins]]></TERM><TERM><![CDATA[Proteome]]></TERM><TERM><![CDATA[public health relevance]]></TERM><TERM><![CDATA[Recombinants]]></TERM><TERM><![CDATA[recombinase]]></TERM><TERM><![CDATA[research study]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[Specificity]]></TERM><TERM><![CDATA[Structure]]></TERM><TERM><![CDATA[Study models]]></TERM><TERM><![CDATA[System]]></TERM><TERM><![CDATA[T cell response]]></TERM><TERM><![CDATA[T-Cell Activation]]></TERM><TERM><![CDATA[T-Cell Receptor]]></TERM><TERM><![CDATA[T-Lymphocyte]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Textbooks]]></TERM><TERM><![CDATA[Vaccine Design]]></TERM><TERM><![CDATA[Vaccines]]></TERM><TERM><![CDATA[Virus]]></TERM><TERM><![CDATA[Virus Diseases]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[MHCII Cross-presentation as a Driver of CD4+ T Cell Responses to Poxviruses]]></PROJECT_TITLE><SERIAL_NUMBER>110542</SERIAL_NUMBER><STUDY_SECTION>IHD</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Immunity and Host Defense Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>209668</DIRECT_COST_AMT><INDIRECT_COST_AMT>114388</INDIRECT_COST_AMT><TOTAL_COST>324056</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9136525</APPLICATION_ID><ACTIVITY>DP3</ACTIVITY><ADMINISTERING_IC>DK</ADMINISTERING_IC><APPLICATION_TYPE>6</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/03/2015</AWARD_NOTICE_DATE><BUDGET_START>09/01/2015</BUDGET_START><BUDGET_END>08/31/2016</BUDGET_END><CFDA_CODE>847</CFDA_CODE><CORE_PROJECT_NUM>DP3DK101078</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-DK-12-020</FOA_NUMBER><FULL_PROJECT_NUM>6DP3DK101078-02</FULL_PROJECT_NUM><FUNDING_ICs>NIDDK:10790\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2013</FY><IC_NAME>NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>BRONX</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>14</ORG_DISTRICT><ORG_DUNS>079783367</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[ALBERT EINSTEIN COLLEGE OF MEDICINE]]></ORG_NAME><ORG_STATE>NY</ORG_STATE><ORG_ZIPCODE>104611975</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: The closed loop system offers patients with type 1 diabetes a better method of managing their disease by way of continuous monitoring of glucose and delivery of insulin without the need for patient intervention. However, this method is not able to respond to the glucose changes due to a meal in an optimal fashion, resulting in higher than desired after-meal glucose sugars. Sitagliptin is a meal-related drug that can be given by mouth and can help patients with diabetes.]]></PHR><PIS><PI><PI_NAME>HEPTULLA, RUBINA A</PI_NAME><PI_ID>7371299</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>ARREAZA-RUBIN, GUILLERMO </PROGRAM_OFFICER_NAME><PROJECT_START>09/30/2013</PROJECT_START><PROJECT_END>08/31/2016</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[Role of Oral vs Injectable Glucagon Suppressors]]></PROJECT_TITLE><SERIAL_NUMBER>101078</SERIAL_NUMBER><STUDY_SECTION>ZDK1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>6461</DIRECT_COST_AMT><INDIRECT_COST_AMT>4329</INDIRECT_COST_AMT><TOTAL_COST>10790</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9146904</APPLICATION_ID><ACTIVITY>U51</ACTIVITY><ADMINISTERING_IC>PS</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/23/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>U51PS004028</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-PS-13-303</FOA_NUMBER><FULL_PROJECT_NUM>5U51PS004028-04</FULL_PROJECT_NUM><FUNDING_ICs>NCHHSTP:54450\</FUNDING_ICs><FUNDING_MECHANISM>OTHERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP)</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>LOS ANGELES</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>34</ORG_DISTRICT><ORG_DUNS>624882309</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[LOS ANGELES CNTY OFF OF AIDS PROGS & POL]]></ORG_NAME><ORG_STATE>CA</ORG_STATE><ORG_ZIPCODE>900054001</ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>KIM-FARLEY, ROBERT </PI_NAME><PI_ID>11839329</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>11/01/2012</PROJECT_START><PROJECT_END>10/31/2016</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[CATEGORY A, PART 1-VIRAL HEPATITIS PREVENTION COORDINATOR]]></PROJECT_TITLE><SERIAL_NUMBER>004028</SERIAL_NUMBER><STUDY_SECTION>ZPS1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>04</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>54450</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9146912</APPLICATION_ID><ACTIVITY>U51</ACTIVITY><ADMINISTERING_IC>PS</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/23/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>U51PS004039</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-PS-13-303</FOA_NUMBER><FULL_PROJECT_NUM>5U51PS004039-04</FULL_PROJECT_NUM><FUNDING_ICs>NCHHSTP:44944\</FUNDING_ICs><FUNDING_MECHANISM>OTHERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP)</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>ATLANTA</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>05</ORG_DISTRICT><ORG_DUNS>968217559</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[GEORGIA STATE DEPARTMENTOF PUBLIC HEALTH]]></ORG_NAME><ORG_STATE>GA</ORG_STATE><ORG_ZIPCODE>303033141</ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>MERCEDES, LYNNE </PI_NAME><PI_ID>12535214</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>11/01/2012</PROJECT_START><PROJECT_END>10/31/2016</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[GA Viral Hepatitis Prevention and Surveillance]]></PROJECT_TITLE><SERIAL_NUMBER>004039</SERIAL_NUMBER><STUDY_SECTION>ZPS1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>04</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>44944</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9146917</APPLICATION_ID><ACTIVITY>U51</ACTIVITY><ADMINISTERING_IC>PS</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/23/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>U51PS004048</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-PS-13-303</FOA_NUMBER><FULL_PROJECT_NUM>5U51PS004048-04</FULL_PROJECT_NUM><FUNDING_ICs>NCHHSTP:39993\</FUNDING_ICs><FUNDING_MECHANISM>OTHERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP)</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>INDIANAPOLIS</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>07</ORG_DISTRICT><ORG_DUNS>824799407</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[INDIANA STATE DEPARTMENT OF HEALTH]]></ORG_NAME><ORG_STATE>IN</ORG_STATE><ORG_ZIPCODE>462043021</ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>GROSS, BRITTANY </PI_NAME><PI_ID>12405593</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>11/01/2012</PROJECT_START><PROJECT_END>10/31/2016</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[Indiana Viral Hepatitis Prevention and Surveillance]]></PROJECT_TITLE><SERIAL_NUMBER>004048</SERIAL_NUMBER><STUDY_SECTION>ZPS1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>04</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>39993</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9146922</APPLICATION_ID><ACTIVITY>U51</ACTIVITY><ADMINISTERING_IC>PS</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/23/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>U51PS004050</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-PS-13-303</FOA_NUMBER><FULL_PROJECT_NUM>5U51PS004050-04</FULL_PROJECT_NUM><FUNDING_ICs>NCHHSTP:54511\</FUNDING_ICs><FUNDING_MECHANISM>OTHERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP)</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>AUGUSTA</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>01</ORG_DISTRICT><ORG_DUNS>809045594</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[MAINE STATE DEPT/HEALTH/HUMAN SERVS]]></ORG_NAME><ORG_STATE>ME</ORG_STATE><ORG_ZIPCODE>043306846</ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>WOLANSKI, LORI </PI_NAME><PI_ID>11545699</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>11/01/2012</PROJECT_START><PROJECT_END>10/31/2016</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[Maine Viral Hepatitis Prevention Coordinator Project]]></PROJECT_TITLE><SERIAL_NUMBER>004050</SERIAL_NUMBER><STUDY_SECTION>ZPS1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>04</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>54511</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9146931</APPLICATION_ID><ACTIVITY>U51</ACTIVITY><ADMINISTERING_IC>PS</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/22/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>U51PS004058</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-PS-13-303</FOA_NUMBER><FULL_PROJECT_NUM>5U51PS004058-04</FULL_PROJECT_NUM><FUNDING_ICs>NCHHSTP:70772\</FUNDING_ICs><FUNDING_MECHANISM>OTHERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP)</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>SACRAMENTO</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>06</ORG_DISTRICT><ORG_DUNS>799150615</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[CALIFORNIA DEPARTMENT OF PUBLIC HEALTH]]></ORG_NAME><ORG_STATE>CA</ORG_STATE><ORG_ZIPCODE>958145015</ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>BAUER, HEIDI M</PI_NAME><PI_ID>9470522</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>11/01/2012</PROJECT_START><PROJECT_END>10/31/2016</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[Viral Hepatitis - Prevention and Surveillance]]></PROJECT_TITLE><SERIAL_NUMBER>004058</SERIAL_NUMBER><STUDY_SECTION>ZPS1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>04</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>70772</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9146939</APPLICATION_ID><ACTIVITY>U51</ACTIVITY><ADMINISTERING_IC>PS</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/26/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>U51PS004074</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-PS-13-303</FOA_NUMBER><FULL_PROJECT_NUM>5U51PS004074-04</FULL_PROJECT_NUM><FUNDING_ICs>NCHHSTP:46838\</FUNDING_ICs><FUNDING_MECHANISM>OTHERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP)</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>AUSTIN</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>10</ORG_DISTRICT><ORG_DUNS>807391511</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[TEXAS STATE DEPT OF HEALTH SERVICES]]></ORG_NAME><ORG_STATE>TX</ORG_STATE><ORG_ZIPCODE>787563101</ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>ROCHA, FELIPE </PI_NAME><PI_ID>10921353</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>11/01/2012</PROJECT_START><PROJECT_END>10/31/2016</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[Viral Hepatitis ? Prevention and Surveillance]]></PROJECT_TITLE><SERIAL_NUMBER>004074</SERIAL_NUMBER><STUDY_SECTION>ZPS1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>04</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>46838</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9147671</APPLICATION_ID><ACTIVITY>U01</ACTIVITY><ADMINISTERING_IC>EB</ADMINISTERING_IC><APPLICATION_TYPE>3</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/04/2015</AWARD_NOTICE_DATE><BUDGET_START>11/04/2015</BUDGET_START><BUDGET_END>06/30/2016</BUDGET_END><CFDA_CODE>286</CFDA_CODE><CORE_PROJECT_NUM>U01EB015521</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PAR-12-053</FOA_NUMBER><FULL_PROJECT_NUM>3U01EB015521-03S1</FULL_PROJECT_NUM><FUNDING_ICs>NIBIB:104514\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>LOS ANGELES</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[NEUROSURGERY]]></ORG_DEPT><ORG_DISTRICT>33</ORG_DISTRICT><ORG_DUNS>092530369</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIVERSITY OF CALIFORNIA LOS ANGELES]]></ORG_NAME><ORG_STATE>CA</ORG_STATE><ORG_ZIPCODE>900952000</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE:  It now seems possible to apply three interventions (epidural stimulation, administration of pharmacological agents, and motor training) to control the excitability of localized neural circuits in humans with a cervical spinal cord injury (SCI), thus enabling these individuals to regain use of their arms and hands.  This enabling effect is similar to that observed with improved postural and locomotor function after a mid-thoracic SCI.  We will reach critical milestones that will provide the basis for a series of clinical trials for furter defining the efficacy of these interventions.]]></PHR><PIS><PI><PI_NAME>EDGERTON, REGGIE  (contact)</PI_NAME><PI_ID>8365068 (contact)</PI_ID></PI><PI><PI_NAME>LU, DANIEL </PI_NAME><PI_ID>8648108</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>PENG, GRACE </PROGRAM_OFFICER_NAME><PROJECT_START>07/01/2013</PROJECT_START><PROJECT_END>06/30/2018</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Agonist]]></TERM><TERM><![CDATA[Algorithms]]></TERM><TERM><![CDATA[Ankle]]></TERM><TERM><![CDATA[arm]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Bromocriptine]]></TERM><TERM><![CDATA[Buspirone]]></TERM><TERM><![CDATA[Cervical]]></TERM><TERM><![CDATA[Cervical spinal cord injury]]></TERM><TERM><![CDATA[Cervical spinal cord structure]]></TERM><TERM><![CDATA[Chronic]]></TERM><TERM><![CDATA[Clinical Trials]]></TERM><TERM><![CDATA[Complement]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[Devices]]></TERM><TERM><![CDATA[Dose]]></TERM><TERM><![CDATA[Drug Kinetics]]></TERM><TERM><![CDATA[Effectiveness]]></TERM><TERM><![CDATA[Electrodes]]></TERM><TERM><![CDATA[FDA approved]]></TERM><TERM><![CDATA[Felis catus]]></TERM><TERM><![CDATA[Food]]></TERM><TERM><![CDATA[Forelimb]]></TERM><TERM><![CDATA[Frequencies (time pattern)]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Hand]]></TERM><TERM><![CDATA[Hand functions]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Hip region structure]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[human subject]]></TERM><TERM><![CDATA[Implant]]></TERM><TERM><![CDATA[Implanted Electrodes]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[Injury]]></TERM><TERM><![CDATA[Intervention]]></TERM><TERM><![CDATA[Knee]]></TERM><TERM><![CDATA[Leg]]></TERM><TERM><![CDATA[Lesion]]></TERM><TERM><![CDATA[Lower Extremity]]></TERM><TERM><![CDATA[Machine Learning]]></TERM><TERM><![CDATA[Methodology]]></TERM><TERM><![CDATA[minimally invasive]]></TERM><TERM><![CDATA[Modality]]></TERM><TERM><![CDATA[Motor]]></TERM><TERM><![CDATA[motor function recovery]]></TERM><TERM><![CDATA[Motor Skills]]></TERM><TERM><![CDATA[neural circuit]]></TERM><TERM><![CDATA[neuroregulation]]></TERM><TERM><![CDATA[Oral]]></TERM><TERM><![CDATA[Paralysed]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Pharmaceutical Preparations]]></TERM><TERM><![CDATA[Physiological]]></TERM><TERM><![CDATA[Preparation]]></TERM><TERM><![CDATA[Property]]></TERM><TERM><![CDATA[Protocols documentation]]></TERM><TERM><![CDATA[Rattus]]></TERM><TERM><![CDATA[Recovery]]></TERM><TERM><![CDATA[Rehabilitation therapy]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[Retrieval]]></TERM><TERM><![CDATA[Series]]></TERM><TERM><![CDATA[Speed (motion)]]></TERM><TERM><![CDATA[Spinal]]></TERM><TERM><![CDATA[Spinal Cord]]></TERM><TERM><![CDATA[Spinal cord injury]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Thoracic spinal cord structure]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[Toes]]></TERM><TERM><![CDATA[Training]]></TERM><TERM><![CDATA[Translating]]></TERM><TERM><![CDATA[Treatment Efficacy]]></TERM><TERM><![CDATA[Upper Extremity]]></TERM><TERM><![CDATA[Weight-Bearing state]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Enabling forelimb function with agonist drug and epidural stimulation in SCI]]></PROJECT_TITLE><SERIAL_NUMBER>015521</SERIAL_NUMBER><STUDY_SECTION>ZRG1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>03</SUPPORT_YEAR><SUFFIX>S1</SUFFIX><DIRECT_COST_AMT>67866</DIRECT_COST_AMT><INDIRECT_COST_AMT>36648</INDIRECT_COST_AMT><TOTAL_COST>104514</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9149043</APPLICATION_ID><ACTIVITY>U51</ACTIVITY><ADMINISTERING_IC>PS</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/22/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>U51PS004041</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-PS-13-303</FOA_NUMBER><FULL_PROJECT_NUM>5U51PS004041-04</FULL_PROJECT_NUM><FUNDING_ICs>NCHHSTP:38256\</FUNDING_ICs><FUNDING_MECHANISM>OTHERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP)</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>SALT LAKE CITY</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>02</ORG_DISTRICT><ORG_DUNS>959347972</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UTAH STATE DEPARTMENT OF HEALTH]]></ORG_NAME><ORG_STATE>UT</ORG_STATE><ORG_ZIPCODE>841144003</ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>BROWN, JENNIFER </PI_NAME><PI_ID>9142984</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>11/01/2012</PROJECT_START><PROJECT_END>10/31/2016</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[VIRAL HEPATITIS PREVENTION & SURVEILLANCE]]></PROJECT_TITLE><SERIAL_NUMBER>004041</SERIAL_NUMBER><STUDY_SECTION>ZPS1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>04</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>38256</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9149050</APPLICATION_ID><ACTIVITY>U51</ACTIVITY><ADMINISTERING_IC>PS</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/26/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>U51PS004063</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-PS-13-303</FOA_NUMBER><FULL_PROJECT_NUM>5U51PS004063-04</FULL_PROJECT_NUM><FUNDING_ICs>NCHHSTP:54454\</FUNDING_ICs><FUNDING_MECHANISM>OTHERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP)</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>OKLAHOMA CITY</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>04</ORG_DISTRICT><ORG_DUNS>143673015</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[OKLAHOMA STATE DEPARTMENT OF HEALTH]]></ORG_NAME><ORG_STATE>OK</ORG_STATE><ORG_ZIPCODE>731171299</ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>FOX, JAN </PI_NAME><PI_ID>9531039</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>11/01/2012</PROJECT_START><PROJECT_END>10/31/2016</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[PROVIDES THE FUNDING FOR THE VIRAL HEPATITIS PREVENTION COORDINATOR (VHPC) ]]></PROJECT_TITLE><SERIAL_NUMBER>004063</SERIAL_NUMBER><STUDY_SECTION>ZPS1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>04</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>54454</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9149054</APPLICATION_ID><ACTIVITY>U51</ACTIVITY><ADMINISTERING_IC>PS</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/23/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>U51PS004068</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-PS-13-303</FOA_NUMBER><FULL_PROJECT_NUM>5U51PS004068-04</FULL_PROJECT_NUM><FUNDING_ICs>NCHHSTP:67697\</FUNDING_ICs><FUNDING_MECHANISM>OTHERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP)</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>PORTLAND</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>03</ORG_DISTRICT><ORG_DUNS>878144021</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[PUBLIC HEALTH SERVICES]]></ORG_NAME><ORG_STATE>OR</ORG_STATE><ORG_ZIPCODE>972322162</ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>THOMAS, ANN </PI_NAME><PI_ID>11537475</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>11/01/2012</PROJECT_START><PROJECT_END>10/31/2016</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[SURVEILLANCE AND PREVENTION OF VIRAL HEPATITS IN OREGON]]></PROJECT_TITLE><SERIAL_NUMBER>004068</SERIAL_NUMBER><STUDY_SECTION>ZPS1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>04</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>67697</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9170402</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>MD</ADMINISTERING_IC><APPLICATION_TYPE>7</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>10/30/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>06/30/2016</BUDGET_END><CFDA_CODE>375</CFDA_CODE><CORE_PROJECT_NUM>R01MD010241</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF PUBLIC HEALTH]]></ED_INST_TYPE><FOA_NUMBER>RFA-MD-15-001</FOA_NUMBER><FULL_PROJECT_NUM>7R01MD010241-02</FULL_PROJECT_NUM><FUNDING_ICs>NIMHD:436364\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2015</FY><IC_NAME>NATIONAL INSTITUTE ON MINORITY HEALTH AND HEALTH DISPARITIES</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>ATLANTA</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[PSYCHOLOGY]]></ORG_DEPT><ORG_DISTRICT>05</ORG_DISTRICT><ORG_DUNS>066469933</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[EMORY UNIVERSITY]]></ORG_NAME><ORG_STATE>GA</ORG_STATE><ORG_ZIPCODE>303224250</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: The Healthy People 2020 goals highlight the need to address broad social determinants of health to achieve health equity and eliminate health disparities. We propose a 3-phase study, including a strong empirical evaluation of the effects of multiple state-level family economic security policies on reducing the significant income and race/ethnic disparities in infant and childhood mortality that exist today, and that are, in fact, increasing. he results of the proposed study will directly guide law-making to effectively and efficiently improve
child health outcomes and reduce disparities.   
   
      

]]></PHR><PIS><PI><PI_NAME>KOMRO, KELLI ANN (contact)</PI_NAME><PI_ID>6204217 (contact)</PI_ID></PI><PI><PI_NAME>WAGENAAR, ALEXANDER CLARENCE</PI_NAME><PI_ID>1885017</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>ALVIDREZ, JENNIFER L</PROGRAM_OFFICER_NAME><PROJECT_START>06/25/2015</PROJECT_START><PROJECT_END>06/30/2019</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[Adopted]]></TERM><TERM><![CDATA[Adult]]></TERM><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[age group]]></TERM><TERM><![CDATA[alcohol policy information system]]></TERM><TERM><![CDATA[Area]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Biological Models]]></TERM><TERM><![CDATA[Cause of Death]]></TERM><TERM><![CDATA[Child]]></TERM><TERM><![CDATA[Child health care]]></TERM><TERM><![CDATA[Child Mortality]]></TERM><TERM><![CDATA[Childhood]]></TERM><TERM><![CDATA[Control Groups]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Data Analyses]]></TERM><TERM><![CDATA[Data Collection]]></TERM><TERM><![CDATA[Databases]]></TERM><TERM><![CDATA[deprivation]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[Dimensions]]></TERM><TERM><![CDATA[disability]]></TERM><TERM><![CDATA[Economic Conditions]]></TERM><TERM><![CDATA[Economics]]></TERM><TERM><![CDATA[Empirical Research]]></TERM><TERM><![CDATA[Ethnicity aspects]]></TERM><TERM><![CDATA[Evaluation]]></TERM><TERM><![CDATA[Experimental Designs]]></TERM><TERM><![CDATA[Family]]></TERM><TERM><![CDATA[Foundations]]></TERM><TERM><![CDATA[Geographic state]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[health disparity]]></TERM><TERM><![CDATA[health equity]]></TERM><TERM><![CDATA[health inequalities]]></TERM><TERM><![CDATA[Health Policy]]></TERM><TERM><![CDATA[Healthy People 2020]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[Income]]></TERM><TERM><![CDATA[indexing]]></TERM><TERM><![CDATA[Infant]]></TERM><TERM><![CDATA[Infant Mortality]]></TERM><TERM><![CDATA[Knowledge]]></TERM><TERM><![CDATA[Laws]]></TERM><TERM><![CDATA[Legal]]></TERM><TERM><![CDATA[Life]]></TERM><TERM><![CDATA[Literature]]></TERM><TERM><![CDATA[longitudinal design]]></TERM><TERM><![CDATA[Low Birth Weight Infant]]></TERM><TERM><![CDATA[low socioeconomic status]]></TERM><TERM><![CDATA[Measurement]]></TERM><TERM><![CDATA[Measures]]></TERM><TERM><![CDATA[Minority Groups]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Mortality Vital Statistics]]></TERM><TERM><![CDATA[National Institute on Alcohol Abuse and Alcoholism]]></TERM><TERM><![CDATA[Outcome]]></TERM><TERM><![CDATA[Paper]]></TERM><TERM><![CDATA[Pattern]]></TERM><TERM><![CDATA[Phase]]></TERM><TERM><![CDATA[phase 3 study]]></TERM><TERM><![CDATA[Police]]></TERM><TERM><![CDATA[Policies]]></TERM><TERM><![CDATA[Policy Analysis]]></TERM><TERM><![CDATA[Poverty]]></TERM><TERM><![CDATA[public health medicine (field)]]></TERM><TERM><![CDATA[public health relevance]]></TERM><TERM><![CDATA[Quality of life]]></TERM><TERM><![CDATA[Race]]></TERM><TERM><![CDATA[Regulation]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[research study]]></TERM><TERM><![CDATA[Risk Factors]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Security]]></TERM><TERM><![CDATA[Shapes]]></TERM><TERM><![CDATA[social health determinants]]></TERM><TERM><![CDATA[social inequality]]></TERM><TERM><![CDATA[Societies]]></TERM><TERM><![CDATA[Socioeconomic Factors]]></TERM><TERM><![CDATA[Socioeconomic Status]]></TERM><TERM><![CDATA[socioeconomics]]></TERM><TERM><![CDATA[Solutions]]></TERM><TERM><![CDATA[System]]></TERM><TERM><![CDATA[theories]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[Time Series Analysis]]></TERM><TERM><![CDATA[Variant]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Family Economic Security Policy: Effects on Child Health Disparities]]></PROJECT_TITLE><SERIAL_NUMBER>010241</SERIAL_NUMBER><STUDY_SECTION>ZMD1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>335095</DIRECT_COST_AMT><INDIRECT_COST_AMT>101269</INDIRECT_COST_AMT><TOTAL_COST>436364</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9172476</APPLICATION_ID><ACTIVITY>R21</ACTIVITY><ADMINISTERING_IC>HL</ADMINISTERING_IC><APPLICATION_TYPE>6</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/05/2015</AWARD_NOTICE_DATE><BUDGET_START>11/05/2015</BUDGET_START><BUDGET_END>06/30/2016</BUDGET_END><CFDA_CODE>837</CFDA_CODE><CORE_PROJECT_NUM>R21HL120782</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-HL-13-027</FOA_NUMBER><FULL_PROJECT_NUM>6R21HL120782-03</FULL_PROJECT_NUM><FUNDING_ICs>NHLBI:168624\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2015</FY><IC_NAME>NATIONAL HEART, LUNG, AND BLOOD INSTITUTE</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>BRONX</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>14</ORG_DISTRICT><ORG_DUNS>079783367</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[ALBERT EINSTEIN COLLEGE OF MEDICINE]]></ORG_NAME><ORG_STATE>NY</ORG_STATE><ORG_ZIPCODE>104611975</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: This Project is in response to the RFA-HL-13-027 Functional Assays to Screen Genomic Hits (R21/R33). The number of genomic variants that is amassing in the scientific literature and scientific databases has been increasing with advances in DNA sequencing technology and the discovery of disease-associated regions of our DNA. As we approach an era of personal whole genomic sequencing it becomes important to determine which variants in genes are likely to increase risk of disease an which are innocuous. We have chosen several sites or loci within the genome where over 1000 variants have been described that may or may not lead to risk for fatal cardiac rhythm disturbance. We propose to characterize as many of these in high- throughput system to determine if each variant puts one at risk or not for cardiac disease. The main deliverable of this work will be a Web-based database that will allow clinicians and investigators to have an improved ability to predict whether a genetic variant in a given patient is likely to cause disease.]]></PHR><PIS><PI><PI_NAME>MCDONALD, THOMAS V</PI_NAME><PI_ID>1858348</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>LATHROP, DAVID A.</PROGRAM_OFFICER_NAME><PROJECT_START>08/07/2014</PROJECT_START><PROJECT_END>06/30/2016</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[Arrhythmia]]></TERM><TERM><![CDATA[Awareness]]></TERM><TERM><![CDATA[Behavior]]></TERM><TERM><![CDATA[Behavior Therapy]]></TERM><TERM><![CDATA[Biochemical]]></TERM><TERM><![CDATA[Biological Assay]]></TERM><TERM><![CDATA[Biology]]></TERM><TERM><![CDATA[Cardiac]]></TERM><TERM><![CDATA[Cardiovascular system]]></TERM><TERM><![CDATA[cDNA Expression]]></TERM><TERM><![CDATA[Cell physiology]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[Clinical Management]]></TERM><TERM><![CDATA[clinical phenotype]]></TERM><TERM><![CDATA[cohort]]></TERM><TERM><![CDATA[Complementary DNA]]></TERM><TERM><![CDATA[Computer Simulation]]></TERM><TERM><![CDATA[Databases]]></TERM><TERM><![CDATA[Death, Sudden, Cardiac]]></TERM><TERM><![CDATA[Defect]]></TERM><TERM><![CDATA[Defibrillators]]></TERM><TERM><![CDATA[Diagnosis]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Disease susceptibility]]></TERM><TERM><![CDATA[disorder risk]]></TERM><TERM><![CDATA[DNA]]></TERM><TERM><![CDATA[DNA Sequence]]></TERM><TERM><![CDATA[Electrophysiology (science)]]></TERM><TERM><![CDATA[Exhibits]]></TERM><TERM><![CDATA[exome]]></TERM><TERM><![CDATA[Explosion]]></TERM><TERM><![CDATA[Family member]]></TERM><TERM><![CDATA[functional genomics]]></TERM><TERM><![CDATA[Generations]]></TERM><TERM><![CDATA[Genes]]></TERM><TERM><![CDATA[Genetic]]></TERM><TERM><![CDATA[Genetic Databases]]></TERM><TERM><![CDATA[Genetic Polymorphism]]></TERM><TERM><![CDATA[Genetic screening method]]></TERM><TERM><![CDATA[genetic variant]]></TERM><TERM><![CDATA[Genome]]></TERM><TERM><![CDATA[Genomics]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Healthcare Systems]]></TERM><TERM><![CDATA[Heart Diseases]]></TERM><TERM><![CDATA[heart rhythm]]></TERM><TERM><![CDATA[Hereditary Disease]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[Human Cell Line]]></TERM><TERM><![CDATA[Implant]]></TERM><TERM><![CDATA[implantation]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[Inherited]]></TERM><TERM><![CDATA[Internet]]></TERM><TERM><![CDATA[Ion Channel]]></TERM><TERM><![CDATA[Ion Channel Protein Gene]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[Life]]></TERM><TERM><![CDATA[Life Style]]></TERM><TERM><![CDATA[Literature]]></TERM><TERM><![CDATA[loss of function]]></TERM><TERM><![CDATA[Medical Genetics]]></TERM><TERM><![CDATA[Mission]]></TERM><TERM><![CDATA[Modification]]></TERM><TERM><![CDATA[mutant]]></TERM><TERM><![CDATA[Mutation]]></TERM><TERM><![CDATA[National Heart, Lung, and Blood Institute]]></TERM><TERM><![CDATA[next generation sequencing]]></TERM><TERM><![CDATA[Online Systems]]></TERM><TERM><![CDATA[Pacemakers]]></TERM><TERM><![CDATA[Patient Self-Report]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Pharmaceutical Preparations]]></TERM><TERM><![CDATA[Phenotype]]></TERM><TERM><![CDATA[Physicians]]></TERM><TERM><![CDATA[Population]]></TERM><TERM><![CDATA[Procedures]]></TERM><TERM><![CDATA[Proteins]]></TERM><TERM><![CDATA[public health relevance]]></TERM><TERM><![CDATA[Reporting]]></TERM><TERM><![CDATA[Research Personnel]]></TERM><TERM><![CDATA[Resources]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[Risk]]></TERM><TERM><![CDATA[Side]]></TERM><TERM><![CDATA[Site]]></TERM><TERM><![CDATA[Source]]></TERM><TERM><![CDATA[Surface]]></TERM><TERM><![CDATA[Susceptibility Gene]]></TERM><TERM><![CDATA[Symptoms]]></TERM><TERM><![CDATA[System]]></TERM><TERM><![CDATA[Technology]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[trafficking]]></TERM><TERM><![CDATA[United States National Institutes of Health]]></TERM><TERM><![CDATA[Variant]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Large-scale functional phenotyping of ion channel arrhythmia genomic variants]]></PROJECT_TITLE><SERIAL_NUMBER>120782</SERIAL_NUMBER><STUDY_SECTION>ZHL1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>03</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>122049</DIRECT_COST_AMT><INDIRECT_COST_AMT>46575</INDIRECT_COST_AMT><TOTAL_COST>168624</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9174293</APPLICATION_ID><ACTIVITY>U2G</ACTIVITY><ADMINISTERING_IC>PS</ADMINISTERING_IC><APPLICATION_TYPE>3</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/05/2015</AWARD_NOTICE_DATE><BUDGET_START>09/30/2014</BUDGET_START><BUDGET_END>09/29/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>U2GPS002800</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-PS-10-069</FOA_NUMBER><FULL_PROJECT_NUM>3U2GPS002800-05S2</FULL_PROJECT_NUM><FUNDING_ICs>COGH:175000\</FUNDING_ICs><FUNDING_MECHANISM>OTHERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP)</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>DAR ES SALAAM</ORG_CITY><ORG_COUNTRY>TANZANIA U REP</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT></ORG_DISTRICT><ORG_DUNS></ORG_DUNS><ORG_FIPS>TZ</ORG_FIPS><ORG_NAME><![CDATA[TANZANIA COMMISSION FOR AIDS]]></ORG_NAME><ORG_STATE></ORG_STATE><ORG_ZIPCODE></ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>KAMWELA, JEROME </PI_NAME><PI_ID>10468242</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>09/30/2010</PROJECT_START><PROJECT_END>09/29/2016</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[2 SUPPORT FOR A NATIONAL MONITORING AND EVALUATION SYSTEM, STRATEGIC INFORMATION ]]></PROJECT_TITLE><SERIAL_NUMBER>002800</SERIAL_NUMBER><STUDY_SECTION>ZPS1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>05</SUPPORT_YEAR><SUFFIX>S2</SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>175000</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
</PROJECTS>
